Rank	Title	Status	Study Results	Conditions	Interventions	Locations	URL
1	De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma	Completed	Has Results	Liver Carcinoma	Drug: Sirolimus	University of Alberta, Edmonton, Alberta, Canada	https://ClinicalTrials.gov/show/NCT00328770
2	Relenvatinib in the Tatment of Recurrence of Hepatocellular Carcinoma After Liver Transplantation	Not yet recruiting	No Results Available	Hepatocellular Carcinoma|Liver Transplantation	Drug: relenvatinib		https://ClinicalTrials.gov/show/NCT04237740
3	Y90 Radioembolization Prior to Surgical Resection or Radiofrequency for Hepatocellular Carcinoma in Cirrhotic Liver	Terminated	No Results Available	Hepatocellular Carcinoma|Liver Cirrhosis	Device: Sirsphere trans-arterial radioembolization	Institut Jules Bordet, Brussels, Belgium|Erasme Hosptial, Brussels, Belgium	https://ClinicalTrials.gov/show/NCT01686880
4	Liver Stiffness Measurement (LSM) in Predicting Progress of Liver Fibrosis After TACE for Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma|Liver Failure	Procedure: TACE		https://ClinicalTrials.gov/show/NCT03285867
5	Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma	Not yet recruiting	No Results Available	Carcinoma, Hepatocellular|Liver Cell Carcinoma	Drug: Tislelizumab	Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States	https://ClinicalTrials.gov/show/NCT05366829
6	Surgical Stages of Liver Cirrhosis In Patients With Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma|Liver Cirrhosis		Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China	https://ClinicalTrials.gov/show/NCT04076631
7	Liver Transplantation With ADV-TK Gene Therapy Improves Survival in Patients With Advanced Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma|Liver Transplantation	Genetic: ADV-TK (adenovirus-thymidine kinase enzyme) gene therapy	Beijing Chao Yang Hospital, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT00300521
8	Study of Palliative Radiotherapy for Symptomatic Hepatocellular Carcinoma and Liver Metastases	Recruiting	No Results Available	Hepatocellular Carcinoma|Liver Metastases	Other: Best Supportive Care|Radiation: Palliative Radiation Therapy	Cross Cancer Institute, Edmonton, Alberta, Canada|Dr. H. Bliss Murphy Cancer Centre, St. John's, Newfoundland and Labrador, Canada|Royal Victoria Regional Health Centre, Barrie, Ontario, Canada|Kingston Health Sciences Centre, Kingston, Ontario, Canada|Ottawa Hospital Research Institute, Ottawa, Ontario, Canada|Odette Cancer Centre, Toronto, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|CHUM-Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada|Hotel-Dieu de Quebec, Quebec City, Quebec, Canada|Centre hospitalier regional de Trois-Rivieres, Trois-Rivieres, Quebec, Canada|Allan Blair Cancer Centre, Regina, Saskatchewan, Canada	https://ClinicalTrials.gov/show/NCT02511522
9	Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma Beyond Milan/UCSF Criteria Who Underwent Liver Transplantation	Recruiting	No Results Available	Hepatocellular Carcinoma|Liver Transplantation	Other: Transarterial chemoinfusion (TAI) with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)	Nanjing Drum tower hospital, Nanjing, Jiangsu, China	https://ClinicalTrials.gov/show/NCT04595864
10	Study of Factors Predicting Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma (HCC)	Completed	No Results Available	Hepatocellular Carcinoma|Liver Cirrhosis|Evidence of Liver Transplantation	Other: search of factors predicting tumor recurrence	Clinique Universitaire d'Hépato-gastroentérologie, Grenoble, France	https://ClinicalTrials.gov/show/NCT01198704
11	Pembrolizumab and LENvatinib in Participants With Hepatocellular Carcinoma (HCC) Before Liver Transplant	Recruiting	No Results Available	Liver Transplant; Complications|Hepatocellular Carcinoma Recurrent	Drug: Pembrolizumab Injection [Keytruda]|Drug: Lenvatinib Oral Product	Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China	https://ClinicalTrials.gov/show/NCT04425226
12	Liver Perfusion MRI With Quantification of Tumoral Perfusion for Early Assessment of the Response of Antiangiogenics Treatments in Hepatocellular Carcinoma	Terminated	No Results Available	Hepatocellular Carcinoma	Device: liver Perfusion MRI	Service d'Imagerie, MédicaleHôpital Croix-Rousse, Lyon, France	https://ClinicalTrials.gov/show/NCT02585687
13	Lenvatinib Following Liver Transplantation in Patients of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus	Not yet recruiting	No Results Available	Hepatocellular Carcinoma|Portal Vein Tumor Thrombus|Liver Transplantation	Drug: lenvatinib|Drug: Placebo		https://ClinicalTrials.gov/show/NCT04319484
14	Prospective Liver Tumor (ProLiT) Database	Unknown status	No Results Available	Hepatocellular Carcinoma|Evidence of Liver Transplantation		University of Alberta, Edmonton, Canada	https://ClinicalTrials.gov/show/NCT01607788
15	Impacts of the α-fetoprotein (AFP) Score in Real Life for Patient Selection for Liver Transplantation (LT) for Hepatocellular Carcinoma (HCC)	Completed	No Results Available	Hepatocellular Carcinoma	Other: Data collecting	University Hospital, Grenoble Alpes, Grenoble, France	https://ClinicalTrials.gov/show/NCT03156582
16	Lenvatinib Following Liver Transplantation in Patients With High-Risk Hepatocellular Carcinoma	Not yet recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Lenvatinib|Drug: Placebo|Drug: Immunosuppressive regimen		https://ClinicalTrials.gov/show/NCT04168944
17	Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria	Not yet recruiting	No Results Available	Hepatocellular Carcinoma|Hepatocellular Cancer	Drug: Atezolizumab|Drug: Bevacizumab	Houston Methodist Research Institute, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT05185505
18	Study of Pembrolizumab Following TACE in Primary Liver Carcinoma	Recruiting	No Results Available	Primary Liver Carcinoma	Drug: Pembrolizumab|Combination Product: Trans-arterial chemoembolization	Imperial College Healthcare NHS Trust, London, United Kingdom	https://ClinicalTrials.gov/show/NCT03397654
19	PET TDM FDG-Choline as a Decision-making Tool for Routine Care on the Liver Transplant List for HCC	Recruiting	No Results Available	Hepatocellular Carcinoma|Liver Transplant	Radiation: PET TDM FDG-Choline	Hop Claude Huriez Chu Lille, Lille, France	https://ClinicalTrials.gov/show/NCT04792801
20	Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma	Terminated	No Results Available	Liver Carcinoma	Drug: AVE1642|Drug: sorafenib|Drug: erlotinib	Sanofi-Aventis Administrative Office, Paris, France	https://ClinicalTrials.gov/show/NCT00791544
21	Serum Visfatin and Serum Vaspin in Patients With Hepatocellular Carcinoma on Top of Liver Cirrhosis	Not yet recruiting	No Results Available	Hepatocellular Carcinoma			https://ClinicalTrials.gov/show/NCT04763707
22	Safety Study of Liver Natural Killer Cell Therapy for Hepatoma Liver Transplantation	Completed	Has Results	Liver Cirrhosis|Hepatocellular Carcinoma|Evidence of Liver Transplantation	Biological: Liver NK cell inoculation	University of Miami, Miami, Florida, United States	https://ClinicalTrials.gov/show/NCT01147380
23	Risk Factors of Hepatocellular Carcinomas Developed on Non-fibrotic Liver: Case-control Study (NoFlic Study)	Completed	No Results Available	Hepatocellular Carcinoma	Other: Blood test and self-administrated questionnaires	CHU Amiens, Amiens, France|AP-HP Jean Verdier, Bondy, France|CHU Bordeaux, Bordeaux, France|CHU Caen, Caen, France|AP-HP Hopital Antoine Béclère, Clamart, France|AP-HP Hopital Beaujon, Clichy, France|CHI Créteil, Créteil, France|CHU Grenoble, Grenoble, France|Hopital Edouard Herriot, Lyon, France|Hospices Civiles de Lyon, Lyon, France|AP-HP Cochin, Paris, France|AP-HP Hopital Henri Mondor, Paris, France|AP-HP Hopital Saint Antoine, Paris, France|CHU Villejuif, Villejuif, France	https://ClinicalTrials.gov/show/NCT03852238
24	Use of DwI-MR to Predict Chemotherapy Response of Liver Metastases and Hepatocarcinoma	Completed	No Results Available	Liver Metastases|Hepatocarcinoma		Stefano Colagrande, Florence, Italy	https://ClinicalTrials.gov/show/NCT01411579
25	A Study of exoASO-STAT6 (CDK-004) in Patients With Advanced Hepatocellular Carcinoma (HCC) and Patients With Liver Metastases From Primary Gastric Cancer and Colorectal Cancer (CRC)	Recruiting	No Results Available	Advanced Hepatocellular Carcinoma (HCC)|Gastric Cancer Metastatic to Liver|Colorectal Cancer Metastatic to Liver	Drug: CDK-004	City of Hope National Medical Center, Duarte, California, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States	https://ClinicalTrials.gov/show/NCT05375604
26	An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE)	Recruiting	No Results Available	Hepatocellular Carcinoma|Non-small Cell Lung Cancer Metastatic|Liver Metastases	Drug: Atezolizumab|Drug: Bevacizumab	Princess Margaret Cancer Centre, Toronto, Ontario, Canada	https://ClinicalTrials.gov/show/NCT04563338
27	Safety, Tolerability, PK, Anti-Tumor Activity of STP705 Injected IT in Cholangiocarcinoma, Hepatocellular Carcinoma or Liver Metastases in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy	Recruiting	No Results Available	Hepatocellular Carcinoma|Liver Metastases|Cholangiocarcinoma	Drug: STP705	Honor Health, Scottsdale, Arizona, United States|City of Hope, Duarte, California, United States|USC Norris Comprehensive Cancer Center, Los Angeles, California, United States|Hartford Healthcare, Hartford, Connecticut, United States|Atlantic Health System, Morristown, New Jersey, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States	https://ClinicalTrials.gov/show/NCT04676633
28	Portal Hypertension and Liver Resection in Patients With Hepatocellular Carcinoma	Unknown status	No Results Available	Primary Liver Cancers	Procedure: Liver resection	Henri Mondor University Hospital, Creteil, France	https://ClinicalTrials.gov/show/NCT02145013
29	Standard Versus Radiobiologically-Guided Dose Selected SBRT in Liver Cancer	Recruiting	No Results Available	Hepatocellular Carcinoma|Liver Metastases	Radiation: Radiation therapy	London Regional Cancer Program, London, Ontario, Canada	https://ClinicalTrials.gov/show/NCT04745390
30	Hepatocellular Carcinoma in Patients With a Cirrhosis Due to an Alcoholic or a Non Alcoholic Fatty Liver Disease	Unknown status	No Results Available	Hepatocellular Carcinoma	Other: blood collection	CHU de Nice, Nice, France	https://ClinicalTrials.gov/show/NCT03307408
31	AFP - L3% and DCP as Screening Marker for a Hepatocellular Carcinoma in Patients With Cirrhosis of the Liver	Completed	No Results Available	Liver Cirrhosis		University Medical Center Freiburg, Freiburg, Baden-Württemberg, Germany|University Medical Center Mainz, Mainz, Rheinland-Pfalz, Germany	https://ClinicalTrials.gov/show/NCT01361061
32	Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular Carcinoma	Not yet recruiting	No Results Available	Hepatocellular Carcinoma|Cancer of Liver	Drug: PXS-5505 and Atezolizumab and Bevacizumab		https://ClinicalTrials.gov/show/NCT05109052
33	Combined Ipsilateral Liver Lobe Devascularization and Alcohol Treatment of the Large Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma	Procedure: Combined Treatment	Ribat University Hospital, Khartoum, Sudan	https://ClinicalTrials.gov/show/NCT03138044
34	Gadoxetic Acid-enhanced MR Evaluation of Hepatocellular Carcinoma and Dysplastic Nodules in the Cirrhotic Liver	Withdrawn	No Results Available	Liver Cirrhosis|Carcinoma, Hepatocellular		Asan Medical Center, Seoul, Korea, Republic of|Division of Abdomen, Department of Radiology & Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT01501240
35	SU011248 in Advanced Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma|Liver Cancer	Drug: SU011248	Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States	https://ClinicalTrials.gov/show/NCT00361309
36	Safety and Efficacy of PD-1 Inhibitors in Patients With Liver Transplant	Recruiting	No Results Available	Hepatocellular Carcinoma|Liver Transplantation	Drug: JS001(PD-1 inhibitor)	Shanghai Zhongshan Hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT03966209
37	AFP Model and Liver Transplantation.	Completed	No Results Available	Liver Carcinoma|Liver Transplant Disorder	Procedure: Liver transplantation	Universidad Austral, Pilar, Buenos Aires, Argentina|Henri Mondor Hospital, University of Paris-Est., Creteil, Paris, France	https://ClinicalTrials.gov/show/NCT03775863
38	An Analysis of Urinary Proteases as Biomarkers for Hepatocellular Carcinoma-101423	Completed	No Results Available	Hepatocellular Carcinoma|Liver Disease			https://ClinicalTrials.gov/show/NCT01316679
39	Safety and Efficacy of Camrelizumab (Anti-PD-1 Antibody) in Recurrent HCC After Liver Transplantation	Recruiting	No Results Available	Hepatocellular Carcinoma|Liver Transplantation	Drug: Camrelizumab treatment	Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT04564313
40	Magnetic Resonance With Gadoxetic Acid for the Diagnosis of Hepatocellular Carcinoma in Patients With Liver Cirrhosis. Evaluation of Its Impact for the Non-invasive Diagnosis	Completed	No Results Available	Hepatocellular Carcinoma	Drug: GADOXETIC ACID	Hospital Clinic of Barcelona, Barcelona, Spain	https://ClinicalTrials.gov/show/NCT01575574
41	Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil/Leucovorin Versus Sorafenib in Advanced Hepatocellular Carcinoma	Completed	No Results Available	Liver Cancer|Hepatic Carcinoma	Drug: FOLFOX regimen|Drug: Sorafenib 200Mg Tab	Minimally Invasive Interventional Division, Department of Medical Imaging and Interventional Radiology, Sun Yat-sen University Cancer Center,, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT03164382
42	Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular Carcinoma	Terminated	Has Results	Hepatocellular Carcinoma|Liver Cancer	Drug: Sorafenib|Radiation: Stereotactic Body Radiotherapy (SBRT)	UAB, Birmingham, Alabama, United States	https://ClinicalTrials.gov/show/NCT01005875
43	Prospective Cohort of Patients With Hepatocellular Carcinoma in France	Recruiting	No Results Available	Cancer of Liver|Hepatocellular Carcinoma		CHU Amiens, Amiens, France	https://ClinicalTrials.gov/show/NCT04348838
44	Annual MRI Versus Biannual US for Surveillance of Hepatocellular Carcinoma in Liver Cirrhosis	Unknown status	No Results Available	Liver Cirrhosis	Device: annual noncontrast MRI|Device: biannual ultrasonography	Seoul St.Mary's Hospital, Seoul, Korea, Republic of|Korean University Guro Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|St.Vincent's Hospital, Suwon, Korea, Republic of|Uijeongbu St.Mary's Hospital, Uijeongbu, Korea, Republic of	https://ClinicalTrials.gov/show/NCT02551250
45	Boramae Hospital Liver Cirrhosis Patient Cohort Study	Completed	No Results Available	Liver Cirrhosis|Hepatocellular Carcinoma	Procedure: Liver biopsy|Device: Hepatic venous pressure gradient (HVPG) measurement	SNU-SMG Boramae Medical Center, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT01943318
46	Evaluation of Remnant Liver Function Using Primovist-enhanced MRI Before Resection/Ablation of Hepatocellular Carcinoma	Completed	No Results Available	Carcinoma, Hepatocellular|Liver Dysfunction	Drug: Gd-EOB-DTPA|Procedure: MRI	Cheonnam University Hwasun Hospital, Hwasun-Gun, Cheonnam Province, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT01490203
47	Prospective Post Y90 Liver Hypertrophy	Unknown status	No Results Available	Hepatocellular Carcinoma|Liver Hypertrophy	Other: CT volumetric measurement after Y90 radioembolization	Singapore General Hospital, Singapore, Singapore	https://ClinicalTrials.gov/show/NCT02783261
48	Proton Beam Therapy for Treatment of Hepatocellular Carcinoma	Completed	Has Results	Liver Cancer|Hepatocellular Carcinoma	Radiation: Proton radiation therapy	Loma Linda University Medical Center / James M. Slater Proton Treatment Center, Loma Linda, California, United States	https://ClinicalTrials.gov/show/NCT00614913
49	Doxorubicin By Infusion or Chemoembolization in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer)	Unknown status	No Results Available	Liver Cancer	Drug: doxorubicin hydrochloride|Procedure: hepatic artery embolization	Cancer Research UK Clinical Trials Unit - Birmingham, Birmingham, England, United Kingdom|Bristol Haematology and Oncology Centre, Bristol, England, United Kingdom|Addenbrooke's Hospital at Cambridge University Hospitals NHS Foundation Trust, Cambridge, England, United Kingdom|Royal Liverpool University Hospital, Liverpool, England, United Kingdom|Hammersmith Hospital, London, England, United Kingdom|Freeman Hospital, Newcastle-Upon-Tyne, England, United Kingdom|Royal South Hants Hospital, Southampton, England, United Kingdom|Royal Infirmary of Edinburgh at Little France, Edinburgh, Scotland, United Kingdom|Royal Infirmary Edinburgh, Edinburgh, Scotland, United Kingdom|West of Scotland Cancer Centre, Glasgow, Scotland, United Kingdom	https://ClinicalTrials.gov/show/NCT00079027
50	Sorafenib in Liver Function Impaired Advanced Hepatocellular Carcinoma	Completed	No Results Available	Liver Cancer	Drug: Sorafenib|Other: Best Supportive Care	Qingdao Central Hospital, Qingdao Cancer Hospital, Qingdao, Shandong, China	https://ClinicalTrials.gov/show/NCT01932385
51	Ipsilateral Liver Lobe Devascularization of the Large Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma	Procedure: HALED	Ribat University Hospital, Khartoum, Sudan	https://ClinicalTrials.gov/show/NCT03129685
52	Detection of Hepatocellular Carcinoma (HCC) With Octanoate Breath ID Test Compared to MRI	Terminated	Has Results	Chronic Liver Disease|Hepatocellular Carcinoma (HCC)	Drug: 13C Sodium Octanoate	Toronto General Hospital, Toronto, Ontario, Canada	https://ClinicalTrials.gov/show/NCT01433016
53	Low-Dose Thalidomide as Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma|Liver Cancer	Drug: thalidomide	Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT00728078
54	Nucleoid as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma|Liver Cancer	Procedure: RFA|Drug: lamivudine or entecavir	Department of Hepatobilliary Surgery, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT00555334
55	Laparoscopic Versus Open Liver Resection in the Treatment of Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma	Procedure: Laparoscopic liver resection|Procedure: Open liver resection	Department of General Surgery, Institute of Minimally Invasive Surgery, Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, China	https://ClinicalTrials.gov/show/NCT01768741
56	Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma ( Dulect2020-1 )	Recruiting	No Results Available	Liver Carcinoma|Liver Transplant; Complications	Drug: Durvalumab Injection|Drug: Lenvatinib 4 MG	Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China	https://ClinicalTrials.gov/show/NCT04443322
57	Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of HCC Before Liver Transplant	Unknown status	No Results Available	Hepatocellular Carcinoma|Liver Transplant	Drug: Camrelizumab plus apatinib	The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, Zhejiang, China	https://ClinicalTrials.gov/show/NCT04035876
58	Bevacizumab Biosimilar Plus FOLFOX4 in the Treatment of Recurrent HCC After Liver Transplantation	Not yet recruiting	No Results Available	Post-orthotopic Liver Transplantation|Hepatocellular Carcinoma Recurrent	Drug: Bevacizumab Biosimilar IBI305	Jiangsu Province Hospital, Nanjing, Jiangsu, China	https://ClinicalTrials.gov/show/NCT05355155
59	Preliminary Results for the Double-dose Adenovirus-mediated Adjuvant Therapy Improving Outcome of Liver Transplantation in Patients With Advanced Hepatocellular Carcinoma	Completed	No Results Available	Liver Cancer|Hepatocellular Carcinoma	Procedure: LT|Drug: ADV-TK|Drug: ganciclovir		https://ClinicalTrials.gov/show/NCT02202564
60	HELIO Liver Test Performance Study in China (HEPATIC)	Enrolling by invitation	No Results Available	Hepatocellular Carcinoma and Liver Disease	Diagnostic Test: Helio Liver Test	People's Liberation Army General Hospital, Beijing, Beijing, China|The First Affiliated Hospital of Guangzhou Medical University, Beijing, China	https://ClinicalTrials.gov/show/NCT05053412
61	TCR-Redirected T Cell Infusions to Prevent Hepatocellular Carcinoma Recurrence Post Liver Transplantation	Unknown status	No Results Available	Hepatocellular Carcinoma	Other: Biological: HBV antigen specific TCR redirected T cell	The First Affiliated Hospital, Sun-Yat Sen University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT02686372
62	A Clinical Trial Using Irreversible Electroporation for the Treatment of Liver Cancers	Completed	No Results Available	Hepatocellular Carcinoma|Metastatic Liver Cancers	Device: Irreversible Electroporation (IRE) System	National Taiwan University Hospital, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT02828865
63	FDGal PET/CT to Detect Hepatocellular Carcinoma	Withdrawn	No Results Available	Hepatocellular Carcinoma|Liver Cirrhosis|Chronic Liver Disease	Drug: Diagnostic PET/CT scans	BC Cancer Agency, Vancouver, British Columbia, Canada	https://ClinicalTrials.gov/show/NCT02899325
64	An International Phase 2 Study Of SU011248 In Patients With Inoperable Liver Cancer	Completed	Has Results	Liver Neoplasms|Unresectable Hepatocellular Carcinoma	Drug: Sunitinib (SU011248)	Pfizer Investigational Site, Clichy Cedex, France|Pfizer Investigational Site, Rennes Cedex, France|Pfizer Investigational Site, Saint Herrblain Cedex, France|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT00247676
65	Positron Emission Tomography Using Carbon-11 Acetate and Fludeoxyglucose F 18 in Detecting Hepatocellular Carcinoma (Liver Cancer) in Patients With Known or Suspected Liver Cancer	Completed	No Results Available	Liver Cancer	Procedure: 18F-Fluorodeoxyglucose-PET (FDG-PET)|Procedure: 11Carbon-Acetate-PET	Washington University School of Medicine, St. Louis, Missouri, United States	https://ClinicalTrials.gov/show/NCT00081094
66	Radiotherapy as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma|Liver Cancer	Procedure: RFA|Procedure: radiotherapy after RFA	Department of Hepatobilliary Surgery, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT00557024
67	TACE as an Adjuvant Therapy After Radiofrequency Ablation (RFA) for Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma|Liver Cancer	Procedure: radiofrequency ablation|Procedure: TACE after RFA	Department of Hepatobiliary Surgery, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT00556803
68	Erlotinib for Hepatocellular Carcinoma Chemoprevention	Not yet recruiting	No Results Available	Cirrhosis, Liver	Drug: Erlotinib Hydrochloride		https://ClinicalTrials.gov/show/NCT04172779
69	SorAfenib Versus RADIOEMBOLIZATION in Advanced Hepatocellular Carcinoma	Completed	No Results Available	Liver Carcinoma	Drug: sorafenib|Drug: SIR-Sphere	CHU Amiens #2, Amiens, France|CHU Angers #3, Angers, France|CHRU Besançon Hôpital Jean Minjoz #21, Besançon, France|Hôpital Jean Verdier #25, Bondy, France|Hôpital Côte de Nacre #4, Caen, France|Hôpital Antoine Béclère #29, Clamart, France|Hopital beaujon #1, Clichy, France|Henri Mondor #24, Créteil, France|CHU Dijon Hôpital Bocage #22, Dijon, France|CHU Grenoble #5, Grenoble, France|Hôpital Edouard Herriot #6, Lyon, France|Lyon La croix Rousse #27, Lyon, France|Institut Paoli Calmettes #7, Marseille, France|CHU Marseille Hôpital La Timone #23, Marseille, France|Hôpital Saint Eloi #8, Montpellier, France|Hôpital de Brabois #9, Nancy, France|Hotel Dieu #10, Nantes, France|Hôpital de L'Archet #11, Nice, France|Hôpital Européen Georges Pompidou #13, Paris, France|Hôpital Haut Leveque #14, Pessac, France|CHU Poitiers La Milétrie, Poitiers, France|CHU Robert Debré #28, Reims, France|CHU Saint Etienne Hôpital Nord #17, Saint-Priest en Jarez, France|Hôpital de Hautepierre #18, Strasbourg, France|Paul Brousse #19, Villejuif, France|Institut Gustave Roussy #20, Villejuif, France	https://ClinicalTrials.gov/show/NCT01482442
70	The Effect of Vitamin D Repletion in Patients With Hepatocellular Carcinoma on the Orthotopic Liver Transplant List	Unknown status	No Results Available	Vitamin D Deficiency|Hepatocellular Carcinoma	Drug: Vitamin D3 4000 IU|Drug: Vitamin D3 2000 IU	The Mount Sinai Hospital, New York, New York, United States	https://ClinicalTrials.gov/show/NCT01575717
71	Branched-chain Amino Acid Supplementation for Hepatocellular Carcinoma	Withdrawn	No Results Available	Hepatocellular Carcinoma|Cirrhosis|Liver Failure	Drug: Branch Chain Amino Acid|Other: maltodextrin	University Medical Center New Orleans, New Orleans, Louisiana, United States	https://ClinicalTrials.gov/show/NCT03908255
72	Analysis of Body Composition in Patients With Hepatocellular Carcinoma in Radioablation	Withdrawn	No Results Available	Liver Carcinoma	Behavioral: HCC under treatment with radioablation	Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, D.f., Mexico	https://ClinicalTrials.gov/show/NCT01744639
73	Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By Surgery	Completed	Has Results	Hepatocellular Carcinoma|Liver Cancer	Drug: Bevacizumab (Avastin)|Drug: Erlotinib	UT MD Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT00242502
74	The Illness of Uncertainty, Personality and Coping Strategies in Patients With Hepatocellular Carcinoma	Unknown status	No Results Available	Liver Carcinoma		Research Nurse, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT01380392
75	Radiofrequency Ablation Versus Liver Resection for Elderly Patients With Hepatocellular Carcinoma (HCC) Within the Milan Criteria	Unknown status	No Results Available	Hepatocellular Carcinoma	Procedure: HR|Procedure: RFA	Cancer Center, Sun Yat-set University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT01570075
76	Comparison of Criteria for Liver Transplantation in Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma|Liver Cancer|Advanced Adult Hepatocellular Carcinoma|Cirrhosis, Liver|Unresectable Liver Cancer|Liver Transplant Disorder		Liver Transplantation Institute, Inonu University, Malatya, Battalgazi, Turkey	https://ClinicalTrials.gov/show/NCT04576572
77	Immunosuppression in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Drug: CNI, MMF, Steroids, Aza etc. (mTOR inhibitor free)|Drug: Sirolimus	Regensburg University, Regensburg, Bavaria, Germany	https://ClinicalTrials.gov/show/NCT00355862
78	Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Hepatocellular Carcinoma	Recruiting	No Results Available	Liver Cell Carcinoma	Genetic: CATCH T cells|Drug: Cytoxan|Drug: Fludara	Houston Methodist Hospital, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT05103631
79	A Study to Evaluate the Safety, Tolerability and Efficacy of Cabozantinib in Patients With Hepatocellular Carcinoma and Impaired Liver Function	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Cabozantinib	Department of Internal Medicine I, Johannes Gutenberg University Mainz, Mainz, Germany	https://ClinicalTrials.gov/show/NCT04454762
80	Liver Resection Versus Transarterial Chemoembolization for the Treatment of Intermediate-stage Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma	Procedure: liver resection|Procedure: transarterial chemoembolization|Drug: carboplatin|Drug: lipiodol|Drug: epirubicin , pirarubicin , hydroxycamptothecin and fluorouracil|Other: absorbable gelatin sponge particles	The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT02755311
81	MRI-Guided Stereotactic Body Radiation Therapy in Treating Patients With Liver Metastases or Liver Cancer	Completed	No Results Available	Adult Hepatocellular Carcinoma|Metastatic Malignant Neoplasm in the Liver	Radiation: Image-Guided Adaptive Radiation Therapy|Radiation: Stereotactic Body Radiation Therapy	UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States	https://ClinicalTrials.gov/show/NCT02683200
82	Oblimersen and Doxorubicin in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)	Completed	No Results Available	Liver Cancer	Biological: oblimersen sodium|Drug: doxorubicin hydrochloride	British Columbia Cancer Agency - Vancouver Cancer Centre, Vancouver, British Columbia, Canada|London Regional Cancer Program at London Health Sciences Centre, London, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada	https://ClinicalTrials.gov/show/NCT00047229
83	Laparoscopic Versus Open Liver Resection for Hepatocellular Carcinoma	Active, not recruiting	No Results Available	Hepatocellular Carcinoma	Procedure: laparoscopic hepatectomy|Procedure: Open hepatectomy	Huashan hospital, Shanghai, China	https://ClinicalTrials.gov/show/NCT02526043
84	Effects of Statin on Hepatocellular Carcinoma Recurrence After Liver Transplantation	Completed	No Results Available	Hepatocellular Carcinoma	Drug: Statin	Division of Endocrinology and Metabolism Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT03490461
85	To Evaluate the Efficacy and Safety of (18F-FCH) Comparing With (18F-FDG) for Detecting Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma|Liver Disease	Drug: 18F- fluorocholine|Drug: 18F- fluorodeoxyglucose	National Taiwan University Hospital, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT02074202
86	Effect of Vascular Inflow Occlusion in Open Liver Resection for Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Procedure: Pringle	The Prince of Wales Hospital, Hong Kong, China	https://ClinicalTrials.gov/show/NCT01759901
87	HR Versus RFA for Early Stage HCC	Not yet recruiting	No Results Available	Hepatocellular Carcinoma|Liver Cancer	Other: Hepatic resection|Other: Radiofrequency ablation	Department of Hepatobilliary Surgery, Affiliated Tumor of Guangxi University, Nanning, Guangxi, China	https://ClinicalTrials.gov/show/NCT02169765
88	A Study Combining Personalized Neoantigen-based Dendritic Cell Vaccine With Microwave Ablation for the Treatment of Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma|Liver Cancer, Adult	Biological: Neoantigen Vaccines|Procedure: Microwave Ablation	Chinese PLA General Hospital, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT03674073
89	Study of Botanical PHY906 Plus Capecitabine for Advanced Unresectable Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma|Liver Cancer	Drug: PHY906|Drug: capecitabine	City of Hope National Medical Center, Duarte, California, United States|Stanford Hospital and Clinics, Stanford, California, United States|Yale University, New Haven, Connecticut, United States|VA Connecticut Cancer Center, West Haven, Connecticut, United States|National Institute of Cancer Research, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT00076609
90	Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer	Completed	Has Results	Hepatocellular Carcinoma|Liver Cancer	Drug: bavituximab (0.3 mg/kg) and sorafenib|Drug: bavituximab (1.0 mg/kg ) and sorafenib|Drug: bavituximab (3.0 mg/kg) and sorafenib	UT Southwestern Medical Center, Dallas, Texas, United States	https://ClinicalTrials.gov/show/NCT01264705
91	To Study the Effects of Addition of Mebendazole to Lenvatinib in Cirrhotics With Advanced Hepatocellular Carcinoma.	Recruiting	No Results Available	Hepatocellular Carcinoma|Liver Cirrhosis	Drug: Lenvatinib|Drug: Mebendazole|Other: Placebo	Institute of Liver & Biliary Sciences, New Delhi, Delhi, India	https://ClinicalTrials.gov/show/NCT04443049
92	Safety Study of NK Cells From Sibship to Treat the Recurrence of HCC After Liver Transplantation	Unknown status	No Results Available	Hepatocellular Carcinoma	Biological: Low Dose NK cells ×4 times|Biological: Normal Dose NK cells ×4 times|Biological: Normal Dose NK cells ×8 times	Wang Guoying, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT02399735
93	Genetic Profiling of Liver Cancer in Patients Undergoing Liver Transplantation	Unknown status	No Results Available	Hepatocellular Carcinoma	Other: None - Standard of Care	Baylor University Medical Center, Dallas, Texas, United States	https://ClinicalTrials.gov/show/NCT02412579
94	A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective	Completed	Has Results	Metastatic Hepatocellular Carcinoma|Advanced Liver Cancer	Drug: Ascorbic Acid + Sorafenib|Drug: Sorafenib	Thomas Jefferson University, Philadelphia, Pennsylvania, United States	https://ClinicalTrials.gov/show/NCT01754987
95	Hepatocellular Carcinoma Treated With Iodine-125 Implantation	Completed	No Results Available	Liver Carcinoma	Procedure: Radiofrequency Ablation|Radiation: iodine		https://ClinicalTrials.gov/show/NCT01717729
96	Efficacy of Sirolimus In Liver Transplantation for Hepatocellular Carcinoma (HCC)	Completed	No Results Available	Hepatocellular Carcinoma	Drug: Sirolimus|Drug: m-TOR inhibitor free	Seoul National University Hospital, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT01374750
97	TCR-Redirected T Cell Treatment in Patients With Recurrent HBV-related Hepatocellular Carcinoma Post Liver Transplantation	Active, not recruiting	No Results Available	Recurrent Hepatocellular Carcinoma	Biological: TCR-T cells	The First Affiliated Hospital of Sun-Yat Sen University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT04677088
98	TAC-101 in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)	Completed	No Results Available	Liver Cancer	Drug: TAC-101	MD Anderson Cancer Center at University of Texas, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT00077142
99	Anatomical Resection of the Liver for Hepatocellular Carcinoma: a New Ultrasound Guided Approach	Completed	No Results Available	Hepatocellular Carcinoma	Procedure: IOUS-GUIDED INTRAHEPATIC VESSEL COMPRESSION	Istituto Clinico Humanitas Irccs, Rozzano, Milano, Italy	https://ClinicalTrials.gov/show/NCT00829335
100	Interventional Radiology Liver Directed Therapies and Hypofractionated Image-Guided Radiation Therapy in Veteran and Non-Veteran, Non-surgical Hepatocellular Carcinoma Patients	Recruiting	No Results Available	Liver Cancer	Other: Quality of life questionnaires	Durham Veterans Administration Health Care System (DVAHCS), Durham, North Carolina, United States|Duke Cancer Center, Durham, North Carolina, United States	https://ClinicalTrials.gov/show/NCT04933435
101	Radiotherapy Versus no Intervention in Adult Patients With Hepatocellular Carcinoma Not Eligible for Transarterial Chemoembolization or Ablation Prior to Liver Transplant (RADBRI)	Withdrawn	No Results Available	Hepatocellular Carcinoma	Radiation: Stereotactic body radiotherapy		https://ClinicalTrials.gov/show/NCT03172559
102	Tumor Characteristics, Pre-transplant Treatments and Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma	Completed	No Results Available	Liver Transplantation	Procedure: Pre-treatment|Drug: Sirolimus based immunosuppression		https://ClinicalTrials.gov/show/NCT02995096
103	HepatoPredict Prognostic Tool for the Decision of Liver Transplant in Hepatocellular Carcinoma	Not yet recruiting	No Results Available	Hepatocellular Carcinoma, Scirrhous|Recurrence Tumor	Procedure: liver transplant	Centro Hepato-bilio-pancreático e de Transplantação do Hospital Curry Cabral, Lisboa, Portugal	https://ClinicalTrials.gov/show/NCT04499833
104	Safety and Bioactivity of Ipilimumab and Nivolumab Combination Prior to Liver Resection in Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Biological: Ipilimumab|Biological: Nivolumab	Imperial College Healthcare NHS Trust, London, Greater London, United Kingdom	https://ClinicalTrials.gov/show/NCT03682276
105	Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer	Completed	No Results Available	Hepatocellular Cancer|Liver Cancer	Drug: OMP-54F28 with Sorafenib	USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Indiana University Simon Cancer Center, Indianapolis, Indiana, United States|Massachussetts General Hospital, Boston, Massachusetts, United States|Mount Sinai Medical Center, New York, New York, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States	https://ClinicalTrials.gov/show/NCT02069145
106	Observational Prospective Study on Chemoembolization With Doxorubicin for Unresectable Hepatocellular Carcinoma	Unknown status	No Results Available	Liver Cell Carcinoma Non-resectable		Azienda Ospedaliera Ospedali Riuniti Marche Nord, Presidio Ospedaliero San Salvatore, Pesaro, PU, Italy	https://ClinicalTrials.gov/show/NCT01891539
107	Dynamic Contrast-enhanced Magnetic Resonance Imaging in Evaluation of Liver Functional Status and Treatment Efficacy in Patients With Hepatocellular Carcinoma After Locoregional Therapy	Unknown status	No Results Available	Hepatocellular Carcinoma		National Taiwan University Hospital, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT01281683
108	Liver Transplant for Larger Hepatocellular Carcinoma in Malatya: The Role of GGT and AFP	Completed	No Results Available	Hepatocellular Carcinoma|Liver Transplant Disorder	Procedure: Liver transplantation		https://ClinicalTrials.gov/show/NCT04412161
109	Comparison of Liver and Renal Function After Transarterial Chemoembolization for Primary Hepatocellular Carcinoma With Iso-osmolar Contrast Media and Low Osmolar Contrast Media	Unknown status	No Results Available	Primary Hepatocellular Carcinoma		Zhongda Hospital, Southeast University, Nanjing, Jiangsu, China	https://ClinicalTrials.gov/show/NCT01563484
110	Adjuvant Lenvatinib Prevents Recurrence of High-risk Patients With HBV-related HCC After Liver Transplantation	Completed	No Results Available	Hepatocellular Carcinoma	Drug: Lenvatinib	Xinhua Hospital Affiliated to Shanghai Jiao Tong University Medical School, Shanghai, China	https://ClinicalTrials.gov/show/NCT04415567
111	Sorafenib Plus Doxorubicin Versus Sorafenib Alone for the Treatment of Advanced Hepatocellular Carcinoma: a Randomized Phase II Trial	Unknown status	No Results Available	Liver Carcinoma	Drug: Doxorubicin|Drug: Sorafenib	Medizinische Klinik und Poliklinik, Heinrich-Heine-Universität, Düsseldorf, Germany|Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany|Universitätsklinikum des Saarlande, Homburg/Saar, Germany|Ortenau Klinikum Lahr-Ettenheim, Lahr, Germany|Universitätsklinikum Leipzig, Leipzig, Germany|Klinikum Ludwigsburg, Ludwigsburg, Germany	https://ClinicalTrials.gov/show/NCT01272557
112	Pravastatin Intervention to Delay Hepatocellular Carcinoma Recurrence	Terminated	Has Results	Hepatocellular Carcinoma|Liver Cirrhoses	Drug: Pravastatin Pill|Drug: Placebo Oral Tablet	Cedars-Sinai Medical Center, Los Angeles, California, United States	https://ClinicalTrials.gov/show/NCT03219372
113	Early Detection of Hepatocellular Carcinoma in a High-risk Prospective Cohort (ELEGANCE)	Recruiting	No Results Available	Liver Diseases		National University Hospital, Singapore, Singapore|SingHealth Polyclinics - Bukit Merah, Singapore, Singapore|SingHealth Polyclinics - Outram, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|National Cancer Center Singapore, Singapore, Singapore|Tan Tock Seng Hospital, Singapore, Singapore|SingHealth Polyclinics - Marine Parade, Singapore, Singapore|SingHealth Polyclinics - Bedok, Singapore, Singapore|SingHealth Polyclinics - Pasir Ris, Singapore, Singapore|SingHealth Polyclinics - Tampines, Singapore, Singapore|Changi General Hospital, Singapore, Singapore|Sengkang General Hospital, Singapore, Singapore|SingHealth Polyclinics - Sengkang, Singapore, Singapore|SingHealth Polyclinics - Punggol, Singapore, Singapore	https://ClinicalTrials.gov/show/NCT04965259
114	Radiolabeled Glass Beads Used for Treating Patients With Primary Liver Cancer When Surgery is Not an Option	Completed	No Results Available	Liver Cancer|Hepatoma	Device: Yttrium 90 (TheraSphere)		https://ClinicalTrials.gov/show/NCT00740753
115	Autologous Immune Killer Cells to Treat Liver Cancer Patients as an Adjunct Therapy	Unknown status	No Results Available	HepatoCellular Carcinoma|Liver Cancer	Biological: IKC (Immune Killer Cells)|Procedure: TACE (Transcatheter Arterial Chemoembolization)	Tri Service General Hospital, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT03592706
116	EXALT: EXercise Attenuates Liver Tumors Trial	Terminated	No Results Available	Hepatocellular Carcinoma	Behavioral: Exercise intervention	Penn State Hershey Medical Center, Hershey, Pennsylvania, United States	https://ClinicalTrials.gov/show/NCT03979547
117	Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC)	Withdrawn	No Results Available	Fibrolamellar Hepatocellular Carcinoma|Hepatocellular Carcinoma (Fibrolamellar Variant)|Hepatocellular Carcinoma	Procedure: living related donor partial liver transplantation|Radiation: Total body irradiation|Procedure: Bone marrow transplant from same donor|Drug: Cyclophosphamide|Drug: Mesna|Drug: Filgrastim|Drug: Tacrolimus|Drug: mycophenolate mofetil|Drug: Prednisone|Drug: Antithymocyte globulin|Drug: fludarabine	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States	https://ClinicalTrials.gov/show/NCT02702960
118	A Study of LioCyx in Patient With Recurrent HBV-related HCC Post Liver Transplantation	Not yet recruiting	No Results Available	Recurrent Hepatocellular Carcinoma	Biological: LioCyx	The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangzhou, China|The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangzhou, China|National University Hospital, Singapore, Singapore	https://ClinicalTrials.gov/show/NCT03634683
119	Research on Surgery and Micro-Invasive Treatment in Recurrent Primary Liver Cancer	Completed	No Results Available	Hepatocellular Carcinoma	Other: PRFA or PMCT|Procedure: surgery	Eastern Hepatobiliary Surgery Hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT00822562
120	Assessment of Liver Cancer Response to TACE Using MultiHance-Enhanced MRI.	Completed	Has Results	Hepatocellular Carcinoma	Drug: gadobenate dimeglumine (MultiHance)	The Johns Hopkins Hospital, Baltimore, Maryland, United States	https://ClinicalTrials.gov/show/NCT00539253
121	Longitudinal Assessment of Muscle Health in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma	Not yet recruiting	No Results Available	NAFLD|Hepatocellular Carcinoma|Liver Diseases|Liver Cancer|Cirrhosis, Liver|Hepatitis C		Columbia University Medical Center, New York, New York, United States	https://ClinicalTrials.gov/show/NCT05184283
122	The Effect of Gut Microbiota on Postoperative Liver Function Recovery in Patients With Hepatocellular Carcinoma	Completed	No Results Available	Gut Microbiota|Hepatocellular Carcinoma		The hepatic surgery of Tongji hospital, Wuhan, Hubei, China	https://ClinicalTrials.gov/show/NCT04303286
123	TACE Combined With Lenvatinib Versus TACE Sequential Lenvatinib in the Treatment of Intermediate/Advanced Liver Cancer	Recruiting	No Results Available	Hepatocellular Carcinoma	Procedure: TACE(Transcatheter arterial chemoembolization)|Drug: Lenvatinib	Department of Minimally Invasive and Interventional Radiology, Liver Cancer Study and Service Group, Sun Yat-sen University Cancer Center,, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT05220020
124	PET/CT in Diagnosing Patients With Liver Cancer Undergoing Surgical Resection	Completed	Has Results	Adult Hepatocellular Carcinoma|Localized Resectable Adult Liver Carcinoma	Diagnostic Test: Computed Tomography|Drug: 18F-fluoromethylcholine|Diagnostic Test: Positron Emission Tomography	University of Hawaii Cancer Center, Honolulu, Hawaii, United States	https://ClinicalTrials.gov/show/NCT01395030
125	Trial of Beads Versus Doxorubicin Eluting Beads for Arterial Embolization of Hepatocellular Carcinoma	Active, not recruiting	No Results Available	Hepatocellular Carcinoma|Liver Cancer|Hepatoma	Device: Bead Block microspheres|Other: Bead + Dox Arm	Memorial Sloan Kettering Cancer Center, New York, New York, United States	https://ClinicalTrials.gov/show/NCT00539643
126	Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers	Recruiting	No Results Available	Hepatocellular Carcinoma|Hepatocellular Cancer|Metastatic Pancreatic Cancer|Metastatic Colorectal Cancer|Liver Metastasis	Drug: nivolumab|Drug: tadalafil|Drug: oral vancomycin	National Institutes of Health Clinical Center, Bethesda, Maryland, United States	https://ClinicalTrials.gov/show/NCT03785210
127	Microwave Ablation of Resectable Liver Tumors	Withdrawn	No Results Available	Hepatocellular Carcinoma|Liver Cancer	Device: Microwave Ablation	The Center for Cancer Prevention & Treatment at St. Joseph Hospital, Orange, California, United States	https://ClinicalTrials.gov/show/NCT00892255
128	[18F]FMISO PET/CT After Transcatheter Arterial Embolization in Imaging Tumors in Patients With Liver Cancer	Completed	Has Results	Adult Liver Carcinoma|Liver Cirrhosis	Drug: 18F-Fluoromisonidazole|Procedure: Arterial Embolization|Diagnostic Test: Computed Tomography|Diagnostic Test: Positron Emission Tomography	VA Palo Alto Healthcare System, Palo Alto, California, United States	https://ClinicalTrials.gov/show/NCT02695628
129	Effects of Telephone Consultations on Discharged Liver Cancer	Completed	No Results Available	Hepatocellular Carcinoma	Behavioral: telephone consultations about psychoeducation program	National Taiwan University Hospital, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT01595243
130	Bortezomib in Treating Patients With Hepatocellular Carcinoma (Liver Cancer)	Completed	No Results Available	Adult Primary Hepatocellular Carcinoma|Advanced Adult Primary Liver Cancer|Localized Unresectable Adult Primary Liver Cancer|Recurrent Adult Primary Liver Cancer	Drug: bortezomib|Other: laboratory biomarker analysis	Mayo Clinic, Rochester, Minnesota, United States	https://ClinicalTrials.gov/show/NCT00077441
131	Multi-center Clinical Application of Hangzhou Criteria in Liver Transplantation for Hepatocellular Carcinoma	Unknown status	No Results Available	HCC|Liver Transplantation			https://ClinicalTrials.gov/show/NCT03985644
132	Transarterial Chemoembolization (TACE) Versus TACE Plus Stereotactic Body Radiation Therapy (SBRT) in Liver Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Radiation: Stereotactic Body Radiation|Drug: Transarterial Chemoembolization	London Health Sciences Centre, London Regional Cancer Program, London, Ontario, Canada	https://ClinicalTrials.gov/show/NCT03895359
133	Epirubicin and Celecoxib in Treating Patients With Hepatocellular Carcinoma	Completed	No Results Available	Liver Cancer	Drug: celecoxib|Drug: epirubicin hydrochloride	Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States	https://ClinicalTrials.gov/show/NCT00057980
134	Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery	Completed	Has Results	Adult Hepatocellular Carcinoma|Advanced Adult Hepatocellular Carcinoma|Localized Non-Resectable Adult Liver Carcinoma|Recurrent Adult Liver Carcinoma	Radiation: Stereotactic Radiosurgery	Albert Einstein College of Medicine, Bronx, New York, United States	https://ClinicalTrials.gov/show/NCT01899261
135	Hepatocyte-specific Versus Extracellular Contrast Agents for Liver MRI: Prospective, Intra-individual Comparison of Diagnostic Performance for Hepatocellular Carcinoma	Not yet recruiting	No Results Available	Chronic Hepatitis|Liver Cirrhosis	Other: hepatocyte-specific contrast agent, extracellular contrast agent	Yonsei University College of Medicine, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT03892681
136	Chemoembolisation of Hepatocellular Carcinomas Not Subject to Interventive Care by Idarubicin-loaded Beads - IDASPHERE II	Completed	No Results Available	Liver Cancer	Drug: idarubicin|Device: Dc- Beads 300-500µm	CHU Amiens, Amiens, France|CHU d'ANGERS, Angers, France|CHU - Hôpital François Mitterand, Dijon, France|Hôpital La Croix Rousse, Lyon, France|Hôpital Edouard Herriot, Lyon, France|CHU St Eloi, Montpellier, France|Hôpital de l'Archet II, Nice, France	https://ClinicalTrials.gov/show/NCT02185768
137	Gefitinib in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer)	Completed	No Results Available	Adult Primary Hepatocellular Carcinoma|Advanced Adult Primary Liver Cancer|Localized Unresectable Adult Primary Liver Cancer|Recurrent Adult Primary Liver Cancer	Drug: gefitinib|Other: laboratory biomarker analysis	Eastern Cooperative Oncology Group, Boston, Massachusetts, United States	https://ClinicalTrials.gov/show/NCT00071994
138	Camrelizumab Utilization on Patients With Advanced Liver Cancer	Recruiting	No Results Available	Advanced Hepatocellular Carcinoma	Other: camrelizumab	First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, China	https://ClinicalTrials.gov/show/NCT04487704
139	A Study of ThermoDox™ in Combination With Radiofrequency Ablation (RFA) in Primary and Metastatic Tumors of the Liver	Completed	No Results Available	Hepatocellular Carcinoma|Liver Neoplasms	Drug: ThermoDox	Northshore Hospital - Long Island Jewish Health System, Manhasset, New York, United States	https://ClinicalTrials.gov/show/NCT00441376
140	The Role of Long Non-coding RNAs WRAP53 and UCA-1 as Potential Biomarkers in Diagnosis of Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma|Liver Cirrhosis|Diagnoses Disease	Diagnostic Test: WRAP53, UCA-1	Alexandria University, faculty of medicine, Alexandria, Egypt|Alexandria University, medical research institute, Alexandria, Egypt	https://ClinicalTrials.gov/show/NCT05088811
141	MRI of the Liver With Eovist	Terminated	No Results Available	Hepatocellular Carcinoma			https://ClinicalTrials.gov/show/NCT01215838
142	Efficacy of Loco-regional Treatment for Hepatocellular Carcinoma Prior to Living Donor Liver Transplantation in Egypt	Completed	No Results Available	Hepatocellular Carcinoma (HCC)|Living Donor Liver Transplantation	Procedure: loco regional therapies for HCC		https://ClinicalTrials.gov/show/NCT02990351
143	First-in-Human Safety, Tolerability and Antitumour Activity Study of MTL-CEBPA in Patients With Advanced Liver Cancer	Active, not recruiting	No Results Available	Hepatocellular Carcinoma|Liver Cancer	Drug: MTL-CEBPA|Drug: Sorafenib 200mg	National University Hospital, Singapore, Singapore|National Taiwan University Hospital, Taipei, Taiwan|University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom|Cambridge University Hospitals NHS Trust, Cambridge, United Kingdom|The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, United Kingdom|Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom|Imperial College Healthcare NHS Trust, London, United Kingdom|The Royal Free London NHS Foundation Trust, London, United Kingdom|University College London Hospitals NHS Foundation Trust, London, United Kingdom|Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, United Kingdom	https://ClinicalTrials.gov/show/NCT02716012
144	Lung Dose in Patients Treated With Yttrium-90 for Hepatocellular Carcinoma	Completed	No Results Available	Liver Neoplasms		Radiation Oncology, University of Rochester, Medical Center, Rochester, New York, United States	https://ClinicalTrials.gov/show/NCT02489838
145	Role PET Imaging in Response Assessment for Hepatocellular Carcinoma (HCC)	Unknown status	No Results Available	Primary Liver Cancer	Procedure: MRI of the liver before start of treatment|Procedure: MRI after treatment|Procedure: PET-scan before treatment start|Procedure: PET scan after treatment	University Hospital Ghent, Ghent, Belgium	https://ClinicalTrials.gov/show/NCT01116804
146	A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer	Active, not recruiting	Has Results	Advanced Hepatocellular Carcinoma|HCC|Liver Cancer	Drug: PD-0332991	Thomas Jefferson University, Philadelphia, Pennsylvania, United States	https://ClinicalTrials.gov/show/NCT01356628
147	A Study of Chromosomal Abnormalities as a Predictor of Staging and Prognosis in Patients With Liver Cancer	Enrolling by invitation	No Results Available	Hepatocellular Carcinoma	Procedure: Liver resection method	The First Affiliated Hospital，College of Medicine，Zhejiang University, Hangzhou, Zhejiang, China	https://ClinicalTrials.gov/show/NCT05371873
148	PET Scan as a Screening Tool for Liver Transplant in Patients With Hepatocellular Carcinoma (HCC)	Completed	No Results Available	Hepatocellular Carcinoma	Other: PET Scan	McGill Univeristy Health Centre, Montreal, Quebec, Canada	https://ClinicalTrials.gov/show/NCT01320852
149	PVE/PVL Combined With DEB-TACE in the Treatment of Patients With Large and Unresectable Liver Cancer	Not yet recruiting	No Results Available	Hepatocellular Carcinoma	Procedure: DEB-TACE|Procedure: PVL/PVE+DEB-TACE		https://ClinicalTrials.gov/show/NCT05103007
150	Cabozantinib to Treat Recurrent Liver Cancer Post Transplant	Recruiting	No Results Available	Hepatocellular Carcinoma|Recurrent Cancer|Liver Transplant	Drug: Cabozantinib	Princess Margaret Cancer Centre, Toronto, Ontario, Canada	https://ClinicalTrials.gov/show/NCT04204850
151	To Evaluate the Safety and Efficacy of Microwave Ablation Therapy in Patients With Primary Liver Cancer	Recruiting	No Results Available	Hepatocellular Carcinoma	Device: microwave ablation	Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China|The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China|Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China|Henan Cancer Hospital, Zhengzhou, Henan, China|Zhongda Hospital Southeast University, Nanjing, Jiangsu, China|The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China|Shandong Provincial Hospital, Jinan, Shandong, China|Ruijin Hospital,Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China|Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China|Zhongshan Hospital, Shanghai, Shanghai, China|Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China|The Central Hospital of Lishui City, Lishui, Zhejiang, China	https://ClinicalTrials.gov/show/NCT04520906
152	Blood Volume Assessment of Hepatocellular and Metastatic Carcinomas in the Liver	Completed	No Results Available	Hepatocellular Carcinoma|Metastatic Carcinoma to the Liver		Rush University Medical Center, Chicago, Illinois, United States	https://ClinicalTrials.gov/show/NCT02288910
153	Study on the Effectiveness and Safety of Carrelizumab Combined With Apatinib Mesylate and Radiotherapy in the Treatment of Advanced Liver Cancer	Not yet recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Camrelizumab Apatinib Mesylas		https://ClinicalTrials.gov/show/NCT04523662
154	Evaluation of Liver Stiffness by Ultrasound Elastography for Predicting Early HCC Recurrence After Treatment	Not yet recruiting	No Results Available	Hepatocellular Carcinoma	Device: Ultrasound ELastography		https://ClinicalTrials.gov/show/NCT04552236
155	Prospective, Observational Study of Biomarkers in Liver Cancer - Identification of Actionable Events	Withdrawn	No Results Available	Hepatocellular Carcinoma			https://ClinicalTrials.gov/show/NCT01963949
156	Blood Sample Collection for Experimental Blood Test to Track Liver Cancer	Recruiting	No Results Available	Hepatocellular Carcinoma		Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States	https://ClinicalTrials.gov/show/NCT04720430
157	A Study to Evaluate a Study Drug, DCB-BO1202, for Alleviating Liver Fibrosis in Liver Cancer Patients	Withdrawn	No Results Available	Liver Fibrosis|HEPATITIS B CHRONIC|Hepatocellular Carcinoma	Drug: DCB-BO1202|Drug: Placebo|Drug: DCB-BO1202+Placebo	National Taiwan University Hospital, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT02289300
158	Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer	Recruiting	No Results Available	Hepatocellular Carcinoma	Other: Quality-of-Life Assessment|Other: Questionnaire Administration|Radiation: Stereotactic Body Radiation Therapy	OHSU Knight Cancer Institute, Portland, Oregon, United States	https://ClinicalTrials.gov/show/NCT03812289
159	Safety of 32P BioSilicon in Patients With Hepatocellular Carcinoma	Unknown status	No Results Available	Liver Cancer	Device: 32P BioSilicon	Singapore General Hospital, Outram Road, Singapore	https://ClinicalTrials.gov/show/NCT00247260
160	Radiofrequency Ablation With or With Transcatheter Arterial Embolization for Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma|Liver Cancer	Procedure: Radiofrequency ablation|Procedure: TACE	Department of Hepatobilliary Surgery, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT00554905
161	Study on Effectiveness and Safety of Hepatocellular Carcinoma Patients Treated With CyberKnife	Unknown status	No Results Available	Liver Neoplasms	Radiation: CyberKnife	Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China	https://ClinicalTrials.gov/show/NCT02363218
162	Clinical Study on BIFICO Accelerating Postoperative Liver Function Recovery in Patients With Hepatocellular Carcinoma	Recruiting	No Results Available	Gut Microbiota|Hepatocellular Carcinoma|Bifidobacterium	Drug: BIFICO	The hepatic surgery of Tongji hospital, Wuhan, Hubei, China	https://ClinicalTrials.gov/show/NCT05178524
163	Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant	Recruiting	No Results Available	Hepatocellular Carcinoma|Cirrhosis|Portal Hypertension	Drug: Durvalumab|Drug: Tremelimumab|Procedure: Liver Transplant	University of Cincinnati, Cincinnati, Ohio, United States	https://ClinicalTrials.gov/show/NCT05027425
164	Anlotinib for Hepatocellular Carcinoma	Recruiting	No Results Available	Liver Neoplasms	Drug: Anlotinib	People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China	https://ClinicalTrials.gov/show/NCT04954521
165	Liquid Biopsy-based Monitoring System for Relapse of HCC After Liver Transplantation: A Multi-center and Prospective Study	Unknown status	No Results Available	Hepatocellular Carcinoma	Other: Risk model of tumor relapse		https://ClinicalTrials.gov/show/NCT03708705
166	Multicenter RCT of ADV-TK Gene Therapy Improving the Outcome of Liver Transplantation for Advanced HCC	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: ADV-Tk|Procedure: LT	Beijing Youan Hospital, Beijing, Beijing, China|301 Military Hospital, Beijing, China|General Hospital of Chinese People's Armed Police, Beijing, China|The Third XiangYa Hospital of Central South University, Changsha, China|West China Hospital of Sichuan University, Chengdu, China|The Third Affiliated Hospital,Sun Yat-sen University, Guangzhou, China|The First Affiliated Hospital, Zhejiang University, Hangzhou, China|Zhongshan Hospital of Fudan University, Shanghai, China|The First Affiliated Hospital of China Medical University, Shenyang, China|The First Center Hospital of Tianjin, Tianjin, China|The First Hospital of Xinjiang Medical University, Urumqi, China	https://ClinicalTrials.gov/show/NCT03313596
167	Radical Surgery Followed by Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen for the Treatment of Hepatocellular Carcinoma	Unknown status	No Results Available	Liver Cancer	Procedure: Postoperative routine treatment|Biological: DC-PMAT treatment	Eastern Hepatobiliary Surgery Hospital, Shanghai, China	https://ClinicalTrials.gov/show/NCT02632188
168	Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer	Completed	No Results Available	Hepatocellular Carcinoma|Liver Cancer|Localized Unresectable Liver Cancer	Drug: sorafenib tosylate|Drug: doxorubicin hydrochloride|Drug: cisplatin|Drug: mitomycin C|Procedure: transarterial chemoembolization|Procedure: hepatic artery embolization	Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States	https://ClinicalTrials.gov/show/NCT01042041
169	Prospective Randomized Trial of Laparoscopic Versus Open Liver Resection for HCC	Unknown status	No Results Available	Hepatocellular Carcinoma	Procedure: Liver resection	Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea, Republic of	https://ClinicalTrials.gov/show/NCT00606385
170	Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer	Completed	No Results Available	Hepatocellular Cancer|Liver Cancer	Drug: Trametinib|Drug: Sorafenib	H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States	https://ClinicalTrials.gov/show/NCT02292173
171	LC Drug Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed	Completed	Has Results	Hepatocellular Carcinoma	Drug: LC Bead loaded with doxorubicin	UPMC Liver Cancer Center, Montefiore 7 South, 3459 Fifth Avenue, Pittsburgh, Pennsylvania, United States	https://ClinicalTrials.gov/show/NCT00877071
172	Liver Cancer Immunotherapy: Placebo-controlled Clinical Trial of Hepcortespenlisimut-L	Unknown status	No Results Available	Hepatocellular Carcinoma|HCC|Liver Cancer	Biological: hepcortespenlisimut-L|Biological: Placebo	Immunitor LLC, Ulaanbaatar, Mongolia|Immunitor LLC, Ulaanbaatar, Mongolia	https://ClinicalTrials.gov/show/NCT02232490
173	Y-90 Alone or With Sorafenib for Pre-Transplant Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Drug: Sorafenib|Drug: Yttrium-90 (Y-90)	Northwestern Memorial Hospital, Chicago, Illinois, United States	https://ClinicalTrials.gov/show/NCT00846131
174	Relationship Between 18FDG PET/MRI Patterns and ctDNA to Predict HCC Recurrence After Liver Transplantation	Recruiting	No Results Available	Hepatocellular Carcinoma	Device: PET MRI	Toronto General Hospital, Toronto, Ontario, Canada	https://ClinicalTrials.gov/show/NCT03839706
175	Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)	Active, not recruiting	No Results Available	Liver Neoplasms	Drug: Regorafenib (Stivarga, BAY73-4506)	Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|St. Joseph´s Hospital and Medical Center, Phoenix, Arizona, United States|University of Florida Health, Gainesville, Florida, United States|University of Louisville - Clinical Trials Unit, Louisville, Kentucky, United States|University Medical Center, New Orleans, Louisiana, United States|Mercy Medical Center, Baltimore, Maryland, United States|University of Michigan, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Rutgers University, Newark, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|C.R.Wood Cancer Center, Glen Falls Hospital, Glens Falls, New York, United States|University of Cincinatti, Cincinnati, Ohio, United States|Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania, United States|Einstein Medical Center, Philadelphia, Pennsylvania, United States|UT Southwestern Medical Center, Dallas, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Many locations, Multiple Locations, Argentina|Many locations, Multiple Locations, Austria|Many locations, Multiple Locations, Belgium|Many locations, Multiple Locations, Canada|Many locations, Multiple Locations, China|Many locations, Multiple Locations, Denmark|Many locations, Multiple Locations, Egypt|Many locations, Multiple Locations, France|Many locations, Multiple Locations, Greece|Many locations, Multiple Locations, Italy|Many locations, Multiple Locations, Japan|Many locations, Multiple Locations, Korea, Republic of|Many locations, Multiple Locations, Netherlands|Many locations, Multiple Locations, Russian Federation|Many locations, Multiple Locations, Saudi Arabia|Many locations, Multiple Locations, Spain|Many locations, Multiple Locations, Sweden|Many locations, Multiple Locations, Taiwan|Many locations, Multiple Locations, Thailand|Many locations, Multiple Locations, Turkey	https://ClinicalTrials.gov/show/NCT03289273
176	Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma, Childhood|Fibrolamellar Carcinoma|Liver Cancer|Liver Cancer, Pediatric	Drug: Pembrolizumab	University of California San Francisco, San Francisco, California, United States|Children's Hospital Boston, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Cincinnati Children's Medical Center, Cincinnati, Ohio, United States	https://ClinicalTrials.gov/show/NCT04134559
177	Long-term Outcomes of Ablation, Liver Resection, and Liver Transplant as First-line Treatment for Solitary HCC of 3 cm or Less	Completed	No Results Available	Hepatocellular Carcinoma	Procedure: Radiofrequency ablation|Procedure: Liver resection|Procedure: Liver transplantation		https://ClinicalTrials.gov/show/NCT05193253
178	Seocalcitol Versus Placebo in Advanced Hepatocellular Carcinoma	Terminated	No Results Available	Liver Neoplasms	Drug: Seocalcitol	E.g. University Health Network Toronto General Hospital (numerous facilities are recruiting in Canada), Toronto, Alberta, Canada|E.g. Notre-Dame de Bon Secours, Service d´Hepato-Gastro-Enterologie (numerous facilities are recruiting in France), Metz, France|E.g. Osp. Maggiore, Policlinico di Milano (numerous facilities are recruiting in Italy), Milano, Italy|E.g. Hospital Clinic Provincial de Barcelona (numerous facilities are recruiting in Spain), Barcelona, Spain|E.g. The University of Edinburgh Royal Infirmary (numerous facilities are recruiting in UK), Edinburgh, United Kingdom	https://ClinicalTrials.gov/show/NCT00051532
179	A Study of TCR-Redirected T Cell Infusion in Subject With Recurrent HBV-related HCC Post Liver Transplantation	Unknown status	No Results Available	Recurrent Hepatocellular Carcinoma	Biological: Biological: TCR-T	Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT02719782
180	Nano Drug Interventional Therapy Using Digital Subtraction Angiography（DSA） for Liver Carcinoma	Completed	No Results Available	Liver Cancer	Procedure: interventional therapy	Central laboratory in Fuda cancer hospital, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT02449109
181	A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation	Active, not recruiting	No Results Available	Hepatocellular Carcinoma|Liver Cancer	Biological: Nivolumab|Other: Placebo	Pinnacle Research Group, Llc, Anniston, Alabama, United States|Arizona Oncology Associates, PC - HOPE, Tucson, Arizona, United States|UCLA School Of Medicine, Los Angeles, California, United States|Stanford Cancer Center, Palo Alto, California, United States|California Pacific Medical Center Research Institute, San Francisco, California, United States|University Of Colorado, Aurora, Colorado, United States|Miami VA Healthcare System, Miami, Florida, United States|Sylvester Comprehensive Cancer Center/ UMHC, Miami, Florida, United States|H. Lee Moffit Cancer center and research institute, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|University of Kansas Cancer Center, Westwood, Kansas, United States|Local Institution - 0086, New Orleans, Louisiana, United States|University of Michigan, Ann Arbor, Michigan, United States|Minnesota Oncology Hematology, P.A., Minneapolis, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Laura and Issac Perlmutter Cancer Center at NYU Langone - Belleview Hospital, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|White Plains Hospital, White Plains, New York, United States|Providence Portland Medical Center, Portland, Oregon, United States|Texas Oncology Central Austin Dba, Austin, Texas, United States|Texas Oncology Sammons Cancer Center, Dallas, Texas, United States|Ut Southwestern Medical Center, Dallas, Texas, United States|Texas Oncology-Tyler, Tyler, Texas, United States|McGuire VA Medical Center, Richmond, Virginia, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Hospital Italiano De Buenos Aires, Gorriti, Buenos Aires, Argentina|Hospital Universitario Austral, Pilar, Buenos Aires, Argentina|Hospital Provincial Del Centenario, Rosario, Santa FE, Argentina|Blacktown Hospital, Blacktown, New South Wales, Australia|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|Concord Repatriation General Hospital, Concord, New South Wales, Australia|The Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Warringal Private Hospital, Heidelberg, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Local Institution, Graz, Austria|Local Institution, Vienna, Austria|Local Institution, Wien, Austria|Local Institution, Brussels, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Edegem, Belgium|Local Institution, Gent, Belgium|Local Institution, Leuven, Belgium|Local Institution, Belo Horizonte, Minas Gerais, Brazil|Local Institution, Barretos, Sao Paulo, Brazil|Local Institution, Cerqueira Cesar, SAO Paulo, Brazil|Local Institution, Sao Jose Do Rio Preto, Sao Paulo, Brazil|Local Institution, São Paulo, SAO Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Calgary, Alberta, Canada|Local Institution, Edmonton, Canada|Local Institution, Santiago de Chile, Metropolitana, Chile|Local Institution, Santiago, Metropolitana, Chile|Local Institution - 0245, Santiago, Región Metropolitana De Santiago, Chile|Local Institution, Vina del Mar, Valparaiso, Chile|Local Institution, Bogota, Colombia|Hopital Avicenne, Bobigny, France|Local Institution, Brest, France|CHU Estaing, Clermont Ferrand, France|Hopitaux Universitaires Paris Nord Val de Seine - Hopital Beaujon, Clichy, France|Hopital Henri Mondor, Creteil Cedex, France|Centre Hospitalier Universitaire De Grenoble- Hopital Albert Michallon, Grenoble Cedex 09, France|Hopital Huriez - CHRU de Lille, Lille, France|Local Institution, Lyon Cedex 04, France|Local Institution, Montpellier Cedex, France|Local Institution, Nice, France|Local Institution, Poitiers, France|Local Institution, Reims, France|Local Institution, Rennes Cedex 9, France|CHU St Etienne Hopital Nord, Saint-Priest-en-Jarez, France|Local Institution - 0011, Vandoeuvre Les Nancy Cedex, France|Hopital Paul Brousse, Villejuif, France|Local Institution, Aachen, Germany|Charite - Universitatsmedizin Berlin, Berlin, Germany|Local Institution, Bonn, Germany|Local Institution, Essen, Germany|Local Institution, Frankfurt am Main, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Local Institution, Homburg, Germany|Universitaetsklinikum Koeln, Koln, Germany|Local Institution, Leipzig, Germany|Local Institution, Magdeburg, Germany|Local Institution, Mainz, Germany|Universitatsmedizin Mannheim, Mannheim, Germany|Local Institution, Muenchen, Germany|Local Institution, Tuebingen, Germany|Local Institution, Wuerzburg, Germany|Local Institution, Hong Kong, Hong Kong|Local Institution, Hong Kong, Hong Kong|Local Institution, Messina, ME, Italy|Azienda Ospedaliero Universitaria Di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy|A.O.U. Careggi, Firenze, Italy|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy|Local Institution, Milano, Italy|Local Institution, Modena, Italy|Local Institution, Monserrato, Italy|Azienda Ospedaliera Specialistica dei Colli Monaldi-Cotugno-CTO, Napoli, Italy|Local Institution, Napoli, Italy|Local Institution, Padova, Italy|Fondazione Policlinico Gemelli - Universita Cattolica del Sacro Cuore, Rome, Italy|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Kashiwa-shi, Chiba, Japan|Local Institution, Kurume-shi, Fukuoka, Japan|Local Institution, Hiroshima-Shi, Hiroshima, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution - 0200, Sapporo-shi, Hokkaido, Japan|Local Institution, Nishinomiya-shi, Hyogo, Japan|Local Institution, Kanazawa-shi, Ishikawa, Japan|Local Institution, Morioka-shi, Iwate, Japan|Local Institution - 0197, Kawasaki-shi, Kanagawa, Japan|Local Institution, Kumamoto-shi, Kumamoto, Japan|Local Institution, Osaka-sayama, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Suita-shi, Osaka, Japan|Local Institution, Tokushima-shi, Tokushima, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Mitaka-shi, Tokyo, Japan|Local Institution, Musashino-shi, Tokyo, Japan|Local Institution, Shinjuku-ku, Tokyo, Japan|Local Institution, Suwon-si, Gyeonggi-do, Korea, Republic of|Local Institution, Daegu, Korea, Republic of|Local Institution, Goyang-si, Korea, Republic of|Local Institution, Gyeongsangnam-do, Korea, Republic of|Local Institution, Jeollanam-do, Korea, Republic of|Local Institution, Seongnam-si, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Consultorio medico de la Dra. Alma Laura Ladran de Guevara Cetina, Cuauhtemoc, Durango, Mexico|Local Institution, Monterrey, Nuevo Leon, Mexico|Local Institution, Monterrey, Mexico|Local Institution, San Luis Potosi, Mexico|Local Institution, Maastricht, Netherlands|Local Institution, Utrecht, Netherlands|Local Institution, Auckland, New Zealand|Fundacion De Investigacion De Diego, San Juan, Puerto Rico|Local Institution, Brasov, Romania|Local Institution, Bucharest, Romania|Local Institution, Cluj-Napoca, Romania|Local Institution, Constanta, Romania|Local Institution, Craiova, Romania|S.C. Oncocenter Oncologie Clinica S.R.L., Timisoara, Romania|Arkhangelsk Clinical Oncological Dispensary, Arkhangelsk, Russian Federation|Local Institution, Leningrad Region, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Local Institution, San Sebastian, Guipuzcoa, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Local Institution - 0031, Barcelona, Spain|Hospital Universitario Reina Sofia, Córdoba, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Local Institution, Madrid, Spain|Clinica Universidad De Navarra, Pamplona, Spain|Hospital de Sabadell, Sabadell (Barcelona), Spain|Local Institution, Sevilla, Spain|Local Institution, Valencia, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain|Local Institution, Chiayi, Taiwan|Local Institution, Kaohsiung, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Tainan, Taiwan|Local Institution, Tainan, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taoyuan, Taiwan|Local Institution, Yunlin, Taiwan|Local Institution, London, United Kingdom|Kings College Hospital-King's College Hospital NHS Foundation Trust, London, United Kingdom|Wellcome Trust Imperial Clinical Research Facility (CRF) (Sir John McMichael Centre (SJMC)), London, United Kingdom|Local Institution, Manchester, United Kingdom|Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, United Kingdom	https://ClinicalTrials.gov/show/NCT03383458
182	Novel Molecular Spectrometric Biomarkers in Blood Plasma as an Early Diagnostic Tool in HCC	Recruiting	No Results Available	Liver Cancer|Hepatocellular Carcinoma|Cirrhosis, Liver	Other: blood sampling	Central Military Hospital, Prague, Czechia	https://ClinicalTrials.gov/show/NCT04221347
183	Influence of Probiotics Administration Before Liver Resection in Liver Disease	Completed	No Results Available	Liver Fibrosis|Liver Cirrhosis|Permeability; Increased|Hepatocellular Carcinoma	Dietary Supplement: Probiotic|Dietary Supplement: Placebo	University Hospital, Rouen, Haute Normandie, France	https://ClinicalTrials.gov/show/NCT02021253
184	Risk of Hepatocellular Carcinoma in Patient With Liver Cirrhosis	Unknown status	No Results Available	Carcinoma, Hepatocellular		Azienda Ospedaliera Universitaria Policlinico Di Modena, Modena, MO, Italy	https://ClinicalTrials.gov/show/NCT03083002
185	Lenalidomide as Second-line Treatment for Advanced Hepatocellular Carcinoma	Completed	No Results Available	Liver Cancer	Drug: Lenalidomide	National Taiwan University Hospital, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT01545804
186	Radioembolization With Yttrium-90 Microspheres for Intermediate or Advanced Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma|Liver Cancer	Device: Yttrium-90 microspheres (Therasphere MDS Nordion)	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Milano, Italy	https://ClinicalTrials.gov/show/NCT00910572
187	Seocalcitol Versus Placebo in the Adjuvant Treatment of Hepatocellular Carcinoma	Terminated	No Results Available	Liver Neoplasms	Drug: Seocalcitol	E.g., University Health Network Toronto General Hospital (numerous facilities in Canada are recruiting), Toronto, Ontario, Canada|E.g., Hopital Notre-Dame de Bon Secour, Service de Hepato-gastro-enterologie (numerous facilities are recruiting in France), Metz, France|E.g., Osp. Maggiore, Policlinico di Milano, Divisione di Medicina Interna (numerous facilities are recruiting in Italy), Milano, Italy|E.g. Hospital Clinic Provincial de Barcelona (numerous facilities are recruiting in Spain), Barcelona, Spain|E.g., The University of Edinburgh Royal Infirmary (numerous facilities are recruiting in UK), Edinburgh, United Kingdom	https://ClinicalTrials.gov/show/NCT00051545
188	FAST-IRM for HCC suRveillance in pAtients With High risK of Liver Cancer.	Not yet recruiting	No Results Available	Hepatocellular Carcinoma|Liver Cancer|Cirrhosis|Chronic Liver Disease	Other: Liver ultrasound and fast-MRI|Other: Liver ultrasound	Assistance Publique Hôpitaux de Paris - Hôpital Avicenne, Bondy, France	https://ClinicalTrials.gov/show/NCT05095714
189	Factors Influencing the 3-Year Recurrence of Liver Carcinoma After Surgery	Completed	No Results Available	Liver Cancer|Recurrence	Other: Recurrence Rate of HCC after surgery|Other: Recurrence Rate of CCA after surgery		https://ClinicalTrials.gov/show/NCT02941861
190	The Safety and Efficacy of Spherical Microwave Ablation for the Treatment of Malignant Liver Tumors	Withdrawn	No Results Available	Hepatocellular Carcinoma (HCC)	Procedure: The Solero Microwave Ablation	National Taiwan University Hospital, Taipei, Test2, Taiwan	https://ClinicalTrials.gov/show/NCT04044326
191	Radioembolization of Primary and Secondary Liver Malignancies and The Effect On The Immune System	Recruiting	No Results Available	Hepatocellular Carcinoma|Secondary Malignant Neoplasm of Liver	Other: Yttrium-90	University of Minnesota, Minneapolis, Minnesota, United States	https://ClinicalTrials.gov/show/NCT03889093
192	Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma|Hepatoma|Liver Cancer, Adult|Liver Cell Carcinoma, Adult	Drug: TKM-080301	Arizona Clinical Research Center, Tucson, Arizona, United States|University of California San Francisco, San Francisco, California, United States|Kansas City Research Institute, Kansas City, Missouri, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Mary Crowley Cancer Research Centers, Dallas, Texas, United States|Princess Margaret Hospital, Toronto, Ontario, Canada|Queen Mary Hospital, Hong Kong, China|Seoul National University Hospital, Seoul, Gyeonggi-do, Korea, Republic of|Samsung Medical Center, Seoul, Gyeonggi-do, Korea, Republic of|ASAN Medical Center, Seoul, Gyeonggi-do, Korea, Republic of|Severence Hospital, Yonsei, University Health System, Seoul, Korea, Republic of|National University Hospital, Singapore, Singapore|National Taiwan University Hospital, Taipei, Taiwan|Taipei Medical University Hospital, Shuang-Ho Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT02191878
193	Estimation of Functional Liver Reserve Using Cholinesterases	Completed	No Results Available	Hepatocellular Carcinoma|Cirrhosis|Liver Neoplasm|Liver Disease		Liver Surgery Unit, Third Department of Surgery, University of MIlan, IRCCS Istituto Clinico Humanitas, Rozzano, Milan, Milan, Italy	https://ClinicalTrials.gov/show/NCT00883454
194	The Potential Role of Ga-68-PSMA in Staging, Restaging and Monitoring Response in Primary Liver Cancer: Comparison With F-18-FDG	Unknown status	No Results Available	Hepatocellular Carcinoma (HCC)	Radiation: Ga-68-PSMA scan, and PET -CT F-18-FDG		https://ClinicalTrials.gov/show/NCT03138239
195	Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy	Completed	No Results Available	Liver Cancer	Drug: Bevacizumab|Drug: Erlotinib	University of Texas MD Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT01180959
196	TACE Study-Liver Embolization Perfusion (VGH Radiology LIU)	Completed	No Results Available	Unresectable Hepatocellular Carcinoma|Undergoing Chemoembolization and Radioembolization		Vancouver General Hospital, Vancouver, British Columbia, Canada	https://ClinicalTrials.gov/show/NCT02093104
197	HEPAR Primary: Holmium-166-radioembolization in Hepatocellular Carcinoma Patients	Unknown status	No Results Available	Hepatocellular Carcinoma|Hepatocellular Carcinoma Non-resectable	Device: Holmium-166 radioembolization	Erasmus Medical Center, Rotterdam, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands	https://ClinicalTrials.gov/show/NCT03379844
198	The Effect of Percutaneous Radiofrequency Ablation of Feeding Arterial for Hepatocellular Carcinoma	Unknown status	No Results Available	Liver Neoplasms	Other: PAFA|Other: tumor ablation	Beijing Cancer Hospital, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT03143140
199	Treatment of Hepatocellular Carcinoma With Radiofrequency Ablation (RFA) Associated With Postoperative TACE	Unknown status	No Results Available	Cancer of Liver	Procedure: radiofrequency ablation associated with TACE|Procedure: radiofrequency ablation only	Institute of hepatobiliary surgery, Chongqing, Chongqing, China	https://ClinicalTrials.gov/show/NCT00730860
200	A Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer	Terminated	Has Results	Liver Cancer|Hepatocellular Cancer	Drug: Oxaliplatin|Drug: Capecitabine	City of Hope Medical Center, Duarte, California, United States	https://ClinicalTrials.gov/show/NCT03026803
201	TheraSphere® for Treatment of Unresectable Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma|Liver Cancer|Liver Neoplasm|Primary Liver Cancer	Device: TheraSphere	Chao Family Comprehensive Cancer Center, Orange, California, United States	https://ClinicalTrials.gov/show/NCT00906984
202	Value of Functional Magnetic Resonance Imaging of Hepatocellular Carcinoma After Transarterial Chemoembolization or Transarterial Radioembolization	Terminated	No Results Available	Liver Neoplasm	Diagnostic Test: MRI	University Hospital Zurich, Zurich, Switzerland	https://ClinicalTrials.gov/show/NCT04702230
203	Gadoxetic Acid-MRI Versus Ultrasonography for the Surveillance of Hepatocellular Carcinoma in High-risk Patients	Completed	Has Results	Cirrhosis of Liver		Asan Medical Center, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT01446666
204	Bridge to Orthotopic Liver Transplantation (OLT) - Surefire Precision vs Endhole Embolization With DEBTACE	Terminated	Has Results	Hepatocellular Carcinoma of the Liver|Subjects Eligible for Liver Transplantation	Device: Surefire Precision Infusion System	University of Colorado Hospital, Aurora, Colorado, United States	https://ClinicalTrials.gov/show/NCT03170869
205	Use of Sorafenib and/or Regorafenib in Liver Cancer (Hepatocellular Carcinoma) Subsequent to Another Systemic First-line Treatment	Terminated	No Results Available	Hepatocellular Carcinoma	Drug: Regorafenib (Stivarga, BAY73-4506)|Drug: Sorafenib (Nexavar, BAY43-9006)	Many Locations, Multiple Locations, Germany	https://ClinicalTrials.gov/show/NCT03644511
206	Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1)	Recruiting	No Results Available	Hepatocellular Carcinoma|Liver Cancer|Liver Neoplasm|Metastatic Liver Cancer	Biological: ET140203 autologous T cell product	City of Hope Medical Center, Duarte, California, United States|UC Irvine, Irvine, California, United States|UC Davis, Sacramento, California, United States|Kansas University Medical Center, Westwood, Kansas, United States	https://ClinicalTrials.gov/show/NCT04502082
207	Transarterial Chemoembolization Versus Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma	Terminated	No Results Available	Liver Neoplasms	Radiation: Radiation therapy|Device: chemoembolization	UH Antwerp, Antwerp, Belgium|UH Leuven, Leuven, Belgium|UH Lille, Lille, France|Erasmus MC, Rotterdam, ZH, Netherlands|AMC, Amsterdam, Netherlands|VU MC, Amsterdam, Netherlands|LUMC, Leiden, Netherlands|Maastro, Maastricht, Netherlands|UMC Maastricht, Maastricht, Netherlands|UMC St Radboud, Nijmegen, Netherlands|UMC Utrecht, Utrecht, Netherlands	https://ClinicalTrials.gov/show/NCT02470533
208	Study of ET140202 T Cells in Adults With Advanced Hepatocellular Carcinoma	Terminated	No Results Available	Hepatocellular Carcinoma|Liver Cancer|Liver Neoplasm|Metastatic Liver Cancer	Biological: ET140202 autologous T cell product	City of Hope Medical Center, Duarte, California, United States|UC Irvine, Irvine, California, United States|UC Davis, Sacramento, California, United States	https://ClinicalTrials.gov/show/NCT03998033
209	Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer	Active, not recruiting	No Results Available	Adult Primary Hepatocellular Carcinoma|Advanced Adult Primary Liver Cancer|Recurrent Adult Primary Liver Cancer	Drug: sorafenib tosylate|Radiation: stereotactic body radiation therapy	Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|UCSF Medical Center-Mount Zion, San Francisco, California, United States|UCSF Medical Center-Mission Bay, San Francisco, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|Saint Vincent's Medical Center, Bridgeport, Connecticut, United States|University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States|Queen's Medical Center, Honolulu, Hawaii, United States|Northwestern University, Chicago, Illinois, United States|University of Illinois, Chicago, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Northwestern Medicine Cancer Center Warrenville, Warrenville, Illinois, United States|Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|Iowa Methodist Medical Center, Des Moines, Iowa, United States|Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States|University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Boston Medical Center, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Montefiore Medical Center - Moses Campus, Bronx, New York, United States|Columbia University/Herbert Irving Cancer Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|Case Western Reserve University, Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Providence Portland Medical Center, Portland, Oregon, United States|Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States|University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States|M D Anderson Cancer Center, Houston, Texas, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States|University of Vermont Medical Center, Burlington, Vermont, United States|Hunter Holmes McGuire Veterans Administration Medical Center, Richmond, Virginia, United States|ProCure Proton Therapy Center-Seattle, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada|London Regional Cancer Program, London, Ontario, Canada|University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada|CHUM - Hopital Notre-Dame, Montreal, Quebec, Canada|CHUM - Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada|The Research Institute of the McGill University Health Centre (MUHC), Montreal, Quebec, Canada|Pamela Youde Nethersole Eastern Hospital, Chai Wan, Hong Kong|Samsung Medical Center, Seoul, Korea, Korea, Republic of	https://ClinicalTrials.gov/show/NCT01730937
210	Anlotinib in the Treatment of Advanced Hepatocellular Carcinoma (HCC)	Unknown status	No Results Available	Cancer of Liver	Drug: Anlotinib		https://ClinicalTrials.gov/show/NCT03766776
211	S-1/LV One Week on and One Week Off Regimen in Advanced Hepatocellular Carcinoma (HCC)	Unknown status	No Results Available	Carcinoma|Liver Diseases|Hepatocellular Carcinoma	Drug: S-1 combined with Leucovorin	Eastern Hepatobiliary Surgery Hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT01533324
212	Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by Surgery	Terminated	Has Results	Adult Primary Hepatocellular Carcinoma|Advanced Adult Primary Liver Cancer|Recurrent Adult Primary Liver Cancer	Drug: dasatinib	University of Southern California, Norris, Los Angeles, California, United States	https://ClinicalTrials.gov/show/NCT00459108
213	A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib	Completed	No Results Available	Hepatocellular Carcinoma|Liver Cancer|HCC	Biological: JX-594 recombinant vaccina GM-CSF|Other: Best Supportive Care	Moores University of California San Diego Cancer Center, La Jolla, California, United States|Chao Family Comprehensive Cancer Center, Orange, California, United States|California Pacific Medical Center, San Francisco, California, United States|Stanford Hospital and Clinics, Stanford, California, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Billings Clinic, Billings, Montana, United States|Saint Joseph's Hospital, Paterson, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|Gabrail Cancer Center, Canton, Ohio, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|The Methodist Hospital Department of Surgery, Houston, Texas, United States|University of Alberta, Edmonton, Alberta, Canada|University of British Columbia, Vancouver, British Columbia, Canada|Juravinski Cancer Centre, Hamilton, Ontario, Canada|Ottawa Hopsital Research Institute, Ottawa, Ontario, Canada|Hôpitaux Universitaires de Strasbourg - Hôpital Civil, Strasbourg Cedex, Alsace, France|Centre Hospitalier Universitaire Hôpital Saint André, Bordeaux, Aquitaine, France|CHU d'Estaing, Clermont-Ferrand, Auvergne, France|Hôpital Saint Antoine, CPP Ile de France V, Paris, Ile-de-France, France|Hôpital Purpan, Toulouse, Midi-Pyrenees, France|Hôpital de la Croix Rousse, Lyon Cedex, Rhone-Alpes, France|Klinikum Rechts der Isar der Technischen Universität München, München, Bayern, Germany|Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany|Johannes Gutenberg-Universität Mainz, Mainz, Rheinland-Pfalz, Germany|Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany|Queen Mary Hospital, Hong Kong, Hong Kong|Korea University Ansan Hospital, Ansan-si, Gyeonggi-Do, Korea, Republic of|Kyungpook National University Hospital, Daegu, Korea, Republic of|Pusan National University Hospital, Pusan, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital,Yonsei University Health System, Seoul, Korea, Republic of|Pusan National University Yangsan Hospital, Yangsan, Korea, Republic of|National Cheng-Kung University Hospital, TPE, Taiwan|National Taiwan University Hospital, TPE, Taiwan|Taipei Veterans General Hospital, TPE, Taiwan	https://ClinicalTrials.gov/show/NCT01387555
214	Sorafenib Tosylate Before and After Hepatic Arterial Chemoembolization With Doxorubicin Hydrochloride and Mitomycin C in Treating Patients With Localized Liver Cancer That Cannot Be Removed by Surgery	Completed	No Results Available	Liver Cancer	Drug: sorafenib tosylate, HACE : Doxorubicin Hydrochloride and Mitomycin C|Other: laboratory biomarker analysis	Rutgers University Hospital, Newark, New Jersey, United States	https://ClinicalTrials.gov/show/NCT00949182
215	MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer Patients	Recruiting	No Results Available	Advanced Hepatocellular Carcinoma (HCC)	Drug: MGD013 monotherapy|Drug: MGD013 in combination with Brivanib Alaninate	Prince of Wales Hospital, Hong Kong, Hong Kong, China	https://ClinicalTrials.gov/show/NCT04212221
216	Heterogeneity and Evolution of hepatoceLlular Carcinoma in Post-transplant HCC Recurrence	Recruiting	No Results Available	Hepatocellular Carcinoma Recurrent|Liver Transplant; Complications	Procedure: liver transplant|Diagnostic Test: ctDNA|Diagnostic Test: whole exome sequencing	Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China	https://ClinicalTrials.gov/show/NCT04506398
217	Stiffness Measurement of Liver Tumors and Visceral Parenchyma	Unknown status	No Results Available	Hepatocellular Carcinoma	Other: stiffness measurement using ARFI	Hepatogastroenterology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan	https://ClinicalTrials.gov/show/NCT01343212
218	Cediranib Maleate in Treating Patients With Locally Advanced or Metastatic Liver Cancer	Completed	No Results Available	Adult Primary Hepatocellular Carcinoma|Advanced Adult Primary Liver Cancer|Localized Unresectable Adult Primary Liver Cancer	Drug: cediranib maleate|Other: laboratory biomarker analysis	North Central Cancer Treatment Group, Rochester, Minnesota, United States	https://ClinicalTrials.gov/show/NCT00238394
219	Comparing Diagnostic Accuracy for Liver Tumours Between the Combination of CEUS and CEMRI Versus CECT and CEMRI	Completed	No Results Available	Hepatocellular Carcinoma (HCC)	Diagnostic Test: Sonazoid- CEUS, CEMRI, CECT	National Taiwan University Hospital, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT03267290
220	Combination of Irreversible Electroporation and NK Immunotherapy for Recurrent Liver Cancer	Completed	No Results Available	Recurrent Liver Carcinoma	Device: Irreversible Electroporation|Biological: Natural killer	Fuda cancer institute of Fuda cancer hospital, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT03008343
221	Combining Biomarkers (AFP, AFP-L3, and PIVKA-II) and Image Tools for Early Detection of Hepatocellular Carcinoma	Recruiting	No Results Available	Liver Cirrhosis|Hepatocellular Carcinoma|Surveillance	Diagnostic Test: AFP-L3|Diagnostic Test: AFP|Diagnostic Test: PIVKA-II|Diagnostic Test: Sonography|Diagnostic Test: CT	Korea University Ansan Hospital, Ansan, Gyeonggi-do, Korea, Republic of|The Catholic University of Korea Uijeongbu St.Mary's Hospital, Uijeongbu, Gyeonggi-do, Korea, Republic of|Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of|Inje University SangGye Paik Hospital, Seoul, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Soonchunhyang University Seoul Hospital, Seoul, Korea, Republic of|Hanyang University Hospital, Seoul, Korea, Republic of|Konkuk University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|The Catholic University of Korea Seoul St.Mary's Hospital, Seoul, Korea, Republic of|Chung-Ang University Hosptial, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT04414956
222	Erlotinib in Treating Patients With Liver Cancer That Cannot be Surgically Removed	Terminated	No Results Available	Adult Primary Hepatocellular Carcinoma|Advanced Adult Primary Liver Cancer|Localized Unresectable Adult Primary Liver Cancer	Drug: erlotinib hydrochloride|Other: laboratory biomarker analysis|Other: pharmacological study	M D Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT00047333
223	Usefulness of Non-contrast MagnetIc Resonance imAging Versus Non-Contrast Ultrasonography for surveiLlancE of HepatoCellular Carcinoma [MIRACLE-HCC]	Active, not recruiting	No Results Available	Compensated Liver Cirrhosis	Radiation: Ultrasonography|Radiation: non-contrast MRI	Institute of Gastroenterology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT02514434
224	Application of Watson for Oncology in Hepatocellular Carcinoma Surgery	Unknown status	No Results Available	Liver Resection	Other: Watson on oncology surgery decision evaluation	Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT03904667
225	FAST (Focused Abbreviated Screening Technique)-MRI Study	Enrolling by invitation	No Results Available	Hepatocellular Carcinoma (HCC)|Liver Cirrhosis		Icahn School of Medicine at Mount Sinai, New York, New York, United States	https://ClinicalTrials.gov/show/NCT04539717
226	Assessment of Novel MRI Quantification Free Breathing Technique in Evaluation of Liver Lesions	Completed	Has Results	Hepatocellular Carcinoma	Procedure: liver biopsy|Device: free-breathing MRI	University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States	https://ClinicalTrials.gov/show/NCT02095678
227	Trans-parenchymal Compressing Suture in Major Liver Resection	Completed	No Results Available	Liver Carcinoma Resectable	Procedure: TCS		https://ClinicalTrials.gov/show/NCT03215290
228	Percutaneous Irreversible Electroporation for Unresectable Hepatic Carcinoma in Poor Liver Function	Completed	No Results Available	Hepatic Carcinoma	Device: NanoKnife LEDC System	FUDA Cancer Hospital, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT02352935
229	Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma	Withdrawn	No Results Available	HepatoCellular Carcinoma|Unresectable HepatoCellular Carcinoma|Liver Cancer	Radiation: Stereotactic Body Radiation Therapy (SBRT)|Drug: Sorafenib|Drug: Bavituximab	H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States	https://ClinicalTrials.gov/show/NCT02989870
230	Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors	Active, not recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Pembrolizumab|Drug: Regorafenib (Stivarga, BAY73-4506)	University of Arizona Cancer Center, Tucson, Arizona, United States|City of Hope National Medical Center, Duarte, California, United States|University of Southern California, Los Angeles, California, United States|University of California Irvine Medical Center, Orange, California, United States|Medical Oncology Hematology Consultants, PA, Newark, Delaware, United States|University of Miami Miller School of Medicine, Miami, Florida, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Hôpital Beaujon - Clichy, Clichy, France|Center Hospitalier Michallon - Grenoble, La Tronche, France|Hôpital Claude Huriez - Lille, Lille, France|Hôpital de la Croix Rousse, Lyon, France|Hôpital de la Timone - Marseille, Marseille, France|Hôpital Saint-Eloi, Montpellier Cedex, France|Centre François Magendie - Pessac, Pessac, France|Centre Hospitalier Universitaire de Nancy, Vandoeuvre les Nancy, France|Hôpital Paul Brousse - Villejuif, Villejuif, France|Eberhard-Karls-Universität Tübingen, Tübingen, Baden-Württemberg, Germany|Klinikum der Universität München Grosshadern, München, Bayern, Germany|Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Nordrhein-Westfalen, Germany|Universitätsklinikum Köln, Köln, Nordrhein-Westfalen, Germany|Universitätsmedizin der Johannes Gutenberg Universität Mainz, Mainz, Rheinland-Pfalz, Germany|Rambam Health Corporation, Haifa, Israel|Clalit Health Services Rabin Medical Center-Beilinson Campus, Petah Tikva, Israel|Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel|Istituto Clinico Humanitas - Humanitas Mirasole S.p.A., Milano, Lombardia, Italy|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Lombardia, Italy|A.O.U. Pisana, Pisa, Toscana, Italy|Istituto Oncologico Veneto IRCCS (IOV), Padova, Veneto, Italy|Chiba University Hospital, Chiba-shi, Chiba, Japan|National Cancer Center Hospital East, Kashiwa-shi, Chiba, Japan|Japanese Red Cross Society Musashino Red Cross Hospital, Musashino-shi, Tokyo, Japan|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Institut Català d'Oncologia Hospitalet, Hospitalet de Llobregat, Barcelona, Spain|Hospital Clínic i Provincial de Barcelona, Barcelona, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain	https://ClinicalTrials.gov/show/NCT04696055
231	Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer	Active, not recruiting	No Results Available	Adult Primary Hepatocellular Carcinoma|Localized Resectable Adult Primary Liver Cancer|Localized Unresectable Adult Primary Liver Cancer|Recurrent Adult Primary Liver Cancer	Drug: sorafenib tosylate|Other: placebo|Other: laboratory biomarker analysis	University of Alabama, Birmingham, Alabama, United States|Jonsson Comprehensive Cancer Center, Los Angeles, California, United States|University of Colorado, Denver, Colorado, United States|Mount Sinai Hospital, Hartford, Connecticut, United States|Lombardi Comprehensive Cancer Center at Georgetown University, Washington, District of Columbia, United States|Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Johns Hopkins University, Baltimore, Maryland, United States|Lahey Clinic Medical Center, Burlington, Massachusetts, United States|University of Michigan University Hospital, Ann Arbor, Michigan, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|University of Pennsylvania Health System, Cherry Hill, New Jersey, United States|New York University Langone Medical Center, New York, New York, United States|New York Presbyterian-The University Hospital of Columbia and Cornell, New York, New York, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Integris-Baptist Medical, Oklahoma City, Oklahoma, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Vanderbilt University, Nashville, Tennessee, United States|Baylor College of Medicine, Houston, Texas, United States|The Methodist Hospital Research Institute, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT01624285
232	Immune Responses in Hepatocellular Carcinoma Patients After Treatment With Direct Acting Antiviral Drugs	Completed	No Results Available	Drug-Induced Liver Injury	Diagnostic Test: Flow cytometry and Western Blot analysis	Assiut University, Assiut, Egypt	https://ClinicalTrials.gov/show/NCT03602703
233	Transarterial Chemoembolization Prior to Transplantation for Hepatocellular Carcinoma	Terminated	No Results Available	Hepatocellular Carcinoma	Other: Intra-arterial administration of DC BeadsR	Hôpital Henri Mondor - Assistance Publique-Hôpitaux de Paris, Créteil, France|Hôpital Michalon, CHU de Grenoble, Grenoble, France|Hôpital Claude Huriez, CHU de Lille, Lille, France|Hôpital de la Croix Rousse, HCL, Lyon, Lyon, France|Hôpital Saint-Antoine / APHP, Paris, France|Hôpital Pontchaillou, Rennes, France|Hôpital Trousseau, CHU de Tours, Tours, France	https://ClinicalTrials.gov/show/NCT01676194
234	Prospective Randomised Study of Doxorubicin in the Treatment of Hepatocellular Carcinoma by Drug-Eluting Bead Embolisation	Completed	No Results Available	Primary Liver Cancer	Device: Transarterialchemoembolisation (TACE)|Device: DC Bead with Doxorubicin	Medizinische Universitat Innsbruck, Innsbruck, Austria|Allgemines Krankenhaus Vienna, Vienna, Austria|L'Hopital Beaujon, Clichy, France|Hopital Claude Huriez, Lille, France|Groupement Hospitalier Edouard Herriot, Lyon, France|Hopital Archet II, Nice, France|Hopital Pitie Salpetriere, Paris, France|CHU Rangueil, Toulouse, France|Institut Gustave Roussy, Villejuif, France|Klinikum der Johann-Wolfgang-Goethe-Universitat, Frankfurt am Main, Germany|Medicinische Hochschule Hannover, Hannover, Germany|Klinikum der Johannes Guttenberg, Mainz, Germany|Fakultat fur Klinische Medizin Mannheim Universitat, Mannheim, Germany|Inselspital Bern, Bern, Switzerland|Hopitaux Universitaires de Geneve, Geneve, Switzerland|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland|Universitatsspital Zurich, Zurich, Switzerland	https://ClinicalTrials.gov/show/NCT00261378
235	Accuracy Assessment for Computer-assisted Surgical Interventions of the Liver	Completed	No Results Available	Adult Liver Cancer	Other: Abdominal surgery	Dep. of visceral and Transplant Surgery, Bern University Hospital, Berne, Switzerland	https://ClinicalTrials.gov/show/NCT01474694
236	Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma|Anti-PD1 Antibody|Liver Diseases	Drug: Lenvatinib|Drug: Opdivo|Drug: Camrelizumab|Drug: Keytruda|Drug: Toripalimab|Drug: Sintilimab|Drug: Tislelizumab	Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT04627012
237	Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant	Recruiting	No Results Available	Recurrent Hepatocellular Carcinoma|Stage III Hepatocellular Carcinoma AJCC v8|Stage IIIA Hepatocellular Carcinoma AJCC v8|Stage IIIB Hepatocellular Carcinoma AJCC v8|Stage IV Hepatocellular Carcinoma AJCC v8|Stage IVA Hepatocellular Carcinoma AJCC v8|Stage IVB Hepatocellular Carcinoma AJCC v8|Unresectable Hepatocellular Carcinoma	Other: Laboratory Biomarker Analysis|Drug: Lenvatinib	Mayo Clinic Arizona, Scottsdale, Arizona, United States|Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States	https://ClinicalTrials.gov/show/NCT05103904
238	Phase III Trial of Oral Thalidomide in Advanced Hepatocellular Carcinoma With Poor Liver Reserve	Terminated	No Results Available	Carcinoma, Hepatocellular	Drug: Thalidomide(Thado)	Taiwan Cooperative Oncology Group, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT00225290
239	Study to Evaluate Tumour Response in Cancer Patients With Advanced Hepatocellular Carcinoma (Liver Cancer) With AMT2003	Terminated	No Results Available	Hepatocellular Carcinoma	Drug: AMT2003	University Hospital Freiburg, Dept. of Internal Medicine II, Freiburg im Breisgau, Baaden-Wuerttemberg, Germany|Clinic SanaFontis, Freiburg im Breisgau, Germany	https://ClinicalTrials.gov/show/NCT00405873
240	Chemoembolization Using Doxorubicin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery	Completed	Has Results	Liver Cancer	Device: Drug-eluting beads loaded with doxorubicin hydrochloride	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States	https://ClinicalTrials.gov/show/NCT00293397
241	Genetic Polymorphisms of Interleukin-1B and TNF-A and HBV-Related Hepatocellular Carcinoma	Completed	No Results Available	Hepatitis B|Hepatocellular Carcinoma|Chronic Liver Disease	Genetic: Polymorphism of IL-1 beta and TNF-alpha	Kaohsiung Medical University Chung-Ho Hospital, Kaohsiung, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan	https://ClinicalTrials.gov/show/NCT00629486
242	MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy	Terminated	Has Results	Adult Hepatocellular Carcinoma|Advanced Adult Hepatocellular Carcinoma|Localized Non-Resectable Adult Liver Carcinoma|Recurrent Adult Liver Carcinoma	Drug: Akt Inhibitor MK2206|Other: Laboratory Biomarker Analysis	Tower Cancer Research Foundation, Beverly Hills, California, United States|City of Hope Medical Center, Duarte, California, United States|USC Norris Comprehensive Cancer Center, Los Angeles, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Joliet Oncology-Hematology Associates Limited, Joliet, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|Central Illinois Hematology Oncology Center, Springfield, Illinois, United States|Southern Illinois University, Springfield, Illinois, United States|Fort Wayne Medical Oncology and Hematology Inc-Parkview, Fort Wayne, Indiana, United States|Northern Indiana Cancer Research Consortium, South Bend, Indiana, United States|University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States|University of Michigan, Ann Arbor, Michigan, United States|Oncology Care Associates PLLC, Saint Joseph, Michigan, United States|Saint John's Mercy Medical Center, Saint Louis, Missouri, United States|Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States|Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States	https://ClinicalTrials.gov/show/NCT01239355
243	Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer	Completed	No Results Available	Adult Hepatocellular Carcinoma|Advanced Adult Hepatocellular Carcinoma|Localized Non-Resectable Adult Liver Carcinoma|Recurrent Adult Liver Carcinoma	Biological: Cixutumumab|Other: Laboratory Biomarker Analysis|Drug: Sorafenib Tosylate	City of Hope Comprehensive Cancer Center, Duarte, California, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|Penn State Hershey Cancer Institute-Clinical Trials Office, Hershey, Pennsylvania, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States|University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States	https://ClinicalTrials.gov/show/NCT01008566
244	Microwave Ablation Versus Liver Resection For Early Hepatocellular Carcinoma in Patients With Borderline Liver Function	Recruiting	No Results Available	Carcinoma, Hepatocellular	Procedure: Microwave ablation|Procedure: Liver resection	Prince of Wales Hospital, Shatin, Hong Kong	https://ClinicalTrials.gov/show/NCT03766555
245	A Phase 3 Study of Talaporfin Sodium and Interstitial Light Emitting Diodes Treating Hepatocellular Carcinoma (HCC)	Completed	No Results Available	Carcinoma, Hepatocellular|Liver Neoplasms	Drug: Talaporfin sodium|Device: Interstitial Light Emitting Diodes|Procedure: Percutaneous placement of device in the liver|Procedure: Standard Care	University Hospital Dubrava, Zagreb, Croatia|Tuen Mun Hospital, Tuen Mun, New Territories, Hong Kong|Prince of Wales Hospital, Dept. of Clincal Oncology, New Territories, Hong Kong|Dr. Kamakshi Memorial Hospital, Chennai, India|SMS Medical College, Jaipur, India|Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India|Cancer Clinic, Nagpur, India|Shatabdi Super Specialty Hospital, Nasik, India|Pusan National University Hospital, Busan, Korea, Republic of|Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of|Korea University Medical Center Anam Hospital, Seoul, Korea, Republic of|Kyunghee Univeristy Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Sinchon Severance Hospital, Yonsei University, Seoul, Korea, Republic of|Hospital Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia|University Malaya Medical Centre, Kuala Lumpur, Malaysia|Island Hospital, Penang, Malaysia|Lam Wah Ee Hospital, Penang, Malaysia|Cebu Doctors University Hospital, Cebu City, Philippines|Vicente Sotto Memorial Medical Center, Cebu City, Philippines|Santo Tomas University Hospital, Manila, Philippines|The Medical City, Pasig City, Philippines|National Kidney and Transplant Institute, Quezon City, Philippines|St. Luke's Medical Center, Quezon City, Philippines|Szpital Uniwersytecki CMUJ, Krakow, Poland|Centralny Szpital Kliniczny MSWiA, Warsaw, Poland|Clinical Center of Serbia, Institute for Gastroenterology and Hepatology, Belgrade, Serbia|Clinical Center of Serbia, Belgrade, Serbia|Military Medical Academy, Belgrade, Serbia|Singapore General Hospital, Singapore, Singapore|National Cancer Centre, Singapore, Singapore|Karolinska University Hospital, Stockholm, Sweden|Mahidol University, Siriraj Hospital, Bangkok, Thailand|Chiang Mai University, Chiang Mai, Thailand	https://ClinicalTrials.gov/show/NCT00355355
246	Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With Liver Cancer That Cannot be Removed by Surgery	Completed	No Results Available	Adult Primary Hepatocellular Carcinoma|Advanced Adult Primary Liver Cancer|Localized Unresectable Adult Primary Liver Cancer	Drug: thalidomide|Drug: doxorubicin hydrochloride|Other: laboratory biomarker analysis	New York University Langone Medical Center, New York, New York, United States	https://ClinicalTrials.gov/show/NCT00006016
247	Contrast-Enhanced CT and MRI in Diagnosing and Staging Liver Cancer Using UNOS Policy	Active, not recruiting	No Results Available	Liver Cancer	Drug: iodinated contrast dye|Drug: motexafin gadolinium|Other: Eovist-enhanced MRI	UAB Comprehensive Cancer Center, Birmingham, Alabama, United States|Mayo Clinic Scottsdale, Scottsdale, Arizona, United States|USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States|Georgetown University Hospital, Washington, District of Columbia, United States|Lahey Clinic Medical Center - Burlington, Burlington, Massachusetts, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Washington University, St. Louis, Saint Louis, Missouri, United States|Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|The Methodist Hospital for Liver Disease and Transplant, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT01082224
248	Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer	Completed	Has Results	Adult Primary Hepatocellular Carcinoma|Localized Unresectable Adult Primary Liver Cancer|Recurrent Adult Primary Liver Cancer	Biological: bevacizumab	Montefiore Medical Center - Moses Campus, Bronx, New York, United States	https://ClinicalTrials.gov/show/NCT00055692
249	Postoperative Antimicrobial Prophylaxis Versus Placebo for Infection Prevention in HCC After Liver Resection	Suspended	No Results Available	Hepatocellular Carcinoma|Postoperative Infection	Drug: postoperative antimicrobial prophylaxis|Other: No postoperative antimicrobial prophylaxis	The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT03990974
250	Radiofrequency Ablation in Treating Patients With Liver Cancer and Cirrhosis	Completed	Has Results	Liver Cancer	Device: radiofrequency ablation	Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham, Birmingham, Alabama, United States|Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, Los Angeles, California, United States|Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States|University of California Davis Cancer Center, Sacramento, California, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|UMASS Memorial Cancer Center - University Campus, Worcester, Massachusetts, United States|William Beaumont Hospital - Royal Oak Campus, Royal Oak, Michigan, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States|Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Rhode Island Hospital Comprehensive Cancer Center, Providence, Rhode Island, United States|Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina, United States|M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Scott and White Cancer Institute, Temple, Texas, United States	https://ClinicalTrials.gov/show/NCT00132041
251	Gene Therapy in Treating Patients With Cancer of The Liver	Terminated	No Results Available	Liver Cancer	Biological: Ad5CMV-p53 gene	Albert Einstein Comprehensive Cancer Center, Bronx, New York, United States|University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States	https://ClinicalTrials.gov/show/NCT00003147
252	Sorafenib Tosylate in Treating Patients With Liver Cancer That Can Be Removed by Surgery	Unknown status	No Results Available	Liver Cancer	Drug: sorafenib tosylate|Other: laboratory biomarker analysis|Procedure: neoadjuvant therapy|Procedure: therapeutic conventional surgery	Hopital Beaujon, Clichy, France	https://ClinicalTrials.gov/show/NCT01182272
253	Alternative Surgical Policy for Central Liver Tumors	Completed	No Results Available	Colorectal Liver Metastases|Hepatocellular Carcinoma	Procedure: Ultrasound-guided hepatectomy	Istituto Clinico Humanitas, IRCCS, Rozzano, Milano, Italy	https://ClinicalTrials.gov/show/NCT00600522
254	Surveillance and Treatment Of Primary Hepatocellular Carcinoma: An International Prospective Observational Cohort Study of High-Risk Patients for HCC Using Liquid Biopsy	Active, not recruiting	No Results Available	Liver Cancer|Liver Cirrhosis|Hepatocellular Carcinoma|Early Stage Liver Cancer	Other: GALAD Score	King Faisal Specialist Hospital and Research Center in Jeddah, Jeddah, Saudi Arabia|National Guard Hospital in Jeddah, Jeddah, Saudi Arabia|King Faisal Specialist Hospital and Research Centre in Riyadh, Riyadh, Saudi Arabia|King Saud University Medical Center, Riyadh, Saudi Arabia|National Guard Hospital in Riyadh, Riyadh, Saudi Arabia|Binh An Hospital, Rach Gia, Kien Giang, Vietnam|Medic Ca Mau, Ca Mau, Vietnam|Dong Da Hospital, Ha Noi, Vietnam|Institute of Gastroenterology and Hepatology, Ha Noi, Vietnam|Medic Medical Center-Ho Chi Minh City, Ho Chi Minh City, Vietnam	https://ClinicalTrials.gov/show/NCT05342350
255	Genetic Polymorphisms of TNF-α Promoter and HBV Genotype on Outcome of HBV-Related Chronic Liver Disease	Unknown status	No Results Available	Chronic Liver Disease|Hepatocellular Carcinoma	Genetic: TNF-alpha and HBV genotype|Other: TNF-alpha and HBV genotypes	Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan	https://ClinicalTrials.gov/show/NCT00629668
256	Internal Radiation Therapy for Hepatocellular Carcinomas With Therasphere: Optimized Dosimetry Versus Standard Dosimetry	Completed	No Results Available	Adenoma, Liver Cell	Radiation: Optimized Internal Radiation Therapy|Radiation: Standard Internal Radiation Therapy	CHU Henri Mondor, Créteil, France|CHU Saint Eloi, Montpellier, France|Centre Eugène Marquis, Rennes, France|Gustave Roussy, Villejuif, France	https://ClinicalTrials.gov/show/NCT02582034
257	T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR)	Withdrawn	No Results Available	Hepatocellular Carcinoma|Hepatoblastoma	Genetic: TEGAR T cells|Drug: Cytoxan|Drug: Fludarabine		https://ClinicalTrials.gov/show/NCT04093648
258	Radioactive Iodine in Treating Patients Who Have Undergone Surgery for Liver Cancer	Unknown status	No Results Available	Liver Cancer	Procedure: adjuvant therapy|Radiation: iodine I 131 ethiodized oil	National Cancer Centre - Singapore, Singapore, Singapore|Tan Tock Seng Hospital, Singapore, Singapore|Changi General Hospital, Singapore, Singapore	https://ClinicalTrials.gov/show/NCT00027768
259	Yttrium Y 90 Resin Microspheres Data Collection in Unresectable Liver Cancer: the RESIN Study	Completed	No Results Available	Localized Non-Resectable Adult Liver Carcinoma	Other: Yttrium-90 Resin Microspheres	University of Alabama, Birmingham, Alabama, United States|University of Arizona Health Sciences, Tucson, Arizona, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|California Pacific Medical Center, San Francisco, California, United States|University of California, San Francisco, San Francisco, California, United States|Stanford University, Stanford, California, United States|University of Colorado, Denver, Denver, Colorado, United States|Sky Ridge Medical Center, Englewood, Colorado, United States|Christiana Care Health System, Wilmington, Delaware, United States|Georgetown University, Washington, District of Columbia, United States|Baptist Hospital of Miami, Miami, Florida, United States|University of Miami, Miami, Florida, United States|Sarasota Memorial Hospital, Sarasota, Florida, United States|Tampa General Hospital, Tampa, Florida, United States|Cancer Treatment Centers of America, Atlanta, Georgia, United States|Emory University, Atlanta, Georgia, United States|Piedmont Hospital, Atlanta, Georgia, United States|Advocate Christ Medical Center, Oak Lawn, Illinois, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|University of Maryland School of Medicine, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|Saint Louis University, Saint Louis, Missouri, United States|Albany Medical Center, Albany, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Northwell Health- Lenox Hill Hospital, New York, New York, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Wake Forest Medical Center, Winston-Salem, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States|Penn State Health Saint Joseph Medical Center, Reading, Pennsylvania, United States|Spartanburg Regional Healthcare System, Spartanburg, South Carolina, United States|Sanford USD Medical Center, Sioux Falls, South Dakota, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States|Methodist Health System, Dallas, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|The University of Utah, Salt Lake City, Utah, United States|Providence Sacred Heart Medical Center and Children's Hospital, Spokane, Washington, United States	https://ClinicalTrials.gov/show/NCT02685631
260	Clinical Study of ET1402L1-CAR T Cells in AFP Expressing Hepatocellular Carcinoma	Terminated	No Results Available	Hepatocellular Carcinoma|Liver Cancer|Liver Neoplasms|Metastatic Liver Cancer	Biological: autologous ET1402L1-CART cells	Renmin Hospital of Wuhan University, Wuhan, Hubei, China	https://ClinicalTrials.gov/show/NCT03349255
261	ET1402L1-ARTEMIS™2 T Cells in Alpha Fetoprotein (AFP) Expressing Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma|Liver Cancer|Liver Neoplasms|Metastatic Liver Cancer	Biological: ET1402L1-ARTEMIS™ T cells -IV|Biological: ET1402L1-ARTEMIS™ T cells -intra-hepatic artery|Biological: ET1402L1-ARTEMIS™ T cells -Intratumoral Injections	The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China	https://ClinicalTrials.gov/show/NCT03888859
262	Viral Therapy in Treating Patient With Refractory Liver Cancer or Advanced Solid Tumors	Active, not recruiting	No Results Available	Advanced Malignant Solid Neoplasm|Hepatocellular Carcinoma	Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Biological: Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta	Mayo Clinic in Arizona, Scottsdale, Arizona, United States	https://ClinicalTrials.gov/show/NCT01628640
263	Gemcitabine and Oxaliplatin for Hepatocellular Carcinoma With Platelet Counts Greater Than 100,000 Per Microliter	Completed	No Results Available	Liver Cancer	Drug: Gemcitabine and Oxaliplatin	Hematology Oncology Associates, Albuquerque, New Mexico, United States|Lovelace Sandia Health Systems Dept of Hematology, Albuquerque, New Mexico, United States|University of New Mexico, Albuquerque, New Mexico, United States|St. Vincent Regional Medical Center, Santa Fe, New Mexico, United States	https://ClinicalTrials.gov/show/NCT00250822
264	The Evaluation of Surgical Decisions and Prognosis of the Radiomics and Watson Artificial Intelligence in Patients With Hepatocellular Carcinoma	Recruiting	No Results Available	Liver Resection	Device: Radiomics and Watson artificial intelligence	Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT03917017
265	Doxorubicin and Bortezomib in Treating Patients With Liver Cancer	Completed	Has Results	Adult Primary Hepatocellular Carcinoma|Advanced Adult Primary Liver Cancer|Localized Unresectable Adult Primary Liver Cancer|Recurrent Adult Primary Liver Cancer	Drug: doxorubicin|Drug: bortezomib	Eastern Cooperative Oncology Group, Boston, Massachusetts, United States	https://ClinicalTrials.gov/show/NCT00083226
266	Sorafenib Tosylate With or Without Everolimus in Treating Patients With Localized, Unresectable, or Metastatic Liver Cancer	Completed	No Results Available	Liver Cancer	Drug: everolimus|Drug: sorafenib tosylate	Medizinische Universität Wien, Wien, Austria|Szent Laszlo Korhaz, Budapest, Hungary|Saint Claraspital AG, Basel, Switzerland|Clinical Cancer Research Center at University Hospital Basel, Basel, Switzerland|Istituto Oncologico della Svizzera Italiana - Ospedale Regionale Bellinzona e Valli, Bellinzona, Switzerland|Inselspital Bern, Bern, Switzerland|Kantonsspital Bruderholz, Bruderholz, Switzerland|Hopital Cantonal Universitaire de Geneve, Geneva, Switzerland|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland|Kantonsspital Liestal, Liestal, Switzerland|CHCVS - Hôpital de Sion, Sion, Switzerland|Kantonsspital - St. Gallen, St. Gallen, Switzerland|Regionalspital, Thun, Switzerland|City Hospital Triemli, Zurich, Switzerland|UniversitaetsSpital Zuerich, Zurich, Switzerland	https://ClinicalTrials.gov/show/NCT01005199
267	Change of Lactate Concentration During Hartmann Solution Infusion for Hepatic Resection	Completed	No Results Available	Hepatocellular Carcinoma|Liver Disease	Other: hartmann solution	Samsung Medical Center, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT02329821
268	Sorafenib and Micro-therapy Guided by Primovist Enhanced MRI in Patients With Inoperable Liver Cancer	Completed	No Results Available	Hepatocellular Carcinoma	Procedure: RFA|Procedure: Radioembolization (SIRT)	University of Magdeburg, Magdeburg, Germany	https://ClinicalTrials.gov/show/NCT01126645
269	The Safety and Efficacy of Thermal Ablation Combined With Apatinib and Carilimub for Advanced Liver Cancer	Recruiting	No Results Available	BCLC Stage B Hepatocellular Carcinoma|BCLC Stage C Hepatocellular Carcinoma	Drug: Apatinib Mesylate	Chinese PLA General Hospital, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT04204577
270	A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors	Recruiting	No Results Available	Hepatocellular Carcinoma|Hepatoma|Liver Cancer, Adult|Liver Cell Carcinoma|Liver Cell Carcinoma, Adult	Biological: Nivolumab|Biological: Relatlimab	Local Institution - 0019, Buenos Aires, Distrito Federal, Argentina|Local Institution, Ciudad Autónoma de Buenos Aires, Distrito Federal, Argentina|Local Institution - 0017, Rosario, Santa FE, Argentina|Local Institution, San Miguel de Tucumán, Tucuman, Argentina|Local Institution, Camperdown, New South Wales, Australia|Local Institution, Belo Horizonte MG, Minas Gerais, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution - 0016, Barretos, SAO Paulo, Brazil|Local Institution - 0014, Ribeirao Preto, SAO Paulo, Brazil|Local Institution - 0015, São Paulo, SAO Paulo, Brazil|Local Institution - 0024, Temuco, Araucania, Chile|Local Institution, Santiago, Metropolitana, Chile|Local Institution - 0018, Santiago, Metropolitana, Chile|Local Institution, Harbin, Heilongjiang, China|Local Institution, Changsha, Hunan, China|Local Institution, Xi'an, Shan3xi, China|Local Institution, Xi'an, Shan3xi, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Barranquilla, Colombia|Local Institution, Bogota, Colombia|Local Institution - 0048, Brno, Czechia|Local Institution - 0047, Hradec Kralove, Czechia|Local Institution - 0046, Prague, Czechia|Local Institution - 0068, Clichy, France|Local Institution, Grenoble, France|Hopital De La Croix Rousse, Lyon, France|Local Institution - 0067, Pessac, France|Local Institution - 0069, Vandoeuvre les Nancy, France|Local Institution - 0077, Hksar, Hong Kong|Local Institution, Hong Kong, Hong Kong|Local Institution, Hong Kong, Hong Kong|Local Institution, Matsuyama-shi, Ehime, Japan|Local Institution, Yokohama, Kanagawa, Japan|Local Institution - 0076, Yokohama, Kanagawa, Japan|Local Institution, Osakasayama, Osaka, Japan|Local Institution - 0075, Ishikawa, Japan|Local Institution - 0071, Kyoto, Japan|Local Institution - 0020, Seongnam-si, Korea, Republic of|Local Institution - 0011, Seoul, Korea, Republic of|Local Institution - 0043, Seoul, Korea, Republic of|Local Institution - 0100, Cuauhtémoc, Estado DE Mexico, Mexico|Local Institution - 0101, San Luis Potosí, SAN LUIS Potosi, Mexico|Local Institution - 0106, Oaxaca, Mexico|Local Institution, Auckland, New Zealand|Local Institution, Bytom, Poland|Local Institution, Kraków, Poland|Local Institution, Myslowice, Poland|Local Institution - 0039, Warszawa, Poland|Local Institution, Bucuresti, Romania|Local Institution, București, Romania|Local Institution, Cluj-Napoca, Romania|Local Institution, Craiova, Romania|Local Institution, Suceava, Romania|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Singapore, Singapore|Local Institution - 0001, Singapore, Singapore|Local Institution - 0004, Singapore, Singapore|Local Institution - 0066, Barcelona, Spain|Local Institution - 0073, Cordoba, Spain|Local Institution - 0051, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution - 0058, Pamplona, Spain|Local Institution - 0050, San Sebastian, Spain|Local Institution - 0041, Taichung, Taiwan|Local Institution - 0034, Tainan, Taiwan|Local Institution, Taipei City, Taiwan|Local Institution - 0042, Taipei, Taiwan|Local Institution - 0032, Taoyuan, Taiwan|Local Institution, Ankara, Turkey|Local Institution, Ankara, Turkey|Local Institution, Edirne, Turkey|Local Institution, Istanbul, Turkey|Local Institution, Turkey, Turkey	https://ClinicalTrials.gov/show/NCT04567615
271	A Study of Lenvima (Lenvatinib) in Korean Unresectable Hepatocellular Carcinoma (uHCC) Participants	Active, not recruiting	No Results Available	Liver Neoplasms|Carcinoma, Hepatocellular	Other: Non-interventional	Site #32, Cheonan, Chungcheongnam-do, Korea, Republic of|Site #35, Bucheon, Gyeonggi-do, Korea, Republic of|Site #38, Bucheon, Gyeonggi-do, Korea, Republic of|Site #06, Goyang, Gyeonggi-do, Korea, Republic of|Site #03, Seongnam, Gyeonggi-do, Korea, Republic of|Site #13, Suwon, Gyeonggi-do, Korea, Republic of|Site #27, Suwon, Gyeonggi-do, Korea, Republic of|Site #15, Uijeongbu, Gyeonggi-do, Korea, Republic of|Site #37, Changwon, Gyeongsangnam-do, Korea, Republic of|Site #28, Yangsan, Gyeongsangnam-do, Korea, Republic of|Site #29, Yangsan, Gyeongsangnam-do, Korea, Republic of|Site #31, Busan, Korea, Republic of|Site #39, Busan, Korea, Republic of|Site #40, Busan, Korea, Republic of|Site #17, Daegu, Korea, Republic of|Site #18, Daegu, Korea, Republic of|Site #26, Daegu, Korea, Republic of|Site #30, Daegu, Korea, Republic of|Site #41, Daegu, Korea, Republic of|Site #19, Daejeon, Korea, Republic of|Site #20, Daejeon, Korea, Republic of|Site #24, Daejeon, Korea, Republic of|Site #34, Daejeon, Korea, Republic of|Site #21, Incheon, Korea, Republic of|Site #33, Incheon, Korea, Republic of|Site #36, Incheon, Korea, Republic of|Site #01, Seoul, Korea, Republic of|Site #02, Seoul, Korea, Republic of|Site #04, Seoul, Korea, Republic of|Site #07, Seoul, Korea, Republic of|Site #08, Seoul, Korea, Republic of|Site #09, Seoul, Korea, Republic of|Site #10, Seoul, Korea, Republic of|Site #12, Seoul, Korea, Republic of|Site #16, Seoul, Korea, Republic of|Site #22, Seoul, Korea, Republic of|Site #23, Seoul, Korea, Republic of|Site #25, Seoul, Korea, Republic of|Site #42, Seoul, Korea, Republic of|Site #43, Seoul, Korea, Republic of|Site #44, Seoul, Korea, Republic of|Site #11, Ulsan, Korea, Republic of	https://ClinicalTrials.gov/show/NCT05225207
272	Expansion of Conventional Criteria for Liver Transplantation in Hepatocellular Carcinoma Through Downstaging	Completed	No Results Available	Carcinoma, Hepatocellular|Cirrhosis	Procedure: Liver transplantation	Ospedali Riuniti di Bergamo, Bergamo, Italy|Ospedale Maggiore di Milano Policlinico, Milano, Italy|Istituto Nazionale Tumori, Milano, Italy|Azienda Ospedaliera Ospedale Niguarda Ca' Granda, Milano, Italy|Azienda Ospedaliera Universitaria di Padova, Padova, Italy|Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione (ISMETT), Palermo, Italy|Policlinico Tor Vergata, Roma, Italy|Ospedale "Lazzaro Spallanzani", Roma, Italy|Ospedale Umberto Iº Policlinico di Roma, Roma, Italy|Ospedale Universitario Molinette S. Giovanni Battista di Torino, Torino, Italy	https://ClinicalTrials.gov/show/NCT01387503
273	Modeling Cancer-specific Prognosis in Liver Transplantation for Hepatocellular Carcinoma (HCC)	Completed	No Results Available	HCC|Liver Transplantation|Alphafetoprotein|Mortality|Competing Risk|Selection Criteria|Cancer Recurrence	Procedure: Liver transplantation		https://ClinicalTrials.gov/show/NCT02898415
274	Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot be Removed by Surgery	Recruiting	No Results Available	Adult Primary Hepatocellular Carcinoma|Advanced Adult Primary Liver Cancer|Localized Unresectable Adult Primary Liver Cancer|Recurrent Adult Primary Liver Cancer	Radiation: yttrium Y 90 glass microspheres|Other: laboratory biomarker analysis	Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States	https://ClinicalTrials.gov/show/NCT02072356
275	Combination of TATE and PD-1 Inhibitor in Liver Cancer	Recruiting	No Results Available	Hepatocellular Carcinoma|Gastric Cancer	Drug: Nivolumab Injectable Product|Combination Product: Trans-arterial tirapazamine embolization	University of California, Irvine, Orange, California, United States	https://ClinicalTrials.gov/show/NCT03259867
276	Trial of Sorafenib in Hepatocellular Cancer (HCC) Transplant Patients	Completed	No Results Available	Hepatocellular Cancer	Drug: Sorafenib	University of Southern California, Los Angeles, California, United States|University of California, Los Angeles, Los Angeles, California, United States|Columbia University Medical Center, New York, New York, United States	https://ClinicalTrials.gov/show/NCT00997022
277	A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver	Completed	Has Results	Hepatocellular Carcinoma	Biological: IMC-A12 (cixutumumab) - 10 milligrams/kilogram (mg/kg)|Biological: IMC-A12 (cixutumumab) - 20 mg/kg|Drug: Sorafenib	ImClone Investigational Site, Scottsdale, Arizona, United States|ImClone Investigational Site, Los Angeles, California, United States|ImClone Investigational Site, Chicago, Illinois, United States|ImClone Investigational Site, Metairie, Louisiana, United States|ImClone Investigational Site, Burlington, Massachusetts, United States|ImClone Investigational Site, New York, New York, United States|ImClone Investigational Site, Philadelphia, Pennsylvania, United States	https://ClinicalTrials.gov/show/NCT00906373
278	A Treatment of Unresectable Hepatocellular Carcinoma With TheraSphere®	Completed	No Results Available	Liver Tumors|Hepatocellular Carcinoma|Hepatoma|Neoplasms	Device: TheraSphere®	The Center for Cancer Prevention & Treatment at St. Joseph Hospital of Orange, Orange, California, United States	https://ClinicalTrials.gov/show/NCT00877136
279	Radiation Therapy in Treating Patients With Hepatocellular Carcinoma, Cholangiocarcinoma, or Liver Metastasis Who Have Impaired Liver Function	Recruiting	No Results Available	Cholangiocarcinoma|Cirrhosis|Hepatocellular Carcinoma|Metastatic Malignant Neoplasm in the Liver	Other: Laboratory Biomarker Analysis|Procedure: Magnetic Resonance Imaging|Radiation: Radiation Therapy|Other: Survey Administration	M D Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT02626312
280	Celebrex and Metformin for Postoperative Hepatocellular Carcinoma	Unknown status	No Results Available	Liver Cancer	Drug: Celebrex plus Metformin|Drug: Celebrex|Drug: Metformin	Affiliated Tumor Hospital of Guangxi Medical University, Nanjing, Guangxi, China	https://ClinicalTrials.gov/show/NCT03184493
281	CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer	Completed	Has Results	Advanced Hepatocellular Carcinoma|Liver Cancer|Hepatic Cancer|Liver Neoplasms	Drug: CS-1008 2 mg/kg|Drug: Sorafenib|Drug: CS-1008 6/2 mg/kg|Drug: CS-1008 6/6 mg/kg|Drug: CS-1008 4 mg/kg|Drug: CS-1008 6 mg/kg	Kenmar Research Group, Los Angeles, California, United States|Georgetown-Lombardi Cancer Center, Washington, District of Columbia, United States|The Mount Sinai Medical Center, New York, New York, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Kurume University Hospital, Kurume-shi, Fukuoka, Japan|Hiroshima University, Hiroshima-city, Hiroshima, Japan|Kanazawa University, Kanazawa, Ishikawa, Japan|Kinki University Hospital, Osaka, Osaka-sayama, Japan|Yamaguchi University Hospital, Ube, Yamaguchi, Japan|Chiba University Hospital, Chiba, Japan|Okayama University Hospital, Okayama, Japan|Osaka Med Center Cancer and Cardiovascular Disease, Osaka, Japan|Musashino Red-Cross Hospital, Tokyo, Japan|Keimyung University Dongsan Hospital, Daegu, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Catholic Univ. of Korea, Seoul St. Mary's Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Kaohiung Chang Gung Hospital, Kaohsiung, Niaosung Hsiang, Taiwan|Changhua Christian Hospital, Changhua, Taiwan|Chang Gung Memorial Hospital, Chiayi City, Taiwan|Kaohslung Medical University Hospital, Kaohsiung, Taiwan|National Cheng-Kung University Hospital, Tainan city, Taiwan|Chi-Mei Medical Center, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Chang Gung Medical Foundation-Linkuo, Taoyuan, Taiwan	https://ClinicalTrials.gov/show/NCT01033240
282	Comparison of Response and Recurrence Rates Following Percutaneous Microwave Coagulation Therapy Versus Percutaneous Radiofrequency Ablation	Unknown status	No Results Available	Thermoablation|Chronic Liver Disease|Hepatocellular Carcinoma	Other: Percutaneous Radiofrequency Ablation|Other: Percutaneous Microwave Ablation	CHU Dijon Bourgogne, Dijon, France	https://ClinicalTrials.gov/show/NCT02859753
283	Tumor Ablation With Talaporfin Sodium and Interstitial Light Emitting Diodes Treating Hepatocellular Carcinoma (HCC)	Completed	No Results Available	Carcinoma, Hepatocellular|Liver Neoplasms	Procedure: Photodynamic therapy|Drug: Talaporfin Sodium	Queen Mary Hospital, Hong Kong, Hong Kong|National Cancer Centre Singapore, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|Kaohsiung Chang Gung Memorial Hospital, Kaohsiung Hsien, Taiwan|Kaohsiung Medical University Hospital, Kaohsiung, Taiwan|Mackay Memorial Hospital, Taipei, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital - Linkou, Taoyuan Hsien, Taiwan	https://ClinicalTrials.gov/show/NCT00122876
284	Clinical Study of Antiviral and Aspirin Treatment in Liver Cancer After Radical Surgery	Recruiting	No Results Available	Hepatocellular Carcinoma|Recurrence	Drug: Aspirin|Drug: Lamivudine	Liver Cancer Institute, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT01936233
285	Case-Control Study of the Glycotest™ HCC Panel vs AFP for the Detection of Early-stage Hepatocellular Carcinoma	Recruiting	No Results Available	Carcinoma, Hepatocellular|Cirrhosis, Liver		Cedars- Sinai Medical Center, Los Angeles, California, United States|University of California Los Angeles, Los Angeles, California, United States|Kaiser Permanente Northern California, San Francisco, California, United States|University of California- San Francisco, San Francisco, California, United States|Stanford University School of Medicine, Stanford, California, United States|University of Florida, Gainesville, Florida, United States|Miami VA Healthcare System, Miami, Florida, United States|Northwestern University, Chicago, Illinois, United States|University of Maryland, Baltimore, Baltimore, Maryland, United States|University of Michigan, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Montefiore Medical Center, Bronx, New York, United States|NYU Langone Health, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Hospital of the University of Pennsylvania (HUP), Philadelphia, Pennsylvania, United States|Baylor Scott & White Research Institute, Dallas, Texas, United States|The University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Hebrew University- Hadassah Medical Center, Jerusalem, Israel	https://ClinicalTrials.gov/show/NCT03878550
286	Low Contrast Agent and Radiation Dose Protocol for Liver CT in Patients With HCC	Completed	No Results Available	Hepatocellular Carcinoma	Radiation: Low radiation dose CT|Radiation: Conventional CT (radiation)|Drug: Low contrast dose CT|Drug: Conventional CT (contrast agent)|Other: Deep-learning based contrast boosting algorithms	Seoul National University Hospital, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT04722120
287	Sorafenib and Vorinostat in Treating Patients With Advanced Liver Cancer	Completed	No Results Available	Liver Cancer	Drug: sorafenib tosylate|Drug: vorinostat	Hunter Holmes McGuire VA Medical Center, Richmond, Virginia, United States|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States	https://ClinicalTrials.gov/show/NCT01075113
288	Trans-arterial Chemoembolization in Patients With Hepatocellular Carcinoma: A Study of Different Outcomes and Their Predictive Factors	Recruiting	No Results Available	Liver Cancer	Procedure: TACE	Assiut, Assiut, Egypt	https://ClinicalTrials.gov/show/NCT04739501
289	Detection Evaluation of a Novel Blood-based DNA Methylation Assay in Early-stage Hepatocellular Carcinoma Patients	Enrolling by invitation	No Results Available	Liver Cancer		Beijing Youan Hospital,Capital Medical University Beijing Institute of Hepatology, Beijing, China|Xiangya Hospital of Central South University, Changsha, China|West China School of Medicine/West China Hospital of Sichuan University, Chengdu, China|Guangzhou eighth People's Hospital ,Guangzhou Medilcal University, Guangzhou, China|The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China|Nantong Tumor Hospital, Nantong, China|Ruijin Hospital, Shanghai Jiaotong University School, Shanghai, China|Wuxi No.5 People's Hospital, Wuxi, China|The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China	https://ClinicalTrials.gov/show/NCT05343832
290	Clinical Trial Comparing TACE With TACE + SABR in Stage BCLC B HCC (HepSTAR)	Terminated	No Results Available	Liver Neoplasms|Hepatocellular Cancer	Procedure: Trans-arterial Chemo-Embolization|Drug: Doxorubicin|Radiation: Stereotactic Ablative Radiotherapy	Hôpital de JOLIMONT, Jolimont, Hainaut, Belgium|Centre Hospitalier Universitaire/CHC Saint Joseph, Liege, Liège, Belgium|Cliniques Universitaires Saint Luc, Brussels, Woluwé Saint Lambert, Belgium|Institut Jules Bordet/Hôpital Erasme, Brussels, Belgium|Clinique et Maternité Sainte Elisabeth/CHU Mont Godinne, Namur, Belgium	https://ClinicalTrials.gov/show/NCT02958163
291	Contrast-Enhanced Ultrasound for the Evaluation of Changes in Tumor Blood Flow Surrounding HAE	Recruiting	No Results Available	Hepatocellular Carcinoma|Liver Cancer	Diagnostic Test: Lumason®	Moffitt Cancer Center, Tampa, Florida, United States	https://ClinicalTrials.gov/show/NCT04150874
292	Palliative Radiotherapy (RT) for Liver Metastases (Mets) and Hepatocellular Carcinoma (HCC)(COLD 4)	Completed	No Results Available	Hepatocellular Carcinoma|Hepatic Metastasis	Radiation: Palliative RT	University Health Network, Princess Margaret Hospital, Toronto, Ontario, Canada	https://ClinicalTrials.gov/show/NCT00923897
293	Cisplatin or Carboplatin and Sorafenib in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery	Completed	Has Results	Liver Cancer	Drug: Carboplatin|Drug: Cisplatin|Drug: Sorafenib	University of Miami Sylvester Comprehensive Cancer Center - Miami, Miami, Florida, United States	https://ClinicalTrials.gov/show/NCT00875615
294	Radiofrequency Ablation Using Octopus Electrodes for Treatment of Focal Liver Malignancies: Follow-up Study	Completed	No Results Available	Hepatocellular Carcinoma	Device: Separable clustered electrodes	Seoul National University Hospital, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT02745483
295	A Worldwide Score for Hepatocellular Cancer and Liver Transplantation	Completed	No Results Available	Liver Cancer|Dropout, Patient|Recurrence	Procedure: Liver transplantation	UCL, Brussels, Belgium	https://ClinicalTrials.gov/show/NCT03595345
296	Safety and Tolerability of I.V. Infusion of MB07133 in Patients With Unresectable Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Drug: MB07133 300mg/m2/day|Drug: MB07133 600 mg/m2/day|Drug: MB07133 1200 mg/m2/day|Drug: MB07133 1800 mg/m2/day|Drug: MB07133 2400 mg/m2/day	University of California at Irvine, Orange, California, United States|Prince of Wales Hospital - Comprehensive Cancer Trial Unit, Shatin, New Territories, Hong Kong|Tri-Services General Hospital, Taipei, Nei Hu District, Taiwan|Chang-Gung Memorial Hospital, Taipei, Taoyuan County, Taiwan	https://ClinicalTrials.gov/show/NCT00073736
297	Clinical Application of Image-Guided Liver Surgery	Terminated	Has Results	Hepatocellular Cancer	Device: Explorer Liver Image Guided System|Device: Explorer Liver Passive Tracking|Procedure: Liver surgery|Procedure: Liver abalation	Washington University School of Medicine, Saint Louis, Missouri, United States	https://ClinicalTrials.gov/show/NCT00878215
298	Single Session Combined Locoregional Therapies for Hepatocellular Carcinoma	Recruiting	No Results Available	Liver Cancer	Drug: Transarterial chemoembolization (TACE)|Procedure: Radiofrequency ablation combined with TACE|Procedure: Microwave ablation combined with TACE	Tanta university hospital, Tanta, Egypt	https://ClinicalTrials.gov/show/NCT02646137
299	Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery	Active, not recruiting	No Results Available	Liver Cancer	Radiation: yttrium Y 90 glass microspheres	Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States	https://ClinicalTrials.gov/show/NCT00530010
300	Evaluation of Gd-EOB-DTPA MRI for Detection and Characterization of Liver Nodules in Cirrhotic Patients Undergoing Liver Transplantation and Potential Impact on Transplant Eligibility	Recruiting	No Results Available	Hepatocellular Carcinoma	Diagnostic Test: Primovist MRI	University Health Network, Toronto, Ontario, Canada	https://ClinicalTrials.gov/show/NCT03342677
301	Application of 3D Printing in Laparoscopic Surgery of Liver Tumors	Recruiting	No Results Available	Liver Cancer|Hepatocellular Carcinoma|Liver Metastases	Procedure: Laparoscopic liver resection|Device: 3D printing model	2nd Department of General Surgery Jagiellonian Univeristy Medical College, Kraków, Małopolskie, Poland	https://ClinicalTrials.gov/show/NCT03744624
302	A Protocol of the Canadian Prospective Study for Hepatocellular Carcinoma Surveillance Using Biomarkers	Unknown status	No Results Available	Cirrhosis|Chronic Liver Diseases		Toronto General Hospital, Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada	https://ClinicalTrials.gov/show/NCT02272504
303	Anatomical Right Posterior Sectionectomy of the Liver by IOUS-Guided Finger Compression	Unknown status	No Results Available	Colorectal Liver Metastases|Hepatocellular Carcinoma|Liver Malignancies	Procedure: Anatomical right posterior sectionectomy of the liver by IOUS-guided finger compression.	University of Milan School of Medicine, IRCCS Istituto Clinico Humanitas, Rozzano, Milan, Italy	https://ClinicalTrials.gov/show/NCT00797251
304	A Phase II Study of Intra-arterial Chemotherapy With Cisplatin and Mitomycin-C in Patients With Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma|Liver Cancer	Drug: mitomycin-c, cisplatin	U.S.C. / Norris Comprehensive Cancer Center, Los Angeles, California, United States	https://ClinicalTrials.gov/show/NCT00183885
305	Identification of New Serum Diagnostic Markers of Hepatocellular Carcinoma	Recruiting	No Results Available	Liver Cancer		Stanford University School of Medicine, Stanford, California, United States	https://ClinicalTrials.gov/show/NCT00373347
306	Tamoxifen in Treating Patients With Primary Liver Cancer	Completed	No Results Available	Liver Cancer	Drug: tamoxifen citrate	Prince of Wales Hospital, Shatin, New Territories, Hong Kong|University of Udayana, Sanglah, Denpasar, Bali, Indonesia|Universiti Kebangsaan Malaysia, Bangi, Malaysia|Wellington Cancer Centre, Wellington, New Zealand|National Cancer Institute - Karachi, Karachi, Pakistan|Nishtar Medical College, Multan, Multan, Pakistan|Tan Tock Seng Hospital, Singapore, Singapore|National Cancer Centre - Singapore, Singapore, Singapore	https://ClinicalTrials.gov/show/NCT00003424
307	Sorafenib Tosylate and Chemoembolization With Doxorubicin Hydrochloride and Mitomycin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery	Completed	No Results Available	Liver Cancer	Drug: doxorubicin hydrochloride|Drug: mitomycin C|Drug: sorafenib tosylate|Other: laboratory biomarker analysis|Other: pharmacological study	Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States|Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States	https://ClinicalTrials.gov/show/NCT01011010
308	NeuWave HCC China Study	Active, not recruiting	No Results Available	Liver Tumor|Hepatocellular Carcinoma	Device: Microwave ablation	Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China|The First Affiliated Hospital，Sun Yat-sen University, Guangzhou, Guangdong, China|Chinese PLA General Hospital, Beijing, China|Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China	https://ClinicalTrials.gov/show/NCT03783871
309	Radiofrequency Versus Laser Ablation for Hepatocellular Carcinoma	Completed	No Results Available	Carcinoma, Hepatocellular|Neoplasms, Liver	Procedure: percutaneous radiofrequency ablation|Procedure: percutaneous laser ablation	Liver Unit - Cardarelli Hospital, Naples, Italy	https://ClinicalTrials.gov/show/NCT01096914
310	Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC	Recruiting	No Results Available	Hepatocellular Carcinoma|Hepatocellular Cancer|Colorectal Cancer|Colorectal Carcinoma|Liver Metastases	Biological: Neoantigen Dendritic Cell Vaccine|Drug: Nivolumab	National Cancer Center Singapore, Singapore, Singapore	https://ClinicalTrials.gov/show/NCT04912765
311	Radiolabeled Glass Beads (TheraSphere®) in Treating Patients With Primary Liver Cancer That Cannot Be Removed by Surgery	Withdrawn	No Results Available	Liver Cancer	Radiation: yttrium Y 90 glass microspheres	UPMC Liver Cancer Center, Pittsburgh, Pennsylvania, United States	https://ClinicalTrials.gov/show/NCT00039078
312	Celecoxib and Erlotinib in Treating Patients With Liver Cancer	Withdrawn	No Results Available	Liver Cancer	Drug: celecoxib|Drug: erlotinib hydrochloride|Procedure: adjuvant therapy	UCSF Comprehensive Cancer Center, San Francisco, California, United States	https://ClinicalTrials.gov/show/NCT00293436
313	Immunotherapy for Advanced Liver Cancer	Not yet recruiting	No Results Available	Hepatocellular Carcinoma	Biological: AlloStim® immunotherapy|Drug: FOLFOX regimen|Other: Best Supportive Care	Hospital Pulau Pinang, Pulau Pinang, George Town, Malaysia|Sultan Ismail Hospital, Johor Bahru, Johor, Malaysia|Sultanah Bahiyah Hospital, Alor Setar, Kedah, Malaysia|Nilai Medical Center, Bandar Permaisuri, Negeri Sembilan, Malaysia|Siriraj Hospital, Bangkok Noi, Bangkok, Thailand|Ramathibodi Hospital, Ratchathewi, Bangkok, Thailand|Prince of Songkla University (Songklanagarind Hospital), Hat Yai, Songkhla, Thailand|Naresuan University Hospital, Phitsanulok, Tha Pho, Thailand	https://ClinicalTrials.gov/show/NCT05033522
314	Chemoembolization of the Liver With or Without Sunitinib Malate in Treating Patients With Liver Cancer	Completed	Has Results	Liver Cancer	Drug: sunitinib malate|Drug: Placebo|Procedure: transarterial chemoembolization	CHU Nord, Amiens, France|CHR, Annecy, France|Institut Sainte Catherine, Avignon, France|CHU J Minjoz, Besancon, France|Institut Bergonié, Bordeaux, France|CH, Béziers, France|CHU Côte de Nacre, Caen, France|CHU, Clermont Ferrand, France|Clinique des Cèdres, Cornebarrieu, France|CHU Bocage, Dijon, France|CH, Guilherand Granges, France|Hôpital Claude Huriez, Lille, France|Hopital Dupuytren, Limoges, France|CHBS, Lorient, France|Hôpital Privé Jean Mermoz, Lyon, France|CH Ambroise Paré, Marseille, France|CH Conception, Marseille, France|CHU La Timone, Marseille, France|Hôpital Saint Joseph, Marseille, France|CHRU Saint Eloi, Montpellier, France|CHU -Hôpital de l'Archet II, Nice, France|CHR, Orléans, France|Hopital Tenon, Paris, France|Groupe Hospitalier Paris St Joseph, Paris, France|Hôpital Européen Georges Pompidou, Paris, France|CHU Jean Bernard, Poitiers, France|CHU Robert Debré, Reims, France|CAC, Rennes, France|CHU, Rouen, France|CHU, Tours, France|Institut Gustave Roussy, Villejuif, France	https://ClinicalTrials.gov/show/NCT01164202
315	A Randomized Double-blind, Placebo-controlled Japanese Phase III Trial of ARQ 197 in Hepatocellular Carcinoma (HCC)	Completed	No Results Available	Liver Cancer	Drug: ARQ197|Drug: Placebo	Cancer Centers in Japan, Tokyo, Japan	https://ClinicalTrials.gov/show/NCT02029157
316	The Regression of Liver Fibrosis and Risk for Hepatocellular Carcinoma (ROLFH) Study	Withdrawn	No Results Available	Chronic Hepatitis C|Chronic Hepatitis B	Other: Regression of fibrosis|Other: Specific risk factors related to hepatocellular carcinoma	University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|University of Calgary, Calgary, Alberta, Canada|University of Toronto, Toronto, Ontario, Canada	https://ClinicalTrials.gov/show/NCT01831037
317	A Humanitarian Device Exemption Treatment Protocol of TheraSphere For Treatment of Unresectable Hepatocellular Carcinoma	Approved for marketing	No Results Available	Liver Cancer	Device: Therasphere	Stanford University School of Medicine, Stanford, California, United States	https://ClinicalTrials.gov/show/NCT01076517
318	Lenalidomide for Advanced Hepatocellular Cancer:A Phase II Trial	Completed	Has Results	Liver Cancer	Drug: lenalidomide	Montefiore Medical Center, Bronx, New York, United States|Memorial Hospital of Rhode island, Pawtucket, Rhode Island, United States|Lifespan Hospitals, Providence, Rhode Island, United States	https://ClinicalTrials.gov/show/NCT00717756
319	Hepatocellular Cancer (HCC) Screening in Zhongshan City	Active, not recruiting	No Results Available	Liver Neoplasms	Biological: Biomarker testing and Ultrasonography	Zhongshan People's Hospital, Zhongshan, Guangdong, China	https://ClinicalTrials.gov/show/NCT02501980
320	Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer	Completed	Has Results	Liver Cancer	Biological: bevacizumab|Drug: erlotinib hydrochloride|Drug: sorafenib tosylate	USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States|California Pacific Medical Center, San Francisco, California, United States|Columbia University/ New York Presbyterian Hospital, New York, New York, United States|Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina, United States|Tennessee Oncology, PLLCat Sarah Cannon Cancer Center, Nashville, Tennessee, United States|UVA Cancer Center, Charlottesville, Virginia, United States	https://ClinicalTrials.gov/show/NCT00881751
321	Transarterial Chemoembolization With Doxorubicin With or Without Everolimus in Treating Patients With Liver Cancer	Terminated	No Results Available	Liver Cancer	Drug: doxorubicin-eluting beads|Drug: everolimus|Other: placebo	Inselspital Bern, Bern, Switzerland|Kantonsspital Graubuenden, Chur, Switzerland|Hopital Cantonal Universitaire de Geneve, Geneva, Switzerland|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland|Clinica Luganese di Moncucco, Lugano, Switzerland|Institut Central des Hopitaux Valaisans / Hôpital de Sion, Sion, Switzerland|Kantonsspital - St. Gallen, St. Gallen, Switzerland|UniversitaetsSpital Zuerich, Zurich, Switzerland	https://ClinicalTrials.gov/show/NCT01009801
322	T900607 in Treating Patients With Unresectable Liver Cancer	Completed	No Results Available	Liver Cancer	Drug: T900607	Ireland Cancer Center, Cleveland, Ohio, United States	https://ClinicalTrials.gov/show/NCT00054262
323	A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular Cancer	Terminated	Has Results	Liver Cancer	Drug: Sorafenib and OSI-906	Emory University Winship Cancer Institute, Atlanta, Georgia, United States|University of Michigan, Ann Arbor, Michigan, United States|Ohio State University, Columbus, Ohio, United States	https://ClinicalTrials.gov/show/NCT01334710
324	The Methylation Phenotype Screening and Determination Mode Study of Liver Cancer Prognosis Related Gene	Completed	No Results Available	Hepatocellular Carcinoma;|Radical Hepatic Resection;		Eastern Hepatobiliary Surgery Hospital, Shanghai, Shanghai, China|Eastern hepatobilliary surgery hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT01786980
325	Chemoembolization and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed With Surgery	Completed	Has Results	Liver Cancer	Biological: bevacizumab	Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States	https://ClinicalTrials.gov/show/NCT00049322
326	Megestrol in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery	Completed	No Results Available	Liver Cancer	Drug: megestrol acetate	Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh|Rumah Sakit Sanglah, Denpasar, Bali, Indonesia|St. Vincent Hospital, Suwon, Korea, Republic of|Yangon General Hospital, Yangon, Myanmar|Auckland City Hospital, Auckland, New Zealand|Davao Doctors Hospital, Davao City, Philippines|National Cancer Centre - Singapore, Singapore, Singapore|Changi General Hospital, Singapore, Singapore|Chang-Gung Memorial Hospital - Taipei, Taipei, Taiwan|Ramathibodi Hospital, Bangkok, Thailand|National Cancer Institute, Ha Noi, Vietnam|Cho Ray Hospital, Ho Chi Minh City, Vietnam	https://ClinicalTrials.gov/show/NCT00041275
327	Risk Factors and Molecular Genomics of U.S. Patients With Chronic Liver Disease and Hepatocellular Cancer	Completed	No Results Available	Carcinoma, Hepatocellular		Stanford University School of Medicine, Stanford, California, United States	https://ClinicalTrials.gov/show/NCT01034865
328	Adjuvant Therapy of Gefitinib (Iressa, ZD1839) in Patients With Resectable Hepatocellular Carcinoma	Unknown status	No Results Available	Liver Cancer	Drug: Gefetinib (Iressa)	Tan Tock Seng Hospital, Singapore, Singapore	https://ClinicalTrials.gov/show/NCT00282100
329	Therasphere for Unresectable Primary or Secondary Liver Neoplasia	No longer available	No Results Available	Liver Cancer|Liver Neoplasms|HepatoCellular Carcinoma	Device: TheraSphere Treatment	H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States	https://ClinicalTrials.gov/show/NCT02960620
330	Transient Elastography in Hepatectomy for Hepatocellular Carcinoma	Unknown status	No Results Available	Surgery|Hepatocellular Carcinoma	Procedure: FibroScan (Transient Elastography measurement)	General Surgery and Organ Transplantation Unit, Policlinico Sant'Orsola-Malpighi, Bologna, Italy	https://ClinicalTrials.gov/show/NCT01441453
331	Preoperative Oral Supplementation With Branched-Chain Amino Acids (BCAA) Improves Postoperative Quality of Life	Completed	No Results Available	Hepatocellular Carcinoma|Chronic Liver Disease	Drug: Aminoleban EN	Kochi Medical School, Nankoku, Kochi, Japan|Kochi Medical School, Kochi University, Nankoku-City, Kohasu-Okocho, Japan	https://ClinicalTrials.gov/show/NCT00945568
332	Risk Stratification of Hepatocarcinogenesis Using a Deep Learning Based Clinical, Biological and Ultrasound Model in High-risk Patients	Recruiting	No Results Available	Hepatocellular Carcinoma|Chronic Liver Disease	Other: Video acquisition	CHU Angers, Angers, France|Hôpital Avicenne, Bobigny, France|Hôpital Beaujon, Clichy, France|Hospices Civils de Lyon, Hôpital Edouard Herriot, Lyon, France|Groupement Hospitalier Nord, Hôpital de la Croix-Rousse, Lyon, France|CHU Montpellier, Montpellier, France|IHU Strasbourg, Strasbourg, France	https://ClinicalTrials.gov/show/NCT04802954
333	Doxorubicin and Interleukin-2 in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery	Completed	No Results Available	Liver Cancer	Biological: aldesleukin|Drug: doxorubicin hydrochloride	Roswell Park Cancer Institute, Buffalo, New York, United States	https://ClinicalTrials.gov/show/NCT00004248
334	Radiofrequency Ablation With Gradual RF Energy Increment for HCC Treatment	Recruiting	No Results Available	Hepatocellular Carcinoma|Liver Cirrhosis|Chronic Liver Disease	Procedure: Radiofrequency ablation using gradual RF energy delivery with Octopus electrodes	Seoul National University Hospital, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT05397860
335	Radiation Therapy in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery	Completed	No Results Available	Liver Cancer	Radiation: 3-dimensional conformal radiation therapy|Radiation: intensity-modulated radiation therapy|Radiation: stereotactic body radiation therapy	Maastro Lab at University of Maastricht, Maastricht, Netherlands|Kantonsspital Aarau, Aarau, Switzerland|Universitaetsspital-Basel, Basel, Switzerland|Istituto Oncologico della Svizzera Italiana - Ospedale San Giovanni, Bellinzona, Switzerland|Inselspital Bern, Bern, Switzerland|Kantonsspital - St. Gallen, St. Gallen, Switzerland	https://ClinicalTrials.gov/show/NCT00777894
336	Stratification of Patients With Chronic Liver Disease Using Multi Spectral CT	Completed	No Results Available	Chronic Liver Disease|HepatoCellular Carcinoma|Liver Fibrosis	Device: Multispectral CT of the liver	Massachusetts General Hospital,, Boston, Massachusetts, United States	https://ClinicalTrials.gov/show/NCT01825213
337	Prognosis Analysis of Elderly Donor Liver in Liver Transplantation	Completed	No Results Available	Liver Transplantation|Hepatocellular Carcinoma|Survival	Other: Age		https://ClinicalTrials.gov/show/NCT05355662
338	Trial of Thalidomide, a- Interferon +/- Octreotide in Patients With Unresectable Hepatocellular Carcinoma	Completed	No Results Available	Liver|Cancer	Drug: Thalidomide, alpha interferon|Drug: Thalidomide, interferon, Octreotide	University of New Mexico, Albuquerque, New Mexico, United States|New Mexico Cancer Care Associates, Santa Fe, New Mexico, United States	https://ClinicalTrials.gov/show/NCT00250796
339	Sorafenib Tosylate in Treating Patients With Liver Cancer Who Have Undergone a Liver Transplant	Completed	No Results Available	Adult Primary Hepatocellular Carcinoma|Advanced Adult Primary Liver Cancer|Localized Resectable Adult Primary Liver Cancer|Localized Unresectable Adult Primary Liver Cancer|Recurrent Adult Primary Liver Cancer	Drug: sorafenib tosylate|Other: laboratory biomarker analysis	Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States	https://ClinicalTrials.gov/show/NCT00844168
340	Taiwan ACE Beads for Hepatoma Embolization Therapy	Completed	Has Results	Cancer of Liver	Device: Taiwan ACE Beads	National Cheng Kung University Hospital, Tainan, Taiwan	https://ClinicalTrials.gov/show/NCT02825550
341	Temsirolimus in Treating Patients With Advanced Liver Cancer and Cirrhosis	Terminated	No Results Available	Liver Cancer	Drug: temsirolimus	Centre Hospitalier Universitaire Henri Mondor, Creteil, France	https://ClinicalTrials.gov/show/NCT01079767
342	Study of GNS561 in Patients With Liver Cancer	Terminated	No Results Available	Hepatocellular Carcinoma|Cholangiocarcinoma, Intrahepatic	Drug: GNS561	Memorial Sloan Kettering, New York, New York, United States|Jules Bordet Institute, Brussel, Belgium|CHU Grenoble, Grenoble, France|Croix-Rousse Hospital, Lyon, France|Saint-Joseph Hospital, Paris, France	https://ClinicalTrials.gov/show/NCT03316222
343	HCCBloodTest for Detection of Hepatocellular Carcinoma (HCC)	Completed	No Results Available	Cirrhosis, Liver|Hepatic Cirrhosis|Hepatocellular Carcinoma|Liver Cancer		USC Keck Medical Center, Los Angeles, California, United States|California Liver Research Institute, Pasadena, California, United States	https://ClinicalTrials.gov/show/NCT03804593
344	IMC-A12 in Treating Patients With Advanced Liver Cancer	Completed	Has Results	Adult Primary Hepatocellular Carcinoma|Advanced Adult Primary Liver Cancer|Localized Unresectable Adult Primary Liver Cancer|Recurrent Adult Primary Liver Cancer	Biological: cixutumumab|Procedure: computed tomography|Procedure: contrast-enhanced magnetic resonance imaging	Memorial Sloan-Kettering Cancer Center, New York, New York, United States	https://ClinicalTrials.gov/show/NCT00639509
345	AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer	Terminated	Has Results	Adult Primary Hepatocellular Carcinoma|Advanced Adult Primary Liver Cancer|Localized Unresectable Adult Primary Liver Cancer|Recurrent Adult Primary Liver Cancer	Drug: cediranib maleate|Other: laboratory biomarker analysis|Procedure: computed tomography|Procedure: dynamic contrast-enhanced magnetic resonance imaging|Other: pharmacological study	Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States	https://ClinicalTrials.gov/show/NCT00427973
346	Stereotactic Body Radiation Therapy in Liver Cancer That Cannot be Removed by Surgery or Transplant	Withdrawn	No Results Available	Adult Primary Hepatocellular Carcinoma|Advanced Adult Primary Liver Cancer|Localized Unresectable Adult Primary Liver Cancer|Recurrent Adult Primary Liver Cancer	Radiation: stereotactic body radiation therapy		https://ClinicalTrials.gov/show/NCT01194206
347	ABT-888 and Temozolomide for Liver Cancer	Terminated	Has Results	Hepatocellular Carcinoma	Drug: Temozolomide|Drug: ABT-888	Lombardi Comprehensive Cancer Center at Georgetown University Medical Center, Washington, District of Columbia, United States	https://ClinicalTrials.gov/show/NCT01205828
348	Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer	Completed	Has Results	Adult Primary Hepatocellular Carcinoma|Advanced Adult Primary Liver Cancer|Localized Unresectable Adult Primary Liver Cancer|Recurrent Adult Primary Liver Cancer	Drug: selumetinib|Other: pharmacological study	H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States|Vanderbilt University, Nashville, Tennessee, United States|Virginia Commonwealth University, Richmond, Virginia, United States	https://ClinicalTrials.gov/show/NCT00604721
349	Hepatocarcinoma Recurrence on the Liver Study - Part2	Not yet recruiting	No Results Available	Liver Cancer|Surgery|Recurrence Tumor|Cirrhosis	Other: liver resection	Chirurgia Rubino - Policlinico di Bari, Bari, Italy|Ospedale Maggiore- AUSL, Bologna, Italy|Chirurgia Generale Bolzano, Bolzano, Italy|Fondazione Poliambulanza - Istituto Ospedaliero, Brescia, Italy|Spedali Civili, Brescia, Italy|Chirurgia Generale Ospedale Pierantoni - Morgagni, Forlì, Italy|Ospedale A. Manzoni - ASST Lecco, Lecco, Italy|ASST-Mantova, Mantova, Italy|Asst-Fbf-Sacco Polo Universitario H. Sacco Chirurgia 2, Milan, Italy|IRCCS Osp. San Raffaele, Divisione Chirurgia Generale Epatobiliare, Milan, Italy|Policlinico di Monza, Monza, Italy|UOS Chirurgia Oncologica ad inidirzzo epato-bilio-pancreatico, Parma, Italy|Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy|Irccs Istituto Nazionale Tumori Regina Elena, Rome, Italy|Humanitas Research Hospital, Rozzano, Italy|Ospedale San Paolo, Savona, Italy|Chirurgia 4 Ospedale Ca'Foncello, Treviso, Italy|Chirurgia Epatobiliare Università degli studi di Verona, Verona, Italy	https://ClinicalTrials.gov/show/NCT04053231
350	Proton Therapy and Bevacizumab for Primary Liver Tumors	Terminated	No Results Available	Liver Cancer|Hepatocellular Carcinoma|Cholangiocarcinoma	Drug: Bevacizumab|Radiation: Proton Radiation Therapy	U.T. M.D. Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT00426829
351	In-Situ Therapeutic Cancer Vaccine for Refractory Liver Cancer	Withdrawn	No Results Available	Hepatocellular Carcinoma	Biological: AlloStim	Hadassah-Hebrew University Medical Center, Jerusalem, Israel	https://ClinicalTrials.gov/show/NCT01923233
352	Panobinostat and Sorafenib in Treating Patients With Liver Cancer That is Metastatic and/or Cannot Be Removed by Surgery	Terminated	No Results Available	Liver Cancer	Drug: panobinostat|Drug: sorafenib tosylate	Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States	https://ClinicalTrials.gov/show/NCT00873002
353	Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCC	Not yet recruiting	No Results Available	Hepatocellular Carcinoma|Liver Cancer, Adult|Liver Cell Carcinoma	Biological: LioCyx-M|Drug: Lenvatinib		https://ClinicalTrials.gov/show/NCT05195294
354	Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer	Terminated	Has Results	Adult Primary Hepatocellular Carcinoma|Advanced Adult Primary Liver Cancer|Localized Unresectable Adult Primary Liver Cancer|Recurrent Adult Primary Liver Cancer	Drug: sunitinib malate|Drug: capecitabine	Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States	https://ClinicalTrials.gov/show/NCT00787787
355	Feasibility 3D Perfusion Ultrasound for Liver Cancer SABR Planning and Response Evaluation	Recruiting	No Results Available	Liver Cancer|Liver Tumor|Hepatocellular Carcinoma|Liver Carcinoma	Drug: perflutren lipid microspheres|Diagnostic Test: 3D ultrasound	Stanford University, School of Medicine, Stanford, California, United States	https://ClinicalTrials.gov/show/NCT02424955
356	Internal Radiation Therapy in Treating Patients With Primary Liver Cancer That Cannot Be Removed by Surgery	Terminated	No Results Available	Liver Cancer	Procedure: quality-of-life assessment|Radiation: yttrium Y 90 resin microspheres	Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States	https://ClinicalTrials.gov/show/NCT00469963
357	Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery	Completed	Has Results	Adult Primary Hepatocellular Carcinoma|Advanced Adult Primary Liver Cancer|Localized Unresectable Adult Primary Liver Cancer|Recurrent Adult Primary Liver Cancer	Drug: belinostat	University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Cancer Therapeutics Research Group, Singapore, Singapore	https://ClinicalTrials.gov/show/NCT00321594
358	Stereotactic Radiation Therapy in Treating Patients With Advanced Liver Cancer	Completed	No Results Available	Liver Cancer	Radiation: stereotactic body radiation therapy	UNMC Eppley Cancer Center at the University of Nebraska Medical Center, Omaha, Nebraska, United States	https://ClinicalTrials.gov/show/NCT00607828
359	Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study	Recruiting	No Results Available	Hepatocellular Carcinoma|Nonalcoholic Steatohepatitis	Drug: Lisinopril|Other: Questionnaire Administration	Cedars-Sinai Cancer - Tarzana, Tarzana, California, United States|Mount Sinai Hospital, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States	https://ClinicalTrials.gov/show/NCT04550481
360	Antiangiogenic Treatment of Hepatocellular Cancer With Bevacizumab and RAD001	Completed	No Results Available	Hepatocellular Carcinoma	Drug: Everolimus, Bevacizumab	Medizinische Klinik 1 University of Erlangen, Erlangen, Bavaria, Germany|Zollernalbklinikum, Balingen, Germany|Charité, Campus Virchow Klinikum, Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Berlin, Germany|Universitaetsklinikum Bonn, Medizinische Klinik und Poliklinik I, Bonn, Germany|Klinikum der J.-W.-Goethe-Universitaet, Medizinische Klinik I, Frankfurt, Germany|Medizinische Universitaetsklinik Freiburg, Innere Medizin II, Freiburg, Germany|Martin-Luther-Universitaet Halle-Wittenberg, Universitaetsklinik und Poliklinik für Innere Medizin I, Halle, Germany|Medizinische Hochschule Hannover, Zentrum Innere Medizin, Hannover, Germany|Universitätsklinikum des Saarlandes Klinik für Innere medizin II, Homburg/Saar, Germany|Medizinische Fakultaet der Otto-von-Guericke-Universitaet, Klinik für Gastroenterologie, Hepatologie und Infektiologie, Magdeburg, Germany	https://ClinicalTrials.gov/show/NCT00775073
361	TRC105 for Liver Cancer That Has Not Responded to Sorafenib	Completed	Has Results	Hepatocellular Carcinoma|Hepatocellular Cancer|Carcinoma, Hepatocellular	Drug: TRC105	National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States	https://ClinicalTrials.gov/show/NCT01375569
362	Sunitinib in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery	Completed	No Results Available	Liver Cancer	Drug: sunitinib malate	Kantonsspital - St. Gallen, St. Gallen, Switzerland	https://ClinicalTrials.gov/show/NCT00514228
363	Yttrium Y 90 Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery	No longer available	No Results Available	Liver Cancer	Radiation: brachytherapy|Radiation: yttrium Y 90 glass microspheres	City of Hope Medical Center, Duarte, California, United States	https://ClinicalTrials.gov/show/NCT00589030
364	Oxaliplatin, Capecitabine, and Cetuximab in Treating Patients With Advanced Liver Cancer	Completed	Has Results	Liver Cancer	Biological: cetuximab|Drug: capecitabine|Drug: oxaliplatin	Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States	https://ClinicalTrials.gov/show/NCT00483405
365	Sorafenib in Treating Patients With Locally Advanced or Metastatic Liver Cancer and Cirrhosis	Terminated	No Results Available	Liver Cancer	Drug: sorafenib tosylate	Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States	https://ClinicalTrials.gov/show/NCT00767468
366	GEN2 Directed Cancer Immunotherapy Trial	Recruiting	No Results Available	Hepatocellular Carcinoma|Metastatic Cancer	Drug: GEN2 (HSV-Thymidine Kinase-m2 and hGM-CSF Genes)	Makati Medical Center, Makati City, Philippines|The Medical City, Pasig City, Philippines|National Kidney and Transplant Institute, Quezon City, Philippines|St. Luke's Medical Center, Quezon City, Philippines	https://ClinicalTrials.gov/show/NCT04313868
367	Octreotide in Treating Patients With Locally Advanced or Metastatic Liver Cancer	Completed	No Results Available	Liver Cancer	Drug: octreotide acetate	The University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States	https://ClinicalTrials.gov/show/NCT00257426
368	Sorafenib Tosylate With or Without Pravastatin in Treating Patients With Liver Cancer and Cirrhosis	Completed	No Results Available	Liver Cancer	Drug: pravastatin sodium|Drug: sorafenib tosylate	Hopital Du Bocage, Dijon, France	https://ClinicalTrials.gov/show/NCT01075555
369	Sirolimus and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery	Completed	No Results Available	Liver Cancer	Drug: Rapamycin|Drug: Bevacizumab	National Cancer Centre - Singapore, Singapore, Singapore|Johns Hopkins Singapore International Medical Centre, Singapore, Singapore	https://ClinicalTrials.gov/show/NCT00467194
370	Drug-loadable（T-ACE Beads）for Hepatoma Embolization Therapy	Completed	No Results Available	Cancer of Liver	Device: Taiwan ACE Beads with doxorubicin	National Cheng Kung University Hospital, Tainan, Taiwan	https://ClinicalTrials.gov/show/NCT03299036
371	A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy	Not yet recruiting	No Results Available	Hepatocellular Carcinoma|Liver Cancer	Drug: Cabozantinib|Drug: Nivolumab	M D Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT05039736
372	Epirubicin and Thalidomide in Treating Patients With Liver Cancer	Completed	No Results Available	Liver Cancer	Drug: epirubicin hydrochloride|Drug: thalidomide	Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States	https://ClinicalTrials.gov/show/NCT00058487
373	Sunitinib Malate (SUO11248) In Subjects W/ Metastatic And/Or Surgically Unresectable Hepatocellular Cancers (HCC)	Terminated	Has Results	Liver Cancer	Drug: Sunitinib Malate	H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States	https://ClinicalTrials.gov/show/NCT00495625
374	Bevacizumab and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery	Completed	Has Results	Liver Cancer	Biological: bevacizumab|Drug: chemotherapy|Drug: embolization therapy|Procedure: hepatic artery infusion	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States	https://ClinicalTrials.gov/show/NCT00335829
375	Safety and Efficacy of DEB-TACE Performed With a Novel Reflux-control Microcatheter in Patients With HCC	Recruiting	No Results Available	Hepatocellular Carcinoma|Liver Cancer	Combination Product: Chemoembolization with preloaded microparticles 100 micron and reflux control microcatheter	Juan Jose Ciampi Dopazo, Granada, Spain	https://ClinicalTrials.gov/show/NCT04653701
376	Different Protocols for Repeated Transarterial Chemoembolization in the Treatment of Patients With Hepatocellular Carcinoma	Completed	No Results Available	Liver Cancer	Procedure: transarterial chemoembolization	Department of Interventional Radiology; Cancer Center; Guangdong General Hospital, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT02038296
377	Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer	Completed	Has Results	Liver Cancer	Biological: bevacizumab|Drug: sorafenib tosylate	Mayo Clinic Scottsdale, Scottsdale, Arizona, United States|Aurora Presbyterian Hospital, Aurora, Colorado, United States|Boulder Community Hospital, Boulder, Colorado, United States|Penrose Cancer Center at Penrose Hospital, Colorado Springs, Colorado, United States|St. Anthony Central Hospital, Denver, Colorado, United States|Porter Adventist Hospital, Denver, Colorado, United States|Presbyterian - St. Luke's Medical Center, Denver, Colorado, United States|St. Joseph Hospital, Denver, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|CCOP - Colorado Cancer Research Program, Denver, Colorado, United States|Swedish Medical Center, Englewood, Colorado, United States|St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center, Grand Junction, Colorado, United States|North Colorado Medical Center, Greeley, Colorado, United States|Sky Ridge Medical Center, Lone Tree, Colorado, United States|Hope Cancer Care Center at Longmont United Hospital, Longmont, Colorado, United States|McKee Medical Center, Loveland, Colorado, United States|St. Mary - Corwin Regional Medical Center, Pueblo, Colorado, United States|North Suburban Medical Center, Thornton, Colorado, United States|Exempla Lutheran Medical Center, Wheat Ridge, Colorado, United States|Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center, Hartford, Connecticut, United States|Illinois CancerCare - Bloomington, Bloomington, Illinois, United States|St. Joseph Medical Center, Bloomington, Illinois, United States|Graham Hospital, Canton, Illinois, United States|Illinois CancerCare - Canton, Canton, Illinois, United States|Illinois CancerCare - Carthage, Carthage, Illinois, United States|Memorial Hospital, Carthage, Illinois, United States|Eureka Community Hospital, Eureka, Illinois, United States|Illinois CancerCare - Eureka, Eureka, Illinois, United States|Galesburg Clinic, PC, Galesburg, Illinois, United States|Illinois CancerCare - Galesburg, Galesburg, Illinois, United States|Illinois CancerCare - Havana, Havana, Illinois, United States|Mason District Hospital, Havana, Illinois, United States|Illinois CancerCare - Kewanee Clinic, Kewanee, Illinois, United States|Illinois CancerCare - Macomb, Macomb, Illinois, United States|McDonough District Hospital, Macomb, Illinois, United States|Trinity Cancer Center at Trinity Medical Center - 7th Street Campus, Moline, Illinois, United States|Moline, Illinois, United States|Illinois CancerCare - Monmouth, Monmouth, Illinois, United States|OSF Holy Family Medical Center, Monmouth, Illinois, United States|BroMenn Regional Medical Center, Normal, Illinois, United States|Community Cancer Center, Normal, Illinois, United States|Illinois CancerCare - Community Cancer Center, Normal, Illinois, United States|Community Hospital of Ottawa, Ottawa, Illinois, United States|Oncology Hematology Associates of Central Illinois, PC - Ottawa, Ottawa, Illinois, United States|Cancer Treatment Center at Pekin Hospital, Pekin, Illinois, United States|Illinois CancerCare - Pekin, Pekin, Illinois, United States|Proctor Hospital, Peoria, Illinois, United States|CCOP - Illinois Oncology Research Association, Peoria, Illinois, United States|Oncology Hematology Associates of Central Illinois, PC - Peoria, Peoria, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|OSF St. Francis Medical Center, Peoria, Illinois, United States|Illinois CancerCare - Peru, Peru, Illinois, United States|Illinois Valley Community Hospital, Peru, Illinois, United States|Illinois CancerCare - Princeton, Princeton, Illinois, United States|Perry Memorial Hospital, Princeton, Illinois, United States|Illinois CancerCare - Spring Valley, Spring Valley, Illinois, United States|Bettendorf, Iowa, United States|Medical Oncology and Hematology Associates - West Des Moines, Clive, Iowa, United States|CCOP - Iowa Oncology Research Association, Des Moines, Iowa, United States|John Stoddard Cancer Center at Iowa Methodist Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates at John Stoddard Cancer Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates at Mercy Cancer Center, Des Moines, Iowa, United States|Mercy Cancer Center at Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|John Stoddard Cancer Center at Iowa Lutheran Hospital, Des Moines, Iowa, United States|Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States|Mercy Medical Center - Sioux City, Sioux City, Iowa, United States|St. Luke's Regional Medical Center, Sioux City, Iowa, United States|Cancer Center of Kansas, PA - Chanute, Chanute, Kansas, United States|Cancer Center of Kansas, PA - Dodge City, Dodge City, Kansas, United States|Cancer Center of Kansas, PA - El Dorado, El Dorado, Kansas, United States|Cancer Center of Kansas - Fort Scott, Fort Scott, Kansas, United States|Cancer Center of Kansas-Independence, Independence, Kansas, United States|Cancer Center of Kansas, PA - Kingman, Kingman, Kansas, United States|Lawrence Memorial Hospital, Lawrence, Kansas, United States|Cancer Center of Kansas, PA - Liberal, Liberal, Kansas, United States|Cancer Center of Kansas, PA - Newton, Newton, Kansas, United States|Cancer Center of Kansas, PA - Parsons, Parsons, Kansas, United States|Cancer Center of Kansas, PA - Pratt, Pratt, Kansas, United States|Cancer Center of Kansas, PA - Salina, Salina, Kansas, United States|Cancer Center of Kansas, PA - Wellington, Wellington, Kansas, United States|Associates in Womens Health, PA - North Review, Wichita, Kansas, United States|Cancer Center of Kansas, PA - Medical Arts Tower, Wichita, Kansas, United States|Cancer Center of Kansas, PA - Wichita, Wichita, Kansas, United States|CCOP - Wichita, Wichita, Kansas, United States|Via Christi Cancer Center at Via Christi Regional Medical Center, Wichita, Kansas, United States|Cancer Center of Kansas, PA - Winfield, Winfield, Kansas, United States|Saint Joseph Mercy Cancer Center, Ann Arbor, Michigan, United States|CCOP - Michigan Cancer Research Consortium, Ann Arbor, Michigan, United States|Battle Creek Health System Cancer Care Center, Battle Creek, Michigan, United States|Mecosta County Medical Center, Big Rapids, Michigan, United States|Oakwood Cancer Center at Oakwood Hospital and Medical Center, Dearborn, Michigan, United States|Green Bay Oncology, Limited - Escanaba, Escanaba, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Butterworth Hospital at Spectrum Health, Grand Rapids, Michigan, United States|CCOP - Grand Rapids, Grand Rapids, Michigan, United States|Lacks Cancer Center at Saint Mary's Health Care, Grand Rapids, Michigan, United States|Van Elslander Cancer Center at St. John Hospital and Medical Center, Grosse Pointe Woods, Michigan, United States|Dickinson County Healthcare System, Iron Mountain, Michigan, United States|Foote Memorial Hospital, Jackson, Michigan, United States|Sparrow Regional Cancer Center, Lansing, Michigan, United States|St. Mary Mercy Hospital, Livonia, Michigan, United States|Mercy General Health Partners, Muskegon, Michigan, United States|St. Joseph Mercy Oakland, Pontiac, Michigan, United States|Mercy Regional Cancer Center at Mercy Hospital, Port Huron, Michigan, United States|Seton Cancer Institute at Saint Mary's - Saginaw, Saginaw, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|St. John Macomb Hospital, Warren, Michigan, United States|Metro Health Hospital, Wyoming, Michigan, United States|MeritCare Bemidji, Bemidji, Minnesota, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Mercy and Unity Cancer Center at Mercy Hospital, Coon Rapids, Minnesota, United States|Duluth Clinic Cancer Center - Duluth, Duluth, Minnesota, United States|CCOP - Duluth, Duluth, Minnesota, United States|Miller - Dwan Medical Center, Duluth, Minnesota, United States|Fairview Southdale Hospital, Edina, Minnesota, United States|Fergus Falls Medical Group, PA, Fergus Falls, Minnesota, United States|Mercy and Unity Cancer Center at Unity Hospital, Fridley, Minnesota, United States|Hutchinson Area Health Care, Hutchinson, Minnesota, United States|HealthEast Cancer Care at St. John's Hospital, Maplewood, Minnesota, United States|Minnesota Oncology Hematology, PA - Maplewood, Maplewood, Minnesota, United States|Virginia Piper Cancer Institute at Abbott - Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center - Minneapolis, Minneapolis, Minnesota, United States|Hubert H. Humphrey Cancer Center at North Memorial Outpatient Center, Robbinsdale, Minnesota, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|CCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States|Park Nicollet Cancer Center, Saint Louis Park, Minnesota, United States|Regions Hospital Cancer Care Center, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|St. Francis Cancer Center at St. Francis Medical Center, Shakopee, Minnesota, United States|Lakeview Hospital, Stillwater, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Willmar Cancer Center at Rice Memorial Hospital, Willmar, Minnesota, United States|Minnesota Oncology Hematology, PA - Woodbury, Woodbury, Minnesota, United States|Goldschmidt Cancer Center, Jefferson City, Missouri, United States|Missouri Baptist Cancer Center, Saint Louis, Missouri, United States|Comprehensive Cancer Care, PC, Saint Louis, Missouri, United States|CCOP - Montana Cancer Consortium, Billings, Montana, United States|St. Vincent Healthcare Cancer Care Services, Billings, Montana, United States|Hematology-Oncology Centers of the Northern Rockies - Billings, Billings, Montana, United States|Billings Clinic - Downtown, Billings, Montana, United States|Bozeman Deaconess Cancer Center, Bozeman, Montana, United States|St. James Healthcare Cancer Care, Butte, Montana, United States|Great Falls Clinic - Main Facility, Great Falls, Montana, United States|Sletten Cancer Institute at Benefis Healthcare, Great Falls, Montana, United States|Northern Montana Hospital, Havre, Montana, United States|St. Peter's Hospital, Helena, Montana, United States|Glacier Oncology, PLLC, Kalispell, Montana, United States|Kalispell Medical Oncology at KRMC, Kalispell, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Montana Cancer Specialists at Montana Cancer Center, Missoula, Montana, United States|Montana Cancer Center at St. Patrick Hospital and Health Sciences Center, Missoula, Montana, United States|Bismarck Cancer Center, Bismarck, North Dakota, United States|Medcenter One Hospital Cancer Care Center, Bismarck, North Dakota, United States|Mid Dakota Clinic, PC, Bismarck, North Dakota, United States|St. Alexius Medical Center Cancer Center, Bismarck, North Dakota, United States|CCOP - MeritCare Hospital, Fargo, North Dakota, United States|MeritCare Broadway, Fargo, North Dakota, United States|Natalie Warren Bryant Cancer Center at St. Francis Hospital, Tulsa, Oklahoma, United States|Geisinger Cancer Institute at Geisinger Health, Danville, Pennsylvania, United States|Geisinger Hazleton Cancer Center, Hazleton, Pennsylvania, United States|Geisinger Medical Group - Scenery Park, State College, Pennsylvania, United States|Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center, Wilkes-Barre, Pennsylvania, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|Medical X-Ray Center, PC, Sioux Falls, South Dakota, United States|Sanford Cancer Center at Sanford USD Medical Center, Sioux Falls, South Dakota, United States|Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center, Green Bay, Wisconsin, United States|Green Bay Oncology, Limited at St. Mary's Hospital, Green Bay, Wisconsin, United States|St. Mary's Hospital Medical Center - Green Bay, Green Bay, Wisconsin, United States|St. Vincent Hospital Regional Cancer Center, Green Bay, Wisconsin, United States|Holy Family Memorial Medical Center Cancer Care Center, Manitowoc, Wisconsin, United States|Bay Area Cancer Care Center at Bay Area Medical Center, Marinette, Wisconsin, United States|Green Bay Oncology, Limited - Oconto Falls, Oconto Falls, Wisconsin, United States|St. Nicholas Hospital, Sheboygan, Wisconsin, United States|Green Bay Oncology, Limited - Sturgeon Bay, Sturgeon Bay, Wisconsin, United States|Rocky Mountain Oncology, Casper, Wyoming, United States|Welch Cancer Center at Sheridan Memorial Hospital, Sheridan, Wyoming, United States	https://ClinicalTrials.gov/show/NCT00867321
378	Iodine I 131 Ethiodized Oil in Preventing Recurrent Cancer in Patients Who Have Undergone Treatment for Liver Cancer	Completed	No Results Available	Liver Cancer	Drug: ethiodized oil|Radiation: iodine I 131 ethiodized oil	Hopital Edouard Herriot - Lyon, Lyon, France	https://ClinicalTrials.gov/show/NCT00870558
379	Liver and Biliary Tumor Tissue Registry	Recruiting	No Results Available	Hepatocellular Carcinoma|Cholangiocarcinoma		Mayo Clinic, Jacksonville, Florida, United States	https://ClinicalTrials.gov/show/NCT02917759
380	Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)	Completed	No Results Available	Hepatocellular Carcinoma	Drug: GC33(RO5137382)|Drug: Sorafenib	California Pacific Medical Center, San Francisco, California, United States|University of Miami, Miami, Florida, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan Univercity Hospital, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT00976170
381	SB-715992 in Treating Patients With Locally Advanced, Recurrent, or Metastatic Liver Cancer	Completed	No Results Available	Liver Cancer	Drug: ispinesib	BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada|Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada|Cancer Centre of Southeastern Ontario at Kingston, Kingston, Ontario, Canada|Univ. Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada	https://ClinicalTrials.gov/show/NCT00095992
382	Determine the Pharmacokinetics and Safety of Brivanib in Chinese Subjects With Advanced Primary Liver Cancer (Hepatocellular Carcinoma: HCC)	Completed	No Results Available	Hepatocellular Carcinoma	Drug: Brivanib	Local Institution, Beijing, Beijing, China|Local Institution, Ha Erbin, Heilongjiang, China|Local Institution, Nanjing, Jiangsu, China	https://ClinicalTrials.gov/show/NCT01540461
383	Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver Dysfunction	Completed	No Results Available	Adult Primary Hepatocellular Carcinoma|Advanced Adult Primary Liver Cancer|Localized Unresectable Adult Primary Liver Cancer|Recurrent Adult Primary Liver Cancer	Drug: erlotinib hydrochloride|Other: pharmacological study|Other: laboratory biomarker analysis	M D Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT00047346
384	Protein Biomarker in Hepatocellular Carcinoma	Terminated	No Results Available	Normal Volunteers|Hepatitis|Liver Cirrhosis|Hepatocellular Carcinoma		Johns Hopkins Singapore International Medical Center, Singapore, Singapore	https://ClinicalTrials.gov/show/NCT00465842
385	To Study the Effects of Host Genetic Factors on Liver Cirrhosis and Hepatocellular Carcinoma (HCC)	Unknown status	No Results Available	Liver Cirrhosis		National Taiwan University Hospital, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT00709085
386	Sorafenib With or Without Gemcitabine and Oxaliplatin in Treating Patients With Locally Advanced, Unresectable, or Metastatic Liver Cancer	Completed	No Results Available	Liver Cancer	Drug: gemcitabine hydrochloride|Drug: oxaliplatin|Drug: sorafenib tosylate	Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle, Montpellier, France	https://ClinicalTrials.gov/show/NCT00941967
387	Treatment Patients With Pulmonary Metastasis of Liver Cancer With Apatinib Combination With TACE: a Clinical Study	Unknown status	No Results Available	Hepatocellular Carcinoma|Pulmonary Metastasis	Drug: Apatinib|Procedure: TACE		https://ClinicalTrials.gov/show/NCT02702323
388	Gemcitabine Plus Docetaxel in Treating Patients With Unresectable or Metastatic Liver Cancer	Completed	No Results Available	Liver Cancer	Drug: docetaxel|Drug: gemcitabine hydrochloride	CCOP - Scottsdale Oncology Program, Scottsdale, Arizona, United States|Mayo Clinic, Jacksonville, Florida, United States|CCOP - Atlanta Regional, Atlanta, Georgia, United States|MBCCOP - Hawaii, Honolulu, Hawaii, United States|CCOP - Illinois Oncology Research Association, Peoria, Illinois, United States|CCOP - Carle Cancer Center, Urbana, Illinois, United States|CCOP - Cedar Rapids Oncology Project, Cedar Rapids, Iowa, United States|CCOP - Iowa Oncology Research Association, Des Moines, Iowa, United States|Siouxland Hematology-Oncology, Sioux City, Iowa, United States|CCOP - Wichita, Wichita, Kansas, United States|CCOP - Duluth, Duluth, Minnesota, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|Medcenter One Health System, Bismarck, North Dakota, United States|CCOP - Toledo Community Hospital, Toledo, Ohio, United States|CCOP - Geisinger Clinic and Medical Center, Danville, Pennsylvania, United States|CCOP - Sioux Community Cancer Consortium, Sioux Falls, South Dakota, United States|Allan Blair Cancer Centre, Regina, Saskatchewan, Canada	https://ClinicalTrials.gov/show/NCT00006010
389	Radiation Therapy With Sorafenib for TACE-Resistant Hepatocellular Carcinoma	Withdrawn	No Results Available	Hepatocellular Carcinoma|Hepatocellular Cancer|Hepatoma|Liver Cancer	Drug: Sorafenib|Radiation: Conventional fractionation (2 Gy per day) external beam radiation therapy	Froedtert Memorial Lutheran Hospital, Milwaukee, Wisconsin, United States	https://ClinicalTrials.gov/show/NCT01618253
390	Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With Chemotherapy	Completed	Has Results	Hepatocellular Carcinoma	Biological: Ramucirumab (IMC-1121B)	ImClone Investigational Site, Los Angeles, California, United States|ImClone Investigational Site, Chicago, Illinois, United States|ImClone Investigational Site, Metairie, Louisiana, United States|ImClone Investigational Site, Boston, Massachusetts, United States|ImClone Investigational Site, Burlington, Massachusetts, United States|ImClone Investigational Site, Philadelphia, Pennsylvania, United States	https://ClinicalTrials.gov/show/NCT00627042
391	Chemoembolization Versus Radioembolization in Treating Patients With Liver Cancer That Cannot Be Treated With Radiofrequency Ablation Or Surgery	Completed	Has Results	Liver Cancer	Radiation: yttrium Y 90 glass microspheres|Drug: Doxorubicin	Northwestern University, Northwestern Memorial Hospital, Chicago, Illinois, United States	https://ClinicalTrials.gov/show/NCT00956930
392	The Follow-up Study of Chronic Hepatitis B Patients With Liver Cirrhosis Receiving Anti-HBV Therapy	Unknown status	No Results Available	Hepatitis B Virus-Related Hepatocellular Carcinoma		National Taiwan University Hospital, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT01957618
393	Gadolinium Contrast-enhanced Abbreviated MRI (AMRI) vs. Standard Ultrasound for Hepatocellular Carcinoma (HCC) Surveillance in Patients With Cirrhosis	Recruiting	No Results Available	Liver Cancer|Liver Cirrhoses|Liver Carcinoma	Drug: Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid	University of California, San Diego, La Jolla, California, United States	https://ClinicalTrials.gov/show/NCT04288323
394	Phase III Study of PI-88 in Post-resection Hepatocellular Carcinoma	Terminated	No Results Available	Cancer|Liver Cancer|Primary Liver Cancer|Hepatocellular Carcinoma|Hepatoma	Drug: PI-88|Drug: placebo	United States of America, New York, United States|Australia, Australia|Canada, Canada|Hong Kong, Hong Kong|Italy, Italy|Malaysia, Malaysia|Singapore, Singapore|Spain, Spain|Taiwan, Taiwan|Thailand, Thailand	https://ClinicalTrials.gov/show/NCT00568308
395	Sho-Saiko-To Following Removal of Liver Cancer By Embolization in Treating Patients With Liver Cancer That Cannot Be Surgically Removed	Completed	No Results Available	Liver Cancer	Dietary Supplement: Sho-saiko-to	Memorial Sloan-Kettering Cancer Center, New York, New York, United States	https://ClinicalTrials.gov/show/NCT00040898
396	Vaccine Therapy in Treating Patients With Stage II, Stage IIIA, Stage IIIB, or Stage IVA Liver Cancer	Withdrawn	No Results Available	Liver Cancer	Biological: alpha fetoprotein adenoviral vector vaccine|Biological: alpha fetoprotein plasmid DNA vaccine|Biological: sargramostim plasmid DNA hepatocellular carcinoma vaccine adjuvant		https://ClinicalTrials.gov/show/NCT00093548
397	A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma	Terminated	Has Results	Hepatocellular Carcinoma|Hepatoma|Liver Cell Carcinoma	Device: DEB-TACE|Drug: Sorafenib	University of Alabama Hospital, Birmingham, Alabama, United States|University of Southern California, Los Angeles, California, United States|University of Louisville, Louisville, Kentucky, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Oregon Health & Science University, Portland, Oregon, United States|MD Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT02460991
398	Hepatic Arterial Chemoembolization With Cisplatin or Internal Radiation Therapy in Treating Patients With Advanced Liver Cancer That Cannot Be Removed By Surgery	Completed	No Results Available	Liver Cancer	Drug: cisplatin|Radiation: brachytherapy|Radiation: yttrium Y 90 glass microspheres	Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States	https://ClinicalTrials.gov/show/NCT00109954
399	Stereotactic Body Radiotherapy for Liver Tumors	Completed	Has Results	Liver Metastases|Hepatocellular Carcinoma|Intrahepatic Cholangiocarcinoma	Radiation: Stereotactic body radiosurgery|Radiation: Stereotactic Body Radiotherapy	St. John's Mercy Medical Center, Saint Louis, Missouri, United States	https://ClinicalTrials.gov/show/NCT01347333
400	Nolatrexed Dihydrochloride Compared With Doxorubicin in Treating Patients With Recurrent or Unresectable Liver Cancer	Completed	No Results Available	Liver Cancer	Drug: doxorubicin hydrochloride|Drug: nolatrexed dihydrochloride	Arizona Clinical Research Center, Incorporated, Tucson, Arizona, United States|Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Tower Cancer Research Foundation, Beverly Hills, California, United States|Scripps Cancer Center at Scripps Clinic, La Jolla, California, United States|David and Donna Long Center for Cancer Treatment at Sharp Grossmont Hospital, La Mesa, California, United States|Veterans Affairs Medical Center - Long Beach, Long Beach, California, United States|California Pacific Medical Center - Pacific Campus, San Francisco, California, United States|Olive View - UCLA Medical Center Foundation, Sylmar, California, United States|California Hematology/Oncology Medical Group, Torrance, California, United States|Helen F. Graham Cancer Center, Newark, Delaware, United States|Lombardi Cancer Center at Georgetown University Medical Center, Washington, District of Columbia, United States|Florida Cancer Institute - Bayonet Point, Hudson, Florida, United States|University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Oncology-Hematology Group of South Florida, P.A., Miami, Florida, United States|Ocala Research Institute, Incorporated, Ocala, Florida, United States|Cancer Research Center of Hawaii, Honolulu, Hawaii, United States|Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States|University of Illinois at Chicago Cancer Center, Chicago, Illinois, United States|Holden Comprehensive Cancer Center at University of Iowa, Iowa City, Iowa, United States|Louisiana Oncology Associates - Lafayette, Lafayette, Louisiana, United States|Stanley S. Scott Cancer Center at Louisiana State University Medical Center - New Orleans, New Orleans, Louisiana, United States|Alvin and Lois Lapidus Cancer Institute at Sinai Hospital, Baltimore, Maryland, United States|University of Minnesota Cancer Center, Minneapolis, Minnesota, United States|Saint Louis University Cancer Center, Saint Louis, Missouri, United States|Siteman Cancer Center at Barnes-Jewish Hospital, Saint Louis, Missouri, United States|UNMC Eppley Cancer Center at the University of Nebraska Medical Center, Omaha, Nebraska, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Veterans Affairs Medical Center - Albuquerque, Albuquerque, New Mexico, United States|Albert Einstein Cancer Center at Albert Einstein College of Medicine, Bronx, New York, United States|New York Weill Cornell Cancer Center at Cornell University, New York, New York, United States|Herbert Irving Comprehensive Cancer Center at Columbia University, New York, New York, United States|SUNY Upstate Medical University Hospital, Syracuse, New York, United States|New York Medical College, Valhalla, New York, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|Albert Einstein Cancer Center, Philadelphia, Pennsylvania, United States|Cancer Centers of the Carolinas - Eastside, Greenville, South Carolina, United States|Medical City Dallas Hospital, Dallas, Texas, United States|Joe Arrington Cancer Research and Treatment Center, Lubbock, Texas, United States|St. Boniface General Hospital, Winnipeg, Manitoba, Canada|Ottawa Hospital Regional Cancer Centre - General Campus, Ottawa, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Fundacion de Investagacion De Diego, Santurce, Puerto Rico	https://ClinicalTrials.gov/show/NCT00012324
401	Computer-assisted Tumor Ablation for Patients With Liver Cancer	Completed	No Results Available	Hepatocellular Carcinoma	Procedure: Stereotactic percutaneous image-guided microwave ablation	Department of Visceral Surgery and Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland	https://ClinicalTrials.gov/show/NCT03630068
402	Liver Cancer Disparities in American Indian and Alaska Native Persons	Recruiting	No Results Available	Hepatocellular Carcinoma|Cirrhosis, Liver|Hepatitis B	Diagnostic Test: Ultrasound or abbreviated MRI	Cherokee Nation Health Service, Tahlequah, Oklahoma, United States	https://ClinicalTrials.gov/show/NCT05304234
403	Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Preserved Liver Function	Recruiting	No Results Available	Hepatocellular Carcinoma (HCC)|Second Line Treatment	Drug: Cabozantinib Oral Tablet	HELIOS Klinikum Bad Saarow, Bad Saarow, Germany|BAG / Onkologische Gemeinschaftspraxis, Dresden, Germany|Ev. Kliniken Essen-Mitte, Klinik für Internistische Onkologie, Essen, Germany|Universitätsklinikum Essen, Essen, Germany|Institute for Clinical Cancer Research Krankenhaus Nordwest, Frankfurt, Germany|Klinikum der Johann-Wolfgang-Goethe Universität, Frankfurt, Germany|Universitätsklinikum Gießen und Marburg, Gießen, Germany|Universitätsklinikum Köln AöR, Köln, Germany|Universität Leipzig KöR, Medizinische Fakultät Department für Innere Medizin, Neurologie Klinik für Gastroenterologie, Leipzig, Germany|Klinikum rechts der Isar Technische Universität München Klinik und Poliklinik für Innere Medizin II, Müchen, Germany	https://ClinicalTrials.gov/show/NCT04522908
404	National Registry and Blood Bank of Patients With Liver Cancer	Completed	No Results Available	Liver Cancer	Other: biologic sample preservation procedure|Other: medical chart review|Other: Patient interview	Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Center at Franklin, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States	https://ClinicalTrials.gov/show/NCT00482365
405	Effect of Remote Ischaemic preConditioning on Liver Injury in Patients Undergoing LIVER Resection Surgery	Unknown status	No Results Available	Hepatocellular Cancer	Device: Active RIC|Device: Sham Control	Singapore General Hospital, Singapore, Singapore	https://ClinicalTrials.gov/show/NCT03594929
406	Hepatic Resection Versus TACE+RFA for BCLC Stage B Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma	Procedure: Hepatic resection|Procedure: TACE|Procedure: RFA	Department of Hepatobiliary Surgery, Cancer Center of Sun-Yat Sen University, Guangzhou, Guangdong, China|Department of Hepatobiliary Surgery, Sun-Yat Sen Memorial Hospital, Guangzhou, Guangdong, China|Department of Hepatic Surgery, First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT02616926
407	National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer	Recruiting	No Results Available	Hepatocellular Carcinoma|Liver Cancer|Cholangiocarcinoma		University of California (UCSD), San Diego, California, United States|University of California (UCSF), San Francisco, California, United States|Georgetown University, Washington, District of Columbia, United States|National Institutes of Health Clinical Center, Bethesda, Maryland, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States	https://ClinicalTrials.gov/show/NCT04145141
408	Effect of Pregabalin on the Postoperative Analgesia in RFA of Focal Lesions in the Liver	Unknown status	No Results Available	Hepatocellular Cancer	Drug: Pregabalin 150mg|Other: Placebo	Tanta university - faculty of medicine, Cairo, Elgharbia, Egypt	https://ClinicalTrials.gov/show/NCT03151213
409	HepATocellular Cancer Hcv Therapy Study	Withdrawn	No Results Available	Hepatocellular Carcinoma|Hepatoma|Liver Cell Carcinoma|Hepatitis C	Drug: Elbasvir / Grazoprevir Oral Tablet		https://ClinicalTrials.gov/show/NCT04546802
410	IMRT Plus PD-1 Blockade and Lenvatinib for HCC With PVTT (Vp3) Before Liver Transplantation	Not yet recruiting	No Results Available	Liver Cancer|Liver Transplant; Complications|Hepatocellular Carcinoma|Portal Vein Thrombosis|Radiotherapy; Complications	Radiation: intensity-modulated radiotherapy|Combination Product: Pembrolizumab|Drug: Sintilimab|Drug: Camrelizumab|Drug: Tislelizumab|Drug: Lenvatinib Mesylate Capsule	Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China	https://ClinicalTrials.gov/show/NCT05339581
411	Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer	Recruiting	No Results Available	Hepatocellular Carcinoma	Biological: fhB7H3.CAR-Ts|Drug: Fludarabine|Drug: Cyclophosphamide	The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China	https://ClinicalTrials.gov/show/NCT05323201
412	Chemotherapy in Treating Children With Liver Cancer	Completed	No Results Available	Liver Cancer	Drug: carboplatin|Drug: cisplatin|Drug: doxorubicin hydrochloride|Procedure: conventional surgery	Azienda Ospedaliera di Padova, Padova, Italy	https://ClinicalTrials.gov/show/NCT00003912
413	A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations	Recruiting	No Results Available	Hepatocellular Carcinoma|Intrahepatic Cholangiocarcinoma|Liver Metastases	Drug: MIV-818 (fostroxacitabine bralpamide) + pembrolizumab|Drug: MIV-818 (fostroxacitabine bralpamide) + lenvatinib	Antwerp University Hospital, Antwerp, Belgium|University Hospitals Gasthuisberg, Leuven, Belgium|Beatson West of Scotland Cancer Care, Glasgow, United Kingdom|Guy's Hospital, Oncology and Clinical Trials, London, United Kingdom|Northern Institute for Cancer Research, Newcastle Upon Tyne, United Kingdom|Chruchill Hospital, Cancer and Haematology Centre, Oxford, United Kingdom	https://ClinicalTrials.gov/show/NCT03781934
414	Oxaliplatin in Treating Patients With Liver Cancer	Completed	No Results Available	Adult Primary Hepatocellular Carcinoma|Advanced Adult Primary Liver Cancer|Localized Unresectable Adult Primary Liver Cancer|Recurrent Adult Primary Liver Cancer	Drug: oxaliplatin|Other: laboratory biomarker analysis	City of Hope, Duarte, California, United States	https://ClinicalTrials.gov/show/NCT00052364
415	Combination Chemotherapy and Thalidomide in Treating Younger Patients Undergoing Surgery For Newly Diagnosed Liver Cancer	Unknown status	No Results Available	Liver Cancer	Drug: cisplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: thalidomide|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy	Our Lady's Hospital for Sick Children Crumlin, Dublin, Ireland|Birmingham Children's Hospital, Birmingham, England, United Kingdom|Institute of Child Health at University of Bristol, Bristol, England, United Kingdom|Addenbrooke's Hospital, Cambridge, England, United Kingdom|Leeds Cancer Centre at St. James's University Hospital, Leeds, England, United Kingdom|Leicester Royal Infirmary, Leicester, England, United Kingdom|Royal Liverpool Children's Hospital, Alder Hey, Liverpool, England, United Kingdom|Royal London Hospital, London, England, United Kingdom|Great Ormond Street Hospital for Children, London, England, United Kingdom|Royal Manchester Children's Hospital, Manchester, England, United Kingdom|Sir James Spence Institute of Child Health at Royal Victoria Infirmary, Newcastle-Upon-Tyne, England, United Kingdom|Queen's Medical Centre, Nottingham, England, United Kingdom|Oxford Radcliffe Hospital, Oxford, England, United Kingdom|Children's Hospital - Sheffield, Sheffield, England, United Kingdom|Southampton General Hospital, Southampton, England, United Kingdom|Royal Marsden - Surrey, Sutton, England, United Kingdom|Royal Belfast Hospital for Sick Children, Belfast, Northern Ireland, United Kingdom|Royal Aberdeen Children's Hospital, Aberdeen, Scotland, United Kingdom|Royal Hospital for Sick Children, Edinburgh, Scotland, United Kingdom|Royal Hospital for Sick Children, Glasgow, Scotland, United Kingdom|Childrens Hospital for Wales, Cardiff, Wales, United Kingdom	https://ClinicalTrials.gov/show/NCT00276705
416	Pilot Study Sorafenib as Bridge to Orthotopic Liver Transplantation (OLT)	Terminated	No Results Available	Carcinoma, Hepatocellular	Drug: Nexavar	Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States	https://ClinicalTrials.gov/show/NCT01337492
417	Clinical Study of Targeted Cryoablation Therapy in the Treatment of Hepatic Carcinoma	Unknown status	No Results Available	Liver Neoplasms	Procedure: Targeted Cryoablation Therapy	Shanghai Longhua Hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT02969096
418	DKN-01 Inhibition in Advanced Liver Cancer	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: DKN-01 300 mg|Drug: DKN-01 600 mg|Drug: Sorafenib	Universitätsklinikum Köln, Cologne, Germany|Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany|Med. Hochschule Hannover, Hannover, Germany|Universitätsklinikum Schleswig Holstein Campus Lübeck, Lübeck, Germany|Universitätsmedizin Mainz, I. Med. Klinik und Poliklinik, Mainz, Germany|II. Medizinische Universitätsklinik Gastroenterologie, Hepatologie, Infektiologie, Mannheim, Germany	https://ClinicalTrials.gov/show/NCT03645980
419	Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer	Completed	Has Results	Adult Primary Hepatocellular Carcinoma|Advanced Adult Primary Liver Cancer|Localized Unresectable Adult Primary Liver Cancer|Recurrent Adult Primary Liver Cancer	Biological: bevacizumab|Drug: erlotinib hydrochloride	Mayo Clinic, Rochester, Minnesota, United States	https://ClinicalTrials.gov/show/NCT00365391
420	Single Center Experience Over a Decade in Living Donor Liver Transplantation for Egyptian Patients With Hepatocellular Carcinoma: Stretching the Limits	Completed	No Results Available	Recurrence of HCC After LDLT		Ain Shams Center For Organ Transplantation (ASCOT),Ain Shams university, Cairo,, Egypt	https://ClinicalTrials.gov/show/NCT01937286
421	MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma	Terminated	Has Results	Hepatocellular Carcinoma|Liver Cancer|HCC	Drug: MLN0128|Drug: MLN0128 (RP2D)|Drug: Sorafenib	Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|University of Illinois Cancer Center, Chicago, Illinois, United States|Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|University of Noth Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Penn State Cancer Institute, Hershey, Pennsylvania, United States|University of Wisconsin, Madison, Wisconsin, United States	https://ClinicalTrials.gov/show/NCT02575339
422	Radiation Therapy With Protons or Photons in Treating Patients With Liver Cancer	Recruiting	No Results Available	Unrectable or Locally Recurrent Hepatocellular Carcinoma	Radiation: Proton Therapy (Radiation Therapy)|Radiation: Photon Therapy (Radiation Therapy)	Emory Proton Therapy Center, Atlanta, Georgia, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States|Emory Saint Joseph's Hospital, Atlanta, Georgia, United States|Northwestern Medicine Cancer Center Warrenville, Warrenville, Illinois, United States|Maryland Proton Treatment Center, Baltimore, Maryland, United States|University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Beaumont Hospital - Dearborn, Dearborn, Michigan, United States|William Beaumont Hospital-Royal Oak, Royal Oak, Michigan, United States|William Beaumont Hospital - Troy, Troy, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|New York Proton Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Nassau, Uniondale, New York, United States|University of Cincinnati Cancer Center-UC Medical Center, Cincinnati, Ohio, United States|University of Cincinnati Cancer Center-West Chester, West Chester, Ohio, United States|M D Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT03186898
423	Proof of Concept Study Concerning Efficacy of P03277 MR Imaging in HCC Diagnosis	Completed	Has Results	Chronic Liver Disease|HepatoCellular Carcinoma	Drug: P03277 at 0.1 mmol/kg|Drug: P03277 at 0.05 mmol/kg	CHU Angers, Angers, France|Hôpital Beaujon, Clichy, France	https://ClinicalTrials.gov/show/NCT02973516
424	SBRT as Bridging Therapy for Hepatocellular Carcinoma Patients on Transplant Waitlist	Unknown status	No Results Available	Hepatocellular Carcinoma	Radiation: SBRT	Queen Mary Hospital, Hong Kong, Hong Kong	https://ClinicalTrials.gov/show/NCT03950102
425	Vaccine Therapy in Treating Patients With Liver Cancer	Completed	No Results Available	Liver Cancer	Biological: AFP gene hepatocellular carcinoma vaccine	Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States	https://ClinicalTrials.gov/show/NCT00005629
426	Study of TCM Syndrome of Hepatocellular Carcinoma and Colorectal Cancer Based on System Science	Unknown status	No Results Available	Malignant Tumor of Small Intestine Metastatic to Liver	Drug: Bushen-Jianpi Dedoction|Drug: cinobufotalin injection	Shang Hai TCM University, Shanghai, China	https://ClinicalTrials.gov/show/NCT03189992
427	Gut Microbiota in People With Hepatocellular Carcinoma (HCC)	Withdrawn	No Results Available	Hepatocellular Carcinoma|Liver Cancer|Liver Cell Caricinoma|Liver Neoplasm			https://ClinicalTrials.gov/show/NCT02599909
428	Management of Spontaneous Ruptured Hepatocellular Carcinoma	Completed	No Results Available	Rupture, Spontaneous|Rupture Liver|Hepatocellular Carcinoma	Procedure: Partial hepatectomy		https://ClinicalTrials.gov/show/NCT03516890
429	Infusion of PD1/PDL1 Inhibitor Via Hepatic Arterial Versus Vein for Immunotherapy of Advanced Hepatocellular Carcinoma	Recruiting	No Results Available	Liver Cancer	Drug: PD1/PDL1 inhibitor	The Second Affiliated Hospital of Guangzhou Medical University, Guanzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT03949231
430	Study of High-Dose Oral Vitamin D for the Prevention of Liver Cancer	Withdrawn	No Results Available	Cirrhosis|Hepatocellular Carcinoma	Drug: Vitamin D	Sibley Memorial Hospital /Johns Hopkins University, Washington, District of Columbia, United States	https://ClinicalTrials.gov/show/NCT01956864
431	Safety and Efficacy of Autoimmune Cell Therapy for Patients With Hepatocellular Carcinoma	Not yet recruiting	No Results Available	Hepatocellular Carcinoma	Biological: IPM001	Huashan hospital Fudan university, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT05105815
432	Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver	Active, not recruiting	Has Results	Cirrhosis|Hepatocellular Carcinoma	Drug: Erlotinib|Drug: Erlotinib Hydrochloride|Other: Laboratory Biomarker Analysis|Other: Quality-of-Life Assessment	Mayo Clinic in Florida, Jacksonville, Florida, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States|Mount Sinai Hospital, New York, New York, United States|Case Western Reserve University, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States	https://ClinicalTrials.gov/show/NCT02273362
433	Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Patients With Advanced Hepatocellular Cancer	Withdrawn	No Results Available	Liver Neoplasms	Drug: Temsirolimus 25mg and Pegylated liposomal doxorubicin 25mg/m2		https://ClinicalTrials.gov/show/NCT01281943
434	DX-8951f in Treating Patients With Liver Cancer	Completed	No Results Available	Liver Cancer	Drug: exatecan mesylate	University of Colorado Cancer Center, Denver, Colorado, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|University of Texas - MD Anderson Cancer Center, Houston, Texas, United States|Cancer Therapy & Research Center, San Antonio, Texas, United States	https://ClinicalTrials.gov/show/NCT00004108
435	Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein	Terminated	Has Results	Hepatocellular Carcinoma	Device: TheraSphere®|Drug: Sorafenib	Northwestern Medical Faculty Foundation, Div of Hematology/Oncology, Chicago, Illinois, United States|Mount Sinai School of Medicine, New York, New York, United States|Cliniques Universitaires Saint-Luc, Brussels, Belgium|Paoli-Calmettes Institute, Marseille, France|UO Radiologia, Ospedali Riuniti di Bergamo, Bergamo, Italy|Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy|ASO-Santa Croce e Carle di Cuneo, Cuneo, Italy|Fondazione IRCCS Ca Grande, Milano, Italy|S.C Radiologia Interventistica, A.O.Ospedale Niguarda Ca Granda, Milano, Italy|Fondazione Istituto Nazionale Tumori di Milano, Milano, Italy|Azienda Ospedaliera Ospedali Riuniti "Villa Sofia-Cervello", Palermo, Italy|University of Pisa, Pisa, Italy|Policlinico A. Gemelli, Rome, Italy|Hospital Clínic Barcelona. IDIBAPS. CIBEREHD. Liver Unit, Barcelona, Spain|Bulevar Sur s/n, Madrid, Spain|Hospital Universitario Puerta de Hierro, Gastroenterology & Hepatology Dept, Madrid, Spain|Hospital Universitari i Politecnic la Fe, Valencia, Spain|University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom|Royal Free London NHS Foundation Trust, London, United Kingdom	https://ClinicalTrials.gov/show/NCT01887717
436	Vaccine Therapy in Treating Patients With Liver Cancer	Completed	No Results Available	Liver Cancer	Biological: AFP	Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States	https://ClinicalTrials.gov/show/NCT00022334
437	Biologic Basis of Liver Cancer From Chronic Hepatitis B	Completed	No Results Available	Hepatocellular Carcinoma|Hepatitis B, Chronic	Other: One time blood draw	University of California, Davis, Sacramento, California, United States	https://ClinicalTrials.gov/show/NCT03300414
438	Study to Evaluate the Safety and Effectiveness of Microwave Ablation in Patients With Hepatocellular Carcinoma in Korea	Active, not recruiting	Has Results	Carcinoma, Hepatocellular|Hepatocellular Carcinoma|Hepatocellular Cancer|Cancer, Hepatocellular	Device: Microwave ablation	Samsung Medical Center, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT03586050
439	RALPPS Venus ALPPS for Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma	Procedure: RALPPS|Procedure: ALPPS	Institute of hepatobiliary surgery,Southwest Hospital, Chongqing, Chongqing, China	https://ClinicalTrials.gov/show/NCT02299843
440	Value of Negative 18FDG PET/CT in Milan Out, Up-to-seven in, HCC Transplant Candidates	Recruiting	No Results Available	Hepatocellular Carcinoma	Other: Liver transplantation	University Hospital, Antwerp, Antwerpen, Belgium|Free University of Brussels, Brussels, Belgium|University Hospital, Ghent, Ghent, Belgium|Leuven University hospital, Leuven, Belgium|ULiège, Liège, Belgium|Catholic University of Louvain, Louvain, Belgium	https://ClinicalTrials.gov/show/NCT05276037
441	Exploratory Study to Determine Tissue Alterations of Advanced Hepatocellular Carcinoma Induced by Electromagnetic Waves of Low Energy Amplitude Modulated to Specific Frequencies During Imaging Study by MRI	Completed	No Results Available	Primary or Metastatic Tumor in the Liver Parenchyma	Procedure: Magnetic Resonance + hemodynamic + infusion of gadolinium	Hospital Sírio-Libanês, Sao Paulo, Brazil	https://ClinicalTrials.gov/show/NCT02692365
442	Comparing Lipiodol/Ethanol With Drug-eluting Beads (DEB) for Hepatocellular Carcinoma	Withdrawn	No Results Available	Hepatocellular Carcinoma	Drug: Drug-Eluting Beads (DEB) with Doxorubicin|Drug: Lipiodol Ethanol Mixture	Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States	https://ClinicalTrials.gov/show/NCT01489410
443	Perspective Evaluation of Hormones Involved in Serum Phosphate Homeostasis in Patients With Metastatic Renal Cells Carcinoma or Hepatocellular Carcinoma Treated With Sorafenib (SORHORM)	Unknown status	No Results Available	Kidney Cancer|Liver Cancer	Drug: Sorafenib	Alfredo Berruti, Orbassano (To), Turin, Italy	https://ClinicalTrials.gov/show/NCT01230697
444	Combination Chemotherapy and Interferon Alfa-2b in Treating Patients With Nonmetastatic Liver Cancer That Cannot Be Removed by Surgery	Unknown status	No Results Available	Liver Cancer	Biological: recombinant interferon alfa-2b|Drug: doxorubicin hydrochloride|Drug: fluorouracil|Drug: oxaliplatin|Other: diagnostic laboratory biomarker analysis|Other: immunoenzyme technique|Other: immunohistochemistry staining method|Procedure: adjuvant therapy|Procedure: biopsy|Procedure: neoadjuvant therapy|Procedure: therapeutic conventional surgery	National Cancer Centre - Singapore, Singapore, Singapore	https://ClinicalTrials.gov/show/NCT00471484
445	Evaluation the Growth Factors(IGF-1,IGFBP-3and HGH)in Patients With Chronic Liver Disease	Completed	No Results Available	Hepatitis|Liver Cirrhosis|Hepatocellular Carcinoma		Division of Radio immunoassay lab,Department of Nuclear Medical University Hospital,No.100 Tzyou 1st Road, Kaohsiung, Taiwan	https://ClinicalTrials.gov/show/NCT00679692
446	CIRSE Registry for SIR-Spheres Therapy	Completed	No Results Available	Liver Carcinoma	Device: Yttrium-90 loaded SIR-Spheres microspheres|Behavioral: QLQ-C30 with HCC module	Cardiovascular and Interventional Radiological Society of Europe, Vienna, Austria	https://ClinicalTrials.gov/show/NCT02305459
447	SBRT for Liver Cancer Before Liver Transplantation	Recruiting	No Results Available	Liver Cancer|Liver Transplant Disorder	Radiation: Stereotactic body radiation therapy	Department of Clinical Oncology, Queen Mary Hospital, Hong Kong, Hong Kong	https://ClinicalTrials.gov/show/NCT04186234
448	ESP Block on Patient Outcomes in Patients With Liver Tumor Undergoing Radiofrequency Ablation	Recruiting	No Results Available	Hepatic Carcinoma	Procedure: Group ESP|Other: Non-blocked Group	Özlem Öz Gergin, Kayseri, Turkey	https://ClinicalTrials.gov/show/NCT05009550
449	Radiomics-based Non-invasive Classifier Research for HCC-related Liver Transplantation	Unknown status	No Results Available	Hepatocellular Carcinoma|Liver Transplantation|Magnetic Resonance Imaging	Other: Risk model of tumor relapse		https://ClinicalTrials.gov/show/NCT03981848
450	ECT204 T-Cell Therapy in Adults With Advanced HCC	Recruiting	No Results Available	Hepatocellular Carcinoma|Liver Cancer, Adult|Liver Neoplasm|Metastatic Liver Cancer	Biological: ECT204 T cells	City of Hope, Duarte, California, United States	https://ClinicalTrials.gov/show/NCT04864054
451	Study of Cytokine-induced Killer Cell (CIK) Treatment in Patients After Resection of Liver Cancer	Completed	No Results Available	Hepatocellular Carcinoma	Biological: cytokine-induced killer cell (CIK) treatment	Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT00769106
452	Stereotactic Body Radiotherapy (SBRT) Followed by Immunotherapy in Liver Cancer	Terminated	No Results Available	Hepatocellular Carcinoma	Drug: Nivolumab|Drug: Ipilimumab	University of Chicago, Chicago, Illinois, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States	https://ClinicalTrials.gov/show/NCT03203304
453	Next Generation " Pre-clinical Model for Colorectal Cancer Metastases and Hepatocellular Carcinomas (BORG)	Recruiting	No Results Available	Colorectal Cancer Metastases and Hepatocellular Carcinomas	Procedure: Tumor /metastases removal	ap-HM hopital nord, Marseille, France	https://ClinicalTrials.gov/show/NCT05384184
454	Accuracy of Endoscopic Ultrasound for Detection of Tumors of the Liver	Unknown status	No Results Available	Hepatocellular Carcinoma|Hepatoma|Cholangiocarcinoma|Liver Metastases	Procedure: Endoscopy ultrasound	Central Texas Veterans health Care System, Temple, Texas, United States	https://ClinicalTrials.gov/show/NCT00290316
455	Sorafenib in First-line Treatment of Advanced B Child Hepatocellular Carcinoma	Terminated	No Results Available	Advanced Adult Hepatocellular Carcinoma	Other: Best Supportive Care|Drug: sorafenib	Azienda Ospedaliera G. Rummo, Benevento, BN, Italy|Policlinico Giaccone, Palermo, PA, Italy|S. Orsola-Malpighi, Bologna, Italy|Ospedale Ramazzini di Carpi, Carpi, Italy|Osp. Civile Infermi, Faenza, Italy|Azienda Ospedaliera Careggi, Firenze, Italy|IRCCS-Azienda Ospedaliera Universitaria San Martino-IST, Genova, Italy|AO C. Poma, Mantova, Italy|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy|A.O.U. G.Martino- Policlinico Universita di Messina, Messina, Italy|Istituto Nazionale Tumori, Milano, Italy|A.O.U. Federico II, Napoli, Italy|AOU II Università di Napoli, Napoli, Italy|Istituto Nazionale dei Tumori, Napoli, Italy|Ospedale Cardarelli, Napoli, Italy|Azienda Ospedaliera Universitaria di Padova, Padova, Italy|Istituto Oncologico Veneto, Padova, Italy|A.O. Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy|Azienda Ospedaliero Universitaria di Parma, Parma, Italy|Ospedale Guglielmo da Saliceto, Piacenza, Italy|AO S. Carlo, Potenza, Italy|Policlinico Universitario Tor Vergata, Roma, Italy|Oncologia IRCCS - Casa Sollilevo Sofferenza, S. Giovanni Rotondo, Italy|Azienda Ospedaliera Universitaria Arcispedal, U.O. di Oncologia Clinica, Sant'Anna di Ferrara, Italy|A.O. Trevigilio - Caravaggio, Trevigilio, Italy	https://ClinicalTrials.gov/show/NCT01405573
456	Radiation Dose Escalation Study for Advanced Liver Cancer	Completed	No Results Available	Hepatocellular Carcinoma	Radiation: 3DCRT/IMRT		https://ClinicalTrials.gov/show/NCT00848094
457	Liver Transplantation Results in Hepatocellular Carcinoma Patients With Immunosuppression Without Steroids	Completed	No Results Available	Immunosuppression|Hepatocellular Carcinoma|Liver Transplantation|Post-operative Complications	Drug: solu medrol|Drug: a steroid-free immunosuppression protocol	Shanghai First People's Hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT01137084
458	Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer	Completed	No Results Available	Adult Primary Hepatocellular Carcinoma|Advanced Adult Primary Liver Cancer|Advanced Adult Hepatocellular Carcinoma|BCLC Stage B Adult Hepatocellular Carcinoma|BCLC Stage C Adult Hepatocellular Carcinoma	Dietary Supplement: Chinese herbal formulation PHY906|Drug: sorafenib tosylate|Other: laboratory biomarker analysis|Other: pharmacological study	City of Hope Medical Center, Duarte, California, United States	https://ClinicalTrials.gov/show/NCT01666756
459	Study of Pembrolizumab and Radiotherapy in Liver Cancer	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Pembrolizumab|Radiation: Stereotactic Body Radiotherapy (SBRT)	Princess Margaret Cancer Centre, Toronto, Ontario, Canada	https://ClinicalTrials.gov/show/NCT03316872
460	Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer and Cholangiocarcinoma	Completed	Has Results	Liver Cancer	Radiation: Proton Beam Irradiation	Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Pennsylvania, Roberts Proton Facility, Philadelphia, Pennsylvania, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT00976898
461	Proton Beam Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis	Recruiting	No Results Available	Liver Neoplasm|Portal Vein Tumor Thrombosis|Proton Therapy	Radiation: Proton beam therapy	Samsung Medical Center, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT02571946
462	Genetic Studies in Liver Cancer Patients	Unknown status	No Results Available	Hepatocellular Carcinoma		National Taiwan University Hospital, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT00172640
463	Efficacy Study of Pegylated Recombinant Human Arginase 1 as a Second-line Therapy in Patients With Advanced Liver Cancer	Completed	No Results Available	Hepatocellular Carcinoma	Biological: pegylated recombinant human arginase	Prince of Wales Hospital, the Chinese University of Hong Kong, Hong Kong, Hong Kong	https://ClinicalTrials.gov/show/NCT02089763
464	Comparison of Microwave and Radiofrequency Ablation for Liver	Completed	No Results Available	Hepatocellular Carcinoma	Device: microwave ablation|Device: radiofrequency ablation	Chinese PLA General Hospital, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT02539212
465	Adjuvant Chemotherapy Based on the Adenosine Triphosphate Tumor Chemosensitivity Assay for Hepatocellular Carcinoma After Liver Transplantation	Withdrawn	No Results Available	Hepatocellular Carcinoma	Drug: Individualized Chemotherapy|Drug: mFOLFOX6	First affiliated hospital, Zhejiang University, Hangzhou, Zhejiang, China	https://ClinicalTrials.gov/show/NCT02580253
466	Searching for the Liver Cancer-Related Biomarkers	Unknown status	No Results Available	Hepatocellular Carcinoma		National Taiwan University Hospital, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT00154544
467	A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer	Terminated	Has Results	Hepatocellular Carcinoma	Biological: BMS-986183|Biological: Nivolumab	Local Institution, Ottawa, Ontario, Canada|Local Institution, Seoul, Korea, Republic of|Local Institution, Singapore, Singapore|Local Institution, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT02828124
468	Stereotactic Body Radiation Therapy (SBRT) Versus Trans-Arterial Chemoembolization (TACE) as Bridge to Liver Transplant	Completed	No Results Available	Hepatocellular Carcinoma|HCC	Radiation: Stereotactic Body Radiation Therapy (SBRT)|Procedure: Trans-Arterial Chemoembolization (TACE)|Drug: Doxorubin	Lahey Hospital & Medical Center, Burlington, Massachusetts, United States	https://ClinicalTrials.gov/show/NCT02182687
469	Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma	Terminated	Has Results	Carcinoma, Hepatocellular|Hepatobiliary Neoplasm|Liver Carcinoma	Procedure: TACE|Procedure: SBRT	Stanford University School of Medicine, Stanford, California, United States	https://ClinicalTrials.gov/show/NCT01020812
470	Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical Resection	Active, not recruiting	No Results Available	Hepatocellular Carcinoma	Biological: Nivolumab|Radiation: Yttrium Y 90 Glass Microspheres	Northwestern University, Chicago, Illinois, United States	https://ClinicalTrials.gov/show/NCT03812562
471	Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer	Completed	No Results Available	Hepatocellular Carcinoma	Drug: ADI-PEG 20	Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States	https://ClinicalTrials.gov/show/NCT02101593
472	Safety, Efficacy, and Dosing of Stereotactic Radiosurgery for Hepato-cellular Carc/Colo-rectal Liver Metastases	Completed	Has Results	Liver Neoplasms|Colonic Neoplasms|Metastatic Cancer to Liver	Radiation: Stereotactic Radiosurgery using the CyberKnife System.	University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|East Carolina Medical School, Greenville, North Carolina, United States	https://ClinicalTrials.gov/show/NCT01528878
473	Taxoprexin® Treatment for Advanced Primary Cancers of the Liver	Terminated	No Results Available	Cancer of the Liver	Drug: Taxoprexin	University of Texas, MD Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT00422877
474	Contrast-Enhanced Ultrasound in Diagnosing Patients With Liver Cancer Undergoing Yttrium-90 Radioembolization	Withdrawn	No Results Available	Hepatocellular Carcinoma	Drug: Perflutren Lipid Microspheres|Drug: Sulfur Hexafluoride Lipid Microspheres|Device: Dynamic Contrast-Enhanced Ultrasound Imaging|Device: Positron Emission Tomography|Device: Computed Tomography|Biological: Yttrium-90 (90Y)	USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States	https://ClinicalTrials.gov/show/NCT03300401
475	A Study of Recombinant Vaccinia Virus to Evaluate the Safety and Efficacy of a Transdermal Injection Within the Tumor of Patients With Primary or Metastatic Hepatic Carcinoma	Completed	No Results Available	Neoplasms, Liver	Genetic: JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF)	Dong-A University Hospital, Busan, Korea, Republic of	https://ClinicalTrials.gov/show/NCT00629759
476	A Study to Assess Overall Survival and Treatment Patterns for Advanced Liver Cancer Participants Who Received Nivolumab Therapy	Completed	No Results Available	Hepatocellular Carcinoma		Bristol Myers Squibb, CORDS Research, Princeton, New Jersey, United States	https://ClinicalTrials.gov/show/NCT04161911
477	Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer	Recruiting	No Results Available	Resectable Hepatocellular Carcinoma	Biological: Nivolumab|Biological: Pegargiminase|Procedure: Resection	M D Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT04965714
478	Irinotecan and Flavopiridol in Treating Patients With Advanced Liver Cancer	Completed	No Results Available	Liver Cancer	Drug: alvocidib|Drug: irinotecan hydrochloride	Memorial Sloan-Kettering Cancer Center, New York, New York, United States	https://ClinicalTrials.gov/show/NCT00087282
479	Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors	Recruiting	No Results Available	Hepatocellular Carcinoma|Intrahepatic Cholangiocarcinoma	Drug: SD-101|Biological: Pembrolizumab|Biological: Nivolumab|Biological: Ipilimumab	MD Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT05220722
480	Perflutren Protein-Type A Microspheres and Contrast-Enhanced Ultrasound in Improving Response to Radioembolization Therapy in Patients With Liver Cancer	Recruiting	No Results Available	Hepatocellular Carcinoma	Procedure: Yttrium-90 Microsphere Radioembolization|Drug: Perflutren Protein-Type A Microspheres|Procedure: Dynamic Contrast-Enhanced Ultrasound Imaging	Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States	https://ClinicalTrials.gov/show/NCT03199274
481	Detection of Plasma DNA Methylation in Peripheral Blood From Patients With Resectable Liver Cancer	Recruiting	No Results Available	Resectable Hepatocellular Carcinoma	Procedure: Biospecimen Collection|Other: Electronic Health Record Review	Mayo Clinic in Rochester, Rochester, Minnesota, United States	https://ClinicalTrials.gov/show/NCT04856046
482	Irreversible Electroporation of Unresectable Liver Tumors	Withdrawn	No Results Available	Liver Metastases|Hepatocellular Carcinoma|Bile Duct Cancer	Procedure: Irreversible electroporation	Department of Gastrointestinal Surgery, Aalborg University Hospital, Aalborg, Denmark	https://ClinicalTrials.gov/show/NCT04404647
483	TACE With or Without Radiation Therapy in Treating Patients With Stage A-C Liver Cancer	Withdrawn	No Results Available	Adult Primary Hepatocellular Carcinoma|Recurrent Adult Primary Liver Cancer|Stage I Adult Primary Liver Cancer|Stage II Adult Primary Liver Cancer|Stage IIIA Adult Primary Liver Cancer	Procedure: transarterial chemoembolization|Radiation: stereotactic radiosurgery		https://ClinicalTrials.gov/show/NCT02070419
484	Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver	Completed	Has Results	Liver Cancer|Metastatic Cancer	Drug: cisplatin|Drug: doxorubicin|Drug: mitomycin|Procedure: embolization	Front Range Cancer Specialists, Fort Collins, Colorado, United States|Baptist Cancer Institute - Jacksonville, Jacksonville, Florida, United States|Winship Cancer Institute of Emory University, Altanta, Georgia, United States|Veterans Affairs Medical Center - Atlanta (Decatur), Decatur, Georgia, United States|Rush-Copley Cancer Care Center, Aurora, Illinois, United States|Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States|Hematology and Oncology Associates, Chicago, Illinois, United States|Veterans Affairs Medical Center - Lakeside Chicago, Chicago, Illinois, United States|Mercy Hospital and Medical Center, Chicago, Illinois, United States|Swedish Covenant Hospital, Chicago, Illinois, United States|Hinsdale Hematology Oncology Associates, Hinsdale, Illinois, United States|Midwest Center for Hematology/Oncology, Joliet, Illinois, United States|Joliet Oncology-Hematology Associates, Limited - West, Joliet, Illinois, United States|North Shore Oncology and Hematology Associates, Limited - Libertyville, Libertyville, Illinois, United States|Hematology Oncology Associates - Skokie, Skokie, Illinois, United States|Hematology/Oncology of the North Shore at Gross Point Medical Center, Skokie, Illinois, United States|Carle Cancer Center at Carle Foundation Hospital, Urbana, Illinois, United States|CCOP - Carle Cancer Center, Urbana, Illinois, United States|Saint Anthony Memorial Health Centers, Michigan City, Indiana, United States|Mercy Capitol Hospital, Des Moines, Iowa, United States|CCOP - Iowa Oncology Research Association, Des Moines, Iowa, United States|John Stoddard Cancer Center at Iowa Methodist Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates at John Stoddard Cancer Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates at Mercy Cancer Center, Des Moines, Iowa, United States|Mercy Cancer Center at Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|John Stoddard Cancer Center at Iowa Lutheran Hospital, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates - West Des Moines, West Des Moines, Iowa, United States|Borgess Medical Center, Kalamazooaa, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|Carol G. Simon Cancer Center at Morristown Memorial Hospital, Morristown, New Jersey, United States|Somerset Medical Center, Somerville, New Jersey, United States|Overlook Hospital, Summit, New Jersey, United States|Case Comprehensive Cancer Center, Cleveland, Ohio, United States|St. Rita's Medical Center, Lima, Ohio, United States|Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States|Albert Einstein Cancer Center, Philadelphia, Pennsylvania, United States	https://ClinicalTrials.gov/show/NCT00003907
485	Safety Study of Sorafenib Following Combined Therapy of Radiation and TACE for Liver Cancer	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: Sorafenib	Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT00999843
486	Phenotyping Liver Cancer Registry	Recruiting	No Results Available	Hepatocellular Carcinoma	Device: Image features extraction and clustering|Device: Phenotype signature database building	Assistance Publique - Hôpitaux de Paris (AP-HP) Groupe Hospitalier La Pitié-Salpêtrière, Paris, Ile De France, France	https://ClinicalTrials.gov/show/NCT04681274
487	Clinical Intervention Modelling, Planning and Proof for Ablation Cancer Treatment	Unknown status	No Results Available	Hepatocellular Carcinoma|Liver Metastases	Device: RFA therapy simulator	Medical University Graz, Graz, Austria|University Hospital Turku, Turku, Finland|Department of Diagnostic and Interventional Radiology, University Leipzig, Germany, Leipzig, Saxony, Germany|Radbound Universität Nijmegen, Nijmegen, Netherlands	https://ClinicalTrials.gov/show/NCT02745600
488	Delivering a Diuretic Into the Liver Artery Followed by Plugging up the Artery to Starve Out Liver Cancer Cells	Active, not recruiting	No Results Available	Unresectable Hepatocellular Carcinoma	Procedure: Hepatic artery embolization (HAE)|Drug: Bumetanide	Memoral Sloan Kettering Basking Ridge (Consent and follow-up only), Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth (Consent and follow-up only), Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen (Consent and follow-up only), Montvale, New Jersey, United States|Memorial Sloan Kettering Westchester (Consent and follow-up only), Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States	https://ClinicalTrials.gov/show/NCT03107416
489	Deep Liver Phenotyping and Immunology Study	Recruiting	No Results Available	Hepatocellular Carcinoma|Cholangiocarcinoma		John Radcliffe Hospital, Oxford, Oxfordshire, United Kingdom	https://ClinicalTrials.gov/show/NCT04946773
490	Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer	Active, not recruiting	No Results Available	Unresectable Hepatocellular Carcinoma	Device: TheraSphere	Banner - University Medical Center Phoenix, Phoenix, Arizona, United States|H Lee Moffitt Cancer Center, Tampa, Florida, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Illinois at Chicago, Chicago, Illinois, United States|Northshore Hospital, Evanston, Illinois, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|University of Louisville, Louisville, Kentucky, United States|Wayne State Harper Hospital, Detroit, Michigan, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|Montefiore Medical Center, Bronx, New York, United States|Weill Cornell Medical Center, New York, New York, United States|Miami Valley Hospital, Dayton, Ohio, United States|Legacy Meridian Park Medical Center, Tualatin, Oregon, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|St Marks Hospital, Salt Lake City, Utah, United States|University of Virginia Health System, Charlottesville, Virginia, United States|Sentra Norfolk General Hospital, Norfolk, Virginia, United States|Seattle Cancer Care Alliance/University of Washington Medical Center, Seattle, Washington, United States|CUB Hôpital Erasme, Bruxelles, Belgium|CHU Liege, Liege, Belgium|University of Alberta Hspital, Edmonton, Alberta, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|Toronto General Hospital, Toronto, Ontario, Canada|McGill University Health Centre / Royal Victoria Hospital, Montreal, Quebec, Canada|CHUM St. Luc, Montréal, Canada|Hôpital Jean Verdier, Bondy, France|CHU Estaing, Clermont-Ferrand, France|APHP Hôpital Henri Mondor, Creteil, France|CHU Dijon, Dijon, France|CHU de Grenoble, La Tronche, France|CHU Lyon - Hopital de la Croix Rousse, Lyon, France|Centre Léon-Bérard, Lyon, France|Hopital de la Timone CHU, Marseille, France|Hôpital Saint Eloi, Montpellier, France|CHU Hôtel-Dieu, Nantes, France|CHU de Nice, Nice, France|Hôpital Haut-Lévêque, CHU Bordeaux, Pessac Cedex, France|CHU de Poitiers, Poitiers, France|CHU Reims, Reims Cedex, France|Centre Eugene Marquis, Rennes Cedex, France|CHU Amiens Picardie - Hôpital Sud, Salouël, France|Hôpital de Hautepierre, Strasbourg, France|Hôpital Purpan, Toulouse, France|CHU Nancy, Vandoeuvre-les-Nancy, France|Institut Gustave Roussy, Villejuif Cedex, France|Hôpital Universitaire Paul Brousse, Villejuif, France|Universitätsklinikum Bonn, Bonn, Germany|Universitaetsklinikum Essen, Essen, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitätsklinikum Leipzig, Klinik für Diagnostische und Interventionelle Radiologie, Leipzig, Germany|Universitätsklinikum Tübingen, Diagnostische und Interventionelle Radiologie, Tübingen, Germany|Azienda Ospedaliero -Universitaria di Bologna, Bologna, Italy|St. Mary Hospital, Daegu, Korea, Republic of|Kyungpook National University Hospital, Daegu, Korea, Republic of|Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of|Kyungpook National University Hospital, Daegu, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|VUMC, Amsterdam, Netherlands|AMC, Amsterdam, Netherlands|UMCG, Groningen, Netherlands|LUMC, Leiden, Netherlands|MUMC, Maastricht, Netherlands|Erasmus MC, Rotterdam, Netherlands|National University Hospital, Singapore, Singapore|Hospital Infanta Cristina, Badajoz, Spain|Hospital Clinic i Provincial, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|UDIAT Corporacio Parc Tauli, Barcelona, Spain|Hospital Universitario Reina Sofia, Córdoba, Spain|Hospital Virgen de las Nieves, Granada, Spain|Hospital Universitario Gregorio Marañón, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Servicio de Radiología, Hospital Universitario Virgen de la Arrixaca., Murcia, Spain|Hosptal Universitario Central de Asturias (nuevo HUCA), Oviedo, Spain|Hospital Clínico Universitario, Salamanca, Spain|H. Virgen del Rocio, Sevilla, Spain|Hospital Universitario y Politecnico La Fe, Valencia, Spain|Hospital Clínico Universitario de Valladolid, Valladolid, Spain|Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain|New Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom|Addenbrooks Hospital, Cambridge, United Kingdom|Edinburgh Cancer Centre, Edinburgh, United Kingdom|Royal Surrey Country Hospital, Guildford, United Kingdom|Royal Liverpool University Hospital, Liverpool, United Kingdom|University College London Cancer Institute, London, United Kingdom|King's College Hospital;, London, United Kingdom|Imperial College London, London, United Kingdom|Christie Hospital, Manchester, United Kingdom|Freeman Hospital, Newcastle upon Tyne, United Kingdom|Weston Park Hospital, Sheffield, Sheffield, United Kingdom	https://ClinicalTrials.gov/show/NCT01556490
491	Study of Pegylated Human Recombinant Arginase for Liver Cancer (BCT-100-002)	Completed	No Results Available	Neoplasm|Hepatocellular Carcinoma	Biological: Pegylated Recombinant Human Arginase I	Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The University of Hong Kong, Hong Kong, Hong Kong	https://ClinicalTrials.gov/show/NCT01092091
492	Study of Pegylated Human Recombinant Arginase for Liver Cancer	Completed	No Results Available	Neoplasm|Hepatocellular Carcinoma	Biological: Pegylated Recombinant Human Arginase I|Drug: Doxorubicin	Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The University of Hong Kong, Hong Kong, Hong Kong	https://ClinicalTrials.gov/show/NCT00988195
493	Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC)	Completed	No Results Available	Fibrolamellar Carcinoma|Fibrolamellar Liver Cancer	Drug: everolimus|Drug: letrozole plus leuprolide|Drug: combination of everolimus, letrozole and leuprolide	University of California San Francisco, San Francisco, California, United States|John Hopkins Medical Center, Baltimore, Maryland, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States	https://ClinicalTrials.gov/show/NCT01642186
494	Transarterial Chemoembolization Using Doxorubicin Beads With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery	Unknown status	No Results Available	Liver Cancer	Drug: doxorubicin-eluting beads|Drug: sorafenib tosylate|Other: laboratory biomarker analysis|Other: pharmacogenomic studies|Other: pharmacological study|Procedure: quality-of-life assessment	Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust, Birmingham, England, United Kingdom|Bristol Royal Infirmary, Bristol, England, United Kingdom|Aintree University Hospital, Liverpool, England, United Kingdom|Royal Free Hospital, London, England, United Kingdom|King's College Hospital, London, England, United Kingdom|Royal Marsden - London, London, England, United Kingdom|Queen's Medical Centre, Nottingham, England, United Kingdom|Southampton General Hospital, Southampton, England, United Kingdom	https://ClinicalTrials.gov/show/NCT01324076
495	Study of Liver Resection With Versus Without Hepatic Inflow Occlusion for the HBV-related HCC	Unknown status	No Results Available	Liver Cancer|Surgery	Procedure: non-occlusion technique	Chinese PLA General Hospital, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT02563158
496	An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer	Active, not recruiting	No Results Available	Hepatocellular Carcinoma	Biological: Nivolumab|Drug: Sorafenib|Drug: Ipilimumab|Drug: Cabozantinib	USC Norris Comprehensive Cancer Center, Los Angeles, California, United States|Georgetown University Medical Center Lombardi Cancer Center, Washington, District of Columbia, United States|Sacred Heart Medical Group, Pensacola, Florida, United States|Emory University, Atlanta, Georgia, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Univ Of Michigan, Ann Arbor, Michigan, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Saint Joseph's Regional Medical Center, Paterson, New Jersey, United States|Providence Portland Medical Center, Portland, Oregon, United States|Local Institution, Houston, Texas, United States|QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|University Health Network - Princess Margaret Cancer Centre, Toronto, Ontario, Canada|CHUM, Montreal, Quebec, Canada|Local Institution, Angers, France|Local Institution, Creteil Cedex, France|Local Institution, Marseille Cedex 5, France|Local Institution, Marseille Cedex 9, France|Local Institution, Paris Cedex 13, France|Local Institution, Reims Cedex, France|Local Institution, Vandoeuvre les Nancy, France|Universitaetsklinikum Essen, Essen, Germany|Johann Wolfgang Goethe Universitaet, Frankfurt, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitaetsklinik Heidelberg, Heidelberg, Germany|Local Institution, Hong Kong, Hong Kong|Azienda Ospedaliera Di Bologna S. Orsola-Malpighi, Bologna, Italy|A.O.U. Careggi, Firenze, Italy|IRST Meldola, Meldola (FC), Italy|Istituto Europeo Di Oncologia, Milano, Italy|Istituto Nazionale Tumori, Napoli, Italy|I.O.V. Istituto Oncologico Veneto Ircss, Padova, Italy|Istituto Clinico Humanitas, Rozzano, Italy|Local Institution, Kashiwa-shi, Chiba, Japan|Local Institution, Kurume-shi, Fukuoka, Japan|Local Institution, Yokohama, Kanagawa, Japan|Local Institution, Kyoto-shi, Kyoto, Japan|Local Institution, Osaka-sayama-shi, Osaka, Japan|Local Institution, Saga, Japan|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, San Juan, Puerto Rico|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Pamplona, Spain|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taoyuan, Taiwan|Local Institution, London, Greater London, United Kingdom|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Glasgow, Lanarkshire, United Kingdom|Local Institution, Wirral, Merseyside, United Kingdom|Local Institution, Birmingham, West Midlands, United Kingdom|Local Institution, London, United Kingdom	https://ClinicalTrials.gov/show/NCT01658878
497	Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery	Active, not recruiting	No Results Available	Hepatocellular Carcinoma|Unresectable Hepatocellular Carcinoma	Drug: Cisplatin|Drug: Doxorubicin Hydrochloride|Drug: Doxorubicin-Eluting Beads|Other: Laboratory Biomarker Analysis|Drug: Mitomycin|Other: Pharmacological Study|Other: Placebo Administration|Drug: Sorafenib Tosylate	University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States|University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States|Mayo Clinic in Arizona, Scottsdale, Arizona, United States|University of Arizona Cancer Center-Orange Grove Campus, Tucson, Arizona, United States|Banner University Medical Center - Tucson, Tucson, Arizona, United States|University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States|John L McClellan Memorial Veterans Hospital, Little Rock, Arkansas, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Marin Cancer Care Inc, Greenbrae, California, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|Saint Joseph Hospital - Orange, Orange, California, United States|Stanford Cancer Institute Palo Alto, Palo Alto, California, United States|Zuckerberg San Francisco General Hospital, San Francisco, California, United States|UCSF Medical Center-Mount Zion, San Francisco, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|UCHealth Memorial Hospital Central, Colorado Springs, Colorado, United States|Porter Adventist Hospital, Denver, Colorado, United States|Saint Mary's Hospital and Regional Medical Center, Grand Junction, Colorado, United States|Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut, United States|Yale University, New Haven, Connecticut, United States|Beebe Medical Center, Lewes, Delaware, United States|Christiana Care Health System-Christiana Hospital, Newark, Delaware, United States|Veterans Affairs Medical Center -Washington DC, Washington, District of Columbia, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Lakeland Regional Health Hollis Cancer Center, Lakeland, Florida, United States|Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States|Medical Center of Central Georgia, Macon, Georgia, United States|Pali Momi Medical Center, 'Aiea, Hawaii, United States|Hawaii Cancer Care Inc - Waterfront Plaza, Honolulu, Hawaii, United States|Queen's Medical Center, Honolulu, Hawaii, United States|University of Hawaii Cancer Center, Honolulu, Hawaii, United States|Hawaii Cancer Care Inc-Liliha, Honolulu, Hawaii, United States|Queen's Cancer Center - Kuakini, Honolulu, Hawaii, United States|The Cancer Center of Hawaii-Liliha, Honolulu, Hawaii, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Castle Medical Center, Kailua, Hawaii, United States|Wilcox Memorial Hospital and Kauai Medical Clinic, Lihue, Hawaii, United States|Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States|Saint Luke's Cancer Institute - Boise, Boise, Idaho, United States|Saint Luke's Cancer Institute - Fruitland, Fruitland, Idaho, United States|Saint Luke's Cancer Institute - Meridian, Meridian, Idaho, United States|Saint Luke's Cancer Institute - Nampa, Nampa, Idaho, United States|Saint Luke's Cancer Institute - Twin Falls, Twin Falls, Idaho, United States|Saint Joseph Medical Center, Bloomington, Illinois, United States|Illinois CancerCare-Bloomington, Bloomington, Illinois, United States|Graham Hospital Association, Canton, Illinois, United States|Illinois CancerCare-Canton, Canton, Illinois, United States|Illinois CancerCare-Carthage, Carthage, Illinois, United States|Memorial Hospital, Carthage, Illinois, United States|Hematology and Oncology Associates, Chicago, Illinois, United States|Northwestern University, Chicago, Illinois, United States|John H Stroger Jr Hospital of Cook County, Chicago, Illinois, United States|University of Illinois, Chicago, Illinois, United States|Swedish Covenant Hospital, Chicago, Illinois, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Heartland Cancer Research NCORP, Decatur, Illinois, United States|Eureka Hospital, Eureka, Illinois, United States|Illinois CancerCare-Eureka, Eureka, Illinois, United States|Saint Francis Hospital, Evanston, Illinois, United States|Illinois CancerCare-Galesburg, Galesburg, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Illinois CancerCare-Havana, Havana, Illinois, United States|Mason District Hospital, Havana, Illinois, United States|Hematology Oncology Associates of Illinois-Highland Park, Highland Park, Illinois, United States|Edward Hines Jr VA Hospital, Hines, Illinois, United States|Hinsdale Hematology Oncology Associates Incorporated, Hinsdale, Illinois, United States|Midwest Center for Hematology Oncology, Joliet, Illinois, United States|Presence Saint Mary's Hospital, Kankakee, Illinois, United States|Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States|AMITA Health Adventist Medical Center, La Grange, Illinois, United States|AMG Libertyville - Oncology, Libertyville, Illinois, United States|Illinois CancerCare-Macomb, Macomb, Illinois, United States|Mcdonough District Hospital, Macomb, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Holy Family Medical Center, Monmouth, Illinois, United States|Illinois CancerCare-Monmouth, Monmouth, Illinois, United States|Illinois Cancer Specialists-Niles, Niles, Illinois, United States|Bromenn Regional Medical Center, Normal, Illinois, United States|Carle Cancer Institute Normal, Normal, Illinois, United States|Illinois CancerCare-Community Cancer Center, Normal, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Ottawa Regional Hospital and Healthcare Center, Ottawa, Illinois, United States|Illinois CancerCare-Pekin, Pekin, Illinois, United States|OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center, Pekin, Illinois, United States|Pekin Hospital, Pekin, Illinois, United States|Proctor Hospital, Peoria, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|OSF Saint Francis Medical Center, Peoria, Illinois, United States|Illinois CancerCare-Peru, Peru, Illinois, United States|Illinois Valley Hospital, Peru, Illinois, United States|Illinois CancerCare-Princeton, Princeton, Illinois, United States|Perry Memorial Hospital, Princeton, Illinois, United States|West Suburban Medical Center, River Forest, Illinois, United States|Swedish American Hospital, Rockford, Illinois, United States|SwedishAmerican Regional Cancer Center/ACT, Rockford, Illinois, United States|Hematology Oncology Associates of Illinois - Skokie, Skokie, Illinois, United States|Illinois CancerCare-Spring Valley, Spring Valley, Illinois, United States|Medical Oncology and Hematology Associates-West Des Moines, Clive, Iowa, United States|Iowa Methodist Medical Center, Des Moines, Iowa, United States|Iowa-Wide Oncology Research Coalition NCORP, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Des Moines, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Laurel, Des Moines, Iowa, United States|Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|Iowa Lutheran Hospital, Des Moines, Iowa, United States|HaysMed University of Kansas Health System, Hays, Kansas, United States|Hutchinson Regional Medical Center, Hutchinson, Kansas, United States|University of Kansas Cancer Center-West, Kansas City, Kansas, United States|University of Kansas Cancer Center, Kansas City, Kansas, United States|Menorah Medical Center, Overland Park, Kansas, United States|University of Kansas Cancer Center-Overland Park, Overland Park, Kansas, United States|Saint Luke's South Hospital, Overland Park, Kansas, United States|Ascension Via Christi - Pittsburg, Pittsburg, Kansas, United States|Kansas City NCI Community Oncology Research Program, Prairie Village, Kansas, United States|Salina Regional Health Center, Salina, Kansas, United States|Advent Health - Shawnee Mission Medical Center, Shawnee Mission, Kansas, United States|University of Kansas Health System Saint Francis Campus, Topeka, Kansas, United States|University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States|Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States|LSU Health Sciences Center at Shreveport, Shreveport, Louisiana, United States|Saint Agnes Hospital, Baltimore, Maryland, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Christiana Care - Union Hospital, Elkton, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Boston Medical Center, Boston, Massachusetts, United States|Lahey Hospital and Medical Center, Burlington, Massachusetts, United States|Michigan Cancer Research Consortium NCORP, Ann Arbor, Michigan, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Beaumont Hospital - Dearborn, Dearborn, Michigan, United States|Ascension Saint John Hospital, Detroit, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Genesys Regional Medical Center-West Flint Campus, Flint, Michigan, United States|Allegiance Health, Jackson, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Borgess Medical Center, Kalamazoo, Michigan, United States|Sparrow Hospital, Lansing, Michigan, United States|Saint Mary Mercy Hospital, Livonia, Michigan, United States|UP Health System Marquette, Marquette, Michigan, United States|Saint Joseph Mercy Oakland, Pontiac, Michigan, United States|Lake Huron Medical Center, Port Huron, Michigan, United States|Ascension Saint Mary's Hospital, Saginaw, Michigan, United States|Ascension Providence Hospitals - Southfield, Southfield, Michigan, United States|Saint John Macomb-Oakland Hospital, Warren, Michigan, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Mercy Hospital, Coon Rapids, Minnesota, United States|Fairview Southdale Hospital, Edina, Minnesota, United States|Unity Hospital, Fridley, Minnesota, United States|Hutchinson Area Health Care, Hutchinson, Minnesota, United States|Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota, United States|Saint John's Hospital - Healtheast, Maplewood, Minnesota, United States|Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|North Memorial Medical Health Center, Robbinsdale, Minnesota, United States|Metro Minnesota Community Oncology Research Consortium, Saint Louis Park, Minnesota, United States|Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Saint Francis Regional Medical Center, Shakopee, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Rice Memorial Hospital, Willmar, Minnesota, United States|Minnesota Oncology Hematology PA-Woodbury, Woodbury, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Veterans Administration, Columbia, Missouri, United States|Truman Medical Centers, Kansas City, Missouri, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|Saint Joseph Health Center, Kansas City, Missouri, United States|North Kansas City Hospital, Kansas City, Missouri, United States|Heartland Hematology and Oncology Associates Incorporated, Kansas City, Missouri, United States|Kansas City Veterans Affairs Medical Center, Kansas City, Missouri, United States|The University of Kansas Cancer Center-South, Kansas City, Missouri, United States|Research Medical Center, Kansas City, Missouri, United States|University of Kansas Cancer Center - North, Kansas City, Missouri, United States|University of Kansas Cancer Center - Lee's Summit, Lee's Summit, Missouri, United States|Saint Luke's East - Lee's Summit, Lee's Summit, Missouri, United States|Heartland Regional Medical Center, Saint Joseph, Missouri, United States|Saint Joseph Oncology Inc, Saint Joseph, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Northern Rockies Radiation Oncology Center, Billings, Montana, United States|Saint Vincent Healthcare, Billings, Montana, United States|Montana Cancer Consortium NCORP, Billings, Montana, United States|Saint Vincent Frontier Cancer Center, Billings, Montana, United States|Bozeman Deaconess Hospital, Bozeman, Montana, United States|Saint James Community Hospital and Cancer Treatment Center, Butte, Montana, United States|Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana, United States|Berdeaux, Donald MD (UIA Investigator), Great Falls, Montana, United States|Great Falls Clinic, Great Falls, Montana, United States|Northern Montana Hospital, Havre, Montana, United States|Saint Peter's Community Hospital, Helena, Montana, United States|Glacier Oncology PLLC, Kalispell, Montana, United States|Kalispell Medical Oncology, Kalispell, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Montana Cancer Specialists, Missoula, Montana, United States|Saint Patrick Hospital - Community Hospital, Missoula, Montana, United States|Community Medical Hospital, Missoula, Montana, United States|Guardian Oncology and Center for Wellness, Missoula, Montana, United States|CHI Health Saint Francis, Grand Island, Nebraska, United States|Great Plains Health Callahan Cancer Center, North Platte, Nebraska, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Renown Regional Medical Center, Reno, Nevada, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Cooper Hospital University Medical Center, Camden, New Jersey, United States|Virtua Memorial, Mount Holly, New Jersey, United States|Rutgers New Jersey Medical School, Newark, New Jersey, United States|MD Anderson Cancer Center at Cooper-Voorhees, Voorhees, New Jersey, United States|Virtua Voorhees, Voorhees, New Jersey, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Veteran Affairs New York Harbor Healthcare System-Brooklyn Campus, Brooklyn, New York, United States|Maimonides Medical Center, Brooklyn, New York, United States|Mount Sinai Union Square, New York, New York, United States|Veterans Affairs New York Harbor Healthcare System-Manhattan Campus, New York, New York, United States|Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States|Mount Sinai West, New York, New York, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Novant Health Presbyterian Medical Center, Charlotte, North Carolina, United States|Rutherford Hospital, Rutherfordton, North Carolina, United States|Southeast Clinical Oncology Research Consortium NCORP, Winston-Salem, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|University of Cincinnati Cancer Center-UC Medical Center, Cincinnati, Ohio, United States|Case Western Reserve University, Cleveland, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|ProMedica Flower Hospital, Sylvania, Ohio, United States|University of Toledo, Toledo, Ohio, United States|Mercy Health - Saint Anne Hospital, Toledo, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Oklahoma Cancer Specialists and Research Institute-Tulsa, Tulsa, Oklahoma, United States|Legacy Mount Hood Medical Center, Gresham, Oregon, United States|Legacy Good Samaritan Hospital and Medical Center, Portland, Oregon, United States|Legacy Emanuel Hospital and Health Center, Portland, Oregon, United States|Legacy Meridian Park Hospital, Tualatin, Oregon, United States|Saint Luke's University Hospital-Bethlehem Campus, Bethlehem, Pennsylvania, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Einstein Medical Center Philadelphia, Philadelphia, Pennsylvania, United States|Roger Williams Medical Center, Providence, Rhode Island, United States|AnMed Health Cancer Center, Anderson, South Carolina, United States|AnMed Health Hospital, Anderson, South Carolina, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Prisma Health Cancer Institute - Easley, Easley, South Carolina, United States|Greenville Health System Cancer Institute-Andrews, Greenville, South Carolina, United States|Saint Francis Hospital, Greenville, South Carolina, United States|Prisma Health Cancer Institute - Greer, Greer, South Carolina, United States|Spartanburg Medical Center, Spartanburg, South Carolina, United States|Jackson-Madison County General Hospital, Jackson, Tennessee, United States|University of Tennessee - Knoxville, Knoxville, Tennessee, United States|The Don and Sybil Harrington Cancer Center, Amarillo, Texas, United States|Dell Seton Medical Center at The University of Texas, Austin, Texas, United States|University of Texas Medical Branch, Galveston, Texas, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States|Bon Secours Saint Francis Medical Center, Midlothian, Virginia, United States|Bon Secours Saint Mary's Hospital, Richmond, Virginia, United States|Hunter Holmes McGuire Veterans Administration Medical Center, Richmond, Virginia, United States|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States|MultiCare Auburn Medical Center, Auburn, Washington, United States|Highline Medical Center-Main Campus, Burien, Washington, United States|Providence Regional Cancer System-Centralia, Centralia, Washington, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Saint Francis Hospital, Federal Way, Washington, United States|Saint Clare Hospital, Lakewood, Washington, United States|Providence - Saint Peter Hospital, Olympia, Washington, United States|MultiCare Good Samaritan Hospital, Puyallup, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Kaiser Permanente Washington, Seattle, Washington, United States|MultiCare Allenmore Hospital, Tacoma, Washington, United States|MultiCare Tacoma General Hospital, Tacoma, Washington, United States|Northwest NCI Community Oncology Research Program, Tacoma, Washington, United States|Saint Joseph Medical Center, Tacoma, Washington, United States|Legacy Salmon Creek Hospital, Vancouver, Washington, United States|West Virginia University Healthcare, Morgantown, West Virginia, United States|Princeton Community Hospital, Princeton, West Virginia, United States|University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States|Marshfield Medical Center-Marshfield, Marshfield, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Rocky Mountain Oncology, Casper, Wyoming, United States|Welch Cancer Center, Sheridan, Wyoming, United States	https://ClinicalTrials.gov/show/NCT01004978
498	Pressure-enabled Delivery in Radioembolization (TriNav Study)	Recruiting	No Results Available	Liver Cancer|Hepatocellular Carcinoma|Metastatic Colorectal Cancer	Device: Standard microcatheter|Device: PEDD device	Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States	https://ClinicalTrials.gov/show/NCT05128032
499	HAIC Plus H101 vs HAIC Alone for Unresectable HCC at BCLC A-B	Recruiting	No Results Available	Hepatocellular Carcinoma	Procedure: HAIC of FOLFOX|Drug: H101|Drug: Placebos	Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT03780049
500	Chemoembolization Using LifePearl Polyethylene Glycol Drug Eluting Microspheres With Doxorubicin in HCC	Unknown status	No Results Available	Hepatocellular Carcinoma	Device: Chemoembolization Using LifePearl|Drug: Doxorubicin	Antonio Nicolini, Milano, Italy	https://ClinicalTrials.gov/show/NCT03734068
501	Combination Treatment for Advanced Liver Cancer	Withdrawn	No Results Available	Hepatocellular Carcinoma|Hepatic Portal Vein Tumor Invasion	Procedure: chemoembolization|Device: endovascular stents implantation|Procedure: iodine-125 seed strand implantation	Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT02149771
502	Screening for Liver Cancer With CT vs. Ultrasound in Patients With Advanced Liver Disease	Unknown status	No Results Available	Cirrhosis|End Stage Liver Disease|Hepatitis C	Procedure: Screening	Minneapolis Veterans Affairs Medical Center, Minneapolis, Minnesota, United States	https://ClinicalTrials.gov/show/NCT01350167
503	Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma	Completed	No Results Available	Advanced Hepatocellular Carcinoma|Hepatocellular Carcinoma|Liver Cancer|Liver Neoplasms|Hepatic Cancer|Hepatic Carcinoma	Drug: H3B-6527	USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|UC Irvine Medical Center, Orange, California, United States|UCLA Medical Center, Santa Monica, California, United States|Georgetown Unversity Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States|Northwestern Unversity, Chicago, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|John theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Duke University Cancer Center, Durham, North Carolina, United States|University of Cincinnati Cancer Institute, Cincinnati, Ohio, United States|University of Pennsylsvania - Perelman Cancer Center for Advanced Medicine, Philadelphia, Pennsylvania, United States|Simmons Comprehensive Cancer Center, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|McGuire VA Medical Center, Richmond, Virginia, United States|UCL Cliniques universitaires Saint-Luc, Woluwe-Saint-Lambert, Brussels, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|Cross Cancer Institute, Edmonton, Alberta, Canada|Jurvanski Cancer Center, Hamilton, Ontario, Canada|Institut Bergonié, Bordeaux, France|Centre Oscar Lambret, Lille, France|Hôpital Haut-Lévêque - CHU de Bordeaux, Pessac, France|Centre Eugène Marquis, Rennes, France|IRCCS Istituto Scientifico Romagnolo per lo studio e la cura dei tumori - U.O. di Oncologia Medica, Meldola, Italy|IRCCS Ospedale San Raffaele S.r.l. - PPDS, Milano, Italy|Azienda Ospedaliero Universitaria - Policlinico di Modena, Modena, Italy|Asan Medical Center, Seoul, Korea, Republic of|Altay Regional Oncology Center, Barnaul, Altay, Re, Russian Federation|Russian Oncology Research Center n a N N Blokhin, Moscow, Russian Federation|Omsk Regional Oncology Center, Omsk, Russian Federation|Railway Clinical Hospital JSC RZhD, Saint Petersburg, Russian Federation|City Clinical Oncology Dispensary, Saint Petersburg, Russian Federation|National University Cancer Insitute, Singapore, Singapore|Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain|Clínica Universidad de Navarra, Pamplona, Navarra, Spain|Hospital Universitario de Badajoz, Badajoz, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|General Universitario Gregorio Maranon, Madrid, Spain|START Madrid FJD, Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain|Hospital Universitario HM Sanchinarro, Madrid, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Taichung Veterans General Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|Sarah Cannon Research Institute UK - SCRI - PPDS, London, United Kingdom	https://ClinicalTrials.gov/show/NCT02834780
504	Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery	Completed	Has Results	Advanced Adult Hepatocellular Carcinoma|Non-Resectable Hepatocellular Carcinoma	Drug: Tivozanib (1mg)|Drug: Tivozanib (1.5mg)	Roswell Park Cancer Institute, Buffalo, New York, United States|Case Western Reserve University, Cleveland, Ohio, United States	https://ClinicalTrials.gov/show/NCT01835223
505	18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant	Recruiting	No Results Available	Adult Hepatocellular Carcinoma|Resectable Hepatocellular Carcinoma|Cholangiocarcinoma|Benign Liver Tumor|Metastases to Liver	Biological: Fluorine F 18 L-glutamate Derivative 18F-FSPG|Biological: Carbon C 11 Acetate|Procedure: Positron Emission Tomography|Other: Laboratory Biomarker Analysis|Biological: Fluorine F 18 2-deoxy-2-(18F)fluoro-D-glucose	MD Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT02379377
506	Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery	Completed	No Results Available	Kidney Cancer|Liver Cancer	Drug: hypoxia-activated prodrug TH-302|Drug: sorafenib tosylate	Mayo Clinic Scottsdale, Scottsdale, Arizona, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States	https://ClinicalTrials.gov/show/NCT01497444
507	Comparison of Biannual Ultrasonography and Annual Unenhanced Magnetic Resonance Imaging for HCC Surveillance	Active, not recruiting	No Results Available	Cirrhosis|Hepatocellular Carcinoma	Procedure: Biannual ultrasonography|Procedure: Annual noncontrast liver MRI|Procedure: Contrast enhanced liver CT	Seoul National University Hospital, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT02854241
508	Chemotherapy in Treating Patients With Liver Cancer	Unknown status	No Results Available	Liver Cancer	Drug: cisplatin-e therapeutic implant	Johns Hopkins Oncology Center, Baltimore, Maryland, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|Prince of Wales Hospital, Shatin, New Territories, Hong Kong	https://ClinicalTrials.gov/show/NCT00003044
509	A Study to Determine Whether Chemotherapy, Bevazicumab, and Atezolizumab is Better Than Chemotherapy Alone in Patients With Advanced Liver Cancer	Recruiting	No Results Available	Combined Hepatocellular Carcinoma and Cholangiocarcinoma|Stage III Liver Cancer|Stage IV Liver Cancer|Stage IVA Liver Cancer|Stage IVB Liver Cancer	Biological: Atezolizumab|Biological: Bevacizumab|Drug: Cisplatin|Drug: Gemcitabine Hydrochloride	Carle on Vermilion, Danville, Illinois, United States|Carle Physician Group-Effingham, Effingham, Illinois, United States|Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|The Carle Foundation Hospital, Urbana, Illinois, United States|Memorial Hospital of South Bend, South Bend, Indiana, United States	https://ClinicalTrials.gov/show/NCT05211323
510	Microbiota Study in Liver Transplanted Patients	Unknown status	No Results Available	Cirrhosis|Hepatocellular Carcinoma|Liver Transplant|Microbiota	Other: Multiple sampling	CHU de GRENOBLE ALPES, Grenoble, France	https://ClinicalTrials.gov/show/NCT03507140
511	A Pilot Study to Assess Theragnostically Planned Liver Radiation to Optimize Radiation Therapy	Completed	Has Results	Liver Cancer|Hepatocellular Carcinoma|Cholangiocarcinoma	Diagnostic Test: Hepatobiliary Iminodiacetic Acid (HIDA) scan	Indiana University Melvin & Bren Simon Cancer Center, Indianapolis, Indiana, United States	https://ClinicalTrials.gov/show/NCT03338062
512	Preoperative Pain Control in Liver Surgery Patients	Completed	No Results Available	Pain, Postoperative|Hepatocellular Carcinoma	Drug: Pregabalin|Drug: Placebo (for Pregabalin)	Eastern Hepatobiliary Surgery Hospital, Shanghai, China	https://ClinicalTrials.gov/show/NCT01923948
513	A Non-Randomized Study of Internal Radiation Therapy to the Liver in Patients With Primary Liver Cancer for Whom Surgery is Not Possible.	Unknown status	No Results Available	Liver Cancer	Device: Brachytherapy	St. Joseph's Hospital, Tampa, Florida, United States	https://ClinicalTrials.gov/show/NCT00152087
514	Sonazoid Enhanced Liver Cancer Trial for Early Detection	Unknown status	No Results Available	Hepatocellular Carcinoma|Liver Cirrhosis|Hepatitis B|Hepatitis C	Device: CE-US (Sonazoid™)|Device: B-mode US	Kinki University School of Medicine, Department of Gastroenterology and Hepatology, Osaka-Sayama, Osaka, Japan	https://ClinicalTrials.gov/show/NCT00822991
515	Laparoscopic Hepatectomy Versus Open Hepatectomy for PHC	Completed	No Results Available	Primary Liver Carcinoma	Procedure: Open hepatectomy|Procedure: Laparoscope hepatectomy	Southwest Hospital, Chongqing, Chongqing, China	https://ClinicalTrials.gov/show/NCT02014025
516	A Study to Test the Safety and Feasibility of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Liver Cancer	Recruiting	No Results Available	Liver Cancer	Drug: Drug Eluting Bead Transarterial Chemoembolization|Drug: Nivolumab	Washington University School of Medicine, Saint Louis, Missouri, United States|Memorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States|Memorial Sloan Kettering Cancer Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Nassau, Uniondale, New York, United States|Abramson Cancer Center at University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States	https://ClinicalTrials.gov/show/NCT03143270
517	A Pilot Study to Evaluate the Safety of a 3 Weeks Sitagliptin Treatment in HCC Patients Undergoing Liver Resection	Completed	No Results Available	Hepato Carcinoma	Drug: Sitagliptin	Pitié-Salpêtrière Hospital, Paris, France	https://ClinicalTrials.gov/show/NCT02650427
518	Multi-analyte Blood Test Clinical Trial	Not yet recruiting	No Results Available	Liver Cirrhosis|Liver Cancer|HCC|Hepatocellular Carcinoma	Diagnostic Test: Multi-analyte Blood Test		https://ClinicalTrials.gov/show/NCT05199259
519	The Assesment of MMP-1 Genotypes Polymorphism as a Risk Factor for HCC in Chronic HCV Patients With LC	Not yet recruiting	No Results Available	Hepatocellular Carcinoma	Diagnostic Test: MMP1 genotypes polymorphism		https://ClinicalTrials.gov/show/NCT03722628
520	Fusion Imaging Contrast-enhanced Ultrasound LI-RADS	Not yet recruiting	No Results Available	Hepatocellular Carcinoma	Diagnostic Test: Fusion imaging contrast-enhanced ultrasound	Tianjin Third Central Hospital, Tianjin, Tianjin, China	https://ClinicalTrials.gov/show/NCT04955119
521	Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery	Terminated	Has Results	Liver Cancer	Drug: doxorubicin hydrochloride|Drug: sunitinib malate|Other: laboratory biomarker analysis|Procedure: hepatic artery embolization|Procedure: quality-of-life assessment	Roswell Park Cancer Institute, Buffalo, New York, United States	https://ClinicalTrials.gov/show/NCT00524316
522	Evaluation of Diagnostic Accuracy of CEUS for HCC Diagnosis	Active, not recruiting	No Results Available	Hepatocellular Carcinoma	Diagnostic Test: contrast-enhanced ultrasound|Diagnostic Test: EOB-MRI	Seoul National University Hospital, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT03742453
523	Chemotherapy in Treating Patients With Unresectable Primary or Metastatic Kidney Cancer	Withdrawn	No Results Available	Liver Cancer|Metastatic Cancer	Drug: Pyrazoloacridine		https://ClinicalTrials.gov/show/NCT00003714
524	Neo-TACE-HAIC for BCLC B Stage HCC	Recruiting	No Results Available	Hepatocellular Carcinoma	Procedure: neo-TACE-HAIC+Surgery|Procedure: Surgery alone	Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT04424043
525	Neo-TACE-HAIC for High-risk BCLC A Stage HCC (NeoconceptA)	Recruiting	No Results Available	Hepatocellular Carcinoma	Procedure: neo-TACE-HAIC+Surgery|Procedure: Surgery alone	Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT04777942
526	Effects of Antiviral Therapy on HBV Reactivation	Completed	No Results Available	Liver Cancer	Drug: Entecavir therapy		https://ClinicalTrials.gov/show/NCT02829359
527	to Assess the Accuracy and Reliability of the Ga68-Dolacga Positron Emission Tomography Compared to Computer Tomography Volumetry and Indocyanine Green Retention Test for Measurement of Liver Reserve	Not yet recruiting	No Results Available	Hepatic Carcinoma	Drug: Ga68-Dolacga Injection	Linkon Chang Gung Memorial Hospital, Taoyuan City, Taiwan	https://ClinicalTrials.gov/show/NCT05007548
528	Safety and Effectiveness of Eye90 Microspheres™ in the Treatment of Unresectable HCC and mCRC	Recruiting	No Results Available	Hepatocellular Carcinoma Non-resectable|Metastatic Colorectal Cancer|Liver Cancer	Device: Eye90 Microspheres	Auckland District Health Board, Grafton, New Zealand	https://ClinicalTrials.gov/show/NCT04926376
529	Thalidomide Plus Interferon Alfa in Treating Patients With Progressive Liver Cancer That Cannot be Surgically Removed	Completed	No Results Available	Liver Cancer	Biological: recombinant interferon alfa|Drug: thalidomide	NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States	https://ClinicalTrials.gov/show/NCT00006006
530	TACE With or Without SBRT as Bridging Therapy for Pre-transplant HCC Patients	Active, not recruiting	No Results Available	Hepatocellular Carcinoma	Radiation: TACE transarterial chemoembolization|Radiation: stereotatic body radiotherapy (SBRT)	Loyola University Medical Center, Maywood, Illinois, United States|Oregon Health & Science University, Portland, Oregon, United States|Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States	https://ClinicalTrials.gov/show/NCT01918683
531	Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1	Withdrawn	No Results Available	Hepatocellular Carcinoma	Drug: Sorafenib|Drug: S-1|Drug: Oxaliplatin	First affiliated hospital, Zhejiang University, Hangzhou, China	https://ClinicalTrials.gov/show/NCT02129322
532	Sirolimus-based Immunosuppression Treatment Regimen for Liver Transplantation	Not yet recruiting	No Results Available	Liver Transplantation	Drug: Tacrolimus|Drug: Tacrolimus (Tacrolimus elimination)|Drug: Sirolimus|Drug: MMF and/or steroids	Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China|Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China|First Affiliated Hospital, Sun Yat-Sen University, Guanzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT03500848
533	Prognostic Value of Liver Cancer CTCs Isolated by a Novel Microfluidic Platform	Recruiting	No Results Available	Hepatocellular Carcinoma|Circulating Tumor Cell|Whole Genome Sequencing		the second affiliated hospital of Chongqing Medical University, Chongqing, China	https://ClinicalTrials.gov/show/NCT05242237
534	Dose Escalation Study Combining Oral Capecitabine (Xeloda) and Radiotherapy for Patients With Unresectable Liver or Cholangiocarcinoma	Terminated	No Results Available	Cancer of Liver	Drug: Capecitabine (Xeloda)	James A. Haley Veterans Administration Hospital, Tampa, Florida, United States	https://ClinicalTrials.gov/show/NCT00216437
535	Liver Transplantation From Living Donors For Treatment Of Non-Resectable Colorectal Carcinoma Liver Metastases: A Registry Study	Recruiting	No Results Available	Colorectal Cancer Metastatic	Procedure: Liver transplantation	University of Rochester Medical Center, Rochester, New York, United States	https://ClinicalTrials.gov/show/NCT05248581
536	Sorafenib and TRC105 in Hepatocellular Cancer	Completed	Has Results	Hepatoma|Liver Neoplasms|Adenoma, Liver Cell|Carcinoma, Hepatocellular|Liver Neoplasms, Experimental	Drug: TRC 105|Drug: Sorafenib	National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States	https://ClinicalTrials.gov/show/NCT01306058
537	The Treatment of Bioartificial Liver With hiHep Cells After Extensive Hepatectomy	Recruiting	No Results Available	Hepatoma Resectable	Biological: hiHep bioartificial liver therapy	Department of General Surgery, Institute of Minimally Invasive Surgery, Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, China	https://ClinicalTrials.gov/show/NCT05035108
538	Immunological Response After Ablative Therapy in the Liver	Withdrawn	No Results Available	Hepatocellular Carcinoma|Immune Response	Device: Microwave ablation|Device: Irreversible electroporation	Department of Surgery and Urology, Danderyd Hospital, Stockholm, Sweden	https://ClinicalTrials.gov/show/NCT03040453
539	Vitamin B-6 and Glutathione on Inflammation, Homocysteine, Oxidative Stress and Antioxidant Capacities	Unknown status	No Results Available	Liver Cirrhosis|Liver Cancer	Dietary Supplement: vitamin B-6|Dietary Supplement: Glutathione|Dietary Supplement: Dextrins	Taichung Veterans General Hospital, Taichung, Taiwan	https://ClinicalTrials.gov/show/NCT02321579
540	A Study of Avastin (Bevacizumab) and Transarterial Chemoembolisation (TACE) Treatment in Patients With Liver Cancer	Completed	Has Results	Liver Cancer	Drug: Bevacizumab|Procedure: Transarterial chemoembolisation (TACE)	Hong Kong, Hong Kong|Hong Kong, Hong Kong|Hong Kong, Hong Kong	https://ClinicalTrials.gov/show/NCT00576199
541	MRI With Gadoxetate Disodium in Measuring Tumors in Patients With Liver Cancer	Completed	No Results Available	Adult Hepatocellular Carcinoma|Advanced Adult Hepatocellular Carcinoma|BCLC Stage 0 Adult Hepatocellular Carcinoma|BCLC Stage A Adult Hepatocellular Carcinoma|BCLC Stage B Adult Hepatocellular Carcinoma|BCLC Stage C Adult Hepatocellular Carcinoma|BCLC Stage D Adult Hepatocellular Carcinoma|Localized Non-Resectable Adult Liver Carcinoma|Localized Resectable Adult Liver Carcinoma	Drug: Gadoxetate Disodium|Device: Magnetic Resonance Imaging	USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States	https://ClinicalTrials.gov/show/NCT02578602
542	Relationship Between Liver Cancer and Sarcopenia	Enrolling by invitation	No Results Available	Liver Cancer|Sarcopenia	Diagnostic Test: gait speed; ct scan;grip strength and chair stand test	Gang Chen, Wenzhou, Zhejiang, China	https://ClinicalTrials.gov/show/NCT05339919
543	TheraSpheres Treatment for Unresectable Hepatocarcinoma and Portal Vein Thrombosis	Completed	No Results Available	Liver Cancer|Portal Vein Thrombosis	Device: TheraSphere	Emory University Hospital, Atlanta, Georgia, United States	https://ClinicalTrials.gov/show/NCT01556282
544	Functional-three-dimensional Reconstruction of Liver by 99MTc-GSA-SPECT Scan	Unknown status	No Results Available	Cirrhosis|Hepatic Carcinoma		Peking Union Medical College Hospital, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT01350726
545	Effect of SAMe Treatment on Recurrence After Radical Treatment of Primary Hepatic Carcinoma	Unknown status	No Results Available	Primary Liver Cancer	Drug: S-Adenosyl Methionine		https://ClinicalTrials.gov/show/NCT03178929
546	Prehabilitation and Posttransplant Training Program in Liver Transplantation	Enrolling by invitation	No Results Available	Liver Transplant; Complications|Cirrhosis, Liver|Hepatic Carcinoma	Other: Prehabilitation|Other: Prehabilitation and posttransplant training program	Hospital Universitari i Politècnic La Fe, Valencia, Spain	https://ClinicalTrials.gov/show/NCT04246970
547	A Trial of EVL\GVS Alone vs. EVL\GVS Combined Propranolol	Unknown status	No Results Available	Liver Cirrhosis|Hepatoma	Drug: propranolol	Veteran General Hospital-Taipei, Taipei city, Taiwan	https://ClinicalTrials.gov/show/NCT01298284
548	Pembrolizumab Plus Y90 Radioembolization in HCC Subjects	Active, not recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Pembrolizumab|Device: Y90 radioembolization	Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|University of Washington/Fred Hutchinson Cancer Research Center, Seattle, Washington, United States	https://ClinicalTrials.gov/show/NCT03099564
549	Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer	Recruiting	No Results Available	Advanced Hepatocellular Carcinoma|BCLC Stage B Hepatocellular Carcinoma|BCLC Stage C Hepatocellular Carcinoma	Drug: Cabozantinib S-malate|Biological: Pembrolizumab	Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States	https://ClinicalTrials.gov/show/NCT04442581
550	Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment	Completed	No Results Available	Liver Cancer	Drug: Brivanib|Other: Placebo|Procedure: Best Supportive Care	Mayo Clinic Arizona, Scottsdale, Arizona, United States|Univ Of Ark For Med Sci, Little Rock, Arkansas, United States|Loma Linda University Cancer Center, Loma Linda, California, United States|Richard Finn, M.D., Los Angeles, California, United States|Sharp Clinical Oncology Research, San Diego, California, United States|Pacific Hematology Oncology Associates, San Francisco, California, United States|UF Health Clinical Research Center, Gainesville, Florida, United States|James Graham Brown Cancer Center, Louisville, Kentucky, United States|3912 Taubman Center, Ann Arbor, Michigan, United States|Henry Ford Health System Irb, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Mount Sinai School Of Medicine, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Ohio State University, Columbus, Ohio, United States|Oregon Health & Sci Univ, Portland, Oregon, United States|University Of Pennsylvania, Philadelphia, Pennsylvania, United States|University Of Texas, Houston, Texas, United States|The University Of Texas Health Science Center, San Antonio, Texas, United States|Mcguire Dvamc, Richmond, Virginia, United States|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Rosario, Santa FE, Argentina|Local Institution, Bruxelles, Belgium|Local Institution, Salvador - Ba, Bahia, Brazil|Local Institution, Salvador, Bahia, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Calgary, Alberta, Canada|Local Institution, Vancouver, British Columbia, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Beijing, Beijing, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Guanzhou, Guangdong, China|Local Institution, Nanning, Guangxi, China|Local Institution, Wuhan, Hubei, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Tianjing, Tianjin, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Bordeaux, France|Local Institution, Creteil Cedex, France|Local Institution, Grenoble Cedex 09, France|Local Institution, Lille Cedex, France|Local Institution, Lyon Cedex 04, France|Local Institution, Montpellier Cedex 5, France|Local Institution, Montpellier Cedex, France|Local Institution, Paris Cedex, France|Local Institution, Paris, France|Local Institution, Paris, France|Local Institution, Rennes, France|Local Institution, Toulouse Cedex 09, France|Local Institution, Vandoeuvre Cedex, France|Local Institution, Villejuif, France|Local Institution, Berlin, Germany|Local Institution, Frankfurt, Germany|Local Institution, Freiburg, Germany|Local Institution, Halle, Germany|Local Institution, Hannover, Germany|Local Institution, Mainz, Germany|Local Institution, Ulm, Germany|Local Institution, Wuerzburg, Germany|Local Institution, Kifisia, Greece|Local Institution, Thessaloniki, Greece|Local Institution, Hong Kong, Hong Kong|Local Institution, Kochi, Kerala, India|Local Institution, Chennai, India|Local Institution, Kolkata, India|Local Institution, New Delhi, India|Local Institution, Ancona, Italy|Local Institution, Meldola (fc), Italy|Local Institution, Milano, Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Padova, Italy|Local Institution, Pisa, Italy|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Kashiwa-shi, Chiba, Japan|Local Institution, Ogaki-shi, Gifu, Japan|Local Institution, Yokohama, Kanagawa, Japan|Local Institution, Kochi-shi, Kochi, Japan|Local Institution, Kyoto-shi, Kyoto, Japan|Local Institution, Tsu-shi, MIE, Japan|Local Institution, Higashinari-ku, Osaka, Japan|Local Institution, Osaka-sayama-shi, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Sunto-gun, Shizuoka, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Musashino-shi, Tokyo, Japan|Local Institution, Toyama City, Toyama, Japan|Local Institution, Shimonoseki-shi, Yamaguchi, Japan|Local Institution, Nishinomiya-shi, Japan|Local Institution, Busan, Korea, Republic of|Local Institution, Daegu, Korea, Republic of|Local Institution, Gyeonggi-do, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, D.f., Distrito Federal, Mexico|Local Institution, Toluca, Estado DE Mexico, Mexico|Local Institution, Cuernavaca, Morelos, Mexico|Local Institution, San Juan, Puerto Rico|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Oviedo, Spain|Local Institution, Taichung, Taiwan|Local Institution, Tainan, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taoyuan Hsien, Taiwan	https://ClinicalTrials.gov/show/NCT00825955
551	Evaluate the Efficacy and Safety of 'Immuncell-LC' in Patients Undergoing Liver Transplantation	Recruiting	No Results Available	Liver Transplantation	Biological: Immuncell-LC	Seoul National Hospital, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT03983967
552	A Study to Assess PV-10 Chemoablation of Cancer of the Liver	Recruiting	No Results Available	Cancer Metastatic to the Liver|Hepatocellular Carcinoma|Metastatic Melanoma|Metastatic Ocular Melanoma|Metastatic Uveal Melanoma|Metastatic Lung Cancer|Metastatic Colon Cancer|Metastatic Colorectal Cancer|Metastatic Breast Cancer|Metastatic Pancreatic Cancer	Drug: PV-10 (10% rose bengal disodium)	Sharp Memorial Hospital, San Diego, California, United States|Florida Hospital Tampa, Tampa, Florida, United States|St Luke's University Health Network, Bethlehem, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT00986661
553	Tremelimumab With Chemoembolization or Ablation for Liver Cancer	Completed	Has Results	Heptocellular Cancer|Biliary Tract Neoplasms|Liver Cancer|Hepatocellular Carcinoma|Biliary Cancer	Drug: Tremelimumab|Procedure: RFA|Procedure: TACE|Procedure: Cryoablation	National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States	https://ClinicalTrials.gov/show/NCT01853618
554	Surgery With or Without Hepatic Arterial Chemotherapy in Treating Patients With Liver Cancer	Withdrawn	No Results Available	Localized Resectable Adult Primary Liver Cancer|Stage III Childhood Liver Cancer	Drug: cisplatin|Drug: fluorouracil|Procedure: adjuvant therapy|Procedure: chemotherapy|Procedure: conventional surgery|Procedure: hepatic arterial infusion|Procedure: surgery	Kyoto Prefectural University of Medicine, Kyoto, Japan|Kyoto City Hospital, Kyoto, Japan|Kyoto University Hospital, Kyoto, Japan|Kyoto-Katsura Hospital, Kyoto, Japan	https://ClinicalTrials.gov/show/NCT00238160
555	3-Tesla MRI Response to TACE in HCC (Liver Cancer)	Terminated	Has Results	Adult Primary Hepatocellular Carcinoma|Advanced Adult Primary Liver Cancer|Localized Resectable Adult Primary Liver Cancer|Localized Unresectable Adult Primary Liver Cancer|Stage A Adult Primary Liver Cancer (BCLC)|Stage B Adult Primary Liver Cancer (BCLC)	Device: 3 Tesla Magnetic Resonance Imaging|Drug: Magnevist® (Intravenous (IV) administration of MRI contrast agent)	Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States	https://ClinicalTrials.gov/show/NCT02057874
556	Texas Hepatocellular Carcinoma Consortium (THCCC) Project 5	Active, not recruiting	No Results Available	Carcinoma, Hepatocellular|Liver Neoplasms	Behavioral: Outreach with patient education and patient navigation services	University of Texas Southwestern Medical Center, Dallas, Texas, United States	https://ClinicalTrials.gov/show/NCT02582918
557	Natural History of Liver Cirrhosis Diagnosed by Transient Elastography in HIV/HCV-coinfected Patients	Completed	No Results Available	Liver Cirrhosis|Hepatocellular Carcinoma|HIV|HCV Coinfection		Hospital de La Línea de la Concepción, La Línea de la Concepción, Cádiz, Spain|Hospital Universitario de Puerto Real, Puerto Real, Cádiz, Spain|Hospital Universitario Reina Sofía, Córdoba, Spain|Complejo Hospitalario de Huelva, Huelva, Spain|Complejo Hospitalario de Jaén, Jaén, Spain|Hospital Universitario Virgen de la Victoria, Málaga, Spain|Hospital Universitario de Valme, Sevilla, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain	https://ClinicalTrials.gov/show/NCT02693847
558	TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver Cancer	Recruiting	No Results Available	Adult Primary Liver Cancer|Advanced Adult Primary Liver Cancer|Localized Unresectable Adult Primary Liver Cancer	Drug: TSR-022 and TSR-042	University of Hawaii, Honolulu, Hawaii, United States	https://ClinicalTrials.gov/show/NCT03680508
559	ET 140202 -T Cell Combined With TAE or Sorafenib in the Treatment of Liver Cancer	Recruiting	No Results Available	Hepatocellular Carcinoma|Liver Cancer|Liver Neoplasms|Metastatic Liver Cancer	Combination Product: Sorafenib combined with ET140202-T cell|Combination Product: TAE combined with ET140202-T cell|Biological: ET140202-T cell	The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China	https://ClinicalTrials.gov/show/NCT03965546
560	Artificial Intelligence vs. LIRADS in Diagnosing HCC on CT	Recruiting	No Results Available	HCC|Liver Cancer	Diagnostic Test: Prototype artificial intelligence algorithm|Diagnostic Test: LI-RADS	Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong	https://ClinicalTrials.gov/show/NCT04843176
561	Comparison Between Radiofrequency Versus Ethanol Injection for the Treatment of Hepatocellular Carcinoma	Terminated	No Results Available	Carcinoma, Hepatocellular	Procedure: percutaneous ablation of hepatocellular carcinoma	Azienda Ospedaliera San Giovanni Battista di Torino, Torino, Italy	https://ClinicalTrials.gov/show/NCT00355212
562	Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of Tor Kinase Inhibitor in Liver Cancer Patients	Completed	No Results Available	Cancer|Advanced Hepatocellular Carcinoma	Drug: AZD8055	Research Site, Hong Kong, Hong Kong|Research Site, Seongnam, Gyeonggi-do, Korea, Republic of|Research Site, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT00999882
563	Extracellular RNA Markers of Liver Disease and Cancer	Active, not recruiting	No Results Available	Hepatocellular Carcinoma|Biliary Tract Cancer|Cirrhosis|Liver Diseases	Other: Blood samples	Mayo Clinic Florida, Jacksonville, Florida, United States|The University of Chicago Medical Center, Chicago, Illinois, United States|Mayo Clinic, Rochester, Minnesota, United States|McGuire VA Medical Center, Richmond, Virginia, United States	https://ClinicalTrials.gov/show/NCT02908048
564	A Trial of Licartin for Preventing Tumor Recurrence After Liver Resection	Completed	No Results Available	Hepatocellular Carcinoma	Drug: Licartin (generic name,[131I]metuximab injection)	Eastern hepatobilliary surgery hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT00819650
565	SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Selinexor Pill|Drug: Bevacizumab|Drug: Atezolizumab	Moffitt Cancer Center, Tampa, Florida, United States	https://ClinicalTrials.gov/show/NCT05093608
566	ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatoblastoma|Hepatocellular Carcinoma (HCC)|Liver Neoplasms|Metastatic Liver Cancer|Liver Cancer|HEMNOS	Drug: ET140203 T Cells	Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, United States	https://ClinicalTrials.gov/show/NCT04634357
567	AFP Specific T Cell Receptor Transduced T Cells Injection(C-TCR055) in Unresectable Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma	Biological: AFP Specific T Cell Receptor T Cells	Fudan University Affiliated ZhongShan Hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT03971747
568	Hepatocellular Carcinoma Growth and Molecular Aggressiveness	Completed	No Results Available	Cirrhosis|Hepatocellular Carcinoma		Azienda Ospedaliero-Universitaria, Modena, Italy	https://ClinicalTrials.gov/show/NCT01657695
569	Portal Vein Embolization Using Coils Plus TAGM vs Multiple Coils for Patients With Perihilar Cholangiocarcinoma or Hepatocellular Carcinoma	Recruiting	No Results Available	Portal Vein Occlusion|Cholangiocarcinoma, Perihilar|Hepatocellular Carcinoma|Liver; Hypertrophy, Acute	Procedure: PVE with coils plus TAGM|Procedure: PVE with multiple coils	Easter hepatobiliary surgery hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT04386772
570	Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer	Active, not recruiting	No Results Available	Hepatocellular Carcinoma|Gastrointestinal Cancer Metastatic|Neuroendocrine Tumors	Drug: Tirapazamine|Procedure: Transarterial embolization (TAE)	University of California Irvine Medical Center, Orange, California, United States|Univ. of California, San Francisco, San Francisco, California, United States	https://ClinicalTrials.gov/show/NCT02174549
571	A Phase III PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related HCC After Surgical Resection	Terminated	Has Results	Cancer|Liver Cancer|Hepatocellular Carcinoma	Drug: PI-88|Other: Placebo	The Third Xiangya Hospital of Central South University, Changsha, Hunan, China|Peking Union Medical College Hospital, Beijing, China|The General Hospital of People's Liberation Army (301 hospital), Beijing, China|Fudan University Zhongshan Hospital, Shanghai, China|Queen Mary Hospital, Hong Kong, Hong Kong|Kyungpook National University Hospital (KNUH), Pusan, Korea, Republic of|Pusan National University Hospital (PNUH), Pusan, Korea, Republic of|Pusan National University Yangsan Hospital (PNUYH), Pusan, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Seoul St. Mary Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Ajou University Hospital, Suwon, Korea, Republic of|Changhua Christian Hospital, Changhua City, Taiwan|E-Da Hospital, Kaohsiung City, Taiwan|Chang Gung Memorial Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|Taipei Veterans General Hospital, Taipei City, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital-Linkou Medical Centre, Taoyuan, Taiwan	https://ClinicalTrials.gov/show/NCT01402908
572	A Trial of Adjuvant Transarterial Chemoembolization (TACE) for Preventing Tumor Recurrence After Liver Resection	Completed	No Results Available	Hepatocellular Carcinoma	Drug: epirubicin and lipiodol	Eastern hepatobilliary surgery hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT00820053
573	Impact of Postoperative Adjuvant Chemotherapy in Patients With Hepatocellular Carcinoma After Liver Transplantation	Unknown status	No Results Available	Liver Transplantation|Hepatocellular Carcinoma|Tumor Recurrence and Metastasis|Survival|Adjuvant Chemotherapy	Drug: gemcitabine and oxaliplatin|Drug: doxorubicin, 5-Fu and cisplatin	Shanghai First People's Hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT01125020
574	Drug Monitoring of Sorafenib in Patients With Advanced Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Cancer		Westmead Hospital, Westmead, New South Wales, Australia	https://ClinicalTrials.gov/show/NCT01078311
575	A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein	Completed	Has Results	Hepatocellular Carcinoma	Drug: Ramucirumab|Drug: Placebo	Pacific Hematology and Oncology Associates, Daly City, California, United States|UCLA Medical Center, Los Angeles, California, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|University of Iowa Hospital, Iowa City, Iowa, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Mount Sinai Medical Center, New York, New York, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|OREGON HEALTH and SCIENCE UNIVERSITY, Portland, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kurralta Park, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Woodville, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Linz, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wien, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brussels, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Liege, Belgium|Fundação PIO XII, Barretos, Brazil|"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", Barretos, Brazil|Cenantron - Centro Avançado de Tratamento Oncológico, Belo Horizonte, Brazil|Associação Hospital de Caridade Ijuí, Ijui, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Porto Alegre, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., São Paulo, Brazil|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Montreal, Canada|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Toronto, Canada|"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", Beijing, China|"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", Beijing, China|"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", Beijing, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beijing, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Changsha, China|"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", Changsha, China|"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", Chongqing, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guangdong, China|"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", Guangzhou, China|"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", Hangzhou, China|"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", Hangzhou, China|"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", Hangzhou, China|"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", Hebei, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hefei, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heilongjiang, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Henan, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hubei, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nanjing, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nanjing, China|"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", Nanning, China|"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", Qingdao, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shanghai, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Shanghai, China|"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", Shanghai, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shanghai, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shenyang, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wu Han, China|"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", Xi'an, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brno, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Praha 5, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Amiens, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Avignon, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Besancon, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Caen, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Clermont-Ferrand, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lyon, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Montpellier, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nantes, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pessac, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rennes, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Etienne, France|"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", Bayern, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Berlin, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Essen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Frankfurt, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hannover, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leipzig, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Magdeburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mainz, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., München, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tubingen, Germany|"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", Hong Kong, Hong Kong|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hong Kong, Hong Kong|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Kowloon, Hong Kong|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., ShaTin, Hong Kong|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tuen Mun, Hong Kong|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Haifa, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tel Aviv, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Benevento, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bologna, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cremona, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Padova, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rome, Italy|"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", Chuo Ku, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukuoka, Japan|"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", Fukuoka, Japan|"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", Iizuka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kanazawa, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kashiwa, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kyoto, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Matsuyama, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Osaka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shimotsuke, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Suita-shi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sunto-Gun, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yokohama, Japan|"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", Ōsaka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Incheon, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ulsan, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gdansk, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Poznan, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Warszawa, Poland|Hospital Universitari de Girona Dr. Josep Trueta, Girona, Spain|Hospital Clínico San Carlos, Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santander, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valencia, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bern, Switzerland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kaohsiung city, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Puzi City, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taichung, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tainan, Taiwan|"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", Tainan, Taiwan|"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", Tainan, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei city, Taiwan|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Taipei city, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taoyuan City, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Acton, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Acton, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bebington, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Birmingham, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Manchester, United Kingdom	https://ClinicalTrials.gov/show/NCT02435433
576	Hepatic Arteriography in Liver Cancer Diagnosis and Staging Applications	Unknown status	No Results Available	HepatoCellular Carcinoma	Device: Hepatic Arteriography	TaoBai, Nanning, Guangxi, China	https://ClinicalTrials.gov/show/NCT02936856
577	A Study of Individualized Stereotactic Body Radiation Therapy (SBRT) for Intrahepatic Cancer	Completed	Has Results	Liver Cancer|Hepatocellular Cancer	Radiation: individualized Stereotactic Body Radiation Therapy (SBRT)	University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States	https://ClinicalTrials.gov/show/NCT01522937
578	68Ga-PSMA-Dual-Contrast PET/MRI or PET/CT for Early Detection of Liver Cancer	Recruiting	No Results Available	Hepatocellular Carcinoma	Procedure: Computed Tomography|Drug: Gallium Ga 68 Gozetotide|Procedure: Magnetic Resonance Imaging|Procedure: Positron Emission Tomography	Mayo Clinic in Rochester, Rochester, Minnesota, United States	https://ClinicalTrials.gov/show/NCT04762888
579	HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT	Recruiting	No Results Available	Carcinoma, Hepatocellular|Liver Neoplasms|Sintilimab|Portal Vein Tumor Thrombus	Procedure: Hepatic arterial infusion chemotherapy|Drug: Lenvatinib|Drug: Sintilimab	Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT04618367
580	Adult-to-Adult Living Donor Liver Transplantation Study	Completed	No Results Available	Cirrhosis|Hepatitis C|Hepatocellular Carcinoma		University of California Los Angeles, Los Angeles, California, United States|University of California San Francisco, San Francisco, California, United States|University of Colorado Health System, Denver, Colorado, United States|Northwestern University, Chicago, Illinois, United States|Columbia University, New York, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Virginia, Charlottesville, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States	https://ClinicalTrials.gov/show/NCT00096733
581	A Study of Comparison of TACE Combination With and Without EBRT for Advanced HCC	Unknown status	No Results Available	Hepatocellular Carcinoma	Procedure: Transcatheter arterial chemoembolization|Radiation: External- beam radiotherapy	180 Fenglin Road, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT03116984
582	A Study to Evaluate Vaccines Against COVID-19 in the Real World	Not yet recruiting	No Results Available	Chronic Liver Disease|Hepatic Carcinoma		Humanity & Health Medical Group, Hong Kong, Hong Kong	https://ClinicalTrials.gov/show/NCT04775056
583	A Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Biological: mapatumumab|Drug: sorafenib	Cedars-Sinai Health System, Los Angeles, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|University of Florida, Gainesville, Florida, United States|Mayo Clinic, Rochester, Minnesota, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|University of Pennsylvania- Abramson Cancer Center, Philadelphia, Pennsylvania, United States	https://ClinicalTrials.gov/show/NCT00712855
584	Volatile Organic Compounds for the Assessment of Liver Disease	Recruiting	No Results Available	Cirrhosis|Cirrhosis, Liver|Fibrosis, Liver|Hepatocellular Carcinoma|Hepatocellular Cancer	Diagnostic Test: Breath Analysis	Imperial College Healthcare Trust, London, United Kingdom	https://ClinicalTrials.gov/show/NCT04620538
585	Prospective Tumor Response Evaluation	Terminated	No Results Available	Hepatocellular Cancer|Metastatic Liver Cancer	Procedure: TACE|Procedure: Y-90|Procedure: MWA|Procedure: IRE	University of Texas Health Science Center Houston, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT02787954
586	Integrated Imaging Strategy to Phenotype Progression of Liver Tumors During and After Chemoembolization	Completed	Has Results	Liver Cancer|Liver Neoplasm|Hepatocellular Carcinoma|HCC	Drug: [18F] FMISO	National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States	https://ClinicalTrials.gov/show/NCT02471313
587	Application of the Stem Cell Therapy in the End Stage Liver Disease and Assessment Its Consequences in the Quality of Live Style as Well as Development of HCC.	Unknown status	No Results Available	Hepatocellular Carcinoma in Hepatitis C Virus Infected Patients		Cairo University & National Cancer Institute, Cairo, Egypt	https://ClinicalTrials.gov/show/NCT01729221
588	Survey of Cabozantinib Tablets Used To Treat People With Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Cancer	Drug: Cabozantinib	Takeda Selected Site, Tokyo, Japan	https://ClinicalTrials.gov/show/NCT05100082
589	Trial of TG4023 Combined With Flucytosine in Liver Tumors	Completed	No Results Available	Hepatocellular Carcinoma	Biological: MVA-FCU1, flucytosine	Hôpitaux Civils de Colmar, Colmar, France|Institut Paoli Calmette,, Marseille, France|Hôpitaux Civils de Lyon,, Pierre Benite, France|Centre René Gauducheau, Saint Herblain, France|Hôpitaux Universitaires de Strasbourg, Strasbourg, France|Institut Claudius Regaud, Toulouse, France	https://ClinicalTrials.gov/show/NCT00978107
590	Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE	Recruiting	No Results Available	Hepatocellular Carcinoma	Device: radiotherapy ablation|Device: transarterial chemoembolization(TACE)	Zhongshan hospital Fudan University, Shanghai, China	https://ClinicalTrials.gov/show/NCT03642561
591	Abbreviated MRI for HCC Surveillance	Active, not recruiting	No Results Available	Hepatocellular Carcinoma|Liver Cirrhosis|Chronic Hepatitis	Diagnostic Test: Biannual ultrasonography|Diagnostic Test: Annual abbreviated liver MRI	Seoul National University Hospital, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT03731923
592	Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer	Unknown status	No Results Available	Carcinoma, Hepatocellular	Drug: Everolimus|Drug: Tacrolimus|Drug: Myfortic|Drug: CellCept|Drug: Imuran	University of California at San Francisco, San Francisco, California, United States|Northwestern University School of Medicine, Chicago, Illinois, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Mount Sinai Medical Center, New York, New York, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Tennessee- Methodist University Hospital, Memphis, Tennessee, United States|Baylor University Medical Center, Dallas, Texas, United States	https://ClinicalTrials.gov/show/NCT02081755
593	Impact of Propofol-Based Total Intravenous Anesthesia Versus Anesthesia With Sevoflurane on Long-term Outcomes With Patients Undergoing Elective Excision of Primary Liver Tumors	Not yet recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Propofol|Drug: Sevoflurane		https://ClinicalTrials.gov/show/NCT05331911
594	Electromagnetic Fields Versus Placebo as Third-line Therapy For Patients With Advanced Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Cancer	Device: TheraBionic Device|Drug: Placebo Device|Other: Quality of Life Assessment	Mayo Clinic College of Medicine and Science of Arizona, Phoenix, Arizona, United States|Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, United States|Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States	https://ClinicalTrials.gov/show/NCT04797884
595	TAE and MWA Combination Therapy in Early-stage Hepatocellular Carcinoma	Terminated	Has Results	Hepatocellular Carcinoma|Hepatoma|Liver Cancer, Adult|Liver Cell Carcinoma|Liver Cell Carcinoma, Adult	Device: Transarterial embolization|Procedure: Microwave Ablation	Carolinas Medical Center, Charlotte, North Carolina, United States	https://ClinicalTrials.gov/show/NCT02704130
596	Sorafenib + mFOLFOX for Hepatocellular Carcinoma	Completed	Has Results	Hepatocellular Cancer	Drug: Leucovorin|Drug: Fluorouracil|Drug: Oxaliplatin|Drug: Sorafenib	Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States	https://ClinicalTrials.gov/show/NCT01775501
597	Contrast-Enhanced Ultrasound in Predicting Treatment Response in Patients With Liver Cancer Receiving Transarterial Chemoembolization With Drug Eluting Beads	Completed	No Results Available	Hepatocellular Carcinoma	Drug: Perflutren Lipid Microspheres|Device: Dynamic Contrast-Enhanced Ultrasound Imaging|Device: Contrast-enhanced Magnetic Resonance Imaging		https://ClinicalTrials.gov/show/NCT03045497
598	ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk	Recruiting	No Results Available	Hepatocellular Carcinoma|Hepatocellular Cancer|Hepatitis B|Cirrhosis|Liver Cancer	Device: Study CT/MRI Imaging|Device: Standard of Care CT/MRI Imaging|Diagnostic Test: Oncoguard™ Liver Test	Arizona Health Research, Chandler, Arizona, United States|Franco Felizarta, MD, Bakersfield, California, United States|Gastroenterology & Liver Institute, Escondido, California, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|Providence Facey Medical Foundation, Mission Hills, California, United States|United Medical Doctors, Murrieta, California, United States|VA Palo Alto Healthcare System, Palo Alto, California, United States|California Liver Research Institute, Pasadena, California, United States|Cadena Care Institute, Poway, California, United States|Inland Empire Clinical Trials, Rialto, California, United States|Research & Education, Inc, San Diego, California, United States|University of Florida Hepatology Research at CTRB, Gainesville, Florida, United States|San Marcus Research Clinic, Miami Lakes, Florida, United States|Indiana University, Indianapolis, Indiana, United States|Indianapolis Gastroenterology Research Foundation, Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Delta Research Partners, Monroe, Louisiana, United States|Louisiana Research Center, LLC, Shreveport, Louisiana, United States|University of Michigan, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Southern Therapy and Advanced Research LLC (STAR), Jackson, Mississippi, United States|St. Louis University, Saint Louis, Missouri, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Manhattan Clinical Research, LLC, New York, New York, United States|Digestive Health Partners, Asheville, North Carolina, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Xiaoli Ma Md, Philadelphia, Pennsylvania, United States|Einstein Medical Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Gastro One, Germantown, Tennessee, United States|Texas Gastro Clinic, El Paso, Texas, United States|UVA Gastroenterology, Charlottesville, Virginia, United States|Digestive & Liver Disease Specialists, Norfolk, Virginia, United States|Velocity Clinical Research, Spokane, Washington, United States	https://ClinicalTrials.gov/show/NCT05064553
599	Effect of a Perioperative Oral Nutritional Supplementation on Patients Undergoing Hepatic Surgery for Liver Cancer	Terminated	No Results Available	Liver Cancer|Hepatocellular Carcinoma|Cirrhosis|Liver Fibrosis	Drug: Oral Impact®|Drug: Placebo	Service de Réanimation Chirurgicale - Hôpital Pontchaillou, Rennes, France	https://ClinicalTrials.gov/show/NCT00151671
600	TACE Using Doxorubicin-eluting Beads for Patients With HCC and Marginal Hepatic Reserve	Terminated	Has Results	Hepatocellular Carcinoma|Chemoembolization	Device: LC Bead	University of California San Francisco, San Francisco, California, United States	https://ClinicalTrials.gov/show/NCT02147301
601	HCV-RNA Kinetics During Sorafenib for Hepatocellular Carcinoma (HCC)	Terminated	Has Results	Hepatocellular Cancer	Drug: Sorafenib	Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States	https://ClinicalTrials.gov/show/NCT01849588
602	Radiofrequency Ablation in Treating Patients With Liver Cancer (Hepatocellular Carcinoma)	Withdrawn	No Results Available	Carcinoma, Hepatocellular	Procedure: radiofrequency ablation|Procedure: laparoscopy		https://ClinicalTrials.gov/show/NCT01669668
603	Resection for Multiple Hepatocellular Carcinomas (HCC)	Completed	No Results Available	Hepatocellular Carcinoma|Multiple Tumors|Cirrhosis	Procedure: hepatic resection	University of Milan IRCCS Istituto Clinico Humanitas, Rozzano, Milan, MI, Italy	https://ClinicalTrials.gov/show/NCT01387061
604	IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer	Recruiting	No Results Available	Recurrent Hepatocellular Carcinoma|Refractory Liver Carcinoma|Stage IV Hepatocellular Carcinoma AJCC v8|Stage IVA Hepatocellular Carcinoma AJCC v8|Stage IVB Hepatocellular Carcinoma AJCC v8	Drug: Cyclophosphamide|Biological: Cytokine-based Biologic Agent IRX-2|Biological: Nivolumab	HonorHealth Research Institute, Scottsdale, Arizona, United States|City of Hope Medical Center, Duarte, California, United States|Texas Oncology at Baylor Charles A Sammons Cancer Center, Dallas, Texas, United States	https://ClinicalTrials.gov/show/NCT03655002
605	Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer	Active, not recruiting	No Results Available	Hepatocellular Carcinoma|Resectable Hepatocellular Carcinoma	Biological: Ipilimumab|Biological: Nivolumab	M D Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT03222076
606	Evaluation of Liver Cancer With Magnetic Resonance Imaging (MRI)	Completed	Has Results	Hepatocellular Carcinoma|HCC	Device: Magnetic Resonance Imaging	Icahn School of Medicine at Mount Sinai, New York, New York, United States	https://ClinicalTrials.gov/show/NCT01871545
607	Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer	Completed	Has Results	Hepatocellular Cancer	Drug: Sorafenib|Procedure: radiofrequency ablation	Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States	https://ClinicalTrials.gov/show/NCT00813293
608	Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611	Active, not recruiting	No Results Available	Hepatocellular Carcinoma|Liver Metastases|Cutaneous or Subcutaneous Lymph Node|Liver Tumors	Drug: Talimogene Laherparepvec|Drug: Pembrolizumab	HonorHealth Research Institute, Scottsdale, Arizona, United States|University of California Los Angeles, Santa Monica, California, United States|Georgetown-Howard University Center for Clinical Translational Science, Washington, District of Columbia, United States|University of Louisville James Graham Brown Cancer Center, Louisville, Kentucky, United States|Washington University School of Medicine, Center for Advanced Medicine, Saint Louis, Missouri, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Liverpool Hospital, Liverpool, New South Wales, Australia|Melanoma Institute Australia, North Sydney, New South Wales, Australia|Tasman Oncology Research, Southport, Queensland, Australia|Landeskrankenhaus Salzburg, Salzburg, Austria|Universite Catholique de Louvain Cliniques Universitaires Saint Luc, Bruxelles, Belgium|Universitair Ziekenhuis Antwerpen, Edegem, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|Charite Universitätsmedizin Berlin, Charité Campus Virchow-Klinikum, Berlin, Germany|Universitätsklinikum Bonn, Bonn, Germany|Kreiskliniken Reutlingen - Klinikum am Steinenberg, Reutlingen, Germany|Universitätsklinikum Tübingen, Tübingen, Germany|Cha Bundang Medical Center, Cha University, Seongnam-si, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital Yonsei University Health System, Seoul, Korea, Republic of|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Hospital Universitari Vall d Hebron, Barcelona, Cataluña, Spain|Hospital Clinic i Provincial de Barcelona, Barcelona, Cataluña, Spain|Hospital General Universitario Gregorio Marañon, Madrid, Spain|Hospital Universitario Madrid Sanchinarro, Madrid, Spain|Hopitaux Universitaires de Geneve, Geneva 14, Switzerland|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland|Kantonsspital Winterthur, Winterthur, Switzerland|Universitaetsspital Zuerich, Zurich, Switzerland	https://ClinicalTrials.gov/show/NCT02509507
609	LDE225 in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A/B7 Cirrhosis	Completed	No Results Available	Hepatocellular Carcinoma|Cirrhosis	Drug: LDE225	UCSD Moores Cancer Center, La Jolla, California, United States	https://ClinicalTrials.gov/show/NCT02151864
610	The Effects of Vitamin B-6 and Coenzyme Q10 Status on Oxidative Stress, Antioxidant Capacities, and Inflammatory Responses in Patients With Liver Cancer	Completed	No Results Available	Hepatocellular Carcinoma.	Dietary Supplement: Vitamin B-6|Dietary Supplement: Coenzyme Q10|Dietary Supplement: Vitamin B-6+Coenzyme Q10|Other: Placebo	Taichung Verterans General Hospital, Taichung, Taiwan	https://ClinicalTrials.gov/show/NCT01964001
611	BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer	Recruiting	No Results Available	Advanced Hepatocellular Carcinoma|BCLC Stage B Hepatocellular Carcinoma|BCLC Stage C Hepatocellular Carcinoma|Refractory Hepatocellular Carcinoma	Biological: Nanoplexed Poly I:C BO-112|Biological: Pembrolizumab	UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States	https://ClinicalTrials.gov/show/NCT04777708
612	Stereotactic Body Proton Radiotherapy for the Treatment of Liver Cancer	Recruiting	No Results Available	Recurrent Hepatocellular Carcinoma|Stage I Hepatocellular Carcinoma AJCC v8|Stage II Hepatocellular Carcinoma AJCC v8|Stage III Hepatocellular Carcinoma AJCC v8	Radiation: Proton Stereotactic Body Radiation Therapy|Other: Quality-of-Life Assessment	Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States	https://ClinicalTrials.gov/show/NCT04805788
613	Indocyanine Green and Portal Pressure in Viral and Alcoholic Cirrhotic Patients With Hepatocarcinoma	Completed	No Results Available	Carcinoma, Hepatocellular|Alcoholic Cirrhosis|Viral Cirrhosis|Postoperative Hepatic Failure		Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Vaud, Switzerland	https://ClinicalTrials.gov/show/NCT00827723
614	Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer	Recruiting	No Results Available	Primary Liver Cancer|Hepatocellular Carcinoma|Intrahepatic Cholangiocarcinoma|Combined Hepatocellular-cholangiocarcinoma	Other: Observation	Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, P.R.China., China	https://ClinicalTrials.gov/show/NCT05292443
615	c-Met Second-Line Hepatocellular Carcinoma	Completed	Has Results	Carcinoma, Hepatocellular	Drug: Tepotinib	Please contact the Merck KGaA Communication Center located in, Darmstadt, Germany	https://ClinicalTrials.gov/show/NCT02115373
616	Study of Sorafenib, Gemcitabine, and Cisplatin in Advanced Hepatocellular Carcinoma (HCC)	Withdrawn	No Results Available	Hepatocellular Carcinoma	Drug: Gemcitabine / Cisplatin / Sorafenib	Lahey Clinic, Burlington, Massachusetts, United States	https://ClinicalTrials.gov/show/NCT00808145
617	Cancer Stem Cells Vaccine Therapy in Treating Hepatocellular Cancer Patients	Completed	No Results Available	Neoplasms, Liver	Biological: cancer stem cell vaccine	Biological treatment center in Fuda cancer hospital, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT02089919
618	Contrast-enhanced MRI in Detecting Benign and Malignant Liver Lesions	Recruiting	No Results Available	Hepatocellular Carcinoma|Liver and Intrahepatic Bile Duct Disorder|Metastatic Malignant Neoplasm in the Liver|Primary Malignant Liver Neoplasm	Procedure: Contrast-enhanced Magnetic Resonance Imaging|Drug: Gadobutrol|Drug: Gadoxetate Disodium	M D Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT02156739
619	Endoscopic Cyanoacrylate Obliteration vs. Nadolol Treatment in the Prevention of Gastric Variceal Rebleeding	Unknown status	No Results Available	Liver Cirrhosis and Hepatoma.|Gastric Variceal Bleeding	Drug: Nadolol	Veteran General Hospital-Taipei, Taipei city, Taiwan, China	https://ClinicalTrials.gov/show/NCT00567216
620	BOLD MRI and FMISO PET for the Assessment of Hypoxic Tumor Microenvironment in Patients With Oligometastatic Liver Cancer Undergoing Yttirum-90 Selective Internal Radiation Therapy	Recruiting	No Results Available	BCLC Stage A Hepatocellular Carcinoma|BCLC Stage B Hepatocellular Carcinoma|BCLC Stage C Hepatocellular Carcinoma|Hepatocellular Carcinoma	Other: 18F-Fluoromisonidazole|Procedure: Biopsy|Procedure: Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Procedure: Positron Emission Tomography	Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States	https://ClinicalTrials.gov/show/NCT05250895
621	Major RF Ablations of Hepatomas Under MR Thermometry Monitoring	Terminated	No Results Available	Hepatocellular Cancer	Procedure: Multipolar Radiofrequency ablation	CHU Jean VERDIER, Bondy, France	https://ClinicalTrials.gov/show/NCT01486134
622	Stereotaxic Irradiation of Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Radiation: Fiducials|Radiation: CyberKnife	Centre François Baclesse, Caen, France|Centre Oscar LAMBRET, Lille, France|Centre Léon Bérard, Lyon, France|Centre Alexis Vautrin, Vandoeuvre Les Nancy, France	https://ClinicalTrials.gov/show/NCT01165346
623	A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases	Active, not recruiting	No Results Available	Carcinoma, Hepatocellular|Biliary Tract Cancer|Secondary Liver Cancer|Liver Metastases	Drug: RO7119929|Drug: Tocilizumab	City of Hope Cancer Center, Duarte, California, United States|Rigshospitalet; Onkologisk Klinik, København Ø, Denmark|Queen Mary Hospital; Dept of Medicine, Hong Kong, Hong Kong|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Clínica Universidad de Navarra, Pamplona, Navarra, Spain|Hospital Universitari Vall d'Hebron; Oncology, Barcelona, Spain|Clinica Universidad de Navarra Madrid; Servicio de Oncología, Madrid, Spain|National Taiwan Uni Hospital, Taipei City, Taiwan|Tri-Service General Hospital, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT04338685
624	Safety Margin Assessment After RFA Using the Registration of Pre-ablation MRI and Post-ablation CT	Completed	No Results Available	HCC|Liver Tumor	Procedure: RFA	Seoul National University Hospital, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT02985034
625	Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis	Not yet recruiting	No Results Available	Hepatocellular Carcinoma|Cirrhosis	Drug: Namodenoson|Drug: Placebo	Rabin Medical Center Beilinson Hospital, Petach Tikva, Israel	https://ClinicalTrials.gov/show/NCT05201404
626	TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC	Not yet recruiting	No Results Available	Hepatocellular Carcinoma	Procedure: TACE/HAIC|Drug: Lenvatinib|Drug: Sintilimab|Procedure: liver resection	Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT05250843
627	Radiofrequency-assisted Hepatectomy on the Outcomes of HCC Patients With Cirrhosis	Unknown status	No Results Available	Hepatocellular Carcinoma|Cirrhosis	Procedure: Radiofrequency-assisted Hepatectomy|Procedure: Conventional Hepatectomy	Institute of Hepatobiliry surgery,Southwest Hospital, Chongqing, Chongqing, China	https://ClinicalTrials.gov/show/NCT01992978
628	Percutaneous Irreversible Electroporation to Treat Liver Cancer Close to the Gallbladder	Completed	No Results Available	Hepatic Carcinoma	Device: NanoKnife	中国, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT02332551
629	Immunization With AFP + GM CSF Plasmid Prime and AFP Adenoviral Vector Boost in Patients With Hepatocellular Carcinoma	Terminated	No Results Available	Hepatocellular Carcinoma|Hepatoma|Liver Cancer, Adult|Liver Cell Carcinoma|Liver Cell Carcinoma, Adult|Cancer of Liver|Cancer of the Liver|Cancer, Hepatocellular|Hepatic Cancer|Hepatic Neoplasms|Hepatocellular Cancer|Liver Cancer|Neoplasms, Hepatic|Neoplasms, Liver	Drug: AFP + GM-CSF Plasmid Prime and AFP Adenoviral Vector Boost	University of California, Los Angeles, California, United States|University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States	https://ClinicalTrials.gov/show/NCT00669136
630	Dynamic Contrast Enhanced HCC SABR Liver Study	Unknown status	No Results Available	Carcinoma, Hepatocellular	Procedure: Perfusion Imaging	BC Cancer Agency Fraser Valley Centre, Surrey, British Columbia, Canada|BC Cancer Agency Vancouver Centre, Vancouver, British Columbia, Canada	https://ClinicalTrials.gov/show/NCT02847767
631	Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)	Terminated	Has Results	Infection	Drug: Pegylated Interferon Alfa 2a|Drug: Ribavirin|Drug: Telaprevir	University of Texas MD Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT01821963
632	Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)	Completed	Has Results	Hepatocellular Carcinoma	Drug: ThermoDox|Drug: 5% Dextrose Solution	UCLA, Los Angeles, California, United States|Mayo Clinic - Jacksonville, Florida, Jacksonville, Florida, United States|University Of Louisville, Louisville, Kentucky, United States|Mayo Clinic, Rochester, Minnesota, United States|Mount Sinai School of Medicine, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Geisinger Health System, Wilkes Barre, Pennsylvania, United States|University of Texas Health Science Center, San Antonio, Texas, United States|Vancouver General Hospital, Vancouver, British Columbia, Canada|Toronto General Hospital, Toronto, Ontario, Canada|The 1st Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian, China|Tongji Hospital, Wuhan, Hubei, China|Nanjing Drum Tower Hospital, The Affilitated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China|The First Affiliated Hospital of Suzhou University, Suzhou, Jiangsu, China|The First Hospital of Jilin University, Changchun, Jilin, China|Tianjin Cancer Hospital, Tianjin, Tianjin, China|The First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China|Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China|Beijing Cancer Hospital, Peking University School of Oncology, Beijing, China|Beijing You An Hospital, Capital Medical University, Beijing, China|Beijing You An Hospital，Capital Medical University, Beijing, China|Southwest Hospital, The First Affiliated Hospital of the Third Military Medical University, Chongqing, China|Sun Yat-Sen University Cancer Center, Guangzhou, China|Oncology Center of Nanfang Hospital, Southern Medical University, Guangzhou, China|Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China|Tianjin No. 3 Central Hospital, Tianjin, China|Queen Mary Hospital, Hong Kong, Hong Kong|Azienda Ospedaliera di Padova, Padova, Veneto, Italy|Azienda Ospedaliero-Universitaria di Bologna Policlinico S.Orsola Malpighi, Bologna, Italy|Ospedale Classificato San Giuseppe, Milano, Milano, Italy|Azienda Ospedaliera San Gerardo, Monza, Italy|Istituto Nazionale per lo Studio e la Cura dei Tumori "Fondazione Pascale" di Napoli, Napoli, Italy|Azienda Ospedaliero-Univeristaria Pisana, Pisa, Italy|Istituto dei Tumori Regina Elena, Roma, Italy|Azienda Sanitaria Ospedaliera Ordine Mauriziano di Torino Presidio Ospedaliero "Umberto I", Torino, Italy|Chiba University Hospital, Chiba, Japan|Iwate Medical University Hospital, Iwate, Japan|Yamanashi Prefectural Central Hospital, Koufu City, Japan|Mie University Hospital, Mie, Japan|Saiseikai Niigata Daini Hospital, Niigata City, Japan|Okayama University Hospital, Okayama City, Japan|Kyoundo Hospital, Tokyo, Japan|The University of Tokyo Hospital, Tokyo, Japan|Japanese Red Cross Medical Center, Tokyo, Japan|JR Tokyo General Hospital, Tokyo, Japan|Kanto Central Hospital, Tokyo, Japan|Wakayama Medical University, Wakayama, Japan|Yokohama City University Medical Center, Yokohama City, Japan|Soonchunhyang University Bucheon Hospital, Gyeonggi-do, Bucheon-si, Korea, Republic of|Samsung Medical Center, Seoul, Gangnam-gu, Korea, Republic of|Inje University Ilsan Paik Hospital, Gyeonggi-do, Goyang-si, Korea, Republic of|Kyungpook National University Hospital, Daegu, Gyeongsangbuk-do, Korea, Republic of|Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of|Kyungpook National University Hospital, Daegu, Jung-gu, Korea, Republic of|The Catholic University of Korea, Kangnam St.Mary's Hospital, Seoul, Seocho-gu, Korea, Republic of|Pusan National University Hospital, Busan, Korea, Republic of|Seoul National University Bundang Hospital, Gyunggido, Korea, Republic of|Yonsei University Severance Hospital, Seoul, Korea, Republic of|Korea University Medical Center Anam Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|University Malaya Medical Centre, Kuala Lumpur, Malaysia|The Medical City, Pasig City, Metro Manila, Philippines|St. Luke's Medical Center, Quezon City, Philippines|Cardinal Santos Medical Center, San Juan City, Philippines|Chinese General Hospital and Medical Center, Sta Cruz, Manila, Philippines|Chang-Gung Memorial Hospital - Chiayi Branch, Putzu City, Chiayi, Taiwan|Chang Gung Memorial Hospital - Kao Shiung, KaoShiung, Kaohsiung County, Taiwan|Chang Gung Memorial Hospital - Linkou, Linkou, Taoyuan, Taiwan|Chang Gung Memorial Hospital - Keelung, Keelung, Taiwan|China Medical University Hospital, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan|Songklanagarind Hospital, Hat Yai, Songkla, Thailand|King Chulalongkorn Memorial Hospital, Bangkok, Thailand|Siriraj Hospital, Bangkok, Thailand|Thammasat University Hospital, Pathumthani, Thailand	https://ClinicalTrials.gov/show/NCT00617981
633	Utility Study of Primovist-MRI on HCC Staging	Unknown status	No Results Available	Hepatocellular Carcinoma	Procedure: Primovist-enhanced MRI	Jin-Woo Lee, Incheon, Korea, Republic of	https://ClinicalTrials.gov/show/NCT01764438
634	Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer	Recruiting	No Results Available	Hepatocellular Cancer	Drug: Sorafenib (SOR)|Drug: Hydroxychloroquine (HCQ)	University of Texas Health Cancer Center, San Antonio, Texas, United States	https://ClinicalTrials.gov/show/NCT03037437
635	Patupilone Activity in Advanced/Metastatic Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Drug: Patupilone	Novartis Investigative Site, San Francisco, California, United States|Novartis Investigative Site, Hong Kong, Shatin, NT, Hong Kong|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Taipei, Taiwan ROC, Taiwan|Novartis Investigative Site, Tai Chung Municipality, Taiwan	https://ClinicalTrials.gov/show/NCT00273312
636	Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer	Terminated	Has Results	Hepatocellular Cancer	Drug: Tivozanib	Emory University, Winship Cancer Institute, Atlanta, Georgia, United States	https://ClinicalTrials.gov/show/NCT01807156
637	Endoscopic Ultrasound Guided Liver Biopsy	Completed	No Results Available	Hepatic Cancer|Hepatic Neoplasm|Hepatic Carcinoma	Other: 22 gauge needle liver biopsy	Center for Interventional Endoscopy - Florida Hospital, Orlando, Florida, United States	https://ClinicalTrials.gov/show/NCT03307811
638	A Phase I Study of GC33 in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)	Completed	No Results Available	Advanced or Metastatic HCC	Drug: GC33	USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Karmanos Cancer Center at the Detroit Medical Center, Detroit, Michigan, United States|Washington University, St. Louis, Missouri, United States|Columbia University Medical Center, New York, New York, United States|Methodist Hospital, Houston, Texas, United States|Swedish Cancer Institute at the Swedish Medical Center, Seattle, Washington, United States	https://ClinicalTrials.gov/show/NCT00746317
639	Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer	Completed	Has Results	Adult Hepatocellular Carcinoma|Advanced Adult Hepatocellular Carcinoma|Endometrial Serous Adenocarcinoma|Localized Non-Resectable Adult Liver Carcinoma|Lung Carcinoid Tumor|Malignant Pancreatic Gastrinoma|Malignant Pancreatic Glucagonoma|Malignant Pancreatic Insulinoma|Malignant Pancreatic Somatostatinoma|Metastatic Digestive System Neuroendocrine Tumor G1|Ovarian Carcinosarcoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Seromucinous Carcinoma|Ovarian Serous Surface Papillary Adenocarcinoma|Pancreatic Alpha Cell Adenoma|Pancreatic Beta Cell Adenoma|Pancreatic Delta Cell Adenoma|Pancreatic G-Cell Adenoma|Pancreatic Polypeptide Tumor|Recurrent Adult Liver Carcinoma|Recurrent Digestive System Neuroendocrine Tumor G1|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Pancreatic Neuroendocrine Carcinoma|Recurrent Primary Peritoneal Carcinoma|Recurrent Uterine Corpus Carcinoma|Regional Digestive System Neuroendocrine Tumor G1|Stage IIIA Fallopian Tube Cancer|Stage IIIA Ovarian Cancer|Stage IIIA Primary Peritoneal Cancer|Stage IIIA Uterine Corpus Cancer|Stage IIIB Fallopian Tube Cancer|Stage IIIB Ovarian Cancer|Stage IIIB Primary Peritoneal Cancer|Stage IIIB Uterine Corpus Cancer|Stage IIIC Fallopian Tube Cancer|Stage IIIC Ovarian Cancer|Stage IIIC Primary Peritoneal Cancer|Stage IIIC Uterine Corpus Cancer|Stage IV Fallopian Tube Cancer|Stage IV Ovarian Cancer|Stage IV Primary Peritoneal Cancer|Stage IVA Uterine Corpus Cancer|Stage IVB Uterine Corpus Cancer|Uterine Carcinosarcoma	Biological: Bevacizumab|Drug: Temsirolimus	Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Tower Cancer Research Foundation, Beverly Hills, California, United States|City of Hope Comprehensive Cancer Center, Duarte, California, United States|Los Angeles County-USC Medical Center, Los Angeles, California, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|City of Hope South Pasadena, South Pasadena, California, United States|University of Connecticut, Farmington, Connecticut, United States|Hartford Hospital, Hartford, Connecticut, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Emory University/Winship Cancer Institute, Atlanta, Georgia, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Cancer Care Center of Decatur, Decatur, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States|University of Maryland Saint Joseph Medical Center, Towson, Maryland, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Mercy Hospital, Coon Rapids, Minnesota, United States|Fairview-Southdale Hospital, Edina, Minnesota, United States|Unity Hospital, Fridley, Minnesota, United States|Hutchinson Area Health Care, Hutchinson, Minnesota, United States|Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota, United States|Saint John's Hospital - Healtheast, Maplewood, Minnesota, United States|Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|North Memorial Medical Health Center, Robbinsdale, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Metro Minnesota Community Oncology Research Consortium, Saint Louis Park, Minnesota, United States|Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Saint Francis Regional Medical Center, Shakopee, Minnesota, United States|Lakeview Hospital, Stillwater, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Rice Memorial Hospital, Willmar, Minnesota, United States|Minnesota Oncology Hematology PA-Woodbury, Woodbury, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Mercy Hospital Saint Louis, Saint Louis, Missouri, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Montefiore Medical Center - Moses Campus, Bronx, New York, United States|Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Weill Medical College of Cornell University, New York, New York, United States|Memorial Sloan Kettering Sleepy Hollow, Sleepy Hollow, New York, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Case Western Reserve University, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States|M D Anderson Cancer Center, Houston, Texas, United States|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States|Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada|London Regional Cancer Program, London, Ontario, Canada|Trillium Health Partners - Credit Valley Hospital, Mississauga, Ontario, Canada|University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada	https://ClinicalTrials.gov/show/NCT01010126
640	Feasibility of High Dose PROton Therapy On Unresectable Primary Carcinoma Of Liver: Prospective Phase II Trial	Recruiting	No Results Available	Liver Neoplasm|Proton Therapy	Radiation: Proton arm	Samsung Medical Center, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT02632864
641	Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma	Completed	Has Results	Carcinoma, Hepatocellular	Drug: Tepotinib 300 mg|Drug: Tepotinib 500 mg|Drug: Tepotinib 1000 mg|Drug: Tepotinib|Drug: Sorafenib	307 Hosptial of PLA, Beijing, Beijing, China|Peking University Cancer Hospital, Beijing, Beijing, China|Fuzhou General Hospital of Nanjing Military Area Command of Chinese PLA, Fuzhou, Fujian, China|Sun Yat-sen University, Cancer Center, Guangzhou, Guangdong, China|Nanfang Hospital, Guangzhou, Guangdong, China|Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China|The Third Xiangya Hospital of Central South University, Changsha, Hunan, China|Nanjing Bayi Hospital, Nanjing, Jiangsu, China|Nanjing First Hospital Affiliated to Nanjing Medical University, Nanjing, Jiangsu, China|Jilin Cancer Hospital, Changchun, Jilin, China|Shanghai Cancer Hospital, Fudan University, Shanghai, Shanghai, China|Zhongshan Hospital Fudan University, Shanghai, Shanghai, China|Cancer Hospital, Tianjin Medical University, Tianjin, Zhejiang, China|Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine, Zhejiang, Zhejiang, China|Beijing Friendship Hospital, Capital Medical University, Beijing, China|Dong-A University Hospital, Busan, Korea, Republic of|Pusan National University Hospital, Busan, Korea, Republic of|Keimyung University Dongsan Hospital, Daegu, Korea, Republic of|Kyungpook National University Hospital, Daegu, Korea, Republic of|National Cancer Center, Goyang-si, Korea, Republic of|CHA Bundang Medical Center, CHA University, Seongnam-si,, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Kyung Hee University Hospital, Seoul, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Gangnam Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Ajou University Hospital, Suwon-si, Korea, Republic of|Pusan National University Yangsan Hospital, Yangsan, Korea, Republic of|Changhua Christian Hospital, Changhua, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|Chi Mei Medical Center, Liou Ying, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Mackay Memorial Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan	https://ClinicalTrials.gov/show/NCT01988493
642	Anatomy-based Resection or Margin-based Resection for Hepatocellular Carcinoma	Not yet recruiting	No Results Available	Hepatocellular Carcinoma by BCLC Stage	Procedure: anatomical liver resection	Hepatic Surgery Center of Tongji Hospital, Wuhan, Hubei, China	https://ClinicalTrials.gov/show/NCT03652896
643	T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma Patients	Terminated	No Results Available	Hepatocellular Carcinoma	Drug: T138067 intravenous|Drug: doxorubicin intravenous	University of Alabama, Birmingham, Alabama, United States|University of California at San Francisco, San Francisco, California, United States|VA Medical Center, Miami, Florida, United States|University of Miami, Miami, Florida, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Loyola University of Chicago, Maywood, Illinois, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|UT Southwestern Medical Center - Dallas, Dallas, Texas, United States|Hospital Vera Cruz, Belo Horizonte, Brazil|Hospital Mater Dei - Departamento de Oncologia, Belo Horizonte, Brazil|Irmandade Santa Casa de Misericórdia de Porto Alegre - Unidade de Apoio à Pesquisa, Porto Alegre, Brazil|Hospital das Clínicas da Faculdade de Medicina da USP, São Paulo, Brazil|Cancer Center, Sun Yat-Sen Unversity, Guangzhou, Guangdong, China|Guangzhou Nanfang Hospital, Guangzhou, Guangdong, China|Queen Mary Hospital, Hong Kong, Hong Kong, China|Nanjing Ba Yi Hospital of PLA, Nanjing, Jiangsu, China|1st Affiliated Hospital of Xi An Jiao Tong University, Xi AN, Shanxi, China|Taipei Veteran General Hospital, Taipei, Taiwan, China|Chang Gung Memorial Hospital, Tao-Yuan, Taiwan, China|Cancer Hospital of Chinese Academy of Medical Science (CAMS), Beijing, China|Beijing Cancer Hospital of Peking University, Beijing, China|Gereral Hospital of PLA, Beijing, China|Chongqing Southwest Hospital, Chongqing, China|Prince Wales Hosptial, Hong Kong, China|The Affiliated Hospital of Medical College Qingdao University, Qingdao, China|Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China|Shanghai Changzheng Hospital, Shanghai, China|Katedra i Klinika Onkologii i Radioterapi Akademii Medycznej, GdaDsk, Poland|Oddział Chemioterapii, Olsztyn, Poland|Klinika Katedry Onkologii AM, Poznan, Poland|San Juan Medical Center, San Juan, Puerto Rico|Arkhangelsk Redional Oncology Center, Department of Chemotherapy, Arkhangelsk, Russian Federation|Barnaul, Russian Federation|Cheliabinsk Regional Oncology Center, Chelyabinsk, Russian Federation|Irkutsk Regional Oncology Center, Irkutsk, Russian Federation|Kazan State Medical University, Kazan, Russian Federation|Kazan Republican Oncology Clinical Center, Kazan, Russian Federation|Krasnodar City Oncology Center, Krasnodar, Russian Federation|Krasnoyarsk Regional Oncology Center, Krasnoyarsk, Russian Federation|Lipetsk, Lipetsk, Russian Federation|Blokhin Cancer Research Center, Moscow, Russian Federation|Central Clinical Hospital of the President of the Russian Federation, Moscow, Russian Federation|Central Clinical Hospital of the Ministry of Transport, Moscow, Russian Federation|Novosibirks Municipal Clinical Hospital #1, Novosibirsk, Russian Federation|Russian Academy of Medical Sciences, Obninsk, Russian Federation|Omsk Regional Oncology Center, Omsk 13, Russian Federation|Orenburg Regional Oncology Center, Orenburg, Russian Federation|Moscow Oncology Hospital #62, P/O Stepanovskoye, Russian Federation|Rostov Research Oncology Institute, Rostov-on-Don, Russian Federation|Central Research Institute of Radiology of the Ministry of Health of Russian Federation, St Petersburg, Russian Federation|Medical Academy of Postgraduate Education, St. Petersburg, St Petersburg, Russian Federation|St. Petersburg Mechnikov State Medical Academy, St Petersburg, Russian Federation|St. Petersburg Oncology Center, St Petersburg, Russian Federation|Stavropol Regional Oncology Center, Stavropol, Russian Federation|Tomsk Regional Research Institute of Oncology, Tomsk, Russian Federation|Bashkiria Republican Oncology Center, Ufa, Russian Federation|Voronezh Regional Clinical Oncology Center, Voronezh, Russian Federation|Yaroslavl Regional Oncology Center, Yaroslavl, Russian Federation|Zhitomir Regional Hospital, Zhitomir, Russian Federation|National University Hospital, Singapore, Singapore|Eastern Cape Oncology Centre, Port Elizabeth, South Africa|Khon Kaen University, Khon Kaen, Thailand|Chiangmai University, Muang Chiangmai, Thailand|Dnepropetrovsk State Medical Academy, Dnepropetrovsk, Ukraine|Donetsk Regional Antitumor Center, Donetsk, Ukraine|Kiev Central Military Clinical Hospital, Kiev, Ukraine|Kiev Oncology Institute of Ukrainian Academy of Medical Science, Kiev, Ukraine|Krivorojsky City Oncology Center, Krivoy Rog, Ukraine|Lvov State Medical University, Lvov, Ukraine|Poltava Regional Clinical Oncological Center, Poltava, Ukraine|Vinnitsa Regional Clinical Oncological Center, Vinnitsa, Ukraine|Zaporozhje State Medical Institute of Postgraduate Education, Zaporozhye, Ukraine|Addenbrookes Hospital, Cambridge, United Kingdom|Royal Free Hospital, London, United Kingdom|Hammersmith Hospital, London, United Kingdom|Christie Hospital, Manchester, United Kingdom	https://ClinicalTrials.gov/show/NCT00057382
644	RAD001 in Advanced Hepatocellular Carcinoma	Completed	Has Results	Hepatocellular Carcinoma	Drug: RAD001	Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States	https://ClinicalTrials.gov/show/NCT00516165
645	Hepatocellular Carcinoma in HIV-infected Patients	Completed	No Results Available	Hepatocellular Carcinoma|HIV|Chronic Hepatitis C|Hepatitis B Virus|Liver Cirrhosis		Hospital de Orihuela, Orihuela, Alicante, Spain|Hospital Clínico Universitario de San Juan, San Juan de Alicante, Alicante, Spain|Hospital Marina Baixa, Villajoyosa, Alicante, Spain|Hospital German Trias i Pujol, Badalona, Barcelona, Spain|Hospital General de Castellón, Castellón De La Plana, Castellón, Spain|Hospital de La Linea, La Línea de la Concepción, Cádiz, Spain|Hospital Universitario de Donostia, San Sebastián, Guipúzcua, Spain|Hospital Universitario A Coruña, A Coruna, La Coruña, Spain|Hospital de San Pedro, Logroño, La Rioja, Spain|Hospital de Santa Lucía, Cartagena, Murcia, Spain|Hospital Universitario de Canarias, San Cristóbal de la Laguna, Santa Cruz De Tenerife, Spain|Hospital de San Eloy, Barakaldo, Vizcaya, Spain|Hospital de Basurto, Basurto, Vizcaya, Spain|Hospital de Cruces, Bilbao, Vizcaya, Spain|Hospital de Galdakao, Galdakao, Vizcaya, Spain|Hospital General Universitario de Alicante, Alicante, Spain|Hospital de Puerto Real, Cádiz, Spain|Hospital Universitario Reina Sofía, Córdoba, Spain|Hospital Universitario Virgen de las Nieves, Granada, Spain|Complejo Hospitalario de Huelva, Huelva, Spain|Complejo Hospitalario de Jaén, Jaén, Spain|Hospital Universitario La Princesa, Madrid, Spain|Hospital Universitario Arrixaca, Murcia, Spain|Hospital Regional Carlos Haya, Málaga, Spain|Hospital Virgen de la Victoria, Málaga, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital Clínico de Valencia, Valencia, Spain|Hospital General de Valencia, Valencia, Spain|Hospital Universitario y Politécnico La Fe, Valencia, Spain|Hospital de Txagorritxu, Vitoria, Álava, Spain	https://ClinicalTrials.gov/show/NCT02785835
646	Molecular Basis of Pediatric Liver Cancer	Recruiting	No Results Available	Childhood Liver Cancer|Liver Malignant Tumors|Embryonal Sarcoma of Liver (Disorder)|Hepatoblastoma|Hepatocellular Carcinoma|Rhabdoid Tumor of Liver		UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States	https://ClinicalTrials.gov/show/NCT03959800
647	In Vitro Models of Liver and Pancreatic Cancer	Unknown status	No Results Available	Cholangiocarcinoma|Hepatocellular Carcinoma|Pancreatic Neoplasm	Genetic: Organoid in vitro culture	Addenbrooke's Hospital, Cambridge, United Kingdom	https://ClinicalTrials.gov/show/NCT02436564
648	Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or Stereotactic Ablative Radiation Therapy in Treating Patients With Residual or Recurrent Liver Cancer Undergone Initial Transarterial Chemoembolization	Active, not recruiting	No Results Available	Child-Pugh Class A|Child-Pugh Class B|Recurrent Hepatocellular Carcinoma	Radiation: Stereotactic Body Radiation Therapy|Procedure: Transarterial Chemoembolization|Drug: embolic agent|Drug: lipiodol	Stanford University, School of Medicine, Palo Alto, California, United States|Hokkaido University Hospital, Sapporo, Hokkaido, Japan	https://ClinicalTrials.gov/show/NCT02762266
649	Treatment of Unresectable Hepatocellular Cancer With Opioid Growth Factor	Completed	No Results Available	Hepatocellular Cancer	Drug: Infusion of opioid growth factor	Penn State Hershey Medical Center, Hershey, Pennsylvania, United States	https://ClinicalTrials.gov/show/NCT00706576
650	Response of Hepatic Tumors to Radioembolization	Withdrawn	No Results Available	Hepatocellular Carcinoma|Intrahepatic Cholangiocarcinoma|Liver Metastasis	Radiation: Injection of Ytttrium-90 microspheres into the hepatic artery	University Hospital Zurich, Divisions of Visceral Surgery and Nucelar Medicine, Zurich, ZH, Switzerland	https://ClinicalTrials.gov/show/NCT01775280
651	Diagnosis of Hepatic Tumors in Cirrhosis: Prospective Validation of the Noninvasive Diagnostic Criteria for Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma		Department of Hepatobilliary Surgery, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT00842647
652	Natural History Study of Children and Adults With Fibrolamellar Hepatocellular Carcinoma	Withdrawn	No Results Available	Hepatocellular Carcinoma|Hepatocellular Cancer		National Institutes of Health Clinical Center, Bethesda, Maryland, United States	https://ClinicalTrials.gov/show/NCT03748927
653	A Randomized Phase II Trial of Surgery Plus Sorafenib vs. Sorafenib Alone for Hepatocellular Cancer (HCC) With Portal Vein Invasion	Recruiting	No Results Available	Hepatocellular Cancer	Procedure: hepatic resection|Drug: Sorafenib	Eastern Hepatobiliary Surgery Hospital, Shanghai, China	https://ClinicalTrials.gov/show/NCT03971201
654	Interest of elastoFRM With Force Measure by MRI on Patients With Hepatocellular Cancer	Unknown status	No Results Available	Hepatocellular Cancer	Radiation: IRM with a 5-minute- additional sequence to measure FRM	Valérie Vilgrain, Clichy, France	https://ClinicalTrials.gov/show/NCT02929082
655	Determination of HCC With Octanoate Breath Test vs. MRI Diagnosis	Completed	No Results Available	Hepatocellular Carcinoma (HCC)	Device: ¹³C-Octanoate Breath Test	302 Military Hopsital, Beijing, China|General Hospital of Beijing Military Region, Beijing, China	https://ClinicalTrials.gov/show/NCT02794805
656	Prospective Observational Trial to Evaluate Quality of Life After Stereotactic Ablative Radiation Therapy in Patients With Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Cancer|Quality of Life|Stereotactic Body Radiation Therapy|Observational	Other: observational	Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Bavaria, Germany	https://ClinicalTrials.gov/show/NCT03253536
657	Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer	Withdrawn	No Results Available	Hepatocellular Cancer	Drug: Sorafenib|Radiation: yttrium-90 radioembolization	University of Hawaii, Honolulu, Hawaii, United States	https://ClinicalTrials.gov/show/NCT02288507
658	Low-contrast Dose Liver CT Using Lean Body Weight Low Monoenergetic Images and Deep Learning-based Reconstruction	Completed	No Results Available	Carcinoma, Hepatocellular|Body Weight	Other: low dose CT contrast media - lean body weight|Other: Standard dose CT contrast media	Seoul National University Hospital, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT04027556
659	The Second Multicenter Hemophilia Cohort Study	Completed	No Results Available	Liver Decompensation|Hepatocellular Carcinoma|Non-Hodgkin Lymphoma		University of Arizona, Tucson, Arizona, United States|University of California, Davis, Davis, California, United States|Children's Hospital of Orange County, Orange, California, United States|University of California, San Francisco, San Francisco, California, United States|University of Colorado, Denver, Colorado, United States|Christiana Hospital, Wilmington, Delaware, United States|Georgetown University, Washington, District of Columbia, United States|Childrens National Medical Center, Washington, District of Columbia, United States|Emory University, Atlanta, Georgia, United States|University of Illinois, Chicago, Illinois, United States|Childrens Memorial Hospital, Chicago, Chicago, Illinois, United States|St. Vincent's Hospital, Indianapolis, Indiana, United States|Tulane University, New Orleans, Louisiana, United States|Wayne State University Hutzel Hospital, Detroit, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|University of Mississippi, Jackson, Mississippi, United States|St. Louis University, Saint Louis, Missouri, United States|University of New Mexico, Albuquerque, New Mexico, United States|University of Buffalo, Buffalo, New York, United States|North Shore Long Island Jewish Health System, Lake Success, New York, United States|Cornell University, New York, New York, United States|Mt. Sinai Medical Center, New York, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Wake Forest University, Winston-Salem, North Carolina, United States|Childrens Hospital, Cinncinati, Cincinnati, Ohio, United States|University of Cincinnati, Cincinnati, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Wright State University, Dayton, Ohio, United States|University of Oklahoma, Oklahoma City, Oklahoma, United States|Milton Hershey Medical Center, Hershey, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Palmentto Health Alliance, Columbia, South Carolina, United States|University of Tennessee, Memphis, Tennessee, United States|Vanderbilt University, Nashville, Tennessee, United States|University of Texas, Houston, Houston, Texas, United States|University of Texas, San Antonio, San Antonio, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Childrens Hospital of Wisconsin, Milwaukee, Wisconsin, United States|Hospital Brigadeiro, Sao Paulo, Brazil|University of Sao Paulo, Sao Paulo, Brazil|South East Health Care Corporation, New Brunswick, Canada|Hospices Civils de Lyon, Lyons, France|University of Bonn, Bonn, Germany|Laikon General Hospital of Athens, Athens, Greece|University of Florence, Florence, Italy|University de Milano, Milan, Italy|Karolinska Institute St. Gorans Hospital, Stockholm, Sweden	https://ClinicalTrials.gov/show/NCT00341705
660	Tampa Associating Microwave Liver Ablation With Portal Vein Ligation for Staged Hepatectomy (TAMLAPS)	Enrolling by invitation	No Results Available	Liver Cancer|Liver Tumor|Hepatocellular Carcinoma|Hilar Cholangiocarcinoma		Florida Hospital Tampa, Tampa, Florida, United States	https://ClinicalTrials.gov/show/NCT03739164
661	Radiofrequency Ablation Using Octopus Electrodes for Treatment of Focal Liver Malignancies	Completed	No Results Available	Hepatocellular Carcinoma|Metastasis|Cholangiocarcinoma	Device: Separable cluster electrode (Octopus®)	Seoul National University Hospital, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT02683538
662	Optimization of Health Expenditure in Liver Surgery	Unknown status	No Results Available	Hepatocellular Carcinoma|Hilar Cholangiocarcinoma|Intra Hepatic Cholangiocarcinoma|Liver Metastasis	Procedure: liver surgery	Amiens North Hospital, Amiens, France|Bordeaux Hospital, Bordeaux, France|Beaujon University Hospital, Clichy, France|Lille Regional Hospital, Lille, France|Lyon Hospital, Lyon, France|Marseille Hospital, Marseille, France|Paoli calmette institute, Marseille, France|Saint Antoine Hospital, Paris, France|Strasbourg hospital, Strasbourg, France|Gustave Roussy institute, Villejuif, France|Paul Brousse Hospital, Villejuif, France	https://ClinicalTrials.gov/show/NCT01715402
663	Radiofrequency Ablation Combined With Toripalimab and Lenvatinib in the Treatment of Short-term Recurrent Hepatocellular Carcinoma.	Not yet recruiting	No Results Available	Recurrent Hepatocellular Cancer	Drug: toripalimab|Drug: Lenvatinib|Device: Radiofrequency ablation		https://ClinicalTrials.gov/show/NCT05162898
664	Diagnostic Efficacies of Sonazoid-CEUS and EOB-MRI in Patients With High Risk of HCC	Unknown status	No Results Available	Hepatocellular Cancer|Liver Cirrhoses|Diagnoses Disease	Diagnostic Test: Diagnostic Sonazoid-CEUS and EOB-MRI	Tianjin Third Central Hospital, Tianjin, Tianjin, China	https://ClinicalTrials.gov/show/NCT04212273
665	Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer	Recruiting	No Results Available	Resectable Hepatocellular Carcinoma|Stage I Hepatocellular Carcinoma AJCC v8|Stage IA Hepatocellular Carcinoma AJCC v8|Stage IB Hepatocellular Carcinoma AJCC v8|Stage II Hepatocellular Carcinoma AJCC v8	Biological: Atezolizumab|Biological: Bevacizumab|Procedure: Therapeutic Conventional Surgery	Houston Methodist Hospital, Houston, Texas, United States|M D Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT04721132
666	STA-9090 in Patients With Advanced Hepatocellular Cancer	Completed	No Results Available	Hepatocellular Carcinoma	Drug: STA-9090	Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States	https://ClinicalTrials.gov/show/NCT01665937
667	A Long-term Survival Analysis of Different Surgical Method in Early Hepatocellular Carcinoma	Completed	No Results Available	Long-term Effects of Cancer Treatment	Procedure: liver resection	Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China	https://ClinicalTrials.gov/show/NCT05117047
668	Study of Postoperative 3D-CRT/IMRT in Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Cancer	Radiation: postoperative radiotherapy	Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT01456156
669	Prevention of Recurrent Hepatitis B After Liver Transplantation	Completed	No Results Available	Hepatitis B|Cirrhosis|Acute Liver Failure|Hepatocellular Carcinoma	Drug: HBIG, Epivir, Hepsera	University of Michigan, Ann Arbor, Michigan, United States	https://ClinicalTrials.gov/show/NCT00059267
670	A Study of Pemetrexed in the Treatment of Patients With Advanced Metastatic Cancer of the Liver	Completed	No Results Available	Liver Cancer	Drug: Pemetrexed	For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Denver, Colorado, United States	https://ClinicalTrials.gov/show/NCT00191412
671	Nivolumab and Yttrium Y 90 Glass Microspheres in Treating Patients With Advanced Liver Cancer	Completed	Has Results	Stage IIIA Hepatocellular Carcinoma|Stage IIIB Hepatocellular Carcinoma|Stage IIIC Hepatocellular Carcinoma|Stage IVA Hepatocellular Carcinoma|Stage IVB Hepatocellular Carcinoma	Other: Laboratory Biomarker Analysis|Biological: Nivolumab|Radiation: Yttrium Y 90 Glass Microspheres	Northwestern University, Chicago, Illinois, United States	https://ClinicalTrials.gov/show/NCT02837029
672	Fibroscan Study in HCC	Recruiting	No Results Available	Confirmed Diagnosis of Hepatocellular Carcinoma|Patients Who Are Scheduled to Undergo Transarterial Chemobolization, Systemic Therapy Surgery|Child's A to C Cirrhosis	Other: Fibroscan	Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong, Hong Kong	https://ClinicalTrials.gov/show/NCT01796145
673	Futibatinib and Pembrolizumab for the Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer	Recruiting	No Results Available	Advanced Hepatocellular Carcinoma|BCLC Stage A Hepatocellular Carcinoma|BCLC Stage B Hepatocellular Carcinoma|BCLC Stage C Hepatocellular Carcinoma|Metastatic Hepatocellular Carcinoma	Drug: Futibatinib|Biological: Pembrolizumab|Other: Quality-of-Life Assessment	Mayo Clinic in Rochester, Rochester, Minnesota, United States	https://ClinicalTrials.gov/show/NCT04828486
674	Comparing SonoVue With Sonazoid Using CEUS-LIRADS in HCC	Unknown status	No Results Available	Hepatocellular Carcinoma|Cirrhosis	Drug: Sonovue and Sonazoid|Drug: Sonazoid and Sonovue	Department of Ultrasound, The Second Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China	https://ClinicalTrials.gov/show/NCT04006275
675	Study of Microwave Thermosphere Ablation and Traditional Microwave Ablation in Single Hepatocellular Carcinoma ≤5cm	Not yet recruiting	No Results Available	Hepatocellular Cancer|Microwave Ablation|Microwave Thermosphere Ablation|Prognosis	Device: True circular microwave needle		https://ClinicalTrials.gov/show/NCT05361538
676	Prognostic Impact of Anatomical Resection Vs. Non-anatomical Resection for HCC	Unknown status	No Results Available	Patients Affected by Hepatocellular Carcinoma|Disease-Free Survival|Overall Survival	Procedure: anatomical liver resection|Procedure: Non-anatomical liver resection	IRCCS Istituto Clinico Humanitas, Rozzano, Milan, Italy	https://ClinicalTrials.gov/show/NCT01236989
677	Regorafenib After Progression on Atezolizumab Plus Bevacizumab in Advanced HCC	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: regorafenib	CHA Bundang Medical Center, Seongnam-si, Gyeonggi-do, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT05134532
678	GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Hepatocellular Carcinoma (HCC)	Recruiting	No Results Available	Hepatocellular Carcinoma|Hepatocellular Cancer|Metastatic Hepatocellular Carcinoma	Drug: Cyclophosphamide|Biological: CAR-T cell|Drug: Fludarabine	National Institutes of Health Clinical Center, Bethesda, Maryland, United States	https://ClinicalTrials.gov/show/NCT05003895
679	Pembrolizumab With or Without Elbasvir/Grazoprevir and Ribavirin in Treating Patients With Advanced Refractory Liver Cancer	Active, not recruiting	No Results Available	BCLC Stage B Hepatocellular Carcinoma|BCLC Stage C Hepatocellular Carcinoma|Hepatitis C Infection|Refractory Liver Carcinoma|Stage III Hepatocellular Carcinoma AJCC v7|Stage IIIA Hepatocellular Carcinoma AJCC v7|Stage IIIB Hepatocellular Carcinoma AJCC v7|Stage IIIC Hepatocellular Carcinoma AJCC v7|Stage IV Hepatocellular Carcinoma AJCC v7|Stage IVA Hepatocellular Carcinoma AJCC v7|Stage IVB Hepatocellular Carcinoma AJCC v7	Drug: Elbasvir/Grazoprevir|Other: Laboratory Biomarker Analysis|Biological: Pembrolizumab|Drug: Ribavirin	M D Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT02940496
680	Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation (P02733/MK-4031-085)	Completed	Has Results	Carcinoma, Hepatocellular	Biological: Peginterferon alfa-2b|Other: Observation (no treatment)		https://ClinicalTrials.gov/show/NCT00759109
681	MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.	Completed	Has Results	Unresectable or Metastatic Hepatocellular Carcinoma (HCC)	Drug: MEDI-573 (1 of 3 doses)|Drug: Sorafenib	Research Site, Oxnard, California, United States|Research Site, Golden Springs, Colorado, United States|Research Site, Las Vegas, Nevada, United States	https://ClinicalTrials.gov/show/NCT01498952
682	Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma	Recruiting	No Results Available	Hepatocellular Cancer|Hepatocellular Carcinoma|Metastatic Hepatocellular Carcinoma	Drug: durvalumab|Drug: Doxorubicin-Eluting Beads|Procedure: TACE|Drug: bevacizumab|Drug: Tremelimumab	National Institutes of Health Clinical Center, Bethesda, Maryland, United States	https://ClinicalTrials.gov/show/NCT03937830
683	EXplanted LIver and Ex-vivo Pancreatic Specimen Evaluation by 7 TESLA MRI	Unknown status	No Results Available	Liver Cirrhosis|Liver Steatosis|Hepatocellular Carcinoma|Pancreatic Cancer|Magnetic Resonance Imaging	Diagnostic Test: 7T Magnetic Resonance Imaging	Azienda Ospedaliero Universitaria Pisana, Pisa, PI, Italy	https://ClinicalTrials.gov/show/NCT04012021
684	Study of Hepatoma Treated by Perfusing Cinobufacin Through Hepatic Artery Combining Embolotherapy	Unknown status	No Results Available	Hepatoma|Cinobufacin Injection	Drug: Cinobufacin injection	Department of TCM, Changhai Hospital of Shanghai, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT01236690
685	A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver	Terminated	Has Results	Carcinoma, Hepatocellular	Drug: arsenic trioxide	University of Texas Medical Branch at Galveston, Galveston, Texas, United States	https://ClinicalTrials.gov/show/NCT00582400
686	Clinical Study of Intratumoral Injection of CAR-T Cells in the Treatment of Advanced Liver Tumors	Recruiting	No Results Available	Hepatocellular Carcinoma , Cholangiocarcinoma	Biological: anti-GPC3 CAR-T cells	The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China	https://ClinicalTrials.gov/show/NCT04951141
687	Surgical Specification and Efficacy Evaluation of Total Laparoscopic Left Liver Resection	Recruiting	No Results Available	Laparoscopic Hepatectomy|Hepatocellular Carcinoma	Procedure: laparoscopic hepatectomy|Procedure: open liver resection	Sun Yat-sen Memorial Hospital,Sun Yat-sen University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT02131441
688	Application Value of CEUS Li-RADS in Hepatic Focal Lesions in Patients With Non-high Risk Factors for HCC	Recruiting	No Results Available	Hepatocellular Carcinoma	Diagnostic Test: SonoVue	Beijing Hospital, Beijing, Beijing, China|Fujian Cancer Hospital, Fuzhou, Fujian, China|Shengjing Hospital, Shenyang, Liaoning, China|General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China|Shandong Jining No.1 People's Hospital, Jining, Shandong, China|Sichuan Provincial People's Hospital, Chengdu, Sichuan, China|Tianjin Third Central Hospital, Tianjin, Tianjin, China|Department of Ultrasound, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China|Red Cross Hospital, Hangzhou, China, Hangzhou, Zhejiang, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China	https://ClinicalTrials.gov/show/NCT04920214
689	Chronic Thalidomide Administration in Patients Undergoing Chemoembolization for Unresectable Hepatocellular Cancer	Unknown status	No Results Available	Liver Cancer	Drug: thalidomide|Procedure: chemoembolization with doxorubicin/collagen	Kaplan Comprehensive Cancer Center, New York, New York, United States	https://ClinicalTrials.gov/show/NCT00006198
690	A 5-year Longitudinal Observational Study of the Natural History and Management of Patients With HCC	Recruiting	No Results Available	Hepatocellular Cancer		Banner University Medical Center, Phoenix, Arizona, United States|University of Arkansas, Little Rock, Arkansas, United States|University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, California, United States|Stanford University, Palo Alto, California, United States|California Liver Research Institute, Pasadena, California, United States|University of California-Davis, Sacramento, California, United States|University of California, San Francisco, California, United States|Georgetown University, Washington, District of Columbia, United States|Gastro Florida, Clearwater, Florida, United States|University of Florida Hepatology Research at CTRB, Gainesville, Florida, United States|University of Florida Health Gastroenterology, Jacksonville, Florida, United States|Schiff Center for Liver Diseases/University of Miami, Miami, Florida, United States|Tampa General Medical Group, Tampa, Florida, United States|Piedmont Atlanta Hospital, Atlanta, Georgia, United States|Emory University Hospital, Atlanta, Georgia, United States|Northwestern University Division of Gastroenterology and Hepatology, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Tulane University, New Orleans, Louisiana, United States|Mercy Medical Center, GI Research, Baltimore, Maryland, United States|Johns Hopkins University, Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Southern Therapy and Advanced Research (STAR) LLC, Jackson, Mississippi, United States|Saint Louis University, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States|Northwell Health - Center for Liver Diseases, Manhasset, New York, United States|NYU Langone Health, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Columbia University, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Center for Liver Disease and Transplant at CMC, Charlotte, North Carolina, United States|Providence Health & Services Cancer Clinical Trials, Portland, Oregon, United States|Penn State Hershey Medical Center, Hershey, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Vanderbilt University Medical Center - GI Research Office, Nashville, Tennessee, United States|Clinical Research Institute@ Methodist Dallas Medical Center, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor Scott & White All Saints, Fort Worth, Texas, United States|Research Specialists of Texas, Houston, Texas, United States|University of Virginia, Charlottesville, Virginia, United States|Bon Secours Liver Institute of Virginia, Richmond, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Harborview Medical Center, Seattle, Washington, United States|Wenatchee Valley Hospital & Clinics, Wenatchee, Washington, United States|University of Wisconsin, Madison, Wisconsin, United States|CHU de Nice - Hôpital L'Archet 2, Nice, France|Hôpitaux Universitaires Paris Centre, Paris, France|Universitätsklinikum Aachen, Aachen, Germany|Charité - Universitätsmedizin Berlin, Berlin, Germany|Universitätsklinikum Frankfurt, Frankfurt, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitätsklinikum Leipzig, Leipzig, Germany|Universitätsklinikum Magdeburg, Magdeburg, Germany|Universitätsmedizin Mainz, Mainz, Germany|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy|A.O.U.P. di Palermo, Palermo, Italy|Humanitas Mirasole IRCCS, Rozzano, Italy|IRCCS "Casa Sollievo della Sofferenza", San Giovanni Rotondo, Italy|Complejo Hospitalario Universitario A Coruña, Coruña, Spain|Hospital Puerta de Hierro Majadahonda, Madrid, Spain|Clínica Universidad de Navarra, Pamplona, Spain|Hospital Universitario Marques de Valdecilla, Santander, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Hospital Universitario Politècnic La Fe, Valencia, Spain	https://ClinicalTrials.gov/show/NCT02954094
691	Comparing the Diagnostic Efficiencies of CEUS and EOB-MRI in Patients With High Risk of HCC	Completed	No Results Available	Hepatocellular Cancer|Liver Cirrhoses|Diagnoses Disease	Diagnostic Test: Diagnostic CEUS and EOB-MRI	Tianjin Third Central Hospital, Tianjin, Tianjin, China	https://ClinicalTrials.gov/show/NCT04212286
692	A Comparative Study of the Efficacy of Transcatheter Arterial Chemoembolization (TACE) and Transcatheter Arterial Pegylated Interferon Embolization (TAIE) for Liver Cancer	Unknown status	No Results Available	Carcinoma, Hepatocellular	Procedure: Transcatheter Arterial Chemoembolization (TACE)|Procedure: Transcatheter Arterial Pegylated Interferon Embolization (TAIE)	Queen Mary Hospital, Hong Kong, China	https://ClinicalTrials.gov/show/NCT00563095
693	Ulinastatin Preventing Postoperative Hepatic Failure in Hepatocellular Carcinoma (HCC)	Completed	No Results Available	Hepatocellular Carcinoma	Drug: Ulinastatin|Drug: Diammonium glycyrrhizinate	Eastern Hepatobiliary Surgery Hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT01643447
694	Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer or Hepatic Metastases	Completed	No Results Available	Hepatocellular Cancer|Cholangiocarcinoma|Hepatic Metastases	Procedure: Proton Beam Radiation		https://ClinicalTrials.gov/show/NCT00465023
695	Study of Automatic Image Fusion of a CT Volume With Ultrasound During Percutaneous Ablation Treatment of Hepatic Tumors	Recruiting	No Results Available	Hepatocellular Carcinoma	Radiation: Interact Active Tracker	SERROR, Bobigny, France	https://ClinicalTrials.gov/show/NCT04420026
696	Meclizine for Hepatocellular Carcinoma	Recruiting	No Results Available	Carcinoma, Hepatocellular	Drug: Meclizine Oral Tablet	Baylor College of Medicine -McNair Campus, Houston, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Baylor St. Luke's Medical Center, Houston, Texas, United States|Ben Taub General Hospital, Houston, Texas, United States|Harris Health System- Smith Clinic, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT03253289
697	A2ALL-Patients Safety System Improvements in Living Donor Liver Transplantation	Completed	Has Results	Liver Diseases|Hepatocellular Cancer|Endstage Liver Disease|Liver Cirrhosis	Behavioral: Donor pain management	Northwestern University, Chicago, Illinois, United States|Lahey Clinic, Burlington, Massachusetts, United States|Columbia University, New York, New York, United States|Virginia Commonweath University-Medical College of Virginia, Richmond, Virginia, United States	https://ClinicalTrials.gov/show/NCT02073435
698	Safety and Efficacy of Doxorubicin Adsorbed to Magnetic Beads	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: MTC-DOX for Injection	Cancer Institute & Hosp. CAMS, Beijing, China|Chinese PLA Cancer Ctr. Yang Gongjing, Nanjing City, China|Zhong Shan Hospital, Fudan University, Shanghai, China	https://ClinicalTrials.gov/show/NCT00054951
699	Effects of Anesthetic Methods on Hepatic Cancer Cell Function in Vitro	Completed	No Results Available	Hepatocellular Carcinoma	Procedure: general anesthesia|Procedure: local anesthesia	Renji Hospital affliated to Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT04510935
700	DC Bead LUMI (TM) Loaded With Doxorubicin for Intermediate Hepatocellular Carcinoma (HCC)	Completed	No Results Available	Hepatocellular Cancer|Chemoembolization	Device: chemoembolization	Evgenidion Hospital, Athens, Attiki, Greece	https://ClinicalTrials.gov/show/NCT03474354
701	Effects of Anesthetic Methods on Hepatic Cancer Cell Malignancy	Completed	No Results Available	Hepatocellular Carcinoma	Procedure: anesthetic methods	Renji Hospital affliated to Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT03594188
702	Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma	Completed	No Results Available	Hepatoma|Advanced Solid Tumor	Drug: irinotecan and ON 01910.Na|Drug: oxaliplatin and ON 01910.Na	Mount Sinai Medical Center, New York, New York, United States	https://ClinicalTrials.gov/show/NCT00861783
703	Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer	Completed	Has Results	Childhood Hepatocellular Carcinoma|Papillary Thyroid Cancer|Previously Treated Childhood Rhabdomyosarcoma|Recurrent Childhood Liver Cancer|Recurrent Childhood Rhabdomyosarcoma|Recurrent Thyroid Cancer|Recurrent Wilms Tumor and Other Childhood Kidney Tumors	Drug: sorafenib tosylate|Other: pharmacological study|Other: laboratory biomarker analysis	Children's Hospital of Alabama, Birmingham, Alabama, United States|University of Alabama at Birmingham, Birmingham, Alabama, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Southern California Permanente Medical Group, Downey, California, United States|Miller Children's Hospital, Long Beach, California, United States|Children's Hospital Los Angeles, Los Angeles, California, United States|Children's Hospital Central California, Madera, California, United States|Childrens Hospital of Orange County, Orange, California, United States|Rady Children's Hospital - San Diego, San Diego, California, United States|University of California San Francisco Medical Center-Parnassus, San Francisco, California, United States|Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver, Colorado, United States|Connecticut Children's Medical Center, Hartford, Connecticut, United States|Alfred I duPont Hospital for Children, Wilmington, Delaware, United States|Children's National Medical Center, Washington, District of Columbia, United States|Lee Memorial Health System, Fort Myers, Florida, United States|Nemours Children's Clinic - Jacksonville, Jacksonville, Florida, United States|Florida Hospital, Orlando, Florida, United States|Nemours Children's Clinic - Orlando, Orlando, Florida, United States|Nemours Children's Clinic - Pensacola, Pensacola, Florida, United States|All Children's Hospital, Saint Petersburg, Florida, United States|Saint Joseph Children's Hospital of Tampa, Tampa, Florida, United States|Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States|University of Hawaii, Honolulu, Hawaii, United States|Saint Luke's Mountain States Tumor Institute, Boise, Idaho, United States|Lurie Children's Hospital-Chicago, Chicago, Illinois, United States|University of Illinois, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Saint Jude Midwest Affiliate, Peoria, Illinois, United States|Southern Illinois University, Springfield, Illinois, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|University of Kentucky, Lexington, Kentucky, United States|Kosair Children's Hospital, Louisville, Kentucky, United States|Tulane University Health Sciences Center, New Orleans, Louisiana, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|Mark O Hatfield-Warren Grant Magnuson Clinical Center, Bethesda, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Dana-Farber Harvard Cancer Center, Boston, Massachusetts, United States|Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|University of Minnesota Medical Center-Fairview, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|The Childrens Mercy Hospital, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Children's Hospital and Medical Center of Omaha, Omaha, Nebraska, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Morristown Memorial Hospital, Morristown, New Jersey, United States|UMDNJ - Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States|Overlook Hospital, Summit, New Jersey, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Montefiore Medical Center - Moses Campus, Bronx, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Columbia University Medical Center, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|State University of New York Upstate Medical University, Syracuse, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Novant Health Presbyterian Medical Center, Charlotte, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Children's Hospital Medical Center of Akron, Akron, Ohio, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Rainbow Babies and Childrens Hospital, Cleveland, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Dayton Children's Hospital, Dayton, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Oregon Health and Science University, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Oncology Group, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|BI-LO Charities Children's Cancer Center, Greenville, South Carolina, United States|Greenville Cancer Treatment Center, Greenville, South Carolina, United States|East Tennessee Childrens Hospital, Knoxville, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Driscoll Children's Hospital, Corpus Christi, Texas, United States|Medical City Dallas Hospital, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Cook Children's Medical Center, Fort Worth, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Childrens Hospital-King's Daughters, Norfolk, Virginia, United States|Seattle Children's Hospital, Seattle, Washington, United States|Providence Sacred Heart Medical Center and Children's Hospital, Spokane, Washington, United States|Midwest Children's Cancer Center, Milwaukee, Wisconsin, United States|Sydney Children's Hospital, Randwick, New South Wales, Australia|Princess Margaret Hospital for Children, Perth, Western Australia, Australia|British Columbia Children's Hospital, Vancouver, British Columbia, Canada|IWK Health Centre, Halifax, Nova Scotia, Canada|McMaster Children's Hospital at Hamilton Health Sciences, Hamilton, Ontario, Canada|Hospital for Sick Children, Toronto, Ontario, Canada|The Montreal Children's Hospital of the MUHC, Montreal, Quebec, Canada|Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada|Centre Hospitalier Universitaire de Quebec, Ste-Foy, Quebec, Canada	https://ClinicalTrials.gov/show/NCT01502410
704	A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer	Active, not recruiting	No Results Available	Cancer, Hepatocellular	Drug: nivolumab|Drug: ipilimumab|Procedure: TACE	Southern California Research Center, Coronado, California, United States|Local Institution, La Jolla, California, United States|Local Institution, Washington, District of Columbia, United States|University of Louisville-James Graham Brown Cancer Center, Louisville, Kentucky, United States|Local Institution, Knoxville, Tennessee, United States|The Liver Institute at Methodist Dallas Medical Center, Dallas, Texas, United States|Local Institution, San Antonio, Texas, United States|Local Institution, Charlottesville, Virginia, United States|Local Institution, Wollongong, New South Wales, Australia|Sunshine Coast University Hospital, Birtinya, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|St. Vincents Hospital, Melbourne, Victoria, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia|Local Institution - 0048, Wiener Neustadt, Niederosterreich, Austria|Medizinische Universitat Graz, Graz, Austria|Universitatsklinikum St. Polten - Lilienfeld Standort St. Polten, St. Polten, Austria|Local Institution, Vienna, Austria|Allgemeines Krankenhaus Wien, West Springfield, Austria|Cliniques Univ St Luc - Gastro-Enterology, Brussels, Belgium|Local Institution, Federal District, Belgium|AZ Maria Middelares, Gent, Belgium|Universite Libre de Bruxelles (ULB) - Hopital Erasme, Plainfield, Belgium|Centre Hospitalier Affilie Universitaire - Hotel-Dieu de Quebec, Quebec, Canada|Local Institution, Beijing, Beijing, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Tianjin, Hebei, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Shenyang, Liaoning, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Chengdu, Sichuan, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Fakultni nemocnice Olomouc, Olomouc, Czechia|Local Institution, Praha 5, Czechia|Centre Hospitalier Universitaire Caen, Caen, France|Hopitaux Universitaires Paris Nord Val de Seine - Hopital Beaujon, Clichy, France|Centre Georges-Franois Leclerc, Dijon, France|Hopital Michallon, La Tronche, France|Local Institution - 0014, Lille, France|Hopital Saint Joseph, Marseil, France|Centre Hospitalier Universitaire de Nantes CHU de Nantes, Nantes, France|CHU de Nice - Hospital Larchet, Nice, France|CHU Reims, Reims, France|Gustave Roussy, Villejuif cedex, France|Local Institution, Dresden, Germany|Local Institution, Essen, Germany|Universitatsmedizin Gttingen - Universitat GeottingenKlinik fuer Gastroenterologie und Gastrointesti, Goettingen, Germany|Local Institution, Hannover, Germany|Local Institution, Heidelberg, Germany|Universitatsklinikum Leipzig, Leipzig, Germany|Local Institution, Hong Kong, Hong Kong|Local Institution - 0015, Orbassano, TO, Italy|Local Institution, Messina, Italy|Fondazione IRCCS CA Granda Ospedale Maggiore Policlinico, Milano, Italy|Local Institution, Monserrato, Italy|Local Institution, Parma, Italy|Local Institution, Roma, Italy|A.O.U. Senese Policlinico Le Scotte, Siena, Italy|Azienda ULSS 8 Berica, Vicenza, Italy|Chiba University Hospital, Chiba-shi, Chiba, Japan|Ehime Prefectural Central Hospital, Matsuyama, Ehime, Japan|Sapporo-Kosei General Hospital, Sapporo-shi, Hokkaido, Japan|Kanazawa University Hospital, Kanazawa, Ishikawa, Japan|Toranomon Hospital Kajigaya, Kawasaki, Kanagawa, Japan|Yokohama City University Medical Center, Yokohama-Shi, Kanagawa, Japan|Kanagawa Cancer Center, Yokohama-Shi, Kanagawa, Japan|Kyoto Prefectural University of Medicine KPUM - University Hospital, Kamigyo-ku, Kyoto, Japan|Local Institution, Kashihara-Shi, Nara, Japan|Osaka city University Hospital, Abeno-ku, Osaka, Japan|Local Institution, Tennoji-ku, Osaka, Japan|Local Institution, Saga Shi, Saga, Japan|Juntendo University Shizuoka Hospital, Izunokuni-Shi, Shizuoka, Japan|Toranomon Hospital, Minato-ku, Tokyo, Japan|Local Institution, Mitaka-Shi, Tokyo, Japan|Japanese Red Cross Musashino Hospital, Musashino-shi, Tokyo, Japan|Hiroshima University Hospital, Hiroshima, Japan|Kindai University Hospital, Osaka, Japan|Saitama Medical University Hospital, Saitama, Japan|Local Institution, Daegu, Daegu Gwang Yeogsi, Korea, Republic of|Local Institution - 0114, Busan, Korea, Republic of|Local Institution - 0047, Gyeongsangnam-do, Korea, Republic of|Local Institution, Hwasun-Gun, Korea, Republic of|Local Institution - 0161, Seoul, Korea, Republic of|Local Institution - 0186, Seoul, Korea, Republic of|Local Institution - 0160, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Gdansk, Poland|Local Institution, Warszawa, Poland|Local Institution, Wroclaw, Poland|Local Institution - 0049, San Juan, Puerto Rico|Local Institution - 0016, Barnaul, Russian Federation|A.M.Granovs Russian Scientific Center of Radiology and Surgical Technologies, Saint Petersburg, Russian Federation|City Clinical Oncology Dispensary, Saint-Petersburg, Russian Federation|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Local Institution - 0011, Singapore, Singapore|Local Institution - 0023, Alicante, Spain|Local Institution - 0130, Barcelona, Spain|Hospital Universitario Reina Sofia, Cordoba, Spain|Local Institution - 0101, Madrid, Spain|Clinica Universidad de Navarra-Madrid, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Local Institution - 0018, Madrid, Spain|Clinica Universidad de Navarra, Pamplona, Spain|Parc Tauli Sabadell Hospital Universitari, Sabadell, Spain|Hospital Clinico Universitario de Santiago de Compostela, Santiago de Compostela, Spain|Local Institution, Basel-Stadt, Switzerland|Local Institution, St.Gallen, Switzerland|Local Institution, Zurich, Switzerland|Local Institution, Kaohsiung, Taiwan|Local Institution - 0030, Taichung, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Tainan City, Taiwan|Local Institution - 0002, Taipei, Taiwan|Local Institution, Tapei, Taiwan	https://ClinicalTrials.gov/show/NCT04340193
705	Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery	Unknown status	No Results Available	Hepatocellular Carcinoma|Hepatoma|Cholangiocarcinoma|Gallbladder Neoplasms	Drug: Sevoflurane|Drug: Desflurane	Tokyo Medical and Dental University, Tokyo, Japan	https://ClinicalTrials.gov/show/NCT02174575
706	Transarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular Carcinoma	Active, not recruiting	No Results Available	Carcinoma, Hepatocellular|Hepatic Carcinoma|Hepatocellular Cancer	Drug: Nivolumab|Drug: TACE	Medizinische Hochschule Hannover, Klinik für Gastroenterologie, Hepatologie & Endokrinologie, Hannover, Germany	https://ClinicalTrials.gov/show/NCT03572582
707	AZD6244 and Sorafenib in Advanced Hepatocellular Carcinoma	Terminated	No Results Available	Hepatocellular Carcinoma	Drug: AZD6244 and sorafenib	National University Hospital Singapore, Singapore, Singapore|National Cancer Centre Singapore, Singapore, Singapore	https://ClinicalTrials.gov/show/NCT01029418
708	Environmental, Metabolic and Nutritional Factors of Hepatocellular Carcinoma in Cirrhotic Patients	Completed	No Results Available	Cirrhosis With Hepatocellular Carcinoma|Cirrhosis Without Hepatocellular Carcinoma	Biological: Serum, plasma and DNA samples|Procedure: Radiological exploration by CT scan or MRI	Hôpital Jean Minjoz, Besancon, France|Hôpital du Bocage, Dijon, France|Centre Hospitalier de METZ, Metz, France|CHU Robert DEBRE, Reims, France|Clinique médicale B. Hôpital Civil-Hôpitaux Universitaires, Strasbourg, France|Hôpital de BRABOIS, Vandoeuvre-les-nancy, France	https://ClinicalTrials.gov/show/NCT01798173
709	Intraoperative Chemotherapy Against Hepatocellular Carcinoma Recurrence	Completed	No Results Available	Hepatocellular Carcinoma	Drug: sustained released 5-FU and sustained released cisplatin|Drug: sustained released 5-FU|Procedure: TACE	Eastern Hepatobiliary Surgery Hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT00817895
710	Association Between Autologous Transfusion and Recurrence Among Patients With HCC After Resection	Recruiting	No Results Available	Liver Cancer	Procedure: Autotransfusion|Other: Control group	Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi, China	https://ClinicalTrials.gov/show/NCT02654028
711	A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100)	Completed	Has Results	Carcinoma, Hepatocellular	Drug: Avelumab (MSB0010718C)|Drug: Axitinib (AG-013736)	Aichi Cancer Center Hospital, Nagoya, Aichi, Japan|Iizuka Hospital, Iizuka, Fukuoka, Japan|Kindai University Hospital, Department of Gastroenterology and Hepatology, Osaka-Sayama, Osaka, Japan|National Cancer Center Hospital, Chuo-ku, Tokyo, Japan|Kyorin University Hospital, Department of Medical Oncology, Mitaka-shi, Tokyo, Japan|Japanese Red Cross Musashino Hospital, Musashino, Tokyo, Japan|National Hospital Organization Kyushu Medical Center, Fukuoka, Japan	https://ClinicalTrials.gov/show/NCT03289533
712	Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC)	Not yet recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Pembrolizumab|Drug: Lenvatinib|Drug: Pembrolizumab and Lenvatinib	Queen Elizabeth Hospital, Birmingham, United Kingdom|Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|St James's Hospital, Leeds Teaching Hospital NHS Trust, Leeds, United Kingdom|Clatterbridge Cancer Centre, Liverpool, United Kingdom|Guy's and St Thomas' Hospital, London, United Kingdom|Royal Free Hospital, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|Northern Institute of Cancer Research, Newcastle Upon Tyne, United Kingdom	https://ClinicalTrials.gov/show/NCT05185739
713	A Comparison Between Child-Pugh and Albumin-Bilirubin Scores	Completed	No Results Available	Rupture, Spontaneous|Rupture Liver|Hepatocellular Carcinoma|Hepatic Impairment	Procedure: Liver resection|Other: Transcatheter arterial embolization		https://ClinicalTrials.gov/show/NCT03534843
714	Contrast Enhanced Ultrasound With Lumason in Detecting Liver Cancer in Participants With Cirrhosis	Completed	No Results Available	Cirrhosis	Procedure: Contrast-Enhanced Ultrasound|Drug: Sulfur Hexafluoride Lipid Microspheres|Procedure: Ultrasound	M D Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT03407001
715	Viral & Host Factors Associated With Hepatitis B Virus-related Hepatocellular Carcinoma	Terminated	No Results Available	Liver Cancer|Hepatitis B|Hepatitis C|Hepatobiliary Cancers Liver|Hepatobiliary Cancers		Stanford University School of Medicine, Stanford, California, United States	https://ClinicalTrials.gov/show/NCT00767936
716	A Study of CD147-targeted CAR-T by Hepatic Artery Infusions for Very Advanced Hepatocellular Carcinoma	Unknown status	No Results Available	Advanced Hepatocellular Carcinoma	Biological: CD147-CART	Department of hepato-biliary & Pancreato Splenic Surgery Organ Transplant Center, Xijing Hospital, Xi'an, Shaanxi, China	https://ClinicalTrials.gov/show/NCT03993743
717	MRI Only Radiation Therapy With CPAP	Completed	No Results Available	Carcinoma Liver|Carcinoma, Pancreatic	Device: CPAP machine	Montefiore Medical Center, Bronx, New York, United States	https://ClinicalTrials.gov/show/NCT03397342
718	HR Versus RFA for HCC in Patients With PHT	Recruiting	No Results Available	Carcinoma, Hepatocellular|Liver Neoplasms|Neoplasms, Glandular and Epithelial	Procedure: Hepatic Resection|Procedure: Radiofrequency Ablation	Department of Hepatobilliary Surgery, Affiliated Tumor of Guangxi University, Nanning, Guangxi, China	https://ClinicalTrials.gov/show/NCT02192671
719	Liver Cancer Registry Platform	Recruiting	No Results Available	Hepatocellular Carcinoma (HCC)|Cholangiocarcinoma	Other: Physician's choice according to patient's needs.	Multiple sites all over germany, Multiple Locations, Germany	https://ClinicalTrials.gov/show/NCT04510740
720	TK-based Suicide Gene Therapy for Hepatocellular Carcinoma	Completed	No Results Available	Carcinoma, Hepatocellular	Genetic: TK99UN	Clinica Universitaria de Navarra, Pamplona, Spain	https://ClinicalTrials.gov/show/NCT00844623
721	Safety Study of Foretinib (GSK1363089) in Adults With Liver Cancer	Completed	No Results Available	Carcinoma, Hepatocellular	Drug: Foretinib	GSK Investigational Site, Hong Kong, Hong Kong|GSK Investigational Site, Tainan, Taiwan|GSK Investigational Site, Taipei, Taiwan|GSK Investigational Site, Taipei, Taiwan|GSK Investigational Site, Bangkok, Thailand|GSK Investigational Site, Bangkok, Thailand|GSK Investigational Site, Khon Kaen, Thailand	https://ClinicalTrials.gov/show/NCT00920192
722	HCC Patient Preferences in Japan	Completed	No Results Available	Hepatocellular Cancer	Drug: Hepatocellular Cancer (HCC) treatments including oral anti-cancer therapy [Nexavar (Sorafenib, BAY43-9006)]	Many Locations, Japan	https://ClinicalTrials.gov/show/NCT02616692
723	BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer	Active, not recruiting	No Results Available	Metastatic Hepatocellular Carcinoma|Stage III Hepatocellular Carcinoma AJCC v8|Stage IIIA Hepatocellular Carcinoma AJCC v8|Stage IIIB Hepatocellular Carcinoma AJCC v8|Stage IV Hepatocellular Carcinoma AJCC v8|Stage IVA Hepatocellular Carcinoma AJCC v8|Stage IVB Hepatocellular Carcinoma AJCC v8|Unresectable Hepatocellular Carcinoma	Drug: IDO1 Inhibitor BMS-986205|Biological: Nivolumab	University of California Davis Comprehensive Cancer Center, Sacramento, California, United States	https://ClinicalTrials.gov/show/NCT03695250
724	Circulating Cell-free DNA-based Epigenetic Biomarker mSEPT9 for Hepatocellular Carcinoma Detection in Cirrhosis	Recruiting	No Results Available	Hepatocellular Carcinoma|Cirrhosis	Diagnostic Test: "Epi proColon 2.0 CE" test from Epigenomics, Inc (Berlin, Germany)	University Hospital of Nancy (CHRU de Nancy), Vandoeuvre-lès-Nancy, France	https://ClinicalTrials.gov/show/NCT03311152
725	Safety and Efficacy of Doxorubicin Adsorbed to Magnetic Beads Vs. IV Doxorubicin in Treating Liver Cancer	Terminated	No Results Available	Carcinoma, Hepatocellular	Drug: MTC-DOX for Injection	Long Beach VA Medical Center, Long Beach, California, United States|VAMC San Francisco and Comprehensive Cancer Ctr., San Francisco, California, United States|Northwestern Univ. Med. School, Chicago, Illinois, United States|Weill Medical College of Cornell University, New York, New York, United States|Univ. of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Allegheny-Singer Research Institute, Pittsburgh, Pennsylvania, United States|University of Texas Medical Branch, Galveston, Texas, United States|Scott & White Mem. Hosp. & Clinic, Temple, Texas, United States|McGuire DVAMC, Richmond, Virginia, United States|Landeskrankenhaus Graz University Hospital, Graz, Austria|University Hospital Vienna, Vienna, Austria|University Hospital Cologne, Cologne, Germany|University Hospital Am Main, Frankfurt, Germany|Queen Mary Hospital, University of Hong Kong, Pokfulam, Hong Kong|Chinese Universtiy of Hong Kong, Shatin, N.T., Hong Kong|Central Research Institute of Roentgenology and Radiology, Pesochny, St. Petersburg, Russian Federation|N.N. Blokhin Cancer Research Center RAMS, Moscow, Russian Federation|Chulalongkorn University Hospital, Bangkok, Thailand|Siriraj Hospital, Mahidol University, Bangkok, Thailand|National Cancer Institute, Bangkok, Thailand|Chiang Mai University, Chiang Mai, Thailand|Khon Kaen Universtiy, Khon Kaen, Thailand|Institute of Oncology AMS of Ukraine, Kiev, Ukraine|Queen Elizabeth Hospital, Edgbaston, Birmingham, United Kingdom|Leicester Royal Infirmary, Leicester, England, United Kingdom|St. George's Hospital, London, England, United Kingdom|Edinburgh Royal Infirmary, Edinburgh, Scotland, United Kingdom	https://ClinicalTrials.gov/show/NCT00034333
726	A Pilot Study of "OncozeneTM" Microspheres for Intra-arterial Delivery of Doxorubicin	Active, not recruiting	No Results Available	Hepatocellular Cancer	Other: Oncozene-DEB-TACE	UT Southwestern Medical Center, Dallas, Texas, United States	https://ClinicalTrials.gov/show/NCT02141906
727	A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)	Active, not recruiting	Has Results	Biliary Tract Neoplasms|Liver Cancer|Hepatocellular Carcinoma|Cholangiocarcinoma|Bile Duct Cancer	Drug: Durvalumab|Drug: Tremelimumab|Procedure: Trans-arterial Catheter Chemoembolization (TACE)|Procedure: Radiofrequency Ablation (RFA)|Procedure: Cryoablation	National Institutes of Health Clinical Center, Bethesda, Maryland, United States	https://ClinicalTrials.gov/show/NCT02821754
728	QuiremSpheres Observational Study	Terminated	No Results Available	Liver, Cancer of, Non-Resectable	Device: Selective Internal Radiation Therapy with QuiremSpheres®	Universitätsklinikum Carl Gustav Carus, Dresden, Germany|UMC Utrecht, Utrecht, Netherlands	https://ClinicalTrials.gov/show/NCT03563274
729	Exhaustive Genetic and Immunological Characterization of Colon, Kidney and Liver Tumors	Unknown status	No Results Available	Colorectal Adenocarcinoma|Hepatic Carcinoma|Kidney Adenocarcinoma		AP-HP Jean Verdier Hospital, Bondy, France|AP-HP Cochin Hospital, Paris, France|AP-HP European Georges Pompidou Hospital, Paris, France	https://ClinicalTrials.gov/show/NCT03149523
730	Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer	Recruiting	No Results Available	BCLC Stage B Hepatocellular Carcinoma|BCLC Stage C Hepatocellular Carcinoma|Locally Advanced Hepatocellular Carcinoma|Stage III Hepatocellular Carcinoma AJCC v8|Stage IIIA Hepatocellular Carcinoma AJCC v8|Stage IIIB Hepatocellular Carcinoma AJCC v8|Stage IV Hepatocellular Carcinoma AJCC v8|Stage IVA Hepatocellular Carcinoma AJCC v8|Stage IVB Hepatocellular Carcinoma AJCC v8|Unresectable Hepatocellular Carcinoma	Biological: Durvalumab|Biological: Tremelimumab	City of Hope Medical Center, Duarte, California, United States	https://ClinicalTrials.gov/show/NCT04605731
731	AFPᶜ³³²T in Advanced HCC	Recruiting	No Results Available	Hepatocellular Cancer|AFP Expressing Tumors	Genetic: Autologous genetically modified AFPᶜ³³²T cells	Mayo Clinic Arizona, Phoenix, Arizona, United States|USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States|UCLA, Los Angeles, California, United States|University of California, San Francisco, San Francisco, California, United States|University of Miami, Miami, Florida, United States|Winship Cancer Institute - Emory University, Atlanta, Georgia, United States|University of Maryland, Greenebaum Cancer Center, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Mayo Clinic Clinical Trial Referral Office, Rochester, Minnesota, United States|Washington University - School of Medicine, Saint Louis, Missouri, United States|MD Anderson Cancer Center, Houston, Texas, United States|Fred Hutchinson Cancer Research Centre, Seattle, Washington, United States|SCCA Immunotherapy Trials Intake, Seattle, Washington, United States|Paoli Calmettes Institute, Marseille Cedex, France|Centre Eugène Marquis, Rennes, France|Institute Gustave Roussy, Villejuif, France|University Hospital of Barcelona, Barcelona, Spain|University Hospital of Navarra, Pamplona, Spain|Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|Guy's Hospital, London, United Kingdom|NIHR UCLH Clinical Research, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom	https://ClinicalTrials.gov/show/NCT03132792
732	Study of Autologous Immune Killer Cells in Patients With Late Stage Hepatocellular Carcinoma or Lung Cancer	Completed	No Results Available	NSCLC Stage IIIB|NSCLC Stage IV|Hepatocellular Carcinoma by BCLC Stage|Lung Cancer|Liver Cancer	Biological: Immune Killer Cells (IKC)		https://ClinicalTrials.gov/show/NCT03515252
733	KV-CBCT and Ultrasound Imaging in Guiding Radiation Therapy in Patients With Prostate, Liver, or Pancreatic Cancer	Completed	Has Results	Adult Liver Carcinoma|Malignant Pancreatic Neoplasm|Prostate Carcinoma	Device: Cone-Beam Computed Tomography|Radiation: 3-Dimensional Ultrasound-Guided Radiation Therapy	Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States	https://ClinicalTrials.gov/show/NCT02337465
734	AFP- L3% and DCP as Tumor Markers in Patients With Hepatocellular Carcinoma (HCC) Treated With Transarterial Chemoembolisation (TACE)	Completed	No Results Available	Hepatocellular Carcinoma		University Medical Center Freiburg, Freiburg, Baden-Württemberg, Germany	https://ClinicalTrials.gov/show/NCT01360255
735	Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer	Not yet recruiting	No Results Available	Locally Advanced Hepatocellular Carcinoma|Metastatic Hepatocellular Carcinoma|Stage III Hepatocellular Carcinoma AJCC v8|Stage IIIA Hepatocellular Carcinoma AJCC v8|Stage IIIB Hepatocellular Carcinoma AJCC v8|Stage IV Hepatocellular Carcinoma AJCC v8|Stage IVA Hepatocellular Carcinoma AJCC v8|Stage IVB Hepatocellular Carcinoma AJCC v8|Unresectable Hepatocellular Carcinoma	Biological: Atezolizumab|Drug: Cabozantinib|Drug: Lenvatinib	Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Cleveland Clinic Weston Florida, Weston, Florida, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Carle Cancer Center NCI Community Oncology Research Program, Urbana, Illinois, United States|University Medical Center New Orleans, New Orleans, Louisiana, United States|Michigan Cancer Research Consortium NCORP, Ann Arbor, Michigan, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States	https://ClinicalTrials.gov/show/NCT05168163
736	Hepatic Artery Infusion Pump for NPC Liver Metastases	Completed	No Results Available	Nasopharyngeal Carcinoma|Neoplasm Metastasis|Liver	Procedure: DSA-guided implantation of hepatic artery infusion pump|Drug: Gemcitabine|Drug: Floxuridine|Drug: dexamethasone		https://ClinicalTrials.gov/show/NCT03876574
737	Effect of Enhanced Recovery After Surgery(ERAS) After Liver Resection for Primary Liver Cancer	Unknown status	No Results Available	Carcinoma, Hepatocellular	Procedure: Enhanced Recovery After Surgery	Zhongshan Hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT02644603
738	A Study of Brivanib (BMS-582664) in Patients With Liver Cancer and Mild, Moderate or Severe Liver Dysfunction	Completed	No Results Available	Carcinoma, Hepatocellular	Drug: Brivanib	University Of Alabama At Birmingham, Birmingham, Alabama, United States|Usc/Norris Comprehensive Cancer Center, Los Angeles, California, United States|Case Western Reserve University, Clleveland, Ohio, United States|South Texas Accelerated Research Therapeutics, Llc, San Antonio, Texas, United States|Local Institution, Sevilla, Spain	https://ClinicalTrials.gov/show/NCT00437424
739	Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery	Completed	Has Results	Advanced Adult Hepatocellular Carcinoma|BCLC Stage C Hepatocellular Carcinoma|Recurrent Adult Hepatocellular Carcinoma|Stage III Hepatocellular Carcinoma AJCC v7|Stage IIIA Hepatocellular Carcinoma AJCC v7|Stage IIIB Hepatocellular Carcinoma AJCC v7|Stage IIIC Hepatocellular Carcinoma AJCC v7|Stage IV Hepatocellular Carcinoma AJCC v7|Stage IVA Hepatocellular Carcinoma AJCC v7|Stage IVB Hepatocellular Carcinoma AJCC v7|Unresectable Hepatocellular Carcinoma	Other: Laboratory Biomarker Analysis|Other: Quality-of-Life Assessment|Drug: Sorafenib|Drug: Sorafenib Tosylate|Radiation: Yttrium Y 90 Glass Microspheres	M D Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT01900002
740	Hypofractionated Radiotherapy Followed by Durvalumab With or Without Tremelimumab for the Treatment of Liver Cancer After Progression on Prior PD-1 Inhibition	Recruiting	No Results Available	Advanced Hepatocellular Carcinoma|Stage III Hepatocellular Carcinoma AJCC v8|Stage IIIA Hepatocellular Carcinoma AJCC v8|Stage IIIB Hepatocellular Carcinoma AJCC v8|Stage IV Hepatocellular Carcinoma AJCC v8|Stage IVA Hepatocellular Carcinoma AJCC v8|Stage IVB Hepatocellular Carcinoma AJCC v8	Biological: Durvalumab|Radiation: Hypofractionated Radiation Therapy|Biological: Tremelimumab	University of California, San Francisco, San Francisco, California, United States	https://ClinicalTrials.gov/show/NCT04430452
741	Phase 3 Study of Tislelizumab Versus Sorafenib in Participants With Unresectable HCC	Active, not recruiting	No Results Available	Hepatocellular Carcinoma (HCC)	Drug: Tislelizumab|Drug: Sorafenib	Southern California Research Center, Coronado, California, United States|St. Jude Heritage Healthcare, Fullerton, California, United States|University of California - Hematology and Oncology, Los Angeles, California, United States|Chao Family Comprehensive Cancer Center, Orange, California, United States|Inland Empire Liver Foundation, Rialto, California, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Healthcare Research Network III, LLC, Tinley Park, Illinois, United States|Ochsner Medical Center (OMC) - New Orleans ACCRU Network Sit, New Orleans, Louisiana, United States|University Medical Center New Orleans, New Orleans, Louisiana, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|UMass Memorial Medical Center, Worcester, Massachusetts, United States|Umdnj-Njms, Newark, New Jersey, United States|Northwell Health/Monter Cancer Center, Lake Success, New York, United States|White Plains Hospital Center for Cancer Care - Oncology, White Plains, New York, United States|Precision Cancer Research / Dayton Physicians Network, Kettering, Ohio, United States|Hahnemann University Hospital - Gastroenterology Hepatology, Philadelphia, Pennsylvania, United States|Cancer Treatment Centers of America - Oncology, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center (VUMC), Nashville, Tennessee, United States|The Mays Cancer Center, San Antonio, Texas, United States|The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China|Anhui Provincial Hospital, Hefei, Anhui, China|The First Affiliated Hospital Of Anhui Medical University, Hefei, Anhui, China|Anhui Medical University - The Second Hospital, Hefei, Anhui, China|Beijing Cancer Hospital, Beijing, Beijing, China|Chinese PLA General Hospital, Beijing, Beijing, China|302 Military Hospital of China, Beijing, Beijing, China|Beijing YouAn Hospital, Capital Medical University, Beijing, Beijing, China|Cancer Hopital Chinese Academy of Medical Sciences, Beijing, Beijing, China|Fujian Medical University Union Hospital, Fuzhou, Fujian, China|Fujian Provincial Cancer Hospital, Fuzhou, Fujian, China|Guangdong General Hospital, Guangzhou, Guangdong, China|Nanfang Hospital, Guangzhou, Guangdong, China|Sun Yat-sen Memorial Hospital , Sun Yat-sen University, Guangzhou, Guangdong, China|The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China|The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China|Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China|Henan Cancer Hospital, Zhengzhou, Henan, China|Hubei Cancer Hospital, Wuhan, Hubei, China|Wuhan Union Hospital, Wuhan, Hubei, China|Nanjing Bayi Hospital, Nanjing, Jiangsu, China|Jiangsu Cancer Hospital, Nanjing, Jiangsu, China|The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China|The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China|Jilin Cancer Hospital, Changchun, Jilin, China|The First Hospital of Jilin University, Changchun, Jilin, China|The Affiliated Hospital Of Qingdao University, Qingdao, Shandong, China|Weifang People's Hospital, Weifang, Shandong, China|Shanghai Cancer Hospital of Fudan University, Shanghai, Shanghai, China|Zhongshan Hospital Fudan University, Shanghai, Shanghai, China|The First Affiliated Hospital Of XI'AN Jiaotong University, Xian, Shanxi, China|Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital, Sichuan, Sichuan, China|Zhongnan Hospital of Wuhan University, Wuhan, Wuhan, China|The First Affiliated Hospital of Zhejiang University, HangZhou, Zhejiang, China|Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China|Peking Union Medical College Hospital, Beijing, China|The First Affiliated Hospital of Chongqing Medical University, Chongqing, China|Tianjin Medical University Cancer Institute and Hospital, Tianjin, China|Fakultni nemocnice Brno, Brno, Brno-Mesto, Czechia|Fakultni nemocnice Olomouc, Olomouc, Czechia|Fakultni nemocnice v Motole, Praha 5, Czechia|CHU Amiens-Hopital Nord - Hépato-Gastroentérologie, Somme, Amiens, France|CHU Cote De Nacre - Hepato-Gastro-Enterologie Et N, Caen, Cedex 05, Basse-Normandie, France|Hôpital Privé des Côtes d'Armor - Service oncologie, Plérin, Bretagne, France|Hopital Robert DEBRE, CHU Reims, Reims, Champagne-Ardenne, France|Hospitalier Jean Minjoz, Besançon, Franche-Comté, France|CHU de Grenoble Alpes, La Tronche, Isere, France|Bichat-Beaujon Service Inter Hospitalier De Cancerologie, Clichy Cedex, Lie-de-France, France|Hopital Paul Brousse- Aphp Hopitaux Universitairees Paris Su, Villejuif, Lie-de-France, France|CHU Nantes -hopital hotel Dieu, Nantes, Loire-Atlantique, France|CHU Saint Etienne, Rahon, Lyon, France|CHRU De Lille - Hôpital Claude Huriez, Lille, Nord, France|CHU de Nice - Hôpital de l'Archet II, Nice, Provence-Alpes-Côte-d'Azur, France|CHU Saint Eloi - Pôle Digestif, Bretagne, Rennes Cedex, France|Gustave Roussy - Medical Oncology, Villejuif, Val-de-Marne, France|Hospital of Poitiers, Poitiers, Vienne, France|Krankenhaus Nordwest gGmbH, Frankfurt/Main, Hessen, Germany|Maria Gonzalez-Carmona, Bonn, Nordrhein-Westfalen, Germany|Stefan Pluntke, Essen, Nordrhein-Westfalen, Germany|Universitätsklinikum Düsseldorf, Düsseldorf, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitätsklinikum Köln, Köln, Germany|Universitätsklinikum Leipzig AöR, Leipzig, Germany|Universitätsmedizin Mainz, Mainz, Germany|IRCCS Saverio De Bellis, AO Gastroenterologia, Castellana Grotte, Bari, Italy|Medical Oncology, Feltre, Belluno, Italy|PO G.Rodolico, AOU Policlinico-Vittorio Emanuele di Catania, Catania, Catani, Italy|Ospedale S.Bortolo, AULSS n.6 Vicenza, Vicenza, Veneto, Italy|Policlinico S.Orsola Malpighi, AOU di Bologna - SSD Malattie, Bologna, Italy|PO di Cremona, ASST di Cremona - Oncologia - Cremona - Radiology, Cremona, Italy|Ospedale Vito Fazzi, ASL Lecce, Lecce, Italy|AOU Policlinico di Modena, Modena, Italy|IRCCS Policlinico San Matteo, Pavia, Italy|Ist. Clinici Scientifici Maugeri - Unità Operativa di Oncologia, Pavia, Italy|Regina Elena, Istituto Nazionale dei Tumori, IFO, IRCCS, Roma, Italy|PO Umberto I, AO Ordine Mauriziano, Torino, Italy|Fujita Health University Hospital, Toyoake, Aiti [Aichi], Japan|Ehime Prefectural Central Hospital - Gastroenterology, Matsuyama, Ehime, Japan|Ogaki Municipal Hospital, Ogaki, Gihu [Gifu], Japan|Hokkaido University Hospital - Gastroenterology, Sapporo, Hokkaidô [Hokkaido], Japan|Kanazawa University Hospital, Kanazawa-shi, Isikawa [Ishikawa], Japan|Yokohama City University Medical Center, Yokohama, Kanagawa, Japan|Kanagawa Cancer Center, Yokohama, Kanagawa, Japan|University Hospital, Kyoto Prefectural Univ of Medicine, Kyoto-shi, Kyôto [Kyoto], Japan|Nagasaki Medical Center, Omura, Nagasaki, Japan|Kinki University Hospital, Faculty of Medicine - Hematology & Clinical Oncology, Osaka-sayama, Osaka, Japan|Osaka University Hospital, Suita, Osaka, Japan|Chiba University Hospital, Chiba, Tiba [Chiba], Japan|Sasaki Foundation Kyoundo Hospital, Chiyoda-Ku, Tokyo, Japan|Nihon University Itabashi Hospital - Gastroenterological surgery, Itabashi-ku, Tôkyô [Tokyo], Japan|JRC Medical Center, Shibuya-ku, Tôkyô [Tokyo], Japan|National Center for Global Health and Medicine, Shinjuku-ku, Tôkyô [Tokyo], Japan|Kyushu Medical Center, Fukuoka, Japan|Kumamoto University Hospital, Kumamoto, Japan|Iwate Medical University Hospital, Morioka, Japan|Hyogo College of Medicine Hospital, Nishinomiya-shi, Japan|Osaka International Cancer Institute, Osaka, Japan|Tottori University Hospital, Tottori, Japan|Wakayama Medical University, Wakayama-shi, Japan|Osaka City General Hospital, Osaka, Ôsaka [Osaka], Japan|Osaka National Hospital, Osaka, Ôsaka [Osaka], Japan|Osaka City University Hospital, Osaka, Ôsaka [Osaka], Japan|Centrum Onkologii Instytut im. M. Sklodowskiej-Curie, Warszawa, Mazowieckie, Poland|Clinical Research Center Sp. z o.o., Medic-R Sp. K., Poznan, Wielkopolskie, Poland|Uniwersyteckie Centrum Kliniczne, Gdańsk, Poland|Wojewodzki Szpital Specjalistyczny im. Gromkowskiego we Wroclawiu, Wroclaw, Poland|Institut Catalá d´Oncología (I.C.O.), Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario Vall d'Hebrón, Barcelona, Spain|Hospital Universitario Madrid Sanchinarro Centro integral Oncologico Clara Campal (CIOCC), Madrid, Spain|Hospital Universitari i Politecnic La Fe, Valencia, Spain|Chang Gung Medical Foundation - Kaohsiung Chang Gung Memorial Hospital - Gastroenterology, Kaohsiung, Taiwan|Kaohsiung Medical University - Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|Tri-Service General Hospital - Neihu Branch, New Taipei, Taiwan|China Medical University Hospital - Transplantology - Taichung, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|Chi Mei Medical Center - YongKang, Tainan, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Chang Gung Medical Foundation - LinKou Chang Gung Memorial Hospital, Taipei, Taiwan|Queen Elizabeth Hospital - Clinical Reasearch, Birmingham, United Kingdom|Royal Free Hospital London NHS Trust, London, United Kingdom|King's College Hospital NHS Foundation Trust, London, United Kingdom|The Christie NHS Foundation Trust - Oak Road Treatment Centre, Withington, United Kingdom	https://ClinicalTrials.gov/show/NCT03412773
742	Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer	Active, not recruiting	Has Results	Advanced Adult Hepatocellular Carcinoma|Recurrent Hepatocellular Carcinoma|Stage III Hepatocellular Carcinoma AJCC v7|Stage IIIA Hepatocellular Carcinoma AJCC v7|Stage IIIB Hepatocellular Carcinoma AJCC v7|Stage IIIC Hepatocellular Carcinoma AJCC v7|Stage IV Hepatocellular Carcinoma AJCC v7|Stage IVA Hepatocellular Carcinoma AJCC v7|Stage IVB Hepatocellular Carcinoma AJCC v7|Unresectable Hepatocellular Carcinoma	Drug: Doxorubicin Hydrochloride|Other: Laboratory Biomarker Analysis|Other: Pharmacogenomic Study|Drug: Sorafenib Tosylate	University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States|Providence Hospital, Mobile, Alabama, United States|Southern Cancer Center PC-Providence, Mobile, Alabama, United States|Alaska Regional Hospital, Anchorage, Alaska, United States|Fairbanks Memorial Hospital, Fairbanks, Alaska, United States|Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro, Jonesboro, Arkansas, United States|Kaiser Permanente-Anaheim, Anaheim, California, United States|Kaiser Permanente-Deer Valley Medical Center, Antioch, California, United States|PCR Oncology, Arroyo Grande, California, United States|Kaiser Permanente-Baldwin Park, Baldwin Park, California, United States|Kaiser Permanente-Bellflower, Bellflower, California, United States|East Bay Radiation Oncology Center, Castro Valley, California, United States|Valley Medical Oncology Consultants-Castro Valley, Castro Valley, California, United States|Community Cancer Institute, Clovis, California, United States|University Oncology Associates, Clovis, California, United States|Epic Care-Dublin, Dublin, California, United States|Bay Area Breast Surgeons Inc, Emeryville, California, United States|Epic Care Partners in Cancer Care, Emeryville, California, United States|Kaiser Permanente-Fontana, Fontana, California, United States|Kaiser Permanente-Fremont, Fremont, California, United States|Valley Medical Oncology Consultants-Fremont, Fremont, California, United States|Kaiser Permanente-Fresno, Fresno, California, United States|Marin Cancer Care Inc, Greenbrae, California, United States|Marin General Hospital, Greenbrae, California, United States|Kaiser Permanente - Harbor City, Harbor City, California, United States|Kaiser Permanente-Irvine, Irvine, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Kaiser Permanente West Los Angeles, Los Angeles, California, United States|Contra Costa Regional Medical Center, Martinez, California, United States|Kaiser Permanente-Modesto, Modesto, California, United States|El Camino Hospital, Mountain View, California, United States|Highland General Hospital, Oakland, California, United States|Alta Bates Summit Medical Center - Summit Campus, Oakland, California, United States|Bay Area Tumor Institute, Oakland, California, United States|Hematology and Oncology Associates-Oakland, Oakland, California, United States|Tom K Lee Inc, Oakland, California, United States|Kaiser Permanente-Oakland, Oakland, California, United States|Saint Joseph Hospital - Orange, Orange, California, United States|UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States|Kaiser Permanente - Panorama City, Panorama City, California, United States|East Bay Medical Oncology Hematology Medical Associates Inc-Pleasant Hill, Pleasant Hill, California, United States|Kaiser Permanente-Redwood City, Redwood City, California, United States|Kaiser Permanente-Richmond, Richmond, California, United States|Kaiser Permanente-Riverside, Riverside, California, United States|Kaiser Permanente-Roseville, Roseville, California, United States|Kaiser Permanente-South Sacramento, Sacramento, California, United States|Kaiser Permanente - Sacramento, Sacramento, California, United States|Salinas Valley Memorial, Salinas, California, United States|Kaiser Permanente-San Diego Mission, San Diego, California, United States|Kaiser Permanente-San Diego Zion, San Diego, California, United States|Kaiser Permanente-San Francisco, San Francisco, California, United States|UCSF Medical Center-Mount Zion, San Francisco, California, United States|Kaiser Permanente-Santa Teresa-San Jose, San Jose, California, United States|Kaiser Permanente San Leandro, San Leandro, California, United States|Kaiser Permanente-San Marcos, San Marcos, California, United States|Doctors Medical Center- JC Robinson Regional Cancer Center, San Pablo, California, United States|Kaiser Permanente-San Rafael, San Rafael, California, United States|Kaiser Permanente Medical Center - Santa Clara, Santa Clara, California, United States|Kaiser Permanente-Santa Rosa, Santa Rosa, California, United States|Kaiser Permanente-South San Francisco, South San Francisco, California, United States|Kaiser Permanente-Stockton, Stockton, California, United States|Kaiser Permanente Medical Center-Vacaville, Vacaville, California, United States|Kaiser Permanente-Vallejo, Vallejo, California, United States|Kaiser Permanente-Walnut Creek, Walnut Creek, California, United States|Presbyterian Intercommunity Hospital, Whittier, California, United States|Kaiser Permanente-Woodland Hills, Woodland Hills, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|Kaiser Permanente-Franklin, Denver, Colorado, United States|Valley View Hospital Cancer Center, Glenwood Springs, Colorado, United States|Saint Mary's Hospital and Regional Medical Center, Grand Junction, Colorado, United States|Kaiser Permanente-Rock Creek, Lafayette, Colorado, United States|Kaiser Permanente-Lone Tree, Lone Tree, Colorado, United States|Montrose Memorial Hospital, Montrose, Colorado, United States|Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut, United States|Middlesex Hospital, Middletown, Connecticut, United States|Yale University, New Haven, Connecticut, United States|Beebe Medical Center, Lewes, Delaware, United States|Christiana Gynecologic Oncology LLC, Newark, Delaware, United States|Delaware Clinical and Laboratory Physicians PA, Newark, Delaware, United States|Helen F Graham Cancer Center, Newark, Delaware, United States|Medical Oncology Hematology Consultants PA, Newark, Delaware, United States|Christiana Care Health System-Christiana Hospital, Newark, Delaware, United States|Beebe Health Campus, Rehoboth Beach, Delaware, United States|TidalHealth Nanticoke / Allen Cancer Center, Seaford, Delaware, United States|Christiana Care Health System-Wilmington Hospital, Wilmington, Delaware, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|Veterans Affairs Medical Center -Washington DC, Washington, District of Columbia, United States|AdventHealth Altamonte, Altamonte Springs, Florida, United States|AdventHealth Kissimmee, Kissimmee, Florida, United States|Lakeland Regional Health Hollis Cancer Center, Lakeland, Florida, United States|AdventHealth Orlando, Orlando, Florida, United States|AdventHealth East Orlando, Orlando, Florida, United States|Sacred Heart Hospital, Pensacola, Florida, United States|AdventHealth Winter Park, Winter Park, Florida, United States|Atlanta VA Medical Center, Decatur, Georgia, United States|Medical Center of Central Georgia, Macon, Georgia, United States|Low Country Cancer Care, Savannah, Georgia, United States|Memorial Health University Medical Center, Savannah, Georgia, United States|Summit Cancer Care-Memorial, Savannah, Georgia, United States|Lewis Cancer and Research Pavilion at Saint Joseph's/Candler, Savannah, Georgia, United States|Pali Momi Medical Center, 'Aiea, Hawaii, United States|Hawaii Cancer Care Inc - Waterfront Plaza, Honolulu, Hawaii, United States|Queen's Medical Center, Honolulu, Hawaii, United States|Straub Clinic and Hospital, Honolulu, Hawaii, United States|University of Hawaii Cancer Center, Honolulu, Hawaii, United States|Hawaii Cancer Care Inc-Liliha, Honolulu, Hawaii, United States|Queen's Cancer Center - Kuakini, Honolulu, Hawaii, United States|The Cancer Center of Hawaii-Liliha, Honolulu, Hawaii, United States|Kaiser Permanente Moanalua Medical Center, Honolulu, Hawaii, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Maui Memorial Medical Center, Wailuku, Hawaii, United States|Pacific Cancer Institute of Maui, Wailuku, Hawaii, United States|Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States|Saint Joseph Regional Medical Center, Lewiston, Idaho, United States|Rush - Copley Medical Center, Aurora, Illinois, United States|Saint Joseph Medical Center, Bloomington, Illinois, United States|Illinois CancerCare-Bloomington, Bloomington, Illinois, United States|Illinois CancerCare-Canton, Canton, Illinois, United States|Memorial Hospital of Carbondale, Carbondale, Illinois, United States|Illinois CancerCare-Carthage, Carthage, Illinois, United States|Centralia Oncology Clinic, Centralia, Illinois, United States|Hematology and Oncology Associates, Chicago, Illinois, United States|Northwestern University, Chicago, Illinois, United States|University of Illinois, Chicago, Illinois, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|UChicago Medicine Comprehensive Cancer Center - Saint Joseph Hospital, Chicago, Illinois, United States|Carle on Vermilion, Danville, Illinois, United States|Cancer Care Specialists of Illinois - Decatur, Decatur, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Carle Physician Group-Effingham, Effingham, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|Illinois CancerCare-Eureka, Eureka, Illinois, United States|Illinois CancerCare-Galesburg, Galesburg, Illinois, United States|Western Illinois Cancer Treatment Center, Galesburg, Illinois, United States|Hematology Oncology Associates of Illinois-Highland Park, Highland Park, Illinois, United States|Midwest Center for Hematology Oncology, Joliet, Illinois, United States|Duly Health and Care Joliet, Joliet, Illinois, United States|Presence Saint Mary's Hospital, Kankakee, Illinois, United States|Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States|AMITA Health Adventist Medical Center, La Grange, Illinois, United States|AMG Libertyville - Oncology, Libertyville, Illinois, United States|Illinois CancerCare-Macomb, Macomb, Illinois, United States|Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois, United States|Good Samaritan Regional Health Center, Mount Vernon, Illinois, United States|Illinois Cancer Specialists-Niles, Niles, Illinois, United States|Cancer Care Center of O'Fallon, O'Fallon, Illinois, United States|Advocate Christ Medical Center, Oak Lawn, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Radiation Oncology of Northern Illinois, Ottawa, Illinois, United States|Illinois CancerCare-Pekin, Pekin, Illinois, United States|OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center, Pekin, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|OSF Saint Francis Radiation Oncology at Peoria Cancer Center, Peoria, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|OSF Saint Francis Medical Center, Peoria, Illinois, United States|Illinois CancerCare-Peru, Peru, Illinois, United States|Valley Radiation Oncology, Peru, Illinois, United States|Illinois CancerCare-Princeton, Princeton, Illinois, United States|Swedish American Hospital, Rockford, Illinois, United States|SwedishAmerican Regional Cancer Center/ACT, Rockford, Illinois, United States|Hematology Oncology Associates of Illinois - Skokie, Skokie, Illinois, United States|Central Illinois Hematology Oncology Center, Springfield, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Springfield Clinic, Springfield, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|The Carle Foundation Hospital, Urbana, Illinois, United States|Rush-Copley Healthcare Center, Yorkville, Illinois, United States|Franciscan Saint Francis Health-Beech Grove, Beech Grove, Indiana, United States|Elkhart Clinic, Elkhart, Indiana, United States|Michiana Hematology Oncology PC-Elkhart, Elkhart, Indiana, United States|Elkhart General Hospital, Elkhart, Indiana, United States|Fort Wayne Medical Oncology and Hematology Inc-Parkview, Fort Wayne, Indiana, United States|Franciscan Health Indianapolis, Indianapolis, Indiana, United States|Community Howard Regional Health, Kokomo, Indiana, United States|IU Health La Porte Hospital, La Porte, Indiana, United States|Franciscan Saint Anthony Health-Michigan City, Michigan City, Indiana, United States|Woodland Cancer Care Center, Michigan City, Indiana, United States|Cancer Care Partners LLC, Mishawaka, Indiana, United States|Memorial Regional Cancer Center Day Road, Mishawaka, Indiana, United States|Michiana Hematology Oncology PC-Mishawaka, Mishawaka, Indiana, United States|Saint Joseph Regional Medical Center-Mishawaka, Mishawaka, Indiana, United States|Michiana Hematology Oncology PC-Plymouth, Plymouth, Indiana, United States|Reid Health, Richmond, Indiana, United States|Memorial Hospital of South Bend, South Bend, Indiana, United States|Michiana Hematology Oncology PC-South Bend, South Bend, Indiana, United States|South Bend Clinic, South Bend, Indiana, United States|Northern Indiana Cancer Research Consortium, South Bend, Indiana, United States|Michiana Hematology Oncology PC-Westville, Westville, Indiana, United States|Mary Greeley Medical Center, Ames, Iowa, United States|McFarland Clinic PC - Ames, Ames, Iowa, United States|University of Iowa Healthcare Cancer Services Quad Cities, Bettendorf, Iowa, United States|McFarland Clinic PC-Boone, Boone, Iowa, United States|Medical Oncology and Hematology Associates-West Des Moines, Clive, Iowa, United States|Mercy Cancer Center-West Lakes, Clive, Iowa, United States|Alegent Health Mercy Hospital, Council Bluffs, Iowa, United States|Medical Oncology and Hematology Associates-Laurel, Des Moines, Iowa, United States|Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|McFarland Clinic PC-Trinity Cancer Center, Fort Dodge, Iowa, United States|University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States|Iowa City VA Healthcare System, Iowa City, Iowa, United States|McFarland Clinic PC-Jefferson, Jefferson, Iowa, United States|McFarland Clinic PC-Marshalltown, Marshalltown, Iowa, United States|Ottumwa Regional Health Center, Ottumwa, Iowa, United States|Siouxland Regional Cancer Center, Sioux City, Iowa, United States|Mercy Medical Center-Sioux City, Sioux City, Iowa, United States|Saint Luke's Regional Medical Center, Sioux City, Iowa, United States|Mercy Medical Center-West Lakes, West Des Moines, Iowa, United States|Cancer Center of Kansas - Chanute, Chanute, Kansas, United States|Cancer Center of Kansas - Dodge City, Dodge City, Kansas, United States|Cancer Center of Kansas - El Dorado, El Dorado, Kansas, United States|Cancer Center of Kansas - Fort Scott, Fort Scott, Kansas, United States|Cancer Center of Kansas-Independence, Independence, Kansas, United States|Providence Medical Center, Kansas City, Kansas, United States|Cancer Center of Kansas-Kingman, Kingman, Kansas, United States|Lawrence Memorial Hospital, Lawrence, Kansas, United States|Cancer Center of Kansas-Liberal, Liberal, Kansas, United States|Cancer Center of Kansas-Manhattan, Manhattan, Kansas, United States|Cancer Center of Kansas - McPherson, McPherson, Kansas, United States|Cancer Center of Kansas - Newton, Newton, Kansas, United States|Menorah Medical Center, Overland Park, Kansas, United States|Saint Luke's South Hospital, Overland Park, Kansas, United States|Cancer Center of Kansas - Parsons, Parsons, Kansas, United States|Kansas City NCI Community Oncology Research Program, Prairie Village, Kansas, United States|Cancer Center of Kansas - Pratt, Pratt, Kansas, United States|Cancer Center of Kansas - Salina, Salina, Kansas, United States|Advent Health - Shawnee Mission Medical Center, Shawnee Mission, Kansas, United States|Cotton O'Neil Cancer Center / Stormont Vail Health, Topeka, Kansas, United States|Cancer Center of Kansas - Wellington, Wellington, Kansas, United States|Associates In Womens Health, Wichita, Kansas, United States|Cancer Center of Kansas-Wichita Medical Arts Tower, Wichita, Kansas, United States|Ascension Via Christi Hospitals Wichita, Wichita, Kansas, United States|Cancer Center of Kansas - Wichita, Wichita, Kansas, United States|Wesley Medical Center, Wichita, Kansas, United States|Wichita NCI Community Oncology Research Program, Wichita, Kansas, United States|Cancer Center of Kansas - Winfield, Winfield, Kansas, United States|Flaget Memorial Hospital, Bardstown, Kentucky, United States|Commonwealth Cancer Center-Corbin, Corbin, Kentucky, United States|Saint Joseph Radiation Oncology Resource Center, Lexington, Kentucky, United States|Saint Joseph Hospital East, Lexington, Kentucky, United States|University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States|Jewish Hospital, Louisville, Kentucky, United States|Doctors Carrol, Sheth, Raghavan, Louisville, Kentucky, United States|Saints Mary and Elizabeth Hospital, Louisville, Kentucky, United States|UofL Health Medical Center Northeast, Louisville, Kentucky, United States|Jewish Hospital Medical Center South, Shepherdsville, Kentucky, United States|LSU Health Baton Rouge-North Clinic, Baton Rouge, Louisiana, United States|Baton Rouge General Medical Center, Baton Rouge, Louisiana, United States|Hematology/Oncology Clinic PLLC, Baton Rouge, Louisiana, United States|Louisiana Hematology Oncology Associates LLC, Baton Rouge, Louisiana, United States|Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, United States|Ochsner Health Center-Summa, Baton Rouge, Louisiana, United States|Our Lady of the Lake Physicians Group - Medical Oncology, Baton Rouge, Louisiana, United States|Ochsner Health Center-Covington, Covington, Louisiana, United States|Mary Bird Perkins Cancer Center - Houma, Houma, Louisiana, United States|West Jefferson Medical Center, Marrero, Louisiana, United States|Robert Veith MD LLC, Metairie, Louisiana, United States|Louisiana State University Health Science Center, New Orleans, Louisiana, United States|Tulane University Health Sciences Center, New Orleans, Louisiana, United States|University Medical Center New Orleans, New Orleans, Louisiana, United States|Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States|LSU Health Sciences Center at Shreveport, Shreveport, Louisiana, United States|York Hospital, York, Maine, United States|University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States|Greater Baltimore Medical Center, Baltimore, Maryland, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|Saint Agnes Hospital, Baltimore, Maryland, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|Christiana Care - Union Hospital, Elkton, Maryland, United States|Northwest Hospital Center, Randallstown, Maryland, United States|Boston Medical Center, Boston, Massachusetts, United States|Bixby Medical Center, Adrian, Michigan, United States|Hickman Cancer Center, Adrian, Michigan, United States|Michigan Cancer Research Consortium NCORP, Ann Arbor, Michigan, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|Beaumont Hospital - Dearborn, Dearborn, Michigan, United States|Ascension Saint John Hospital, Detroit, Michigan, United States|Green Bay Oncology - Escanaba, Escanaba, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Genesys Regional Medical Center-West Flint Campus, Flint, Michigan, United States|Genesys Regional Medical Center, Grand Blanc, Michigan, United States|Green Bay Oncology - Iron Mountain, Iron Mountain, Michigan, United States|Allegiance Health, Jackson, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Borgess Medical Center, Kalamazoo, Michigan, United States|Sparrow Hospital, Lansing, Michigan, United States|Saint Mary Mercy Hospital, Livonia, Michigan, United States|Mercy Memorial Hospital, Monroe, Michigan, United States|Toledo Clinic Cancer Centers-Monroe, Monroe, Michigan, United States|Lakeland Hospital Niles, Niles, Michigan, United States|Saint Joseph Mercy Oakland, Pontiac, Michigan, United States|Lake Huron Medical Center, Port Huron, Michigan, United States|Ascension Saint Mary's Hospital, Saginaw, Michigan, United States|Lakeland Medical Center Saint Joseph, Saint Joseph, Michigan, United States|Marie Yeager Cancer Center, Saint Joseph, Michigan, United States|Ascension Providence Hospitals - Southfield, Southfield, Michigan, United States|Saint John Macomb-Oakland Hospital, Warren, Michigan, United States|Essentia Health Saint Joseph's Medical Center, Brainerd, Minnesota, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Mercy Hospital, Coon Rapids, Minnesota, United States|Essentia Health Cancer Center, Duluth, Minnesota, United States|Essentia Health Saint Mary's Medical Center, Duluth, Minnesota, United States|Miller-Dwan Hospital, Duluth, Minnesota, United States|Fairview Southdale Hospital, Edina, Minnesota, United States|Unity Hospital, Fridley, Minnesota, United States|Hutchinson Area Health Care, Hutchinson, Minnesota, United States|Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota, United States|Saint John's Hospital - Healtheast, Maplewood, Minnesota, United States|Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Minneapolis VA Medical Center, Minneapolis, Minnesota, United States|Health Partners Inc, Minneapolis, Minnesota, United States|New Ulm Medical Center, New Ulm, Minnesota, United States|North Memorial Medical Health Center, Robbinsdale, Minnesota, United States|Metro Minnesota Community Oncology Research Consortium, Saint Louis Park, Minnesota, United States|Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Saint Francis Regional Medical Center, Shakopee, Minnesota, United States|Lakeview Hospital, Stillwater, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Rice Memorial Hospital, Willmar, Minnesota, United States|Minnesota Oncology Hematology PA-Woodbury, Woodbury, Minnesota, United States|Hattiesburg Clinic - Hematology/Oncology Clinic, Hattiesburg, Mississippi, United States|Forrest General Hospital / Cancer Center, Hattiesburg, Mississippi, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Central Care Cancer Center - Bolivar, Bolivar, Missouri, United States|Parkland Health Center-Bonne Terre, Bonne Terre, Missouri, United States|Cox Cancer Center Branson, Branson, Missouri, United States|Saint Francis Medical Center, Cape Girardeau, Missouri, United States|Southeast Cancer Center, Cape Girardeau, Missouri, United States|Veterans Administration, Columbia, Missouri, United States|University of Missouri - Ellis Fischel, Columbia, Missouri, United States|Centerpoint Medical Center LLC, Independence, Missouri, United States|Capital Region Southwest Campus, Jefferson City, Missouri, United States|Freeman Health System, Joplin, Missouri, United States|Mercy Hospital Joplin, Joplin, Missouri, United States|Truman Medical Centers, Kansas City, Missouri, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|Saint Joseph Health Center, Kansas City, Missouri, United States|North Kansas City Hospital, Kansas City, Missouri, United States|Heartland Hematology and Oncology Associates Incorporated, Kansas City, Missouri, United States|Research Medical Center, Kansas City, Missouri, United States|Saint Luke's East - Lee's Summit, Lee's Summit, Missouri, United States|Liberty Radiation Oncology Center, Liberty, Missouri, United States|Delbert Day Cancer Institute at PCRMC, Rolla, Missouri, United States|Mercy Clinic-Rolla-Cancer and Hematology, Rolla, Missouri, United States|Heartland Regional Medical Center, Saint Joseph, Missouri, United States|Saint Joseph Oncology Inc, Saint Joseph, Missouri, United States|Saint Louis Cancer and Breast Institute-South City, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, United States|Center for Cancer Care and Research, Saint Louis, Missouri, United States|Comprehensive Cancer Care PC, Saint Louis, Missouri, United States|Mercy Hospital Saint Louis, Saint Louis, Missouri, United States|Sainte Genevieve County Memorial Hospital, Sainte Genevieve, Missouri, United States|Cancer Research for the Ozarks NCORP, Springfield, Missouri, United States|Mercy Hospital Springfield, Springfield, Missouri, United States|CoxHealth South Hospital, Springfield, Missouri, United States|Missouri Baptist Sullivan Hospital, Sullivan, Missouri, United States|Missouri Baptist Outpatient Center-Sunset Hills, Sunset Hills, Missouri, United States|CHI Health Saint Francis, Grand Island, Nebraska, United States|Heartland Hematology and Oncology, Kearney, Nebraska, United States|CHI Health Good Samaritan, Kearney, Nebraska, United States|Saint Elizabeth Regional Medical Center, Lincoln, Nebraska, United States|Great Plains Health Callahan Cancer Center, North Platte, Nebraska, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|Alegent Health Immanuel Medical Center, Omaha, Nebraska, United States|Hematology and Oncology Consultants PC, Omaha, Nebraska, United States|Alegent Health Bergan Mercy Medical Center, Omaha, Nebraska, United States|Alegent Health Lakeside Hospital, Omaha, Nebraska, United States|Creighton University Medical Center, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Midlands Community Hospital, Papillion, Nebraska, United States|Cancer and Blood Specialists-Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada - Henderson, Henderson, Nevada, United States|Las Vegas Cancer Center-Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada-Southeast Henderson, Henderson, Nevada, United States|GenesisCare USA - Henderson, Henderson, Nevada, United States|University Medical Center of Southern Nevada, Las Vegas, Nevada, United States|Cancer and Blood Specialists-Shadow, Las Vegas, Nevada, United States|Radiation Oncology Centers of Nevada Central, Las Vegas, Nevada, United States|GenesisCare USA - Las Vegas, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-San Martin, Las Vegas, Nevada, United States|Radiation Oncology Centers of Nevada Southeast, Las Vegas, Nevada, United States|Cancer Therapy and Integrative Medicine, Las Vegas, Nevada, United States|Cancer and Blood Specialists-Tenaya, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada - Northwest, Las Vegas, Nevada, United States|GenesisCare USA - Vegas Tenaya, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Tenaya, Las Vegas, Nevada, United States|Alliance for Childhood Diseases/Cure 4 the Kids Foundation, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada-Summerlin, Las Vegas, Nevada, United States|Summerlin Hospital Medical Center, Las Vegas, Nevada, United States|Las Vegas Cancer Center-Medical Center, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|GenesisCare USA - Fort Apache, Las Vegas, Nevada, United States|OptumCare Cancer Care at Fort Apache, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada - Central Valley, Las Vegas, Nevada, United States|Nevada Cancer Research Foundation NCORP, Las Vegas, Nevada, United States|Renown Regional Medical Center, Reno, Nevada, United States|Saint Mary's Regional Medical Center, Reno, Nevada, United States|Radiation Oncology Associates, Reno, Nevada, United States|Cancer Care Specialists - Reno, Reno, Nevada, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Cooper Hospital University Medical Center, Camden, New Jersey, United States|Veterans Adminstration New Jersey Health Care System, East Orange, New Jersey, United States|Inspira Medical Center Mullica Hill, Mullica Hill, New Jersey, United States|Rutgers New Jersey Medical School, Newark, New Jersey, United States|Inspira Medical Center Vineland, Vineland, New Jersey, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Memorial Medical Center - Las Cruces, Las Cruces, New Mexico, United States|Hematology Oncology Associates of Central New York-Auburn, Auburn, New York, United States|Montefiore Medical Center-Weiler Hospital, Bronx, New York, United States|Montefiore Medical Center - Moses Campus, Bronx, New York, United States|James J Peters VA Medical Center, Bronx, New York, United States|Veteran Affairs New York Harbor Healthcare System-Brooklyn Campus, Brooklyn, New York, United States|Veterans Affairs Western New York Health Care System-Buffalo, Buffalo, New York, United States|Hematology Oncology Associates of Central New York-East Syracuse, East Syracuse, New York, United States|Glens Falls Hospital, Glens Falls, New York, United States|Northwell Health NCORP, Lake Success, New York, United States|Northwell Health/Center for Advanced Medicine, Lake Success, New York, United States|Hematology Oncology Associates of Central New York-Liverpool, Liverpool, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Garnet Health Medical Center, Middletown, New York, United States|Long Island Jewish Medical Center, New Hyde Park, New York, United States|Mount Sinai Union Square, New York, New York, United States|Mount Sinai West, New York, New York, United States|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|NYP/Weill Cornell Medical Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|Hematology Oncology Associates of Central New York-Rome, Rome, New York, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|State University of New York Upstate Medical University, Syracuse, New York, United States|Hematology Oncology Associates of Central New York-Onondaga Hill, Syracuse, New York, United States|New York Medical College, Valhalla, New York, United States|Mission Hospital, Asheville, North Carolina, United States|Mountain Radiation Oncology PA, Asheville, North Carolina, United States|AdventHealth Infusion Center Asheville, Asheville, North Carolina, United States|Messino Cancer Centers, Asheville, North Carolina, United States|Hope Women's Cancer Centers-Asheville, Asheville, North Carolina, United States|Transylvania Regional Hospital, Brevard, North Carolina, United States|Novant Health Presbyterian Medical Center, Charlotte, North Carolina, United States|Sampson Radiation Oncology, Clinton, North Carolina, United States|Southeastern Medical Oncology Center-Clinton, Clinton, North Carolina, United States|Angel Medical Center, Franklin, North Carolina, United States|Southeastern Medical Oncology Center-Goldsboro, Goldsboro, North Carolina, United States|Wayne Memorial Hospital, Goldsboro, North Carolina, United States|Wayne Radiation Oncology, Goldsboro, North Carolina, United States|AdventHealth Hendersonville, Hendersonville, North Carolina, United States|Onslow Memorial Hospital, Jacksonville, North Carolina, United States|Southeastern Medical Oncology Center-Jacksonville, Jacksonville, North Carolina, United States|Vidant Oncology-Kinston, Kinston, North Carolina, United States|Mission Hospital McDowell, Marion, North Carolina, United States|Rutherford Hospital, Rutherfordton, North Carolina, United States|Blue Ridge Regional Hospital, Spruce Pine, North Carolina, United States|Iredell Memorial Hospital, Statesville, North Carolina, United States|Southeast Clinical Oncology Research Consortium NCORP, Winston-Salem, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Mid Dakota Clinic, Bismarck, North Dakota, United States|Saint Alexius Medical Center, Bismarck, North Dakota, United States|Sanford Bismarck Medical Center, Bismarck, North Dakota, United States|Essentia Health Cancer Center-South University Clinic, Fargo, North Dakota, United States|Trinity Cancer Care Center, Minot, North Dakota, United States|Summa Health System - Akron Campus, Akron, Ohio, United States|Summa Health System - Barberton Campus, Barberton, Ohio, United States|Mary Rutan Hospital, Bellefontaine, Ohio, United States|Strecker Cancer Center-Belpre, Belpre, Ohio, United States|Toledo Clinic Cancer Centers-Bowling Green, Bowling Green, Ohio, United States|Aultman Health Foundation, Canton, Ohio, United States|Adena Regional Medical Center, Chillicothe, Ohio, United States|Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio, United States|Bethesda North Hospital, Cincinnati, Ohio, United States|TriHealth Cancer Institute-Westside, Cincinnati, Ohio, United States|TriHealth Cancer Institute-Anderson, Cincinnati, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|North Coast Cancer Care-Clyde, Clyde, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Mount Carmel East Hospital, Columbus, Ohio, United States|Columbus Oncology and Hematology Associates Inc, Columbus, Ohio, United States|Riverside Methodist Hospital, Columbus, Ohio, United States|Columbus NCI Community Oncology Research Program, Columbus, Ohio, United States|Grant Medical Center, Columbus, Ohio, United States|The Mark H Zangmeister Center, Columbus, Ohio, United States|Mount Carmel Health Center West, Columbus, Ohio, United States|Doctors Hospital, Columbus, Ohio, United States|Grandview Hospital, Dayton, Ohio, United States|Good Samaritan Hospital - Dayton, Dayton, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|Miami Valley Hospital North, Dayton, Ohio, United States|Dayton Veterans Affairs Medical Center, Dayton, Ohio, United States|Delaware Health Center-Grady Cancer Center, Delaware, Ohio, United States|Delaware Radiation Oncology, Delaware, Ohio, United States|Grady Memorial Hospital, Delaware, Ohio, United States|Hematology Oncology Center Incorporated, Elyria, Ohio, United States|Mercy Cancer Center-Elyria, Elyria, Ohio, United States|Blanchard Valley Hospital, Findlay, Ohio, United States|Atrium Medical Center-Middletown Regional Hospital, Franklin, Ohio, United States|Wayne Hospital, Greenville, Ohio, United States|Kettering Medical Center, Kettering, Ohio, United States|Fairfield Medical Center, Lancaster, Ohio, United States|Lancaster Radiation Oncology, Lancaster, Ohio, United States|Saint Rita's Medical Center, Lima, Ohio, United States|Lima Memorial Hospital, Lima, Ohio, United States|Marietta Memorial Hospital, Marietta, Ohio, United States|Saint Luke's Hospital, Maumee, Ohio, United States|Toledo Clinic Cancer Centers-Maumee, Maumee, Ohio, United States|Toledo Radiation Oncology at Northwest Ohio Onocolgy Center, Maumee, Ohio, United States|Knox Community Hospital, Mount Vernon, Ohio, United States|Licking Memorial Hospital, Newark, Ohio, United States|Newark Radiation Oncology, Newark, Ohio, United States|Fisher-Titus Medical Center, Norwalk, Ohio, United States|Saint Charles Hospital, Oregon, Ohio, United States|Toledo Clinic Cancer Centers-Oregon, Oregon, Ohio, United States|Southern Ohio Medical Center, Portsmouth, Ohio, United States|North Coast Cancer Care, Sandusky, Ohio, United States|Springfield Regional Medical Center, Springfield, Ohio, United States|ProMedica Flower Hospital, Sylvania, Ohio, United States|Mercy Hospital of Tiffin, Tiffin, Ohio, United States|ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital, Toledo, Ohio, United States|Saint Vincent Mercy Medical Center, Toledo, Ohio, United States|University of Toledo, Toledo, Ohio, United States|Toledo Community Hospital Oncology Program CCOP, Toledo, Ohio, United States|Mercy Health - Saint Anne Hospital, Toledo, Ohio, United States|Toledo Clinic Cancer Centers-Toledo, Toledo, Ohio, United States|Upper Valley Medical Center, Troy, Ohio, United States|Fulton County Health Center, Wauseon, Ohio, United States|Saint Ann's Hospital, Westerville, Ohio, United States|Clinton Memorial Hospital, Wilmington, Ohio, United States|Greene Memorial Hospital, Xenia, Ohio, United States|Genesis Healthcare System Cancer Care Center, Zanesville, Ohio, United States|Cancer Care Associates-Norman, Norman, Oklahoma, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Mercy Physicians of Oklahoma-Lakeside, Oklahoma City, Oklahoma, United States|Oklahoma Cancer Specialists and Research Institute-Tulsa, Tulsa, Oklahoma, United States|Kaiser Permanente Northwest, Portland, Oregon, United States|Jefferson Abington Hospital, Abington, Pennsylvania, United States|Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania, United States|Butler Memorial Hospital, Butler, Pennsylvania, United States|VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States|Guthrie Medical Group PC-Robert Packer Hospital, Sayre, Pennsylvania, United States|Reading Hospital, West Reading, Pennsylvania, United States|Roger Williams Medical Center, Providence, Rhode Island, United States|AnMed Health Cancer Center, Anderson, South Carolina, United States|AnMed Health Hospital, Anderson, South Carolina, United States|Prisma Health Cancer Institute - Spartanburg, Boiling Springs, South Carolina, United States|Prisma Health Cancer Institute - Easley, Easley, South Carolina, United States|Greenville Health System Cancer Institute-Andrews, Greenville, South Carolina, United States|Saint Francis Hospital, Greenville, South Carolina, United States|Prisma Health Cancer Institute - Butternut, Greenville, South Carolina, United States|Prisma Health Cancer Institute - Faris, Greenville, South Carolina, United States|Prisma Health Greenville Memorial Hospital, Greenville, South Carolina, United States|Saint Francis Cancer Center, Greenville, South Carolina, United States|Prisma Health Cancer Institute - Eastside, Greenville, South Carolina, United States|Self Regional Healthcare, Greenwood, South Carolina, United States|Prisma Health Cancer Institute - Greer, Greer, South Carolina, United States|Gibbs Cancer Center-Pelham, Greer, South Carolina, United States|Carolina Blood and Cancer Care Associates PA-Lancaster, Lancaster, South Carolina, United States|Carolina Blood and Cancer Care Associates PA, Rock Hill, South Carolina, United States|Prisma Health Cancer Institute - Seneca, Seneca, South Carolina, United States|Spartanburg Medical Center, Spartanburg, South Carolina, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Avera McKennan Hospital and University Health Center, Sioux Falls, South Dakota, United States|Bristol Regional Medical Center, Bristol, Tennessee, United States|Wellmont Medical Associates Oncology and Hematology-Bristol, Bristol, Tennessee, United States|Memorial Hospital, Chattanooga, Tennessee, United States|Pulmonary Medicine Center of Chattanooga-Hixson, Hixson, Tennessee, United States|Jackson-Madison County General Hospital, Jackson, Tennessee, United States|Ballad Health Cancer Care - Kingsport, Kingsport, Tennessee, United States|Wellmont Holston Valley Hospital and Medical Center, Kingsport, Tennessee, United States|University of Tennessee - Knoxville, Knoxville, Tennessee, United States|Nashville Oncology Associates PC, Nashville, Tennessee, United States|Meharry Medical College, Nashville, Tennessee, United States|Memorial GYN Plus, Ooltewah, Tennessee, United States|The Don and Sybil Harrington Cancer Center, Amarillo, Texas, United States|Texas Tech University Health Sciences Center-El Paso, El Paso, Texas, United States|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States|Baylor Saint Luke's Medical Center, Houston, Texas, United States|Ben Taub General Hospital, Houston, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Michael E DeBakey VA Medical Center, Houston, Texas, United States|Central Vermont Medical Center/National Life Cancer Treatment, Berlin, Vermont, United States|University of Vermont and State Agricultural College, Burlington, Vermont, United States|White River Junction Veteran Administration Medical Center, White River Junction, Vermont, United States|Danville Regional Medical Center, Danville, Virginia, United States|Fredericksburg Oncology Inc, Fredericksburg, Virginia, United States|Sovah Health Martinsville, Martinsville, Virginia, United States|Southwest VA Regional Cancer Center, Norton, Virginia, United States|Cancer Care Center at Island Hospital, Anacortes, Washington, United States|MultiCare Auburn Medical Center, Auburn, Washington, United States|Virginia Mason Bainbridge Island Medical Center, Bainbridge Island, Washington, United States|Overlake Medical Center, Bellevue, Washington, United States|PeaceHealth Saint Joseph Medical Center, Bellingham, Washington, United States|Harrison HealthPartners Hematology and Oncology-Bremerton, Bremerton, Washington, United States|Harrison Medical Center, Bremerton, Washington, United States|Highline Medical Center-Main Campus, Burien, Washington, United States|Providence Regional Cancer System-Centralia, Centralia, Washington, United States|Swedish Cancer Institute-Edmonds, Edmonds, Washington, United States|Saint Elizabeth Hospital, Enumclaw, Washington, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Virginia Mason Federal Way Medical Center, Federal Way, Washington, United States|Saint Francis Hospital, Federal Way, Washington, United States|Tacoma/Valley Radiation Oncology Centers-Gig Harbor, Gig Harbor, Washington, United States|MultiCare Gig Harbor Medical Park, Gig Harbor, Washington, United States|Swedish Cancer Institute-Issaquah, Issaquah, Washington, United States|Kadlec Clinic Hematology and Oncology, Kennewick, Washington, United States|Northwest Cancer Clinic, Kennewick, Washington, United States|Providence Regional Cancer System-Lacey, Lacey, Washington, United States|Saint Clare Hospital, Lakewood, Washington, United States|Virginia Mason Lynnwood Medical Center, Lynnwood, Washington, United States|Skagit Valley Hospital, Mount Vernon, Washington, United States|Providence - Saint Peter Hospital, Olympia, Washington, United States|Capital Medical Center, Olympia, Washington, United States|Harrison HealthPartners Hematology and Oncology-Poulsbo, Poulsbo, Washington, United States|Peninsula Cancer Center, Poulsbo, Washington, United States|MultiCare Good Samaritan Hospital, Puyallup, Washington, United States|Tacoma/Valley Radiation Oncology Centers-Puyallup, Puyallup, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Harborview Medical Center, Seattle, Washington, United States|Minor and James Medical PLLC, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Kaiser Permanente Washington, Seattle, Washington, United States|Swedish Medical Center-First Hill, Seattle, Washington, United States|University of Washington Medical Center - Montlake, Seattle, Washington, United States|PeaceHealth United General Medical Center, Sedro-Woolley, Washington, United States|Cancer Care Northwest - Spokane South, Spokane, Washington, United States|Evergreen Hematology and Oncology PS, Spokane, Washington, United States|Rockwood Clinic, Spokane, Washington, United States|Tacoma/Valley Radiation Oncology Centers-Jackson Hall, Tacoma, Washington, United States|Franciscan Research Center-Northwest Medical Plaza, Tacoma, Washington, United States|MultiCare Allenmore Hospital, Tacoma, Washington, United States|MultiCare Tacoma General Hospital, Tacoma, Washington, United States|Northwest Medical Specialties PLLC, Tacoma, Washington, United States|Northwest NCI Community Oncology Research Program, Tacoma, Washington, United States|Saint Joseph Medical Center, Tacoma, Washington, United States|Tacoma/Valley Radiation Oncology Centers-Saint Joe's, Tacoma, Washington, United States|Wenatchee Valley Hospital and Clinics, Wenatchee, Washington, United States|Langlade Hospital and Cancer Center, Antigo, Wisconsin, United States|Green Bay Oncology at Saint Vincent Hospital, Green Bay, Wisconsin, United States|Saint Vincent Hospital Cancer Center Green Bay, Green Bay, Wisconsin, United States|Green Bay Oncology Limited at Saint Mary's Hospital, Green Bay, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Saint Mary's, Green Bay, Wisconsin, United States|Gundersen Lutheran Medical Center, La Crosse, Wisconsin, United States|Holy Family Memorial Hospital, Manitowoc, Wisconsin, United States|Bay Area Medical Center, Marinette, Wisconsin, United States|ProHealth D N Greenwald Center, Mukwonago, Wisconsin, United States|Cancer Center of Western Wisconsin, New Richmond, Wisconsin, United States|ProHealth Oconomowoc Memorial Hospital, Oconomowoc, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Oconto Falls, Oconto Falls, Wisconsin, United States|HSHS Saint Nicholas Hospital, Sheboygan, Wisconsin, United States|Green Bay Oncology - Sturgeon Bay, Sturgeon Bay, Wisconsin, United States|ProHealth Waukesha Memorial Hospital, Waukesha, Wisconsin, United States|Aspirus Regional Cancer Center, Wausau, Wisconsin, United States|Tom Baker Cancer Centre, Calgary, Alberta, Canada|BCCA-Vancouver Cancer Centre, Vancouver, British Columbia, Canada|CancerCare Manitoba, Winnipeg, Manitoba, Canada|The Moncton Hospital, Moncton, New Brunswick, Canada|Grand River Regional Cancer Centre at Grand River Hospital, Kitchener, Ontario, Canada|London Regional Cancer Program, London, Ontario, Canada|Ottawa Hospital and Cancer Center-General Campus, Ottawa, Ontario, Canada|University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada|McGill University Department of Oncology, Montreal, Quebec, Canada|CHUM - Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada|The Research Institute of the McGill University Health Centre (MUHC), Montreal, Quebec, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada|Fundacion De Investigacion de Diego, San Juan, Puerto Rico	https://ClinicalTrials.gov/show/NCT01015833
743	A Phase I Study of Pazopanib in Adult Patients With Liver Cancer	Completed	No Results Available	Carcinoma, Hepatocellular	Drug: pazopanib	GSK Investigational Site, San Francisco, California, United States|GSK Investigational Site, Hong Kong, Hong Kong|GSK Investigational Site, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT00370513
744	Transradial Versus Transfemoral Arterial Access in Liver Cancer Embolization: Randomized Trial to Assess Patient Outcomes and Satisfaction (BEST ACCESS Trial).	Completed	No Results Available	Hepatic Carcinoma|Chemoembolizaton|Transarterial Embolization	Procedure: Transarterial embolization	Medical University of South Carolina, Charleston, South Carolina, United States	https://ClinicalTrials.gov/show/NCT03163186
745	Probiotics in the Prevention of Hepatocellular Carcinoma in Cirrhosis	Not yet recruiting	No Results Available	Microbiota|Hepatocellular Carcinoma|Cirrhosis	Dietary Supplement: Probiotics		https://ClinicalTrials.gov/show/NCT03853928
746	Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer	Recruiting	No Results Available	Stage III Hepatocellular Carcinoma AJCC v8|Stage IIIA Hepatocellular Carcinoma AJCC v8|Stage IIIB Hepatocellular Carcinoma AJCC v7|Stage IIIC Hepatocellular Carcinoma AJCC v7|Stage IV Hepatocellular Carcinoma AJCC v8|Stage IVA Hepatocellular Carcinoma AJCC v8|Stage IVB Hepatocellular Carcinoma AJCC v8	Biological: Nivolumab|Drug: Sorafenib	University of California, Davis, Sacramento, California, United States|University of California, San Francisco, San Francisco, California, United States	https://ClinicalTrials.gov/show/NCT03439891
747	Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer	Terminated	No Results Available	Carcinoma, Hepatocellular	Drug: CC-122|Drug: Sorafenib	University of California San Francisco, San Francisco, California, United States|University of Florida College of Med, Gainesville, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Indiana University Cancer Center, Indianapolis, Indiana, United States|Henry Ford Hospital, Detroit, Michigan, United States|Greenville Hospital System, Greenville, South Carolina, United States|University of Utah Huntsman Cancer Institute, Salt Lake City, Utah, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States	https://ClinicalTrials.gov/show/NCT02323906
748	Stereotactic Body Radiation Therapy and Transarterial Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery	Completed	No Results Available	Child-Pugh Class A|Child-Pugh Class B|Stage IIIA Hepatocellular Carcinoma|Stage IIIB Hepatocellular Carcinoma|Stage IIIC Hepatocellular Carcinoma|Stage IVA Hepatocellular Carcinoma|Stage IVB Hepatocellular Carcinoma	Other: Laboratory Biomarker Analysis|Radiation: Stereotactic Body Radiation Therapy|Procedure: Transarterial Chemoembolization	Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States	https://ClinicalTrials.gov/show/NCT02507765
749	Assessment of Frailty in Patients With Advanced Hepatocellular Cancers	Completed	No Results Available	Hepatocellular Cancer		Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom	https://ClinicalTrials.gov/show/NCT02482259
750	A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer	Recruiting	No Results Available	Carcinoma, Hepatocellular	Drug: Relatlimab|Drug: Nivolumab|Drug: Bevacizumab|Other: Placebo	Local Institution, Bondy, France|Pan American Center for Oncology Trials, LLC, Rio Piedras, Puerto Rico|Local Institution - 0019_NA, San Juan, Puerto Rico|Local Institution, Taichung, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT05337137
751	Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer	Unknown status	No Results Available	Breast Cancer|Colorectal Cancer|Gastric Cancer|Liver Cancer|Melanoma (Skin)|Metastatic Cancer|Ovarian Cancer|Pancreatic Cancer	Drug: cyclophosphamide|Drug: poly ICLC|Procedure: hepatic artery embolization|Radiation: 3-dimensional conformal radiation therapy	Rutgrers University Hospital, Newark, New Jersey, United States	https://ClinicalTrials.gov/show/NCT00553683
752	A Study of the Safety and Antitumoral Efficacy of Nivolumab After SIRT for the Treatment of Patients With HCC	Completed	No Results Available	Hepatocellular Carcinoma	Drug: Nivolumab|Device: SIR-Spheres	Hospital Universitario de Cruces, Baracaldo, Spain|Hospital Clinic, Barcelona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Gregorio Marañon, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario Central de Asturias, Oviedo, Spain|Clinica Universidad de Navarra, Pamplona, Spain|Hospital Universitario Donostia, San Sebastián, Spain|Hospital Universitario Lozano Blesa, Zaragoza, Spain	https://ClinicalTrials.gov/show/NCT03380130
753	Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)	Completed	Has Results	Hepatocellular Carcinoma	Drug: Sorafenib Standard Dosing Regimen|Drug: Sorafenib Ramp-Up Regimen	University of Florida Hepatology, Gainesville, Florida, United States|Mayo Clinic, Jacksonville, Florida, United States|Florida Hospital Transplant Center, Orlando, Florida, United States|Tampa General Hospital, Tampa, Florida, United States|Loyola University Medical Center, Maywood, Illinois, United States|Henry Ford Health System, Detroit, Michigan, United States|Drexel University College of Medicine, Philadelphia, Pennsylvania, United States|University of Texas Health Science Center Houston, Houston, Texas, United States|Brooke Army Medical Center, San Antonio, Texas, United States	https://ClinicalTrials.gov/show/NCT01203787
754	Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer	Active, not recruiting	No Results Available	Extrahepatic Bile Duct Adenocarcinoma, Biliary Type|Gallbladder Adenocarcinoma, Biliary Type|Metastatic Pancreatic Adenocarcinoma|Recurrent Cholangiocarcinoma|Recurrent Gallbladder Carcinoma|Recurrent Hepatocellular Carcinoma|Recurrent Intrahepatic Cholangiocarcinoma|Recurrent Pancreatic Carcinoma|Stage III Gallbladder Cancer AJCC V7|Stage III Hepatocellular Carcinoma AJCC v7|Stage III Intrahepatic Cholangiocarcinoma AJCC v7|Stage III Pancreatic Cancer AJCC v6 and v7|Stage IIIA Gallbladder Cancer AJCC v7|Stage IIIA Hepatocellular Carcinoma AJCC v7|Stage IIIB Gallbladder Cancer AJCC v7|Stage IIIB Hepatocellular Carcinoma AJCC v7|Stage IIIC Hepatocellular Carcinoma AJCC v7|Stage IV Gallbladder Cancer AJCC v7|Stage IV Hepatocellular Carcinoma AJCC v7|Stage IV Pancreatic Cancer AJCC v6 and v7|Stage IVA Gallbladder Cancer AJCC v7|Stage IVA Hepatocellular Carcinoma AJCC v7|Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7|Stage IVB Gallbladder Cancer AJCC v7|Stage IVB Hepatocellular Carcinoma AJCC v7|Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7|Unresectable Gallbladder Carcinoma|Unresectable Pancreatic Carcinoma	Biological: Durvalumab|Drug: Guadecitabine	USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States	https://ClinicalTrials.gov/show/NCT03257761
755	Transcatheter Arterial Chemoembolization Therapy In Combination With Sorafenib	Unknown status	No Results Available	Hepatocellular Carcinoma|Unresectable Hepatocellular Carcinoma|Carcinoma, Hepatocellular|Liver Neoplasm	Drug: TACE with sorafenib|Procedure: TACE alone	Kinki University Hospital, Osaka-Sayama, Osaka, Japan	https://ClinicalTrials.gov/show/NCT01217034
756	Treatment of Cirrhosis-related Hepatocellular Carcinoma With the Intrahepatic Arterial Injection of an Emulsion of Lipiodol and Idarubicin (Zavedos®): Phase I Study	Completed	No Results Available	Unresectable Non-metastatic Hepatocellular Carcinoma|Child A/B7 Cirrhosis	Drug: Zavedos®|Other: Blood samples	CHU de Dijon, Dijon, France	https://ClinicalTrials.gov/show/NCT02028949
757	PROLIFICA - West African Treatment Cohort for Hepatitis B	Completed	No Results Available	Hepatitis B, Chronic|Hepatocellular Carcinoma	Drug: Tenofovir disoproxil	MRC Laboratories Hospital, Fajara, Gambia|UFR Sante Thies,, Thies, Senegal	https://ClinicalTrials.gov/show/NCT02129829
758	Yttrium Y-90 Radioembolization in Treating Patients With Metastatic Liver Cancer	Unknown status	No Results Available	Metastatic Liver Carcinoma|Stage IV Liver Cancer|Stage IVA Liver Cancer|Stage IVB Liver Cancer	Procedure: Angiography|Procedure: Computed Tomography|Procedure: Planar Imaging|Radiation: Radioembolization|Procedure: Single Photon Emission Computed Tomography|Radiation: Technetium Tc-99m Albumin Aggregated|Other: Yttrium Y 90 Resin Microspheres	M D Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT03028311
759	Characterization of Methylation Patterns in Hepatocellular Carcinoma	Terminated	No Results Available	Hepatocellular Carcinoma|Hepatocellular Cancer|Cirrhosis	Procedure: Blood collection	Ha'emek Medical Center, Afula, Israel|Carmel Medical Center, Haifa, Israel|Rambam Medical Center, Haifa, Israel|Sheba Medical Center, Ramat Gan, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel	https://ClinicalTrials.gov/show/NCT04264754
760	Changes in Liver Function After Stereotactic Body Radiation Therapy Measured by PET/CT	Completed	No Results Available	Hepatocellular Carcinoma|Cholangiocarcinoma|Metastases|Stereotactic Body Radiotherapy	Other: Measuring liver function by PET/CT	Aarhus University Hospital, Aarhus C, Denmark	https://ClinicalTrials.gov/show/NCT01213758
761	Influence of Social Determinants of Health on the Management of HCC in the French National Cohort Study CHIEF	Recruiting	No Results Available	Hepatocellular Carcinoma		Anna M Borowik, La Tronche, Auvergne-Rhône-Alpes, France	https://ClinicalTrials.gov/show/NCT05128123
762	Assessing BAY86-9766 Plus Sorafenib for the Treatment of Liver Cancer.	Completed	No Results Available	Carcinoma, Hepatocellular	Drug: BAY86-9766 MEK Inhibitor + Sorafenib	Shatin, New Territories, Hong Kong|Hong Kong, Hong Kong|Jung-gu, Daegu Gwang''yeogsi, Korea, Republic of|Goyang-si, Gyeonggido, Korea, Republic of|Busan, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Singapore, Singapore|Singapore, Singapore|Kaohsiung, Taiwan|Tainan, Taiwan|Tainan, Taiwan|Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT01204177
763	Combine TACE and RFA Versus RFA Monotherapy in Unilobar HCC of 3.1 to 7 cm Patient	Unknown status	No Results Available	Hepatocellular Carcinoma	Procedure: Transcatheter Arterial Chemoembolization|Procedure: Radiofrequency ablation|Drug: Doxorubicin	Chang Gung Memorial Hospital, Lin-Kuo, Taoyuan, Taiwan	https://ClinicalTrials.gov/show/NCT01858207
764	Sorafenib Combined With Arsenical in Treating Patients With Recurrent HCC After Liver Transplantation	Recruiting	No Results Available	HCC	Drug: Arsenicals	the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China	https://ClinicalTrials.gov/show/NCT04232722
765	Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.	Completed	No Results Available	Hepatitis C Infection|Viruses|Hepatocellular Carcinoma|Hepatitis, Viral, Human|Liver Cirrhosis	Biological: Civacir® 10%	University of Southern California / Keck Hospital, Los Angeles, California, United States|University of California San Francisco, San Francisco, California, United States|University of Miami Miller School of Medicine, Miami, Florida, United States|Florida Hospital Transplant Institute, Orlando, Florida, United States|Piedmont Hospital, Atlanta, Georgia, United States|Emory University School of Medicine, Atlanta, Georgia, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|University of Kentucky Chandler Medical Center, Lexington, Kentucky, United States|Ochsner Medical Center, New Orleans, Louisiana, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Lahey Hospital, Burlington, Massachusetts, United States|NYU Langone Medical Center, New York, New York, United States|The Mount Sinai Medical Center, New York, New York, United States|Columbia University College of Physicians and Surgeons, New York, New York, United States|Oregon Health & Science University, Portland, Oregon, United States|Methodist University Hospital, Memphis, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Baylor University Medical Center, Dallas, Texas, United States|Advanced Liver Therapies / St. Luke's Episcopal Hospital, Houston, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Houston Methodist, Houston, Texas, United States|University of Utah Health Sciences Center, Salt Lake City, Utah, United States|University of Virginia Health System, Charlottesville, Virginia, United States	https://ClinicalTrials.gov/show/NCT01804829
766	A Rapid 10-minute Liver MRI	Completed	No Results Available	Underlying Liver Disease|Hepatitis|Fibrosis of Liver|Cirrhosis With Suspicion of Liver Cancer|Lesion on a Prior Ultrasound, CT or Outside MRI		University of Nebraska Medical Center, Omaha, Nebraska, United States	https://ClinicalTrials.gov/show/NCT01390194
767	Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer	Terminated	Has Results	Carcinoma, Hepatocellular	Drug: sunitinib malate|Drug: sorafenib	Pfizer Investigational Site, Fountain Valley, California, United States|Pfizer Investigational Site, La Jolla, California, United States|Pfizer Investigational Site, La Jolla, California, United States|Pfizer Investigational Site, Orange, California, United States|Pfizer Investigational Site, San Diego, California, United States|Pfizer Investigational Site, Miami, Florida, United States|Pfizer Investigational Site, Ringgold, Georgia, United States|Pfizer Investigational Site, Iowa City, Iowa, United States|Pfizer Investigational Site, Crestview Hills, Kentucky, United States|Pfizer Investigational Site, Bronx, New York, United States|Pfizer Investigational Site, Cincinnati, Ohio, United States|Pfizer Investigational Site, Cincinnati, Ohio, United States|Pfizer Investigational Site, Cincinnati, Ohio, United States|Pfizer Investigational Site, Cincinnati, Ohio, United States|Pfizer Investigational Site, Cincinnati, Ohio, United States|Pfizer Investigational Site, Cincinnati, Ohio, United States|Pfizer Investigational Site, Fairfield, Ohio, United States|Pfizer Investigational Site, Hamilton, Ohio, United States|Pfizer Investigational Site, Chattanooga, Tennessee, United States|Pfizer Investigational Site, Franklin, Tennessee, United States|Pfizer Investigational Site, Gallatin, Tennessee, United States|Pfizer Investigational Site, Hermitage, Tennessee, United States|Pfizer Investigational Site, Hixson, Tennessee, United States|Pfizer Investigational Site, Lebanon, Tennessee, United States|Pfizer Investigational Site, Murfreesboro, Tennessee, United States|Pfizer Investigational Site, Nashville, Tennessee, United States|Pfizer Investigational Site, Nashville, Tennessee, United States|Pfizer Investigational Site, Nashville, Tennessee, United States|Pfizer Investigational Site, Nashville, Tennessee, United States|Pfizer Investigational Site, Smyrna, Tennessee, United States|Pfizer Investigational Site, Mechanicsville, Virginia, United States|Pfizer Investigational Site, Midlothian, Virginia, United States|Pfizer Investigational Site, Richmond, Virginia, United States|Pfizer Investigational Site, Richmond, Virginia, United States|Pfizer Investigational Site, Seattle, Washington, United States|Pfizer Investigational Site, Concord, New South Wales, Australia|Pfizer Investigational Site, Elizabeth Vale, South Australia, Australia|Pfizer Investigational Site, Woodville South, South Australia, Australia|Pfizer Investigational Site, Melbourne, Victoria, Australia|Pfizer Investigational Site, Parkville, Victoria, Australia|Pfizer Investigational Site, Bruxelles, Belgium|Pfizer Investigational Site, Bruxelles, Belgium|Pfizer Investigational Site, Gent, Belgium|Pfizer Investigational Site, Calgary, Alberta, Canada|Pfizer Investigational Site, Vancouver, British Columbia, Canada|Pfizer Investigational Site, Kingston, Ontario, Canada|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Hefei, Anhui, China|Pfizer Investigational Site, Fuzhou City, Fujian, China|Pfizer Investigational Site, Guangzhou, Guangdong, China|Pfizer Investigational Site, Guangzhou, Guangdong, China|Pfizer Investigational Site, Nanning, Guangxi, China|Pfizer Investigational Site, Wuhan, Hubei, China|Pfizer Investigational Site, Nanjing, Jiangsu, China|Pfizer Investigational Site, Chengdu, Sichuan, China|Pfizer Investigational Site, Hangzhou, Zhejiang, China|Pfizer Investigational Site, Hangzhou, Zhejiang, China|Pfizer Investigational Site, Beijing, China|Pfizer Investigational Site, Beijing, China|Pfizer Investigational Site, Bejing, China|Pfizer Investigational Site, Chong qing, China|Pfizer Investigational Site, Guangzhou, China|Pfizer Investigational Site, Nanjing, China|Pfizer Investigational Site, Shanghai, China|Pfizer Investigational Site, Amiens Cedex 1, France|Pfizer Investigational Site, Bordeaux Cedex, France|Pfizer Investigational Site, Clichy Cedex, France|Pfizer Investigational Site, Creteil Cedex, France|Pfizer Investigational Site, Lille Cedex, France|Pfizer Investigational Site, Nice Cedex 2, France|Pfizer Investigational Site, Paris Cedex 13, France|Pfizer Investigational Site, Paris, France|Pfizer Investigational Site, St Herblain Cedex, France|Pfizer Investigational Site, Strasbourg Cedex, France|Pfizer Investigational Site, Toulouse, France|Pfizer Investigational Site, Vandoeuvre Les Nancy Cedex, France|Pfizer Investigational Site, Villejuif Cedex, France|Pfizer Investigational Site, Hamburg, Germany|Pfizer Investigational Site, Hannover, Germany|Pfizer Investigational Site, Mainz, Germany|Pfizer Investigational Site, Muenchen, Germany|Pfizer Investigational Site, Hong Hong, Hong Kong|Pfizer Investigational Site, Kowloon, Hong Kong|Pfizer Investigational Site, Shatin, New Territories, Hong Kong|Pfizer Investigational Site, Tuen Mun, New Territories, Hong Kong|Pfizer Investigational Site, Meldola, FC, Italy|Pfizer Investigational Site, Bari, Italy|Pfizer Investigational Site, Bologna, Italy|Pfizer Investigational Site, Cattolica (RN), Italy|Pfizer Investigational Site, Milano, Italy|Pfizer Investigational Site, Milano, Italy|Pfizer Investigational Site, Padova, Italy|Pfizer Investigational Site, Pavia, Italy|Pfizer Investigational Site, Ravenna, Italy|Pfizer Investigational Site, Rimini, Italy|Pfizer Investigational Site, Nagoya, Aichi, Japan|Pfizer Investigational Site, Chiba city, Chiba, Japan|Pfizer Investigational Site, Kashiwa-shi, Chiba, Japan|Pfizer Investigational Site, Kurume city, Fukuoka, Japan|Pfizer Investigational Site, Gifu-shi, Gifu, Japan|Pfizer Investigational Site, Sapporo-shi, Hokkaido, Japan|Pfizer Investigational Site, Nishinomiya, Hyogo, Japan|Pfizer Investigational Site, Kanazawa city, Ishikawa, Japan|Pfizer Investigational Site, Omura-shi, Nagasaki, Japan|Pfizer Investigational Site, Osaka-shi, Osaka-fu, Japan|Pfizer Investigational Site, Osaka-Sayama, Osaka, Japan|Pfizer Investigational Site, Izunokuni-shi, Shizuoka, Japan|Pfizer Investigational Site, Bunkyo-ku, Tokyo, Japan|Pfizer Investigational Site, Chiyoda-ku, Tokyo, Japan|Pfizer Investigational Site, Chuo-ku, Tokyo, Japan|Pfizer Investigational Site, Itabashi-ku, Tokyo, Japan|Pfizer Investigational Site, Mitaka-shi, Tokyo, Japan|Pfizer Investigational Site, Setagaya-ku, Tokyo, Japan|Pfizer Investigational Site, Okayama, Japan|Pfizer Investigational Site, Chonju, Chonbuk, Korea, Republic of|Pfizer Investigational Site, Goyang-si, Gyeonggi-do, Korea, Republic of|Pfizer Investigational Site, Hwasun-gun, Jeollanam-do, Korea, Republic of|Pfizer Investigational Site, Busan, Korea, Republic of|Pfizer Investigational Site, Daegu, Korea, Republic of|Pfizer Investigational Site, Daegu, Korea, Republic of|Pfizer Investigational Site, Incheon, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Lembah Pantai, Kuala Lumpur, Malaysia|Pfizer Investigational Site, Subang Jaya, Selangor, Malaysia|Pfizer Investigational Site, Kuala Lumpur, Malaysia|Pfizer Investigational Site, Cebu City, Cebu, Philippines|Pfizer Investigational Site, Cebu City, Philippines|Pfizer Investigational Site, Davao City, Philippines|Pfizer Investigational Site, Manila, Philippines|Pfizer Investigational Site, Manila, Philippines|Pfizer Investigational Site, Quezon City, Philippines|Pfizer Investigational Site, Quezon City, Philippines|Pfizer Investigational Site, Quezon City, Philippines|Pfizer Investigational Site, Warszawa, Poland|Pfizer Investigational Site, Warszawa, Poland|Pfizer Investigational Site, Chelyabinsk, Russian Federation|Pfizer Investigational Site, Pyatigorsk, Russian Federation|Pfizer Investigational Site, St.Petersburg, Russian Federation|Pfizer Investigational Site, Singapore, Singapore|Pfizer Investigational Site, Singapore, Singapore|Pfizer Investigational Site, Parktown, South Africa|Pfizer Investigational Site, Sabadell, Barcelona, Spain|Pfizer Investigational Site, Santander, Cantabria, Spain|Pfizer Investigational Site, Palma de Mallorca, Illes Balears, Spain|Pfizer Investigational Site, El Palmar, Murcia, Spain|Pfizer Investigational Site, Sevilla, Spain|Pfizer Investigational Site, Linkoping, Sweden|Pfizer Investigational Site, Pu-Tz City, Chai-Yi, Taiwan|Pfizer Investigational Site, Kwei-Shan, Taoyuan, Taiwan|Pfizer Investigational Site, Changhua, Taiwan|Pfizer Investigational Site, Kaohsiung, Taiwan|Pfizer Investigational Site, Kaohsiung, Taiwan|Pfizer Investigational Site, Taichung City, Taiwan|Pfizer Investigational Site, Taichung, Taiwan|Pfizer Investigational Site, Tainan, Taiwan|Pfizer Investigational Site, Tainan, Taiwan|Pfizer Investigational Site, Taipei, Taiwan|Pfizer Investigational Site, Taipei, Taiwan|Pfizer Investigational Site, Bangkok Noi, Bangkok, Thailand|Pfizer Investigational Site, Ptumwan, Bangkok, Thailand|Pfizer Investigational Site, Amphoe Mueang, Chiang Mai, Thailand|Pfizer Investigational Site, Ankara, Turkey|Pfizer Investigational Site, Istanbul, Turkey|Pfizer Investigational Site, Cambridge, Cambridgeshire, United Kingdom|Pfizer Investigational Site, London, United Kingdom|Pfizer Investigational Site, London, United Kingdom	https://ClinicalTrials.gov/show/NCT00699374
768	Sirolimus-Based Immunosuppression Therapy in OLT for Patients With HCC Exceeding Milan Criteria	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: sirolimus	Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China	https://ClinicalTrials.gov/show/NCT00554125
769	Comparing Efficacy of Sorafenib Versus Sorafenib in Combination With Low-dose FP in Patients With Advanced HCC	Unknown status	No Results Available	Advanced Hepatocellular Carcinoma|Carcinoma|Carcinoma, Hepatocellular|Liver Neoplasms|Neoplasms	Drug: Sorafenib with Low-dose FP|Drug: Sorafenib	National Cancer Center Hospital East, Kashiwa, Chiba, Japan|Kurume University Medical Center, Kurume, Fukuoka, Japan|Ogaki Municipal Hospital, Ogaki, Gifu, Japan|Sapporo Medical University, Sapporo, Hokkaido, Japan|Sapporo-Kosei General Hospital, Sapporo, Hokkaido, Japan|Japanese Red Cross Takamatsu Hospital, Takamatsu, Kagawa, Japan|Mie University Hospital, Tsu, Mie, Japan|National Hospital Organization Nagasaki Medical Center, Ohmura, Nagasaki, Japan|Kawasaki Medical School Hospital, Kurashiki, Okayama, Japan|Ikeda Municipal Hospital, Ikeda, Osaka, Japan|Kinki University Hospital, Osaka-Sayama, Osaka, Japan|Osaka University Hospital, Suita, Osaka, Japan|Kyorin University Hospital, Mitaka, Tokyo, Japan|Musashino Red Cross Hospital, Musashino, Tokyo, Japan|Juntendo University Nerima Hospital, Nerima, Tokyo, Japan|Yamaguchi University Hospital, Ube, Yamaguchi, Japan|Chiba University Hospital, Chiba, Japan|Gifu Municipal Hospital, Gifu, Japan|Hiroshima City Hospital, Hiroshima, Japan|Hiroshima University Hospital, Hiroshima, Japan|Kumamoto University Hospital, Kumamoto, Japan|Kyoto University Hospital, Kyoto, Japan|Center for Gastroenterological and Hepatological Diseases, Miyazaki, Japan|Saiseikai Niigata Dai-ni Hospital, Niigata, Japan|Niigata University Medical and Dental Hospital, Niigata, Japan|Okayama University Hospital, Okayama, Japan|Osaka Red Cross Hospital, Osaka, Japan|The University of Tokushima Faculty of Medicine, Tokushima, Japan|Kyoundo Hospital, Tokyo, Japan|National Cancer Center Hospital, Tokyo, Japan	https://ClinicalTrials.gov/show/NCT01214343
770	Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)	Terminated	No Results Available	Hepatocellular Carcinoma Non-resectable|Hepatocellular Carcinoma Recurrent|Carcinoma, Hepatocellular|Liver Diseases|Neoplasms by Histologic Type|Digestive System Neoplasms|Carcinoma|Liver Neoplasms|Neoplasms|Neoplasms by Site|Digestive System Diseases|Adenocarcinoma|Neoplasms, Glandular and Epithelial	Drug: ABT-869|Drug: Sorafenib	Site Reference ID/Investigator# 23247, Beverly Hills, California, United States|Site Reference ID/Investigator# 23608, LaVerne, California, United States|Site Reference ID/Investigator# 23852, Orange, California, United States|Site Reference ID/Investigator# 40162, Orange, California, United States|Site Reference ID/Investigator# 23254, Newark, Delaware, United States|Site Reference ID/Investigator# 23253, Gainesville, Georgia, United States|Site Reference ID/Investigator# 23609, Honolulu, Hawaii, United States|Site Reference ID/Investigator# 24848, Honolulu, Hawaii, United States|Site Reference ID/Investigator# 23250, Louisville, Kentucky, United States|Site Reference ID/Investigator# 23257, St. Louis, Missouri, United States|Site Reference ID/Investigator# 23603, Las Vegas, Nevada, United States|Site Reference ID/Investigator# 23244, Durham, North Carolina, United States|Site Reference ID/Investigator# 23252, Portland, Oregon, United States|Site Reference ID/Investigator# 35705, Buenos Aires, Argentina|Site Reference ID/Investigator# 35702, Rosario, Santa Fe, Argentina|Site Reference ID/Investigator# 23152, Camperdown, Australia|Site Reference ID/Investigator# 23150, Concord, Australia|Site Reference ID/Investigator# 27122, Kingswood, Australia|Site Reference ID/Investigator# 23153, Kogarah, Australia|Site Reference ID/Investigator# 24103, Southport, Australia|Site Reference ID/Investigator# 27968, Graz, Austria|Site Reference ID/Investigator# 27969, Innsbruck, Austria|Site Reference ID/Investigator# 27970, Linz, Austria|Site Reference ID/Investigator# 27967, Vienna, Austria|Site Reference ID/Investigator# 38902, Brussels, Belgium|Site Reference ID/Investigator# 23162, Brussels, Belgium|Site Reference ID/Investigator# 23843, Edegem, Belgium|Site Reference ID/Investigator# 23161, Ghent, Belgium|Site Reference ID/Investigator# 23842, Gilly, Belgium|Site Reference ID/Investigator# 23163, Leuven, Belgium|Site Reference ID/Investigator# 26702, Edmonton, Canada|Site Reference ID/Investigator# 25482, Halifax, Canada|Site Reference ID/Investigator# 39614, Montreal, Canada|Site Reference ID/Investigator# 23184, Ottawa, Canada|Site Reference ID/Investigator# 23183, Sherbrooke, Canada|Site Reference ID/Investigator# 24522, Toronto, Canada|Site Reference ID/Investigator# 36967, Temuco, Chile|Site Reference ID/Investigator# 36964, Vina del Mar, Chile|Site Reference ID/Investigator# 23186, Beijing, China|Site Reference ID/Investigator# 43443, Changchun, China|Site Reference ID/Investigator# 23194, Chengdu, China|Site Reference ID/Investigator# 43442, Chongqing, China|Site Reference ID/Investigator# 44444, Dalian, China|Site Reference ID/Investigator# 43444, Fuzhou, China|Site Reference ID/Investigator# 43482, Guangzhou City, China|Site Reference ID/Investigator# 42563, Hangzhou, China|Site Reference ID/Investigator# 44443, Harbin, China|Site Reference ID/Investigator# 44062, Jinan, China|Site Reference ID/Investigator# 23191, Nanjing City, China|Site Reference ID/Investigator# 44063, Nanning City, China|Site Reference ID/Investigator# 42817, Qingdao, China|Site Reference ID/Investigator# 40624, Shanghai, China|Site Reference ID/Investigator# 23189, Shanghai, China|Site Reference ID/Investigator# 40448, Suzhou, China|Site Reference ID/Investigator# 23190, Xian, China|Site Reference ID/Investigator# 23167, Brno, Czech Republic|Site Reference ID/Investigator# 23166, Olomouc, Czech Republic|Site Reference ID/Investigator# 24523, Prague 2, Czech Republic|Site Reference ID/Investigator# 23844, Prague 4, Czech Republic|Site Reference ID/Investigator# 40930, Prague 8, Czech Republic|Site Reference ID/Investigator# 23197, Usti nad Labem, Czech Republic|Site Reference ID/Investigator# 23442, Aarhus C, Denmark|Site Reference ID/Investigator# 23198, Alexandria, Egypt|Site Reference ID/Investigator# 23199, Cairo, Egypt|Site Reference ID/Investigator# 43302, Amiens, France|Site Reference ID/Investigator# 23201, Clichy, France|Site Reference ID/Investigator# 43144, Creteil, France|Site Reference ID/Investigator# 23200, Lille Cedex, France|Site Reference ID/Investigator# 23168, Paris Cedex 12, France|Site Reference ID/Investigator# 40623, Paris Cedex 13, France|Site Reference ID/Investigator# 28345, Rouen Cedex, France|Site Reference ID/Investigator# 23165, Strasbourg Cedex, France|Site Reference ID/Investigator# 28347, Vandoeuvre Les Nancy, France|Site Reference ID/Investigator# 23267, Berlin, Germany|Site Reference ID/Investigator# 23845, Bochum, Germany|Site Reference ID/Investigator# 23266, Frankfurt am Main, Germany|Site Reference ID/Investigator# 23268, Freiburg, Germany|Site Reference ID/Investigator# 23269, Mainz, Germany|Site Reference ID/Investigator# 24525, Athens, Greece|Site Reference ID/Investigator# 24980, Hong Kong, Hong Kong|Site Reference ID/Investigator# 27998, Benevento, Italy|Site Reference ID/Investigator# 23424, Milan, Italy|Site Reference ID/Investigator# 41488, Milan, Italy|Site Reference ID/Investigator# 23425, Palermo, Italy|Site Reference ID/Investigator# 41542, Pavia, Italy|Site Reference ID/Investigator# 23428, Rome, Italy|Site Reference ID/Investigator# 24042, Rome, Italy|Site Reference ID/Investigator# 26506, Aichi, Japan|Site Reference ID/Investigator# 36308, Chiba, Japan|Site Reference ID/Investigator# 37602, Chiba, Japan|Site Reference ID/Investigator# 29758, Fukuoka, Japan|Site Reference ID/Investigator# 37603, Hokkaido, Japan|Site Reference ID/Investigator# 28189, Ibaraki-ken, Japan|Site Reference ID/Investigator# 26505, Kanazawa, Japan|Site Reference ID/Investigator# 29757, Kumamoto, Japan|Site Reference ID/Investigator# 27343, Kurume, Japan|Site Reference ID/Investigator# 29759, Matsuyama-city, Japan|Site Reference ID/Investigator# 26508, Osakasayama, Japan|Site Reference ID/Investigator# 26507, Osaka, Japan|Site Reference ID/Investigator# 27959, Osaka, Japan|Site Reference ID/Investigator# 29756, Shimotsuke, Japan|Site Reference ID/Investigator# 36782, Shizuoka, Japan|Site Reference ID/Investigator# 28187, Tochigi-ken, Japan|Site Reference ID/Investigator# 26503, Tokyo, Japan|Site Reference ID/Investigator# 27242, Tokyo, Japan|Site Reference ID/Investigator# 26504, Yokohama City, Japan|Site Reference ID/Investigator# 26509, Yufu, Japan|Site Reference ID/Investigator# 23447, Busan, Korea, Republic of|Site Reference ID/Investigator# 39003, Busan, Korea, Republic of|Site Reference ID/Investigator# 23445, Busan, Korea, Republic of|Site Reference ID/Investigator# 23444, Daegu, Korea, Republic of|Site Reference ID/Investigator# 26543, Gyeonggi-do, Korea, Republic of|Site Reference ID/Investigator# 23457, Jeollanam-do, Korea, Republic of|Site Reference ID/Investigator# 39002, Jeonju-si, Korea, Republic of|Site Reference ID/Investigator# 23454, Seoul, Korea, Republic of|Site Reference ID/Investigator# 25562, Seoul, Korea, Republic of|Site Reference ID/Investigator# 23449, Seoul, Korea, Republic of|Site Reference ID/Investigator# 23456, Seoul, Korea, Republic of|Site Reference ID/Investigator# 23450, Suwon-si, Korea, Republic of|Site Reference ID/Investigator# 23460, Kuala Lumpur, Malaysia|Site Reference ID/Investigator# 23461, Penang, Malaysia|Site Reference ID/Investigator# 23459, Petaling Jaya, Selangor, Malaysia|Site Reference ID/Investigator# 23155, Durango, DGO., Mexico|Site Reference ID/Investigator# 43102, Monterrey, NL, Mexico|Site Reference ID/Investigator# 43145, Monterrey, NL, Mexico|Site Reference ID/Investigator# 23272, Amsterdam, Netherlands|Site Reference ID/Investigator# 23270, Amsterdam, Netherlands|Site Reference ID/Investigator# 24782, Rotterdam, Netherlands|Site Reference ID/Investigator# 23160, Auckland, New Zealand|Site Reference ID/Investigator# 23846, Oslo, Norway|Site Reference ID/Investigator# 42706, Ponce, Puerto Rico|Site Reference ID/Investigator# 42705, San Juan, Puerto Rico|Site Reference ID/Investigator# 33979, Baia Mare, Romania|Site Reference ID/Investigator# 33344, Bucharest, Romania|Site Reference ID/Investigator# 33343, Cluj Napoca, Romania|Site Reference ID/Investigator# 33977, Craiova, Romania|Site Reference ID/Investigator# 33345, Iasi, Romania|Site Reference ID/Investigator# 33346, Oradea, Romania|Site Reference ID/Investigator# 43202, Chelyabinsk, Russian Federation|Site Reference ID/Investigator# 43203, Kazan, Russian Federation|Site Reference ID/Investigator# 23462, Moscow, Russian Federation|Site Reference ID/Investigator# 23849, Moscow, Russian Federation|Site Reference ID/Investigator# 23159, Singapore, Singapore|Site Reference ID/Investigator# 23158, Singapore, Singapore|Site Reference ID/Investigator# 23466, A Coruna, Spain|Site Reference ID/Investigator# 26063, Madrid, Spain|Site Reference ID/Investigator# 40931, Madrid, Spain|Site Reference ID/Investigator# 23465, Madrid, Spain|Site Reference ID/Investigator# 23463, Madrid, Spain|Site Reference ID/Investigator# 23467, Santander, Spain|Site Reference ID/Investigator# 23468, Zaragoza, Spain|Site Reference ID/Investigator# 23475, Changhua City, Taiwan|Site Reference ID/Investigator# 23472, Kaohsiung County, Taiwan|Site Reference ID/Investigator# 25262, Taichung City, Taiwan|Site Reference ID/Investigator# 23474, Taichung, Taiwan|Site Reference ID/Investigator# 23476, Tainan, Taiwan|Site Reference ID/Investigator# 23478, Tainan, Taiwan|Site Reference ID/Investigator# 23477, Tainan, Taiwan|Site Reference ID/Investigator# 23470, Taipei City, Taiwan|Site Reference ID/Investigator# 43237, Taipei, Taiwan|Site Reference ID/Investigator# 23473, Taipei, Taiwan|Site Reference ID/Investigator# 23469, Taipei, Taiwan|Site Reference ID/Investigator# 23471, Taoyuan, Taiwan	https://ClinicalTrials.gov/show/NCT01009593
771	Changing Trends in HCC Procedures	Unknown status	No Results Available	Hepatocellular Carcinoma		Uhmontpellier, Montpellier, France	https://ClinicalTrials.gov/show/NCT04163627
772	Standardized CEUS Algorithms for Diagnosis of HCC - Prospective German Multicenter Study	Completed	No Results Available	Hepatocellular Carcinoma|Cholangiocarcinoma, Intrahepatic|Liver Cirrhosis|Liver Cancer|Liver Neoplasms|Liver Diseases	Diagnostic Test: contrast enhanced ultrasound (CEUS)|Diagnostic Test: MRI|Diagnostic Test: Histology	University Hospital Erlangen, Department of Medicine 1, Erlangen, Bavaria, Germany	https://ClinicalTrials.gov/show/NCT03405909
773	Open-label Multicenter Phase 1 Study of TBI 302 as Second-Line Therapy in Patients With Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma	Biological: TBI 302	Indiana University Simon Cancer Center, Indianapolis, Indiana, United States	https://ClinicalTrials.gov/show/NCT03908840
774	18F-DCFPyL PET/CT in Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: F18-FDG|Device: MRI|Device: CT|Drug: F18-DCFPyL	National Institutes of Health Clinical Center, Bethesda, Maryland, United States	https://ClinicalTrials.gov/show/NCT05009979
775	Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Drug: sorafenib with temsirolimus	University of California San Francisco, San Francisco, California, United States|Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, United States	https://ClinicalTrials.gov/show/NCT01008917
776	Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	Unknown status	No Results Available	Hepatitis C|Hepatitis B|Autoimmune Hepatitis|Liver Cirrhosis, Biliary|Cholangitis, Sclerosing		Liver Clinic, Toronto Western Hospital, UHN, Toronto, Ontario, Canada	https://ClinicalTrials.gov/show/NCT00160940
777	A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal Antibody With Antiangiogenic Features) In Combination With Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients Affected By Recurrent Liver Cancer	Terminated	Has Results	Carcinoma, Hepatocellular	Drug: PF-03446962|Other: Best Supportive Care|Other: Placebo	Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|National Cancer Center Hospital East, Kashiwa, Chiba, Japan|Kinki University Hospital, Department of Gastroenterology and Hepatology, Osaka-Sayama, Osaka, Japan|National Cancer Center Hospital, Chuo-ku, Tokyo, Japan	https://ClinicalTrials.gov/show/NCT01911273
778	Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib	Active, not recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Sorafenib|Drug: Doxorubicin	Memorial Sloan Kettering Cancer Center at Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States|Memorial Sloan Kettering West Harrison, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center at Mercy Medical Center, Rockville Centre, New York, United States|Memorial Sloan Kettering Cancer Center at Phelps Memorial Hospital Center, Sleepy Hollow, New York, United States	https://ClinicalTrials.gov/show/NCT01840592
779	Factors Affecting Post-treatment Outcomes in Patients With Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Device: Radiofrequency ablation|Drug: Trance-arterial chemoembolization|Procedure: Liver resection|Combination Product: Combined radiofrequency ablation + percutaneous ethanol injection|Drug: Percutaneous ethanol injection|Drug: Systemic chemotherapy|Drug: Sorafenib|Dietary Supplement: Viscum|Drug: Symptomatic treatment		https://ClinicalTrials.gov/show/NCT04553458
780	Intravascular Ultrasound for Hepatocellular Carcinoma Staging	Unknown status	No Results Available	Hepatocellular Carcinoma	Device: Intravascular ultrasound of the liver	University Hospital Geneva, Geneva, Switzerland	https://ClinicalTrials.gov/show/NCT00474734
781	Sorafenib in Hepatocellular Carcinoma Clinical Practice in Italy	Completed	No Results Available	Hepatocellular Carcinoma	Drug: Sorafenib (Nexavar, BAY43-9006)	Many Locations, Italy	https://ClinicalTrials.gov/show/NCT01539681
782	Pilot Study of Irreversible Electroporation (IRE) to Treat Early-Stage Primary Liver Cancer (HCC)	Completed	No Results Available	Carcinoma, Hepatocellular	Device: Ablation with the NanoKnife Low Energy Direct Current (LEDC) System	L'institut de cancerologie Gustave Roussy, Villejuif, Ile-de-France, France|Hopital Beaujon, Paris, France|Universitatsklinikum Magdeburg AoR, Klinik fur Radiologie und Nuklearmedizin, Magdeburg, Germany|University of Pisa School of Medicine, Pisa, Tuscany, Italy|Istituto Nazionale Tumori - Fondazione Pascale, Naples, Italy|Barcelona Clinic Liver Cancer Group, Hospital Clinic i Provincial de Barcelona, Barcelona, Spain	https://ClinicalTrials.gov/show/NCT01078415
783	Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma	Unknown status	No Results Available	PHENYTOIN/SORAFENIB [VA Drug Interaction]|Liver Neoplasms|Carcinoma, Hepatocellular|Digestive System Neoplasms|Neoplasms by Site|Liver Diseases|Adenocarcinoma|Carcinoma|Neoplasms, Glandular and Epithelial|Neoplasms by Histologic Type|DOXORUBICIN/TRASTUZUMAB [VA Drug Interaction]|HBV	Procedure: Transarterial Chemoembolization (TACE)|Other: Sorafenib in combination with TACE	Shandong Cancer Hospital and Institute, Jinan, Shandong, China	https://ClinicalTrials.gov/show/NCT01556815
784	Sharing Decision-making Program for HCC Patients Treatment Decisions	Completed	Has Results	Hepatocellular Cancer	Behavioral: sharing decision-making program	Lo-Hsu medical foundation Lotung Poh-Ai hospital, Yilan, Taiwan	https://ClinicalTrials.gov/show/NCT03926039
785	Ph 2 Trial of ADI PEG 20 Plus Concurrent Transarterial Chemoembolization (TACE) Vs TACE Alone in Patients With Unresectable Hepatocellular Carcinoma	Completed	No Results Available	Unresectable Hepatocellular Carcinoma	Drug: ADI-PEG 20|Drug: Transarterial chemoembolization	CMUH, Taichung City, Taiwan|TP-VGH, Taipei City, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|CGMH-LK, Taoyuan, Taiwan	https://ClinicalTrials.gov/show/NCT02006030
786	Sorafenib vs.TransArterial Chemoembolization Plus RadioTherapy in Hepatocellular Carcinoma With Macrovascular Invasion	Completed	No Results Available	Hepatocellular Carcinoma	Radiation: TACE+External beam RT|Drug: Sorafenib	Asan Medical Center, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT01901692
787	Stereotactic Body Radiation Therapy (SBRT) Hepatocellular Carcinoma (COLD 2)	Completed	No Results Available	Hepatocellular Carcinoma	Radiation: Stereotactic Body Radiation	University Health Network, Princess Margaret Hospital, Toronto, Ontario, Canada	https://ClinicalTrials.gov/show/NCT00914355
788	Pharmacological Manipulation of Intrahepatic Arterial Blood Flow in HCC	Completed	No Results Available	Hepatocellular Carcinoma	Radiation: CT perfusion|Drug: Norepinephrine intra-arteriel/hepatic	Toronto General Hospital, Toronto, Ontario, Canada	https://ClinicalTrials.gov/show/NCT02472249
789	Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma	Completed	Has Results	Advanced Adult Hepatocellular Carcinoma	Drug: Everolimus|Drug: Pasireotide	Moffitt Cancer Center, Tampa, Florida, United States|University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States	https://ClinicalTrials.gov/show/NCT01488487
790	Treatment With IFN After Curative Resection of HCC in HCV-Related Cirrhosis	Completed	No Results Available	Hepatocellular Carcinoma|Hepatitis C Virus Infection|Liver Cirrhosis|Interferon Treatment|Hepatic Resection	Drug: Interferon alpha-2b	National Cancer Institute, Milan, Italy	https://ClinicalTrials.gov/show/NCT00273247
791	Bariatric Embolization of Arteries in Obese Patients With HCC to Allow Salvage Liver Transplantation	Suspended	No Results Available	Obesity|Weight Loss|Body Weight|Hepatocellular Carcinoma|HCC|Hepatitis C|Cirrhosis	Device: Embospheres Microspheres	Saint Louis University, Saint Louis, Missouri, United States	https://ClinicalTrials.gov/show/NCT02935478
792	Effectiveness of Positioning on Back Pain After TACE Among Patients With HCC	Completed	No Results Available	Liver Cancer|Transcatheter Arterial Chemoembolization	Other: Changing body position in bed	National Taiwan University Hospital, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT03784469
793	Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer	Recruiting	No Results Available	Advanced Adult Hepatocellular Carcinoma|Child-Pugh Class A|Stage III Hepatocellular Carcinoma|Stage IIIA Hepatocellular Carcinoma|Stage IIIB Hepatocellular Carcinoma|Stage IIIC Hepatocellular Carcinoma|Stage IV Hepatocellular Carcinoma|Stage IVA Hepatocellular Carcinoma|Stage IVB Hepatocellular Carcinoma	Other: Laboratory Biomarker Analysis|Biological: Pembrolizumab|Drug: Sorafenib Tosylate	Robert H Lurie Comprehensive Cancer Center, Chicago, Illinois, United States|Roswell Park Cancer Institute, Buffalo, New York, United States	https://ClinicalTrials.gov/show/NCT03211416
794	A Clinical Study of Precision TACE (P-TACE) With Surefire	Withdrawn	No Results Available	Unresectable Hepatocellular Carcinoma	Device: SureFire Infusion System|Device: Standard Endhole Microcatheter	University of Miami, Miami, Florida, United States	https://ClinicalTrials.gov/show/NCT03345225
795	Study of G-202 (Mipsagargin) as Second-Line Therapy Following Sorafenib in Hepatocellular Carcinoma	Completed	No Results Available	Advanced Adult Hepatocellular Carcinoma	Drug: G-202	Mary Crowley Cancer Research Center, Dallas, Texas, United States|Oncology Consultants, PA, Houston, Texas, United States|University of Texas Health Sciences Center at Houston, Memorial Hermann Cancer Center, Houston, Texas, United States|The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States	https://ClinicalTrials.gov/show/NCT01777594
796	Yttrium-90 (TARE-Y90) in Children, Adolescents, and Young Adults With Liver Tumors	Recruiting	No Results Available	Hepatoblastoma|Hepatocellular Carcinoma|Rhabdoid Tumor of Liver|Undifferentiated (Embryonal) Sarcoma of the Liver|Pediatric Liver Cancer|Liver Tumors	Behavioral: Quality of Life Assessment|Radiation: Transarterial Radioembolization	Nemours-AI duPont Hospital for Children, Wilmington, Delaware, United States|Nemours Children's Specialty Care, Jacksonville, Florida, United States	https://ClinicalTrials.gov/show/NCT04315883
797	A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma	Completed	Has Results	Carcinoma, Hepatocellular	Drug: Sorafenib (Nexavar, BAY43-9006)|Drug: Placebo	Phoenix, Arizona, United States|Tucson, Arizona, United States|Los Angeles, California, United States|Los Angeles, California, United States|Orange, California, United States|San Francisco, California, United States|Stanford, California, United States|Farmington, Connecticut, United States|New Haven, Connecticut, United States|Gainesville, Florida, United States|Miami, Florida, United States|Tampa, Florida, United States|Atlanta, Georgia, United States|Atlanta, Georgia, United States|Chicago, Illinois, United States|Chicago, Illinois, United States|Lexington, Kentucky, United States|Ann Arbor, Michigan, United States|Detroit, Michigan, United States|St. Louis, Missouri, United States|Omaha, Nebraska, United States|Manhasset, New York, United States|New York, New York, United States|New York, New York, United States|New York, New York, United States|New York, New York, United States|Canton, Ohio, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Houston, Texas, United States|Richmond, Virginia, United States|Seattle, Washington, United States|Seattle, Washington, United States|Mar del Plata, Buenos Aires, Argentina|Pilar, Buenos Aires, Argentina|Bueno Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|San Miguel de Tucumán, Tucuman, Argentina|San Miguel de Tucumán, Tucuman, Argentina|Camperdown, New South Wales, Australia|Randwick, New South Wales, Australia|Westmead, New South Wales, Australia|East Bentleigh, Victoria, Australia|Heidelberg, Victoria, Australia|Melbourne, Victoria, Australia|Brugge, Belgium|Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Gent, Belgium|Leuven, Belgium|Porto Alegre, Rio Grande do Sul, Brazil|Porto Alegre, Rio Grande do Sul, Brazil|Belo Horizonte, Brazil|Belo Horizonte, Brazil|Sao Paulo, Brazil|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Stara Zagora, Bulgaria|Varna, Bulgaria|Calgary, Alberta, Canada|Edmonton, Alberta, Canada|Vancouver, British Columbia, Canada|Winnipeg, Manitoba, Canada|London, Ontario, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Santiago de Chile, Santiago, Chile|Santiago de Chile, Chile|Santiago Región Metropolitana, Chile|Zagreb, Croatia|Bondy, France|Bordeaux, France|Clichy, France|Dijon, France|Lille Cedex, France|Marseille, France|Nantes, France|Paris, France|Rennes Cedex, France|Vandoeuvre-les-nancy, France|Freiburg, Baden-Württemberg, Germany|Tübingen, Baden-Württemberg, Germany|München, Bayern, Germany|München, Bayern, Germany|Regensburg, Bayern, Germany|Frankfurt, Hessen, Germany|Hannover, Niedersachsen, Germany|Bonn, Nordrhein-Westfalen, Germany|Düsseldorf, Nordrhein-Westfalen, Germany|Essen, Nordrhein-Westfalen, Germany|Mainz, Rheinland-Pfalz, Germany|Homburg, Saarland, Germany|Halle, Sachsen-Anhalt, Germany|Magdeburg, Sachsen-Anhalt, Germany|Berlin, Germany|Hamburg, Germany|Haidari, Attica, Greece|Athens, Greece|Ioannina, Greece|Thessaloniki, Greece|Thessaloniki, Greece|Thessaloniki, Greece|Haifa, Israel|Petach Tikva, Israel|Tel Aviv, Israel|Zrifin, Israel|Rozzano, Milano, Italy|Avellino, Italy|Bologna, Italy|Forlì, Italy|Milano, Italy|Milano, Italy|Padova, Italy|Palermo, Italy|Pavia, Italy|Pisa, Italy|Roma, Italy|México, Distrito Federal, Mexico|Monterrey, Mexico|México, D.F., Mexico|México, D.F., Mexico|Auckland, New Zealand|Wellington South, New Zealand|Comas Lima, Peru|Lima Cercado, Peru|Lima, Peru|Gdansk, Poland|Poznan, Poland|Warszawa, Poland|Warszawa, Poland|Timisoara, Timis, Romania|Craiova Dolj, Romania|Iasi, Romania|Ekaterinburg, Russian Federation|Ekaterinburg, Russian Federation|Kazan, Russian Federation|Kirov, Russian Federation|Krasnodar, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|Tolgliatti, Russian Federation|Badalona, Barcelona, Spain|Cruces/Barakaldo, Bilbao, Spain|Alicante, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Córdoba, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Pamplona, Spain|Valencia, Spain|St. Gallen, Sankt Gallen, Switzerland|Bern, Switzerland|Genève, Switzerland|Zürich, Switzerland|Bristol, Avon, United Kingdom|Oxford, Oxfordshire, United Kingdom|Glasgow, Stratchclyde, United Kingdom|London, United Kingdom|London, United Kingdom|Newcastle-upon-Tyne, United Kingdom	https://ClinicalTrials.gov/show/NCT00105443
798	A Safety and Efficacy Study of DENSPM in Patients With Liver Cancer Who Are Not Eligible for Surgical Care	Terminated	No Results Available	Carcinoma, Hepatocellular	Drug: DENSPM )	University of Illinois- Chicago, Chicago, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Partners Cancer Care, Boston, Massachusetts, United States|Vanderbilt University School of Medicine, Nashville, Tennessee, United States|Mary Crowley Medical Research Center, Dallas, Texas, United States|University of Virginia, Charlottesville, Virginia, United States|McGuire VA Medical Center, Richmond, Virginia, United States	https://ClinicalTrials.gov/show/NCT00081900
799	TACE vs TACE+SBRT for Unresectable Hepatocellular Cancer	Recruiting	No Results Available	Carcinoma, Hepatocellular	Radiation: SBRT|Procedure: TACE|Drug: Sorafenib	Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, Maharashtra, India|Advanced Centre of Treatment Research and Education In Cancer,Tata Memorial Centre, Navi Mumbai, Maharashtra, India	https://ClinicalTrials.gov/show/NCT02794337
800	Sorafenib Plus Toripalimab for Unresectable HCC With Portal Vein Tumor Thrombus	Unknown status	No Results Available	Unresectable Hepatocellular Cancer|Portal Vein Tumor Thrombus	Drug: sorafenib; toripalimab		https://ClinicalTrials.gov/show/NCT04069949
801	A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer	Completed	Has Results	Carcinoma, Hepatocellular	Biological: Ramucirumab|Drug: FOLFOX4	For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tainan, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taoyuan City, Taiwan	https://ClinicalTrials.gov/show/NCT02069041
802	Quantitative Real-time Ultrasound Elastography for Characterisation of Liver Tumors	Completed	No Results Available	Haemangioma|Metastases|Cholangiocellular Carcinoma|Hepatocellular Carcinoma|Focal Nodular Hyperplasia	Procedure: Shear wave elastography	University Hospital Dubrava, Zagreb, Croatia	https://ClinicalTrials.gov/show/NCT02156700
803	A Study of Capecitabine (Xeloda) and Peginterferon Alfa-2a (Pegasys) in Treatment-Naive Participants With Advanced Liver Cancer	Completed	No Results Available	Carcinoma, Hepatocellular	Drug: Capecitabine|Drug: Peginterferon alfa-2a	Beijing, China|Guangzhou, China|Kueishan, Taiwan|Tainan, Taiwan|Bangkok, Thailand|Bangkok, Thailand|Chiang Mai, Thailand|Songkhla, Thailand	https://ClinicalTrials.gov/show/NCT02576964
804	A Retrospective Review of Malignant Liver Tumors	Completed	No Results Available	Liver Cancer		The University of Oklahoma College of Medicine, Tulsa - Department of Surgery, Tulsa, Oklahoma, United States	https://ClinicalTrials.gov/show/NCT00728650
805	A Pilot Study of Trans Arterial Chemoembolization (TACE), Followed by Stereotactic Radiation Therapy (SBRT) for Patients With Hepatocellular Carcinoma	Completed	Has Results	Hepatocellular Carcinoma (HCC)	Combination Product: Stereotactic Body Radiation Therapy (SBRT)	University of Alabama at Birmingham, Birmingham, Alabama, United States	https://ClinicalTrials.gov/show/NCT01247298
806	Evaluation of Tumor Ablation Effects by Irreversible Electroporation for Patients With Malignant Liver Tumors	Completed	No Results Available	Malignant Liver Tumors	Procedure: irreversible electroporation|Device: nanoknife AngioDynamics US Ltd	National Taiwan University Hospital, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT02010801
807	Low Dose ICG for Biliary Tract and Tumor Imaging	Recruiting	No Results Available	Cholecystitis|Hepatocellular Carcinoma|Liver Metastases	Drug: Indocyanine green|Device: PINPOINT Endoscopic Fluorescence	University of Florida Health Shands, Gainesville, Florida, United States	https://ClinicalTrials.gov/show/NCT04942665
808	Chemoembolization With or Without Stereotactic Body Radiosurgery for Liver Cancer	Withdrawn	No Results Available	Carcinoma, Hepatocellular	Procedure: Transarterial Chemoembolization (TACE)|Radiation: TACE+Stereotactic Body Radiotherapy		https://ClinicalTrials.gov/show/NCT02304445
809	Comparison of Brivanib and Best Supportive Care (BSC) With Placebo and BSC for Treatment of Liver Cancer in Asian Patients Who Have Failed Sorafenib Treatment	Terminated	No Results Available	Carcinoma, Hepatocellular	Drug: Brivanib|Drug: Placebo	Local Institution, Hefei, Anhui, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Chongqing, Chongqing, China|Local Institution, Fu Zhou, Fujian, China|Local Institution, Fuzhou, Fujian, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Guanzhou, Guangdong, China|Local Institution, Ha Erbin, Heilongjiang, China|Local Institution, Hankou, Hubei, China|Local Institution, Wuhan, Hubei, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Suzhou, Jiangsu, China|Local Institution, Chang Chun, Jilin, China|Local Institution, Changchun, Jilin, China|Local Institution, Shenyang, Liaoning, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Chengdu, Sichuan, China|Local Institution, Tianjing, Tianjin, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Xi An, China|Local Institution, Xi'an, China|Local Institution, Gyeonggi-do, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Singapore, Singapore|Local Institution, Kaohsiung County, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taoyuan, Taiwan	https://ClinicalTrials.gov/show/NCT01108705
810	TheraSphere HUD For Treatment of Unresectable Hepatocellular Carcinoma (HCC)	Completed	No Results Available	Hepatocellular Carcinoma	Radiation: TheraSphere HUD	University of Louisville Hospital / Norton Hospital, Louisville, Kentucky, United States	https://ClinicalTrials.gov/show/NCT00683631
811	Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Cabozantinib|Drug: Sorafenib|Drug: Atezolizumab	Exelixis Clinical Site #208, Phoenix, Arizona, United States|Exelixis Clinical Site #159, Tucson, Arizona, United States|Exelixis Clinical Site #44, La Jolla, California, United States|Exelixis Clinical Site #112, Los Angeles, California, United States|Exelixis Clinical Site #200, Orange, California, United States|Exelixis Clinical Site #2, Rialto, California, United States|Exelixis Clinical Site #207, San Diego, California, United States|Exelixis Clinical Site #109, San Francisco, California, United States|Exelixis Clinical Site #54, San Francisco, California, United States|Exelixis Clinical Site #58, Washington, District of Columbia, United States|Exelixis Clinical Site #191, Miami, Florida, United States|Exelixis Clinical Site #4, Atlanta, Georgia, United States|Exelixis Clinical Site #195, Chicago, Illinois, United States|Exelixis Clinical Site #120, Chicago, Illinois, United States|Exelixis Clinical Site #6, Baltimore, Maryland, United States|Exelixis Clinical Site #7, Burlington, Massachusetts, United States|Exelixis Clinical Site #11, Kansas City, Missouri, United States|Exelixis Clinical Site #5, Kansas City, Missouri, United States|Exelixis Clinical Site #8, Saint Louis, Missouri, United States|Exelixis Clinical Site #1, Las Vegas, Nevada, United States|Exelixis Clinical Site #14, New Brunswick, New Jersey, United States|Exelixis Clinical Site #76, Albuquerque, New Mexico, United States|Exelixis Clinical Site #12, Chapel Hill, North Carolina, United States|Exelixis Clinical Site #39, Toledo, Ohio, United States|Exelixis Clinical Site #176, Portland, Oregon, United States|Exelixis Clinical Site #88, Philadelphia, Pennsylvania, United States|Exelixis Clinical Site #144, Charleston, South Carolina, United States|Exelixis Clinical Site #199, Dallas, Texas, United States|Exelixis Clinical Site #154, Houston, Texas, United States|Exelixis Clinical Site #19, Temple, Texas, United States|Exelixis Clinical Site #13, Seattle, Washington, United States|Exelixis Clinical Site #46, Seattle, Washington, United States|Exelixis Clinical Site #3, Spokane, Washington, United States|Exelixis Clinical Site #217, City of Buenos Aires, Buenos Aires, Argentina|Exelixis Clinical Site #213, City of Buenos Aires, Buenos Aires, Argentina|Exelixis Clinical Site #216, City of Buenos Aires, Buenos Aires, Argentina|Exelixis Clinical Site #219, Pilar, Buenos Aires, Argentina|Exelixis Clinical Site #220, Rosario, Santa Fe, Argentina|Exelixis Clinical Site #201, Rosario, Santa Fe, Argentina|Exelixis Clinical Site #78, Camperdown, New South Wales, Australia|Exelixis Clinical Site #165, Darlinghurst, New South Wales, Australia|Exelixis Clinical Site #171, Kingswood, New South Wales, Australia|Exelixis Clinical Site #126, Kogarah, New South Wales, Australia|Exelixis Clinical Site #155, Westmead, New South Wales, Australia|Exelixis Clinical Site #142, Greenslopes, Queensland, Australia|Exelixis Clinical Site #17, Kurralta Park, South Australia, Australia|Exelixis Clinical Site #107, Box Hill, Victoria, Australia|Exelixis Clinical Site #166, Heidelberg, Victoria, Australia|Exelixis Clinical Site #72, Parkville, Victoria, Australia|Exelixis Clinical Site #190, Nedlands, Western Australia, Australia|Exelixis Clinical Site #150, Klagenfurt, Kärnten, Austria|Exelixis Clinical Site #137, St. Pölten, Lower Austria, Austria|Exelixis Clinical Site #64, Linz, Oberosterreich, Austria|Exelixis Clinical Site #198, Graz, Steiermark, Austria|Exelixis Clinical Site #174, Wien, Austria|Exelixis Clinical Site #50, Brussels, California, Belgium|Exelixis Clinical Site #65, Brussels, Belgium|Exelixis Clinical Site #169, Edegem, Belgium|Exelixis Clinical Site #148, Gent, Belgium|Exelixis Clinical Site #57, Haine-Saint-Paul, Belgium|Exelixis Clinical Site #188, Leuven, Belgium|Exelixis Clinical Site #102, Liège, Belgium|Exelixis Clinical Site #184, Salvador, BA, Brazil|Exelixis Clinical Site #89, Belo Horizonte, MG, Brazil|Exelixis Clinical Site #98, Belo Horizonte, MG, Brazil|Exelixis Clinical Site #113, Curitiba, PR, Brazil|Exelixis Clinical Site #203, Porto Alegre, RS, Brazil|Exelixis Clinical Site #175, Barretos, SP, Brazil|Exelixis Clinical Site #121, Jaú, SP, Brazil|Exelixis Clinical Site #186, São Paulo, SP, Brazil|Exelixis Clinical Site #156, São Paulo, SP, Brazil|Exelixis Clinical Site #187, São Paulo, SP, Brazil|Exelixis Clinical Site #181, São Paulo, SP, Brazil|Exelixis Clinical Site #91, São Paulo, Brazil|Exelixis Clinical Site #71, Calgary, Alberta, Canada|Exelixis Clinical Site #205, Edmonton, Alberta, Canada|Exelixis Clinical Site #34, Winnipeg, Manitoba, Canada|Exelixis Clinical Site #222, Halifax, Nova Scotia, Canada|Exelixis Clinical Site #194, Hamilton, Ontario, Canada|Exelixis Clinical Site #212, Ottawa, Ontario, Canada|Exelixis Clinical Site #85, Montréal, Quebec, Canada|Exelixis Clinical Site #233, Hefei, Anhui, China|Exelixis Clinical Site #228, Fuzhou, Fujian, China|Exelixis Clinical Site #225, Xiamen, Fujian, China|Exelixis Clinical Site #242, Guangzhou, Guangdong, China|Exelixis Clinical Site #227, Harbin, Heilongjiang, China|Exelixis Clinical Site #230, Zhengzhou, Henan, China|Exelixis Clinical Site #231, Changsha, Hunan, China|Exelixis Clinical Site #224, Changsha, Hunan, China|Exelixis Site #241, Changsha, Hunan, China|Exelixis Clinical Site #185, Nanjing, Jiangsu, China|Exelixis Clinical Site #245, Nantong, Jiangsu, China|Exelixis Clinical Site #221, Nanchang, Jiangxi, China|Exelixis Clinical Site #238, Nanchang, Jiangxi, China|Exelixis Clinical Site #234, Jiangyin, Jiansu, China|Exelixis Clinical Site #246, Changchun, Jilin, China|Exelixis Clinical Site #229, Changchun, Jilin, China|Exelixis Clinical Site #236, Shenyang, Liaoning, China|Exelixis Clinical Site #226, Linyi, Shandong, China|Exelixis Clinical Site #235, Chengdu, Sichuan, China|Exelixis Clinical Site #218, Hangzhou, Zhejiang, China|Exelixis Clinical Site #223, Hangzhou, Zhejiang, China|Exelixis Site #239, Beijing, China|Exelixis Clinical Site #237, Beijing, China|Exelixis Site #240, Shanghai, China|Exelixis Clinical Site #232, Shanghai, China|Exelixis Clinical Site #130, Montería, Cordoba, Colombia|Exelixis Clinical Site #18, Hradec Králové, Czechia|Exelixis Clinical Site #37, Olomouc, Czechia|Exelixis Clinical Site #10, Praha 4, Czechia|Exelixis Clinical Site #38, Praha 5, Czechia|Exelixis Clinical Site #43, Amiens, France|Exelixis Clinical Site #27, Besancon, France|Exelixis Clinical Site #56, Bondy Cedex, France|Exelixis Clinical Site #29, Caen Cedex 09, France|Exelixis Clinical Site #48, Clichy, France|Exelixis Clinical Site #23, Grenoble, France|Exelixis Clinical Site #55, Lille Cedex, France|Exelixis Clinical Site #16, Lyon Cedex 4, France|Exelixis Clinical Site #31, Montbeliard, France|Exelixis Clinical Site #49, Montpellier, France|Exelixis Clinical Site #47, Nantes, France|Exelixis Clinical Site #51, Nice, France|Exelixis Clinical Site #20, Pessac, France|Exelixis Clinical Site #32, Vandœuvre-lès-Nancy, France|Exelixis Clinical Site #69, Batumi, Georgia|Exelixis Clinical Site #66, Tbilisi, Georgia|Exelixis Clinical Site #68, Tbilisi, Georgia|Exelixis Clinical Site #67, Tbilisi, Georgia|Exelixis Clinical Site #70, Tbilisi, Georgia|Exelixis Clinical Site #244, Frankfurt, Hessen, Germany|Exelixis Clinical Site #210, Kassel, Hessen, Germany|Exelixis Clinical Site #214, Berlin, Germany|Exelixis Clinical Site #215, Hamburg, Germany|Exelixis Clinical Site #146, Hong Kong, Hong Kong|Exelixis Clinical Site #42, Hong Kong, Hong Kong|Exelixis Clinical Site #9, Hong Kong, Hong Kong|Exelixis Clinical Site #140, Budapest, Hungary|Exelixis Clinical Site #25, Debrecen, Hungary|Exelixis Clinical Site #26, Szeged, Hungary|Exelixis Clinical Site #170, Dublin, Ireland|Exelixis Clinical Site #30, Jerusalem, Israel|Exelixis Clinical Site #33, Petah Tikva, Israel|Exelixis Clinical Site #40, Ramat-Gan, Israel|Exelixis Clinical Site #35, Rehovot, Israel|Exelixis Clinical Site #163, Tricase, Lecce, Italy|Exelixis Clinical Site #53, Rozzano, Milano, Italy|Exelixis Clinical Site #158, Bologna, Italy|Exelixis Clinical Site #152, Brescia, Italy|Exelixis Clinical Site #147, Milan, Italy|Exelixis Clinical Site #149, Napoli, Italy|Exelixis Clinical Site #131, Novara, Italy|Exelixis Clinical Site #167, Roma, Italy|Exelixis Clinical Site #177, Torino, Italy|Exelixis Clinical Site #182, Torino, Italy|Exelixis Clinical Site #243, Udine, Italy|Exelixis Clinical Site #157, Goyang-si, Gyeonggi-do, Korea, Republic of|Exelixis Clinical Site #127, Suwon, Gyeonggi-do, Korea, Republic of|Exelixis Clinical Site #77, Busan, Korea, Republic of|Exelixis Clinical Site #86, Busan, Korea, Republic of|Exelixis Clinical Site #114, Busan, Korea, Republic of|Exelixis Clinical Site #75, Incheon, Korea, Republic of|Exelixis Clinical Site #104, Seoul, Korea, Republic of|Exelixis Clinical Site #105, Seoul, Korea, Republic of|Exelixis Clinical Site #99, Seoul, Korea, Republic of|Exelixis Clinical Site #79, Seoul, Korea, Republic of|Exelixis Clinical Site #93, Seoul, Korea, Republic of|Exelixis Clinical Site #141, Tuxtla Gutiérrez, Chiapas, Mexico|Exelixis Clinical Site #135, León, Guanajuato, Mexico|Exelixis Clinical Site #132, Monterrey, Nuevo Leon, Mexico|Exelixis Clinical Site #133, Ciudad De México, Mexico|Exelixis Clinical Site #160, Mexico City, Mexico|Exelixis Clinical Site #134, San Luis Potosí, Mexico|Exelixis Clinical Site #153, Veracruz, Mexico|Exelixis Clinical Site #92, Maastricht, Limburg, Netherlands|Exelixis Clinical Site #52, Amsterdam, Noord-Holland, Netherlands|Exelixis Clinical Site #84, Rotterdam, Zuid-Holland, Netherlands|Exelixis Clinical Site #36, Utrecht, Netherlands|Exelixis Clinical Site #60, Grafton, Auckland, New Zealand|Exelixis Clinical Site #62, Newton, Wellington, New Zealand|Exelixis Clinical Site #118, Cebu City, Philippines|Exelixis Clinical Site #117, Pasig City, Philippines|Exelixis Clinical Site #136, Quezon City, Philippines|Exelixis Clinical Site #41, Warszawa, Mazowieckie, Poland|Exelixis Clinical Site #24, Gdansk, Pomorskie, Poland|Exelixis Clinical Site #15, Mysłowice, Slaskie, Poland|Exelixis Clinical Site #204, Cluj-Napoca, Cluj, Romania|Exelixis Clinical Site #211, Cluj-Napoca, Cluj, Romania|Exelixis Clinical Site #202, Cluj-Napoca, Cluj, Romania|Exelixis Clinical Site #206, Bucuresti, Romania|Exelixis Clinical Site #209, Iaşi, Romania|Exelixis Clinical Site #74, Kislino, Kursk Region, Russian Federation|Exelixis Clinical Site #81, Kaluga, Russian Federation|Exelixis Clinical Site #95, Krasnodar, Russian Federation|Exelixis Clinical Site #108, Moscow, Russian Federation|Exelixis Clinical Site #101, Murmansk, Russian Federation|Exelixis Clinical Site #80, Nizhny Novgorod, Russian Federation|Exelixis Clinical Site #111, Saint Petersburg, Russian Federation|Exelixis Clinical Site #90, Saint-Petersburg, Russian Federation|Exelixis Clinical Site #73, Sochi, Russian Federation|Exelixis Clinical Site #106, Singapore, Singapore|Exelixis Clinical Site #97, Singapore, Singapore|Exelixis Clinical Site #116, Singapore, Singapore|Exelixis Clinical Site #28, Santander, Cantabria, Spain|Exelixis Clinical Site #21, Majadahonda, Madrid, Spain|Exelixis Clinical Site #22, Majadahonda, Madrid, Spain|Exelixis Clinical Site #59, Pamplona, Navarra, Spain|Exelixis Clinical Site #103, Barcelona, Spain|Exelixis Clinical Site #164, Madrid, Spain|Exelixis Clinical Site #63, Madrid, Spain|Exelixis Clinical Site #168, Valencia, Spain|Exelixis Clinical Site #45, Zaragoza, Spain|Exelixis Clinical Site #115, Basel, Switzerland|Exelixis Clinical Site #172, Bern, Switzerland|Exelixis Clinical Site #110, Saint Gallen, Switzerland|Exelixis Clinical Site #61, Zurich, Switzerland|Exelixis Clinical Site #119, Changhua, Taiwan|Exelixis Clinical Site #162, Kaohsiung, Taiwan|Exelixis Clinical Site #161, Taichung, Taiwan|Exelixis Clinical Site #197, Tainan City, Taiwan|Exelixis Clinical Site #145, Tainan, Taiwan|Exelixis Clinical Site #82, Taipei, Taiwan|Exelixis Clinical Site #128, Taipei, Taiwan|Exelixisi Clinical Site #100, Taipei, Taiwan|Exelixis Clinical Site #94, Taoyuan, Taiwan|Exelixis Clinical Site #96, Pathum Wan, Bangkok, Thailand|Exelixis Clinical Site #183, Muang, Khon Kaen, Thailand|Exelixis Clinical Site #139, Hat Yai, Songkla, Thailand|Exelixis Clinical Site #143, Chiang Mai, Thailand|Exelixis Clinical Site #189, Istanbul, Instanbul, Turkey|Exelixis Clinical Site #193, Ankara, Turkey|Exelixis Clinical Site #178, Ankara, Turkey|Exelixis Clinical Site #173, Edirne, Turkey|Exelixis Clinical Site #179, Istanbul, Turkey|Exelixis Clinical Site #180, Malatya, Turkey|Exelixis Clinical Site #125, Chernivtsi, Ukraine|Exelixis Clinical Site #122, Dnipro, Ukraine|Exelixis Clinical Site #123, Kharkiv, Ukraine|Exelixis Clinical Site #124, Odesa, Ukraine|Exelixis Clinical Site #138, Uzhhorod, Ukraine|Exelixis Clinical Site #83, Bristol, England, United Kingdom|Exelixis Clinical Site #87, Cambridge, England, United Kingdom|Exelixis Clinical Site #151, London, England, United Kingdom|Exelixis Clinical Site #129, London, England, United Kingdom|Exelixis Clinical Site #192, Manchester, England, United Kingdom|Exelixis Clinical Site #196, Belfast, Northern Ireland, United Kingdom	https://ClinicalTrials.gov/show/NCT03755791
812	HAI Via Interventionally Implanted Port Catheter Systems	Unknown status	No Results Available	Colorectal Cancer|Liver Neoplasms|Hepatocellular Carcinoma|Gallbladder Cancer|Bile Duct Cancer	Device: interventionally implanted hepatic arterial port catheter	Charité Centrum Tumormedizin, Medizinische Klinik für Hämatologie und Onkologie, CVK, Berlin, Germany|Klinik für Radiologie und Nuklearmedizin, Otto-von-Guericke Universität Magdeburg, Magdeburg, Germany	https://ClinicalTrials.gov/show/NCT00356161
813	E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular Carcinoma	Completed	Has Results	Hepatocellular Carcinoma	Drug: Sorafenib	Tucson, Arizona, United States|Fort Myers, Florida, United States|Saint Petersburg, Florida, United States|Chapel Hill, North Carolina, United States|Cincinnati, Ohio, United States|Toledo, Ohio, United States|Nashville, Tennessee, United States|Brussels, Belgium|Bruxelles, Belgium|Leuven, Belgium|Rozzano, Milano, Italy|Modena, Italy|Pavia, Italy|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Dnipropetrovsk, Ukraine|Donetsk, Ukraine|Kharkiv, Ukraine|Lviv, Ukraine|London, Greater London, United Kingdom|Manchester, Greater Manchester, United Kingdom|Glasgow, Strathclyde, United Kingdom	https://ClinicalTrials.gov/show/NCT01271504
814	Oxaliplatin and Capecitabine on Top of Sorafenib Versus Sorafenib Alone in Advanced Hepatocellular Carcinoma Patients	Withdrawn	No Results Available	Hepatic Neoplasm Malignant	Drug: oxaliplatin (SR96669)|Drug: capecitabine|Drug: sorafenib		https://ClinicalTrials.gov/show/NCT01245582
815	Study of Axitinib in Patients With Unresectable Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Drug: Axitinib (AG-013736)	Foothills Hospital, Alberta Health Services, Calgary, Alberta, Canada|University Health Network, Princess Margaret Hospital, Toronto, Ontario, Canada	https://ClinicalTrials.gov/show/NCT01334112
816	A Study to Estimate Safety and Efficacy of Sorafenib (BAY43-9006) in the Treatment of Hepatocellular Carcinoma	Completed	Has Results	Carcinoma, Hepatocellular	Drug: Sorafenib (Nexavar, BAY43-9006)	Los Angeles, California, United States|New York, New York, United States|Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Gent, Belgium|Leuven, Belgium|Lille Cedex, France|Marseille, France|Paris, France|Rennes Cedex, France|Saint Herblain, France|Haifa, Israel|Jerusalem, Israel|Petach Tikva, Israel|Rehovot, Israel|Tel Aviv, Israel|Tel Hashomer, Israel|Rozzano, Milano, Italy|Forlì, Italy|Milano, Italy|Pisa, Italy|Verona, Italy	https://ClinicalTrials.gov/show/NCT00044512
817	Microwave Ablation for the Treatment of Malignant Liver Tumors Closed to Intrahepatic Vessels	Withdrawn	No Results Available	Liver Cancer	Device: Microwave ablation		https://ClinicalTrials.gov/show/NCT03063840
818	A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma	Active, not recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Durvalumab|Drug: Bevacizumab|Other: Placebo|Procedure: Transarterial Chemoembolization (TACE)	Research Site, Mobile, Alabama, United States|Research Site, Phoenix, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Costa Mesa, California, United States|Research Site, La Jolla, California, United States|Research Site, Orange, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Washington, District of Columbia, United States|Research Site, Jacksonville, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Honolulu, Hawaii, United States|Research Site, Chicago, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Westwood, Kansas, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Boston, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, Rochester, Minnesota, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Omaha, Nebraska, United States|Research Site, Stony Brook, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Durham, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Cleveland, Ohio, United States|Research Site, Portland, Oregon, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Sioux Falls, South Dakota, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Memphis, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Morgantown, West Virginia, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Benowa, Australia|Research Site, Box Hill, Australia|Research Site, Camperdown, Australia|Research Site, Clayton, Australia|Research Site, Herston, Australia|Research Site, Liverpool, Australia|Research Site, Melbourne, Australia|Research Site, Barretos, Brazil|Research Site, Florianópolis, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Santa Maria, Brazil|Research Site, Sao Paulo, Brazil|Research Site, São José do Rio Preto, Brazil|Research Site, Vitória, Brazil|Research Site, Ottawa, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Changchun, China|Research Site, Changsha, China|Research Site, Chengdu, China|Research Site, Fuzhou, China|Research Site, Fuzhou, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Hangzhou, China|Research Site, Harbin, China|Research Site, Hefei, China|Research Site, Nanchang, China|Research Site, Nanjing, China|Research Site, Nanjing, China|Research Site, Nantong, China|Research Site, Neijiang, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shenyang, China|Research Site, Shenzhen, China|Research Site, Tianjin, China|Research Site, Wuhan, China|Research Site, Wuhan, China|Research Site, Xi'an, China|Research Site, Zhengzhou, China|Research Site, Zhuhai, China|Research Site, Bobigny, France|Research Site, Clichy, France|Research Site, Grenoble cedex 9, France|Research Site, Montpellier CEDEX 5, France|Research Site, Nice Cedex 3, France|Research Site, Paris Cedex 13, France|Research Site, Pessac, France|Research Site, Toulouse Cedex 9, France|Research Site, Vandoeuvre Les Nancy, France|Research Site, Hong Kong, Hong Kong|Research Site, Shatin, Hong Kong|Research Site, Bangalore, India|Research Site, Bengaluru, India|Research Site, Hyderabad, India|Research Site, Kolkata, India|Research Site, Kolkata, India|Research Site, Madurai, India|Research Site, Mumbai, India|Research Site, Nasik, India|Research Site, Pune, India|Research Site, Surat, India|Research Site, Vijayawada, India|Research Site, Vishakhapatnam, India|Research Site, Arezzo, Italy|Research Site, Brescia, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Pisa, Italy|Research Site, Bunkyo-ku, Japan|Research Site, Chiba-shi, Japan|Research Site, Chuo-ku, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Hiroshima-shi, Japan|Research Site, Kurume-shi, Japan|Research Site, Musashino-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Okayama, Japan|Research Site, Osaka-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osakasayama-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Shiwa-gun, Japan|Research Site, Tsu-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Busan, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Goyang-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Alc. Cuauhtémoc, Mexico|Research Site, Culiacan, Mexico|Research Site, Guadalajara, Mexico|Research Site, Mexico, Mexico|Research Site, Monterrey, Mexico|Research Site, Monterrey, Mexico|Research Site, Mérida, Mexico|Research Site, Tuxtla Gutierrez, Mexico|Research Site, Barnaul, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Obninsk, Russian Federation|Research Site, Sankt-Peterburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Bukit Merah, Singapore|Research Site, Córdoba, Spain|Research Site, Madrid, Spain|Research Site, Pamplona, Spain|Research Site, San Sebastián(Guipuzcoa), Spain|Research Site, Kaohsiung, Taiwan|Research Site, Liou Ying Township, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan City, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan City, Taiwan|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Chiang Mai, Thailand|Research Site, Hat Yai, Thailand|Research Site, Khon Kaen, Thailand|Research Site, Phisanulok, Thailand|Research Site, Hanoi, Vietnam|Research Site, Hanoi, Vietnam|Research Site, Ho Chi Minh City, Vietnam|Research Site, Ho Chi Minh, Vietnam	https://ClinicalTrials.gov/show/NCT03778957
819	XIAP Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)	Completed	No Results Available	Advanced Hepatocellular Carcinoma	Drug: AEG35156 antisense IV infusion|Drug: Sorafenib	Tuen Mun Hospital, Tuen Mun, New Territories, Hong Kong, China|Queen Elizabeth Hospital, Hong Kong, China|Queen Mary Hospital, Hong Kong, China	https://ClinicalTrials.gov/show/NCT00882869
820	Stereotactic Body Radiotherapy and Surgery for Early-stage Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma|Hepatectomy|Stereotactic Body Radiotherapy	Procedure: laparoscopic hepatectomy (surgery)|Radiation: stereotactic body radiotherapy	the second affiliated hospital of Zhejiang University, Hangzhou, Zhejiang, China	https://ClinicalTrials.gov/show/NCT03609151
821	Role of Positron Emission Tomography in the Evaluation of Response to Sorafenib in Advanced Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Other: Positron emission tomography with fludeoxyglucose F 18	Miguel Servet University Hospital, Zaragoza, Aragon, Spain	https://ClinicalTrials.gov/show/NCT01157013
822	A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line Treatment	Completed	Has Results	Hepatocellular Carcinoma	Drug: dovitinib|Drug: sorafenib	Novartis Investigative Site, Nanjing, Jiangsu, China|Novartis Investigative Site, Xi'an, Shanxi, China|Novartis Investigative Site, Hangzhou, Zhejiang, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, Shatin, New Territories, Hong Kong|Novartis Investigative Site, Kashiwa, Chiba, Japan|Novartis Investigative Site, Yokohama-city, Kanagawa, Japan|Novartis Investigative Site, OsakaSayama, Osaka, Japan|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Taipei, Taiwan, ROC, Taiwan|Novartis Investigative Site, Kuei-Shan Chiang, Taoyuan/ Taiwan ROC, Taiwan|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Chiang Mai, Thailand|Novartis Investigative Site, Khon Kaen, Thailand|Novartis Investigative Site, Songkla, Thailand	https://ClinicalTrials.gov/show/NCT01232296
823	Stereotactic Body Radiotherapy and Microwave Ablation for Recurrent Small Hepatocellular Carcinoma	Unknown status	No Results Available	Recurrent Hepatocellular Carcinoma|Microwave Ablation|Stereotactic Body Radiotherapy	Device: microwave ablation (MWA)|Radiation: stereotactic body radiotherapy (SBRT)	the second affiliated hospital of Zhejiang University, Hangzhou, Zhejiang, China	https://ClinicalTrials.gov/show/NCT03609268
824	Arsenic Trioxide in Treating Patients With Metastatic Liver Cancer That Cannot Be Removed by Surgery	Completed	No Results Available	Liver Cancer	Drug: arsenic trioxide	UPMC Cancer Centers, Pittsburgh, Pennsylvania, United States	https://ClinicalTrials.gov/show/NCT00128596
825	Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using TACE With Antiangiogenesis	Unknown status	No Results Available	Hepatocellular Carcinoma	Procedure: Transcatheter Arterial Chemoembolization	Department of Interventional Radiology, Zhongda Hospital, Southeast University, Nanjing, Jiangsu, China	https://ClinicalTrials.gov/show/NCT00518557
826	Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients	Not yet recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Lenvatinib|Procedure: Transcatheter Arterial Chemoembolization	Houston Methodist Research Institute, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT05171335
827	Chemotherapy or Not, Following Complete Treatment of Hepatic Cancer in Cirrhotic Patients	Terminated	No Results Available	Liver Neoplasms|Liver Cirrhosis|Carcinoma, Hepatocellular|Recurrence|Neoplasm Recurrence, Local	Drug: Oxaliplatin, gemcitabine, cisplatin, lipiodol	Urc La Pitie Salpetriere,, Poissy, France	https://ClinicalTrials.gov/show/NCT00470340
828	TACE Plus Recombinant Human Adenovirus for Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: Recombinant Human Adenovirus Type 5 Injection|Procedure: Transartery Chemoembolization	Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT01869088
829	Postoperative Adjuvant Therapy With Recombinant Interferon-Alpha Following Curative Resection of HCC	Completed	No Results Available	Hepatocellular Carcinoma	Drug: Interferon alpha-2b		https://ClinicalTrials.gov/show/NCT00234182
830	Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment	Active, not recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Durvalumab|Drug: Bevacizumab|Other: Placebo	Research Site, Birmingham, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Phoenix, Arizona, United States|Research Site, Costa Mesa, California, United States|Research Site, La Jolla, California, United States|Research Site, Long Beach, California, United States|Research Site, Orange, California, United States|Research Site, Sacramento, California, United States|Research Site, Washington, District of Columbia, United States|Research Site, Miami, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Honolulu, Hawaii, United States|Research Site, Chicago, Illinois, United States|Research Site, Westwood, Kansas, United States|Research Site, Louisville, Kentucky, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Detroit, Michigan, United States|Research Site, Grand Rapids, Michigan, United States|Research Site, Rochester, Minnesota, United States|Research Site, Omaha, Nebraska, United States|Research Site, New Brunswick, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, New York, New York, United States|Research Site, Stony Brook, New York, United States|Research Site, Durham, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Cleveland, Ohio, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Spartanburg, South Carolina, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Memphis, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Madison, Wisconsin, United States|Research Site, Kogarah, Australia|Research Site, Melbourne, Australia|Research Site, Nedlands, Australia|Research Site, Westmead, Australia|Research Site, Innsbruck, Austria|Research Site, Linz, Austria|Research Site, St. Pölten, Austria|Research Site, Florianópolis, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Santa Maria, Brazil|Research Site, Santo Andre, Brazil|Research Site, São José do Rio Preto, Brazil|Research Site, Vitória, Brazil|Research Site, Hamilton, Ontario, Canada|Research Site, Kingston, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Quebec, Canada|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Bengbu, China|Research Site, Changchun, China|Research Site, Changsha, China|Research Site, Chengdu, China|Research Site, Fuzhou, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Hangzhou, China|Research Site, Hangzhou, China|Research Site, Hangzhou, China|Research Site, Harbin, China|Research Site, Hefei, China|Research Site, Hohhot, China|Research Site, Nanjing, China|Research Site, Nanjing, China|Research Site, Ningbo, China|Research Site, Shanghai, China|Research Site, Tianjin, China|Research Site, Urumqi, China|Research Site, Wuhan, China|Research Site, Xi'an, China|Research Site, Zhengzhou, China|Research Site, Alexandria, Egypt|Research Site, Assiut, Egypt|Research Site, Cairo, Egypt|Research Site, Cairo, Egypt|Research Site, Cairo, Egypt|Research Site, Dakahlia, Egypt|Research Site, New Cairo, Egypt|Research Site, Shebeen El Kom, Egypt|Research Site, Amiens Cedex 1, France|Research Site, ANGERS Cedex 9, France|Research Site, Besançon, France|Research Site, Clichy, France|Research Site, Dijon Cedex, France|Research Site, Nantes, France|Research Site, Nice, France|Research Site, PARIS Cedex 12, France|Research Site, Pessac, France|Research Site, Toulouse Cedex 9, France|Research Site, TOURS Cedex 9, France|Research Site, Berlin, Germany|Research Site, Bonn, Germany|Research Site, Chemnitz, Germany|Research Site, Freiburg, Germany|Research Site, Heidelberg, Germany|Research Site, Köln, Germany|Research Site, Leipzig, Germany|Research Site, Lübeck, Germany|Research Site, München, Germany|Research Site, Tuebingen, Germany|Research Site, Hong Kong, Hong Kong|Research Site, Hong Kong, Hong Kong|Research Site, HongKong, Hong Kong|Research Site, Kwai Chung, Hong Kong|Research Site, Shatin, Hong Kong|Research Site, Bangalore, India|Research Site, Bangalore, India|Research Site, Hyderabad, India|Research Site, Kolkata, India|Research Site, Mumbai, India|Research Site, New Delhi, India|Research Site, New Delhi, India|Research Site, New Delhi, India|Research Site, Bologna, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Roma, Italy|Research Site, Tricase, Lecce, Italy|Research Site, Verona, Italy|Research Site, Bunkyo-ku, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Gifu-shi, Japan|Research Site, Hiroshima-shi, Japan|Research Site, Koto-ku, Japan|Research Site, Kumamoto-shi, Japan|Research Site, Kurume-shi, Japan|Research Site, Kyoto-shi, Japan|Research Site, Kyoto-shi, Japan|Research Site, Matsuyama-shi, Japan|Research Site, Mitaka-shi, Japan|Research Site, Musashino-shi, Japan|Research Site, Nagasaki-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osakasayama-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sendai-shi, Japan|Research Site, Shinagawa-ku, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Shiwa-gun, Japan|Research Site, Takasaki-shi, Japan|Research Site, Tsu-shi, Japan|Research Site, Wakayama-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Busan, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, San Isidro, Peru|Research Site, Manila, Philippines|Research Site, Muntinlupa City, Philippines|Research Site, Pasig City, Philippines|Research Site, Bydgoszcz, Poland|Research Site, Gdańsk, Poland|Research Site, Poznan, Poland|Research Site, Warszawa, Poland|Research Site, Ponce, Puerto Rico|Research Site, Barnaul, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Obninsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Singapore, Singapore|Research Site, Singapore, Singapore|Research Site, Singapore, Singapore|Research Site, Changhua, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan City, Taiwan|Research Site, Yunlin, Taiwan|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Chiang Mai, Thailand|Research Site, Hat Yai, Thailand|Research Site, Khon Kaen, Thailand|Research Site, Pathumthani, Thailand|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Malatya, Turkey|Research Site, Hanoi, Vietnam|Research Site, Hanoi, Vietnam|Research Site, Ho Chi Minh city, Vietnam|Research Site, Ho Chi Minh, Vietnam|Research Site, Hochiminh, Vietnam	https://ClinicalTrials.gov/show/NCT03847428
831	Biomarkers in Stored Tumor Samples From Younger Patients With Liver Cancer	Withdrawn	No Results Available	Liver Cancer	Genetic: comparative genomic hybridization|Genetic: molecular genetic technique|Genetic: mutation analysis|Genetic: polymerase chain reaction|Genetic: proteomic profiling|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis|Other: mass spectrometry|Other: medical chart review		https://ClinicalTrials.gov/show/NCT00899002
832	Sleep Apnoea Syndrome and Hepatocellular Carcinoma	Withdrawn	No Results Available	Sleep Apnea, Obstructive|Hepatocellular Carcinoma|Non Alcoholic Steato Hepatitis	Diagnostic Test: Nocturnal oximetry	Minovés-Kotzki, La Tronche, Rhones-Alpes, France	https://ClinicalTrials.gov/show/NCT04190498
833	Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC	Active, not recruiting	No Results Available	Carcinoma, Hepatocellular	Drug: Regorafenib(Stivarga, BAY73-4506)|Drug: Pembrolizumab	USC Norris Hospital and Clinics, Los Angeles, California, United States|University of Florida Health Sciences Center, Gainesville, Florida, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Mount Sinai Medical Center, New York, New York, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Universitätsklinikum Köln, Köln, Nordrhein-Westfalen, Germany|Universitätsmedizin der Johannes Gutenberg Universität Mainz, Mainz, Rheinland-Pfalz, Germany	https://ClinicalTrials.gov/show/NCT03347292
834	Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) Therapy	Unknown status	No Results Available	Hepatocellular Carcinoma	Procedure: Transcatheter arterial chemoembolization (TACE)|Drug: Telbivudine	Liver cancer institute, Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT01102335
835	PROtocol of Metabolic and Cryptogenic livEr Disease regisTry for intEgration of Omic Studies	Recruiting	No Results Available	NAFLD - Nonalcoholic Fatty Liver Disease|Diabetes|Obesity|Metabolic Syndrome|Cirrhosis|Liver Cancer|NASH - Nonalcoholic Steatohepatitis|HCC - Hepatocellular Carcinoma|Fatty Liver		Catholic University of Rome, Fondazione Policlinico Gemelli IRCCS, Roma, Rome/lazio/italy, Italy	https://ClinicalTrials.gov/show/NCT04371042
836	A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma	Active, not recruiting	No Results Available	Hepatocellular Carcinoma (HCC)	Drug: Fisogatinib (BLU-554)	Inland Empire Liver Foundation, Rialto, California, United States|University of Miami - Sylvester Comprehensive Cancer Center, Miami, Florida, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Ochsner Cancer Institute, New Orleans, Louisiana, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Mount Sinai Medical Center, New York, New York, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Zhejiang Cancer Hospital, Hangzhou, Gongshu District, China|Nanfang Hospital, Guangzhou, Guangdong, China|Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China|Henan Cancer Hospital, Zhengzhou, Henan, China|Hunan Cancer Hospital, Radioactive Interventional Department, Changsha, Hunan, China|The Chinese People's Liberation Army 81 Hospital, Nanjing, Jiangsu, China|Nantong Tumor Hospital, Nantong, Jiangsu, China|Jilin Cancer Hospital, Changchun, Jilin, China|Jilin University the First Affiliated Hospital, Changchun, Jilin, China|Fudan University Zhongshan Hospital, Xuhui, Shanghai City, China|West China Hospital, Sichuan University, Chengdu, Sichuan, China|Tianjin Medical University Cancer Institute & Hospital, Hepatobiliary Oncology Department, Tianjin, West Lake District, China|Fudan University Shanghai Cancer Center, Shanghai, Xuhui District, China|The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China|Hospital Beaujon, Clichy, France|Institut Gustave Roussy, Villejuif, France|Johannes Gutenberg University Mainz - University Medical Center, Mainz, Rhineland-Palatine, Germany|University of Frankfurt, Frankfurt, Germany|Prince of Wales Hospital, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|IRCCS Foundation - National Institute of Tumors, Milan, Italy|National Cancer Center, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|National Cancer Centre, Singapore, Singapore|Vall d'Hebron Institute of Oncology, Barcelona, Spain|Inselspital Bern, Bern, Switzerland|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|University of Liverpool - Clatterbridge Cancer Centre, Bebington, United Kingdom|Royal Free Hospital, London, United Kingdom|Guy's Hospital, London, United Kingdom|University College London, London, United Kingdom	https://ClinicalTrials.gov/show/NCT02508467
837	Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer	Recruiting	No Results Available	Stage III Hepatocellular Carcinoma AJCC v8|Stage III Intrahepatic Cholangiocarcinoma AJCC v8|Stage IIIA Hepatocellular Carcinoma AJCC v8|Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8|Stage IIIB Hepatocellular Carcinoma AJCC v8|Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8|Stage IV Hepatocellular Carcinoma AJCC v8|Stage IV Intrahepatic Cholangiocarcinoma AJCC v8|Stage IVA Hepatocellular Carcinoma AJCC v8|Stage IVB Hepatocellular Carcinoma AJCC v8|Unresectable Hepatocellular Carcinoma|Unresectable Intrahepatic Cholangiocarcinoma	Radiation: External Beam Radiation Therapy|Biological: Pneumococcal 13-valent Conjugate Vaccine|Biological: Therapeutic Autologous Dendritic Cells	Mayo Clinic in Rochester, Rochester, Minnesota, United States	https://ClinicalTrials.gov/show/NCT03942328
838	LC Bead LUMI Radio-Opaque Embolic Beads to Detect and Characterize the Vascularity of Hepatic Tumors During Treatment With Transarterial Embolization (TAE) Alone or Combined With Thermal Ablation	Enrolling by invitation	No Results Available	Hepatic Cancer|Liver Neoplasms|Hepatocellular Cancer|Liver Cancer	Procedure: TAE|Radiation: RFA|Device: LC Bead LUMI	National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States	https://ClinicalTrials.gov/show/NCT02649868
839	Sulfur Colloid SPECT/CT in Measuring Liver Function in Patients With Primary or Metastatic Liver Cancer Undergoing Radiation Therapy or Surgery	Recruiting	No Results Available	Hepatocellular Carcinoma|Intrahepatic Cholangiocarcinoma|Stage IV Liver Cancer|Stage IVA Liver Cancer|Stage IVB Liver Cancer|Vascular Thrombosis	Procedure: Computed Tomography|Procedure: Single Photon Emission Computed Tomography|Drug: Technetium Tc-99m Sulfur Colloid	Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States|ProCure Proton Therapy Center-Seattle, Seattle, Washington, United States	https://ClinicalTrials.gov/show/NCT02881554
840	The Role of Low Molecular Weight Heparins in Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Drug: LMWH|Procedure: TACE	Eastern Hepatobiliary Surgery Hospital, ShangHai, Shanghai, China	https://ClinicalTrials.gov/show/NCT00827554
841	Magnetic Resonance Elastography (MRE) as a Predictor of HCC Recurrence After Radiofrequency Ablation (RFA)	Active, not recruiting	No Results Available	Hepatic Fibrosis|Hepatocellular Carcinoma	Procedure: Magnetic resonance elastography	Seoul National University Hospital, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT01447667
842	Combined HCC-MFCCC	Completed	No Results Available	Liver Carcinoma|Hepatocellular Carcinoma|Cholangiocarcinoma|Surgery	Procedure: Hepatectomy		https://ClinicalTrials.gov/show/NCT03178409
843	Impact of Integrating an Addiction Team on Post Liver Transplantation Survival for Alcohol-related Liver Disease and Its Complications.	Completed	No Results Available	Alcoholism|Alcohol Use Disorder|Alcohol; Liver	Procedure: Liver transplantation	Uhmontpellier, Montpellier, France	https://ClinicalTrials.gov/show/NCT04964687
844	Screening of Hepatocellular Carcinoma in Patients With Compensated Cirrhosis	Completed	No Results Available	Compensated Cirrhosis	Procedure: Ultrasonographic screening	Hopital Jean Verdier, Paris, Ile de France, France	https://ClinicalTrials.gov/show/NCT00190385
845	An Investigational Scan (Magnetic Resonance Elastography) in Detecting Treatment Response in Patients With Advanced Liver Cancer	Recruiting	No Results Available	Advanced Adult Hepatocellular Carcinoma|Stage III Hepatocellular Carcinoma AJCC v8|Stage IIIA Hepatocellular Carcinoma AJCC v8|Stage IIIB Hepatocellular Carcinoma AJCC v8|Stage IV Hepatocellular Carcinoma AJCC v8|Stage IVA Hepatocellular Carcinoma AJCC v8|Stage IVB Hepatocellular Carcinoma AJCC v8	Procedure: Magnetic Resonance Elastography|Procedure: Magnetic Resonance Imaging	M D Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT04022746
846	Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)	Completed	No Results Available	Hepatocellular Carcinoma	Drug: ThermoDox|Drug: Dummy infusion	UCLA Department of Medicine, Los Angeles, California, United States|Toronto General Hospital, Toronto, Ontario, Canada|Mengchao Hepatobiliary Hospital of Fujian Medicatl University, Fuzhou, Fujian, China|Peking University First Hospital, Beijing, China|Beijing Cancer Hospital, School of Oncology, Peking, Beijing, China|302 Military Hospital of China, Beijing, China|Beijing Hospital of the Ministry of Health, Beijing, China|Chinese PLA General Hospital, Beijing, China|West China Hospital of Sichuan University, Chengdu, China|The Second Hospital of Dalian Medical University, Dalian, China|Guangdong General Hospital, Guangdong, China|Hunan Cancer Hospital, Hunan, China|The First Hospital of Jilin University, Jilin, China|Xijing Hospital, Shaanxi Province, China|Zhongshan Hospital, Fudan University, Shanghai, China|The Sixth People's Hospital of Shenyang, Shenyang, China|The 3rd Hospital of Tianjing, Tianjin, China|The First Hospital of Zhejiang, ZheJiang, China|Zhejiang Cancer Hospital, Zhejiang, China|Institut für Diagnostische und Radiologische Therapie del Uniklinik Frankfurt, Frankfurt, Germany|Klinikum rechts der Isar, II. Medizinische Klinik und Poliklinik (Gastroenterologie), München, Germany|Universitätsklinikum Regensburg, Institut für Röntgendiagnostik, Regensburg, Germany|Universitaetsklinikum des Saarlandes, Klik fuer Allgemeine Chirurgie, Viszeral-, Gefaess und Kinderchirurgie, Saar, Germany|Queen Mary Hospital, Hong Kong, Hong Kong|Cisanello Hospital, Division of Diagnostic Imaging and Intervention, Pisa, Italy|Department of Radiological Sciences and Bioimaging Catholic University of Rome, "A. Gemelli" Hospital, Rome, Italy|Pusan National University Hospital, Busan, Korea, Republic of|Kyungpook National University Hospital, Daegu, Korea, Republic of|Kyungpook National University Medical Center, Daegu, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul St.Mary's Hospital, Seoul, Korea, Republic of|University Malaya Medical Centre, Kuala Lumpur, Malaysia|Chinese General Hospital and Medical Center, Manila, Philippines|St. Lukes Medical Center, Quezon City, Philippines|Cardinal Santos Medical Center, San Juan, Philippines|Singapore General Hospital, Singapore, Singapore|Hospital Madrid Norte Sanchinarro, Madrid, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Spain|National Taiwan University Hospital, Yun-Lin Branch, Douliou City, Taiwan|Chang Gung Memorial Hospital - Kaohsiung, Kaohsiung, Taiwan|Taipei Medical University-Shuang Ho Hospital, New Taipei City, Taiwan|Taichung Veteran General Hospital, Taichung, Taiwan|National Cheng Kung University (NCKU) Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei City, Taiwan|Chang Gung Memorial Hospital - Linkou, Taoyuan, Taiwan|Siriraj Hospital, Bangkok, Thailand|Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand|Srinagarind Hospital, Khon Kaen, Thailand|Thammasat University Hospital, Pathumthani, Thailand|Songklanagarind Hospital, Songkhla, Thailand|Bach Mai Hospital, Hà Nội, Dong Da District, Vietnam|108 Military Central Hospital, Hà Nội, Hai Ba Trung District, Vietnam|Hue Central Hospital, Huế, Vin Ninh Ward, Vietnam|Bach Mai Hospital (Hepato-gastroenterology Department), Hanoi, Vietnam|Can Tho Oncology Hospital, Hanoi, Vietnam|National Cancer Hospital, Hanoi, Vietnam|Viet Duc University Hospital, Hanoi, Vietnam|People's Hospital 115, Ho Chi Minh City, Vietnam	https://ClinicalTrials.gov/show/NCT02112656
847	A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer	Not yet recruiting	No Results Available	Pancreatic Cancer|Breast Cancer|Hepatocellular Carcinoma	Drug: Piflufolastat F18	MD Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT05394259
848	Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery	Recruiting	No Results Available	Childhood Hepatocellular Carcinoma|Childhood Malignant Liver Neoplasm|Fibrolamellar Carcinoma|Hepatoblastoma|Hepatocellular Malignant Neoplasm, Not Otherwise Specified	Drug: Carboplatin|Drug: Cisplatin|Drug: Doxorubicin|Drug: Etoposide|Drug: Fluorouracil|Drug: Gemcitabine|Drug: Irinotecan|Other: Laboratory Biomarker Analysis|Drug: Oxaliplatin|Other: Patient Observation|Drug: Sorafenib|Drug: Vincristine Sulfate	Children's Hospital of Alabama, Birmingham, Alabama, United States|Providence Alaska Medical Center, Anchorage, Alaska, United States|Banner Children's at Desert, Mesa, Arizona, United States|Phoenix Childrens Hospital, Phoenix, Arizona, United States|Arkansas Children's Hospital, Little Rock, Arkansas, United States|Kaiser Permanente Downey Medical Center, Downey, California, United States|Loma Linda University Medical Center, Loma Linda, California, United States|Miller Children's and Women's Hospital Long Beach, Long Beach, California, United States|Children's Hospital Los Angeles, Los Angeles, California, United States|Mattel Children's Hospital UCLA, Los Angeles, California, United States|Valley Children's Hospital, Madera, California, United States|UCSF Benioff Children's Hospital Oakland, Oakland, California, United States|Kaiser Permanente-Oakland, Oakland, California, United States|Children's Hospital of Orange County, Orange, California, United States|Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States|Sutter Medical Center Sacramento, Sacramento, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|Rady Children's Hospital - San Diego, San Diego, California, United States|Naval Medical Center -San Diego, San Diego, California, United States|UCSF Medical Center-Mission Bay, San Francisco, California, United States|Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver, Colorado, United States|Connecticut Children's Medical Center, Hartford, Connecticut, United States|Yale University, New Haven, Connecticut, United States|Alfred I duPont Hospital for Children, Wilmington, Delaware, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|Children's National Medical Center, Washington, District of Columbia, United States|Golisano Children's Hospital of Southwest Florida, Fort Myers, Florida, United States|University of Florida Health Science Center - Gainesville, Gainesville, Florida, United States|Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood, Florida, United States|Nemours Children's Clinic-Jacksonville, Jacksonville, Florida, United States|University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States|Nicklaus Children's Hospital, Miami, Florida, United States|AdventHealth Orlando, Orlando, Florida, United States|Arnold Palmer Hospital for Children, Orlando, Florida, United States|Nemours Children's Hospital, Orlando, Florida, United States|Sacred Heart Hospital, Pensacola, Florida, United States|Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States|Saint Joseph's Hospital/Children's Hospital-Tampa, Tampa, Florida, United States|Saint Mary's Hospital, West Palm Beach, Florida, United States|Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States|Augusta University Medical Center, Augusta, Georgia, United States|Memorial Health University Medical Center, Savannah, Georgia, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Saint Luke's Cancer Institute - Boise, Boise, Idaho, United States|Lurie Children's Hospital-Chicago, Chicago, Illinois, United States|University of Illinois, Chicago, Illinois, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Advocate Children's Hospital-Oak Lawn, Oak Lawn, Illinois, United States|Advocate Children's Hospital-Park Ridge, Park Ridge, Illinois, United States|Saint Jude Midwest Affiliate, Peoria, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|Blank Children's Hospital, Des Moines, Iowa, United States|University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States|University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States|Norton Children's Hospital, Louisville, Kentucky, United States|Children's Hospital New Orleans, New Orleans, Louisiana, United States|Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States|Eastern Maine Medical Center, Bangor, Maine, United States|Maine Children's Cancer Program, Scarborough, Maine, United States|University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|Tufts Children's Hospital, Boston, Massachusetts, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|C S Mott Children's Hospital, Ann Arbor, Michigan, United States|Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States|Ascension Saint John Hospital, Detroit, Michigan, United States|Michigan State University Clinical Center, East Lansing, Michigan, United States|Helen DeVos Children's Hospital at Spectrum Health, Grand Rapids, Michigan, United States|Spectrum Health at Butterworth Campus, Grand Rapids, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Beaumont Children's Hospital-Royal Oak, Royal Oak, Michigan, United States|Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis, Minnesota, United States|University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Columbia Regional, Columbia, Missouri, United States|Children's Mercy Hospitals and Clinics, Kansas City, Missouri, United States|Cardinal Glennon Children's Medical Center, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Mercy Hospital Saint Louis, Saint Louis, Missouri, United States|Children's Hospital and Medical Center of Omaha, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|University Medical Center of Southern Nevada, Las Vegas, Nevada, United States|Sunrise Hospital and Medical Center, Las Vegas, Nevada, United States|Alliance for Childhood Diseases/Cure 4 the Kids Foundation, Las Vegas, Nevada, United States|Summerlin Hospital Medical Center, Las Vegas, Nevada, United States|Renown Regional Medical Center, Reno, Nevada, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Morristown Medical Center, Morristown, New Jersey, United States|Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States|Newark Beth Israel Medical Center, Newark, New Jersey, United States|Saint Joseph's Regional Medical Center, Paterson, New Jersey, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Albany Medical Center, Albany, New York, United States|Montefiore Medical Center - Moses Campus, Bronx, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|The Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park, New York, United States|Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States|Mount Sinai Hospital, New York, New York, United States|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|State University of New York Upstate Medical University, Syracuse, New York, United States|New York Medical College, Valhalla, New York, United States|Mission Hospital, Asheville, North Carolina, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina, United States|Novant Health Presbyterian Medical Center, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Children's Hospital Medical Center of Akron, Akron, Ohio, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Rainbow Babies and Childrens Hospital, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Dayton Children's Hospital, Dayton, Ohio, United States|ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital, Toledo, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Legacy Emanuel Children's Hospital, Portland, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States|Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Penn State Children's Hospital, Hershey, Pennsylvania, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Saint Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Prisma Health Richland Hospital, Columbia, South Carolina, United States|BI-LO Charities Children's Cancer Center, Greenville, South Carolina, United States|Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota, United States|East Tennessee Childrens Hospital, Knoxville, Tennessee, United States|Saint Jude Children's Research Hospital, Memphis, Tennessee, United States|The Children's Hospital at TriStar Centennial, Nashville, Tennessee, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States|Dell Children's Medical Center of Central Texas, Austin, Texas, United States|Driscoll Children's Hospital, Corpus Christi, Texas, United States|Medical City Dallas Hospital, Dallas, Texas, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States|El Paso Children's Hospital, El Paso, Texas, United States|Cook Children's Medical Center, Fort Worth, Texas, United States|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States|M D Anderson Cancer Center, Houston, Texas, United States|Covenant Children's Hospital, Lubbock, Texas, United States|UMC Cancer Center / UMC Health System, Lubbock, Texas, United States|Children's Hospital of San Antonio, San Antonio, Texas, United States|Methodist Children's Hospital of South Texas, San Antonio, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Scott and White Memorial Hospital, Temple, Texas, United States|Primary Children's Hospital, Salt Lake City, Utah, United States|University of Vermont and State Agricultural College, Burlington, Vermont, United States|University of Virginia Cancer Center, Charlottesville, Virginia, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States|Children's Hospital of The King's Daughters, Norfolk, Virginia, United States|Naval Medical Center - Portsmouth, Portsmouth, Virginia, United States|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States|Seattle Children's Hospital, Seattle, Washington, United States|Providence Sacred Heart Medical Center and Children's Hospital, Spokane, Washington, United States|Mary Bridge Children's Hospital and Health Center, Tacoma, Washington, United States|Madigan Army Medical Center, Tacoma, Washington, United States|West Virginia University Charleston Division, Charleston, West Virginia, United States|West Virginia University Healthcare, Morgantown, West Virginia, United States|University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States|Marshfield Medical Center-Marshfield, Marshfield, Wisconsin, United States|Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States|John Hunter Children's Hospital, Hunter Regional Mail Centre, New South Wales, Australia|Sydney Children's Hospital, Randwick, New South Wales, Australia|The Children's Hospital at Westmead, Westmead, New South Wales, Australia|Queensland Children's Hospital, South Brisbane, Queensland, Australia|Women's and Children's Hospital-Adelaide, North Adelaide, South Australia, Australia|Royal Children's Hospital, Parkville, Victoria, Australia|Perth Children's Hospital, Perth, Western Australia, Australia|Alberta Children's Hospital, Calgary, Alberta, Canada|University of Alberta Hospital, Edmonton, Alberta, Canada|CancerCare Manitoba, Winnipeg, Manitoba, Canada|IWK Health Centre, Halifax, Nova Scotia, Canada|McMaster Children's Hospital at Hamilton Health Sciences, Hamilton, Ontario, Canada|Kingston Health Sciences Centre, Kingston, Ontario, Canada|Children's Hospital, London, Ontario, Canada|Hospital for Sick Children, Toronto, Ontario, Canada|The Montreal Children's Hospital of the MUHC, Montreal, Quebec, Canada|Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada|Jim Pattison Children's Hospital, Saskatoon, Saskatchewan, Canada|Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada|Centre Hospitalier Universitaire de Quebec, Quebec, Canada|Starship Children's Hospital, Grafton, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|San Jorge Children's Hospital, San Juan, Puerto Rico|University Pediatric Hospital, San Juan, Puerto Rico|King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia	https://ClinicalTrials.gov/show/NCT03533582
849	A Phase 2a Study of Modified Vaccinia Virus to Treat Sorafenib-naïve Advanced Liver Cancer	Completed	Has Results	Hepatocellular Carinoma	Biological: JX-594 recombinant vaccina GM-CSF	Mayo Clinic, Scottsdale, Arizona, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Pusan National University Hospital, Pusan, Korea, Republic of|Pusan National University Yangsan Hospital, Yangsan, Korea, Republic of|University Clinic of Navarra, Pamplona, Navarra, Spain	https://ClinicalTrials.gov/show/NCT01636284
850	Prediction of Liver-related Outcomes After HCV Cure	Recruiting	No Results Available	Hepatitis C, Chronic|Sustained Virological Response|Direct-acting Antivirals|Hepatocellular Carcinoma|Hepatic Decompensation		Hospital Universitario de Valme, Sevilla, Spain	https://ClinicalTrials.gov/show/NCT04460157
851	Re-Defining Frailty and Improving Outcomes Through Prehabilitation in Patients With Pancreatic, Liver, or Gastric Cancer, The RIOT Trial	Recruiting	No Results Available	Adult Liver Carcinoma|Gastric Carcinoma|Malignant Solid Neoplasm|Pancreatic Carcinoma	Other: Best Practice|Behavioral: Exercise Intervention|Procedure: Physical Therapy|Other: Questionnaire Administration	Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States	https://ClinicalTrials.gov/show/NCT04602026
852	Primary Prevention Hepatocellular Carcinoma by Metformin	Terminated	No Results Available	Hepatocellular Carcinoma|Hepatitis C, Chronic|Cirrhosis	Drug: Metformin|Drug: placebo tablet	Roulot Dominique, Bobigny, France	https://ClinicalTrials.gov/show/NCT02319200
853	Fingerprint Characterization Tyrosine Kinase Inhibitors in Advanced HCC	Recruiting	No Results Available	Hepatocellular Carcinoma|Sorafenib		University Hospital Eberhard Karls University, Tübingen, BW, Germany	https://ClinicalTrials.gov/show/NCT03958669
854	A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev	Recruiting	No Results Available	Hepatic Venous Thrombosis	Drug: Atezolizumab|Procedure: Surgery	Zhongshan hospital, Fudan University, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT04649489
855	Drug-eluting Bead in Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Procedure: DebDox TACE	Seoul National University Hospital, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT01332669
856	Phlebotomy and Risk of Hepatocellular Carcinoma in Patients With Compensated Alcoholic Cirrhosis	Terminated	No Results Available	Alcoholic Cirrhosis|Iron Overload	Procedure: phlebotomy	Amiens University Hospital :, Amiens, France|Avicenne, Bobigny, France|Jean Verdier, Bondy, France|CHU Bordeaux univerity hospital 1, Bordeaux, France|CHU Bordeaux University hospital 2, Bordeaux, France|CHU, Caen, France|Antoine Béclère, Clamart, France|CHU, Grenoble, France|CHU, Lille, France|CHU, Montpellier, France|CHU, Nancy, France|CHU, Nice, France|CHU, Rennes, France|CHU, Rouen, France	https://ClinicalTrials.gov/show/NCT01342705
857	Adjuvant Radiotherapy Comparing TACE for Curative HCC	Unknown status	No Results Available	Hepatocellular Carcinoma	Other: Transarterial chemoembolization|Other: Radiotherapy	Department of Hepatobilliary Surgery, Affiliated Tumor of Guangxi University, Nanning, Guangxi, China	https://ClinicalTrials.gov/show/NCT02125396
858	B-mode Ultrasound Imaging in Detecting Early Liver Cancer	Completed	No Results Available	Cirrhosis|Early Hepatocellular Carcinoma|Fibrosis|Stage I Hepatocellular Carcinoma|Stage II Hepatocellular Carcinoma	Other: Ultrasound Tomography	Stanford University, School of Medicine, Palo Alto, California, United States	https://ClinicalTrials.gov/show/NCT02774161
859	Transarterial Chemoembolization Plus Hypofractionnated Radiotherapy vs. Surgery in Locally Advanced Hepatocellular Carcinoma: an IPTW Comparison	Completed	No Results Available	Non-metastatic Hepatocellular Carcinoma	Other: TACE + hypofractionated EBRT|Procedure: Surgical resection	Croix-Rousse Hospital, Hospices Civils de Lyon, Lyon, France	https://ClinicalTrials.gov/show/NCT04823715
860	Evaluation of Cirrhosis and Malignant Hepatic Lesions Using Novel MR Contrast Agents	Unknown status	No Results Available	Hepatocellular Carcinoma	Procedure: MRI Scan of the Liver enhanced with Eovist	San Francisco VA Medical Center, San Francisco, California, United States	https://ClinicalTrials.gov/show/NCT01341132
861	Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients	Completed	No Results Available	Hepatocellular Carcinoma	Drug: PDR001|Drug: Sorafenib	Karmanos Cancer Institute, Detroit, Michigan, United States|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, Rozzano, MI, Italy|Novartis Investigative Site, Kashiwa, Chiba, Japan|Novartis Investigative Site, Yokohama city, Kanagawa, Japan|Novartis Investigative Site, Pamplona, Navarra, Spain|Novartis Investigative Site, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT02988440
862	Transarterial Chemoembolization (TACE) vs. CyberKnife for Recurrent Hepatocellular Carcinoma (HCC)	Withdrawn	No Results Available	Recurrent Hepatocellular Carcinoma	Procedure: Transarterial Chemoembolization|Radiation: CyberKnife SBRT	Stanford Comprehensive Cancer Center, Stanford, California, United States	https://ClinicalTrials.gov/show/NCT01318200
863	Study in the Treatment of HCC With a Radiopaque (RO) Bead (LC Bead LUMI™) Loaded With Doxorubicin	Withdrawn	No Results Available	Hepatocellular Carcinoma (HCC)	Device: LC Bead LUMI™ (Radiopaque (RO) Bead) loaded with doxorubicin		https://ClinicalTrials.gov/show/NCT03452553
864	An Individualized Anti-Cancer Vaccine Study in Patients With HCC	Withdrawn	No Results Available	Hepatocellular Carcinoma	Biological: AlloVax|Biological: CRCL|Biological: AlloStim	Hebrew University-Hadassah Medical Center, Jerusalem, Israel	https://ClinicalTrials.gov/show/NCT01995227
865	HAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular Carcinama	Not yet recruiting	No Results Available	Hepatocellular Carcinoma|Bevacizumab|Liver Neoplasms|Toripalimab|Oxaliplatin	Procedure: Hepatic arterial infusion chemotherapy|Drug: Bevacizumab|Drug: Toripalimab		https://ClinicalTrials.gov/show/NCT04627363
866	A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy	Terminated	Has Results	Advanced Solid Tumors|Hepatocellular Carcinoma	Drug: Pimasertib	Please contact, Merck Serono Co., Ltd for recruiting locations in, Japan	https://ClinicalTrials.gov/show/NCT01668017
867	Hepatic Resection Versus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Complicated by Portal Vein Tumor Thrombosis	Unknown status	No Results Available	Hepatocellular Carcinoma With PVTT	Procedure: hepatic resection|Procedure: TACE	Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT01350206
868	Exploratory Clinical Study of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric Cancer	Unknown status	No Results Available	Gastric Cancer|Hepatocellular Carcinoma	Drug: apatinib|Drug: SHR-1210	The Affiliated Hospital of the Chinese Academy of Military Medical Sciences, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT02942329
869	A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma	Completed	Has Results	Carcinoma, Hepatocellular	Drug: Sorafenib (Nexavar, BAY43-9006) plus Doxorubicin|Drug: Doxorubicin/Placebo	Birmingham, Alabama, United States|Beverly Hills, California, United States|Orange, California, United States|Palo Alto, California, United States|San Francisco, California, United States|San Francisco, California, United States|Sylmar, California, United States|Miami, Florida, United States|Lafayette, Louisiana, United States|Minneapolis, Minnesota, United States|Hackensack, New Jersey, United States|New York, New York, United States|Rochester, New York, United States|Nashville, Tennessee, United States|Seattle, Washington, United States|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Neuquen, Neuquén, Argentina|Buenos Aires, Argentina|Toronto, Ontario, Canada|Hong Kong, Hong Kong|Kazan, Russian Federation|Kirov, Russian Federation|Krasnodar, Russian Federation|Maidstone, Kent, United Kingdom|Bebington, Merseyside, United Kingdom|Birmingham, West Midlands, United Kingdom|London, United Kingdom|Manchester, United Kingdom	https://ClinicalTrials.gov/show/NCT00108953
870	Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery	Not yet recruiting	No Results Available	Carcinoma|Carcinoma, Hepatocellular|Liver Neoplasms|Digestive System Neoplasms|Antineoplastic Agents|Donafenib|Fluorouracil|Oxaliplatin|Antimetabolites	Procedure: Hepatic arterial infusion chemotherapy|Drug: Folfox Protocol|Drug: Donafenib	Lei Zhang, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT04962958
871	Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: SRF388|Drug: Atezolizumab|Drug: Bevacizumab|Drug: Placebo	City of Hope, Duarte, California, United States|Sarah Cannon Research Institute - Tennessee Oncology, Chattanooga, Tennessee, United States|Sarah Cannon Research Institute - Tennessee Oncology, Nashville, Tennessee, United States	https://ClinicalTrials.gov/show/NCT05359861
872	Biomarker Analyses in Hepatocellular Carcinoma (HCC) Patients Treated With TheraSphere®	Terminated	No Results Available	Hepatocellular Carcinoma	Other: Plasma collection	Northwestern University, Chicago, Illinois, United States	https://ClinicalTrials.gov/show/NCT03203837
873	Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC)	Completed	No Results Available	Hepatocellular Carcinoma	Drug: BIIB022|Drug: Sorafenib	Resesarch Site, Denver, Colorado, United States|Resesarch Site, Ocoee, Florida, United States|Resesarch Site, Indianapolis, Indiana, United States|Resesarch Site, Boston, Massachusetts, United States|Resesarch Site, New York, New York, United States|Resesarch Site, Norfolk, Virginia, United States|Resesarch Site, Singapore, Singapore|Resesarch Site, Tainan, Taiwan|Resesarch Site, Taipei, Taiwan|Resesarch Site, Tao-Yuan, Taiwan|Resesarch Site, Edgbaston, Birmingham, United Kingdom	https://ClinicalTrials.gov/show/NCT00956436
874	Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma	Completed	Has Results	Hepatocellular Carcinoma|Hepatoma	Drug: sorafenib|Procedure: LC Bead-TACE	The Johns Hopkins Hospital, Baltimore, Maryland, United States	https://ClinicalTrials.gov/show/NCT00844883
875	TH-302 Plus Doxorubicin Delivered by Trans-Arterial Chemoembolization (TACE) in Patients With Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: Phase I Dose level -1|Drug: Phase I dose level 1|Drug: Phase I Dose level 2|Drug: Phase I Dose level 3	Scripps Clinic, La Jolla, California, United States	https://ClinicalTrials.gov/show/NCT01721941
876	Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers	Recruiting	No Results Available	Liver Neoplasms|Hepatic Cirrhosis|Hepatic Carcinoma|Liver Cancer|Liver Metastases|Liver Carcinoma|Hepatocellular Carcinoma|Hepatocellular Cancer|Hepatic Atrophy	Drug: Ferumoxytol injection	Allegheny General Hospital, Pittsburgh, Pennsylvania, United States	https://ClinicalTrials.gov/show/NCT04682847
877	Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib	Completed	Has Results	Hepatocellular Carcinoma	Drug: Cabozantinib tablets|Drug: Placebo tablets	Corona, California, United States|Los Angeles, California, United States|San Diego, California, United States|San Francisco, California, United States|Gainesville, Florida, United States|Atlanta, Georgia, United States|Honolulu, Hawaii, United States|Chicago, Illinois, United States|Burlington, Massachusetts, United States|Rochester, Minnesota, United States|Kansas City, Missouri, United States|Saint Louis, Missouri, United States|Las Vegas, Nevada, United States|East Orange, New Jersey, United States|New York, New York, United States|New York, New York, United States|Valhalla, New York, United States|Dallas, Texas, United States|San Antonio, Texas, United States|Seattle, Washington, United States|Seattle, Washington, United States|Spokane, Washington, United States|Camperdown, New South Wales, Australia|Concord, New South Wales, Australia|Darlinghurst, New South Wales, Australia|Kogarah, New South Wales, Australia|Westmead, New South Wales, Australia|Kurralta Park, South Australia, Australia|Melbourne, Victoria, Australia|Perth, Western Australia, Australia|Edegem, Antwerpen, Belgium|La Louvière, Hainaut, Belgium|Gent, Oost-Vlaanderen, Belgium|Liege, Belgium|Calgary, Alberta, Canada|Toronto, Ontario, Canada|Saskatoon, Saskatchewan, Canada|Nice, Alpes-Maritimes, France|Amiens, Somme, France|Creteil, Val-de-Marne, France|Besançon, France|Bordeaux, France|Clermont-Ferrand, France|Lille, France|Lyon, France|Esslingen am Neckar, Baden-Württemberg, Germany|Tübingen, Baden-Württemberg, Germany|München, Bayern, Germany|Frankfurt am Main, Hessen, Germany|Magdeburg, Sachsen-Anhalt, Germany|Berlin, Germany|Freiburg, Germany|Hong Kong, Hong Kong|Dublin, Ireland|Bologna, Emilia-Romagna, Italy|Faenza, Emilia-Romagna, Italy|Meldola, Emilia-Romagna, Italy|Rimini, Emilia-Romagna, Italy|Roma, Lazio, Italy|Roma, Lazio, Italy|Genova, Liguria, Italy|Milan, Lombardia, Italy|Rozzano, Lombardia, Italy|Palermo, Sicilia, Italy|Padova, Veneto, Italy|Goyang, Gyeonggido, Korea, Republic of|Busan, Korea, Republic of|Seongnam, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Suwon-si, Korea, Republic of|Maastricht, Limburg, Netherlands|Amsterdam, Noord-Holland, Netherlands|Amsterdam, Noord-Holland, Netherlands|Leiden, Zuid-Holland, Netherlands|Auckland, North Island, New Zealand|Olsztyn, Warminsko-Mazurskie, Poland|Myslowice, Poland|Poznan, Poland|Cluj-Napoca, Cluj, Romania|Brasov, Romania|Singapore, Singapore|Singapore, Singapore|Singapore, Singapore|Elche, Alicante, Spain|Majadahonda, Madrid, Spain|Torrejon de Ardoz, Madrid, Spain|Madrid, Spain|Madrid, Spain|Zaragoza, Spain|Liuying Township, Tainan, Taiwan|Taichung, Taiwan|Taipei, Taiwan|Edirne, Turkey|Gaziantep, Turkey|Wirral, England, United Kingdom|Birmingham, United Kingdom|London, United Kingdom|London, United Kingdom|Manchester, United Kingdom	https://ClinicalTrials.gov/show/NCT01908426
878	Study of Anti-tumour Effects and Safety of Prolarix™ in Hepatocellular Carcinoma	Terminated	Has Results	Hepatocellular Carcinoma	Drug: Prolarix (tretazicar co-administered with caricotamide)	Cliniques Universitaires Saint-Luc, Brussels, Belgium	https://ClinicalTrials.gov/show/NCT00746590
879	The LC Bead Trial; Transarterial Chemoembolization of Hepatocellular Carcinoma (HCC)With a Drug-eluting Bead	Terminated	Has Results	Hepatocellular Carcinoma	Device: transarterial chemoembolization using a drug-eluting bead	Barnes-Jewish Hospital/Washington Univesity School of Medicine, Saint Louis, Missouri, United States	https://ClinicalTrials.gov/show/NCT01259024
880	Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients	Recruiting	No Results Available	Unresectable Hepatocellular Carcinoma|BCLC Stage A Hepatocellular Carcinoma|BCLC Stage B Hepatocellular Carcinoma|BCLC Stage C Hepatocellular Carcinoma	Device: Resin microspheres containing yttrium-90 (Y-90)	Miami Cardiac and Vascular Institute at Baptist Hospital, Miami, Florida, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, United States|Hospital of the University Pennsylvania, Philadelphia, Pennsylvania, United States|Clinical Research Institute and Methodist Hospital, Dallas, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|UT MD Anderson Cancer Center, Houston, Texas, United States|Inland Imaging, Spokane, Washington, United States	https://ClinicalTrials.gov/show/NCT04736121
881	Risk of Hepatocellular Carcinoma in Patients Treated With ETV vs TDF for Chronic Hepatitis B With Compensated Cirrhosis	Unknown status	No Results Available	Hepatitis B, Chronic|Hepatocellular Carcinoma|Compensated Cirrhosis	Drug: Entecavir|Drug: Tenofovir Disoproxil	Rui Jin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT04160897
882	Comparison of Two Solvents Used With Chemotherapy Agent for Transarterial Chemoembolization of Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Other: Solvent with specific gravity less than lipiodol|Other: Solvent with specific gravity equivalent to lipiodol	Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT01259414
883	Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma	Terminated	Has Results	Hepatocellular Carcinoma	Drug: Sorafenib & Capecitabine	University of New Mexico Cancer Center @ Lovelace Medical Center, Albuquerque, New Mexico, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Cancer Center at Presbyterian Hospital, Albuquerque, New Mexico, United States	https://ClinicalTrials.gov/show/NCT01032850
884	Advanced Image Guidance Utilized in Liver Surgery	Completed	Has Results	Carcinoma, Hepatocellular	Device: Advanced Image Guidance	Carolinas Health System, Charlotte, North Carolina, United States	https://ClinicalTrials.gov/show/NCT01666145
885	An Open Study Assessing the Safety and Tolerability of U3-1784	Terminated	No Results Available	Advanced Solid Tumors|Hepatocellular Cancer (HCC)	Drug: U3-1784	Glasgow, Lanarkshire, United Kingdom|The Royal Marsden Hospital, Sutton, Surrey, United Kingdom|Guy's Hospital, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom	https://ClinicalTrials.gov/show/NCT02690350
886	Non-Interventional Registry Study to Evaluate the Effectiveness of TheraSphere® in the Treatment of Hepatocellular Carcinoma (HCC)	Recruiting	No Results Available	Hepatocellular Carcinoma	Device: TheraSphere	CHU Amiens, Amiens, France|CHU, Angers, Angers, France|CHU Jean Minjoz, Besançon, France|Institut Bergonié, Bordeaux, France|Hôpital Haut Leveque, Bordeaux, France|Centre Hospitalier Régional et Universitaire de Brest, Brest, France|Hôpital Henri Mondor, Créteil, France|Centre George-Francois Leclerc, Dijon, France|CHU Dijon Bourgogne, Dijon, France|CHU Michallon, Grenoble, France|Bicêtre Hôpital, Le Kremlin-Bicêtre, France|CHU Lille, Lille, France|Centre Leon Berard, Lyon, France|Hopital de la Croix-Rousse, Lyon, France|Hopital Edouard Herriot, Lyon, France|CHU de la Timone, Marseille, France|Institut Paoli Calmettes, Marseille, France|CHU Saint Eloi, Montpellier, France|CHU Brabois Adultes, Nancy, France|CHU Site Hotel Dieu, Nantes, France|CHU de l'Archet, Nice, France|CHU de Nîmes, Hôpital Carremeau, Nîmes, France|Hopital Beaujon, Paris, France|Centre Hospitalier de Perpignan, Perpignan, France|Hopital Lyon Sud, Pierre Benite, France|CHU La Milétrie, Poitiers, France|Centre Eugene Marquis, Rennes, France|Centre Henri Becquerel, Rouen, France|CHU Rouen, Rouen, France|Centre Hospitalier Universitaire de St Etienne, Saint-Priest-en-Jarez, France|CHU deHautepierre, Strasbourg, France|Nouvel Hopital Civil, Strasbourg, France|CHU Rangueil, Toulouse, France|Hopital Paul Brousse, Villejuif, France|Intstitut Gustave Roussy, Villejuif, France	https://ClinicalTrials.gov/show/NCT04069468
887	Evaluation of 11 C-Choline PET-CT for Detection of Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: 11C-Choline	CEA-SHFJ, Orsay, France	https://ClinicalTrials.gov/show/NCT01377220
888	YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)	Recruiting	No Results Available	Advanced Hepatocellular Carcinoma	Drug: YIV-906+Sorafenib|Drug: Placebo+Sorafenib	Calvin Pan. MD Gastroenterology & Hepatology Clinic, Flushing, New York, United States|Northwell Monter Cancer Institute, Lake Success, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Beijing You'An Hospital, Capital Medical University, Beijing, Beijing, China|Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China|China-Japan Friendship Hospital, Beijing, Beijing, China|Foshan Hospital of Traditional Chinese Medicine, Foshan, Guangdong, China|Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, Guangdong, China|The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China|Shenzhen People's Hospital, Shenzhen, Guangdong, China|The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China|Hunan Cancer Hospital, Changsha, Hunan, China|LongHua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, Shanghai, China|Shanghai Eastern Hepatobiliary Hospital, Shanghai, Shanghai, China|Shanghai University of Traditional Chinese Medicine Shuguang Hospital, Shanghai, Shanghai, China|Queen Mary Hospital, Hongkong, Hong Kong|Chang Gung Memorial Hospital, Linkou, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|Cancer Research Center, Taipei Municipal Wanfang Hospital, Taipei, Taiwan|Taipei Medical University -Shuang Ho Hospital, Ministry of Health and Welfare, Taipei, Taiwan|Taipei Medical University Cancer Center, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT04000737
889	Study of BGB-A317 in Participants With Previously Treated Unresectable HCC	Active, not recruiting	No Results Available	Hepatocellular Carcinoma (HCC)	Drug: Tislelizumab	Anhui Provincial Hospital, Hefei, Anhui, China|The Second Hospital of Anhui Medical Hospital, Hefei, Anhui, China|302 Military Hospital of China, Beijing, Beijing, China|Beijing Cancer Hospital, Beijing, Beijing, China|Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China|Fujian Medical University Union Hospital, Fuzhou, Fujian, China|Sun Yat-Sen Memorial Hospital,Sun Yat-Sen University, Guangzhou, Guangdong, China|Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China|Peking University Shenzhen Hospital, Shenzhen, Guangdong, China|Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China|Henan Cancer Hospital, Zhengzhou, Henan, China|Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China|Hubei Cancer Hospital, Wuhan, Hubei, China|Xuzhou Central Hospital, Xuzhou, Jiangsu, China|The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China|The First affiliated hospital of Nanchang University, Nanchang, Jiangxi, China|Jilin Cancer Hospital, Changchun, Jilin, China|The First Hospital of Jilin University, Changchun, Jilin, China|Weifang People's Hospital, Weifang, Shandong, China|Shanghai Cancer Hospital, Fudan University, Shanghai, Shanghai, China|Zhongshan Hospital Fudan University, Shanghai, Shanghai, China|Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China|The First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China|The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China|Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China|The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China|Chinese PLA General Hospital Medical School of Chinese PLA, Beijing, China|CHU Nice - Hôpital de l'Archet 2, Nice Cedex 3, Alpes Maritimes, France|Groupe Hospitalier Sud - Hôpital Haut Lévêque, Pessac Cedex, Gironde, France|Hopital Saint Eloi, Montpellier, Herault, France|CRLCC Eugene Marquis, Rennes cedex, Ille Et Vilaine, France|Hopital Beaujon, Clichy, Paris, France|Centre Hospitalier de la Croix Rousse, Lyon, Rhone, France|Centre Hospitalier de la Croix Rousse, Lyon, Rhone, France|Institut Gustave Roussy, Villejuif cedex, Val De Marne, France|CHU Poitiers - Hôpital la Milétrie, Poitiers Cedex, Vienne, France|Kliniken Essen-Mitte, Essen, Nordrhein Westfalen, Germany|Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Rheinland Pflaz, Germany|Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany|Istituto Clinico Humanitas, Rozzano, Milano, Italy|Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII), Bergamo, Italy|Azienda Ospedaliero Universitaria Pisana, Pisa, Italy|Università Campus Bio-Medico di Roma, Roma, Italy|Centrum Badan Klinicznych Piotr Napora Lekarze Spolka Partnerska, Warszawa, Poland|Centrum Onkologii-Instytut im. M. Sklodowskiej Curie, Wroclaw, Poland|ICO l'Hospitalet - Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Universitario Reina Sofia, Córdoba, Spain|Hospital Universitario Ramón Y Cajal, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario HM Madrid Sanchinarro, Madrid, Spain|Chiayi Chang Gung Memorial Hospital of the Chang Gung Medical Foundation, Chiayi City, Taiwan|E-Da Cancer Hospital, Kaohsiung, Taiwan|Chang Gung Memorial Hospital, Kaohsiung, Kaohsiung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan|The Christie NHS Foundation Trust, Manchester, England, United Kingdom|Royal Free Hospital, London, Greater London, United Kingdom|King's College Hospital, London, Greater London, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, Strathclyde, United Kingdom|Queen Elizabeth Hospital, Birmingham, West Midlands, United Kingdom|Freeman Hospital, Newcastle Upon Tyne, United Kingdom	https://ClinicalTrials.gov/show/NCT03419897
890	Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)	Active, not recruiting	No Results Available	Locally Advanced Hepatocellular Carcinoma	Drug: Cabozantinib|Drug: Nivolumab	Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States	https://ClinicalTrials.gov/show/NCT03299946
891	Deep Learning Model for the Prediction of Post-LT HCC Recurrence	Completed	No Results Available	Liver Transplant Disorder|Liver Cancer|Recurrent Cancer	Procedure: Liver transplantation	Quirino Lai, Rome, RM, Italy	https://ClinicalTrials.gov/show/NCT05200195
892	Different Regimens of Transarterial Chemoembolization for Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Procedure: Transarterial chemoembolization (TACE)	Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT00493402
893	Effect of I/R Injuries by Pringle Manoeuvre on the Prognosis of HCC Patients After Curative Hepatectomy	Completed	No Results Available	Hepatocellular Carcinoma	Procedure: curative resection without Pringle|Procedure: curative resection with Pringle manoeuvre	Institute of hepatobiliary surgery,southwest hospital, Chongqing, Chongqing, China	https://ClinicalTrials.gov/show/NCT00725335
894	TheraSphere With and Without Durvalumab and Tremelimumab for HCC	Not yet recruiting	No Results Available	Hepatocellular Carcinoma	Device: TheraSphere Y-90 glass microsphere therapy|Drug: Durvalumab (Imfinzi) immunotherapy|Drug: Tremelimumab immunotherapy		https://ClinicalTrials.gov/show/NCT05063565
895	A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer	Recruiting	No Results Available	Head and Neck Squamous Cell Carcinoma (HNSCC)	Drug: BI 765063|Drug: Ezabenlimab|Drug: BI 836880|Drug: Cetuximab|Other: Investigator´s Choice Chemotherapy	Washington University School of Medicine, Saint Louis, Missouri, United States|Kobe University Hospital, Hyogo, Kobe, Japan|Kanagawa Cancer Center, Kanagawa, Yokohama, Japan|Osaka International Cancer Institute, Osaka, Osaka, Japan|Shizuoka Cancer Center, Shizuoka, Sunto-gun, Japan|Japanese Foundation for Cancer Research, Tokyo, Koto-ku, Japan|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Duran i Reynals, L'Hospitalet de Llobregat, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hammersmith Hospital, London, United Kingdom	https://ClinicalTrials.gov/show/NCT05249426
896	Stereotactic Body Radiation Therapy (SBRT) vs Trans-Arterial Chemoembolization (TACE) as Bridge to Transplant	Active, not recruiting	No Results Available	Hepatocellular Carcinoma|HCC	Radiation: Stereotactic Body Radiation Therapy (SBRT)|Procedure: Trans-Arterial Chemoembolization (TACE)|Drug: Doxorubin	Lahey Hospital & Medical Center, Burlington, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Princess Margaret Hospital, UHN, Toronto, Ontario, Canada	https://ClinicalTrials.gov/show/NCT03960008
897	Study of Sunitinib in Patients With Advanced/Inoperable Fibrolamellar Carcinoma	Terminated	No Results Available	Hepatocellular Carcinoma|Fibrolamellar Hepatocellular Carcinoma	Drug: Sutent	Hôpital Beaujon, Clichy, Hauts de Seine, France	https://ClinicalTrials.gov/show/NCT01215565
898	Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)	Completed	Has Results	Carcinoma, Hepatocellular	Drug: Sorafenib (Nexavar, BAY43-9006)|Drug: Placebo	Nagoya, Aichi, Japan|Kashiwa, Chiba, Japan|Matsuyama, Ehime, Japan|Toon, Ehime, Japan|Iizuka, Fukuoka, Japan|Kitakyushu, Fukuoka, Japan|Kitakyushu, Fukuoka, Japan|Kurume, Fukuoka, Japan|Isesaki, Gunma, Japan|Maebashi, Gunma, Japan|Kure, Hiroshima, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Akashi, Hyogo, Japan|Kobe, Hyogo, Japan|Kasama, Ibaraki, Japan|Kanazawa, Ishikawa, Japan|Isehara, Kanagawa, Japan|Sagamihara, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Sendai, Miyagi, Japan|Sendai, Miyagi, Japan|Matsumoto, Nagano, Japan|Omura, Nagasaki, Japan|Kawachinagano, Osaka, Japan|Moriguchi, Osaka, Japan|Osakasayama, Osaka, Japan|Suita, Osaka, Japan|Izunokuni, Shizuoka, Japan|Sunto, Shizuoka, Japan|Shimotsuke, Tochigi, Japan|Chuo-ku, Tokyo, Japan|Itabashi-ku, Tokyo, Japan|Meguro-ku, Tokyo, Japan|Minato-ku, Tokyo, Japan|Musashino, Tokyo, Japan|Nerima-ku, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan|Yonago, Tottori, Japan|Shimonoseki, Yamaguchi, Japan|Ube, Yamaguchi, Japan|Chuo, Yamanashi, Japan|Chiba, Japan|Fukui, Japan|Fukuoka, Japan|Gifu, Japan|Hiroshima, Japan|Hiroshima, Japan|Hiroshima, Japan|Kagoshima, Japan|Kagoshima, Japan|Kagoshima, Japan|Kumamoto, Japan|Kumamoto, Japan|Kumamoto, Japan|Kyoto, Japan|Miyazaki, Japan|Okayama, Japan|Osaka, Japan|Osaka, Japan|Osaka, Japan|Osaka, Japan|Osaka, Japan|Osaka, Japan|Osaka, Japan|Toyama, Japan|Yamagata, Japan|Seoul, Seoul Teugbyeolsi, Korea, Republic of|Daegu, Korea, Republic of|Incheon, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT00494299
899	Discrepancies in Management of Hepatocellualr Carcinoma Between Practice and Recommendations	Unknown status	No Results Available	Hepatocellular Carcinoma		Uhmontpellier, Montpellier, France	https://ClinicalTrials.gov/show/NCT04189809
900	TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC	Recruiting	No Results Available	Hepatocellular Carcinoma|Liver Neoplasms|Digestive System Neoplasms|Sorafenib|Molecular Mechanisms of Pharmacological Action|Liver Diseases|Antineoplastic Agents|Protein Kinase Inhibitors	Combination Product: TACE combined with sorafenib and PD-1 mAb	Sichuan Cancer Hospital and Research Institute, Chengdu, Sichuan, China	https://ClinicalTrials.gov/show/NCT04518852
901	Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery	Completed	No Results Available	Advanced Adult Hepatocellular Carcinoma|Localized Non-Resectable Adult Hepatocellular Carcinoma|Stage III Childhood Hepatocellular Carcinoma|Stage IIIA Hepatocellular Carcinoma|Stage IIIB Hepatocellular Carcinoma|Stage IIIC Hepatocellular Carcinoma|Stage IV Childhood Hepatocellular Carcinoma|Stage IVA Hepatocellular Carcinoma|Stage IVB Hepatocellular Carcinoma	Other: Laboratory Biomarker Analysis|Drug: Sorafenib Tosylate	Roswell Park Cancer Institute, Buffalo, New York, United States	https://ClinicalTrials.gov/show/NCT02072486
902	Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC	Completed	No Results Available	Advanced Hepatocellular Carcinoma	Drug: PDR001|Drug: INC280	Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Guangzhou, Guangdong, China|Novartis Investigative Site, Shanghai, Shanghai, China|Novartis Investigative Site, Montpellier cedex 5, Herault, France|Novartis Investigative Site, Lille Cedex, France|Novartis Investigative Site, Toulouse Cedex 9, France|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Wuerzburg, Germany|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Rozzano, MI, Italy|Novartis Investigative Site, Modena, MO, Italy|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Tainan, Taiwan|Novartis Investigative Site, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT02795429
903	Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Tremelimumab|Drug: Durvalumab|Procedure: Transarterial Chemoembolization (TACE)|Drug: Lenvatinib	Research Site, Birmingham, Alabama, United States|Research Site, Commack, New York, United States|Research Site, Memphis, Tennessee, United States|Research Site, Barretos, Brazil|Research Site, Brasilia, Brazil|Research Site, Niterói, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Santa Maria, Brazil|Research Site, Santo Andre, Brazil|Research Site, São Paulo, Brazil|Research Site, Vitória, Brazil|Research Site, Toronto, CA, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Kingston, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Changsha, China|Research Site, Chengdu, China|Research Site, Fuzhou, China|Research Site, Fuzhou, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Haikou, China|Research Site, Hangzhou, China|Research Site, Harbin, China|Research Site, Lanzhou, China|Research Site, Lishui, China|Research Site, Nanjing, China|Research Site, Nantong, China|Research Site, Neijiang, China|Research Site, Shanghai, China|Research Site, Suzhou, China|Research Site, Tianjin, China|Research Site, Urumqi, China|Research Site, Wuhan, China|Research Site, Xi'an, China|Research Site, Zhengzhou, China|Research Site, Zhuhai, China|Research Site, Dresden, Germany|Research Site, Hamburg, Germany|Research Site, Heidelberg, Germany|Research Site, Kiel, Germany|Research Site, Ahmedabad, India|Research Site, Ahmedabad, India|Research Site, Anand, India|Research Site, Bangalore, India|Research Site, Bangalore, India|Research Site, Gurugram, India|Research Site, JAipur, India|Research Site, Kolkata, India|Research Site, New Delhi, India|Research Site, New Delhi, India|Research Site, Arezzo, Italy|Research Site, Firenze, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Rozzano, Italy|Research Site, Tricase (Lecce), Italy|Research Site, Chuo-ku, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Kashihara-shi, Japan|Research Site, Morioka-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osakasayama-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Busan, Korea, Republic of|Research Site, Goyang-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, George Town, Malaysia|Research Site, Kuala Lumpur, Malaysia|Research Site, Kuching, Malaysia|Research Site, Selangor, Malaysia|Research Site, Makati, Philippines|Research Site, Manila, Philippines|Research Site, Pasig City, Philippines|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Cordoba, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Oviedo, Spain|Research Site, San Sebastian, Spain|Research Site, Taichung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan City, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan, Taiwan|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Chiang Mai, Thailand|Research Site, Hat Yai, Thailand|Research Site, Khon Kaen, Thailand|Research Site, Phisanulok, Thailand	https://ClinicalTrials.gov/show/NCT05301842
904	SCH 66336 With or Without Gemcitabine Followed by Surgery Compared With Surgery Alone in Treating Patients With Primary Liver Cancer	Withdrawn	No Results Available	Liver Cancer	Drug: gemcitabine hydrochloride|Drug: lonafarnib|Procedure: conventional surgery		https://ClinicalTrials.gov/show/NCT00020774
905	Pangenomic Study During Alcoholic Cirrhosis	Completed	No Results Available	Alcoholic Cirrhosis	Genetic: DNA extraction	Nantes UH, Nantes, France|Jean Verdier UH, Paris, France|Paul Brousse UH, Paris, France|Rennes UH, Rennes, France	https://ClinicalTrials.gov/show/NCT01065233
906	SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma	Terminated	Has Results	Carcinoma, Hepatocellular|Hepatoma	Device: SIR-Spheres microspheres	Thomas Jefferson University - Kimmel Cancer Center, Philadelphia, Pennsylvania, United States|UPMC Liver Cancer Center, Pittsburgh, Pennsylvania, United States|The Liver Institute at Methodist Dallas, Dallas, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT00503867
907	Quality of Life in Patients Undergoing Embolization Using Yttrium Y 90 Glass Microspheres for Primary or Metastatic Liver Cancer	Completed	No Results Available	Liver Cancer|Metastatic Cancer		Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States	https://ClinicalTrials.gov/show/NCT00739167
908	Liver Fibrosis in Zambian HIV-HBV Co-infected Patients	Active, not recruiting	No Results Available	Human Immunodeficiency Virus|HBV|Fibrosis, Liver|Cirrhosis, Liver|Hepatocellular Carcinoma|Hepatitis Delta Virus|Alcoholic Hepatitis	Drug: Anti-HIV Agents	Centre for Infectious Disease Research in Zambia (CIDRZ), Lusaka, Zambia	https://ClinicalTrials.gov/show/NCT02344680
909	Mild Hypothermia and Acute Kidney Injury in Liver Transplantation	Recruiting	No Results Available	Cirrhosis|End Stage Liver Disease|Acute Kidney Injury|Liver Transplant; Complications|Chronic Kidney Diseases|Hepatitis c|Hepatitis B|NASH - Nonalcoholic Steatohepatitis|Alcoholic Cirrhosis|Hepatocellular Carcinoma	Device: Esophageal cooling/warming device|Other: Mild hypothermia|Other: Normothermia	University of California, San Francisco, San Francisco, California, United States|University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States|Houston Methodist Hospital, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT03534141
910	Chemoembolization With or Without Mixing the Chemotherapy With Lipiodol for Unresectable HCC	Completed	No Results Available	Hepatocellular Carcinoma	Other: Embolization|Other: Infusion of anticancer agent|Other: Infusion of mixture of anticancer agent and lipiodol	Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT01229839
911	Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II Trial	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Atezolizumab (neoadjuvant)|Procedure: Percutaneous Radiofrequency|Drug: Bevacizumab (adjuvant)|Drug: Atezolizumab (adjuvant)	CHU Amiens, Amiens, France|CHU d'Angers, Angers, France|Hôpital Jean Verdier, Bondy, France|Hôpital Beaujon, Clichy, France|Centre Georges François Leclerc, Dijon, France|CHU Dijon, Dijon, France|CHU de Grenoble, Grenoble, France|CHU de Lille, Lille, France|Hôpital Saint Joseph, Marseille, France|CHU de Montpellier, Montpellier, France|CHRU de Nancy, Nancy, France|CHU de Nantes, Nantes, France|CHU de Nice, Nice, France|CHU Nîmes, Nîmes, France|Hôpital Cochin, Paris, France|CH Perpignan, Perpignan, France|CHU de Poitiers, Poitiers, France|CHU de Rennes, Rennes, France|Institut Gustave Roussy, Villejuif, France	https://ClinicalTrials.gov/show/NCT04727307
912	Liver Disease and Other Systemic Diseases	Recruiting	No Results Available	Liver Diseases|Humans|Progression|Carcinogenesis|Fatty Liver Disease|Hepatitis C|Hepatitis B|Hepatocellular Carcinoma|Liver Cirrhoses|Treatment Outcome		Ching-Sheng Hsu, New Taipei City, Taiwan	https://ClinicalTrials.gov/show/NCT04525833
913	A Study of HCC High Risk Group Using Two Surveillance Tools	Completed	No Results Available	HCC	Drug: non-ionic monomer iodinated CT contrast media	Seoul National University Hospital, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT02675920
914	Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery	Completed	No Results Available	Adult Acute Lymphoblastic Leukemia in Remission|Adult B Acute Lymphoblastic Leukemia|Adult Hepatocellular Carcinoma|Adult Nasal Type Extranodal NK/T-Cell Lymphoma|Adult Solid Neoplasm|Adult T Acute Lymphoblastic Leukemia|Advanced Adult Hepatocellular Carcinoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-Cell Lymphoma|Chronic Lymphocytic Leukemia|Cutaneous B-Cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Hepatosplenic T-Cell Lymphoma|Intraocular Lymphoma|Localized Non-Resectable Adult Liver Carcinoma|Localized Resectable Adult Liver Carcinoma|Lymphomatous Involvement of Non-Cutaneous Extranodal Site|Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Nodal Marginal Zone Lymphoma|Progressive Hairy Cell Leukemia Initial Treatment|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Lymphoma|Recurrent Adult Liver Carcinoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-Cell Leukemia/Lymphoma|Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides and Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Small Intestinal Lymphoma|Splenic Marginal Zone Lymphoma|Stage II Small Lymphocytic Lymphoma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-Cell Leukemia/Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Small Lymphocytic Lymphoma|Stage IIIA Mycosis Fungoides and Sezary Syndrome|Stage IIIB Mycosis Fungoides and Sezary Syndrome|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-Cell Leukemia/Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma|Stage IVA Mycosis Fungoides and Sezary Syndrome|Stage IVB Mycosis Fungoides and Sezary Syndrome|T-Cell Large Granular Lymphocyte Leukemia|Testicular Lymphoma|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Hairy Cell Leukemia|Waldenstrom Macroglobulinemia	Drug: Dasatinib|Other: Pharmacological Study	City of Hope Comprehensive Cancer Center, Duarte, California, United States|Los Angeles County-USC Medical Center, Los Angeles, California, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|Hays Medical Center, Hays, Kansas, United States|Hutchinson Regional Medical Center, Hutchinson, Kansas, United States|University of Kansas Cancer Center, Kansas City, Kansas, United States|Olathe Cancer Center, Olathe, Kansas, United States|Via Christi Hospital-Pittsburg, Pittsburg, Kansas, United States|Salina Regional Health Center, Salina, Kansas, United States|Saint Francis Hospital and Medical Center - Topeka, Topeka, Kansas, United States|Henry Ford Hospital, Detroit, Michigan, United States|Truman Medical Center, Kansas City, Missouri, United States|Audie L Murphy Veterans Affairs Hospital, San Antonio, Texas, United States|Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio, Texas, United States|University Hospital, San Antonio, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Scott and White Memorial Hospital, Temple, Texas, United States|Swedish Medical Center-Edmonds, Edmonds, Washington, United States|Swedish Cancer Institute-Issaquah, Issaquah, Washington, United States|Swedish Medical Center-Ballard Campus, Seattle, Washington, United States|Swedish Medical Center-First Hill, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States	https://ClinicalTrials.gov/show/NCT00608361
915	IL-2 Expressing, Attenuated Salmonella Typhimurium in Unresectable Hepatic Spread	Completed	Has Results	Cancer of the Liver|Liver Cancer|Hepatoma|Liver Neoplasms|Biliary Cancer	Biological: Salmonella typhimurium	Edward W. Greeno, MD, Minneapolis, Minnesota, United States	https://ClinicalTrials.gov/show/NCT01099631
916	Robotic Endomicroscopy to Better Define Resection Strategies Applied to Hepatic Surgery	Unknown status	No Results Available	Hepatocarcinoma|Hepatic Metastasis|Hepatic Tumor	Device: Confocal Laser Endomicroscopy	Institut Mutualiste Montsouris, Paris, France	https://ClinicalTrials.gov/show/NCT03718078
917	COVID19-FOIE National Observatory	Unknown status	No Results Available	Liver Diseases|COVID19		Ganne, Bondy, France	https://ClinicalTrials.gov/show/NCT04375670
918	National Cohort of Uncomplicated Alcoholic Cirrhosis	Unknown status	No Results Available	Alcoholic Cirrhosis		Jean Verdier hospital (AP-HP), Bondy, France	https://ClinicalTrials.gov/show/NCT01213927
919	The Development of Diagnostic Biomarker Panels for Hepatitis and Liver Cancer	Unknown status	No Results Available	Hepatitis B,Chronic|Carcinoma,Hepatocellular		Sultanah Bahiyah Hospital, Alor Star, Kedah, Malaysia|Queen Elizabeth Hospital, Kota Kinabalu, Sabah, Malaysia|Hospital Umum Kuching Sarawak, Kuching, Sarawak, Malaysia|Selayang Hospital, Selayang, Selangor, Malaysia|Kuala Lumpur Hospital, Kuala Lumpur, Wilayah Persekutuan, Malaysia|Island Hospital, Pulau Pinang, Malaysia|Lam Wah Ee Hospital, Pulau Pinang, Malaysia|Penang Hospital, Pulau Pinang, Malaysia	https://ClinicalTrials.gov/show/NCT01310062
920	Optimization for Regorafenib in HCC	Terminated	No Results Available	Hepatocellular Carcinoma	Drug: Regorafenib 40 MG	Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|VA Long Beach Health System, Long Beach, California, United States|Tulane University, New Orleans, Louisiana, United States|Henry Ford Health Systems, Detroit, Michigan, United States|Cancer and Hematology Centers of Western Michigan, Grand Rapids, Michigan, United States|Saint Louis University, Saint Louis, Missouri, United States|Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Albert Einstein Medical Center, Philadelphia, Pennsylvania, United States	https://ClinicalTrials.gov/show/NCT04476329
921	Atropine for Prevention of Dysrhythmias Caused by Percutaneous Ethanol Instillation for Hepatoma Therapy	Completed	No Results Available	Arrhythmia|Respiratory Arrest	Drug: Atropine|Drug: Placebo	Div. of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria	https://ClinicalTrials.gov/show/NCT00575523
922	TIPS Combined With Microwave Ablation in HCC Patients With Refractory Ascites	Not yet recruiting	No Results Available	Liver Diseases|Portal Hypertension|Cirrhosis, Liver|Ascites|Hepatocellular Carcinoma	Procedure: Transjugular intrahepatic portosystemic shunt (TIPS)|Procedure: microwave ablation (MWA)		https://ClinicalTrials.gov/show/NCT04640116
923	RFA or Surgical Resection Combined With Neo-MASCT for Primary HCC: a Phase II Trial	Recruiting	No Results Available	Primary Liver Cancer|Radiofrequency Ablation|Immunotherapy|Hepatectomy	Biological: Neo-MASCT	The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT03067493
924	A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatocellular Carcinoma	Withdrawn	No Results Available	Carcinoma, Hepatocellular	Drug: ABC294640	Medical University of South Carolina, Charleston, South Carolina, United States	https://ClinicalTrials.gov/show/NCT02939807
925	A Study of Recombinant Vaccinia Virus Prior to Sorafenib to Treat Unresectable Primary Hepatocellular Carcinoma	Completed	No Results Available	Carcinoma, Hepatocellular	Drug: JX-594 followed by sorafenib	Pusan National University Hospital, Busan, Korea, Republic of|Pusan National University Yangsan Hospital, Yangsan, Korea, Republic of	https://ClinicalTrials.gov/show/NCT01171651
926	68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer	Recruiting	No Results Available	Advanced Hepatocellular Carcinoma|Stage III Hepatocellular Carcinoma AJCC v8|Stage IIIA Hepatocellular Carcinoma AJCC v8|Stage IIIB Hepatocellular Carcinoma AJCC v8|Stage IV Hepatocellular Carcinoma AJCC v8|Stage IVA Hepatocellular Carcinoma AJCC v8|Stage IVB Hepatocellular Carcinoma AJCC v8|Unresectable Hepatocellular Carcinoma	Procedure: Computed Tomography|Radiation: Gallium Ga 68 Gozetotide|Procedure: Positron Emission Tomography	Mayo Clinic in Rochester, Rochester, Minnesota, United States	https://ClinicalTrials.gov/show/NCT05176223
927	Resveratrol and Human Hepatocyte Function in Cancer	Withdrawn	No Results Available	Liver Cancer	Dietary Supplement: Resveratrol|Drug: Placebo	University of Louisville, Louisville, Kentucky, United States	https://ClinicalTrials.gov/show/NCT02261844
928	Infrahepatic Inferior Vena Cava Clamping Versus Selective Hepatic Vascular Exclusion Involving the Portal Triad Clamping	Unknown status	No Results Available	Liver Neoplasms|Liver Cirrhosis	Procedure: Infrahepatic inferior vena cava clamping|Procedure: Selective hepatic vascular exclusion|Procedure: Portal triad clamping	Tongji Hospital, Wuhan, Hubei, China	https://ClinicalTrials.gov/show/NCT02405416
929	Radiomics for Diagnosing Liver Diseases and Evaluating Progression	Enrolling by invitation	No Results Available	Hepatitis B / Liver Space-occupying Lesions / Patients After Ablation	Diagnostic Test: radiomics	The department of Ultrasound, the third affiliated hospital of Sun Yat-son University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT03221049
930	TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma	Recruiting	No Results Available	HCC	Procedure: TACE|Radiation: SBRT|Drug: Durvalumab|Drug: Tremelimumab	Department of Surgery, The University of Hong Kong, Hong Kong, Hong Kong|The University of Hong Kong, Hong Kong, Hong Kong	https://ClinicalTrials.gov/show/NCT04988945
931	Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver	Suspended	No Results Available	Metastatic Cholangiocarcinoma|Metastatic Hepatocellular Carcinoma|Stage III Hepatocellular Carcinoma AJCC v8|Stage III Intrahepatic Cholangiocarcinoma AJCC v8|Stage IIIA Hepatocellular Carcinoma AJCC v8|Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8|Stage IIIB Hepatocellular Carcinoma AJCC v8|Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8|Stage IV Hepatocellular Carcinoma AJCC v8|Stage IV Intrahepatic Cholangiocarcinoma AJCC v8|Stage IVA Hepatocellular Carcinoma AJCC v8|Stage IVB Hepatocellular Carcinoma AJCC v8|Unresectable Cholangiocarcinoma|Unresectable Hepatocellular Carcinoma|Unresectable Intrahepatic Cholangiocarcinoma	Drug: Carboplatin|Drug: Paclitaxel|Drug: Pevonedistat	Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States|Anchorage Radiation Therapy Center, Anchorage, Alaska, United States|Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States|Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States|Alaska Women's Cancer Care, Anchorage, Alaska, United States|Anchorage Oncology Centre, Anchorage, Alaska, United States|Katmai Oncology Group, Anchorage, Alaska, United States|Providence Alaska Medical Center, Anchorage, Alaska, United States|Kingman Regional Medical Center, Kingman, Arizona, United States|Cancer Center at Saint Joseph's, Phoenix, Arizona, United States|CHI Saint Vincent Cancer Center Hot Springs, Hot Springs, Arkansas, United States|Mission Hope Medical Oncology - Arroyo Grande, Arroyo Grande, California, United States|PCR Oncology, Arroyo Grande, California, United States|Sutter Auburn Faith Hospital, Auburn, California, United States|Sutter Cancer Centers Radiation Oncology Services-Auburn, Auburn, California, United States|Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States|Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States|Sutter Cancer Centers Radiation Oncology Services-Cameron Park, Cameron Park, California, United States|Eden Hospital Medical Center, Castro Valley, California, United States|Sutter Davis Hospital, Davis, California, United States|City of Hope Comprehensive Cancer Center, Duarte, California, United States|Palo Alto Medical Foundation-Fremont, Fremont, California, United States|Memorial Medical Center, Modesto, California, United States|Palo Alto Medical Foundation-Camino Division, Mountain View, California, United States|Palo Alto Medical Foundation-Gynecologic Oncology, Mountain View, California, United States|Palo Alto Medical Foundation Health Care, Palo Alto, California, United States|Sutter Cancer Centers Radiation Oncology Services-Roseville, Roseville, California, United States|Sutter Roseville Medical Center, Roseville, California, United States|Sutter Medical Center Sacramento, Sacramento, California, United States|California Pacific Medical Center-Pacific Campus, San Francisco, California, United States|Mills Health Center, San Mateo, California, United States|Palo Alto Medical Foundation-Santa Cruz, Santa Cruz, California, United States|Mission Hope Medical Oncology - Santa Maria, Santa Maria, California, United States|Sutter Pacific Medical Foundation, Santa Rosa, California, United States|Palo Alto Medical Foundation-Sunnyvale, Sunnyvale, California, United States|Sutter Cancer Centers Radiation Oncology Services-Vacaville, Vacaville, California, United States|Sutter Solano Medical Center/Cancer Center, Vallejo, California, United States|Penrose-Saint Francis Healthcare, Colorado Springs, Colorado, United States|Rocky Mountain Cancer Centers-Penrose, Colorado Springs, Colorado, United States|UCHealth Memorial Hospital Central, Colorado Springs, Colorado, United States|Memorial Hospital North, Colorado Springs, Colorado, United States|Porter Adventist Hospital, Denver, Colorado, United States|Mercy Medical Center, Durango, Colorado, United States|Southwest Oncology PC, Durango, Colorado, United States|Poudre Valley Hospital, Fort Collins, Colorado, United States|Cancer Care and Hematology-Fort Collins, Fort Collins, Colorado, United States|UCHealth Greeley Hospital, Greeley, Colorado, United States|Saint Anthony Hospital, Lakewood, Colorado, United States|Littleton Adventist Hospital, Littleton, Colorado, United States|Longmont United Hospital, Longmont, Colorado, United States|Rocky Mountain Cancer Centers-Longmont, Longmont, Colorado, United States|Medical Center of the Rockies, Loveland, Colorado, United States|Parker Adventist Hospital, Parker, Colorado, United States|Saint Mary Corwin Medical Center, Pueblo, Colorado, United States|UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States|UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach, Florida, United States|Holy Cross Hospital, Fort Lauderdale, Florida, United States|University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States|UM Sylvester Comprehensive Cancer Center at Kendall, Miami, Florida, United States|UM Sylvester Comprehensive Cancer Center at Plantation, Plantation, Florida, United States|Hawaii Cancer Care - Savio, 'Aiea, Hawaii, United States|Pali Momi Medical Center, 'Aiea, Hawaii, United States|Queen's Cancer Center - Pearlridge, 'Aiea, Hawaii, United States|The Cancer Center of Hawaii-Pali Momi, 'Aiea, Hawaii, United States|Hawaii Cancer Care Inc - Waterfront Plaza, Honolulu, Hawaii, United States|Island Urology, Honolulu, Hawaii, United States|Queen's Cancer Cenrer - POB I, Honolulu, Hawaii, United States|Queen's Medical Center, Honolulu, Hawaii, United States|Straub Clinic and Hospital, Honolulu, Hawaii, United States|University of Hawaii Cancer Center, Honolulu, Hawaii, United States|Hawaii Cancer Care Inc-Liliha, Honolulu, Hawaii, United States|Kuakini Medical Center, Honolulu, Hawaii, United States|Queen's Cancer Center - Kuakini, Honolulu, Hawaii, United States|The Cancer Center of Hawaii-Liliha, Honolulu, Hawaii, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Wilcox Memorial Hospital and Kauai Medical Clinic, Lihue, Hawaii, United States|Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States|Saint Luke's Cancer Institute - Boise, Boise, Idaho, United States|Saint Alphonsus Cancer Care Center-Caldwell, Caldwell, Idaho, United States|Kootenai Health - Coeur d'Alene, Coeur d'Alene, Idaho, United States|Walter Knox Memorial Hospital, Emmett, Idaho, United States|Saint Luke's Cancer Institute - Fruitland, Fruitland, Idaho, United States|Idaho Urologic Institute-Meridian, Meridian, Idaho, United States|Saint Luke's Cancer Institute - Meridian, Meridian, Idaho, United States|Saint Alphonsus Medical Center-Nampa, Nampa, Idaho, United States|Saint Luke's Cancer Institute - Nampa, Nampa, Idaho, United States|Kootenai Clinic Cancer Services - Post Falls, Post Falls, Idaho, United States|Kootenai Cancer Clinic, Sandpoint, Idaho, United States|Saint Luke's Cancer Institute - Twin Falls, Twin Falls, Idaho, United States|Northwestern University, Chicago, Illinois, United States|Northwestern Medicine Lake Forest Hospital, Lake Forest, Illinois, United States|Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|Franciscan Health Indianapolis, Indianapolis, Indiana, United States|Franciscan Health Mooresville, Mooresville, Indiana, United States|Reid Health, Richmond, Indiana, United States|Union Hospital, Terre Haute, Indiana, United States|Mary Greeley Medical Center, Ames, Iowa, United States|McFarland Clinic PC - Ames, Ames, Iowa, United States|McFarland Clinic PC-Boone, Boone, Iowa, United States|Medical Oncology and Hematology Associates-West Des Moines, Clive, Iowa, United States|Mercy Cancer Center-West Lakes, Clive, Iowa, United States|Alegent Health Mercy Hospital, Council Bluffs, Iowa, United States|Greater Regional Medical Center, Creston, Iowa, United States|Iowa Methodist Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Des Moines, Des Moines, Iowa, United States|Broadlawns Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Laurel, Des Moines, Iowa, United States|Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|Iowa Lutheran Hospital, Des Moines, Iowa, United States|McFarland Clinic PC-Trinity Cancer Center, Fort Dodge, Iowa, United States|Trinity Regional Medical Center, Fort Dodge, Iowa, United States|McFarland Clinic PC-Jefferson, Jefferson, Iowa, United States|McFarland Clinic PC-Marshalltown, Marshalltown, Iowa, United States|Methodist West Hospital, West Des Moines, Iowa, United States|Mercy Medical Center-West Lakes, West Des Moines, Iowa, United States|University of Kansas Clinical Research Center, Fairway, Kansas, United States|HaysMed University of Kansas Health System, Hays, Kansas, United States|University of Kansas Cancer Center-West, Kansas City, Kansas, United States|University of Kansas Cancer Center, Kansas City, Kansas, United States|Lawrence Memorial Hospital, Lawrence, Kansas, United States|Olathe Health Cancer Center, Olathe, Kansas, United States|University of Kansas Cancer Center-Overland Park, Overland Park, Kansas, United States|Ascension Via Christi - Pittsburg, Pittsburg, Kansas, United States|Salina Regional Health Center, Salina, Kansas, United States|University of Kansas Health System Saint Francis Campus, Topeka, Kansas, United States|University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas, United States|Flaget Memorial Hospital, Bardstown, Kentucky, United States|Commonwealth Cancer Center-Corbin, Corbin, Kentucky, United States|Saint Joseph Radiation Oncology Resource Center, Lexington, Kentucky, United States|Saint Joseph Hospital East, Lexington, Kentucky, United States|Saint Joseph London, London, Kentucky, United States|Jewish Hospital, Louisville, Kentucky, United States|Saints Mary and Elizabeth Hospital, Louisville, Kentucky, United States|UofL Health Medical Center Northeast, Louisville, Kentucky, United States|Jewish Hospital Medical Center South, Shepherdsville, Kentucky, United States|Lafayette Family Cancer Center-EMMC, Brewer, Maine, United States|Mercy Medical Center, Springfield, Massachusetts, United States|UMass Memorial Medical Center - University Campus, Worcester, Massachusetts, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|Bronson Battle Creek, Battle Creek, Michigan, United States|McLaren Cancer Institute-Bay City, Bay City, Michigan, United States|IHA Hematology Oncology Consultants-Brighton, Brighton, Michigan, United States|Saint Joseph Mercy Brighton, Brighton, Michigan, United States|IHA Hematology Oncology Consultants-Canton, Canton, Michigan, United States|Saint Joseph Mercy Canton, Canton, Michigan, United States|Caro Cancer Center, Caro, Michigan, United States|IHA Hematology Oncology Consultants-Chelsea, Chelsea, Michigan, United States|Saint Joseph Mercy Chelsea, Chelsea, Michigan, United States|Hematology Oncology Consultants-Clarkston, Clarkston, Michigan, United States|McLaren Cancer Institute-Clarkston, Clarkston, Michigan, United States|Newland Medical Associates-Clarkston, Clarkston, Michigan, United States|Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States|Ascension Saint John Hospital, Detroit, Michigan, United States|Great Lakes Cancer Management Specialists-Doctors Park, East China Township, Michigan, United States|Weisberg Cancer Treatment Center, Farmington Hills, Michigan, United States|Genesee Cancer and Blood Disease Treatment Center, Flint, Michigan, United States|Genesee Hematology Oncology PC, Flint, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|McLaren Cancer Institute-Flint, Flint, Michigan, United States|Singh and Arora Hematology Oncology PC, Flint, Michigan, United States|Helen DeVos Children's Hospital at Spectrum Health, Grand Rapids, Michigan, United States|Mercy Health Saint Mary's, Grand Rapids, Michigan, United States|Spectrum Health at Butterworth Campus, Grand Rapids, Michigan, United States|Academic Hematology Oncology Specialists, Grosse Pointe Woods, Michigan, United States|Great Lakes Cancer Management Specialists-Van Elslander Cancer Center, Grosse Pointe Woods, Michigan, United States|Michigan Breast Specialists-Grosse Pointe Woods, Grosse Pointe Woods, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Borgess Medical Center, Kalamazoo, Michigan, United States|Karmanos Cancer Institute at McLaren Greater Lansing, Lansing, Michigan, United States|Mid-Michigan Physicians-Lansing, Lansing, Michigan, United States|Sparrow Hospital, Lansing, Michigan, United States|McLaren Cancer Institute-Lapeer Region, Lapeer, Michigan, United States|Hope Cancer Clinic, Livonia, Michigan, United States|Saint Mary Mercy Hospital, Livonia, Michigan, United States|Great Lakes Cancer Management Specialists-Macomb Medical Campus, Macomb, Michigan, United States|Michigan Breast Specialists-Macomb Township, Macomb, Michigan, United States|Saint Mary's Oncology/Hematology Associates of Marlette, Marlette, Michigan, United States|McLaren Cancer Institute-Macomb, Mount Clemens, Michigan, United States|McLaren Cancer Institute-Central Michigan, Mount Pleasant, Michigan, United States|Mercy Health Mercy Campus, Muskegon, Michigan, United States|Lakeland Hospital Niles, Niles, Michigan, United States|Cancer and Hematology Centers of Western Michigan - Norton Shores, Norton Shores, Michigan, United States|McLaren Cancer Institute-Northern Michigan, Petoskey, Michigan, United States|21st Century Oncology-Pontiac, Pontiac, Michigan, United States|Hope Cancer Center, Pontiac, Michigan, United States|Newland Medical Associates-Pontiac, Pontiac, Michigan, United States|Saint Joseph Mercy Oakland, Pontiac, Michigan, United States|McLaren-Port Huron, Port Huron, Michigan, United States|Spectrum Health Reed City Hospital, Reed City, Michigan, United States|Great Lakes Cancer Management Specialists-Rochester Hills, Rochester Hills, Michigan, United States|Ascension Saint Mary's Hospital, Saginaw, Michigan, United States|Oncology Hematology Associates of Saginaw Valley PC, Saginaw, Michigan, United States|Lakeland Medical Center Saint Joseph, Saint Joseph, Michigan, United States|Marie Yeager Cancer Center, Saint Joseph, Michigan, United States|Bhadresh Nayak MD PC-Sterling Heights, Sterling Heights, Michigan, United States|Ascension Saint Joseph Hospital, Tawas City, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|Advanced Breast Care Center PLLC, Warren, Michigan, United States|Great Lakes Cancer Management Specialists-Macomb Professional Building, Warren, Michigan, United States|Macomb Hematology Oncology PC, Warren, Michigan, United States|Michigan Breast Specialists-Warren, Warren, Michigan, United States|Saint John Macomb-Oakland Hospital, Warren, Michigan, United States|Saint Mary's Oncology/Hematology Associates of West Branch, West Branch, Michigan, United States|Metro Health Hospital, Wyoming, Michigan, United States|Huron Gastroenterology PC, Ypsilanti, Michigan, United States|IHA Hematology Oncology Consultants-Ann Arbor, Ypsilanti, Michigan, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Minnesota Oncology - Burnsville, Burnsville, Minnesota, United States|Cambridge Medical Center, Cambridge, Minnesota, United States|Mercy Hospital, Coon Rapids, Minnesota, United States|Fairview Southdale Hospital, Edina, Minnesota, United States|Unity Hospital, Fridley, Minnesota, United States|Fairview Clinics and Surgery Center Maple Grove, Maple Grove, Minnesota, United States|Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota, United States|Saint John's Hospital - Healtheast, Maplewood, Minnesota, United States|Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Health Partners Inc, Minneapolis, Minnesota, United States|Monticello Cancer Center, Monticello, Minnesota, United States|New Ulm Medical Center, New Ulm, Minnesota, United States|Fairview Northland Medical Center, Princeton, Minnesota, United States|North Memorial Medical Health Center, Robbinsdale, Minnesota, United States|Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Saint Francis Regional Medical Center, Shakopee, Minnesota, United States|Lakeview Hospital, Stillwater, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Rice Memorial Hospital, Willmar, Minnesota, United States|Minnesota Oncology Hematology PA-Woodbury, Woodbury, Minnesota, United States|Fairview Lakes Medical Center, Wyoming, Minnesota, United States|Truman Medical Centers, Kansas City, Missouri, United States|University of Kansas Cancer Center - North, Kansas City, Missouri, United States|University of Kansas Cancer Center - Lee's Summit, Lee's Summit, Missouri, United States|University of Kansas Cancer Center at North Kansas City Hospital, North Kansas City, Missouri, United States|Community Hospital of Anaconda, Anaconda, Montana, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Bozeman Deaconess Hospital, Bozeman, Montana, United States|Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana, United States|Great Falls Clinic, Great Falls, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Saint Patrick Hospital - Community Hospital, Missoula, Montana, United States|Community Medical Hospital, Missoula, Montana, United States|CHI Health Saint Francis, Grand Island, Nebraska, United States|CHI Health Good Samaritan, Kearney, Nebraska, United States|Saint Elizabeth Regional Medical Center, Lincoln, Nebraska, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|Alegent Health Immanuel Medical Center, Omaha, Nebraska, United States|Alegent Health Bergan Mercy Medical Center, Omaha, Nebraska, United States|Alegent Health Lakeside Hospital, Omaha, Nebraska, United States|Creighton University Medical Center, Omaha, Nebraska, United States|Midlands Community Hospital, Papillion, Nebraska, United States|Carson Tahoe Regional Medical Center, Carson City, Nevada, United States|Cancer and Blood Specialists-Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada - Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada-Horizon Ridge, Henderson, Nevada, United States|Las Vegas Cancer Center-Henderson, Henderson, Nevada, United States|OptumCare Cancer Care at Seven Hills, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada-Southeast Henderson, Henderson, Nevada, United States|GenesisCare USA - Henderson, Henderson, Nevada, United States|Las Vegas Urology - Green Valley, Henderson, Nevada, United States|Las Vegas Urology - Pebble, Henderson, Nevada, United States|Urology Specialists of Nevada - Green Valley, Henderson, Nevada, United States|Las Vegas Urology - Pecos, Las Vegas, Nevada, United States|Desert West Surgery, Las Vegas, Nevada, United States|OptumCare Cancer Care at Charleston, Las Vegas, Nevada, United States|University Medical Center of Southern Nevada, Las Vegas, Nevada, United States|Hope Cancer Care of Nevada, Las Vegas, Nevada, United States|Cancer and Blood Specialists-Shadow, Las Vegas, Nevada, United States|Radiation Oncology Centers of Nevada Central, Las Vegas, Nevada, United States|Urology Specialists of Nevada - Central, Las Vegas, Nevada, United States|GenesisCare USA - Las Vegas, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway, Las Vegas, Nevada, United States|Sunrise Hospital and Medical Center, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-San Martin, Las Vegas, Nevada, United States|Las Vegas Prostate Cancer Center, Las Vegas, Nevada, United States|Las Vegas Urology - Sunset, Las Vegas, Nevada, United States|Urology Specialists of Nevada - Southwest, Las Vegas, Nevada, United States|Radiation Oncology Centers of Nevada Southeast, Las Vegas, Nevada, United States|Ann M Wierman MD LTD, Las Vegas, Nevada, United States|Cancer and Blood Specialists-Tenaya, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada - Northwest, Las Vegas, Nevada, United States|GenesisCare USA - Vegas Tenaya, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Tenaya, Las Vegas, Nevada, United States|Las Vegas Urology - Cathedral Rock, Las Vegas, Nevada, United States|Las Vegas Urology - Smoke Ranch, Las Vegas, Nevada, United States|OptumCare Cancer Care at MountainView, Las Vegas, Nevada, United States|Urology Specialists of Nevada - Northwest, Las Vegas, Nevada, United States|Alliance for Childhood Diseases/Cure 4 the Kids Foundation, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada - Town Center, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada-Summerlin, Las Vegas, Nevada, United States|Summerlin Hospital Medical Center, Las Vegas, Nevada, United States|Las Vegas Cancer Center-Medical Center, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|GenesisCare USA - Fort Apache, Las Vegas, Nevada, United States|OptumCare Cancer Care at Fort Apache, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada - Central Valley, Las Vegas, Nevada, United States|University Cancer Center, Las Vegas, Nevada, United States|Hope Cancer Care of Nevada-Pahrump, Pahrump, Nevada, United States|Renown Regional Medical Center, Reno, Nevada, United States|Saint Mary's Regional Medical Center, Reno, Nevada, United States|Radiation Oncology Associates, Reno, Nevada, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Holy Name Hospital, Teaneck, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|University of Rochester, Rochester, New York, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|University of North Carolina-Hillsborough Campus, Hillsborough, North Carolina, United States|Indu and Raj Soin Medical Center, Beavercreek, Ohio, United States|Saint Elizabeth Boardman Hospital, Boardman, Ohio, United States|Dayton Physicians LLC-Miami Valley South, Centerville, Ohio, United States|Miami Valley Hospital South, Centerville, Ohio, United States|Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio, United States|Oncology Hematology Care Inc-Kenwood, Cincinnati, Ohio, United States|Bethesda North Hospital, Cincinnati, Ohio, United States|TriHealth Cancer Institute-Westside, Cincinnati, Ohio, United States|TriHealth Cancer Institute-Anderson, Cincinnati, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|Dayton Physician LLC-Miami Valley Hospital North, Dayton, Ohio, United States|Miami Valley Hospital North, Dayton, Ohio, United States|Armes Family Cancer Center, Findlay, Ohio, United States|Blanchard Valley Hospital, Findlay, Ohio, United States|Orion Cancer Care, Findlay, Ohio, United States|Atrium Medical Center-Middletown Regional Hospital, Franklin, Ohio, United States|Dayton Physicians LLC-Atrium, Franklin, Ohio, United States|Dayton Physicians LLC-Wayne, Greenville, Ohio, United States|Wayne Hospital, Greenville, Ohio, United States|Greater Dayton Cancer Center, Kettering, Ohio, United States|First Dayton Cancer Care, Kettering, Ohio, United States|Kettering Medical Center, Kettering, Ohio, United States|Cleveland Clinic Cancer Center Mansfield, Mansfield, Ohio, United States|Hillcrest Hospital Cancer Center, Mayfield Heights, Ohio, United States|North Coast Cancer Care, Sandusky, Ohio, United States|Cleveland Clinic Cancer Center Strongsville, Strongsville, Ohio, United States|Dayton Physicians LLC-Upper Valley, Troy, Ohio, United States|Upper Valley Medical Center, Troy, Ohio, United States|South Pointe Hospital, Warrensville Heights, Ohio, United States|Saint Joseph Warren Hospital, Warren, Ohio, United States|Cleveland Clinic Wooster Family Health and Surgery Center, Wooster, Ohio, United States|Saint Elizabeth Youngstown Hospital, Youngstown, Ohio, United States|Cancer Centers of Southwest Oklahoma Research, Lawton, Oklahoma, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Saint Alphonsus Medical Center-Baker City, Baker City, Oregon, United States|Saint Charles Health System, Bend, Oregon, United States|Clackamas Radiation Oncology Center, Clackamas, Oregon, United States|Providence Cancer Institute Clackamas Clinic, Clackamas, Oregon, United States|Bay Area Hospital, Coos Bay, Oregon, United States|Providence Newberg Medical Center, Newberg, Oregon, United States|Saint Alphonsus Medical Center-Ontario, Ontario, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence Saint Vincent Medical Center, Portland, Oregon, United States|Saint Charles Health System-Redmond, Redmond, Oregon, United States|Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania, United States|Lehigh Valley Hospital - Muhlenberg, Bethlehem, Pennsylvania, United States|Pocono Medical Center, East Stroudsburg, Pennsylvania, United States|Lehigh Valley Hospital-Hazleton, Hazleton, Pennsylvania, United States|University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States|Prisma Health Cancer Institute - Spartanburg, Boiling Springs, South Carolina, United States|Prisma Health Cancer Institute - Easley, Easley, South Carolina, United States|Prisma Health Cancer Institute - Butternut, Greenville, South Carolina, United States|Prisma Health Cancer Institute - Faris, Greenville, South Carolina, United States|Prisma Health Cancer Institute - Eastside, Greenville, South Carolina, United States|Prisma Health Cancer Institute - Greer, Greer, South Carolina, United States|Prisma Health Cancer Institute - Seneca, Seneca, South Carolina, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Bristol Regional Medical Center, Bristol, Tennessee, United States|Vanderbilt-Ingram Cancer Center at Franklin, Franklin, Tennessee, United States|Vanderbilt-Ingram Cancer Center Cool Springs, Franklin, Tennessee, United States|Ballad Health Cancer Care - Kingsport, Kingsport, Tennessee, United States|Wellmont Holston Valley Hospital and Medical Center, Kingsport, Tennessee, United States|Vanderbilt Breast Center at One Hundred Oaks, Nashville, Tennessee, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States|Saint Joseph Regional Cancer Center, Bryan, Texas, United States|Parkland Memorial Hospital, Dallas, Texas, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States|UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth, Texas, United States|UT Southwestern Clinical Center at Richardson/Plano, Richardson, Texas, United States|Wellmont Medical Associates-Bristol, Bristol, Virginia, United States|Sovah Health Martinsville, Martinsville, Virginia, United States|Southwest VA Regional Cancer Center, Norton, Virginia, United States|Providence Regional Cancer System-Aberdeen, Aberdeen, Washington, United States|Overlake Medical Center, Bellevue, Washington, United States|PeaceHealth Saint Joseph Medical Center, Bellingham, Washington, United States|Harrison HealthPartners Hematology and Oncology-Bremerton, Bremerton, Washington, United States|Harrison Medical Center, Bremerton, Washington, United States|Highline Medical Center-Main Campus, Burien, Washington, United States|Providence Regional Cancer System-Centralia, Centralia, Washington, United States|Swedish Cancer Institute-Edmonds, Edmonds, Washington, United States|Saint Elizabeth Hospital, Enumclaw, Washington, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Saint Francis Hospital, Federal Way, Washington, United States|Swedish Cancer Institute-Issaquah, Issaquah, Washington, United States|Kadlec Clinic Hematology and Oncology, Kennewick, Washington, United States|Providence Regional Cancer System-Lacey, Lacey, Washington, United States|Saint Clare Hospital, Lakewood, Washington, United States|PeaceHealth Saint John Medical Center, Longview, Washington, United States|Harrison HealthPartners Hematology and Oncology-Poulsbo, Poulsbo, Washington, United States|Valley Medical Center, Renton, Washington, United States|Pacific Gynecology Specialists, Seattle, Washington, United States|Swedish Medical Center-Ballard Campus, Seattle, Washington, United States|Swedish Medical Center-First Hill, Seattle, Washington, United States|Swedish Medical Center-Cherry Hill, Seattle, Washington, United States|PeaceHealth United General Medical Center, Sedro-Woolley, Washington, United States|Providence Regional Cancer System-Shelton, Shelton, Washington, United States|Franciscan Research Center-Northwest Medical Plaza, Tacoma, Washington, United States|Northwest Medical Specialties PLLC, Tacoma, Washington, United States|PeaceHealth Southwest Medical Center, Vancouver, Washington, United States|Providence Saint Mary Regional Cancer Center, Walla Walla, Washington, United States|Providence Regional Cancer System-Yelm, Yelm, Washington, United States|University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States|Froedtert Menomonee Falls Hospital, Menomonee Falls, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Cancer Center of Western Wisconsin, New Richmond, Wisconsin, United States|Froedtert West Bend Hospital/Kraemer Cancer Center, West Bend, Wisconsin, United States|Billings Clinic-Cody, Cody, Wyoming, United States|Welch Cancer Center, Sheridan, Wyoming, United States	https://ClinicalTrials.gov/show/NCT04175912
932	Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Systemic Therapy	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: atezolizumab plus bevacizumab	CHA Bundang Medical Center, Seongnam-si, Gyeonggi-do, Korea, Republic of	https://ClinicalTrials.gov/show/NCT05197504
933	Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: atezolizumab plus bevacizumab	CHA Bundang Medical Center, Seongnam-si, Gyeonggi-do, Korea, Republic of	https://ClinicalTrials.gov/show/NCT05173298
934	Efficacy and Safety of TACE on Downstaging Hepatocellular Carcinoma Beyond UCSF Criteria;	Recruiting	No Results Available	Hepatocellular Carcinoma	Procedure: DEB-TACE|Procedure: cTACE|Device: Drug-eluting Beads|Drug: Epirubicin	Beijing Tsinghua Chang Gung Hospital, Beijing, China	https://ClinicalTrials.gov/show/NCT04738188
935	Combined Therapy for Hepatocellular Carcinoma >3-<5 cm	Completed	No Results Available	Hepatocellular Carcinoma	Procedure: Combined therapy|Procedure: Microwave ablation|Procedure: Transarterial chemoembolization		https://ClinicalTrials.gov/show/NCT04721470
936	Liver Transplantation for Unresectable GIST Liver Metastases	Not yet recruiting	No Results Available	Liver Diseases|Liver Cancer|Liver Metastases|Liver Neoplasms|Liver Mass|Liver Carcinoma|Liver Transplant; Complications|Liver Transplant Disorder|GIST|GIST, Malignant|Gastrointestinal Stromal Tumors|Gastrointestinal Stromal Tumor of Duodenum|Gastrointestinal Stromal Tumor of Rectum|Gastrointestinal Stromal Tumor of Other Sites|Gastrointestinal Stromal Tumor, Unspecified Site|Gastrointestinal Stromal Tumor of Stomach|Gastrointestinal Stromal Tumor of Esophagus (Disorder)|Gastrointestinal Stromal Tumor by AJCC V8 Stage|Gastrointestinal Stromal Tumor, Malignant|Gastrointestinal Stromal Tumor (GIST) of the Gastrointestinal Tract|Gastrointestinal Stromal Tumor of Small Intestine (Disorder)|Gastrointestinal Stromal Tumor of Large Intestine (Disorder)|Metastases to Liver|Metastatic Liver Cancer|Metastasis|Metastases|Liver Transplantation|Transplant Oncology	Procedure: Liver Transplantation	Felipe Alconchel, Murcia, Spain	https://ClinicalTrials.gov/show/NCT04825470
937	Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer	Completed	Has Results	Adult Primary Hepatocellular Carcinoma|Advanced Adult Primary Liver Cancer|Localized Unresectable Adult Primary Liver Cancer|Recurrent Adult Primary Liver Cancer|Recurrent Extrahepatic Bile Duct Cancer|Recurrent Gallbladder Cancer|Unresectable Extrahepatic Bile Duct Cancer|Unresectable Gallbladder Cancer	Drug: lapatinib ditosylate|Other: laboratory biomarker analysis	Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States	https://ClinicalTrials.gov/show/NCT00107536
938	Epidemiologic Study of Hepatocellular Carcinoma in the US	Completed	No Results Available	Hepatocellular Carcinoma		Stanford Liver Transplant Clinic, Stanford, California, United States	https://ClinicalTrials.gov/show/NCT02358070
939	Perception of the Doctor/Patient Relationship, Disease and Treatment Among Physicians and Their Patients Treated With Systemic Therapy for Hepatocellular Carcinoma "PERCEPTION1"	Recruiting	No Results Available	Hepatocellular Carcinoma	Other: Hospitalized patient with advanced hepatocellular carcinoma receiving systemic therapy.	Hôpital Avicenne, Bobigny, France|Assistance Publique - Hôpitaux de Paris, Paris, France	https://ClinicalTrials.gov/show/NCT04823754
940	Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer	Completed	No Results Available	Adult Primary Cholangiocellular Carcinoma|Adult Primary Hepatocellular Carcinoma|Advanced Adult Primary Liver Cancer|Cholangiocarcinoma of the Extrahepatic Bile Duct|Cholangiocarcinoma of the Gallbladder|Localized Unresectable Adult Primary Liver Cancer|Recurrent Adult Primary Liver Cancer|Recurrent Extrahepatic Bile Duct Cancer|Recurrent Gallbladder Cancer|Unresectable Extrahepatic Bile Duct Cancer|Unresectable Gallbladder Cancer	Drug: erlotinib hydrochloride|Other: laboratory biomarker analysis	Mayo Clinic, Rochester, Minnesota, United States	https://ClinicalTrials.gov/show/NCT00033462
941	Hepatocellular Carcinoma Imaging Using PSMA PET/CT	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: 18F-DCFPyL	St Vincent's Hospital, Fitzroy, Victoria, Australia|Austin Health, Heidelberg, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|The Royal Melbourne Hospital, Melbourne, Victoria, Australia	https://ClinicalTrials.gov/show/NCT05095519
942	To Compare the Efficacy of Microwave Ablation and Laparoscopic Hepatectomy for Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Procedure: Percutaneous microwave ablation, Laparoscopic hepatectomy	Chinese PLA General Hospital, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT04365751
943	MicroRNAs as Diagnostic Biomarkers in Hepatocellular Carcinoma Among Somali Patients	Unknown status	No Results Available	Hepatocellular Carcinoma			https://ClinicalTrials.gov/show/NCT03227510
944	Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE)	Completed	No Results Available	Hepatocellular Carcinoma	Drug: Cabozantinib group	CHU Amiens Picardie - Hôpital Sud, Amiens, France|CHU Jean Minjoz, Besançon, France|Hôpital Avicenne, Bobigny, France|Centre Hospitalier de Boulogne sur mer, Boulogne-sur-Mer, France|Centre hospitalier universitaire Côte de nacre, Caen, France|Hôpital Beaujon, Clichy, France|CHRU de Lille-Hôpital Claude Huriez, Lille, France|CHU Dupuytren, Limoges, France|Hospices Civils de Lyon - Hôpital de la Croix Rousse, Lyon, France|APHM - Timone, Marseille, France|Centre Hospitalier Universitaire de Montpellier, Montpellier, France|APHP - Hôpital St Antoine, Paris, France|Hôpital haut- lévêque, Pessac, France|Hôpital Robert Debré - CHU de Reims, Reims, France|CHRU Rennes site pontchaillou, Rennes, France|CHU de St Etienne, Saint Priest en Jarez, France|CHU Toulouse PURPAN, Toulouse, France|Hôpital Brabois adulte - CHU de Nancy, Vandoeuvre-les-Nancy, France	https://ClinicalTrials.gov/show/NCT03963206
945	Real-World Effectiveness of Regorafenib in the Treatment of Patients With Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Other: nonintervention	Henan cancer hosiptal, Zhengzhou, Henan, China	https://ClinicalTrials.gov/show/NCT05024539
946	Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Durvalumab|Drug: Tremelimumab (Regimen 1)|Drug: Tremelimumab (Regimen 2)|Drug: Sorafenib|Drug: Durvalumab (Regimen 1)|Drug: Durvalumab (Regimen 2)	Research Site, Los Angeles, California, United States|Research Site, Orange, California, United States|Research Site, San Francisco, California, United States|Research Site, Washington, District of Columbia, United States|Research Site, Fort Myers, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Westwood, Kansas, United States|Research Site, Baltimore, Maryland, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Rochester, Minnesota, United States|Research Site, New York, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Portland, Oregon, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Murray, Utah, United States|Research Site, Barretos, Brazil|Research Site, Curitiba, Brazil|Research Site, Florianopolis, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Kingston, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Quebec City, Quebec, Canada|Research Site, Sherbrooke, Quebec, Canada|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Changchun, China|Research Site, Changsha, China|Research Site, Chengdu, China|Research Site, Dalian, China|Research Site, Fuzhou, China|Research Site, Guangzhou, China|Research Site, Hangzhou, China|Research Site, Harbin, China|Research Site, Hefei, China|Research Site, Nanchang, China|Research Site, Nanjing, China|Research Site, Nanning, China|Research Site, Neijiang, China|Research Site, Shanghai, China|Research Site, Suzhou, China|Research Site, Wuhan, China|Research Site, Xian, China|Research Site, Yibin, China|Research Site, Zhengzhou, China|Research Site, Clichy, France|Research Site, Lile, France|Research Site, Lyon, France|Research Site, Marseille, France|Research Site, Montpellier, France|Research Site, Nancy, France|Research Site, Nantes, France|Research Site, Nice, France|Research Site, Pessac, France|Research Site, Poitiers, France|Research Site, Reims, France|Research Site, Rouen, France|Research Site, Saint-Etienne, France|Research Site, Toulouse, France|Research Site, Villejuif, France|Research Site, Aachen, Germany|Research Site, Essen, Germany|Research Site, Hannover, Germany|Research Site, Heidelberg, Germany|Research Site, Koeln, Germany|Research Site, Leipzig, Germany|Research Site, Mainz, Germany|Research Site, Muenchen, Germany|Research Site, Tuebingen, Germany|Research Site, Ulm, Germany|Research Site, Hong Kong, Hong Kong|Research Site, Bangalore, India|Research Site, Bhubneshwar, India|Research Site, Chennai, India|Research Site, Chennai, India|Research Site, Hubli, India|Research Site, Hyderabad, India|Research Site, Kanpur, India|Research Site, Karmsad, India|Research Site, Ludhiana, India|Research Site, Mumbai, India|Research Site, Mumbai, India|Research Site, Nashik, India|Research Site, New Delhi, India|Research Site, Benevento, Italy|Research Site, Meldola, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Perugia, Italy|Research Site, Pisa, Italy|Research Site, Roma, Italy|Research Site, Rozzano (MI), Italy|Research Site, Bunkyoku, Japan|Research Site, Chiba, Japan|Research Site, Fukuoka, Japan|Research Site, Hiroshima, Japan|Research Site, Iizuka, Japan|Research Site, Kanazawa, Japan|Research Site, Kotoku, Japan|Research Site, Kumamoto, Japan|Research Site, Kurume, Japan|Research Site, Matsuyama, Japan|Research Site, Mitakashi, Japan|Research Site, Musashino, Japan|Research Site, Nagoya, Japan|Research Site, Ogaki, Japan|Research Site, Okayama, Japan|Research Site, Osaka Sayama, Japan|Research Site, Osaka, Japan|Research Site, Osaka, Japan|Research Site, Saga, Japan|Research Site, Sapporo, Japan|Research Site, Shiwa, Japan|Research Site, Suntogun, Japan|Research Site, Tsu, Japan|Research Site, Yokohama, Japan|Research Site, Ilsan, Gyeonggi-do, Korea, Republic of|Research Site, Seongnam-si, Gyeonggi-do, Korea, Republic of|Research Site, Busan, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Murmansk, Russian Federation|Research Site, Nizhniy Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Obninsk, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Ufa, Russian Federation|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Oviedo, Spain|Research Site, Pamplona Madrid, Spain|Research Site, Santander, Spain|Research Site, Chiayi, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan, Taiwan|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Chang Mai, Thailand|Research Site, Khon Kaen, Thailand|Research Site, Phitsanulok, Thailand|Research Site, Songkhla, Thailand|Research Site, Dnipro, Ukraine|Research Site, IvanoFrankivsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kropyvnitskyi, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lviv, Ukraine|Research Site, Odesa, Ukraine|Research Site, Uzhgorod, Ukraine|Research Site, Hanoi, Vietnam|Research Site, Hochiminh, Vietnam	https://ClinicalTrials.gov/show/NCT03298451
947	The Application of Indocyanine-Green(ICG) Fluorescence Imaging in Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: Indocyanine-Green(ICG)	Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT03793322
948	Immunotherapy of Advanced Hepatitis B Related Hepatocellular Carcinoma With γδT Cells	Not yet recruiting	No Results Available	Hepatocellular Carcinoma	Biological: autologous γδT cells	Beijing 302 Hospital of China, Beijing, Beijing, China|Beijing 302 hospital, Beijing, China	https://ClinicalTrials.gov/show/NCT04032392
949	A Pilot Study of Optical Molecular Imaging for Percutaneous Biopsy of Hepatocellular Carcinoma Using Indocyanine Green	Completed	No Results Available	Hepatocellular Carcinoma	Biological: ICG|Device: Optical molecular imaging	Massachusetts General Hospital, Boston, Massachusetts, United States	https://ClinicalTrials.gov/show/NCT01962649
950	Cabozantinib in Patients With Hepatocellular Carcinoma (ACTION)	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Cabozantinib	Hospital Clinic, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Institut Català D'Oncologia - Hospital Duran I Reynals, Barcelona, Spain|Hospital Puerta de Hierro, Madrid, Spain|Hospital Ramon y Cajal, Madrid, Spain|Hospital Central de Asturias, Oviedo, Spain	https://ClinicalTrials.gov/show/NCT04316182
951	Study of Apatinib in Advanced Hepatocellular Carcinoma(HCC)	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: Apatinib	Tianjin Medical University Cancer Institute and Hospital, Tianjin, China	https://ClinicalTrials.gov/show/NCT03046979
952	Study of Apatinib Combined With TACE in Advance Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma	Procedure: TACE|Drug: Apatinib	Tianjin Medical University Cancer Hospital, Tianjin, Tianjin, China	https://ClinicalTrials.gov/show/NCT03398122
953	Evaluation of Treatment Response With Integrated MRI/PET in Patients With Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma	Device: The imaging biomarkers determined by MR-PET	National Taiwan University Hospital, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT02550613
954	A Study to Evaluate Autologous CIK Cells in Patients With Hepatocellular Carcinoma After TACE, PEIT or RFA	Unknown status	No Results Available	Hepatocellular Carcinoma	Biological: CIK Cell		https://ClinicalTrials.gov/show/NCT03124498
955	Neoadjuvant Therapy for Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: Sintilimab Injection|Drug: TACE	the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China	https://ClinicalTrials.gov/show/NCT04174781
956	Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma	Completed	Has Results	Hepatocellular Carcinoma	Drug: Pembrolizumab	University of Miami, Miami, Florida, United States	https://ClinicalTrials.gov/show/NCT02658019
957	18F-FluoroethylCholine Positron Emission Tomography: a Promising Diagnostic Tool for Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma	Device: 18F-FluoroethylCholine PET	Department of liver surgery; Peking Union Medical College Hospital, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT02238769
958	Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Sorafenib	King Saud University Medical City, Riyadh, Saudi Arabia	https://ClinicalTrials.gov/show/NCT02733809
959	Study of the Combination of TACE With Apatinib in Patients With Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma	Procedure: TACE and Apatinib|Procedure: TACE		https://ClinicalTrials.gov/show/NCT03066557
960	Phase I/II Study of OPB-31121 in Patients With Progressive Hepatocellular Carcinoma	Completed	Has Results	Hepatocellular Carcinoma	Drug: OPB-31121|Drug: OPB-31121 phase2	Chiba, Japan|Tokyo, Japan	https://ClinicalTrials.gov/show/NCT01406574
961	ATEZOLIZUMAB - BEVACIZUMAB in the Treatment Hepatocellular Carcinoma Inoperable or	Not yet recruiting	No Results Available	Advanced Hepatocellular Carcinoma			https://ClinicalTrials.gov/show/NCT04730388
962	Contrast Enhanced Ultrasound Guidance Biopsy for the Diagnosis of Liver Tumors	Unknown status	No Results Available	Liver Diseases	Procedure: Contrast enhanced ultrasound guided liver biopsy	Regional Institute of Gastroenterology and Hepatology "Octavian Fodor", Cluj-Napoca, Please Enter The State Or Province, Romania	https://ClinicalTrials.gov/show/NCT03811431
963	TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma	Enrolling by invitation	No Results Available	Hepatocellular Carcinoma	Drug: Lenvatinib|Procedure: TACE	Department of Interventional Radiology, Zhongshan Hospital, Fudan University., Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT04490694
964	Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Biological: ATL administration	Hualien Tzu Chi Hospital, Hualien City, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei City Hospital, RENAI Branch, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT05304481
965	Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma	Completed	Has Results	Hepatocellular Carcinoma	Drug: Axitinib (AG-013736)|Other: Best Supportive Care|Drug: Placebo	Alta Bates Summit Comprehensive Cancer Center, Berkeley, California, United States|UCSD Medical Center- La Jolla, La Jolla, California, United States|Moores UCSD Cancer Center, La Jolla, California, United States|University of California Irvine Medical Center, Orange, California, United States|UCSD Medical Center- Hillcrest, San Diego, California, United States|Florida Hospital Transplant Center, Liver Unit, Orlando, Florida, United States|Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|University of Michigan, Ann Arbor, Michigan, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Penn Presbyterian Medical Center, Philadelphia, Pennsylvania, United States|Universitair Ziekenhuis Gent, Gent, Belgium|CHC Clinique Saint-Joseph, Liège, Belgium|The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China|Guangdong General Hospital, Guangzhou, Guangdong, China|Nanjing Bayi Hospital, Nan Jing, Jiangsu, China|Jiang Su Cancer Hospital, Nanjing, Jiangsu, China|Sir Run Run Shaw Hospital of College of Medicine of Zhejiang University, Hangzhou, Zhejiang, China|The PLA 307 Hospital, Beijing, China|Zhongshan Hospital Fudan University, Shanghai, China|Centre Hospitalier Universitaire d'Amiens, Amiens, France|Hopital Saint André, Bordeaux Cedex, France|CHU Cote de Nacre, Caen, cedex 05, France|Bichat-Beaujon Service Inter Hospitalier De Cancerologie, Clichy, France|Hopital De La Croix-Rousse, Lyon Cedex 04, France|UPCET-CIC Timone, Marseille, France|CHRU Montpellier-Hopital Saint Eloi - Departement Oncologie Medicale, Montpellier Cedex 05, France|Hôpital L'Archet Ii, Nice, France|Hôpital Saint Antoine, Paris, France|Centre Eugène Marquis, Rennes, France|CHRU de Purpan., Toulouse Cedex, France|Medizinische Klinik mit Schwerpunkt, Berlin, Germany|Universitätsklinikum Bonn, Bonn, Germany|Klinikum der Ludwig-Maximilians-Universitaet , Campus Grosshadern, München, Germany|Queen Mary Hospital, Hong Kong, Hong Kong|Prince of Wales Hospital, Shatin, N.T., Hong Kong|Semmelweis Egyetem I.sz. Belgyógyászati Klinika, Budapest, Hungary|Szegedi Tudományegyetem Onkoterápiás Klinika, Szeged, Hungary|Istituto di Ematologia ed Oncologia Medica, Lorenzo ed Ariosto Seragnoli,, Bologna, Italy|Policlinico S.Orsola-Malpighi Dipartimento di Ematologia e Scienze Oncologiche "L. E A. Seragnoli", Bologna, Italy|Ospedale Versilia,Oncologia Medica, Lido Di Camaiore (LU), Italy|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori IRST, Meldola (FC), Italy|Unita Operativa Oncologia Medica IRCCS Fondazione Salvatore Maugeri, Pavia, Italy|Policlinico Universitario Agostino Gemelli, Roma, Italy|Unità Operativa Oncologica Medica, Roma, Italy|Azienda Ospedaliera Universitaria Senese Policlinico Santa Maria aile Scotte, Siena, Italy|Aichi Cancer Center Central Hospital, Diagnostic and Interventional Radiology, Nagoya, Aichi, Japan|Chiba University Hospital, Chiba City, Chiba, Japan|Gifu Municipal Hospital, Gifu-shi, Gifu, Japan|Kanazawa University Hospital, Kanazawa, Ishikawa, Japan|Kinki University Hospital, Osaka-Sayama, Osaka, Japan|Shizuoka Cancer Center, Suntou-gun, Shizuoka, Japan|Sasaki Foundation Kyoundo Hospital, Chiyoda-Ku, Tokyo, Japan|Nihon University Itabashi Hospital, Itabashi-Ku, Tokyo, Japan|Yamanashi Prefectural Central Hospital, Kofu-Shi, Japan|National Cancer Center/ Center for Liver Cancer, Goyang-si, Korea, Republic of|Samsung Medical Center, Division of Hematology-Oncology, Department of Medicine, Seoul, Korea, Republic of|Asan Medical Center, Division of Oncology, Department of Internal Medicine, Seoul, Korea, Republic of|Fakultna nemocnica s poliklinikou F. D. Roosevelta Banska Bystrica, Banska Bystrica, Slovakia|Narodny onkologicky ustav, Bratislava, Slovakia|POKO Poprad s.r.o., Poprad, Slovakia|Nemocnica Poprad, a.s., Poprad, Slovakia|Changhua Christian Hospital, Changhua, Taiwan|Chang Gung Medical Foundation - Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|Chi-Mei Medical Center LiouYing, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Chang Gung Medical Foundation Linkou Branch, Taoyuan, Taiwan|The Christie NHS Foundation Trust, Withington, Manchester, United Kingdom|Clatterbridge Centre for Oncology NHS Foundation Trust, Liverpool, United Kingdom|Royal Liverpool and Broadgreen University Hospital, Liverpool, United Kingdom|Royal Free Hospital, London, United Kingdom|King's College Hospital NHS Foundation Trust, London, United Kingdom|Hammersmith Hospital, London, United Kingdom	https://ClinicalTrials.gov/show/NCT01210495
966	Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy	Not yet recruiting	No Results Available	Hepatocellular Carcinoma	Other: Quantitative assay of GlypicanPC-3		https://ClinicalTrials.gov/show/NCT05263830
967	CT Perfusion Parameters Predict Vascular Pattern in Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Other: CT perfusion examination	Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT04715321
968	Study of PIVKA-II and AFP Measurement in Surveillance Program for Early Detection of Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma	Device: tumor maker interval shortly	Severance Hospital, Seoul, Seodaemun-gu, Korea, Republic of	https://ClinicalTrials.gov/show/NCT01277653
969	Durvalumab Plus Lenvatinib as First-line Treatment for Unresectable Hepatocellular Carcinoma	Not yet recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Durvalumab plus Lenvatinib	the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China	https://ClinicalTrials.gov/show/NCT05312216
970	Study of Sorafenib With Combination of Thalidomide in Hepatocellular Carcinoma (HCC)	Terminated	No Results Available	Hepatocellular Carcinoma	Drug: sorafenib (Nexavar®), thalidomide (Thado®)	Ghang-Gung Memorial Hospital at Chia-Yi, Chia-Yi, Taiwan	https://ClinicalTrials.gov/show/NCT00971126
971	A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma	Completed	Has Results	Carcinoma, Hepatocellular	Genetic: JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF)	Moores UCSD Cancer Center, La Jolla, California, United States|Mayo Clinic, Rochester, Minnesota, United States|Billings Clinic Cancer Center, Billings, Montana, United States|The Ohio State University, Columbus, Ohio, United States|University of Pittsburgh Medical Center - Liver Cancer Center, Pittsburgh, Pennsylvania, United States|McMaster University Medical Centre, Hamilton, Ontario, Canada|Pusan National University Hospital, Busan, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Shin Chon Severance Hospital / Yonsei University Medical Center, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT00554372
972	Donafenib Combined With TACE as Adjuvant Therapy of Patients With Hepatocellular Carcinoma	Not yet recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Donafenib	Chinese Academy of Medical Sciences & Peking Union Medical College Hospital, Beijing, China	https://ClinicalTrials.gov/show/NCT05161143
973	Lenvatinib Combined Toripalimab in Advanced Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Toripalimab plus Lenvatinib	Chinese Academy of Medical Sciences & Peking Union Medical College Hospital, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT04368078
974	Study of Milciclib in Patients With Unresectable/Metastatic Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Drug: Milciclib maleate	Ippokrateio General Hospital of Athens, Athens, Greece|Laiko General Hospital of Athens, Athens, Greece|General University Hospital of Larissa, Larissa, Greece|University General Hospital of Thessaloniki - AHEPA, Thessaloniki, Greece|Rambam Health Corporation, Haifa, Israel|Rabin Medical Center - Beilinson Hospital, Petah Tikva, Israel|The Sheba Academic Medical Center Hospital - Tel Hashomer, Ramat Gan, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|Istituto Clinico Humanitas, Rozzano, MI, Italy|AOU S. Orsola Malpighi Bologna, Bologna, Italy|Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, Italy|Azienda Ospedaliera Universitaria Policlinico di Modena, Modena, Italy|A.O.U. Federico II, Napoli, Italy|A.O. U. Policlinico Paolo Giaccone, Palermo, Italy	https://ClinicalTrials.gov/show/NCT03109886
975	SHR-1210 Combined With Apatinib Mesylate in the Perioperative Therapy for Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Apatinib Mesylate|Drug: Camrelizumab	the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China	https://ClinicalTrials.gov/show/NCT04930315
976	Long Term Follow-Up Study of Immuncell-LC Group and Non-Treatment Group in Hepatocellular Carcinoma Patients.	Completed	No Results Available	Hepatocellular Carcinoma		Seoul National Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Korea University Ansan Hospital, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT01890291
977	Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR)	Active, not recruiting	No Results Available	Hepatocellular Carcinoma	Genetic: GLYCAR T cells|Drug: Cytoxan|Drug: Fludarabine	Houston Methodist Hospital, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT02905188
978	Radioembolization for Hepatocellular Carcinoma With Portal Vein Tumoral Thrombosis	Completed	No Results Available	Hepatocellular Carcinoma	Radiation: yttrium-90 radioembolization		https://ClinicalTrials.gov/show/NCT04771988
979	Novel Gallium Imaging in Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: 68Gallium Citrate	Rutgers New Jersey Medical School, Newark, New Jersey, United States	https://ClinicalTrials.gov/show/NCT03116945
980	Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)	Completed	Has Results	Carcinoma, Hepatocellular	Drug: Nexavar (Sorafenib, BAY43-9006)|Drug: Placebo	Birmingham, Alabama, United States|Phoenix, Arizona, United States|Los Angeles, California, United States|Los Angeles, California, United States|San Francisco, California, United States|Washington, District of Columbia, United States|Miami, Florida, United States|Atlanta, Georgia, United States|Indianapolis, Indiana, United States|Louisville, Kentucky, United States|New Orleans, Louisiana, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Burlington, Massachusetts, United States|Ann Arbor, Michigan, United States|Minneapolis, Minnesota, United States|Minneapolis, Minnesota, United States|New York, New York, United States|Cleveland, Ohio, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Providence Portland Medical Center, Portland, Oregon, United States|Portland, Oregon, United States|Pittsburgh, Pennsylvania, United States|Houston, Texas, United States|Richmond, Virginia, United States|Seattle, Washington, United States|Seattle, Washington, United States|Pilar, Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Rosario, Santa Fe, Argentina|Camperdown, New South Wales, Australia|Randwick, New South Wales, Australia|Brisbane, Queensland, Australia|Heidelberg, Victoria, Australia|Melbourne, Victoria, Australia|Innsbruck, Austria|Linz, Austria|Wien, Austria|Bruxelles - Brussel, Belgium|Gent, Belgium|Leuven, Belgium|Liege, Belgium|Porto Alegre, Rio Grande Do Sul, Brazil|Porto Alegre, Rio Grande Do Sul, Brazil|Porto Alegre, Rio Grande Do Sul, Brazil|São Paulo, Sao Paulo, Brazil|Sao Paulo, Brazil|Plovdiv, Bulgaria|Varna, Bulgaria|Calgary, Alberta, Canada|Edmonton, Alberta, Canada|Vancouver, British Columbia, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Santiago de Chile, Santiago, Chile|Reñaca, Valparaíso, Chile|Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Nanning, Guangxi, China|Wuhan, Hubei, China|Changsha, Hunan, China|Changsha, Hunan, China|Nanjing, Jiangsu, China|Xi'an, Shanxi, China|Xi'an, Shanxi, China|Xi'an, Shanxi, China|Chengdu, Sichuan, China|Chengdu, Sichuan, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Beijng, China|Chongqing, China|Dalian, China|Hefei, China|Shanghai, China|Shanghai, China|Tianjin, China|ANGERS cedex 09, France|Bondy, France|Bordeaux, France|Creteil, France|Lille, France|Lyon, France|Marseille, France|Nice, France|Paris, France|Paris, France|Rennes, France|Toulouse, France|Vandoeuvre-les-nancy, France|Villejuif, France|München, Bayern, Germany|München, Bayern, Germany|Regensburg, Bayern, Germany|Göttingen, Niedersachsen, Germany|Hannover, Niedersachsen, Germany|Aachen, Nordrhein-Westfalen, Germany|Düsseldorf, Nordrhein-Westfalen, Germany|Essen, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Mainz, Rheinland-Pfalz, Germany|Homburg/Saar, Saarland, Germany|Halle/Saale, Sachsen-Anhalt, Germany|Magdeburg, Sachsen-Anhalt, Germany|Berlin, Germany|Hamburg, Germany|Athens / Greece, Greece|Hong Kong, Hong Kong|Kwun Tong, Hong Kong|Shatin, Hong Kong|Benevento, Campania, Italy|Napoli, Campania, Italy|Napoli, Campania, Italy|Bologna, Emilia-Romagna, Italy|Modena, Emilia-Romagna, Italy|Roma, Lazio, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Torino, Piemonte, Italy|Bari, Puglia, Italy|Cagliari, Sardegna, Italy|Catania, Sicilia, Italy|Palermo, Sicilia, Italy|Padova, Veneto, Italy|Kashiwa-shi, Chiba, Japan|Kanazawa, Ishikawa, Japan|Yokohama-shi, Kanagawa, Japan|Osakasayama-shi, Osaka, Japan|Suita, Osaka, Japan|Bunkyo-ku, Tokyo, Japan|Chuo-ku, Tokyo, Japan|Itabashi-ku, Tokyo, Japan|Minato-ku, Tokyo, Japan|Shibuya-ku, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan|Fukuoka, Japan|Kumamoto, Japan|Kyoto, Japan|Okayama, Japan|Osaka, Japan|Tokushima, Japan|Goyang-si, Gyeonggido, Korea, Republic of|Goyang-si, Gyeonggido, Korea, Republic of|Seoul, Seoul Teugbyeolsi, Korea, Republic of|Busan, Korea, Republic of|Daegu, Korea, Republic of|Jeollabuk-do, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|México, D.F., Distrito Federal, Mexico|Monterrey, Nuevo Leon, Mexico|México, D.F., Mexico|Auckland, New Zealand|Coimbra, Portugal|Bucharest, Romania|Cluj-Napoca, Romania|Iasi, Romania|Moscow, Russian Federation|Moscow, Russian Federation|Obninsk, Russian Federation|St. Petersburg, Russian Federation|Singapore, Singapore|Singapore, Singapore|Oviedo, Asturias, Spain|Sabadell, Barcelona, Spain|Cruces/Barakaldo, Bilbao, Spain|Barcelona, Catalunya, Spain|Majadahonda, Madrid, Spain|Badajoz, Spain|Barcelona, Spain|Córdoba, Spain|Madrid, Spain|Madrid, Spain|Valladolid, Spain|Göteborg, Sweden|Stockholm, Sweden|Bern, Switzerland|Zürich, Switzerland|Changhua, Taiwan|Kaohsiung City, Taiwan|Kaohsung, Taiwan|Tainan, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan|Southampton, Hampshire, United Kingdom|Birmingham, West Midlands, United Kingdom|Leeds, West Yorkshire, United Kingdom|London, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Newcastle Upon Tyne, United Kingdom	https://ClinicalTrials.gov/show/NCT00692770
981	Adult-to-Adult Living Donor Transplant Cohort Study	Completed	No Results Available	Liver Diseases|Hepatocellular Cancer|End Stage Liver Disease|Hepatitis C|Liver Cirrhosis		University of California, San Francisco, California, United States|University of Colorado Health Sciences, Aurora, Colorado, United States|Northwestern University, Division of Transplantation, Chicago, Illinois, United States|Lahey Clinic, Burlington, Massachusetts, United States|Columbia University, New York, New York, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Virginia Commonwealth University-Medical College of Virginia, Richmond, Virginia, United States|University of Toronto, Toronto, Ontario, Canada	https://ClinicalTrials.gov/show/NCT01619475
982	Allogeneic "Gammadelta T Cells (γδ T Cells)" Cell Immunotherapy in Phase 1 Hepatocellular Carcinoma Clinical Trial	Recruiting	No Results Available	Hepatocellular Carcinoma	Biological: Ex-vivo expanded allogeneic γδT cells	Beijing 302 Hospital of China, Beijing, Beijing, China|Beijing 302 hospital, Beijing, China	https://ClinicalTrials.gov/show/NCT04518774
983	Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC)	Completed	Has Results	Hepatocellular Carcinoma	Drug: CF102|Drug: Placebo	University of Colorado Cancer Center, Aurora, Colorado, United States|Simmons Cancer Center, Dallas, Texas, United States|Complex Oncology Center - Plovdiv, Plovdiv, Bulgaria|Multiprofile Hospital for Active Treatment Central Onco Hospita, Plovdiv, Bulgaria|Multiprofile Hospital for Active Treatment "Tokuda Hospital Sofia" AD, Sofia, Bulgaria|Multiprofile Hospital for Active Treatment for women's health - Nadezhda, Sofia, Bulgaria|Multiprofile Hospital for Active Treatment Serdica, Sofia, Bulgaria|Multiprofile Hospital for Active Treatment "Sveta Marina" EAD, Varna, Bulgaria|Rabin Medical Center, Petach Tikva, Israel|Institutul Clinic Fundeni - Sectia Oncologie Medicala, Bucuresti, Romania|Clinica Bendis - Oncologie Medicala, Cluj, Romania|Centrul de Oncologie ONCOLAB, Craiova, Romania|Institutul Regional de Oncologie Iasi - Sectia Oncologie Medicala, Iaşi, Romania|Spitalul Pelican Impex SRL- Sectia Oncologie Medicala, Oradea, Romania|SC DACMED SRL - Oncologie, Ploieşti, Romania|Spitalului Clinic Judetean de Urgenta - Sectia Oncologie Medicala, Sibiu, Romania|Spitalul Judetean de Urgenta "Sf. Ioan Cel Nou" - sectia Oncologie Medicala, Suceava, Romania|Vojnomedicinska Akademija Beograd, Belgrade, Serbia|Zdravstveni Centar Kladovo Služba Onkologije, Kladovo, Serbia|Klinički Centar Niš Klinika za Onkologiju, Niš, Serbia|Institut za Onkologiju Vojvodine, Sremska Kamenica, Serbia	https://ClinicalTrials.gov/show/NCT02128958
984	IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC)	Recruiting	No Results Available	Hepatocellular Carcinoma (HCC)	Drug: Pembrolizumab|Procedure: Radio Frequency Ablation (RFA)|Procedure: Microwave Ablation (MWA)|Radiation: Brachytherapy|Drug: Transarterial Chemoembolisation (TACE)	Hannover Medical School, Hannover, Niedersachsen, Germany	https://ClinicalTrials.gov/show/NCT03753659
985	SHR-1210 Combined With Apatinib Mesylate in the Perioperative Treatment of Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Apatinib Combined With SHR-1210 Injection	Jiangsu Province Hospital, Nanjing, Jiangsu, China	https://ClinicalTrials.gov/show/NCT04297202
986	Lipiodol-TACE With Idarubicin for Hepatocellular Carcinoma	Not yet recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Idarubicin Hydrochloride for Injection	Zhongda Hospital, Southeast University, Nanjing, Jiangsu, China	https://ClinicalTrials.gov/show/NCT05280444
987	PET-CT in Determining the Radioembolization Dose Delivered to Patients With Liver Metastasis, Primary Liver Cancer, or Biliary Cancer	Active, not recruiting	No Results Available	Adult Primary Hepatocellular Carcinoma|Advanced Adult Primary Liver Cancer|Metastatic Extrahepatic Bile Duct Cancer|Recurrent Adult Primary Liver Cancer|Recurrent Extrahepatic Bile Duct Cancer|Stage D Adult Primary Liver Cancer (BCLC)|Unspecified Adult Solid Tumor, Protocol Specific	Procedure: PET scan|Procedure: CT Scan|Procedure: hepatic artery embolization	Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States	https://ClinicalTrials.gov/show/NCT02088775
988	Hepatocellular Carcinoma Registry for Turkey (3K Trial)	Completed	No Results Available	Hepatocellular Carcinoma	Other: No Intervention	Multiple Locations, Turkey	https://ClinicalTrials.gov/show/NCT01473121
989	Sorafenib Plus Tegafur/Uracil (UFUR®) for Hepatocellular Carcinoma (HCC)	Completed	No Results Available	Hepatocellular Carcinoma	Drug: Sorafenib|Drug: tegafur/uracil (UFUR®)	National Taiwan University Hospital, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT00464919
990	Hepatocellular Carcinoma - Advanced Stage - Sorafenib Trial in Taiwanese Patients	Completed	No Results Available	Hepatocellular Carcinoma	Drug: Sorafenib (Nexavar, BAY43-9006) Sorafenib (Nexavar, BAY43-9006) + Nerison Fatty Ointment Sorafenib (Nexavar, BAY43-9006)+Neribas Fatty Ointment	Chia Yi, Taiwan|Hualien county, Taiwan|Kaohsiung City, Taiwan|Kaohsiung City, Taiwan|Taichung City, Taiwan|Taipei City,, Taiwan|Taoyuan, Taiwan	https://ClinicalTrials.gov/show/NCT01098760
991	Combination Chemoembolization and Radiofrequency Ablation for Hepatocellular Carcinoma Greater Than 3 cm	Completed	No Results Available	Hepatocellular Carcinoma	Procedure: chemoembolization ,Radiofrequency ablation		https://ClinicalTrials.gov/show/NCT00479050
992	Bevacizumab in Advanced Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: bevacizumab	Institut Gustave Roussy, Villejuif, France	https://ClinicalTrials.gov/show/NCT00162669
993	Sorafenib-RT in Treating Hepatocellular Carcinoma (SHEP)	Completed	No Results Available	Hepatocellular Carcinoma	Drug: Sorafenib	University Health Network, Toronto, Ontario, Canada	https://ClinicalTrials.gov/show/NCT00892658
994	A Phase III Study in Post-operative HBV-related Hepatocellular Carcinoma	Terminated	No Results Available	Hepatocellular Carcinoma	Drug: Adefovir Dipivoxil and Lamivudine	Chang-Gung Memorial Hospital, Kaohsiung, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|Veterans General Hospital-Kaohsiung, Kaohsiung, Taiwan|Chang-Gung Memorial Hospital (Lin-Kou), Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Veterans General Hospital-Taipei, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT00455091
995	Statin for Preventing Hepatocellular Carcinoma Recurrence After Curative Treatment	Recruiting	No Results Available	HepatoCellular Carcinoma	Drug: Atorvastatin|Drug: Placebo Oral Tablet	Ditmanson Medical Foundation Chiayi Christian Hospital, Chiayi City, Taiwan|E-DA Hospital, Kaohsiung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|Tainan Municipal Hospital, Tainan, Taiwan|Mackay Memorial Hospital, Taipei, Taiwan|National Taiwan University Hospital Yun-Lin Branch, Yunlin, Taiwan	https://ClinicalTrials.gov/show/NCT03024684
996	Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma	Not yet recruiting	No Results Available	Hepatocellular Carcinoma	Other: patients with hepatocellular carcinoma		https://ClinicalTrials.gov/show/NCT05044676
997	Laparoscopic Versus Open Major Hepatectomy for HCC Hepatectomy for Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Procedure: Open or laparoscopic surgery	Chinese University of Hong Kong, Hong Kong, Hong Kong	https://ClinicalTrials.gov/show/NCT04852211
998	Study of SIR-Spheres Plus Sorafenib as 1st Line Treatment for Non-resectable Primary Hepatocellular Carcinoma (HCC)	Completed	No Results Available	Hepatocellular Carcinoma	Drug: Sorafenib|Radiation: SIR-Spheres	Seoul National University Bundang Hospital, Seoul, Korea, Republic of|Selayang Hospital, Selangor, Malaysia|Yangon GI & Liver Centre, Yangon, Myanmar|Singapore General Hospital, Singapore, Singapore|National Cancer Centre, Singapore, Singapore	https://ClinicalTrials.gov/show/NCT00712790
999	Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma	Completed	Has Results	Hepatocellular Carcinoma	Drug: Bevacizumab|Drug: Erlotinib	University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Kansas University Medical Center, Kansas City, Kansas, United States	https://ClinicalTrials.gov/show/NCT00287222
1000	A Study of DC-CIK to Treat Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma (HCC)	Biological: Dendritic and Cytokine-induced Killer Cells	The first Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China	https://ClinicalTrials.gov/show/NCT01821482
1001	"Cocktail" Therapy for Hepatitis B Related Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Cyclophosphamide|Biological: Multiple Signals loaded Dendritic Cells Vaccine	Nanfang Hospital, Guangzhou, Guangdong, China|Sun Yat-sen University Cancer center, Guangzhou, Guangdong, China|Sun Yat-sen University, Guangzhou, Guangdong, China|The Third Affiliated Hospital of Zhongshan University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT04317248
1002	Donafenib Combine With Sintilimab and HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）in the First-line Treatment of Unresectable Hepatocellular Carcinoma	Not yet recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Donafenib|Drug: Sintilimab|Other: HAIC		https://ClinicalTrials.gov/show/NCT05166772
1003	Radiofrequency Ablation Combined With Recombinant Human Adenovirus Type 5 in the Treatment of Hepatocellular Carcinoma.	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: H101|Procedure: RFA	Institute of hepatobiliary surgery,Southwest Hospital, Chongqing, Chongqing, China|Institute of hepatobiliary surgery,Southwest Hospital, Chongqing, China	https://ClinicalTrials.gov/show/NCT03790059
1004	Evaluation of Quality of Life and Survival With MS-20 in Patient With Advanced Hepatocellular Carcinoma (FDA IND 74572)	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: MS-20|Drug: Placebo	China Medical University Hospital, TaiChung, Taiwan	https://ClinicalTrials.gov/show/NCT00707681
1005	Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Radiation: Stereotactic body radiotherapy	Inje University Haeundae Paik Hospital, Busan, Korea, Republic of|Dongnam Institute of Radiological & Medical Sciences, Busan, Korea, Republic of|Soon Chun Hyang University Hospital Cheonan, Cheonan, Korea, Republic of|Catholic University Incheon St. Mary's Hospital, Incheon, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Korea, Republic of|Soon Chun Hyang University Hospital Seoul, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT01850667
1006	Stereotactic Ablative Radiotherapy for Hepatocellular Carcinoma ≤ 5 cm	Unknown status	No Results Available	Hepatocellular Carcinoma	Radiation: Stereotactic ablative radiotherapy	Inje University Haeundae Paik Hospital, Busan, Korea, Republic of|Dongnam Institute of Radiological & Medical Sciences, Busan, Korea, Republic of|Soon Chun Hyang University Hospital Cheonan, Cheonan, Korea, Republic of|Catholic University Incheon St. Mary's Hospital, Incheon, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Korea, Republic of|Soon Chun Hyang University Hospital Seoul, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT01825824
1007	Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma	Withdrawn	No Results Available	Advanced Hepatocellular Carcinoma	Drug: INC280|Drug: Placebo	Massachusetts General Hospital Mass General Hospital, Boston, Massachusetts, United States|Research Medical Center Onc Dept, Kansas City, Missouri, United States|Novartis Investigative Site, Kogarah, New South Wales, Australia|Novartis Investigative Site, Heidelberg, Victoria, Australia|Novartis Investigative Site, Clichy, France|Novartis Investigative Site, LILLE Cedex, France|Novartis Investigative Site, Montpellier Cedex 5, France|Novartis Investigative Site, Nice Cedex 3, France|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Würzburg, Germany|Novartis Investigative Site, Hong Kong SAR, Hong Kong|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, Cordoba, Andalucia, Spain|Novartis Investigative Site, Bern, Switzerland|Novartis Investigative Site, Genève, Switzerland	https://ClinicalTrials.gov/show/NCT01964235
1008	Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Hepatocellular Carcinoma	Terminated	No Results Available	Primary Hepatocellular Carcinoma	Drug: CT-011	Hadassah Medical Center, Jerusalem, Israel	https://ClinicalTrials.gov/show/NCT00966251
1009	TACE and Sorafenib for Advanced Hepatocellular Carcinoma (HCC)	Terminated	No Results Available	Hepatocellular Carcinoma	Drug: Sorafenib	Universitätsklinikum Tübingen Innere Medizin I, Tübingen, BW, Germany|Medizinische Universitätsklinik Ulm Innere Medizin I, Ulm, BW, Germany|Klinikum der Universität Großhardern, Muenchen, BY, Germany|Klinikum der Johann-Goethe-Universität, Frankfurt, HE, Germany|Universitätsklinikum Hamburg-Eppendorf Zentrum für Innere Medizin, Hamburg, HH, Germany|Johannes-Gutenberg-Universität Medizinische Klinik, Mainz, RP, Germany	https://ClinicalTrials.gov/show/NCT00618384
1010	A Phase I Clinical Study on a New Oral Pentamidine Formulation in Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Drug: Oral Pentamidine|Other: Placebo	Dr. Kelly Burak, Calgary, Alberta, Canada|Dr Morris Sherman, Toronto, Ontario, Canada|Dr Marc Bilodeau, Montreal, Quebec, Canada	https://ClinicalTrials.gov/show/NCT02210182
1011	Perioperative Therapy for Hepatocellular Carcinoma	Terminated	No Results Available	Hepatocellular Carcinoma	Drug: Sintilimab Injection|Drug: TACE|Radiation: Radiotherapy	the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China	https://ClinicalTrials.gov/show/NCT04653389
1012	Combination of Sintilimab and Stereotactic Body Radiotherapy in Hepatocellular Carcinoma (ISBRT01)	Recruiting	No Results Available	Hepatocellular Carcinoma	Radiation: stereotactic body radiotherapy|Drug: Sintilimab	Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT04167293
1013	Clinical Trial of Radiotherapy in Treating Primary Hepatocellular Carcinoma	Unknown status	No Results Available	Primary Hepatocellular Carcinoma	Radiation: SBRT|Radiation: IMRT|Procedure: Hepatectomy|Procedure: TACE	The Third Xiangya Hospital, Central South University, Changsha, Hunan, China	https://ClinicalTrials.gov/show/NCT03614546
1014	Sequential Treatment of Hepatocellular Carcinoma by Transarterial Chemoembolization and Local Ablation or External Radiation	Completed	No Results Available	Hepatocellular Carcinoma		CHRU de Nancy, Nancy, France	https://ClinicalTrials.gov/show/NCT04813861
1015	The Safety and Efficacy Evaluation of XSLJZ in Advanced Hepatocellular Carcinoma Patients With Multiple Protein Kinase Inhibitor Therapy: A Randomized, Double-Blind, Controlled Trial	Enrolling by invitation	No Results Available	Hepatocellular Carcinoma	Drug: Xiang Sha Liu Jun Zi Decoction dry powder|Drug: XSLJZ Placebo	China Medical University hospital, Taichung, 西屯區, Taiwan	https://ClinicalTrials.gov/show/NCT04562428
1016	Phase I Clinical Trial of CT0180 Cells in the Treatment of Hepatocellular Carcinoma	Recruiting	No Results Available	Advanced Hepatocellular Carcinoma	Drug: CT0180 Cells	First affiliated hospital, Zhejiang University, Hangzhou, Zhejiang, China	https://ClinicalTrials.gov/show/NCT04756648
1017	Phase ⅡStudy of Tyroserleutide for Injection in Hepatocellular Carcinoma(HCC) Patients	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: mitomycin, Fluorouracil	A Research Institute of Tumor, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT00644020
1018	VEGF Signaling Promotes Cell Growth and Metastasis in Hepatocellular Carcinoma in a VEGF Receptor Mediated Pathway	Unknown status	No Results Available	Hepatocellular Carcinoma	Procedure: surgical treatment	First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT01892072
1019	A Study of TAC-101 in Combination With TACE Versus TACE Alone in Asian Patients With Advanced Hepatocellular Carcinoma	Withdrawn	No Results Available	Advanced Hepatocellular Carcinoma	Drug: TAC-101|Drug: Placebo		https://ClinicalTrials.gov/show/NCT00756782
1020	HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure	Recruiting	No Results Available	Unresectable Hepatocellular Carcinoma	Drug: Camrelizumab|Drug: HAIC|Drug: TKI	Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT05135364
1021	Carbon Ion Radiotherapy for the Treatment of Chinese Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Radiation: carbon-ion radiotherapy for tumor away from GI|Radiation: carbon-ion radiotherapy for tumor adjacent to GI	Shanghai Proton and Heavy Ion Center, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT02802124
1022	CyberKnife Stereotactic Body Radiation Therapy for Small Hepatocellular Carcinoma Patients With Decompensated Cirrhosis	Recruiting	No Results Available	Hepatocellular Carcinoma	Radiation: Cyberknife stereotactic body radiation therapy	Beijing 302 hospital, Beijing, China	https://ClinicalTrials.gov/show/NCT04512833
1023	Percutaneous Radiofrequency Ablation Versus Repeat Hepatectomy for Recurrent Hepatocellular Carcinoma	Active, not recruiting	No Results Available	Hepatocellular Carcinoma	Procedure: HR|Procedure: RFA	Cancer Center, Sun Yat-set University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT01570166
1024	Hepatocellular Carcinoma Registry in Asia	Completed	No Results Available	Hepatocellular Carcinoma		Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|Beijing Cancer Hospital, Beijing, Beijing, China|Southwest Hospital of Third Military Medical University, Chongqing, Chongqing, China|Guangxi Medical University Cancer Center, Nanning, Guangxi, China|Nanjing Bayi Hospital, Nanjing, Jiangsu, China|Zhongshan Hospital, Shanghai, Shanghai, China|Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China|Queen Mary Hospital, Hong Kong, Hong Kong|Kinki University School of Medicine, Ōsakasayama, Osaka, Japan|National Cancer Centre, Japan, Chūōku, Tokyo, Japan|Kyorin University School of Medicine, Mitaka-shi, Tokyo, Japan|University of Tokyo, Tokyo, Japan|St Vincent Hospital, Catholic University Medical College, Gyeonggi-do, Korea, Republic of|Ajou University Hospital, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of|Asan Medical Centre, Seoul, Korea, Republic of|St. Mary's Hospital, Seoul, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of|Auckland City Hospital, Grafton, Auckland, New Zealand|National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|National Cancer Centre, Singapore, Singapore|China Medical University Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|Chang Gung Memorial Hospital-KS, Taipei, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Chulabhorn Hospital, Bang Khen, Bangkok, Thailand|Siriraj Hospital, Mahidol University, Bangkok Noi, Bangkok, Thailand|National Cancer Institute, Ratchathewi, Bangkok, Thailand	https://ClinicalTrials.gov/show/NCT03233360
1025	A Phase 3 Trial Comparing TACE and TARE in Unilobar Advanced Hepatocellular Carcinoma	Withdrawn	No Results Available	Hepatocellular Carcinoma	Procedure: transarterial radioembolization (TARE)|Procedure: transarterial chemoembolization (TACE)	Seoul National University Hospital, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT02004210
1026	Epigenetic Changes in Hepatocellular Carcinoma Developed After Direct Acting Antiviral Therapy for Chronic Hepatitis C	Unknown status	No Results Available	Hepatocellular Carcinoma	Genetic: DNA methylation		https://ClinicalTrials.gov/show/NCT04220151
1027	No-touch RFA Versus Traditional RFA for Small Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma	Procedure: Traditional RFA|Procedure: No-touch RFA	Institute of hepatobiliary surgery,Southwest Hospital, Chongqing, Chongqing, China	https://ClinicalTrials.gov/show/NCT02830737
1028	A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Camrelizumab	Shandong Cancer Hospital and Institute, Jinan, Shandong, China	https://ClinicalTrials.gov/show/NCT05099848
1029	Combination Therapy of Microwave Ablation and Cellular Immunotherapy for Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Biological: adoptive immunotherapy|Procedure: MWA	Chinese PLA General Hospital, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT02851784
1030	Neoadjuvant Sorafenib Therapy Prior to Laser Ablation for Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Drug: Sorafenib|Procedure: laser ablation (LA)	UOSC Epatologia - Cardarelli Hospital, Napoli, Italy	https://ClinicalTrials.gov/show/NCT01507064
1031	Safety and Efficacy Study of Sintilimab Combined With IBI305 in Patients With Advanced Hepatocellular Carcinoma	Completed	No Results Available	Advanced Hepatocellular Carcinoma	Drug: Sintilimab+IBI305	National Cancer Center/Cancer Hospital, Chinese ACademy of Medical Sciences and Peking Union Medical College, Beijing, China	https://ClinicalTrials.gov/show/NCT04072679
1032	Transarterial Radioembolization Versus Chemoembolization for the Treatment of Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma	Procedure: Transarterial Radioembolization|Procedure: Transarterial Chemoembolization using drug-eluting beads	King Faisal Specilist Hopsital & Researchc Center, Riyadh, Saudi Arabia	https://ClinicalTrials.gov/show/NCT02729506
1033	The Influence of Resection Margin on the Recurrence of Early-stage Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma	Procedure: Wide resection margin >1cm|Procedure: Narrow resection margin <1cm	Eastern hepatobilliary surgery hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT02525965
1034	Study of Combined Sorafenib With Radiotherapy in Patients With Advanced Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma	Radiation: sorafenib and radiotherapy for hepatocellular carcinoma	Shang-Wen Chen, Taichung, Taiwan|Li-Ching Lin, Tainan, Taiwan|Jeng-Fong Chiou, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT01328223
1035	Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Hepatocellular Carcinoma (HCC)	Completed	No Results Available	Hepatocellular Carcinoma	Drug: NGR-hTNF	Istituto Clinico Humanitas, Rozzano, Milan, Italy|Fondazione San Raffaele del Monte Tabor, Milan, Italy|Istituto Europeo Oncologico, Milan, Italy	https://ClinicalTrials.gov/show/NCT00484211
1036	Phase II Trial of Carbon-ion Radiotherapy Combined With GM-CSF for the Treatment of Hepatocellular Carcinoma	Withdrawn	No Results Available	Hepatocellular Carcinoma	Radiation: carbon-ion radiotherapy	Shanghai Proton and Heavy Ion Center, Shanghai, Shanghai, China|Shanghai Proton and Heavy Ion Center, Shanghai, China	https://ClinicalTrials.gov/show/NCT02946138
1037	A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma	Completed	Has Results	Hepatocellular Carcinoma	Drug: CF102	Rabin Medical Center, Tel Aviv, Israel	https://ClinicalTrials.gov/show/NCT00790218
1038	Neoadjuvant Hypofractionated Stereotactic Body Radiation Therapy Prior to Surgery for Hepatocellular Carcinoma: a Feasibility Study.	Recruiting	No Results Available	Hepatocellular Carcinoma	Combination Product: Surgery with Neoadjuvant stereotactic body radiation therapy	Hop Claude Huriez Chu Lille, Lille, France	https://ClinicalTrials.gov/show/NCT04587739
1039	188RE-SSS Lipiodol to Treat HepatoCellular Carcinomas	Completed	No Results Available	Hepatocellular Carcinomas	Drug: 188Re-SSS Lipiodol	Centre Eugene Marquis, Rennes, France	https://ClinicalTrials.gov/show/NCT01126463
1040	Radiofrequency Ablation Versus Hepatic Resection for the Treatment of Hepatocellular Carcinomas Smaller Than 2 cm	Unknown status	No Results Available	Hepatocellular Carcinoma	Procedure: RFA|Procedure: hepatic resection	Cancer Center, Sun Yat-set University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT01351194
1041	Efficacy and Safety of Apatinib Combined With TACE in Patients With Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization	Drug: Apatinib|Radiation: TACE		https://ClinicalTrials.gov/show/NCT03510416
1042	Efficacy Analysis of Complete Laparoscopic Resection of Recurrent Hepatocellular Carcinoma	Completed	No Results Available	Recurrent Hepatocellular Carcinoma	Procedure: laparoscopic resection		https://ClinicalTrials.gov/show/NCT02613156
1043	Chemoembolization for Hepatocellular Carcinoma	Terminated	No Results Available	Hepatocellular Carcinoma	Procedure: TACE|Drug: Cisplatin	Department of Imaging and Interventional Radiology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong	https://ClinicalTrials.gov/show/NCT02821533
1044	Dose Escalation Trial of Tefinostat for Cancer Associated Inflamation in Hepatocellular Carcinoma (HCC)	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: Tefinostat	Barts Health NHS Trust, London, Greater London, United Kingdom|Beatson Cancer Centre, Glasgow, United Kingdom|Clatterbridge Cancer Centre, Liverpool, United Kingdom|University College London Hospital, London, United Kingdom	https://ClinicalTrials.gov/show/NCT02759601
1045	Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection	Withdrawn	No Results Available	Hepatocellular Carcinoma	Drug: Lenvatinib|Drug: Nivolumab	Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China|Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China|The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China|The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China|Guangzhou Twelfth People 's Hospita, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT04044651
1046	A Prospective Control Study of Cidan Capsule Combined With TACE in Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: Cidan capsule	Eastern Hepatobiliary Surgery Hospital, Shanghai, China	https://ClinicalTrials.gov/show/NCT02253511
1047	The Surveillance of Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Other: Imaging examination and/or blood test	Chinese PLA General Hospital, Beijing, Beijing, China|Chinese PLA general hospital, Beijing, China	https://ClinicalTrials.gov/show/NCT05286099
1048	Antiangiogenic Peptide Vaccine Therapy in Treating Patient With Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma	Biological: antiangiogenic paptide vaccine	Fukushima Medical University Hospital, Fukushima, Japan	https://ClinicalTrials.gov/show/NCT01266707
1049	Evaluate the Treatment With Sintilimab Injection Plus Endostar in Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma Non-resectable		Tongji Hospital, Wuhan, Hubei, China	https://ClinicalTrials.gov/show/NCT03881501
1050	Prospective Cohort Study of Changes in Circulatory MicroRNA of Resected Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma		National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|National Cancer Centre Singapore, Singapore, Singapore|Tan Tock Seng Hospital, Singapore, Singapore|Changi General Hospital, Singapore, Singapore|Sengkang General Hospital, Singapore, Singapore	https://ClinicalTrials.gov/show/NCT05148572
1051	A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma	Active, not recruiting	Has Results	Hepatocellular Carcinoma	Drug: lenvatinib|Drug: pembrolizumab (200 mg)	California Pacific Medical Center (CPMC), San Francisco, California, United States|Ronald Reagan UCLA Medical Center, Santa Monica, California, United States|Mercy Medical Center, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Icahn School of Medicine Mount Sinai, New York, New York, United States|BRCR Global Texas, Edinburg, Texas, United States|Hôpital Haut-Levêque Centre médico-chirurgical Magellan, Pessac, Bordeaux, France|Centre Eugène Marquis de Rennes, Rennes, Brittany, France|CHU Toulouse, Toulouse, Occitanie, France|Hôpital Timone, Marseille, Provence-Alpes-Côte d'Azur, France|IRCCS Istituto Clinico Humanitas, Milan, Lombardy, Italy|Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi, Bologna, Province Of Bologna, Italy|Eisai Trial Site 2, Kashiwa, Chiba, Japan|Eisai Trial Site 4, Kawasaki, Kanagawa, Japan|Eisai Trial Site 3, Sayama, Osaka, Japan|Eisai Trial Site 1, Chuo-ku, Tokyo, Japan|Republican Clinical Oncology Dispensary, Ufa, Bashkortostan, Russian Federation|St. Petersburg City Clinical Oncology Dispansery, Saint Petersburg, Leningrad Oblast, Russian Federation|S.I. Russian Oncological Research Center n.a. N. N. Blokhin RAMS, Moscow, Moscow Oblast, Russian Federation|Altay Regional Oncology Dispensary, Barnaul, Russian Federation|Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Community Of Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Community Of Madrid, Spain|Hospital Infanta Cristina de Badajoz, Badajoz, Province Of Badajoz, Spain|Hospital Universitario de Salamanca, Salamanca, Province Of Salamanca, Spain|Royal Free Hospital, London, Greater London, United Kingdom	https://ClinicalTrials.gov/show/NCT03006926
1052	Study of Sorafenib and Gemcitabine in Advanced Hepatocellular Carcinoma (HCC)	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: sorafenib|Drug: Gemcitabine	Combined Military Hospital, Rawalpindi, Punjab, Pakistan	https://ClinicalTrials.gov/show/NCT00844688
1053	Laparoscopic Hepatectomy and Radiofrequency Ablation in the Treatment of Early Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma	Procedure: Laparoscopic Hepatectomy|Procedure: Radiofrequency Ablation	JianChen, Chongqing, Chongqing, China	https://ClinicalTrials.gov/show/NCT02243384
1054	Trial of Transcatheter Arterial Chemoembolization (TACE) With Sorafenib for Locally Advanced Hepatocellular Carcinoma (HCC)	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: Sorafenib|Procedure: TACE (Transcatheter arterial chemoembolization)	Chung-Ang University Hospital, Dongjak, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT01170104
1055	The Safety and Efficacy of Deferoxamine for Treating Unresectable Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma Non-resectable	Drug: Conventional TACE|Drug: Deferoxamine and conventional TACE	960th hospital of PLA, Jinan, Shandong, China	https://ClinicalTrials.gov/show/NCT03652467
1056	Phase II Trial of SOM230 in Patients With Unresectable Hepatocellular Carcinoma	Completed	Has Results	Hepatocellular Carcinoma	Biological: SOM230	University of Miami, Miami, Florida, United States	https://ClinicalTrials.gov/show/NCT01639352
1057	The Efficiency of Postoperative Interferon-alpha Treatment in p48 Positive Patients With Hepatocellular Carcinoma	Withdrawn	No Results Available	Hepatocellular Carcinoma	Drug: interferon-alpha		https://ClinicalTrials.gov/show/NCT00838968
1058	Pharmacogenetic Study in Hepatocellular Carcinoma Patients.	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Doxorubicin|Drug: Lipiodol	Ain Shams University hepatoma group, EL Demerdash Hospital, Cairo, Egypt., Cairo, Egypt	https://ClinicalTrials.gov/show/NCT05291338
1059	The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Atezolizumab|Drug: Bevacizumab|Procedure: TACE	University Hospital RWTH Aachen, Aachen, Germany|Universitätsklinikum Düsseldorf, Düsseldorf, Germany|Krankenhaus Nordwest, Frankfurt am Main, Germany|Universitätsmedizin Göttingen, Göttingen, Germany|Klinikum Konstanz, Konstanz, Germany|Uniklinik Köln, Köln, Germany|Universitätsmedizin Mainz, Mainz, Germany|Universitätsklinikum Mannheim, Mannheim, Germany|Barcelona Clinic Liver Cancer, Universitat de Bracelona, Barcelona, Spain	https://ClinicalTrials.gov/show/NCT04803994
1060	Hepatic Arterial Infusion of Raltetrexed With Oxaliplatin(SALOX) Versus FOLFOX in Advanced Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Procedure: Raltitrexed, oxaliplatin (SALOX) treatment|Procedure: Oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment	Department of Minimally Invasive and Interventional Radiology, Liver Cancer Study and Service Group, Sun Yat-sen University Cancer Center,, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT05231382
1061	Evaluation of Postoperative Ascites After Somatostatin Infusion Following Hepatectomy for Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: somatostatin infusion|Drug: placebo infusion	APHP - Hôpital Beaujon, Clichy, France|CHRU Lille - Hopital Huriez, Lille, France|Hospices Civils de Lyon - Hôpital de la Croix Rousse, Lyon, France|APHM - Hôpital de la Timone, Marseille, France|CHU de Bordeaux - Hôpital Haut Lévèque, Pessac, France|CHU Rennes - Hôpital Pontchaillou, Rennes, France|CHU de Toulouse - Hopital Rangueil, Toulouse, France	https://ClinicalTrials.gov/show/NCT02799212
1062	A Prospective Randomized Trial Comparing Partial Hepatectomy and TACE Plus PEI for Small Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Other: operation;TACE plus PEI	Eastern Hepatobiliary Surgery Hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT00825474
1063	Treatment of Non-Metastatic Hepatocellular Carcinoma in Humans by Increasing Gabaergic Activity: A Pilot Study	Withdrawn	No Results Available	Hepatocellular Carcinoma	Drug: Baclofen	Liver Unit, Section of Hepatology, Department of Medicine,Health Sciences Centre, Winnipeg, Manitoba, Canada|Liver Unit, health sciences Centre, Winnipeg, Manitoba, Canada	https://ClinicalTrials.gov/show/NCT00493428
1064	Radial Versus Femoral Access for Superselective Embolization of Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma|Hepatocellular Carcinoma Non-resectable	Procedure: Radial TAE - Bland embolization with 40-100 Microparticles|Procedure: Transfemoral TAE - Bland embolization with 40-100 Microparticles	Humanitas Research Hospital, Rozzano, Lombardia, Italy	https://ClinicalTrials.gov/show/NCT03807947
1065	UFUR Plus Thalidomide for Advanced Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Drug: Thalidomide|Drug: Tegafur/Uracil	Department of Oncology , National Taiwan University Hospital, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT00519688
1066	Xihuang Capsules Prevention of Recurrence in Patients With Hepatocellular Carcinoma After Hepatectomy	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: Xihuang Capsules	Eastern Hepatobiliary Surgical Hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT02399033
1067	Study of Peretinoin for Suppressing Recurrence of HCV-positive HCC	Completed	Has Results	Hepatic Neoplasm Malignant Recurrent	Drug: NIK-333(peretinoin)|Drug: Placebo	Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Kashiwa, Chiba, Japan|Matsuyama, Ehime, Japan|Iizuka, Fukuoka, Japan|Kurume, Fukuoka, Japan|Ogaki, Gifu, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Himeji, Hyogo, Japan|Kobe, Hyogo, Japan|Nishinomiya, Hyogo, Japan|Kanazawa, Ishikawa, Japan|Kawasaki, Kanagawa, Japan|Sagamihara, Kanagawa, Japan|Sagamihara, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Nankoku, Kochi, Japan|Kurashiki, Okayama, Japan|Ikeda, Osaka, Japan|Moriguchi, Osaka, Japan|Osakasayama, Osaka, Japan|Sakai, Osaka, Japan|Suita, Osaka, Japan|Iruma, Saitama, Japan|Sunto-gun, Shizuoka, Japan|Shimotsuke, Tochigi, Japan|Musashino, Tokyo,, Japan|Bunkyo-ku,, Tokyo, Japan|Bunkyo-ku, Tokyo, Japan|Bunkyo-ku, Tokyo, Japan|Chiyoda-ku, Tokyo, Japan|Chuo-ku, Tokyo, Japan|Minato-ku, Tokyo, Japan|Ota-ku, Tokyo, Japan|Setagaya-ku, Tokyo, Japan|Shibuya-ku, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan|Shimonoseki, Yamaguchi, Japan|Ube, Yamaguchi, Japan|Kofu, Yamanashi, Japan|Chiba, Japan|Fukuoka, Japan|Fukuoka, Japan|Gifu, Japan|Gifu, Japan|Hiroshima, Japan|Hiroshima, Japan|Kagoshima, Japan|Kumamoto, Japan|Nagasaki, Japan|Niigata, Japan|Oita, Japan|Okayama, Japan|Osaka, Japan|Osaka, Japan|Osaka, Japan|Osaka, Japan|Osaka, Japan|Saga, Japan|Saga, Japan|Tokushima, Japan|Tokushima, Japan|Wakayama, Japan	https://ClinicalTrials.gov/show/NCT01640808
1068	Radiofrequency Ablation Assisted Hepatectomy Versus Hepatectomy Alone for Advanced Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma	Procedure: RFA assisted Hepatectomy|Procedure: Hepatectomy	Institute of hepatobiliary surgery,Southwest Hospital, Chongqing, Chongqing, China	https://ClinicalTrials.gov/show/NCT01713244
1069	Durvalumab for Advanced Hepatocellular Carcinoma in Patients With Active Chronic Hepatitis B Virus Infection	Recruiting	No Results Available	Advanced Hepatocellular Carcinoma	Drug: Durvalumab	National Taiwan University Hospital, Taipei City, Taiwan	https://ClinicalTrials.gov/show/NCT04294498
1070	Treatment of Portal Vein Tumor Thrombus After Hepatocellular Carcinoma Resection	Completed	No Results Available	Hepatocellular Carcinoma	Drug: TACE|Procedure: Laser ablation	Eastern Hepatobiliary Surgery Hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT00825669
1071	Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity	Recruiting	No Results Available	Lung Cancer, Nonsmall Cell|Renal Cell Carcinoma|Melanoma|Gastric Cancer|Hepatocellular Carcinoma|Endometrial Cancer|Mesothelioma	Diagnostic Test: Blood screening|Diagnostic Test: Tissue screening	Westmead Hospital, Sydney, New South Wales, Australia|Blacktown Mt Druitt Hospital, Sydney, New South Wales, Australia	https://ClinicalTrials.gov/show/NCT04631731
1072	TheraSphere for the Treatment of Unresectable Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Radiation: TheraSphere	Thomas Jefferson University, Philadelphia, Pennsylvania, United States	https://ClinicalTrials.gov/show/NCT01349075
1073	Immunotherapy of Hepatocellular Carcinoma by Induction of Anti-alpha Fetoprotein Response	Terminated	No Results Available	Hepatocellular Carcinoma	Procedure: injection of the cell therapy product	University Hospital of Angers, Angers, France|CHD La Roche-sur-Yon, La Roche-sur-Yon, France|Nantes University Hospital, Nantes, France|CH Saint Nazaire, Saint Nazaire, France	https://ClinicalTrials.gov/show/NCT01128803
1074	Comparison of TACE Versus TACE/TACI Combination in Advanced Hepatocellular Carcinoma With Portal Vein Invasion	Withdrawn	No Results Available	Hepatocellular Carcinoma	Drug: Doxorubicin|Drug: Cisplatin	Seoul National University Hospital, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT01857726
1075	Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Nivolumab|Drug: Relatlimab	Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States	https://ClinicalTrials.gov/show/NCT04658147
1076	Transarterial Chemoembolization (TACE) Therapy of Hepatocellular Carcinoma (HCC) With Blocking Tumor Blood Temporarily and Enhancing Perfusion	Completed	No Results Available	Hepatocellular Carcinoma	Procedure: balloon catheter	Eastern hepatobilliary surgery hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT00826384
1077	Immunotherapy Using Pluripotent Killer-Programmed Cell Death 1 (PIK-PD-1) Cells for the Treatment of Advanced Hepatocellular Carcinoma	Unknown status	No Results Available	Advanced Hepatocellular Carcinoma	Biological: PIK-PD-1 cells|Biological: DC-PMAT	Eastern Hepatobiliary Surgery Hospital, Shanghai, China	https://ClinicalTrials.gov/show/NCT02632006
1078	A Study of Second-line Treatment With Apatinib After TACE in Advanced Hepatocellular Carcinoma Patients	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: Apatinib	Department of Interventional Therapy, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT02727309
1079	Cetuximab in Patients With Unresectable or Metastatic Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Drug: Cetuximab	Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States	https://ClinicalTrials.gov/show/NCT00142428
1080	Cytokine Change in Hepatocellular Carcinoma Treated by Thermal Ablation	Recruiting	No Results Available	Hepatocellular Carcinoma	Device: Radiofrequency ablation or microwave ablation	Chinese University of Hong Kong, Hong Kong, Hong Kong	https://ClinicalTrials.gov/show/NCT04555265
1081	A National Phase II Study of Proton Therapy in Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Radiation: Proton therapy	Herlev Hospital, Herlev, Hovedstaden, Denmark|Aarhus University Hospital, Aarhus, Midtjylland, Denmark|Odense University Hospital, Odense, Syd, Denmark	https://ClinicalTrials.gov/show/NCT05203120
1082	Hepatectomy Versus Hepatectomy With Lymphadenectomy in Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Procedure: hepatectomy combined with lymphadenectomy|Procedure: hepatectomy alone	Sun Yat-sen University Cancer Center, GuangZhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT02031952
1083	Characterization of Baseline Biomarker Variability in Participants With Hepatocellular Carcinoma (MK-0000-215)	Terminated	Has Results	Hepatocellular Carcinoma	Procedure: MRI|Procedure: Pathology|Procedure: Blood Samples		https://ClinicalTrials.gov/show/NCT01521780
1084	A Phase II Study of Radiotherapy for Locally Advanced Hepatocellular Carcinoma (HCC)	Completed	No Results Available	Hepatocellular Carcinoma	Procedure: radiotherapy		https://ClinicalTrials.gov/show/NCT00154817
1085	Evaluation of the Efficacy of Long-acting Release Octreotide in Patients With Advanced Hepatocellular Carcinoma	Completed	No Results Available	Advanced Hepatocellular Carcinoma	Drug: Octreotide		https://ClinicalTrials.gov/show/NCT00241020
1086	Radiofrequency Ablation Plus Systematic Neoadjuvant Therapy for Recurrent Hepatocellular Carcinoma (RANT Study)	Recruiting	No Results Available	Hepatocellular Carcinoma Recurrent	Drug: Tislelizumab/Sintilimab+Lenvatinib/Bevacizumab|Procedure: RFA	Institute of hepatobiliary surgery,Southwest Hospital, Chongqing, Chongqing, China	https://ClinicalTrials.gov/show/NCT05277675
1087	Hepatectomy Versus Chemoembolization for Resectable Hepatocellular Carcinoma Beyond Milan Criteria	Unknown status	No Results Available	Resectable Hepatocellular Carcinoma Beyond Milan Criteria	Procedure: Chemoembolization and Response-Dependent Resection|Procedure: Immediate Resection	Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT02138981
1088	GPC3-CAR-T Cells for the Hepatocellular Carcinoma	Suspended	No Results Available	Hepatocellular Carcinoma	Biological: GPC3-CAR-T cells	Beijing Tsinghua Changgung Hospital, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT04506983
1089	Adjuvant Radiotherapy for Resected Hepatocellular Carcinoma With MVI	Completed	Has Results	Hepatocellular Carcinoma	Radiation: Stereotactic radiotherapy	Second Military Medical University, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT04891874
1090	Adjuvant Therapy With Thalidomide for Chemoembolization in Advanced Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: Thalidomide|Drug: TACE	Liver Cancer Institute, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT00921531
1091	Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma	Not yet recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Axitinib|Drug: Avelumab|Drug: Bavituximab	The University of Texas Southwestern Medical Center, Dallas, Texas, United States	https://ClinicalTrials.gov/show/NCT05249569
1092	Tislelizumab in the Systematic Treatment of Advanced Hepatocellular Carcinoma	Active, not recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Tislelizumab	Fudan University Shanghai Cancer Center, Shanghai, China	https://ClinicalTrials.gov/show/NCT04996459
1093	GPC3 Targeted Fluorescence Image Guided Surgery of Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Anti-GPC3-IRDye800CW	Zhuhai People's Hospital, Zhuhai, Guangdong, China|The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China	https://ClinicalTrials.gov/show/NCT05047510
1094	Pathological Results of Aggressive Hepatocellular Carcinomas Treated Using SIRT	Completed	No Results Available	Hepatocellular Carcinoma		Uhmontpellier, Montpellier, France	https://ClinicalTrials.gov/show/NCT05045573
1095	Study Efficacy and Safety of INC280 in Patients With Advanced Hepatocellular Carcinoma.	Active, not recruiting	No Results Available	Advanced Hepatocellular Carcinoma With c-MET Dysregulation	Drug: INC280	Novartis Investigative Site, Nanjing, Jiangsu, China|Novartis Investigative Site, Xi'an, Shanxi, China|Novartis Investigative Site, Hangzhou, Zhejiang, China|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Khon Kaen, THA, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand	https://ClinicalTrials.gov/show/NCT01737827
1096	Adjuvant Immune Checkpoint Inhibitors in Postoperative Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Immune Checkpoint Inhibitors Based Adjuvant therapy	Jian-Hong Zhong, Nanning, Guangxi, China	https://ClinicalTrials.gov/show/NCT05221398
1097	A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib	Completed	Has Results	Hepatocellular Carcinoma	Biological: Placebo|Biological: Ramucirumab DP (IMC-1121B)|Other: BSC	ImClone Investigational Site, Orange, California, United States|ImClone Investigational Site, San Francisco, California, United States|ImClone Investigational Site, New Haven, Connecticut, United States|ImClone Investigational Site, Jacksonville, Florida, United States|ImClone Investigational Site, New Orleans, Louisiana, United States|ImClone Investigational Site, Boston, Massachusetts, United States|ImClone Investigational Site, Worcester, Massachusetts, United States|ImClone Investigational Site, Ann Arbor, Michigan, United States|ImClone Investigational Site, St Louis, Missouri, United States|ImClone Investigational Site, Newark, New Jersey, United States|ImClone Investigational Site, New York, New York, United States|ImClone Investigational Site, Winston-Salem, North Carolina, United States|ImClone Investigational Site, Dayton, Ohio, United States|ImClone Investigational Site, Philadelphia, Pennsylvania, United States|ImClone Investigational Site, Charleston, South Carolina, United States|ImClone Investigational Site, Lubbock, Texas, United States|ImClone Investigational Site, Seattle, Washington, United States|ImClone Investigational Site, Milwaukee, Wisconsin, United States|ImClone Investigational Site, Bankstown, New South Wales, Australia|ImClone Investigational Site, Kogarah, New South Wales, Australia|ImClone Investigational Site, Liverpool Bc, New South Wales, Australia|ImClone Investigational Site, Kurralta Park, South Australia, Australia|ImClone Investigational Site, Prahran, Victoria, Australia|ImClone Investigational Site, Linz, Austria|ImClone Investigational Site, Salzburg, Austria|ImClone Investigational Site, Steyr, Austria|ImClone Investigational Site, Vienna, Austria|ImClone Investigational Site, Bonheiden, Belgium|ImClone Investigational Site, Brussels, Belgium|ImClone Investigational Site, Charleroi, Belgium|ImClone Investigational Site, Edegem, Belgium|ImClone Investigational Site, Leuven, Belgium|ImClone Investigational Site, Liège, Belgium|ImClone Investigational Site, Ottignies, Belgium|ImClone Investigational Site, Belo Horizonte, Brazil|ImClone Investigational Site, Botucatu, Brazil|ImClone Investigational Site, Brasilia, Brazil|ImClone Investigational Site, Campinas, Brazil|ImClone Investigational Site, Ijui, Brazil|ImClone Investigational Site, Ribeirao Preto, Brazil|ImClone Investigational Site, Rio De Janeiro, Brazil|ImClone Investigational Site, Salvador, Brazil|ImClone Investigational Site, Sao Jose Rio Preto, Brazil|ImClone Investigational Site, São Paulo, Brazil|ImClone Investigational Site, Plovdiv, Bulgaria|ImClone Investigational Site, Sofia, Bulgaria|ImClone Investigational Site, Varna, Bulgaria|ImClone Investigational Site, Ottawa, Ontario, Canada|ImClone Investigational Site, Brib, Czech Republic|ImClone Investigational Site, Hradec Kralove, Czech Republic|ImClone Investigational Site, Olomouc, Czech Republic|ImClone Investigational Site, Prague, Czech Republic|ImClone Investigational Site, Helsinki, Finland|ImClone Investigational Site, Amiens, France|ImClone Investigational Site, Angers, France|ImClone Investigational Site, Avignon, France|ImClone Investigational Site, Besancon, France|ImClone Investigational Site, Bordeaux, France|ImClone Investigational Site, Clermont-Ferrand, France|ImClone Investigational Site, La Roche Sur Yon, France|ImClone Investigational Site, Limoges, France|ImClone Investigational Site, Marseille, France|ImClone Investigational Site, Nice, France|ImClone Investigational Site, Paris, France|ImClone Investigational Site, Poitiers, France|ImClone Investigational Site, Reims, France|ImClone Investigational Site, Saint-Etienne, France|ImClone Investigational Site, Berlin, Germany|ImClone Investigational Site, Bielefeld, Germany|ImClone Investigational Site, Bonn, Germany|ImClone Investigational Site, Düsseldorf, Germany|ImClone Investigational Site, Essen, Germany|ImClone Investigational Site, Frankfurt, Germany|ImClone Investigational Site, Freiburg, Germany|ImClone Investigational Site, Hamburg, Germany|ImClone Investigational Site, Hannover, Germany|ImClone Investigational Site, Homburg, Germany|ImClone Investigational Site, Leipzig, Germany|ImClone Investigational Site, Magdeburg, Germany|ImClone Investigational Site, Munich, Germany|ImClone Investigational Site, Münster, Germany|ImClone Investigational Site, Tübingen, Germany|ImClone Investigational Site, Ulm, Germany|ImClone Investigational Site, Weiden, Germany|ImClone Investigational Site, Kowloon, Hong Kong|ImClone Investigational Site, Pokfulam, Hong Kong|ImClone Investigational Site, Shatin, Hong Kong|ImClone Investigational Site, Budapest, Hungary|ImClone Investigational Site, Beer Sheva, Israel|ImClone Investigational Site, Petah Tiqva, Israel|ImClone Investigational Site, Tel Aviv, Israel|ImClone Investigational Site, Bari, Italy|ImClone Investigational Site, Benevento, Italy|ImClone Investigational Site, Bologna, Italy|ImClone Investigational Site, Genova, Italy|ImClone Investigational Site, Lecce, Italy|ImClone Investigational Site, Milano, Italy|ImClone Investigational Site, Modena, Italy|ImClone Investigational Site, Padova, Italy|ImClone Investigational Site, Palermo, Italy|ImClone Investigational Site, Pavia, Italy|ImClone Investigational Site, Rome, Italy|ImClone Investigational Site, Udine, Italy|ImClone Investigational Site, Chiba, Japan|ImClone Investigational Site, Fukuoka, Japan|ImClone Investigational Site, Hyogo, Japan|ImClone Investigational Site, Ishikawa, Japan|ImClone Investigational Site, Kanagawa, Japan|ImClone Investigational Site, Kochi, Japan|ImClone Investigational Site, Kyoto, Japan|ImClone Investigational Site, Miyagi, Japan|ImClone Investigational Site, Osaka-Pref, Japan|ImClone Investigational Site, Osaka, Japan|ImClone Investigational Site, Saga, Japan|ImClone Investigational Site, Tochigi, Japan|ImClone Investigational Site, Tokushima, Japan|ImClone Investigational Site, Tokyo, Japan|ImClone Investigational Site, Anyang, Korea, Republic of|ImClone Investigational Site, Incheon, Korea, Republic of|ImClone Investigational Site, Seodaemun-Gu, Korea, Republic of|ImClone Investigational Site, Seoul, Korea, Republic of|ImClone Investigational Site, Amsterdam, Netherlands|ImClone Investigational Site, Rotterdam, Netherlands|ImClone Investigational Site, Oslo, Norway|ImClone Investigational Site, Quezon City, Philippines|ImClone Investigational Site, Lisbon, Portugal|ImClone Investigational Site, Santa Maria Da Feira, Portugal|ImClone Investigational Site, Bucharest, Romania|ImClone Investigational Site, Cluj-Napoca, Romania|ImClone Investigational Site, Craiova, Romania|ImClone Investigational Site, Avila, Spain|ImClone Investigational Site, Girona, Spain|ImClone Investigational Site, Madrid, Spain|ImClone Investigational Site, Ourense, Spain|ImClone Investigational Site, Valencia, Spain|ImClone Investigational Site, Stockholm, Sweden|ImClone Investigational Site, Bern, Switzerland|ImClone Investigational Site, Changhua, Taiwan|ImClone Investigational Site, Kuei Shan Hsiang, Taiwan|ImClone Investigational Site, Liouying/Tainan, Taiwan|ImClone Investigational Site, Niaosung, Taiwan|ImClone Investigational Site, Taichung, Taiwan|ImClone Investigational Site, Tainan, Taiwan|ImClone Investigational Site, Taipei, Taiwan|ImClone Investigational Site, Bangkok, Thailand|ImClone Investigational Site, Hat Yai, Thailand	https://ClinicalTrials.gov/show/NCT01140347
1098	A Head-to-head Comparison of MRI, CT, 18F-FDGal and 18F-choline in Patients With Hepatocellular Carcinoma	Not yet recruiting	No Results Available	Hepatocellular Carcinoma	Diagnostic Test: 18F-FDGal PET/CT and 18F-choline PET/CT	Aarhus University Hospital, Aarhus, Denmark	https://ClinicalTrials.gov/show/NCT05359939
1099	Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy	Completed	No Results Available	Hepatocellular Carcinoma	Drug: ADI-PEG 20 (arginine deiminase formulated with polyethylene glycol)|Drug: Placebo|Other: Best Supportive Care	University of Alabama, Birmingham, Alabama, United States|Southern California Research Center, Coronado, California, United States|Catherine Frenette, La Jolla, California, United States|Stanford University, Palo Alto, California, United States|University of California at San Diego Moores Cancer Center, San Diego, California, United States|Pacific Medical Center, San Francisco, California, United States|Piedmont Research Institute, Atlanta, Georgia, United States|University of Hawaii, Honolulu, Hawaii, United States|University of Maryland Greenbaum Cancer Center, Baltimore, Maryland, United States|Johns Hopkins University Hospital, Baltimore, Maryland, United States|Wayne State University School of Medicine, Dept Oncology, Detroit, Michigan, United States|University of Minnesota Cancer Center, Minneapolis, Minnesota, United States|Nebraska Hem-Onc, Lincoln, Nebraska, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|University of Oregon, Portland, Oregon, United States|Drexel University, Philadelphia, Pennsylvania, United States|University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, United States|UPMC Cancer Centers, Pittsburgh, Pennsylvania, United States|UT Southwestern, Dallas, Texas, United States|Michael E. DeBakey VA Medical Center, Houston, Texas, United States|University of Washington, Seattle, Washington, United States|A ward of Oncology-287 Changhuai Rd, Bengbu, Anhui, China|Oncology, No. 678, Furong Rd, Hefei, Anhui, China|The First Hospital of Medical University Of Anhui, Hefei, Anhui, China|5th Fl, Inpatient Bldg, No. 8,, Fengtai Distrcit, Beijing, China|No. 156 North Road of West Second Ring, Gulou District, Fujian, China|15th Floor, In-patient Building (East), No. 651 Dongfeng East Road, Guangzhou, Guangdong, China|5th Fl, Inpatient Bldg, No. 71, Heti Rd, Qingxiu Disttrict, Guangxi, China|3rd Floor, Medicine Building, No. 150 Haping Rd, Harbin, Heilongjiang, China|Oncology, 185 Road Juqian Street, Changzhou, Jiangsu, China|The Chinese people's liberation army 81 hospital, Nanjing, Jiangsu, China|5th Floor, Medical Building, No. 1018 Huguang Rd, Changchun, Jilin, China|No. 193, Lianhe Rd, Shahekou Dist., Dalian, Liaoning, China|No. 596, Xinsi Rd., Baqiao Dist., Xi'an, Shaanxi, China|Floor 7, 3rd Inpatient Building No. 37, Guoxue Xiang, Cheng Du, Sichuan, China|13th Floor, Internal Medicine Building, No. 29 Gaotanyan Main St., ChongQing, China|Bldg No. 5, 3rd Floor, Dongan Rd, Shanghai, China|Istituto Tumori "Giovanni Paolo II", Bari, Italy|Policlinico S. Orsola-Malpighi, Bologna, Italy|Azienda Ospedaliera Niguarda Cà Granda, Milan, Italy|Fondazione Centro San Raffaele del Monte Tabor, Milan, Italy|Fondazione IRCCs "Ca Granda" Ospedale Maggiore Policlinico, Milan, Italy|Policlinico di Monza, Monza, Italy|Istituto Nazionale per lo Studio e la Cura dei Tumori, Naples, Italy|Azienda Ospedaliera di Padova, Padova, Italy|Azienda Ospedaliera San Camillo Forlanini, Roma, Italy|Instituto Nazionale pler le Malattie Infettive, Rome, Italy|Asan Medical Center, Seoul, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul St. Mary's Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|CGMHCY, ChiaYi, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, Taiwan|Chang Gung Medical Foundation-Kaohsiung, Kaohsiung County, Taiwan|China Medicine University Hospital, Taichung, Taiwan|CMMC-LY, Tainan City, Taiwan|CMMC-YK, Tainan City, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|Northern Taiwan University Hospital, Taipei City, Taiwan|Mackay Memorial Hospital-Taipei Branch, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Chang Gung Medical Foundation-Linkou, Taoyuan County, Taiwan|Clatterbridge Cancer Center, Bebington, United Kingdom|University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom|Hammersmith Hospital, London, United Kingdom|King's College Hospital, London, United Kingdom|Royal Free Hospital, London, United Kingdom|St. Bartholomew's Hospital, London, United Kingdom|The Royal Marsden Hospital, London, United Kingdom|Christie NHS Trust, Manchester, United Kingdom|Nottingham University Hospital, Nottingham, United Kingdom|Royal Marsden, Sutton, United Kingdom	https://ClinicalTrials.gov/show/NCT01287585
1100	Combination Chemoembolization and Stereotactic Body Radiation Therapy in Unresectable Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Radiation: SBRT|Drug: TACE	Icahn School of Medicine at Mount Sinai, New York, New York, United States	https://ClinicalTrials.gov/show/NCT02513199
1101	Yang Yin Fu Zheng Jie Du Therapy in HBV Related Hepatocellular Carcinoma Induced Anemia (YYFZJDTIHBVRHCIA)	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Yang Yin Fu Zheng Jie Du therapy|Other: Routine medical care	Zhiyun Yang, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT05088733
1102	Observational Study on Patients With Hepatocellular Carcinoma (HCC)	Recruiting	No Results Available	Hepatocellular Carcinoma	Other: No intervention	Nanfang Hospital, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT04021056
1103	TACE Combined With PD-1 Knockout Engineered T Cell in Advanced Hepatocellular Carcinoma.	Recruiting	No Results Available	Advanced Hepatocellular Carcinoma	Procedure: Transcatheter arterial chemoembolization|Biological: PD-1 knockout engineered T cells	The 3rd Xiangya Hospital of Central South University, Changsha, Hunan, China	https://ClinicalTrials.gov/show/NCT04417764
1104	the Efficacy and Safety of Ginsenoside Rg3 Capsule in Prevention of Postoperative Recurrence of Hepatocellular Carcinoma	Completed	No Results Available	Stage I Hepatocellular Carcinoma|Stage II Hepatocellular Carcinoma	Drug: the ginsenoside Rg3|Drug: Placebo	The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China|Tumor Hospital,Sun Yat-san University, Guangzhou, Guangdong, China|The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China|Tongji Hospital,Huazhong University of Science ＆ Technology, Wuhan, Hubei, China|Zhongshan hospital,Fudan University, Shanghai, China	https://ClinicalTrials.gov/show/NCT01717066
1105	A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET)	Recruiting	No Results Available	Unresectable Hepatocellular Carcinoma|Hepatocellular Carcinoma by BCLC Stage	Drug: Hepatic Arterial Infusion(mFOLFOX7) combined with Bevacizumab and Sintilimab	Yang-Kui Gu, Guangzhou, Guangdong, China|Sun Yat-Sen Memorial Hospital, Guangzhou, Guangdong, China|Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China|The Third Affiliated Hospital of Sun Yat-Sen University, Guanzhou, Guangdong, China|Xiangya Hospital of Central South University, Changsha, Hunan, China	https://ClinicalTrials.gov/show/NCT05214339
1106	Balloon Assisted Transarterial Therapy for Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Procedure: The balloon catheter is placed at the various arterial feeders of the tumor	Department of Imaging and Interventional Radiology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong	https://ClinicalTrials.gov/show/NCT04780802
1107	Multi-pronged Ethanol Ablation and Radiofrequency Ablation of Early-stage Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Procedure: multi-pronged ethanol ablation|Procedure: radiofrequency ablation	The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT00844454
1108	A Study of Neoadjuvant Tislelizumab With SBRT in Patients With Resectable Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Combination Product: PD-1 plus stereotactic body radiotherapy	Shandong Cancer Hospital and Institute, Jinan, Shandong, China	https://ClinicalTrials.gov/show/NCT05185531
1109	Surufatinib in Advanced Hepatocellular Carcinoma Based on Single-cell Sequencing of Tumor Samples	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Surufatinib	Nanjing Drum tower hospital, Nanjing, Jiangsu, China	https://ClinicalTrials.gov/show/NCT05171439
1110	SBRT Versus Ablation for Perivascular Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Radiation: Stereotactic Body Radiation Therapy|Procedure: radiofrequency ablation	The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT04434989
1111	Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Monitoring Circulating Tumor DNA	Not yet recruiting	No Results Available	Hepatocellular Carcinoma	Other: circulating tumor DNA dosage		https://ClinicalTrials.gov/show/NCT05375370
1112	Immunomonitoring of Interventional Radiology Procedures in the Management of Hepatocellular Carcinoma	Not yet recruiting	No Results Available	Hepatocellular Carcinoma	Procedure: Percutaneous ablation		https://ClinicalTrials.gov/show/NCT04892810
1113	Combined Immunotherapy and Targeted Therapy for Hepatocellular Carcinoma	Unknown status	No Results Available	HepatoCellular Carcinoma	Drug: PD-1|Drug: Sorafenib	TaoBai, Nanning, Guangxi, China	https://ClinicalTrials.gov/show/NCT04152356
1114	Surgery Versus Non-Surgical Treatment for Clinical Complete Responders After Non-Curative Therapy for Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Procedure: Liver Resection	Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT05349331
1115	68 Ga PSMA PET/MRI for Hepatocellular Carcinoma	Active, not recruiting	No Results Available	Hepatocellular Carcinoma	Drug: 68Ga-PSMA-11 PET/MRI	Mayo Clinic in Rochester, Rochester, Minnesota, United States	https://ClinicalTrials.gov/show/NCT03982407
1116	Combined Radiotherapy and Radiofrequency Ablation for Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma	Radiation: Radiofrequency ablation|Device: IMRT & SBRT	TaoBai, Nanning, Guangxi, China	https://ClinicalTrials.gov/show/NCT04202523
1117	SBRT and Durvalumab for Inoperable/Unresectable Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Durvalumab|Radiation: Stereotactic body radiation therapy	Department of Clinical Oncology, Queen Mary Hospital, Hong Kong, Hong Kong	https://ClinicalTrials.gov/show/NCT04913480
1118	Accuracy of Contrast-Enhanced Ultrasound for Hepatocellular Carcinoma Post TACE	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Lumason	Penn State Hershey Medical Center, Hershey, Pennsylvania, United States	https://ClinicalTrials.gov/show/NCT04569799
1119	Recurrence Risk Factors of Early-Stage Hepatocellular Carcinoma After Radio Frequency Ablation	Active, not recruiting	No Results Available	Hepatocellular Carcinoma	Procedure: MESS-RFA	Southwest hospital, Chongqing, Chongqing, China	https://ClinicalTrials.gov/show/NCT02046356
1120	Impact of "Teaching the Teachers" Concept on Global Education and Application of Hepatocellular Carcinoma Diagnosis Guidelines	Recruiting	No Results Available	Hepatocellular Carcinoma	Other: Survey Administration	M D Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT05143619
1121	A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Biological: TC-CAR031	the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China|The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China，310000, Hangzhou, China	https://ClinicalTrials.gov/show/NCT05155189
1122	The Clinicopathological and Prognostic Factors of Hepatocellular Carcinoma; 10 Years' Tertiary Center Experience in Egypt	Recruiting	No Results Available	Hepatocellular Carcinoma	Other: Morphological classifications of HCC	National Liver Intitute, Shibīn Al Kawm, Menoufia, Egypt	https://ClinicalTrials.gov/show/NCT05047146
1123	Idarubicin vs. Epirubicin TACE in the Treatment of Hepatocellular Carcinoma	Not yet recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Idarubicin Hydrochloride for Injection|Drug: Epirubicin	Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China	https://ClinicalTrials.gov/show/NCT05053386
1124	Assessment of the Efficacy of Lenvatinib Versus Sorafenib in the Management of Advanced Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Lenvatinib	Department of Hepatology, Dhaka, Bangladesh|Sir Salimullah Medical College, Dhaka, Bangladesh	https://ClinicalTrials.gov/show/NCT05391867
1125	Value of the Laparoscopic Approach in the Surgical Management of Resectable Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Procedure: Laparoscopy|Procedure: Laparotomy	Chirurgie Digestive - CHU Amiens, Amiens, France|Chirurgie viscérale et digestive - CHU Besançon, Besançon, France|Chirurgie Hépatologie - Hôpital Beaujon, Clichy, France|Chirurgie Digestive et Hépatobiliaire - Hôpital Henri-Mondor, Créteil, France|Chirurgie Digestive et de l'Urgence - CHU Grenoble, Grenoble, France|Chirurgie Digestive et Transplantations - Hôpital Huriez, Lille, France|Chirurgie Générale, Digestive et de la Transplantation hépatique - Hôpital de la Croix Rousse, Lyon, France|Chirurgie Digestive - Hôpital La Timone, Marseille, France|Chirurgie Digestive - CHU Montpellier, Montpellier, France|Chirurgie digestive - Institut Mutualiste Montsouris, Paris, France|Cochin hospital, Paris, France|Chirurgie hépato-biliaire et greffe de foie - La Pitié, Paris, France|Chirurgie viscérale et digestive - CHU Rouen, Rouen, France|Chirurgie hépato-bilio-pancréatique et Transplantation - Hôpital Rangueil, Toulouse, France|Chirurgie digestive Oncologique Endocrinienne et Transplantation hépatique - CHU Tours, Tours, France|Centre hépatobiliaire de transplantation hépatique - Hopital Paul Brousse, Villejuif, France	https://ClinicalTrials.gov/show/NCT04791735
1126	Fu Zheng Jie Du Hua Yu Principle For Treatment Of Severe HBV Related Hepatocellular Carcinoma (FZJDHYPFTOSHBVHCC)	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Fu Zheng Jie Du Hua Yu therapy	Zhiyun Yang, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT05152498
1127	A Phase I, Open-label Study to Assess the Safety and Efficacy of Poly-ICLC Plus Nivolumab in Unresectable Hepatocellular Carcinoma Patients	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Poly ICLC	NTUH, Taipei City, Zhongzheng Dist, Taiwan	https://ClinicalTrials.gov/show/NCT05281926
1128	Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma (GOING)	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Regorafenib|Drug: Nivolumab	Hospital Clinic, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Gregorio Marañon, Madrid, Spain|Hospital Puerta de Hierro, Madrid, Spain|Hospital Ramon y Cajal, Madrid, Spain|Hospital Central de Asturias, Oviedo, Spain|Clinica Universidad de Navarra, Pamplona, Spain	https://ClinicalTrials.gov/show/NCT04170556
1129	Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma	Active, not recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Abemaciclib|Drug: Nivolumab	Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States	https://ClinicalTrials.gov/show/NCT03781960
1130	Safety and Efficacy of Degradable Microsphere in Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Device: Nexsphere™	Asan Medical Center, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT05072041
1131	Tislelizumab in Combination With TACE in Advanced Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Tislelizumab in combination with cTACE	Centre of Interventional Radiology and Vascular Surgery, Department of Radiology, Zhongda Hospital, Southeast University, Nanjing, Jiangsu, China	https://ClinicalTrials.gov/show/NCT04652492
1132	Analysis of Expression of Specific Markers and Their Prognostic Significance in Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Other: Retrospective analysis of already archived samples	GSK Investigational Site, Taipei, Taiwan|GSK Investigational Site, Bangkok, Thailand|GSK Investigational Site, Chiangmai, Thailand	https://ClinicalTrials.gov/show/NCT00911196
1133	Study of Anlotinib After Lenvatinib in Patients With Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: Anlotinib	180 Fenglin Road, Shanghai, China	https://ClinicalTrials.gov/show/NCT04080154
1134	Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Procedure: Hepatic arterial infusion chemotherapy|Drug: Lenvatinib|Drug: Camrelizumab	Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT05003700
1135	A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma	Not yet recruiting	No Results Available	Hepatocellular Carcinoma	Drug: TACE+Camrelizumab+Apatinib mesylate|Procedure: TACE		https://ClinicalTrials.gov/show/NCT05320692
1136	Cabozantinib Treatment in a Phase II Study for Patients With Hepatocellular Carcinoma (HCC) Refractory to PD-1 Inhibitors	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Cabozantinib	Technische Universität Dresden, Medizinische Fakultät Carl Gustav Carus Medizinische Klinik und Poliklinik I, Dresden, Saxonia, Germany|University Hospital Leipzig, Leipzig, Saxonia, Germany|Charite Universitätsmedizin, Campus Virchow Klinikum, Klinik für Hepatologie/Gastroenterologie, Berlin, Germany	https://ClinicalTrials.gov/show/NCT04767906
1137	Oral Chemotherapy Versus Supportive Therapy In The Treatment Of Unresectable Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: Oral|Other: Supportive	All India Institute of Medical Sciences, New Delhi, Delhi, India	https://ClinicalTrials.gov/show/NCT01438450
1138	Effect of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Sorafenib For Advanced Hepatocellular Carcinoma (HCC) (HEPANOVA)	Active, not recruiting	No Results Available	Hepatocellular Carcinoma	Device: NovoTTF-100L(P) device|Drug: Sorafenib	University Hospital Fakultni Nemocnice Olomouc, Oncology Clinic, Olomouc, Czechia|CHU de Nantes, Nantes Cedex 01, France|University Medical Center - University of Freiburg, Freiburg, Germany|Ulm University Hospital, Ulm, Germany|Università Campus Bio-Medico di Roma, Rome, Italy|Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, Poznań, Poland|Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain|HM Hospitales - Centro Integral Oncológico Clara Campal, Madrid, Spain	https://ClinicalTrials.gov/show/NCT03606590
1139	Toripalimab Plus Sorafenib in Patients With Advanced-Stage Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Toripalimab|Drug: Sorafenib	Zhongshan Hospital, Shanghai, China	https://ClinicalTrials.gov/show/NCT04926532
1140	A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma	Active, not recruiting	Has Results	Hepatocellular Carcinoma	Biological: Tremelimumab|Biological: Durvalumab|Biological: Bevacizumab	Research Site, Phoenix, Arizona, United States|Research Site, San Francisco, California, United States|Research Site, New Haven, Connecticut, United States|Research Site, Jacksonville, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Boston, Massachusetts, United States|Research Site, New York, New York, United States|Research Site, Stony Brook, New York, United States|Research Site, Durham, North Carolina, United States|Research Site, Portland, Oregon, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Nashville, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Seattle, Washington, United States|Research Site, Hangzhou, China|Research Site, Nanjing, China|Research Site, Shanghai, China|Research Site, Hong Kong, Hong Kong|Research Site, Sha Tin, Hong Kong|Research Site, Benevento, Italy|Research Site, Milano, Italy|Research Site, Roma, Italy|Research Site, Chuo-ku, Japan|Research Site, Kashiwa, Japan|Research Site, Osakasayama-shi, Japan|Research Site, Busan, Korea, Republic of|Research Site, Jung-gu, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Bukit Merah, Singapore|Research Site, Singapore, Singapore|Research Site, Singapore, Singapore|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Cordoba, Spain|Research Site, Pamplona, Spain|Research Site, Kaohsiung City, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan City, Taiwan	https://ClinicalTrials.gov/show/NCT02519348
1141	Radiofrequency Ablation Plus Radiotherapy for Small Hepatocellular Carcinoma	Not yet recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Radiofrequency ablation with radiotherapy|Drug: Radiofrequency ablation alone		https://ClinicalTrials.gov/show/NCT03988998
1142	AFP Specific T Cell Receptor Transduced T Cells Injection(C-TCR055) in Unresectable Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma	Biological: Autologous C-TCR055	the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China	https://ClinicalTrials.gov/show/NCT04368182
1143	Safety and Efficacy of Allogeneic NK Cells Therapy in Patients With Advanced Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Biological: allogeneic NK cells therapy	The Fifth Medical Center of PLA General Hospital, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT04162158
1144	PSMA PET/MRI or PSMA PET/CT for Evaluation of Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Ga-68 labeled PSMA-11|Procedure: Possible liver biopsy for locoregional therapy group	Mayo Clinic in Rochester, Rochester, Minnesota, United States	https://ClinicalTrials.gov/show/NCT04310540
1145	Sintilimab Combined With Lenvatinib in Local Advanced Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Biological: Sintilimab|Drug: Lenvatinib	Beijing Cancer Hospital, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT04042805
1146	[68Ga]DOTATATE-PET/MRI in Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Drug: [68Ga]DOTATATE-PET/MRI	University of Alabama at Birmingham Medical Center, Birmingham, Alabama, United States	https://ClinicalTrials.gov/show/NCT03648073
1147	Contrast-enhanced Ultrasound With Perfluorobutane and Sulfur Hexafluoride for Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Diagnostic Test: contrast enhanced ultrasound|Diagnostic Test: Dynamic CT|Diagnostic Test: Liver MRI	Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of	https://ClinicalTrials.gov/show/NCT04847726
1148	Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)	Recruiting	No Results Available	Hepatocellular Carcinoma	Other: Y-90 TARE|Drug: Atezolizumab|Drug: Bevacizumab	Georgetown University, Washington, District of Columbia, United States|Moffitt Cancer Center, Tampa, Florida, United States|University of Maryland, Baltimore, Maryland, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States	https://ClinicalTrials.gov/show/NCT04541173
1149	TACE Combined With Sintilimab Plus Bevacizumab Biosimilar in Patients With Advanced Hepatocellular Carcinoma (TASK-02)	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Sintilimab|Combination Product: TACE	Fudan University Shanghai Cancer Center, Shanghai, China	https://ClinicalTrials.gov/show/NCT04954794
1150	SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: SCT-I10A|Drug: SCT510|Drug: Sorafenib 200mg	307 Hospital of PLA, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT04560894
1151	Multi-center Study on Therapy-oriented Molecular Subtyping of Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma			https://ClinicalTrials.gov/show/NCT03668158
1152	A Study of Sintilimab Combined With Apatinib and Capecitabine in Advanced Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Sintilimab Combined With Apatinib and Capecitabine	Department of Medical Oncology, Central Hospital of Yichang City, the First Clinical Medical College of Three Gorges University, Yichang, Hubei, China	https://ClinicalTrials.gov/show/NCT04411706
1153	Study of TG02 Citrate in Patients With Advanced Hepatocellular Carcinoma	Withdrawn	No Results Available	Hepatocellular Carcinoma	Drug: TG02 Citrate		https://ClinicalTrials.gov/show/NCT03738111
1154	Study of Hepatocellular Carcinoma in Cirrhotic Patients	Completed	No Results Available	Hepatocellular Carcinoma			https://ClinicalTrials.gov/show/NCT01904942
1155	Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: HX008|Drug: Bevacizumab|Drug: Lenvatinib	The Fist Affiliated Hospital of USTC(Anhui Provincial hospital), Hefei, Anhui, China|Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China|Beijing Yuhe Integrated Traditional Chinese and Western Medicine Rehabilitation Hospital, Beijing, Beijing, China|Cancer Hospital Chinese Academy of Medical Sciences, shenzhen center, Shenzhen, Guangdong, China|Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China|Henan Cancer Hospital, Zhengzhou, Henan, China|Hunan Provincial People's Hospital, Changsha, Hunan, China|The First Affiliated University of Nanhua University, Hengyang, Hunan, China|The Sixth People's Hospital of Shenyang, Shenyang, Liaoning, China|The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China|West China Hospital, Sichuan University, Chengdu, Sichuan, China|Tianjin Cancer Hospital, Tianjin, Tianjin, China|The Central Hospital of Lishui City, Lishui, Zhejiang, China	https://ClinicalTrials.gov/show/NCT04741165
1156	Perfusion and Dual Energy Computer Tomography in Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Radiation: perfusion Computed Tomography	CHU Paul Brousse, Villejuif, France	https://ClinicalTrials.gov/show/NCT03754192
1157	TACE Combined With Anti-PD-1 Antibody in Patients With Advanced Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Sintilimab|Combination Product: TACE	Fudan University Shanghai Cancer Center, Shanghai, China	https://ClinicalTrials.gov/show/NCT04297280
1158	A Survey for Factors That Influence Postoperative Treatment Decision-making for Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma		Shanghai Zhongshan Hospital, Shanghai, China	https://ClinicalTrials.gov/show/NCT04239781
1159	Role of LDH as a Predictor of Treatment Outcomes in Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma	Other: LDH serum level		https://ClinicalTrials.gov/show/NCT03338166
1160	Safety and Efficacy of Lenvatinib and Anti-PD1 Antibody Combined With Radiotherapy Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Sintilimab|Drug: Lenvatinib|Radiation: radiotherapy	Beijing Tsinghua Changgung Hospital, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT05225116
1161	Yang Yin Fu Zheng Jie Du Therapy in HBV Associated Hepatocellular Carcinoma Based on the Platelet Count/Splenic Length-Diameter Ratio	Active, not recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Yang Yin Fu Zheng Jie Du therapy|Drug: Routine medical care	Zhiyun Yang, doctor, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT05154812
1162	Jiu-wei-zhen-xiao Granule for Advanced Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Drug: Jiu-wei-zhen-xiao Granule	Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, Hubei, China	https://ClinicalTrials.gov/show/NCT03851471
1163	A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Alone or in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Biological: AK104 lenvatinib|Biological: AK104	The first affilited hospital zhejiang university school of medcine, Hangzhou, Zhejiang, China	https://ClinicalTrials.gov/show/NCT04728321
1164	The Efficacy of Transarterial Chemoinfusion (TAI) Combine Lenvatinib in Advanced Hepatocellular Carcinoma (HCC)	Recruiting	No Results Available	Hepatocellular Carcinoma	Combination Product: TAI combine lenvatinib|Drug: Lenvatinib	SUN YAT-SEN University Cancer Center, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT04053985
1165	A Clinical Study to Observe the Effectiveness and Safety of IBI310, Bevacizumab Combined With Sintilimab in the Treatment of Advanced Hepatocellular Carcinoma	Not yet recruiting	No Results Available	Hepatocellular Carcinoma	Drug: IBI310（0.5mg/kg）|Drug: IBI310（0.3mg/kg）|Drug: sintilimab|Drug: bevacizumab		https://ClinicalTrials.gov/show/NCT05363722
1166	Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Nivolumab|Drug: Ipilimumab	Gustave Roussy, Villejuif, France	https://ClinicalTrials.gov/show/NCT04823403
1167	Radiotherapy Plus Thalidomide in Locally Advanced Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: Thalidomide	NTUH, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT00155272
1168	The Combination Therapy of TACE and Ablation With Durvalumab in Hepatocellular Carcinoma at Intermediate Stage (TAD)	Not yet recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Durvalumab|Procedure: Transcatheter Hepatic Arterial Chemoembolization (TACE)|Procedure: Ablation		https://ClinicalTrials.gov/show/NCT04517227
1169	Procalcitonin in Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma		Tropical medicine department and hepatocellular carcinoma clinic, Cairo, Egypt	https://ClinicalTrials.gov/show/NCT01518829
1170	SHR-1210 Plus Apatinib in Patients With Advanced-Stage Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: SHR-1210|Drug: apatinib	Zhongshan Hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT04014101
1171	DEB-TACE Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: DEB-TACE plus Sorafenib|Drug: DEB-TACE plus Lenvatinib|Drug: DEB-TACE plus PD-1 inhibitor	Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China	https://ClinicalTrials.gov/show/NCT04229355
1172	A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Tivozanib|Drug: Durvalumab	Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|City of Hope, Duarte, California, United States|University of California - Irvine, Orange, California, United States|Sarcoma Oncology Research Center, Santa Monica, California, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Montefiore Medical Center, Bronx, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|UT Southwestern Medical Center, Dallas, Texas, United States|The University of Texas Health Science Center at Houston (UTHealth), Houston, Texas, United States|The University of Texas Health Science Center at Tyler (UTHealth), Tyler, Texas, United States|Swedish Medical Center, Seattle, Washington, United States	https://ClinicalTrials.gov/show/NCT03970616
1173	The Efficacy of Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Durvalumab (HILL) in Advanced Hepatocellular Carcinoma (HCC)	Recruiting	No Results Available	Hepatocellular Carcinoma	Procedure: Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Durvalumab (HILL)	SUN YAT-SEN University Cancer Center, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT04961918
1174	The Efficacy and Safety of TACE, Lenvatinib and Camrelizumab in the Treatment of BCLC Stage B/C Hepatocellular Carcinoma: a Single-arm, Single-center, Open-label Study	Recruiting	No Results Available	Hepatocellular Carcinoma	Combination Product: TACE+Lenvatininb+Camrelizumab	Wuhan Union Hospital, Wuhan, Hubei, China	https://ClinicalTrials.gov/show/NCT04909866
1175	A Study of CS1003 in Subjects With Advanced Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: CS1003+Lenvatinib|Drug: CS1003 Placebo+Lenvatinib	Southern California GI and Liver Centers, Coronado, California, United States|Inland Empire Liver Foundation, Rialto, California, United States|Mercy Medical Center, Baltimore, Maryland, United States|UMass Memorial Health, Worcester, Massachusetts, United States|Stony Brook University Hospital, Stony Brook, New York, United States|Zhongshan Hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT04194775
1176	A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Pembrolizumab|Drug: Bavituximab	University of Texas Southwestern Medical Center, Dallas, Texas, United States	https://ClinicalTrials.gov/show/NCT03519997
1177	Phase I Clinical Trial of CT0181 Cells in the Treatment of Hepatocellular Carcinoma	Recruiting	No Results Available	Advanced Hepatocellular Carcinoma	Biological: CT0181 Cells	Peking University, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT04973098
1178	A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Biological: AK104|Drug: Lenvatinib	Chinese PLA General Hospital, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT04444167
1179	Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen Combined With Transcatheter Arterial Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma	Unknown status	No Results Available	Recurrence Hepatocellular Carcinoma|Advanced Hepatocellular Carcinoma	Procedure: TACE|Biological: Dendritic Cell|Drug: lipiodol|Drug: Mitomycin (MMC)|Drug: Epirubicin(EADM)|Biological: Precision Multiple Antigen T Cell	Eastern Hepatobiliary Surgery Hospital, Shanghai, China	https://ClinicalTrials.gov/show/NCT02638857
1180	Evaluation of Treatment Predictors Reflecting Beta-catenin Activation in Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma Non-resectable	Combination Product: Fluorine-18 fluorocholine	The Queen's Medical Center, Honolulu, Hawaii, United States	https://ClinicalTrials.gov/show/NCT04965454
1181	Recurrence of Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma		Tropical medicine department, Cairo, Egypt	https://ClinicalTrials.gov/show/NCT01520779
1182	Intrabucally Administered Electromagnetic Fields Versus Placebo as Third-line Therapy For Patients With Advanced Hepatocellular Carcinoma	Withdrawn	No Results Available	Hepatocellular Carcinoma	Device: TheraBionic Device|Device: Placebo Device	Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States	https://ClinicalTrials.gov/show/NCT04526080
1183	Cytidine-phosphate-guanosine (CpG) DNA in Hepatocellular Carcinoma Combination Therapy	Not yet recruiting	No Results Available	Hepatocellular Carcinoma	Drug: CpG DNA|Procedure: transcatheter arterial chemoembolization|Drug: Placebo - Concentrate		https://ClinicalTrials.gov/show/NCT03235167
1184	Itacitinib in Advanced Hepatocellular Carcinoma	Recruiting	No Results Available	Advanced Hepatocellular Carcinoma	Drug: Itacitinib (INCB039110)	Imperial College Healthcare NHS Trust, London, United Kingdom	https://ClinicalTrials.gov/show/NCT04358185
1185	A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC)	Active, not recruiting	No Results Available	Hepatocellular Carcinoma	Biological: AK105|Drug: Anlotinib Hydrochloride	Chinese PLA General Hospital, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT04172571
1186	A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor	Recruiting	No Results Available	Neoplasms|Carcinoma, Hepatocellular|Liver Neoplasms	Drug: E7386|Drug: Lenvatinib	Eisai Trial Site #2, Kashiwa, Chiba, Japan|Eisai Trial Site #3, Osakasayama, Osaka, Japan|Eisai Trial Site #1, Chuo-Ku, Tokyo, Japan	https://ClinicalTrials.gov/show/NCT04008797
1187	the Effect of Different Oxaliplatin Dose in Transarterial Infusion (TAI) in Unresectable Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Procedure: transarterial infusion	SUN YAT-SEN University Cancer Center, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT03777475
1188	Anti-angiogenic Targeted Drugs Plus Rg3 to Improve the Efficacy of TACE for Unresectable Hepatocellular Carcinoma	Not yet recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Anti-angiogenic Targeted Drugs|Drug: Ginsenoside Rg3|Procedure: TACE	Eastern hepatobilliary surgery hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT04523467
1189	TACE Combined With Methylcantharidimide Tablets in the Treatment of Large and Unresectable Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: methylcantharidimide tablets	Suzhou Municipal Hospital, Suzhou, Jiangsu, China	https://ClinicalTrials.gov/show/NCT03996681
1190	Preoperative Estimation of Microvascular Invasion in Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma	Diagnostic Test: contrast-enhanced ultrasound|Diagnostic Test: contrast-enhanced computed tomography		https://ClinicalTrials.gov/show/NCT03110068
1191	Role of Choline PET/CT in Predicting Survival in Patients With Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Procedure: Hepatectomy		https://ClinicalTrials.gov/show/NCT03430635
1192	By Developing a Radiomics Model to Predict the Prognosis of Patients With Hepatocellular Carcinoma After Microwave Ablation	Unknown status	No Results Available	Hepatocellular Carcinoma	Procedure: Microwave abaltion	Chinese PLA General Hospital, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT03880721
1193	A Phase Ib/II Study of Fisogatinib(BLU-554) in Subjects With Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: Fisogatinib in combination with CS1001	Nanfang Hospital,, Guangzhou, Guangdong, China|Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China|Shanghai East Hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT04194801
1194	A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma	Completed	Has Results	Hepatocellular Carcinoma (HCC)	Drug: Lenvatinib|Drug: Sorafenib	Facility # 1, Los Angeles, California, United States|Facility # 1, Sacramento, California, United States|Facility # 1, San Francisco, California, United States|Facility # 1, Washington, District of Columbia, United States|Facility # 1, Tampa, Florida, United States|Facility # 1, Duluth, Georgia, United States|Facility # 1, Lawrenceville, Georgia, United States|Facility # 1, Baltimore, Maryland, United States|Facility # 1, Detroit, Michigan, United States|Facility # 1, Kansas City, Missouri, United States|Facility # 1, Saint Louis, Missouri, United States|Facility # 1, East Orange, New Jersey, United States|Facility # 1, Brooklyn, New York, United States|Facility # 1, Lake Success, New York, United States|Facility # 1, New York, New York, United States|Facility # 1, Charlotte, North Carolina, United States|Facility # 1, Durham, North Carolina, United States|Facility # 1, Portland, Oregon, United States|Facility # 1, Austin, Texas, United States|Facility # 1, Lubbock, Texas, United States|Facility # 1, Seattle, Washington, United States|Facility # 1, Camperdown, New South Wales, Australia|Facility # 1, Wentworthville, New South Wales, Australia|Facility # 1, Woolloongabba, Queensland, Australia|Facility # 1, Fitzroy, Victoria, Australia|Facility # 1, Melbourne, Victoria, Australia|Facility # 2, Melbourne, Victoria, Australia|Facility # 1, Nedlands, Western Australia, Australia|Facility # 1, Bruxelles, Belgium|Facility # 1, Edegem, Belgium|Facility # 1, Liege, Belgium|Facility # 1, Ottawa, Ontario, Canada|Facility # 1, Hefei, Anhui, China|Facility # 1, Beijing, Beijing, China|Facility # 2, Beijing, Beijing, China|Facility # 3, Beijing, Beijing, China|Facility # 1, Chongqing, Chongqing, China|Facility # 1, Fuzhou, Fujian, China|Facility # 2, Fuzhou, Fujian, China|Facility # 1, Guangzhou, Guangdong, China|Facility # 1, Harbin, Heilongjiang, China|Facility # 1, Changsha, Hunan, China|Facility # 1, Nanjing, Jiangsu, China|Facility # 1, Suzhou, Jiangsu, China|Facility # 1, Changchun, Jilin, China|Facility # 1, Dalian, Liaoning, China|Facility # 1, Jinan, Shandong, China|Facility # 1, Shanghai, Shanghai, China|Facility # 3, Shanghai, Shanghai, China|Facility # 1, Xi'an, Shanxi, China|Facility # 2, Xi'an, Shanxi, China|Facility # 1, Hangzhou, Zhejiang, China|Facility # 1, Tianjin, Zhejiang, China|Facility # 1, Nice Cedex 3, Alpes Maritimes, France|Facility # 1, Pessac Cedex, Gironde, France|Facility # 1, Pessac, Gironde, France|Facility # 1, Toulouse, Haute Garonne, France|Facility # 1, Montpellier cedex 5, Herault, France|Facility # 1, Rennes cedex, Ille Et Vilaine, France|Facility # 1, Vandoeuvre les Nancy, Meurthe Et Moselle, France|Facility # 1, Amiens cedex 1, Somme, France|Facility # 1, Creteil Cedex, Val De Marne, France|Facility # 1, Bordeaux, France|Facility # 1, Lille cedex, France|Facility # 1, Lyon, France|Facility # 1, Nord, France|Facility # 1, Paris cedex 12, France|Facility # 1, Paris, France|Facility # 1, Rhone, France|Facility # 1, Heidelberg, Baden Wuerttemberg, Germany|Facility # 1, Tuebingen, Baden Wuerttemberg, Germany|Facility # 1, Marburg, Hessen, Germany|Facility # 1, Hannover, Niedersachsen, Germany|Facility # 1, Essen, Nordrhein Westfalen, Germany|Facility # 1, Koeln, Nordrhein Westfalen, Germany|Facility # 1, Mainz, Rheinland Pfalz, Germany|Facility # 1, Hong Kong, Hong Kong|Facility # 2, Hong Kong, Hong Kong|Facility # 3, Hong Kong, Hong Kong|Facility # 1, Kowloon, Hong Kong|Facility # 1, Petach Tikva, Israel|Facility # 1, Petah Tiqwa, Israel|Facility # 1, Torrette, Ancona, Italy|Facility # 1, Bari, Italy|Facility # 1, Benevento, Italy|Facility # 1, Bologna, Italy|Facility # 1, Napoli, Italy|Facility # 2, Napoli, Italy|Facility # 1, Palermo, Italy|Facility # 1, Roma, Italy|Facility # 1, Nagoya, Aichi, Japan|Facility # 1, Kashiwa, Chiba, Japan|Facility # 1, Matsuyama, Ehime, Japan|Facility # 1, Kurume, Fukuoka, Japan|Facility # 1, Sapporo, Hokkaido, Japan|Facility # 2, Sapporo, Hokkaido, Japan|Facility # 1, Nishinomiya, Hyogo, Japan|Facility # 1, Kanazawa, Ishikawa, Japan|Facility # 1, Kawasaki, Kanagawa, Japan|Facility # 1, Yokohama, Kanagawa, Japan|Facility # 1, Tsu, Mie, Japan|Facility # 1, Omura, Nagasaki, Japan|Facility # 1, Osaka-Sayama, Osaka, Japan|Facility # 1, Bunkyo-Ku, Tokyo, Japan|Facility # 1, Chuo-ku, Tokyo, Japan|Facility # 1, Koto-ku, Tokyo, Japan|Facility # 1, Minato-ku, Tokyo, Japan|Facility # 1, Musashino, Tokyo, Japan|Facility # 1, Shimonoseki, Yamaguchi, Japan|Facility # 1, Fukuoka, Japan|Facility # 1, Hiroshima, Japan|Facility # 1, Okayama, Japan|Facility # 2, Osaka, Japan|Facility # 1, Saga, Japan|Facility # 2, Saga, Japan|Facility # 1, Goyang-si, Gyeonggi-do, Korea, Republic of|Facility # 1, Seongnam-Si, Gyeonggi-do, Korea, Republic of|Facility # 2, Seongnam-Si, Gyeonggi-do, Korea, Republic of|Facility # 1, Suwon, Gyeonggi-do, Korea, Republic of|Facility # 1, Daegu, Gyeongsangbuk-do, Korea, Republic of|Facility # 1, Hwasun, Jeollanam-do, Korea, Republic of|Facility # 1, Busan, Korea, Republic of|Facility # 2, Busan, Korea, Republic of|Facility # 3, Busan, Korea, Republic of|Facility # 1, Incheon, Korea, Republic of|Facility # 1, Seoul, Korea, Republic of|Facility # 2, Seoul, Korea, Republic of|Facility # 3, Seoul, Korea, Republic of|Facility # 4, Seoul, Korea, Republic of|Facility # 5, Seoul, Korea, Republic of|Facility # 6, Seoul, Korea, Republic of|Facility # 7, Seoul, Korea, Republic of|Facility # 8, Seoul, Korea, Republic of|Facility # 1, Kuantan, Pahang, Malaysia|Facility # 1, Penang, Pulau Pinang, Malaysia|Facility # 1, Miri, Sarawak, Malaysia|Facility # 1, Batu Caves, Selangor, Malaysia|Facility # 1, Kuala Lumpur, Malaysia|Facility # 1, Cebu City, Philippines|Facility # 2, Cebu City, Philippines|Facility # 1, Davao City, Philippines|Facility # 1, Quezon City, Philippines|Facility # 2, Quezon City, Philippines|Facility # 1, Gdansk, Poland|Facility # 1, Warszawa, Poland|Facility # 1, Wroclaw, Poland|Facility # 1, Arkhangelsk, Russian Federation|Facility # 1, Moscow, Russian Federation|Facility # 2, Moscow, Russian Federation|Facility # 3, Saint Petersburg, Russian Federation|Facility # 4, Saint Petersburg, Russian Federation|Facility # 1, Ufa, Russian Federation|Facility # 1, Singapore, Singapore|Facility # 2, Singapore, Singapore|Facility # 3, Singapore, Singapore|Facility # 4, Singapore, Singapore|Facility # 1, L'Hospitalet de Llobregat, Barcelona, Spain|Facility # 1, Santander, Cantabria, Spain|Facility # 1, Badajoz, Spain|Facility # 1, Girona, Spain|Facility # 1, Madrid, Spain|Facility # 2, Madrid, Spain|Facility # 3, Madrid, Spain|Facility # 4, Madrid, Spain|Facility # 1, Kaohsiung, Taiwan|Facility # 2, Kaohsiung, Taiwan|Facility # 1, Taichung, Taiwan|Facility # 2, Taichung, Taiwan|Facility # 1, Tainan, Taiwan|Facility # 2, Tainan, Taiwan|Facility # 1, Taipei, Taiwan|Facility # 2, Taipei, Taiwan|Facility # 3, Taipei, Taiwan|Facility # 4, Taipei, Taiwan|Facility # 5, Taipei, Taiwan|Facility # 1, Taoyuan City, Taiwan|Facility # 1, Bangkoknoi, Bangkok, Thailand|Facility # 1, Pathum Wan, Bangkok, Thailand|Facility # 1, Ratchathewi, Bangkok, Thailand|Facility # 1, Muang, Chiang Mai, Thailand|Facility # 1, Muang, Chiang Rai, Thailand|Facility # 2, London, Greater London, United Kingdom|Facility # 1, London, Greater London, United Kingdom|Facility # 3, London, Greater London, United Kingdom|Facility # 1, Manchester, Greater Manchester, United Kingdom|Facility # 1, Liverpool, Merseyside, United Kingdom|Facility # 1, Glasgow, Strathclyde, United Kingdom|Facility # 1, Birmingham, West Midlands, United Kingdom	https://ClinicalTrials.gov/show/NCT01761266
1195	Correlation Between Sorafenib Plasma Concentrations, Toxicity and Disease Control Rate in Patients Treated by Sorafenib for Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma (HCC)	Biological: Sorafenib plasma concentration 4 weeks after treatment initiation	Institut Bergonié, Bordeaux, France|CHU de Limoges, Limoges, France|CHU de Montpellier, Montpellier, France|CHU de Bordeaux, Pessac, France|CHU de Toulouse, Toulouse, France	https://ClinicalTrials.gov/show/NCT02834546
1196	TACE Combined With RFA/MV Treatment in Hepatocellular Carcinoma Beyond Milan Criterial	Completed	No Results Available	Hepatocellular Carcinoma	Device: Transcatheter arterial chemoembolization|Device: radiofrequency ablation/microwave ablation	liver cancer institute ,Fudan University, Shanghai, China	https://ClinicalTrials.gov/show/NCT03636620
1197	A Study on the Safety and Effectiveness of IBI318 Combined With Conventional TACE (cTACE) as a Perioperative Treatment for Potentially Resected Hepatocellular Carcinoma	Not yet recruiting	No Results Available	Hepatocellular Carcinoma	Drug: IBI318|Procedure: cTACE|Drug: placebo	The First Affiliated Hospital Zhejiang University, Hangzhou, Zhejiang, China	https://ClinicalTrials.gov/show/NCT04635527
1198	Volumetric Analysis of Hepatocellular Carcinoma After Transarterial Chemoembolization	Completed	No Results Available	Hepatocellular Carcinoma|Hepatocellular Carcinoma by BCLC Stage	Procedure: Transarterial Chemoembolization		https://ClinicalTrials.gov/show/NCT04780789
1199	Stereotactic Body Radiation Therapy Combined With Anti-PD-1 Antibody in Patients With Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma	Radiation: anti-PD-1 antibody	180 Fenglin Road, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT03857815
1200	Study of Chiauranib in Patients With Advanced Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Drug: Chiauranib	Zhongshan Hospital of Fudan University, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT03245190
1201	Sorafenib and Transarterial Chemoembolization for Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Drug: Sorafenib|Procedure: Transarterial chemoembolisation (TACE)	Abteilung Gastroenterologie und Hepatologie, Medizinische Universität und AKH Wien, Vienna, Austria	https://ClinicalTrials.gov/show/NCT00768937
1202	A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Nivolumab|Drug: Ipilimumab|Drug: Sorafenib|Drug: lenvatinib	Local Institution, Birmingham, Alabama, United States|The University of Arizona Cancer Center - North, Tucson, Arizona, United States|Southern California Research Center, Coronado, California, United States|City of Hope National Medical Center, Duarte, California, United States|Local Institution, Orange, California, United States|Local Institution, Palo Alto, California, United States|Local Institution - 0077, Washington, District of Columbia, United States|Local Institution, Tampa, Florida, United States|Local Institution, Iowa City, Iowa, United States|Local Institution, Louisville, Kentucky, United States|Local Institution - 0027, Louisville, Kentucky, United States|John Hopkins Medicine, Baltimore, Maryland, United States|Local Institution, Baltimore, Maryland, United States|Local Institution, Ann Arbor, Michigan, United States|Local Institution - 0018, Detroit, Michigan, United States|Local Institution, Duluth, Minnesota, United States|Local Institution, Minneapolis, Minnesota, United States|Local Institution - 0295, Newark, New Jersey, United States|Local Institution, New York, New York, United States|Local Institution, New York, New York, United States|Local Institution, Rochester, New York, United States|Local Institution, Williamsville, New York, United States|Local Institution, Cleveland, Ohio, United States|Toledo Clinic Cancer Center, Toledo, Ohio, United States|Local Institution, Hershey, Pennsylvania, United States|Allegheny General Hospital AGH - Allegheny Cancer Center, Pittsburgh, Pennsylvania, United States|Local Institution, Pittsburgh, Pennsylvania, United States|The Liver Institute at Methodist Dallas Medical Center, Dallas, Texas, United States|Houston Methodist Cancer Center, Houston, Texas, United States|Joe Arrington Can Reserch Cnt, Lubbock, Texas, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|Local Institution, Charlottesville, Virginia, United States|Local Institution, Seattle, Washington, United States|Local Institution, Madison, Wisconsin, United States|Local Institution - 0136, Caba, Buenos Aires, Argentina|Local Institution - 0037, Caba, Buenos Aires, Argentina|Local Institution - 0194, Pilar, Buenos Aires, Argentina|Local Institution - 0282, Rosario, Santa FE, Argentina|Local Institution - 0058, Tucuman, Argentina|Saint George Hospital, Kogarah, New South Wales, Australia|Liverpool Hospital, Liverpool, New South Wales, Australia|Local Institution - 0002, Northmead, New South Wales, Australia|Local Institution - 0004, Birtinya, Queensland, Australia|Local Institution - 0013, Herston, Queensland, Australia|Local Institution - 0009, Adelaide, South Australia, Australia|Monash Health, Clayton, Victoria, Australia|St Vincents Hospital Melbourne, Fitzroy, Victoria, Australia|Local Institution - 0001, Melbourne, Victoria, Australia|Western Health, St Albans, Victoria, Australia|Local Institution - 0057, Wiener Neustadt, Niederosterreich, Austria|Local Institution - 0188, Graz, Austria|Local Institution, Graz, Austria|Local Institution, Innsbruck, Austria|Local Institution - 0065, Klagenfurt, Austria|Local Institution - 0114, St. Polten, Austria|Medizinische Universitat Wien AKH - Allgemeines Krankenhaus Wien, Viena, Austria|Local Institution - 0034, Brussels, Belgium|AZ Maria Middelares, Gent, Belgium|Local Institution, Gent, Belgium|Local Institution - 0099, Haine-Saint-Paul, Belgium|UZ Leuven, Leuven, Belgium|Local Institution - 0104, Liege, Belgium|Local Institution, Salvador, Bahia, Brazil|Local Institution - 0061, Salvador, Bahia, Brazil|Local Institution, Fortaleza, Ceara, Brazil|Local Institution - 0181, Brasilia, DF, Brazil|Local Institution - 0008, Brasilia, Distrito Federal, Brazil|Local Institution - 0278, Vitoria, Espirito Santo, Brazil|Local Institution - 0016, Curitiba, Parana, Brazil|Local Institution - 0279, Ijui, RIO Grande DO SUL, Brazil|Local Institution - 0060, Pelotas, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution - 0054, Jau, SAO Paulo, Brazil|Local Institution - 0280, Sao Jose do Rio Preto, SAO Paulo, Brazil|Local Institution, Rio de Janeiro, Brazil|COI Clinicas Oncologicas Integradas SA, Rio de Janeiro, Brazil|Local Institution - 0023, Sao Paulo, Brazil|Local Institution - 0022, Sao Paulo, Brazil|Local Institution - 0050, Sao Paulo, Brazil|Local Institution - 0192, Edmonton, Alberta, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution - 0296, Temuco, Araucania, Chile|Local Institution - 0094, La Serena, Coquimbo, Chile|Local Institution - 0024, Santiago, Metropolitana, Chile|Local Institution - 0156, Santiago, Metropolitana, Chile|Local Institution - 0095, Santiago, Metropolitana, Chile|Local Institution - 0283, Santiago, RM, Chile|Centro de Investigaciones Clinicas Vina del Mar, Vina del Mar, Valparaiso, Chile|Local Institution - 0012, Viña del Mar, Valparaiso, Chile|Local Institution - 0120, Hefei Shi, Anhui, China|Local Institution, Hefei, Anhui, China|Local Institution, Beijing, Beijing, China|Local Institution - 0175, Beijing, Beijing, China|Local Institution - 0152, Beijing, Beijing, China|Local Institution - 0121, Fuzhou City, Fujian, China|Local Institution - 0151, Fuzhou, Fujian, China|Local Institution - 0125, Guangzhou, Guangdong, China|Local Institution - 0150, Guangzhou, Guangdong, China|Local Institution - 0135, Harbin, Heilongjiang, China|Local Institution - 0059, Changsha, Hunan, China|Local Institution - 0109, Changsha, Hunan, China|Local Institution - 0130, Nanjing, Jiangsu, China|Local Institution - 0145, Nanchang, Jiangxi, China|Local Institution - 0149, Nanchang, Jiangxi, China|Local Institution - 0166, Changchun, Jilin, China|Local Institution - 0162, Changchun, Jilin, China|Local Institution, Dalian, Liaoning, China|Local Institution - 0123, Shenyang, Liaoning, China|Local Institution - 0132, Shenyang, Liaoning, China|Local Institution - 0147, Xian, Shaanxi, China|Local Institution - 0133, Xian, Shan3xi, China|Local Institution - 0153, Qingdao, Shandong, China|Local Institution - 0134, Shanghai, Shanghai, China|Local Institution - 0179, Chongqing, Sichuan, China|Local Institution - 0108, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution - 0307, Xi'an, China|Local Institution - 0274, Praha, Prague, Czechia|Local Institution, Brno, Czechia|Local Institution - 0068, Amiens, France|Local Institution - 0116, Caen, France|Local Institution - 0069, Clichy, France|Centre Georges-Franois Leclerc, Dijon, France|Local Institution - 0081, Grenoble Cedex 9, France|Local Institution - 0070, Lyon, France|Local Institution, Marseille, France|Local Institution - 0082, Montpellier, France|Local Institution - 0067, Nice, France|Local Institution - 0025, Pessac, France|Local Institution - 0137, Poitiers, France|Local Institution, Reims, France|Local Institution, Rennes, France|Local Institution - 0042, Toulouse Cedex 9, France|Local Institution - 0071, Vandoeuvre les Nancy, France|Local Institution - 0051, Villejuif, France|Local Institution, Berlin, Germany|Universitaetsklinikum Bonn, Bonn, Germany|Local Institution - 0052, Essen, Germany|Local Institution - 0005, Frankfurt, Germany|Local Institution, Freiburg I. Breisgau, Germany|Local Institution - 0185, Freiburg, Germany|Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany|Local Institution - 0102, Hannover, Germany|Local Institution - 0028, Koeln, Germany|Local Institution - 0118, Leipzig, Germany|Local Institution, Magdeburg, Germany|Local Institution - 0031, Mainz, Germany|Local Institution - 0056, Mannheim, Germany|Local Institution, Munchen, Germany|Local Institution, Munich, Germany|KEM - Evang. Kliniken Essen-Mitte/Huyssens-Stift gGmbH, North Rhine-Westphalia, Germany|Local Institution, Wurzburg, Germany|Local Institution - 0032, Hong Kong, Hong Kong|Local Institution - 0036, Hong Kong, Hong Kong|Local Institution - 0110, Meldola, Forli-Cesena, Italy|Local Institution - 0101, Rozzano, Milano, Italy|Local Institution, Bergamo, Italy|Fondazione del Piemonte per lOncologia (IRCCS), Candiolo, Italy|Local Institution - 0039, Milano, Italy|Local Institution, Milano, Italy|Azienda Ospedaliero-Universitaria Maggiore della Carita, Novara, Italy|Local Institution - 0219, Padova, Italy|Local Institution - 0033, Parma, Italy|Local Institution - 0112, Roma, Italy|Local Institution, Roma, Italy|Local Institution - 0079, Rome, Italy|A.O.U.Senese - Policl.S.Maria alle Scotte, Siena, Italy|Local Institution - 0044, Vicenza, Italy|Chiba University Hospital, Chiba-shi, Chiba, Japan|Local Institution - 0193, Kashiwa-shi, Chiba, Japan|Local Institution - 0203, Matsuyama, Ehime, Japan|Local Institution - 0155, Sapporo, Hokkaido, Japan|Kanazawa University Hospital, Kanazawa, Ishikawa, Japan|Local Institution - 0200, Yokohama-Shi, Kanagawa, Japan|Local Institution - 0262, Yokohama-shi, Kanagawa, Japan|Local Institution - 0189, Kyoto-shi, Kyoto, Japan|Local Institution, Kyoto-shi, Kyoto, Japan|Nara Medical University Hospital, Kashihara City, Nara, Japan|Local Institution - 0263, Abeno-ku, Osaka, Japan|Local Institution - 0127, Osakasayama, Osaka, Japan|Local Institution - 0281, Saga Shi, Saga, Japan|Local Institution - 0259, Izunokuni-shi, Shizuoka, Japan|Toranomon Hospital, Minato-ku, Tokyo, Japan|Local Institution - 0201, Mitaka, Tokyo, Japan|Local Institution - 0199, Musashino-shi, Tokyo, Japan|Kurume University Hospital, Fukuoka, Japan|Local Institution - 0177, Hiroshima, Japan|Local Institution - 0122, Kanagawa, Japan|Local Institution - 0258, Saitama, Japan|Local Institution - 0062, Jongno-gu, Seoul, Korea, Republic of|Local Institution - 0142, Busan, Korea, Republic of|Local Institution - 0097, Gyeonggi-do, Korea, Republic of|Local Institution - 0098, Gyeongsangnam-do, Korea, Republic of|Local Institution - 0143, Seongnam-si, Korea, Republic of|Local Institution - 0141, Seoul, Korea, Republic of|Local Institution - 0140, Seoul, Korea, Republic of|Local Institution - 0139, Seoul, Korea, Republic of|Local Institution - 0167, Seoul, Korea, Republic of|Local Institution - 0047, Auckland, New Zealand|Local Institution - 0148, Gdansk, Poland|Local Institution - 0049, Otwock, Poland|Local Institution - 0092, Warszawa, Poland|Local Institution - 0289, Rio Piedras, Puerto Rico|Local Institution - 0035, San Juan, Puerto Rico|Local Institution - 0164, Bucharest, Romania|Local Institution - 0165, Cluj Napoca, Romania|Local Institution - 0103, Craiova, Romania|Local Institution, Craiova, Romania|S.C. Oncocenter Oncologie Clinica S.R.L., Timisoara, Romania|Local Institution - 0029, Arkhangelsk, Russian Federation|Local Institution - 0066, Barnaul, Russian Federation|Local Institution - 0074, Chelyabinsk, Russian Federation|Local Institution, Krasnoyarsk, Russian Federation|Local Institution - 0007, Moscow, Russian Federation|Local Institution - 0072, Pyatigorsk, Russian Federation|Local Institution - 0075, Saint-Petersburg, Russian Federation|Local Institution - 0091, Saint-Petersburg, Russian Federation|Local Institution - 0073, Sochi, Russian Federation|Local Institution - 0048, Singapore, Singapore|Local Institution - 0017, Singapore, Singapore|Local Institution - 0174, Singapore, Singapore|Local Institution - 0297, Barcelona, Spain|Local Institution - 0055, Barcelona, Spain|Local Institution - 0089, Barcelona, Spain|Local Institution - 0090, Cordoba, Spain|Local Institution - 0087, El Palmar, Spain|Local Institution - 0041, Madrid, Spain|Local Institution - 0093, Madrid, Spain|Local Institution - 0290, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution - 0045, Majadahonda, Spain|Clinica Universidad de Navarra, Pamplona, Spain|Local Institution - 0088, Santander, Spain|Local Institution, Valladolid, Spain|Local Institution - 0040, Zaragoza, Spain|Local Institution - 0063, Bern, Switzerland|Local Institution, Zuerich, Switzerland|Local Institution, Zurich, Switzerland|Local Institution, Kaohsiung, Taiwan|Local Institution - 0096, Kaohsiung, Taiwan|Local Institution - 0105, Taichung, Taiwan|Local Institution - 0271, Taichung, Taiwan|Local Institution - 0168, Tainan, Taiwan|Local Institution, Tainan, Taiwan|Local Institution, Taipei, Taiwan|Local Institution - 0173, Taoyuan, Taiwan|Local Institution - 0078, Tapei, Taiwan|Local Institution - 0171, London, Greater London, United Kingdom|Royal Surrey County Hospital, Guildford, Surrey, United Kingdom|Local Institution, Bristol, United Kingdom|Local Institution, Christchurch, United Kingdom|Local Institution - 0160, Edinburgh, United Kingdom|Kings College Hospital NHS Foundation Trust, London, United Kingdom	https://ClinicalTrials.gov/show/NCT04039607
1203	Neoadjuvant HAIC for Resectable Hepatocellular Carcinoma Beyond Milan Criteria	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: FOLFOX|Procedure: Hepatic resection	Dongguan People's Hospital, Dongguan, Guangdong, China|Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China|The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China|Guangzhou Twelfth People's Hospital, Guangzhou, Guangdong, China|Kaiping Central Hospital, Kaiping, Guangdong, China|The First Affiliated Hospital of University Of South China, Hengyang, Hunan, China|First Affiliated Hospital Of Xi'an Jiaotong University, Xi'an, Shanxi, China	https://ClinicalTrials.gov/show/NCT03469479
1204	Radiotherapy in Hepatocellular Carcinomas After Hepatectomy With Narrow Margin (<1 cm) and / or Microvascular Invasion	Recruiting	No Results Available	HepatoCellular Carcinoma	Radiation: Postoperative radiotherapy|Drug: Postoperative TACE	TaoBai, Nanning, Guangxi, China	https://ClinicalTrials.gov/show/NCT02678806
1205	Preoperative Prediction of Microvascular Invasion in Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma	Diagnostic Test: Magnetic resonance image	The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT03198975
1206	SHR-1210 Plus Apatinib in Patients With Hepatocellular Carcinoma After Surgery	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: SHR-1210|Drug: apatinib	Zhongshan Hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT03722875
1207	The Efficacy of Transarterial Chemoinfusion (TAI) Combine Toripalimab in Advanced Hepatocellular Carcinoma (HCC)	Unknown status	No Results Available	Hepatocellular Carcinoma	Combination Product: Transarterial Chemoinfusion (TAI) Combine Toripalimab	SUN YAT-SEN University Cancer Center, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT03851939
1208	The Study of The Treatment of Postoperative Adjuvant Apatinib vs. TACE in Hepatocellular Carcinoma Patients	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: Apatinib|Drug: Chemotherapy drugs+Iodized oil		https://ClinicalTrials.gov/show/NCT03511703
1209	Anti-GPC3 CAR-T for Treating GPC3-positive Advanced Hepatocellular Carcinoma (HCC)	Unknown status	No Results Available	Hepatocellular Carcinoma	Biological: Retroviral vector-transduced autologous T cells to express anti-GPC3 CARs|Drug: Fludarabine|Drug: Cyclophosphamide	Department of Oncology, Xinqiao Hospital, ChongQing, Chongqing, China	https://ClinicalTrials.gov/show/NCT03084380
1210	Yang Yin Fu Zheng Jie Du Therapy in Recurrence of Hepatocellular Carcinoma Less Than 3 cm in Diameter	Completed	No Results Available	Hepatocellular Carcinoma	Drug: Yang Yin Fu Zheng Jie Du therapy|Other: Routine medical care	Zhiyun Yang, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT04264962
1211	CAR-GPC3 T Cells in Patients With Refractory Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Genetic: CAR-GPC3 T cells	Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT03146234
1212	Clemizole HCl for Subjects With Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: Clemizole Hydrochloride	University of Ankara, Ankara, Turkey	https://ClinicalTrials.gov/show/NCT03069508
1213	Evaluation Effectiveness and Safety of (cTACE or DEB-TACE + FOLFOX Regimen HAIC) Combined With Camrelizumab and Apatinib Mesylas in the Treatment of Advanced Hepatocellular Carcinoma	Not yet recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Camrelizumab		https://ClinicalTrials.gov/show/NCT04479527
1214	Yang Yin Fu Zheng Therapy in HBV Associated Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Drug: Yang Yin Fu Zheng therapy|Drug: Routine medical care	Zhiyun Yang, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT02927626
1215	Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular Carcinoma	Terminated	No Results Available	Hepatocellular Carcinoma	Drug: Nivolumab|Drug: Bevacizumab	Huntsman Cancer Institute, Salt Lake City, Utah, United States	https://ClinicalTrials.gov/show/NCT03382886
1216	Treatment for Patients With Multiple Hepatocellular Carcinomas Based on the NDR Scoring System	Unknown status	No Results Available	Hepatocellular Carcinoma	Procedure: Hepatectomy|Procedure: TACE	Eastern hepatobilliary surgery hospital, Shanghai, Shanghai, China|Eastern hepatobilliary surgery hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT02525952
1217	Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Toripalimab (JS001 )|Drug: Toripalimab (JS001 ) Lenvatinib	Fudan University Zhongshan Hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT03867370
1218	Hepatocellular Carcinoma Using Stereotactic Body Radiotherapy	Unknown status	No Results Available	Hepatocellular Carcinoma	Radiation: Stereotactic Ablative Radiotherapy	BC Cancer Agency, Vancouver, British Columbia, Canada	https://ClinicalTrials.gov/show/NCT01850316
1219	A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma	Completed	Has Results	Advanced Hepatocellular Carcinoma	Drug: Enzalutamide|Drug: Placebo	Site US10003, San Francisco, California, United States|Site US10009, Skokie, Illinois, United States|Site US10017, Minneapolis, Minnesota, United States|Site US10021, Lebanon, New Hampshire, United States|Site US10008, Portland, Oregon, United States|Site US10014, Philadelphia, Pennsylvania, United States|Site US10019, Philadelphia, Pennsylvania, United States|Site US10016, Milwaukee, Wisconsin, United States|Site CA15001, Toronto, Ontario, Canada|Site CA15002, Montreal, Quebec, Canada|Site CA15003, Montreal, Canada|Site HK85202, Kowloon, Hong Kong|Site HK85204, Shatin, Hong Kong|Site IT39008, Rozzano, Milan, Italy|Site IT39005, Benevento, Italy|Site IT39006, Milano, Italy|Site IT39002, Milan, Italy|Site IT39011, Padova, Italy|Site IT39004, Pavia, Italy|Site KR82002, Seongnam-Si, Gyeonggi-do, Korea, Republic of|Site KR82005, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Site KR82006, Seoul, Korea, Republic of|Site KR82007, Seoul, Korea, Republic of|Site KR82004, Seoul, Korea, Republic of|Site KR82001, Seoul, Korea, Republic of|Site US10001, San Juan, Puerto Rico|Site ES34003, Barcelona, Spain|Site ES34006, Cordoba, Spain|Site ES34004, Madrid, Spain|Site TW88603, Douliu, Taiwan|Site TW88606, Tainan, Taiwan|Site TW88605, Tainan, Taiwan|Site TW88604, Taipei City, Taiwan|Site GB44007, Birmingham, United Kingdom|Site GB44004, London, United Kingdom|Site GB44008, London, United Kingdom|Site GB44005, Manchester, United Kingdom|Site GB44002, Wirral, United Kingdom	https://ClinicalTrials.gov/show/NCT02528643
1220	Apatinib Combined With Capecitabine Compared With Apatinib Treat Advanced Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: Capecitabine|Drug: Apatinib		https://ClinicalTrials.gov/show/NCT03114085
1221	Recombinant Human Endostatin(Rh-endostatin) Combine With Radiotherapy in the Treatment of Hepatocellular Carcinoma(HCC)	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: recombinant human endostatin	Chinese PLA Gereral Hospital, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT03208335
1222	Dual TORC1/TORC2 Inhibitor ATG-008 (CC-223) in HBV Positive Advanced Hepatocellular Carcinoma (HCC) Subjects	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: ATG-008	Oncology Hospital of Haerbin Medical University, Harbin, Heilongjiang, China|China People PLA 81 Hospital, Nanjing, Jiangsu, China|West China Hospital Sichuan University, Chengdu, Sichuan, China|Yunnan Cancer Hospital, Kunming, Yunnan, China|The first Hospital of Jilin University, Changchun, China|Hunan Province Oncology Hospital, Changsha, China|Daping Hospital, Chongqing, China|The first hospital of Chongqing medical university, Chongqing, China|Xiehe Hospital of Fujian Medical University, Fuzhou, China|Nanfang Hospital of Nanfang Medical University, Guangzhou, China|The first affiliated Hospital of Zhejiang University, Hangzhou, China|Zhejiang Province Oncology Hospital, Hangzhou, China|The first affiliated hospital of Anhui medical university, Hefei, China|The second affiliated hospital of Anhui medical university, Hefei, China|The first affiliated hospital of Guangxi Medical University, Nanning, China|Oncology Hospital of Fudan University, Shanghai, China|Zhongshan Hospital of Fudan University, Shanghai, China|General Hospital of the Northern War Zone of the Chinese People's Liberation Army, Shenyang, China|Tangdu Hospital of China PLA fourth medical university, Xi'an, China|Dong-A University Hospital, Busan, Korea, Republic of|Pusan National Univ. Hospital, Busan, Korea, Republic of|Kyungpook National Univ. Hospital, Daegu, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|China Medical University Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Medical University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital-Linkuo, Taoyuan, Taiwan	https://ClinicalTrials.gov/show/NCT03591965
1223	Recurrence and Distant Metastases in Hepatocellular Carcinoma Treated by Transcatheter Arterial Chemoembolization	Completed	No Results Available	Hepatocellular Carcinoma		Kaohsiung Medical University Hospital, Kaohsiung, Taiwan	https://ClinicalTrials.gov/show/NCT00834028
1224	A Study of Anlotinib in Patients With Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: Anlotinib	Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT02809534
1225	Prospective Cohort Study on the Clinical Trajectory of Resected Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma		University Malaya Medical Centre, Kuala Lumpur, Malaysia|The Medical Centre, Philippines, Manila, Philippines|National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|National Cancer Centre Singapore, Singapore, Singapore|National Cancer Institute Thailand, Bangkok, Thailand	https://ClinicalTrials.gov/show/NCT03267641
1226	Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Radical Resection	Active, not recruiting	No Results Available	Hepatocellular Carcinoma	Biological: TORIPALIMAB INJECTION(JS001 )	Zhongshan Hospital,Fudan University, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT03859128
1227	Hypoxic Changes in Hepatocellular Carcinoma (HCC) Following Trans Arterial Chemo Embolization and Stereotactic Radiation: Fluorine18 (18F) Fluoromisonidazole (FMISO) Imaging	Terminated	Has Results	Hepatocellular Carcinoma	Drug: FMISO	UAB Advanced Imaging Facility, Birmingham, Alabama, United States	https://ClinicalTrials.gov/show/NCT03303469
1228	HAIC Versus TACE for Large Hepatocellular Carcinoma Staged BCLC A/B.	Unknown status	No Results Available	HepatoCellular Carcinoma	Procedure: Hepatic arterial infusion chemotherapy|Procedure: Transarterial chemoembolization|Drug: Folfox Protocol|Drug: TACE Drug Protocol	The First People's Hospital of Foshan, Foshan, Guangdong, China|Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China|Guangzhou Twelfth People's Hospital, Guangzhou, Guangdong, China|Kaiping Central Hospital, Kaiping, Guangdong, China	https://ClinicalTrials.gov/show/NCT02973685
1229	The Efficacy of Transarterial Chemoinfusion (TAI) Combine Stereotactic Body Radiation Therapy (SBRT) in Unresectable Hepatocellular Carcinoma (HCC)	Unknown status	No Results Available	Hepatocellular Carcinoma	Combination Product: TAI combine SBRT	SUN YAT-SEN University Cancer Center, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT03851887
1230	Study of Y90-Radioembolization With Nivolumab in Asians With Hepatocellular Carcinoma	Active, not recruiting	No Results Available	HepatoCellular Carcinoma	Radiation: Y-90 Radioembolization|Drug: Nivolumab	National Cancer Centre - Singapore, Singapore, Singapore	https://ClinicalTrials.gov/show/NCT03033446
1231	Phase II Trial of Sorafenib Combined With Concurrent HAIC for Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Procedure: Hepatic arterial infusion chemotherapy|Drug: Folfox Protocol	Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT02981498
1232	Myeloid Derived Suppressor Cells Control by Signal Regulatory Protein-alpha: Investigation in Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Procedure: Collection of human samples		https://ClinicalTrials.gov/show/NCT02868255
1233	LEE001 and Chemoembolization In Patients With Advanced Hepatocellular Carcinoma	Terminated	Has Results	Hepatocellular Carcinoma	Drug: LEE011|Procedure: Chemoembolization	UT Southwestern Medical Center, Dallas, Texas, United States	https://ClinicalTrials.gov/show/NCT02524119
1234	A Study of Apatinib for Advanced Hepatocellular Carcinoma Patients After First-line Treatment Failure	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: Apatinib Mesylate Tablets		https://ClinicalTrials.gov/show/NCT02772029
1235	Hepatic Arterial Infusion Chemotherapy(HAIC) for Hepatoma After Resection	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: Oxaliplatin(OXA), 5-fluorouracil (5-FU)|Procedure: Hepatic arterial catheter implantation	Beijing Cancer Hospital, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT02767375
1236	A Pilot Study of Individualized Adaptive Radiation Therapy for Hepatocellular Carcinoma	Active, not recruiting	No Results Available	Hepatocellular Carcinoma	Radiation: Adaptive Radiation Therapy	Rogel Comprehensive Cancer Center, Ann Arbor, Michigan, United States	https://ClinicalTrials.gov/show/NCT02460835
1237	HAIC Versus TACE for Large and Unresectable Hepatocellular Carcinoma Staged BCLC A/B	Completed	No Results Available	Hepatocellular Carcinoma	Procedure: Hepatic arterial infusion|Procedure: Transarterial chemoembolization|Drug: Folfox Protocol|Drug: TACE Drug Protocol	Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT03048123
1238	Clinical Significance of Hepatic and Circulating microRNAs miR-221 and miR-222 in Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma	Other: Analysis of microRNA expression	Fiammetta Soggiu, Aberdeen, United Kingdom	https://ClinicalTrials.gov/show/NCT02928627
1239	Adjuvant Hepatic Arterial Infusional Chemotherapy After Curative Resection of Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Drug: Adjuvant group	Severance Hospital, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT01088581
1240	A Study of MG4101 (Allogeneic Natural Killer Cell) for Intermediate-stage of Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Biological: MG4101	Seoul National University Hospital, Seoul, Korea, Republic of|Seoul Asan Medical center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Korea Univ. Guro Hospital, Seoul, Korea, Republic of|Severance hospital, Seoul, Korea, Republic of|Ajou Univ. Hospital, Suwon, Korea, Republic of	https://ClinicalTrials.gov/show/NCT02854839
1241	Study on Recurrence Monitoring of Hepatocellular Carcinoma With 5-Hydroxymethylcytosine Test	Unknown status	No Results Available	Hepatocellular Carcinoma	Diagnostic Test: 5hmC profile in plasma cell-free DNA after liver resection	Zhongshan Hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT03493763
1242	Study of Tocilizumab in Patients With Hepatocellular Carcinoma (HCC) Undergoing Transarterial Chemoembolization (TACE)	Withdrawn	No Results Available	Hepatocellular Carcinoma	Drug: Tocilizumab|Procedure: Transcatheter Arterial Chemoembolization	The University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States	https://ClinicalTrials.gov/show/NCT02997956
1243	Multimodality Therapy for Palliative Resectable Hepatocellular Carcinoma With Intrahepatic Vessels Invasion	Unknown status	No Results Available	Hepatocellular Carcinoma	Procedure: Hepatectomy|Procedure: TACE combined with local regional therapies without hepatectomy	Department of Hepatobilliary Surgery, Cancer Center, Sun Yat-sen University,, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT00501813
1244	A Clinical Study Evaluating the Use of HLX10 in Combination With HLX04 for the Treatment of Advanced Hepatocellular Carcinoma (HCC) Patients	Active, not recruiting	No Results Available	Hepatocellular Carcinoma	Drug: HLX10 3mg/kg|Drug: HLX04 5mg/kg|Drug: HLX04 10mg/kg	Ethics committee of zhongshan hospital affiliated to fudan university, Shanghai, China	https://ClinicalTrials.gov/show/NCT03973112
1245	The Study of Apatinib Plus Radiotherapy vs. Apatinib in the Treatment of Hepatocellular Carcinoma With BCLC-C Stage I and Stage II Portal Vein Tumor Thrombus	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: Apatinib|Device: Radiotherapy		https://ClinicalTrials.gov/show/NCT03520257
1246	Study of Enzalutamide With and Without Sorafenib in Advanced Hepatocellular Carcinoma Patients	Completed	No Results Available	Hepatocellular Carcinoma	Drug: Enzalutamide|Drug: Enzalutamide with Sorafenib	University of California San Francisco, San Francisco, California, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States	https://ClinicalTrials.gov/show/NCT02642913
1247	IMA970A Plus CV8102 in Very Early, Early and Intermediate Stage Hepatocellular Carcinoma Patients	Completed	No Results Available	Hepatocellular Carcinoma	Drug: IMA970A plus CV8102 and Cyclophosphamide	Universitair Ziekenhuis Antwerpen (UZA), Division of Gastroenterology and Hepatology, Edegem, Belgium|Universitätsklinik für Allgemeine, Viszeral- und Transplantationschirurgie, Tübingen, Germany|Istituto Nazionale Tumori "Pascale" (INTNA), Napoli, Italy|Ospedale Sacro Cuore-Don Calabria U.O.C. Oncologica Medica, Negrar, Italy|Universidad de Navarra (NAVAR), Internal Medicine, Pamplona, Spain|The University of Birmingham, School of Immunity and Infection, College of Medical and Dental Science (BHAM), Birmingham, United Kingdom	https://ClinicalTrials.gov/show/NCT03203005
1248	Total Hemihepatic Vascular Exclusion in Hepatectomy in Hepatocellular Carcinoma Treatment	Completed	No Results Available	Hepatocellular Carcinoma	Procedure: Total hemihepatic vascular exclusion|Procedure: Hemihepatic vascular Clamping|Procedure: Pringle's Maneuver	Eastern hepatobilliary surgery hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT00827047
1249	Continued Administration of G-202 for One Patient With Advanced Hepatocellular Carcinoma	No longer available	No Results Available	Hepatocellular Carcinoma	Drug: G-202		https://ClinicalTrials.gov/show/NCT02082691
1250	Hypofractionated Proton Beam Radiotherapy for Inoperable Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Radiation: Proton Beam Therapy	National Cancer Center, Korea, Goyang-si, Gyeonggi-do, Korea, Republic of	https://ClinicalTrials.gov/show/NCT02395523
1251	Evaluation of Performance of Automatic Fusion for Radiofrequency Ablation of Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Device: Automatic Imaging fusion of ultrasonography and MRI|Device: Manual Imaging fusion of ultrasonography and MRI	Seoul St.Mary's Hospital, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT02705118
1252	Quality of Life in Patients With Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma		Asan Medical Center, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT02420678
1253	The Impact on Survival of Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Beyond Milan Criteria BCLC Stage A/B Hepatocellular Carcinoma Who Underwent Hepatectomy	Recruiting	No Results Available	Hepatocellular Carcinoma	Procedure: TAI	SUN YAT-SEN University Cancer Center, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT03851913
1254	Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC)	Completed	Has Results	Hepatocellular Carcinoma	Drug: Lenvatinib	Kashiwa-shi, Chiba, Japan|Kurume-shi, Fukuoka, Japan|Sapporo-shi, Hokkaido, Japan|Kawasaki-shi, Kanagawa, Japan|Osaka-shi, Osaka, Japan|Osakasayama-shi, Osaka, Japan|Saga-shi, Saga, Japan|Chuo-ku, Tokyo, Japan|Minato-ku, Tokyo, Japan|Musashino-shi, Tokyo, Japan|Gangnam-gu, Seoul, Korea, Republic of|Songpa-gu, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT00946153
1255	Camrelizumab in Patients With Unresectable Hepatocellular Carcinoma	Not yet recruiting	No Results Available	Unresectable Hepatocellular Carcinoma	Drug: Camrelizumab		https://ClinicalTrials.gov/show/NCT04947956
1256	Lenvatinib Combined With TACE to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma	Active, not recruiting	No Results Available	Hepatocellular Carcinoma	Drug: lenvatinib|Procedure: TACE	Huashan hospital, Shanghai, China	https://ClinicalTrials.gov/show/NCT03838796
1257	4SC-201 (Resminostat) and Sorafenib in Advanced Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Drug: 4SC-201|Drug: Sorafenib	ONKOPLUS Beratung und Hilfe für Menschen mit Krebs, Berlin, Germany|Universitätsklinikum Essen (Innere Klinik/Tumorforschung und Zentrum für Innere Medizin), Essen, Germany|Medizinische Fakultät der Martin-Luther-Universität Halle-Wittenberg (Klinik und Poliklinik für Innere Medizin I), Halle, Germany|Universitätsklinikum Hamburg-Eppendorf (I. Medizinische Klinik und Poliklinik), Hamburg, Germany|Universitätsklinikum Heidelberg (Medizinische Universitätsklinik/Innere Medizin IV/Nationales Centrum für Tumorerkrankungen), Heidelberg, Germany|Johannes Gutenberg-Universität Mainz (I. Medizinische Klinik und Poliklinik), Mainz, Germany|Klinikum rechts der Isar der Technischen Universität München (Medizinische Klinik und Poliklinik II/Gastroenterologie), Munich, Germany|Universitätsklinikum Tübingen (Medizinische Klinik/Innere Medizin I), Tübingen, Germany|l'Azienda Ospedaliero-Universitaria di Bologna-Policlinico S. Orsola Malpighi, Bologna, Italy|l'Università degli Studi di Genova (Dipartimento di Medicina Interna e Specialità Mediche), Genova, Italy|Istituto Europea di Oncologia EIO, Milano, Italy|A.O.R.N. Monaldi-Cotugno-CTO, Napoli, Italy|l'Azienda Ospedaliera di Padova and l'Istituto Oncologico Veneto IOV, Padova, Italy|l'Ente "Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone", Palermo, Italy|L'Istituto Clinico Humanitas-Humanitas Mirasole S.p.A., Rozzano-Milano, Italy	https://ClinicalTrials.gov/show/NCT00943449
1258	A Neoadjuvant Hepatocellular Carcinoma Study of Camrelizumab in Combination With Apatinib and Oxaliplatin	Not yet recruiting	No Results Available	Hepatocellular Carcinoma Resectable	Drug: Apatinib Mesylate|Drug: Camrelizumab|Drug: Oxaliplatin		https://ClinicalTrials.gov/show/NCT04850040
1259	TACE With or Without Sorafenib in Intermediate Stage Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: Sorafenib|Procedure: TACE	Xijing Hospital of digestive disease, Fourth Military Medical University, Xi'an, Shaanxi, China	https://ClinicalTrials.gov/show/NCT02529761
1260	Doxorubicin-eluting LC Bead M1 for Patients With Hepatocellular Carcinoma	Completed	Has Results	Hepatocellular Carcinoma	Device: DEBDOX	The Johns Hopkins Hospital, Baltimore, Maryland, United States	https://ClinicalTrials.gov/show/NCT02007954
1261	The Effect of Fluorouracil Implants Regional Chemotherapy During the Surgical Treatment for Early Stage Hepatocellular Carcinoma	Unknown status	No Results Available	Early Stage Hepatocellular Carcinoma	Procedure: Radical resection|Drug: Fluorouracil Implants	Eastern Hepatobiliary Surgery Hospital, Shanghai, China	https://ClinicalTrials.gov/show/NCT01055743
1262	Sorafenib Plus Vitamin K1 Versus Sorafenib in Advanced Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Drug: Sorafenib 400mg twice daily + intravenous infusion ofVit K1|Drug: Sorafenib 400 mg twice daily + Intravenousinfusion of placebo	Institute of Liver & Biliary Sciences, New Delhi, Delhi, India	https://ClinicalTrials.gov/show/NCT02259647
1263	Stereotactic Ablative Radiotherapy for Oligometastatic Hepatocellular Carcinoma	Recruiting	No Results Available	Oligometastasis Hepatocellular Carcinoma	Radiation: Stereotactic body radiotherapy	Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT05173610
1264	Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224)	Active, not recruiting	Has Results	Hepatocellular Carcinoma	Biological: Pembrolizumab		https://ClinicalTrials.gov/show/NCT02702414
1265	Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis	Completed	No Results Available	Hepatocellular Carcinoma	Procedure: transcatheter arterial chemoembolization	Cancer Canter Sun Yat-Sen University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT00646100
1266	Study of Oligo-Fucoidan in Advanced Hepatocellular Carcinoma (HCC)	Recruiting	No Results Available	Advanced Hepatocellular Carcinoma	Dietary Supplement: Oligo Fucoidan|Dietary Supplement: Placebo	Fudan University Zhongshan Hospital, Shanghai, China	https://ClinicalTrials.gov/show/NCT04066660
1267	GPC3-targeting LCAR-H93T Cell in Treatment of Advanced Hepatocellular Carcinoma	Not yet recruiting	No Results Available	Advanced Hepatocellular Carcinoma	Biological: LCAR-H93T Cells	Beijing Gobroad Boren Hospital, Beijing, Beijing, China|Chinese PLA General Hospital, Beijing, Beijing, China|The First Affiliated Hospital of Xi 'an Jiaotong University School of Medicine, Xi'an, Shanxi, China	https://ClinicalTrials.gov/show/NCT05352542
1268	A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma.	Active, not recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Sintilimab|Drug: IBI305|Drug: Sorafenib	Hospital of Fudan University, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT03794440
1269	Efficacy and Safety of Sorafenib in Previously Treated Advanced Hepatocellular Carcinoma: SOPT Study	Not yet recruiting	No Results Available	Advanced Hepatocellular Carcinoma	Drug: Sorafenib		https://ClinicalTrials.gov/show/NCT05117957
1270	Vancomycin in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLC) Oral	Withdrawn	No Results Available	Metastatic Hepatocellular Carcinoma|Hepatocellular Carcinoma	Drug: vancomycin	National Institutes of Health Clinical Center, Bethesda, Maryland, United States	https://ClinicalTrials.gov/show/NCT04025567
1271	Determination of Autonomic Responses to the Exposure of Low Energy Electromagnetic Fields With Frequency Modulation in Patients With Advanced Hepatocellular Carcinoma and Healthy Individuals.	Unknown status	No Results Available	Hepatocellular Carcinoma	Other: measuring hemodynamic parameters heart beat to heart beat during single-frequency exposure	Hospital Sírio-Libanês, São Paulo, Brazil	https://ClinicalTrials.gov/show/NCT03448757
1272	A Study of BBI608 Administrated With Sorafenib in Adult Patients With Advanced Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Drug: BBI608|Drug: Sorafenib	4 Sites, Tokyo,etc, Japan	https://ClinicalTrials.gov/show/NCT02358395
1273	Systemic Chemotherapy Versus Transcatheter Arterial Chemoembolization(TACE) for Hepatocellular Carcinoma	Withdrawn	No Results Available	Hepatocellular Carcinoma	Drug: Pirarubicin|Drug: Oxaliplatin|Drug: Lipiodol|Device: Gelfoam		https://ClinicalTrials.gov/show/NCT02585479
1274	A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma	Recruiting	No Results Available	Unresectable Hepatocellular Carcinoma	Drug: Atezolizumab|Drug: Bevacizumab	University of Illinois Cancer Center, Chicago, Illinois, United States|Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Univeristy of Wisconsin, Madison, Wisconsin, United States	https://ClinicalTrials.gov/show/NCT04829383
1275	Clinical Trial for GALNT14 Genotype - Guided, Sorafenib in Combination With TACE in Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: sorafenib|Procedure: TACE	Chang Gung Memorial Hospital, Taoyuan, Taiwan	https://ClinicalTrials.gov/show/NCT02504983
1276	A Study of LY2157299 in Participants With Advanced Hepatocellular Carcinoma	Completed	Has Results	Hepatocellular Carcinoma	Drug: LY2157299|Drug: Sorafenib|Drug: Placebo	For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beijing, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bengbu, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Changchun, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hangzhou, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hefei, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hong Kong, Hong Kong|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kowloon, Hong Kong|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Incheon, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gwei Shan Township, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Liouying/Tainan, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Puzih City, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tainan, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taoyuan, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bangkok, Thailand	https://ClinicalTrials.gov/show/NCT02178358
1277	Study to Compare Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (HCC)	Unknown status	No Results Available	Hepatocellular Carcinoma	Device: SIR-Spheres|Drug: Sorafenib tosylate	The Brunei Cancer Centre, Jerudong, Brunei, Brunei Darussalam|Queen Mary Hospital, Hong Kong, Hong Kong, China|University of Udayana, Rumah Sakit Sanglah, Indonesia, Denpasar, Bali, Indonesia|Cipto Mangunkusumo Hospital ,University of Indonesia, Jakarta, Indonesia|Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Seoul St. Mary's Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Seoul National University Bundang Hospital, Seoul, Korea, Republic of|Sarawak General Hospital, Kuching, Sarawak, Malaysia|University Malaya Medical Center, Kuala Lumpur, Malaysia|Penang Adventist Hospital, Penang, Malaysia|National Cancer Center of Mongolia, Ulaanbaatar, Mongolia|Yangon GI & Liver Centre, Yangon, Myanmar|Auckland City Hospital, Grafton, Auckland, New Zealand|Makati Medical Center, Manila, Makati City, Philippines|The Medical City, Pasig City, Manila, Philippines|St. Luke's Medical Center, Philippines, Quezon City, Manila, Philippines|Davao Doctors Hospital, Davao, Philippines|National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|National Cancer Center Singapore, Singapore, Singapore|Khoo Teck Puat Hospital, Singapore, Singapore|National Taiwan University Hospital, Taipei City, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei City, Taipei, Taiwan|Chang Gung Memorial Hospital, Taoyuan, Taoyuan Hsien, Taiwan|Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|Chulabhorn Hospital, Bangkok, Thailand	https://ClinicalTrials.gov/show/NCT01135056
1278	Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)	Recruiting	No Results Available	Hepatocellular Carcinoma	Biological: Pembrolizumab|Drug: Placebo	Banner MD Anderson Cancer Center ( Site 0026), Gilbert, Arizona, United States|The University of Arizona Cancer Center - North Campus ( Site 0039), Tucson, Arizona, United States|City of Hope Medical Center ( Site 0027), Duarte, California, United States|Smilow Cancer Hospital at Yale New Haven ( Site 0042), New Haven, Connecticut, United States|Regional Cancer Center ( Site 0054), Fort Myers, Florida, United States|Indiana University Simon Cancer Center ( Site 0075), Indianapolis, Indiana, United States|University of Iowa ( Site 0067), Iowa City, Iowa, United States|James Graham Brown Cancer Center ( Site 0088), Louisville, Kentucky, United States|University of Louisville ( Site 0059), Louisville, Kentucky, United States|University Medical Center New Orleans ( Site 0014), New Orleans, Louisiana, United States|Massachusetts General Hospital ( Site 0062), Boston, Massachusetts, United States|Boston Medical Center ( Site 0025), Boston, Massachusetts, United States|Beth Israel Deaconess Medical Ctr. ( Site 0033), Boston, Massachusetts, United States|University of Massachusetts Worcester ( Site 0017), Worcester, Massachusetts, United States|Henry Ford Hospital-GI/Hepatology Research ( Site 0047), Detroit, Michigan, United States|University of New Mexico ( Site 0041), Albuquerque, New Mexico, United States|North Shore-Long Island Jewish Health System ( Site 0068), Lake Success, New York, United States|Miami Valley Hospital South ( Site 0093), Centerville, Ohio, United States|University of Cincinnati Medical Center ( Site 0084), Cincinnati, Ohio, United States|ProMedica Flower Hospital ( Site 0090), Sylvania, Ohio, United States|Stephenson Cancer Center ( Site 0045), Oklahoma City, Oklahoma, United States|Vanderbilt Ingram Cancer Center ( Site 0006), Nashville, Tennessee, United States|Baylor Scott & White Medical Center - Temple ( Site 0089), Temple, Texas, United States|Virginia Mason Medical Center ( Site 0028), Seattle, Washington, United States|Hospital Universitario Austral ( Site 0795), Pilar, Buenos Aires, Argentina|Fundación favaloro para la Docencia e Investigación Médica ( Site 0808), Buenos Aires, Caba, Argentina|Hospital Provincial del Centenario ( Site 0794), Rosario, Santa Fe, Argentina|Hospital Aleman ( Site 0806), Buenos Aires, Argentina|Hospital Italiano ( Site 0793), Buenos Aires, Argentina|Hospital Britanico de Buenos Aires ( Site 0792), Buenos Aires, Argentina|Clinica de nefrologia urologia y enfermedades cardiovasculares ( Site 0802), Santa Fe, Argentina|Royal Prince Alfred Hospital AW ( Site 0225), Camperdown, New South Wales, Australia|Liverpool Hospital ( Site 0226), Liverpool, New South Wales, Australia|Princess Alexandra Hospital ( Site 0228), Woollongabba, Queensland, Australia|Royal Adelaide Hospital ( Site 0234), Adelaide, South Australia, Australia|Monash Health ( Site 0233), Clayton, Victoria, Australia|St Vincents Hospital Melbourne ( Site 0227), Fitzroy, Victoria, Australia|Alfred Health ( Site 0230), Melbourne, Victoria, Australia|Royal Perth Hospital ( Site 0229), Perth, Western Australia, Australia|University Hospital Antwerp (UZA) ( Site 0374), Edegem, Antwerpen, Belgium|Erasme Hospital ( Site 0376), Bruxelles, Bruxelles-Capitale, Region De, Belgium|UZ Gent ( Site 0375), Gent, Oost-Vlaanderen, Belgium|UZ Leuven ( Site 0377), Leuven, Vlaams-Brabant, Belgium|CIONC - Centro Integrado de Oncologia de Curitiba ( Site 0813), Curitiba, Parana, Brazil|Hospital de Cancer de Pernambuco ( Site 0815), Recife, Pernambuco, Brazil|Hospital de Clinicas de Porto Alegre ( Site 0824), Porto Alegre, Rio Grande Do Sul, Brazil|Clinica de Oncologia Reichow ( Site 0818), Blumenau, Santa Catarina, Brazil|Centro de Novos Tratamentos Itajai - Clinica de Neoplasias Litoral ( Site 0820), Itajai, Santa Catarina, Brazil|Hospital Paulistano ( Site 0829), São Paulo, Sao Paulo, Brazil|Instituto COI de Pesquisa Educacao e Gestao ( Site 0825), Rio de Janeiro, Brazil|Instituto do Cancer do Estado de Sao Paulo - ICESP ( Site 0826), Sao Paulo, Brazil|Real e Benemerita Associacao Portuguesa de Beneficencia ( Site 0828), Sao Paulo, Brazil|A.C. Camargo Cancer Center ( Site 0827), Sao Paulo, Brazil|Casa de Saude Santa Marcelina ( Site 0821), Sao Paulo, Brazil|Complex Cancer Center Plovdiv-First Medical Oncology Department ( Site 0982), Plovdiv, Bulgaria|Nova Scotia Health Authority QEII-HSC ( Site 0208), Halifax, Nova Scotia, Canada|Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0211), Montreal, Quebec, Canada|McGill University Health Centre ( Site 0207), Montreal, Quebec, Canada|Anhui Provincil Hospital South District ( Site 0181), Hefei, Anhui, China|Cancer Hospital Chinese Academy of Medical Sciences ( Site 0156), Beijing, Beijing, China|Peking University People's Hospital ( Site 0191), Beijing, Beijing, China|Beijing Cancer Hospital ( Site 0155), Beijing, Beijing, China|Fujian Provincial Cancer Hospital ( Site 0165), Fuzhou, Fujian, China|900 Hospital of the Joint ( Site 0197), Fuzhou, Fujian, China|Guangdong General Hospital ( Site 0166), Guangzhou, Guangdong, China|Southern Medical University Nanfang Hospital ( Site 0172), Guangzhou, Guangdong, China|Wuhan Union Hospital ( Site 0173), Wuhan, Hubei, China|Hubei Cancer Hospital ( Site 0189), Wuhan, Hubei, China|The Third Xiangya Hospital of Central South University ( Site 0167), Changsha, Hunan, China|Hunan Provincial People Hospital ( Site 0192), Changsha, Hunan, China|Hunan Cancer Hospital ( Site 0168), Changsha, Hunan, China|Fudan University Shanghai Cancer Center ( Site 0161), Shanghai, Shanghai, China|Zhongshan Hospital Fudan University ( Site 0193), Shanghai, Shanghai, China|Renji Hospital Shanghai Jiaotong University School of Medicine ( Site 0174), Shanghai, Shanghai, China|Zhongshan Hospital affiliated to Fudan University ( Site 0153), Shanghai, Shanghai, China|The First Affiliated Hospital of Xi an Jiaotong University ( Site 0164), XI An, Shanxi, China|West China Hospital of Sichuan University ( Site 0162), Chengdu, Sichuan, China|Affiliated Tumor Hospital of Xinjiang Medical University ( Site 0157), Urumqi, Xinjiang, China|Zhejiang Cancer Hospital ( Site 0171), Hangzhou, Zhejiang, China|Herlev Hospital ( Site 0421), Herlev, Hovedstaden, Denmark|Aarhus Universitets hospital ( Site 0420), Aarhus N, Midtjylland, Denmark|Odense Universitets Hospital ( Site 0422), Odense C, Syddanmark, Denmark|HUS Hopital Hautepierre ( Site 0445), Strasbourg, Bas-Rhin, France|Hopital de la Timone ( Site 0442), Marseille, Bouches-du-Rhone, France|CHU Bordeaux Haut-Leveque ( Site 0437), Pessac, Gironde, France|CHU Rangueil ( Site 0441), Toulouse, Haute-Garonne, France|Hopital Beaujon ( Site 0439), Clichy, Hauts-de-Seine, France|CHU Montpellier. ( Site 0443), Montpellier, Herault, France|Hopital Claude Huriez CHRU LILLE ( Site 0440), Lille, Nord, France|Hopital Paul Brousse ( Site 0447), Villejuif, Val-de-Marne, France|SLK-Kliniken Heilbronn GmbH ( Site 0460), Heilbronn, Baden-Wurttemberg, Germany|Universitaetsklinikum Tuebingen ( Site 0466), Tuebingen, Baden-Wurttemberg, Germany|Klinikum rechts der Isar der Technischen Universitaet ( Site 0470), Muenchen, Bayern, Germany|Universitaetsklinikum Wuerzburg ( Site 0468), Wuerzburg, Bayern, Germany|Krankenhaus Nord-West GmbH ( Site 0472), Frankfurt am Main, Hessen, Germany|Universitaetsklinikum Frankfurt ( Site 0467), Frankfurt, Hessen, Germany|Medizinische Hochschule Hannover ( Site 0458), Hannover, Niedersachsen, Germany|Universitaetsklinikum Duesseldorf ( Site 0461), Duesseldorf, Nordrhein-Westfalen, Germany|Universitaetsklinikum Koeln ( Site 0463), Koeln, Nordrhein-Westfalen, Germany|Staedtisches Klinikum Dresden ( Site 0471), Dresden, Sachsen, Germany|Universitatsklinikum Carl Gustav Carus ( Site 0459), Dresden, Sachsen, Germany|Charite - Campus Virchow Klinikum ( Site 0457), Berlin, Germany|Universitaetsklinikum Hamburg-Eppendorf ( Site 0469), Hamburg, Germany|Prince of Wales Hospital ( Site 0268), Hong Kong, Hong Kong|Pamela Youde Nethersole Eastern Hospital ( Site 0271), Hong Kong, Hong Kong|Queen Mary Hospital ( Site 0267), Hong Kong, Hong Kong|Tuen Mun Hospital ( Site 0272), Tuen Mun, Hong Kong|Bacs-Kiskun Megyei Korhaz-Onkoradiologiai Kozpont ( Site 0483), Kecskemét, Bacs-Kiskun, Hungary|SZTE Szent-Gyorgyi Albert Klinikai Kozpont ( Site 0482), Szeged, Csongrad, Hungary|Somogy Megyei Kaposi Mór Oktató Kórház-Oncology center ( Site 0484), Kaposvár, Somogy, Hungary|Semmelweis University ( Site 0480), Budapest, Hungary|Debreceni Egyetem Klinikai Kozpont Onkologiai Tanszek ( Site 0481), Debrecen, Hungary|St Vincent's University Hospital ( Site 0498), Dublin, Ireland|Tallaght University Hospital ( Site 0499), Dublin, Ireland|Rambam Medical Center ( Site 0524), Haifa, Israel|Haddassah Medical Organization - Ein Kerem ( Site 0519), Jerusalem, Israel|Rabin Medical Center ( Site 0520), Petah Tikva, Israel|Chaim Sheba Medical Center ( Site 0523), Ramat Gan, Israel|Sourasky Medical Center ( Site 0522), Tel Aviv, Israel|A O U Policlinico di Modena ( Site 0548), Modena, Abruzzo, Italy|Azienda Ospedaliera Ordine Mauriziano di Torino ( Site 0542), Torino, Piemonte, Italy|Azienda Ospedaliera Ospedali Riuniti Villa Sofia-Cervello ( Site 0547), Palermo, Sicilia, Italy|Istituto Tumori Giovanni Paolo II ( Site 0543), Bari, Italy|Policlinico S. Orsola-Malpighi ( Site 0541), Bologna, Italy|Azienda Ospedaliero Universitaria Careggi ( Site 0549), Firenze, Italy|Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico ( Site 0550), Milano, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 0540), Milano, Italy|Ospedale del Mare ( Site 0545), Napoli, Italy|Azienda Ospedaliero Universitaria Pisana ( Site 0546), Pisa, Italy|Ehime University Hospital ( Site 0123), Toon, Ehime, Japan|Kurume University Hospital ( Site 0119), Kurume, Fukuoka, Japan|Hokkaido P.W.F.A.C Sapporo-Kosei General Hospital ( Site 0102), Sapporo, Hokkaido, Japan|Kanazawa University Hospital ( Site 0111), Kanazawa, Ishikawa, Japan|Kagawa University Hospital ( Site 0121), Kita-gun, Kagawa, Japan|Kagawa Prefectural Central Hospital ( Site 0122), Takamatsu, Kagawa, Japan|Toranomon Hospital Kajigaya ( Site 0109), Kawasaki, Kanagawa, Japan|Yokohama City University Medical Center ( Site 0110), Yokohama, Kanagawa, Japan|Kindai University Hospital ( Site 0116), Osakasayama, Osaka, Japan|Saitama Medical University Hospital ( Site 0104), Iruma-gun, Saitama, Japan|Kyorin University Hospital ( Site 0106), Mitaka, Tokyo, Japan|Musashino Red Cross Hospital ( Site 0107), Musashino, Tokyo, Japan|Chiba University Hospital ( Site 0103), Chiba, Japan|National Hospital Organization Kyushu Medical Center ( Site 0118), Fukuoka, Japan|Hiroshima University Hospital ( Site 0117), Hiroshima, Japan|University Hospital, Kyoto Prefectural University of Medicine ( Site 0112), Kyoto, Japan|Japanese Red Cross Osaka Hospital ( Site 0113), Osaka, Japan|Osaka City University Hospital ( Site 0114), Osaka, Japan|Saga-Ken Medical Centre Koseikan ( Site 0120), Saga, Japan|Toranomon Hospital ( Site 0108), Tokyo, Japan|The University of Tokyo Hospital ( Site 0105), Tokyo, Japan|Wakayama Medical University Hospital ( Site 0115), Wakayama, Japan|National Cancer Center ( Site 0314), Goyang-si, Kyonggi-do, Korea, Republic of|Seoul National University Bundang Hospital ( Site 0313), Seongnam-si, Kyonggi-do, Korea, Republic of|Seoul National University Hospital ( Site 0312), Seoul, Korea, Republic of|Severance Hospital Yonsei University Health System ( Site 0309), Seoul, Korea, Republic of|Asan Medical Center ( Site 0310), Seoul, Korea, Republic of|Samsung Medical Center ( Site 0311), Seoul, Korea, Republic of|The Catholic University of Korea. Seoul St. Mary s Hospital ( Site 0315), Seoul, Korea, Republic of|Hospital Universiti Sains Malaysia ( Site 0295), Kubang Kerian, Kelantan, Malaysia|Penang Adventist Hospital ( Site 0289), George Town, Pulau Pinang, Malaysia|Gleneagles Penang ( Site 0290), Penang, Pulau Pinang, Malaysia|Sarawak General Hospital ( Site 0293), Kuching, Sarawak, Malaysia|Institut Kanser Negara - National Cancer Institute ( Site 0294), Putrajaya Wilayah Persekutuan, Wilayah Persekutuan Putrajaya, Malaysia|University Malaya Medical Centre ( Site 0288), Kuala Lumpur, Malaysia|Christchurch Hospital ( Site 0247), Christchurch, Canterbury, New Zealand|Auckland City Hospital ( Site 0246), Auckland, New Zealand|Oslo Universitetssykehus HF. Ulleval ( Site 0433), Oslo, Norway|Izerskie Centrum Pulmonologii i Chemioterapii IZER-MED Spolka z o.o. ( Site 0607), Szklarska Poreba, Dolnoslaskie, Poland|Samodzielny Publiczny Szpital Kliniczny nr 1 w Lublinie ( Site 0620), Lublin, Lubelskie, Poland|MTZ Clinical Research Sp. z o. o. ( Site 0608), Warsaw, Mazowieckie, Poland|Copernicus PL Sp. z o.o. ( Site 0603), Gdansk, Pomorskie, Poland|ID Clinic ( Site 0619), Myslowice, Slaskie, Poland|SPZOZ MSWIA z Warminsko-Mazurskim Centrum Onkologii w Olsztynie ( Site 0606), Olsztyn, Warminsko-mazurskie, Poland|Szpital Wojewodzki im. Mikolaja Kopernika ( Site 0604), Koszalin, Zachodniopomorskie, Poland|Altay Regional Oncology Dispensary ( Site 0919), Barnaul, Altayskiy Kray, Russian Federation|Siberian Clinical Center of FMBA ( Site 0918), Krasnoyarsk, Krasnoyarskiy Kray, Russian Federation|Krasnoyarsk Regional Clinical Oncological Dispensary ( Site 0648), Krasnoyarsk, Krasnoyarskiy Kray, Russian Federation|Blokhin National Medical Oncology ( Site 0645), Moscow, Moskva, Russian Federation|City Clinical Hospital 1 na. NI. Pirogov ( Site 0662), Moscow, Moskva, Russian Federation|First Moscow State Medical University n.a. I.M.Sechenov ( Site 0661), Moscow, Moskva, Russian Federation|Hadassah Medical-Clinical Research Department ( Site 0920), Moscow, Moskva, Russian Federation|National Medical Research Radiological Centre ( Site 0660), Moscow, Moskva, Russian Federation|Privolzhsky District Medical Center ( Site 0655), Nizhniy Novgorod, Nizhegorodskaya Oblast, Russian Federation|Samara Regional Clinical Oncology Center ( Site 0656), Samara, Samarskaya Oblast, Russian Federation|Road Hospital JSC Russian railways ( Site 0649), Saint Petersburg, Sankt-Peterburg, Russian Federation|Russian Scientific Center of Radiology and Surgical Technologies ( Site 0665), Saint Petersburg, Sankt-Peterburg, Russian Federation|City Clinical Oncology Center ( Site 0646), Saint Petersburg, Sankt-Peterburg, Russian Federation|Tomsk Scientific Research Institute of Oncology ( Site 0657), Tomsk, Tomskaya Oblast, Russian Federation|Hospital Central de Asturias ( Site 0667), Oviedo, Asturias, Spain|Hospital Universitari Parc Tauli ( Site 0681), Sabadell, Barcelona, Spain|Hospital Universitario de Donostia ( Site 0671), San Sebastian, Gipuzkoa, Spain|Complejo Hospitalario Universitario de Santiago ( Site 0668), Santiago de Compostela, La Coruna, Spain|Hospital Universitario Puerta de Hierro ( Site 0678), Majadahonda, Madrid, Spain|Hospital Universitari Vall d Hebron ( Site 0674), Barcelona, Spain|Hospital General Universitario Gregorio Maranon ( Site 0676), Madrid, Spain|Hospital Ramon y Cajal ( Site 0673), Madrid, Spain|Hospital Universitario La Paz ( Site 0677), Madrid, Spain|Hospital Universitario Virgen del Rocio ( Site 0670), Sevilla, Spain|Hospital Universitario Miguel Servet-Gastroenterology ( Site 0682), Zaragoza, Spain|Skane University Hospital ( Site 0692), Malmo, Skane Lan, Sweden|Karolinska Universitetssjukhuset, Huddinge ( Site 0689), Stockholm, Stockholms Lan, Sweden|Norrlands Universitetssjukhus ( Site 0687), Umea, Vasterbottens Lan, Sweden|Sahlgrenska Universitetssjukhuset ( Site 0691), Goteborg, Vastra Gotalands Lan, Sweden|University Hospital Basel ( Site 0709), Basel, Aargau, Switzerland|Universitaetsspital Bern ( Site 0710), Bern, Aargau, Switzerland|Kantonsspital St. Gallen ( Site 0708), St. Gallen, Sankt Gallen, Switzerland|CHUV (centre hospitalier universitaire vaudois) ( Site 0712), Lausanne, Vaud, Switzerland|Kantonsspital Winterthur ( Site 0714), Winterthur, Zurich, Switzerland|Hopitaux Universitaires de Geneve HUG ( Site 0711), Geneve, Switzerland|Universitaetsspital Zurich ( Site 0713), Zurich, Switzerland|Chang Gung Medical Foundation. Kaohsiung Branch ( Site 0335), Kaohsiung, Taiwan|China Medical University Hospital ( Site 0333), Taichung, Taiwan|National Cheng Kung University Hospital ( Site 0334), Tainan, Taiwan|National Taiwan University Hospital ( Site 0330), Taipei, Taiwan|Taipei Veterans General Hospital ( Site 0331), Taipei, Taiwan|Chang Gung Medical Foundation. Linkou ( Site 0332), Taoyuan, Taiwan|Ramathibodi Hospital. ( Site 0352), Bangkok, Krung Thep Maha Nakhon, Thailand|Siriraj Hospital ( Site 0351), Bangkok, Krung Thep Maha Nakhon, Thailand|Maharaj Nakorn Chiangmai Hospital ( Site 0353), Chiang Mai, Thailand|Srinagarind Hospital ( Site 0354), Khon Kaen, Thailand|Namik Kemal Universitesi Tip Fakultesi ( Site 0738), Tekirdag, Tekirdas, Turkey|Baskent Unv. Adana Uyg. ve Arast. Hastanesi ( Site 0733), Adana, Turkey|Gulhane Egitim ve Arastirma Hastanesi ( Site 0741), Ankara, Turkey|Ankara Sehir Hastanesi ( Site 0731), Ankara, Turkey|Adnan Menderes University Medical Faculty ( Site 0737), Aydin, Turkey|Bezmialem Vakif University School of Medicine ( Site 0732), Istanbul, Turkey|Acıbadem Maslak Hastanesi ( Site 0742), Istanbul, Turkey|Göztepe Prof. Dr. Süleyman Yalçın Şehir Hastanesi-oncology ( Site 0730), Istanbul, Turkey|Dokuz Eylul Universitesi ( Site 0740), Izmir, Turkey|Konya Necmettin Erbakan University Medical Faculty ( Site 0736), Konya, Turkey|Inonu University Faculty of Medicine ( Site 0729), Malatya, Turkey|VM Medical Park Hastanesi ( Site 0739), Mersin, Turkey|Regional Clinical Onco Dispensary_ State Medical University ( Site 0782), Chernivtsi, Chernivetska Oblast, Ukraine|Regional Oncology Center of Kharkiv ( Site 0777), Kharkiv, Kharkivska Oblast, Ukraine|National Cancer Institute of the MoH of Ukraine ( Site 0779), Kyiv, Kyivska Oblast, Ukraine|Shalimov s NI of Surgery and Transplantation ( Site 0781), Kyiv, Kyivska Oblast, Ukraine|MI Odessa Regional Oncological Centre ( Site 0776), Odesa, Odeska Oblast, Ukraine|CI City Clinical Hospital # 3 ( Site 0783), Zaporizhzhia, Zaporizka Oblast, Ukraine|Universal Clinic Oberig-Oncology Center ( Site 0786), Kyiv, Ukraine|Medical Center Dobrobut Clinic ( Site 0785), Kyiv, Ukraine|Cambridge University Hospitals NHS Trust ( Site 0755), Cambridge, Cambridgeshire, United Kingdom|Weston Park Hospital ( Site 0753), Sheffield, Derbyshire, United Kingdom|The Beatson West of Scotland Cancer Centre ( Site 0750), Glasgow, Glasgow City, United Kingdom|Kings College Hospital NHS Foundation Trust ( Site 0758), London, London, City Of, United Kingdom|Belfast City Hospital ( Site 0752), Belfast, Northern Ireland, United Kingdom|The Clatterbridge Cancer Centre NHS Foundation Trust ( Site 0757), Birkenhead, Wirral, United Kingdom|University Hospital Coventry and Warwickshire NHS Trust ( Site 0754), Coventry, United Kingdom|Leeds Teaching Hospitals NHS Trust ( Site 0751), Leeds, United Kingdom|Nottingham University Hospitals NHS Trust ( Site 0756), Nottingham, United Kingdom	https://ClinicalTrials.gov/show/NCT03867084
1279	Global Study Looking at the Combination of RAD001 and Sorafenib to Treat Patients With Advanced Hepatocellular Carcinoma	Terminated	No Results Available	Hepatocellular Carcinoma	Drug: RAD001|Drug: RAD001, sorafenib	City of Hope Medical Center, Duarte, California, United States|UCLA Department of Medicine, Los Angeles, California, United States|Duke University, Durham, North Carolina, United States|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Barcelona, Spain|Novartis Invstigative Site, Madrid, Spain|Novartis Investigative Site, Tainan, Taiwan	https://ClinicalTrials.gov/show/NCT00828594
1280	Efficacy and Safety Study of TLC388 to Advanced Hepatocellular Carcinoma	Terminated	No Results Available	Hepatocellular Carcinoma	Drug: Lipotecan	307 Hospital of PLA, Beijin, China|Nanjing Bayi Hospital, Nanjing, China|Shanghai Cancer Hospital, Fudan University, Shanghai, China|Zhongshan Hospital, Fudan University, Shanghai, China|Chiayi Chang Gung Memorial Hosipital, Chiayi City, Taiwan|Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan|China Medical University Hosipital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|Mackay Memorial Hosipital, Taipei City, Taiwan|National Taiwan University Hosipital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|LinKou Chang Gung Memorial Hosipital, Taoyuan, Taiwan	https://ClinicalTrials.gov/show/NCT02267213
1281	Hepatectomy Versus Radiofrequency Ablation for Hepatocellular Carcinoma Adjacent to Major Blood Vessels	Completed	No Results Available	Hepatocellular Carcinoma	Procedure: surgical resection|Procedure: percutaneous radiationfrequency ablation	Eastern Hepatobiliary Surgery Hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT00814242
1282	Gemcitabine Plus Oxaliplatin Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma	Withdrawn	No Results Available	Hepatocellular Carcinoma	Drug: GEMOX|Drug: FOLFOX4		https://ClinicalTrials.gov/show/NCT02534337
1283	Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Patients With Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Drug: Gemcitabine|Drug: Oxaliplatin|Drug: Bevacizumab	Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States	https://ClinicalTrials.gov/show/NCT00142467
1284	Hepatocellular Carcinoma (HCC) Transarterial Chemoembolisation (TACE) +Axitinib	Completed	No Results Available	Hepatocellular Carcinoma	Drug: Axitinib	Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong, Hong Kong	https://ClinicalTrials.gov/show/NCT01352728
1285	A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma	Completed	Has Results	Advanced Adult Hepatocellular Carcinoma|Hepatocellular Carcinoma Metastatic	Drug: AZD9150	Research Site, Hongkong, Hong Kong|Research Site, Chuo-ku, Japan|Research Site, Kashiwa-shi, Japan|Research Site, Matsuyama-shi, Japan|Research Site, Seoul, Korea, Republic of|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT01839604
1286	Adjuvant Transcatheter Arterial Chemoembolization Versus Adjuvant Systemic Chemotherapy for Hepatocellular Carcinoma	Withdrawn	No Results Available	Hepatocellular Carcinoma	Drug: systemic chemotherapy|Drug: Transcatheter Arterial Chemoembolization		https://ClinicalTrials.gov/show/NCT02584556
1287	Sintilimab and Bevacizumab Combined With Radiotherapy for Advanced Recurrent Hepatocellular Carcinoma	Recruiting	No Results Available	Recurrent Hepatocellular Carcinoma	Drug: Sintilimab and Bevacizumab Combined with Radiotherapy	The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT05010434
1288	Hypofractionated Proton Beam Radiotherapy for Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Radiation: Proton Beam Therapy	National Cancer Center, Korea, Goyang-si, Gyeonggi-do, Korea, Republic of	https://ClinicalTrials.gov/show/NCT01643824
1289	Liposomal Doxorubicin Plus Gemcitabine Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma	Withdrawn	No Results Available	Hepatocellular Carcinoma	Drug: Liposomal Doxorubicin+Gemcitabine|Drug: FOLFOX4		https://ClinicalTrials.gov/show/NCT02527772
1290	B010-A Injection for Treating Patients With GPC3 Positive Advanced Hepatocellular Carcinoma	Recruiting	No Results Available	Advanced Hepatocellular Carcinoma	Biological: Biological/Vaccine: Low-dose group|Biological: Biological/Vaccine: Mid-dose group|Biological: Biological/Vaccine: High-dose group	Shanghai Tenth People's Hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT05070156
1291	Resminostat (YHI-1001) in Combination With Sorafenib in Asian Patients With Advanced Hepatocellular Carcinoma (HCC)	Completed	No Results Available	Hepatocellular Carcinoma	Drug: Resminostat|Drug: Sorafenib	Chiba, Japan|Ishikawa, Japan|Kanagawa, Japan|Kochi, Japan|Kyoto, Japan|Osaka, Japan|Saga, Japan|Shizuoka, Japan|Tokyo, Japan|Busan, Korea, Republic of|Daegu, Korea, Republic of|Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT02400788
1292	Biomarker Analysis in Sorafenib Treated Hepatocellular Carcinoma Patients	Completed	No Results Available	Hepatocellular Carcinoma		Samsung medical Center, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT01481805
1293	Investigation of Immune Modulation by Modern Acupuncture in Gastroenterologic Cancers	Completed	No Results Available	Hepatocellular Cancer|Gastrointestinal Cancer|Immunosuppression	Other: Modern acupuncture	WanFangH, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT04692454
1294	The Impact on Recurrence Risk of Adjuvant Lenvatinib for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Lenvatinib	SUN YAT-SEN University Cancer Center, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT04053972
1295	Efficacy of Localized Concurrent Chemo-radiation Therapy and Sorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Radiation: CCRT|Drug: sorafenib	Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT02425605
1296	Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy in Hepatocellular Carcinoma	Completed	Has Results	Hepatocellular Carcinoma	Device: TANDEM™	Klinikum der Universitat Heidelberg, Heidelberg, Baden-Wuerttemberg, Germany|SLK-Kliniken Heilbronn GmbH, Heilbronn, Baden-Wuerttemberg, Germany|Klinikum Stuttgart- Katharinenhospital, Stuttgart, Baden-Wuerttemberg, Germany|Klinikum Bogenhausen, Munchen, Bayern, Germany|Kilinikum Darmstadt, Darmstadt, Hessen, Germany|Universitatsklinikum Essen, Essen, Nordrhein-Westfalen, Germany|University Hospital Regensburg, Regensburg, Germany	https://ClinicalTrials.gov/show/NCT01798134
1297	Dose-Escalation Study Evaluating the Safety and Pharmacokinetics of Artesunate in Patients With Hepatocellular Carcinoma	Terminated	No Results Available	Hepatocellular Carcinoma	Drug: Artesunate	Dept. of Hepatology & Gastroenterology Ghent University Hospital, Ghent, East-Flandres, Belgium	https://ClinicalTrials.gov/show/NCT02304289
1298	Frequency of Circulating Tumor Cells (CTCs) and Amount of Cell-free DNA (cfDNA) in Cirrhotic Patients With Hepatocellular Carcinoma (HCC)	Completed	No Results Available	Hepatocellular Carcinoma	Other: Cirrhosis with HCC|Other: Cirrhosis without HCC	Institute of Liver and Biliary Sciences, New Delhi, Delhi, India	https://ClinicalTrials.gov/show/NCT03162198
1299	Transarterial Chemotherapy Compared With Oral Chemotherapy in the Treatment of Advanced Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma	Procedure: Transarterial chemotherapy|Drug: Oral chemotherapy	AII India Institute of Medical Sciences, New Delhi, Delhi, India	https://ClinicalTrials.gov/show/NCT02240771
1300	SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)	Completed	Has Results	Hepatocellular Carcinoma	Drug: SGI-110	City of Hope National Medical Center, Duarte, California, United States|USC Norris Comprehensive Cancer Center, Los Angeles, California, United States|UC Davis Comprehensive Cancer Center, Sacramento, California, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Northwestern University: Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States|University of Louisville James Graham Brown Cancer Center, Louisville, Kentucky, United States|Columbia University Medical Center - Herbert Irving Comprehensive Cancer Center, New York, New York, United States|The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Hollings Cancer Center, Charleston, South Carolina, United States|The Jones Clinic, PC, Germantown, Tennessee, United States|Mary Crowley Medical Research Center, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Swedish Cancer Institute, Seattle, Washington, United States|UW Carbone Cancer Center, Madison, Wisconsin, United States|University of British Columbia and Vancouver General Hospital, Vancouver, British Columbia, Canada|The Ottawa Hospital Cancer Center, Ottawa, Ontario, Canada|Sunnybrook HealthScience Centre, Toronto, Ontario, Canada|CHUM Hopital St-Luc, Montreal, Quebec, Canada|Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada|University of Liverpool Clatterbridge Cancer Center, Liverpool, United Kingdom|Cambridge University Hospitals NHS Foundation Trust, London, United Kingdom|Imperial College Healthcare NHS Foundation Trust, London, United Kingdom|University College London, London, United Kingdom	https://ClinicalTrials.gov/show/NCT01752933
1301	HLX07 Combination Therapy or Motherapy in Patient With Advanced Hepatocellular Carcinoma	Not yet recruiting	No Results Available	Advanced Hepatocellular Carcinoma	Drug: HLX07|Drug: HLX10|Drug: HLX04|Drug: lenvatinib		https://ClinicalTrials.gov/show/NCT05290220
1302	A Simple Prognostic Scoring System for Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma		Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT02061956
1303	Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240)	Completed	Has Results	Hepatocellular Carcinoma	Biological: Pembrolizumab|Drug: Placebo|Other: Best Supportive Care		https://ClinicalTrials.gov/show/NCT02702401
1304	Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy	Completed	Has Results	Hepatocellular Carcinoma	Drug: Tivantinib|Drug: Placebo	Tucson, Arizona, United States|Los Angeles, California, United States|Orange, California, United States|Washington, District of Columbia, United States|Gainesville, Florida, United States|Chicago, Illinois, United States|Westwood, Kansas, United States|New Orleans, Louisiana, United States|Scarborough, Maine, United States|Boston, Massachusetts, United States|Detroit, Michigan, United States|Minneapolis, Minnesota, United States|Hackensack, New Jersey, United States|New York, New York, United States|Philadelphia, Pennsylvania, United States|Charleston, South Carolina, United States|Dallas, Texas, United States|Galveston, Texas, United States|Houston, Texas, United States|Seattle, Washington, United States|Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Buenos Aires, Caba, Argentina|Pilar, Argentina|Camperdown, New South Wales, Australia|Heidelberg, Victoria, Australia|Melbourne, Victoria, Australia|Nedlands, Western Australia, Australia|Graz, Austria|Innsbruck, Austria|Linz, Austria|Wien, Austria|Brussels, Belgium|Ghent, Belgium|Leuven, Belgium|Liege, Belgium|Porto Alegre, RS, Brazil|Sao Paulo, SP, Brazil|Barretos, Brazil|Rio de Janeiro, Brazil|Vancouver, British Columbia, Canada|Toronto, Ontario, Canada|Amiens Cedex 1, France|Bordeaux Cedex, France|Caen Cedex 09, France|Clichy, France|Creteil, France|Grenoble, France|Lille Cedex, France|Marseille Cedex 09, France|Montpellier, France|Paris Cedex 12, France|Paris Cedex, France|Reims Cedex, France|Rennes Cedex, France|Toulouse Cedex 09, France|Villejuif Cedex, France|Aachen, Germany|Berlin, Germany|Bonn, Germany|Duesseldorf, Germany|Essen, Germany|Frankfurt am Main, Germany|Hamburg, Germany|Hannover, Germany|Heidelberg, Germany|Leipzig, Germany|Magdeburg, Germany|Mainz, Germany|Muenchen, Germany|Munich, Germany|Regensburg, Germany|Tuebingen, Germany|Ulm, Germany|Wuerzburg, Germany|Meldola, Forli-Cesena, Italy|Rozzano, Milano, Italy|Orbassano (TO), Torino, Italy|Benevento, Italy|Bergamo, Italy|Bologna, Italy|Catania, Italy|Firenze, Italy|Milano, Italy|Modena, Italy|Napoli, Italy|Padova, Italy|Parma, Italy|Pavia, Italy|Pisa, Italy|Reggio Emilia, Italy|Roma, Italy|Turin, Italy|Amsterdam, Netherlands|Auckland, New Zealand|Lisboa, Portugal|Porto, Portugal|Vila Real, Portugal|Santiago de Compostela, A Coruña, Spain|Oviedo, Asturias, Spain|Majadahonda, Madrid, Spain|Pamplona, Navarra, Spain|Alicante, Spain|Barcelona, Spain|Cordoba, Spain|Madrid, Spain|Sabadell, Spain|Santander, Spain|Valencia, Spain|Zaragoza, Spain|Gothenburg, Sweden|Stockholm, Sweden|Bern, Switzerland|Zurich, Switzerland	https://ClinicalTrials.gov/show/NCT01755767
1305	Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	Completed	Has Results	Hepatocellular Carcinoma	Drug: Temsirolimus|Drug: Sorafenib:	University of California, San Francisco, San Francisco, California, United States|Robert H Lurie Comprehensive Cancer Center, Chicago, Illinois, United States	https://ClinicalTrials.gov/show/NCT01687673
1306	Carbon Ion Radiotherapy for Hepatocellular Carcinoma	Active, not recruiting	No Results Available	Hepatocellular Carcinoma	Radiation: Carbon Ion Radiotherapy	University Hospital of Heidelberg, Radiation Oncology, Heidelberg, Germany	https://ClinicalTrials.gov/show/NCT01167374
1307	Phase I Safety Study of Dendritic Cell Vaccine to Treat Patients With Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Biological: COMBIG-DC (ilixadencel)	Dept. of Transplantation and Liver Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden	https://ClinicalTrials.gov/show/NCT01974661
1308	A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma	Completed	Has Results	Hepatocellular Carcinoma	Drug: BBI608|Drug: BBI503|Drug: Sorafenib	Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|Mayo Clinic, Phoenix, Arizona, United States|Southern California Research Center, Coronado, California, United States|California Center Associates for Research and Excellence, Inc. (Ccare), Encinitas, California, United States|USC Norris Comprehensive Cancer Center, Los Angeles, California, United States|USOR - Rocky Mountain Cancer Centers, Denver, Colorado, United States|Baptist Health Medical Group Oncology, LLC, Miami, Florida, United States|Piedmont Cancer Institute, P.C., Atlanta, Georgia, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Minnesota Oncology Hematology, P.A., Minneapolis, Minnesota, United States|Kansas City Research Institure, Kansas City, Missouri, United States|USOR - Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|The Valley Hospital Luckow Pavilion, Paramus, New Jersey, United States|USOR - New York Oncology Hematology, Albany, New York, United States|University of Rochester, Wilmot Cancer Institute, Rochester, New York, United States|Carolinas Health Care System, Charlotte, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|University of Cincinnati, Vontz Center, Cincinnati, Ohio, United States|Drexel University, Philadelphia, Pennsylvania, United States|USOR - Texas Oncology, Austin Midtown, Austin, Texas, United States|Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|Texas Oncology - El Paso Cancer Treatment Center Joe Battle, El Paso, Texas, United States|USOR - Texas Oncology, Fort Worth 12th Ave, Fort Worth, Texas, United States|Oncology Consultants, Houston, Texas, United States|Texas Oncology-McAllen South Second Street, McAllen, Texas, United States|USOR - Texas Oncology, Tyler, Tyler, Texas, United States|Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care, Roanoke, Virginia, United States	https://ClinicalTrials.gov/show/NCT02279719
1309	Blood Sample Collection to Evaluate Biomarkers for Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma|Hepatocellular Carcinoma Surveillance	Other: Blood Sample Collection	Cedars Sinai Medical Center, Los Angeles, California, United States|Facey Medical Foundation, Los Angeles, California, United States|Office of Dr. John D. Homan MD, Newport Beach, California, United States|UC Irvine Health, Orange, California, United States|FOMAT Medical Research, Oxnard, California, United States|Alliance Clinical Research, Poway, California, United States|Medical Center of Homestead, Homestead, Florida, United States|Mayo Clinc, Jacksonville, Florida, United States|Precision Clinical Research, LLC, Lauderdale Lakes, Florida, United States|Guardian Angel Research Center, Inc., Tampa, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Indiana University Medical Center, Indianapolis, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|Mercy Medical Research, Baltimore, Maryland, United States|University of Michigan, Ann Arbor, Michigan, United States|Henry Ford Hospital (HFH), Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Stony Brook Cancer Center, Stony Brook, New York, United States|CMC Center for Liver Disease, Charlotte, North Carolina, United States|OnSite Clinical Solutions, Charlotte, North Carolina, United States|PMG Research of Winston-Salem, LLC, Winston-Salem, North Carolina, United States|UH Cleveland Medical Center, Cleveland, Ohio, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Einstein Medical Center, Philadelphia, Pennsylvania, United States|The Jackson Clinic, Jackson, Tennessee, United States|Methodist Healthcare University Hospital, Memphis, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|ARC Clinical Research at Wilson Parke, Austin, Texas, United States|UT Southwestern Medical Center, Dallas, Texas, United States|ADP Clinical Research, Magnolia, Texas, United States|University of Virginia, Charlottesville, Virginia, United States|Bon Secours Liver Institute of Hampton Roads, Newport News, Virginia, United States|Hunter Holmes McGuire Medical, Richmond, Virginia, United States|South Perry Endoscopy, Spokane, Washington, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|CHU de Besancon Hopital Jean Minjoz, Besançon, France|CHU Caen, Caen, France|Hopital Henri Mondor, Créteil, France|Centre Hospitalier Universitaire de Grenoble, La Tronche, France|CHRU de LILLE - Hospital HURIEZ, Lille, France|Chru Brabois, Nancy, France|CHU Reims, Hopital Robert Debre, Reims, France|CHU Pontchaillou, Rennes, France|Helios Klinikum Berlin-Buch, Berlin, Germany|Universitätsklinikum Bonn, Bonn, Germany|Gastroenterologische Studienambulanz, Koln, Germany|Universitat Leipzig, Leipzig, Germany|Otto-von-Guericke-Universitaet Magdeburg, Magdeburg, Germany|Medizinische Klinik und Poliklinik II, München, Germany|Policlinico Sant' Orsola Malpighi, Bologna, Italy|AOU Cagliary, Cagliari, Italy|A.O.U. Policlinico G.Martino, Messina, Italy|Ospedale San Gerardo, Monza, Italy|Ospedale Sant'Andrea Hospital, Roma, Italy|Hgu Alicante, Alicante, Spain|Hospital de Mar - Parc de Salut Mar, Barcelona, Spain|Hospital Reina Sofia, Córdoba, Spain|Universidad Autonoma de Madrid - Hospital Universitario La Paz, Madrid, Spain|Parc Tauli Hospital Universitari, Sabadell, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Spain|Hospital Universitario de Rio Hortega, Valladolid, Spain|Changhua Christian Hospital, Chang Hua, Taiwan|Kaohsiung Medical University Hospital, Kaohsiung, Taiwan|Chang Gung Medical Foundation, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|Liver DIS Center, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|Chi Mei Medical Center - Liuying, Tainan, Taiwan|Chang Gung Medical Foundation, Taoyuan, Taiwan|Phramongkutklao Hospital, Bangkok, Thailand|Sririraj Hospital, Bangkok, Thailand|Chiang Mai University, Chiang Mai, Thailand	https://ClinicalTrials.gov/show/NCT03628651
1310	Phase I Study of RNA Oligonucleotide, MTL-CEBPA, Atezolizumab and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma.	Recruiting	No Results Available	Advanced Hepatocellular Carcinoma	Drug: MTL-CEBPA|Drug: Atezolizumab|Drug: Bevacizumab	National University Hospital, Singapore, Singapore	https://ClinicalTrials.gov/show/NCT05097911
1311	Randomized Phase I/II of RAD001 in Advanced Hepatocellular Carcinoma (HCC)	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: RAD001 (everolimus)	National Cheng Kung University Hospital, Tainan, Taiwan|Tri-Service General Hospital, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT00390195
1312	An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma	Active, not recruiting	Has Results	Hepatocellular Carcinoma	Drug: Nivolumab|Drug: Sorafenib	University Of Alabama At Birmingham, Birmingham, Alabama, United States|Ucla-Division Of Hematology/Oncology, Los Angeles, California, United States|Pacific Hematology Oncology Associates, San Francisco, California, United States|University Of California San Francisco, San Francisco, California, United States|University Of Chicago, Chicago, Illinois, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Icahn School Of Medicine At Mount Sinai, New York, New York, United States|Memorial Sloan Kettering Nassau, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|University Of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Ut Southwestern Medical Center, Dallas, Texas, United States|The University Of Texas Health Science Center, San Antonio, Texas, United States|Scott & White Memorial Hospital And Clinic, Temple, Texas, United States|Virginia Mason Medical Center, Seattle, Washington, United States|University of Washington - Seattle Cancer Care Alliance, Seattle, Washington, United States|University Of Wisconsin, Madison, Wisconsin, United States|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Monash Medical Centre Clayton, Clayton, Victoria, Australia|Austin Hospital, Heidelberg, Victoria, Australia|The Alfred Hospital, Prahran, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Universitaetsklinikum Graz, Graz, Austria|AKH Wien, Wien, Austria|Local Institution, Bruxelles, Belgium|Local Institution, Leuven, Belgium|Local Institution, Liege, Belgium|Tom Baker Cancer Centre, Calgary, Alberta, Canada|British Columbia Cancer Agency-Vancouver Ctr, Vancouver, British Columbia, Canada|CHU de Quebec - Universite Laval, Quebec, Canada|Local Institution, Hefei, Anhui, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Fuzhou, Fujian, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Nanning, Guangxi, China|Local Institution, Harbin, Heilongjiang, China|Local Institution, Changsha, Hunan, China|Local Institution, Changzhou, Jiangsu, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Changchun, Jilin, China|Local Institution, Changchun, Jilin, China|Local Institution, Dalian, Liaoning, China|Local Institution, Xi'an, Shan3xi, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Tianjin, Tianjin, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Klinika komplexni onkologicke pece, Brno, Czechia|Klinika onkologie a radioterapie, Hradec Kralove, Czechia|Onkologicka klinika, Olomouc, Czechia|Local Institution, La Tronche, France|Local Institution, Lille Cedex, France|Local Institution, Lyon, France|Local Institution, Montpellier Cedex, France|Local Institution, Paris Cedex 13, France|Local Institution, Pessac, France|Centre Eugene Marquis, Rennes Cedex, France|Local Institution, Toulouse Cedex 9, France|Charite Campus Virchow Klinikum, Berlin, Germany|Klinik Essen-Mitte, Essen, Germany|Klinikum Der Johann Wolfgang Goethe-Universitat, Frankfurt, Germany|Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany|Universitaetsklinikum Leipzig, Leipzig, Germany|Johannes -Gutenberg Universitat, Mainz, Germany|Klinikum Grosshadern, Munich, Germany|Universitaetsklinikum Regensburg, Regensburg, Germany|Universitaetsklinikum Tuebingen, Tuebingen, Germany|Local Institution, Hong Kong, Hong Kong|Local Institution, Haifa, Israel|Local Institution, Jerusalem, Israel|Local Institution, Petah-tikva, Israel|Local Institution, Tel Aviv, Israel|Ospedale G.Rummo, Benevento, Italy|Azienda Ospedaliera Papa Giovanni Xxiii, Bergamo, Italy|Istituto Nazionale Per Lo Studio E La Cura, Milano, Italy|Local Institution, Orbassano, Italy|AOUS - Policlinico S.Maria Alle Scotte, Siena, Italy|Local Institution, Chiba City, Chiba, Japan|Local Institution, Matsuyama-shi, Ehime, Japan|Local Institution, Kurume-shi, Fukuoka, Japan|Local Institution, Ogaki-shi, Gifu, Japan|Local Institution, Hiroshima-Shi, Hiroshima, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Kanazawa-shi, Ishikawa, Japan|Local Institution, Kawasaki-shi, Kanagawa, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Kyoto-shi, Kyoto, Japan|Local Institution, Osaka-Sayama-Shi, Osaka, Japan|Local Institution, Suita, Osaka, Japan|Local Institution, Saga-shi, Saga, Japan|Local Institution, Chiyoda-ku, Tokyo, Japan|Local Institution, Mitaka-shi, Tokyo, Japan|Local Institution, Musashino-shi, Tokyo, Japan|Local Institution, Shinjuku-ku, Tokyo, Japan|Local Institution, Seoul, Seocho-gu, Korea, Republic of|Local Institution, Daegu, Korea, Republic of|Local Institution, Gyeonggi-do, Korea, Republic of|Local Institution, Jeollanam-do, Korea, Republic of|Local Institution, Seoul-si, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Uniwersyteckie Centrum Kliniczne Klinika Onkologii I Radiote, Gdansk, Poland|Klinika Gastroenterologii Onkologicznej, Warszawa, Poland|Oddzial Onkologii, Wroclaw, Poland|Local Institution, Moscow, Russian Federation|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Local Institution, Alicante, Spain|Local Institution, Majadahonda - Madrid, Spain|Local Institution, Pamplona, Spain|Local Institution, Santiago Compostela, Spain|Local Institution, Goteborg, Sweden|Local Institution, Stockholm, Sweden|Universitaetsspital Basel, Basel, Switzerland|Inselspital Bern, Bern, Switzerland|Local Institution, Kaohsiung County, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Tainan, Taiwan|Local Institution, Tainan, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taoyuan County, Taiwan|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Glasgow, Lanarkshire, United Kingdom|Local Institution, Liverpool, United Kingdom	https://ClinicalTrials.gov/show/NCT02576509
1313	Cryoablation Combined With Tislelizumab Plus Lenvatinib as Second-line or Later Therapy in Advanced Hepatocellular Carcinoma	Recruiting	No Results Available	Advanced Hepatocellular Carcinoma	Drug: Tislelizumab|Drug: lenvatinib|Combination Product: US/CT-guided Percutaneous Cryoablation	Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT05057845
1314	Transarterial Ethanol Ablation(TEA) for Unresectable Hepatocellular Carcinoma(HCC)	Completed	No Results Available	Hepatocellular Carcinoma	Procedure: TEA	Department of Clinicl Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong|Department of Imaging and Interventional Radiology, Prince of Wales Hospital, The Chinsese University of Hong Kong, Hong Kong, Hong Kong|Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong	https://ClinicalTrials.gov/show/NCT01837381
1315	Axitinib as Second-line Treatment for Advanced Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Drug: AG-013736	National Taiwan University Hospital, Taipei City, Taiwan|Taipei Veterans General Hospital, Taipei City, Taiwan|Tri-Service General Hospital, Taipei City, Taiwan	https://ClinicalTrials.gov/show/NCT01273662
1316	Donafenib and Toripalimab Combined With TACE in Patients With Unresectable Hepatocellular Carcinoma	Recruiting	No Results Available	Unresectable Hepatocellular Carcinoma	Drug: Donafenib Tosilate Tablets|Biological: Toripalimab Injection	Hunan Cancer Hospital, Changsha, Hunan, China	https://ClinicalTrials.gov/show/NCT04605185
1317	Phase II Study of Concurrent Sorafenib and Intensity-modulated Radiotherapy (IMRT) for Advanced Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma, Radiotherapy, Sorafenib	Radiation: concurrent sorafenib and IMRT, followed sorafenib maintenance	Bo Chen, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT03535259
1318	SBRT + TACE for Primary Hepatocellular Carcinoma	Withdrawn	No Results Available	Hepatocellular Carcinoma	Radiation: Stereotactic Body Radiation Therapy (SBRT)|Procedure: Transcatheter Arterial Chemoembolization (TACE)	UPMC Presbyterian/Montifore, Pittsburgh, Pennsylvania, United States|Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|UPMC Cancer Pavilion, Pittsburgh, Pennsylvania, United States|UPMC Shadyside Radiation Oncology, Pittsburgh, Pennsylvania, United States	https://ClinicalTrials.gov/show/NCT00746655
1319	Toripalimab Combined With Donafenib in the Treatment of Advanced Hepatocellular Carcinoma	Recruiting	No Results Available	Advanced Hepatocellular Carcinoma	Drug: Donafenib Tosilate Tablets|Drug: Toripalimab Injection	No.81 Hospital of PLA, Nanjing, Jiangsu, China	https://ClinicalTrials.gov/show/NCT04503902
1320	Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma	Terminated	Has Results	Hepatocellular Carcinoma	Drug: DCR-MYC	Mayo Clinic, Scottsdale, Arizona, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States|Asan Medical Center, Seoul, Korea, Republic of|National University Hospital of Singapore, Singapore, Singapore|National Cancer Centre Singapore, Singapore, Singapore	https://ClinicalTrials.gov/show/NCT02314052
1321	Sorafenib Combined With Aspirin to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma	Terminated	No Results Available	Hepatocellular Carcinoma	Other: control|Drug: sorafenib|Drug: aspirin	Huashan hospital, Shanghai, China	https://ClinicalTrials.gov/show/NCT02748304
1322	Ib Study of the Efficacy and Safety of IBI310 Combined With Sintilimab in Advanced Hepatocellular Carcinoma	Recruiting	No Results Available	Advanced Hepatocellular Carcinoma	Drug: IBI308 200mg	Zhongshan Hospital Affiliated to Fudan University, Shanghai, China	https://ClinicalTrials.gov/show/NCT04401813
1323	Regorafenib Plus Tislelizumab as First-line Systemic Therapy for Patients With Advanced Hepatocellular Carcinoma	Recruiting	No Results Available	Advanced Hepatocellular Carcinoma	Drug: Tislelizumab+regorafenib for part 1;Tislelizumab+regorafenib for group 1 of part 2; Regorafenib for group 2 of part 2.	National Taiwan University Hospital, Taipei, Zhongzheng Dist, Taiwan	https://ClinicalTrials.gov/show/NCT04183088
1324	Temsirolimus + Sorafenib in Advanced Hepatocellular Carcinoma (HCC)	Withdrawn	No Results Available	Hepatocellular Carcinoma	Drug: Temsirolimus + Sorafenib	University Hospital Giessen and Marburg, Marburg, Germany	https://ClinicalTrials.gov/show/NCT01335074
1325	Effect of S-Adenosyl Methionine Treatment on Recurrence After Curative Resection of Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: S-Adenosyl Methionine	Eastern hepatobilliary surgery hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT02586285
1326	Safety and Efficacy of Oncoxin in Hepatocellular Carcinoma (HCC)	Unknown status	No Results Available	Hepatocellular Carcinoma	Dietary Supplement: Oncoxin|Other: Supportive treatment	Farabi General Hospital, Dhaka, Bangladesh	https://ClinicalTrials.gov/show/NCT01392131
1327	Interest of Functional MRI (Magnetic Resonance Imagery) (in Patients Suffering From Hepatocellular Carcinoma and Treated With Yttrium	Completed	No Results Available	Hepatocellular Carcinoma	Other: Additional RMIs	Centre Eugène Marquis, Rennes, France	https://ClinicalTrials.gov/show/NCT02003339
1328	Sorafenib With Capecitabine and Oxaliplatin for Advanced or Metastatic Hepatocellular Carcinoma	Unknown status	No Results Available	Advanced Hepatocellular Carcinoma|Metastatic Hepatocellular Carcinoma	Drug: Sorafenib with Capecitabine and Oxaliplatin	Queen Mary Hospital, Hong Kong, China	https://ClinicalTrials.gov/show/NCT00752063
1329	Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma	Not yet recruiting	No Results Available	Resectable Hepatocellular Carcinoma	Drug: Tislelizumab combined with Lenvatinib	Tianjin Medical University Cancer Insititute and Hospital, Tianjin, Tianjin, China	https://ClinicalTrials.gov/show/NCT04834986
1330	A Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) Plus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma (HCC)	Withdrawn	No Results Available	Hepatocellular Carcinoma	Drug: Sorafenib|Radiation: Stereotactic radiotherapy	Indiana University, Indianapolis, Indiana, United States	https://ClinicalTrials.gov/show/NCT01801163
1331	Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma	Recruiting	No Results Available	Resectable Hepatocellular Carcinoma	Drug: Camrelizumab:200mg， iv，d1 q2w;apatinib:250mg,po，qd，q2w	Tianjin Medical University Cancer Insititute and Hospital, Tianjin, Tianjin, China	https://ClinicalTrials.gov/show/NCT04701060
1332	A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma (HCC)	Drug: ERY974|Drug: Tocilicumab|Drug: Atezolizumab|Drug: Bevacizumab	National Cancer Center Hospital East, Kashiwa, Chiba, Japan|Kanagawa Cancer Center, Yokohama, Kanagawa, Japan|National Cancer Center Hospital, Chuo Ku, Tokyo, Japan|National Taiwan University Hospital, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT05022927
1333	Pre-operative Neoadjuvant Therapy Combined With Surgery for Treating Stage III Hepatocellular Carcinoma	Not yet recruiting	No Results Available	Hepatocellular Carcinoma Stage III	Procedure: Transhepatic Arterial Chemotherapy And Embolization (TACE)|Procedure: Surgery		https://ClinicalTrials.gov/show/NCT04961138
1334	P2 Study of Postoperative Interferon/Fluorouracil vs Cisplatin/Fluorouracil for Hepatocellular Carcinoma.	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: Interferon Alfa、Fluorouracil|Drug: Cisplatin、Fluorouracil	Osaka University, Graduate School of Medicine, Osaka, Japan	https://ClinicalTrials.gov/show/NCT01834963
1335	Standard Treatments of Very-early Stage Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma|Very-early Stage	Procedure: RFA|Procedure: MWV|Procedure: PEI	Eastern hepatobilliary surgery hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT02728193
1336	Adjuvant Stereotactic Body Radiation Therapy After Trans-arterial Chemoembolization in Hepatocellular Carcinoma	Not yet recruiting	No Results Available	Hepatocellular Carcinoma Non-resectable	Procedure: TACE|Radiation: SBRT		https://ClinicalTrials.gov/show/NCT04996914
1337	Selective Internal Radiation Therapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Hepatocellular Carcinoma (HCC).	Completed	No Results Available	Hepatocellular Carcinoma	Procedure: DEB TACE|Procedure: SIRT		https://ClinicalTrials.gov/show/NCT01798160
1338	Effectiveness of Microwave Ablation of Hepatocellular Carcinoma as Compared to Radiofrequency Ablation	Completed	No Results Available	Hepatocellular Carcinoma	Procedure: Microwave ablation|Procedure: Radiofrequency ablation	Prince of Wales Hospital, Hong Kong, China	https://ClinicalTrials.gov/show/NCT01340105
1339	The Impact on Survival of Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) Who Underwent Hepatectomy : A Random, Controlled, Stage III Clinical Trial.	Recruiting	No Results Available	Hepatocellular Carcinoma	Procedure: TAI	Cancer Center of Sun Yat-Sen University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT03368651
1340	Cytoreductive Surgery and Transarterial Chemoembolization (TACE) Versus TACE for Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Procedure: Cytoreductive Surgery|Procedure: TACE	Eastern Hepatobiliary Surgery Hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT00820157
1341	The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.	Recruiting	No Results Available	Hepatocellular Carcinoma	Procedure: adjuvant transarterial chemoinfusion (TAI)|Drug: mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)	Cancer Center of Sun Yat-Sen University, Guangzhou, China	https://ClinicalTrials.gov/show/NCT03192618
1342	Phase I/II Study of TSU-68 for Advanced Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Drug: Orantinib (TSU-68)	Chiba University Hospital, Inohana Chuo-ku Chiba, Chiba, Japan	https://ClinicalTrials.gov/show/NCT00784290
1343	Surgical Resection Versus Percutaneous Local Ablative Therapy for Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma With CSPH	Procedure: SR|Procedure: PLAT	Eastern Hepatobiliary Surgery Hospital, Shanghai, China|Eastern Hepatobiliary Surgery Hospital, Shanghai, China	https://ClinicalTrials.gov/show/NCT01860222
1344	Anlotinib Hydrochloride Combined With Sintilimab Injection in the Treatment of Advanced Hepatocellular Carcinoma (HCC)	Unknown status	No Results Available	Advanced Hepatocellular Carcinoma	Drug: Anlotinib and Sintilimab injection	Jiangsu Province Hospital, Nanjing, Jiangsu, China	https://ClinicalTrials.gov/show/NCT04052152
1345	Immunotherapy of Hepatocellular Carcinoma With Gamma Delta T Cells	Terminated	No Results Available	Hepatocellular Carcinoma	Other: T gamma delta lymphocytes	Unité de Thérapie Cellulaire, Laboratoire de Cytogénétique et Biologie Cellulaire, CHU Rennes, Rennes, France|Département d'Oncologie Médicale - CRLCC Eugène Marquis, Rennes, France|Service de Chirugie Viscérale - Hôpital de Pontchaillou, Rennes, France	https://ClinicalTrials.gov/show/NCT00562666
1346	A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Hepatocellular Carcinoma	Completed	No Results Available	Advanced Hepatocellular Carcinoma	Drug: Cabozantinib	Aichi Cancer Center Hospital, Nagoya, Aichi, Japan|National Cancer Center Hospital East, Kashiwa, Chiba, Japan|Iizuka Hospital, Iizuka, Fukuoka, Japan|Kurume University Hospital, Kurume, Fukuoka, Japan|Sapporo-Kosei General Hospital, Sapporo, Hokkaido, Japan|Kanazawa University Hospital, Kanazawa, Ishikawa, Japan|Kanagawa Cancer Center, Yokohama, Kanagawa, Japan|Yokohama City University Medical Center, Yokohama, Kanagawa, Japan|Kindai University Hospital, Osakasayama, Osaka, Japan|National Cancer Center Hospital, Chuo-ku, Tokyo, Japan|Kyorin University Hospital, Mitaka, Tokyo, Japan|Japanese Red Cross Musashino Hospital, Musashino, Tokyo, Japan|Chiba University Hospital, Chiba, Japan|Hiroshima University Hospital, Hiroshima, Japan|Okayama University Hospital, Okayama, Japan|Osaka City University Hospital, Osaka, Japan|Osaka International Cancer Institute, Osaka, Japan	https://ClinicalTrials.gov/show/NCT03586973
1347	Trial of S-1 in Combination With Sorafenib for Patients With Advanced Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Drug: sorafenib, TS-1	Samsung Medical Center, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT01131689
1348	Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)	Recruiting	No Results Available	Advanced Hepatocellular Carcinoma	Biological: Pembrolizumab/Quavonlimab|Drug: Lenvatinib|Biological: Pembrolizumab	City of Hope Comprehensive Cancer Center ( Site 0002), Duarte, California, United States|Johns Hopkins Hospital-Sidney Kimmel Comprehensive Cancer Center - GI and Immunology ( Site 0013), Baltimore, Maryland, United States|Icahn School of Medicine at Mount Sinai ( Site 0009), New York, New York, United States|Oregon Health and Science University ( Site 0006), Portland, Oregon, United States|Charleston Oncology ( Site 0003), Charleston, South Carolina, United States|Blue Ridge Cancer Care ( Site 0008), Roanoke, Virginia, United States|Virginia Mason Medical Center ( Site 0004), Seattle, Washington, United States|Anhui Provincial Hospital ( Site 0113), Hefei, Anhui, China|Beijing Cancer hospital-Department of Hepato-Pancreato-Biliary Surgery II ( Site 0107), Beijing, Beijing, China|Fuzhou General hospital of Nanjing Military Command-Oncology Department ( Site 0105), Fuzhou, Fujian, China|Southern Medical University Nanfang Hospital-Liver Cancer Department ( Site 0106), Guangzhou, Guangdong, China|Wuhan Union Hospital Cancer Center ( Site 0108), Wuhan, Hubei, China|Hunan Cancer Hospital-intervention department ( Site 0109), Changsha, Hunan, China|The First Affiliated Hospital of Xian Jiaotong University ward1 depattment of medical oncology ( Sit, Xi'an, Shaanxi, China|Zhongshan Hospital,Fudan University ( Site 0103), Shanghai, Shanghai, China|Huashan Hospital Affiliated Fudan University-Surgery Department ( Site 0118), Shanghai, Shanghai, China|Ospedale San Raffaele-Oncologia Medica ( Site 0227), Milano, Lombardia, Italy|Humanitas-U.O di Oncologia medica ed Ematologia ( Site 0231), Rozzano, Milano, Italy|Istituto Nazionale Tumori IRCCS Fondazione Pascale-Department of Abdominal Oncology ( Site 0230), Napoli, Italy|National Cancer Center Hospital East ( Site 0153), Kashiwa, Chiba, Japan|Toranomon Hospital Kajigaya ( Site 0154), Kawasaki, Kanagawa, Japan|Kindai University Hospital- Osakasayama Campus-Department of Gastroenterology and Hepatology ( Site, Osakasayama, Osaka, Japan|Hiroshima University Hospital ( Site 0156), Hiroshima, Japan|Seoul National University Bundang Hospital-Medical Oncology ( Site 0290), Seongnam, Kyonggi-do, Korea, Republic of|Samsung Medical Center ( Site 0288), Seoul, Kyonggi-do, Korea, Republic of|Asan Medical Center ( Site 0289), Seoul, Korea, Republic of|Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Onkologii i Radioterapii ( Site, Warszawa, Mazowieckie, Poland|Wojewódzki Szpital im. Św. Ojca Pio w Przemyślu ( Site 0249), Przemysl, Podkarpackie, Poland|Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 0247), Gdańsk, Pomorskie, Poland|Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie-Oddzial Dzienny Chemioterapii ( Site 0246), Koszalin, Zachodniopomorskie, Poland|Hospital Universitario Central de Asturias-Hepatology ( Site 0309), Oviedo, Asturias, Spain|Hospital Universitari Vall d'Hebron-Liver Unit - Department of Internal Medicine ( Site 0310), Barcelona, Spain|Hôpitaux Universitaires de Genève (HUG) ( Site 0335), Genève, Geneve, Switzerland|Cantonal Hospital St.Gallen-Klinik für Gastroenterologie / Hepatologie ( Site 0334), st.Gallen, Sankt Gallen, Switzerland|CHUV (centre hospitalier universitaire vaudois) ( Site 0333), Lausanne, Vaud, Switzerland|UniversitätsSpital Zürich-Gastroenterologie & Hepatologie ( Site 0332), Zürich, Zurich, Switzerland|Inselspital Bern-Universitätsklinik für Viszerale Chirurgie und Medizin ( Site 0331), Berne, Switzerland|NATIONAL CHENG-KUNG UNI. HOSP.-Clinical Trial Research Team of Liver Diseases ( Site 0354), Tainan, Taiwan|National Taiwan University Hospital-Oncology ( Site 0351), Taipei, Taiwan|Taipei Veterans General Hospital-Division of Gastroenterology & Hepatology, Department of Medicine (, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT04740307
1349	Radioembolization With Yittrium-90 for Intermediate and Advanced Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma|Radioembolization	Procedure: TACE|Procedure: radioembolization with Y-90	Eastern hepatobilliary surgery hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT02724436
1350	Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma	Terminated	No Results Available	Hepatocellular Carcinoma	Drug: Lenalidomide|Drug: Sorafenib	Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States	https://ClinicalTrials.gov/show/NCT01348503
1351	A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab	Recruiting	No Results Available	Unresectable Hepatocellular Carcinoma	Drug: Atezolizumab|Drug: Lenvatinib|Drug: Sorafenib	Uniklinikum Salzburg, LKH; Univ.Klinik f. Innere Medizin III der PMU, Salzburg, Austria|AZ KLINA, Brasschaat, Belgium|Cliniques Universitaires St-Luc, Bruxelles, Belgium|UZ Gent, Gent, Belgium|UZ Leuven, Leuven, Belgium|Hospital Sao Rafael - HSR, Salvador, BA, Brazil|Sociedade beneficente de senhoras Hospital Sirio Libanes, Brasilia, DF, Brazil|Clinicas Oncologicas Integradas - COI, Rio De Janeiro, RJ, Brazil|Hospital Sao Lucas - PUCRS, Porto Alegre, RS, Brazil|YNOVA Pesquisa Clinica, Florianopolis, SC, Brazil|Hospital Beneficência Portuguesa, São Paulo, SP, Brazil|Tom Baker Cancer Centre-Calgary, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|Juravinski Cancer Centre, Hamilton, Ontario, Canada|Princess Margaret Cancer Center, Toronto, Ontario, Canada|Hospital Clinico de La Universidad de Chile J.J.A.; Oncologia, Santiago, Chile|Centro de Estudios Clínicos SAGA, Santiago, Chile|Pontificia Universidad Catolica de Chile; Clinica San Carlos de Apoquindo, Santiago, Chile|Peking University People's Hospital, Beijing, China|Sichuan Provincial Cancer Hospital, Chengdu, China|Fujian Provincial Hospital, Fuzhou City, China|The First Affiliated Hospital, Sun Yat-sen University, Guangzhou City, China|Sun Yet-sen University Cancer Center, Guangzhou, China|Nanfang Hospital, Southern Medical University, Guangzhou, China|Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China|Harbin Medical University Cancer Hospital, Harbin, China|Anhui Province Cancer Hospital, Hefei, China|Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University), Nanjing City, China|Zhongshan Hospital Fudan University, Shanghai, China|Shengjing Hospital of China Medical University, ShenYang, China|Tianjin Cancer Hospital, Tianjin, China|Tongji Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan City, China|Clinica CIMCA, San José, Costa Rica|ICIMED Instituto de Investigación en Ciencias Médicas, San José, Costa Rica|Clinical Hospital Centre Zagreb, Zagreb, Croatia|Docrates Cance Center; Docrates, Helsinki, Finland|TAYS Radius rakennus; onkologinen lääketutkimusyksikkö, Tampere, Finland|Turku Uni Central Hospital; Oncology Clinics, Turku, Finland|CHRU de Lille - Hopital Claude Huriez, Lille, France|Aphm; Cpcet, Marseille, France|CH Saint Eloi, Montpellier, France|CHU de Nantes - Hotel Dieu, Nantes, France|CHU Nice - Hôpital de l'Archet 2; service Hepato gastro enterologie, Nice Cedex, France|APHP - Hopital Saint Antoine, Paris, France|CHU Bordeaux, Pessac, France|CHU de Toulouse - Hôpital Rangueil, Toulouse Cedex 09, France|Hopitaux de Brabois - Gastro-Entereologie, Vandoeuvre-les-nancy, France|Hopital Paul Brousse; Centre Hepatologie Biliaire, Villejuif, France|Klinikum Esslingen; Allg. Innere Med., Onkologie, Hämatologie, Gastroenterologie und Infektiologie, Esslingen, Germany|Med. Hochschule Hannover; Gastroenterologie, Hannover, Germany|Uniklinik Mainz; I. Medizinische Klinik, Mainz, Germany|Universität Tübingen; Med. Klinik; Innere Medizin I, Tübingen, Germany|Universitätsklinikum Ulm; Zentrum für Innere Medizin Klinik für Innere Medizin I, Ulm, Germany|Laiko General Hospital Athen; Uni Clinic of Gastrenterology, Athens, Greece|Agioi Anargiroi Hospital of Kifissia; University Internal Medicine Clinic, Nea Kifissia, Greece|Anticancer Hospital of Thessaloniki " Theagenio", Thessaloniki, Greece|Hippokratio Hospital; 4Th Internal Medicine Dpt, Thessaloniki, Greece|Rambam Health Care Campus; Oncology, Haifa, Israel|Rabin Medical Center; Oncology Dept, Petach Tikva, Israel|Sourasky Medical Center; Oncology Department, Tel-Aviv, Israel|Fondazione Pascale; U.O. Sperimentazioni Cliniche, Napoli, Campania, Italy|Azienda Osp Uni Seconda Università Degli Studi Di Napoli; Unità Operativa Oncologia Medica, Napoli, Campania, Italy|Ospedale del Mare; UOC di Oncologia, Napoli, Campania, Italy|A.O. S. Orsola Malpighi; Ambulatorio Epatocarcinoma (Bolondi), Bologna, Emilia-Romagna, Italy|Azienda Ospedaliera San Camillo Forlanini, Roma, Lazio, Italy|Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Lazio, Italy|Fondazione IRCCS Ospedale Maggiore Policlinico; Gastroenterologia, Milano, Lombardia, Italy|Azienda Ospedaliera Ordine Mauriziano di Torino, Torino, Piemonte, Italy|A.O.U. Policlinico Paolo Giaccone; Gastroenterologia ed Epatologia, Palermo, Sicilia, Italy|Azienda Ospedaliero-Universitaria Careggi;S.C. Oncologia Medica 1, Firenze, Toscana, Italy|Azlenda Ospendaliero-Universitaria Pisana; C.O. Oncologia 2, Pisa, Toscana, Italy|IRCCS Istituto Oncologico Veneto (IOV); Oncologia Medica Seconda, Padova, Veneto, Italy|Chiba University Hospital, Chiba, Japan|National Cancer Center Hospital East, Chiba, Japan|Yokohama City University Medical Center, Kanagawa, Japan|Kindai University Hospital, Osaka, Japan|Toranomon Hospital, Tokyo, Japan|National Cancer Center, Goyang-si, Korea, Republic of|CHA Bundang Medical Center, Gyeonggi-do, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Institute Kanser Negara (IKN), Putrajaya, FED. Territory OF Kuala Lumpur, Malaysia|Beacon International Specialist Centre; Clinical Research Department, Level 2, Petaling Jaya, Selangor, Selangor, Malaysia|Uni Malaya Medical Center; Clinical Oncology Unit, Menara Timur, Kuala Lumpur, Malaysia|Makati Medical Center, Makati City, Philippines|Moscow City Oncology Hospital #62; Outpatient Care Center, Moscow, Moskovskaja Oblast, Russian Federation|Group of companies "Medci", Moskva, Moskovskaja Oblast, Russian Federation|I.M.Sechenov First Moscow State Medical University (1st MSMU), Moskva, Moskovskaja Oblast, Russian Federation|Clinical Hospital Lapino (LLC Haven), Yudino, Moskovskaja Oblast, Russian Federation|LLC "Oncology scientific centre", Pesochny, Sankt Petersburg, Russian Federation|FSBI "National Medical Research Center of Oncology N.N. Blokhin", Moscow, Russian Federation|University Medical Center Ljubljana; Clinical Dept. of Gastroenterology, Ljubljana, Slovenia|Corporacio Sanitaria Parc Tauli; Servicio de Hepatologia, Sabadell, Barcelona, Spain|Hospital Son Llatzer; Servicio de Oncologia, Palma de Mallorca, Islas Baleares, Spain|Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Oncologia, Santiago de Compostela, LA Coruña, Spain|Clinica Universitaria de Navarra; Servicio de Hepatologia, Pamplona/iruña, Navarra, Spain|Hospital Universitari Vall d'Hebron; Servicio de Hepatologia, Barcelona, Spain|Hospital Universitario Reina Sofia; Servicio de Hepatologia, Cordoba, Spain|Clinica Universidad de Navarra Madrid; Servicio de Oncología, Madrid, Spain|Hospital Clinico San Carlos; Servicio de Oncologia, Madrid, Spain|START Madrid. Centro Integral Oncologico Clara Campal; CIOCC, Madrid, Spain|Hospital Universitario la Fe; Servicio de Oncologia, Valencia, Spain|Hospital Universitario Miguel Servet; Servicio Oncologia, Zaragoza, Spain|Inselspital Bern Medizin Gastroenterologie, Bern, Switzerland|Universitätsspital Zürich Medizin Gastroenterologie; Klinik für Gastroenterologie und Hepatologie, Zürich, Switzerland|Chi-Mei Medical Centre; Hematology & Oncology, Tainan, Taiwan|National Taiwan University Hospital; Oncology, Zhongzheng Dist., Taiwan|Chulalongkorn Hospital; Medical Oncology, Bangkok, Thailand|Faculty of Med. Siriraj Hosp.; Med.-Div. of Med. Oncology, Bangkok, Thailand|Adana Acıbadem Hospital Oncology Department, Adana, Turkey|Memorial Ankara Hastanesi, Ankara, Turkey|Bakirkoy Dr. Sadi Konuk Egitim ve Arastirma Hastanesi, Tibbi Onkoloji, Bakirkoy / Istanbul, Turkey|Uludag Uni Hospital; Oncology, Bursa, Turkey|Medipol Mega Üniversite Hastanesi Göztepe, Istanbul, Turkey|Hacettepe Uni Medical Faculty Hospital; Oncology Dept, Sihhiye/Ankara, Turkey|Acıbadem Altunizade Hastanesi; Oncology, Üsküdar, Turkey|The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, United Kingdom|Royal Free Hospital, London, United Kingdom|King College Hospital NHS Foundation Trust, London, United Kingdom|Hammersmith Hospital; Clinical trials unit, London, United Kingdom|Christie Hospital Nhs Trust; Medical Oncology, Manchester, United Kingdom|Churchill Hospital; Department of Oncology, Oxford, United Kingdom	https://ClinicalTrials.gov/show/NCT04770896
1352	Yttrium-90 Radioembolization With Glass Microspheres (TheraSphere) for Patients With Hepatocellular Carcinoma	Terminated	Has Results	Hepatocellular Carcinoma	Device: Selective internal radiation therapy of the liver with Yttrium-90 glass microspheres (TheraSphere)	University of California San Francisco, San Francisco, California, United States	https://ClinicalTrials.gov/show/NCT01290523
1353	Efficacy of Radiation Therapy and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma (HCC)	Withdrawn	No Results Available	Hepatocellular Carcinoma	Other: Radiation therapy|Other: Transarterial chemoembolization		https://ClinicalTrials.gov/show/NCT01432314
1354	Transarterial Chemoembolization (TACE) Plus Sorafenib Versus TACE for Advanced Hepatocellular Carcinoma	Unknown status	No Results Available	Advanced Hepatocellular Carcinoma	Procedure: TACE+Sorafenib|Procedure: TACE	Eastern Hepatobiliary Surgery Hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT02150317
1355	Individualized Dosimetry for Holmium-166-radioembolization in Patients With Unresectable Hepatocellular Carcinoma	Not yet recruiting	No Results Available	Hepatocellular Carcinoma Non-resectable	Device: Holmium-166 radioembolization		https://ClinicalTrials.gov/show/NCT05114148
1356	Tumor Growth Factors in Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Biological: tumor growth factor concentration	Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan	https://ClinicalTrials.gov/show/NCT00764140
1357	Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC)	Completed	No Results Available	Unresectable Hepatocellular Carcinoma (HCC)	Drug: Lenvatinib	Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China|Shanghai Cancer Hospital, Fudan University, Shanghai, Shanghai, China|Zhongshan Hospital Fudan University, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT02953743
1358	Combined Chemoembolization and Systemic Hyperthermia for Unresectable Hepatocellular Carcinoma	Terminated	No Results Available	Hepatocellular Carcinoma	Procedure: TACE with Hyperthermia Treatment	Department of Clinical Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong|Department of Imaging and Interventional Radiology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong	https://ClinicalTrials.gov/show/NCT01817205
1359	Evaluating the Safety and Efficacy of SB Injection in Patients With Advanced or Primary Hepatocellular Carcinoma (HCC)	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: SB injection	Inha University Hospital, Incheon, Jung-gu, Korea, Republic of	https://ClinicalTrials.gov/show/NCT01308645
1360	Orantinib In Combination With Transcatheter Arterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma	Terminated	Has Results	Hepatocellular Carcinoma	Drug: Orantinib (TSU-68)|Drug: Placebo	Local Institution, Osaka-sayama, Osaka, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Chiba, Japan|Local Institution, Goyang-si, Gyeonggi-do, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT01465464
1361	Multiple Antigen Specific Cell Therapy (MASCT) for Hepatocellular Carcinoma(HCC) Patients After Radical Resection or Radio Frequency Ablation(RFA).	Suspended	No Results Available	Hepatocellular Carcinoma	Biological: MASCT:Multiple Antigens Specific Cellular Therapy|Other: The foundation treatment including against hepatitis b virus treatment using nucleoside analogue drug and protect liver treatment	JOE ZHOU, Shenzhen, Guangdong, China	https://ClinicalTrials.gov/show/NCT02026362
1362	STOPPER CHINA:With Tandem Microspheres in the Treatment of Localized Hepatocellular Carcinoma	Completed	Has Results	Localized Hepatocellular Carcinoma	Device: Tandem Microsphere loaded with Epirubicin	Beijing Cancer Hospital, Beijing, Beijing, China|Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China|Guangdong Nanfang Hospital, Guangzhou, Guangdong, China|Henan Cancer Hospital, Zhengzhou, Henan, China|Zhongda Hospital Affiliated Southeast University, Nanjing, Jiangsu, China|Shengjing Hospital Affiliated China Medical University, Shenyang, Liaoning, China|Shanghai Zhongshan Hospital, Shanghai, Shanghai, China|Second Aff. Hosp. of Zhejiang University College of Medicine, Hangzhou, Zhejiang, China|The First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China	https://ClinicalTrials.gov/show/NCT03113955
1363	Performance of Imaging for the Diagnosis of Small Hepatocellular Carcinoma (< 3 cm)on Cirrhosis	Unknown status	No Results Available	Hepatocellular Carcinoma	Other: 3 imaging techniques are done	CHU Angers, Angers, France|Hôpital Saint-André, Bordeaux, France|Chu, Caen, France|hôpital Beaujon, Clichy, France|hôpital Henri Mondor, Créteil, France|Hôpital Du Bocage, Dijon, France|CHU, Grenoble, France|Hôpital de la croix rousse, Lyon, France|Hôpital E. Herriot, Lyon, France|Hôpital Saint Éloi, Montpellier, France|Hôpital Brabois, Nancy, France|Hôpital Hôtel Dieu, Nantes, France|hôpital archet II, Nice, France|Hôpital Saint Antoine, Paris, France|Hôpital Haut-Lévèque, Pessac, France|Hôpital Pontchaillou, Rennes, France|Hôpital Nord, Saint Étienne, France|Hôpital Paul Brousse, Villejuif, France|Institut Gustave Roussy, Villejuif, France	https://ClinicalTrials.gov/show/NCT00848952
1364	Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer	Recruiting	No Results Available	Hepatocellular Carcinoma|Biliary Tract Cancer	Drug: Tremelimumab|Drug: Durvalumab|Radiation: Radiation	Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States	https://ClinicalTrials.gov/show/NCT03482102
1365	Analysis of Expression of Specific Markers in Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Other: Retrospective analysis of already archived samples	GSK Investigational Site, Firenze, Toscana, Italy	https://ClinicalTrials.gov/show/NCT00858000
1366	A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma	Unknown status	No Results Available	HEPATOCELLULAR CARCINOMA	Drug: Darinaparsin	Miami, Florida, United States|Atlanta, Georgia, United States|Boston, Massachusetts, United States|Kansas City, Missouri, United States|New York, New York, United States|Seattle, Washington, United States	https://ClinicalTrials.gov/show/NCT00423306
1367	Relationship Between Polymorphism of Heat Shock Protein 70 Gene and Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Genetic: Polymorphisms of HSP70 and TNF promoter	Kaohsiung Medical University, Kaohsiung, Kaohsiun, Taiwan|Kaohsiung Medical University, Kaohsiung, Taiwan	https://ClinicalTrials.gov/show/NCT00769535
1368	Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone	Completed	Has Results	Hepatocellular Carcinoma (HCC)	Biological: Pexastimogene Devacirepvec (Pexa Vec)|Drug: Sorafenib	University of Alabama, Birmingham, Alabama, United States|Mayo Clinic Arizona, Scottsdale, Arizona, United States|UC Irvine Medical Center, Orange, California, United States|Stanford University School of Medicine, Palo Alto, California, United States|University of Florida Shands Hospital, Gainesville, Florida, United States|University of Chicago, Chicago, Illinois, United States|University of Kansas Cancer Center, Kansas City, Kansas, United States|University of Louisville, Louisville, Kentucky, United States|Tulane University Health Sciences Center, New Orleans, Louisiana, United States|Mercy Medical Center, Inc., Baltimore, Maryland, United States|University of Minnesota, Minneapolis, Minnesota, United States|Kansas City Research Institute, Kansas City, Missouri, United States|Saint Louis University, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Billings Clinic, Billings, Montana, United States|Morristown Medical Center, Morristown, New Jersey, United States|St. Joseph's Hospital, Paterson, New Jersey, United States|Ohio State University, Columbus, Ohio, United States|Hospital of The University of Pennsylvania, Philadelphia, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|University of Tennessee Medical Center, Knoxville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Benaroya Research Institute at Virginia Mason Hospital, Seattle, Washington, United States|Site No. 8409, Adelaide, Australia|Site No. 8412, Adelaide, Australia|Site No. 8403, Brisbane, Australia|Site No. 8401, Camperdown, Australia|Site No. 8407, Clayton, Australia|Site No. 8406, Concord, Australia|Site No. 8408, Fitzroy, Australia|Site No. 8405, Footscray, Australia|Site No. 8414, Heidelberg, Australia|Site No. 8411, Melbourne, Australia|Site No. 8402, Parkville, Australia|Site No. 8415, Perth, Australia|Site No. 8413, Sydney, Australia|University of Alberta Hospital, Edmonton, Alberta, Canada|Juravinski Cancer Centre, Hamilton, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Site 8829, Changchun, China|Site No. 8821, Changsha, China|Site 8811, Fuzhou, China|Site 8820, Fuzhou, China|Site No.8816, Guangdong, China|Site 8827, Guangzhou, China|Site No.8828, Guangzhou, China|Site 8832, Hangzhou, China|Site No. 8802, Harbin, China|Site 8805, Hefei, China|Site No. 8808, Hefei, China|Site No.8815, Hefei, China|Site No. 8801, Nanjing, China|Site 8833, Qingdao, China|Site 8806, Shanghai, China|Site 8822, Shanghai, China|Site 8831, Shanghai, China|Site No. 8823, Xi'an, China|Site No. 8825, Xi'an, China|Site No. 9013, Bondy, France|Site No. 9005, Bordeaux, France|Site No. 9003, Créteil, France|Site No. 9006, Lille, France|Site 9012, Montpellier, France|Site No. 9008, Nantes, France|Site No. 9010, Nice, France|Site No. 9007, Paris, France|Site No. 9014, Paris, France|Site No. 9011, Rennes, France|Site No. 9001, Strasbourg, France|Site No. 9002, Toulouse, France|Site No. 9009, Vandœuvre-lès-Nancy, France|Site No. 9111, Aachen, Germany|Site No. 9113, Bonn, Germany|Site No. 9109, Dresden, Germany|Site No. 9108, Frankfurt am Main, Germany|Site No. 9106, Hamburg, Germany|Site No 9105, Hannöver, Germany|Site No. 9112, Heidelberg, Germany|Site No. 9101, Mainz, Germany|Site No. 9102, München, Germany|Site No. 9104, Tübingen, Germany|Site No. 9110, Ulm, Germany|Site No. 8601, Hong Kong, Hong Kong|Site No. 9707, Afula, Israel|Site 9704, Haifa, Israel|Site No. 9702, Haifa, Israel|Site No. 9705, Jerusalem, Israel|Site No. 9703, Ramat-Gan, Israel|Site No. 9706, Tel Aviv, Israel|Site No.9205, Modena, Italy|Site No. 9204, Napoli, Italy|Site No. 9201, Palermo, Italy|Site No. 9203, Parma, Italy|Site No. 8208, Ansan, Korea, Republic of|Site No. 8211, Bucheon, Korea, Republic of|Site No. 8201, Busan, Korea, Republic of|Site 8216, Daegu, Korea, Republic of|Site No. 8207, Daegu, Korea, Republic of|Site No. 8213, Daegu, Korea, Republic of|Site No. 8220, Daegu, Korea, Republic of|Site 8224, Goyang, Korea, Republic of|Site No. 8221, Jinju-si, Korea, Republic of|Site No. 8218, Pusan, Korea, Republic of|Site No. 8219, Seongnam-si, Korea, Republic of|Site No. 8222, Seongnam, Korea, Republic of|Site No. 8202, Seoul, Korea, Republic of|Site No. 8203, Seoul, Korea, Republic of|Site No. 8205, Seoul, Korea, Republic of|Site No. 8209, Seoul, Korea, Republic of|Site No. 8212, Seoul, Korea, Republic of|Site No. 8215, Seoul, Korea, Republic of|Site No. 8223, Seoul, Korea, Republic of|Site No. 8210, Suwon, Korea, Republic of|Site No. 8217, Ulsan, Korea, Republic of|Auckland City Hospital, Auckland, New Zealand|Site No. 8902, Christchurch, New Zealand|Site No. 9404, Coimbra, Portugal|Site No. 9405, Coimbra, Portugal|Site No. 9403, Lisboa, Portugal|Site No. 9401, Porto, Portugal|Site No. 9402, Porto, Portugal|Site 8702, Singapore, Singapore|Site 8703, Singapore, Singapore|Site No. 8701, Singapore, Singapore|Site No. 8305, Kaohsiung, Taiwan|Site No. 8307, Linkou, Taiwan|Site No. 8306, Taichung, Taiwan|Site No. 8302, Tainan City, Taiwan|Site No. 8301, Taipei, Taiwan|Site No. 8303, Taipei, Taiwan|Site No. 8502, Bangkok, Thailand|Site No. 8505, Bangkok, Thailand|Site No. 8503, Chiang Mai, Thailand|Site No. 8507, Hat Yai, Thailand|Site No. 8501, Khon Kaen, Thailand|Site No. 8506, Phitsanulok, Thailand|Site No. 9501, Birmingham, United Kingdom|Site No. 9505, Guildford, United Kingdom|Site No. 9503, Leeds, United Kingdom|Site No. 9502, London, United Kingdom|Site No. 9504, London, United Kingdom|Site No. 9506, London, United Kingdom	https://ClinicalTrials.gov/show/NCT02562755
1369	Association of Conformational High-dose Radiotherapy and of Hyperselective Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Other: TACE|Other: TACE+ RTC	CHU Amiens, Amiens, France|CHU d'Angers, Angers, France|CH Avignon, Avignon, France|Institut Sainte Catherine, Avignon, France|CHU de Bordeaux, Bordeaux, France|AP-HP Henri Mondor, Créteil, France|CHU Dijon, Dijon, France|CHD les Oudairies, La Roche-sur-Yon, France|CHR de Lille Hôpital Claude Huriez, Lille, France|CHU de Lyon, Lyon, France|CHU de Nancy Hôpital Brabois, Nancy, France|CHU Nantes, Nantes, France|CHR Orléans, Orléans, France|AP-HP Paul Brousse Villejuif, Paris, France|Hôpital Tenon, Paris, France|La Pitié-Salpétrière, Paris, France|CHU de Reims, Reims, France|Centre Eugene Marquis, Rennes, France	https://ClinicalTrials.gov/show/NCT01300143
1370	Study of ARQ 197 in Hepatocellular Carcinoma (HCC)	Completed	No Results Available	Advanced Hepatocellular Carcinoma	Drug: ARQ 197	Kashiwa-city, Chiba, Japan	https://ClinicalTrials.gov/show/NCT01656265
1371	Siliphos in Advanced Hepatocellular Carcinoma	Completed	No Results Available	Advanced Hepatocellular Carcinoma	Drug: Silybin	Columbia University Medical Center, New York, New York, United States	https://ClinicalTrials.gov/show/NCT01129570
1372	A Dose Escalation Trial of Radiation Therapy (RT) for Hepatocellular Carcinoma (HCC)	Unknown status	No Results Available	Hepatocellular Carcinoma	Radiation: 3DCRT or IMRT	National Taiwan University Hospital, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT00960167
1373	Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)	Recruiting	No Results Available	Hepatocellular Carcinoma (HCC)	Drug: nivolumab, ipilimumab	Chang-Gung Memorial Hospital, Kaohsiung, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Cheng-Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Mackay Memorial Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan|Chang-Gung Memorial Hospital, Linkou, Taoyuan, Taiwan	https://ClinicalTrials.gov/show/NCT03510871
1374	Sequential TransArterial Chemoembolization and Stereotactic RadioTherapy With ImmunoTherapy for Downstaging Hepatocellular Carcinoma for Hepatectomy	Recruiting	No Results Available	HCC	Procedure: TACE|Radiation: SBRT|Drug: Immune Checkpoint Inhibitor	Department of Clinical Oncology, Hong Kong, Hong Kong	https://ClinicalTrials.gov/show/NCT03817736
1375	A Phase II, Non-randomized, Single Arm, Translational Study of Cabozantinib for Patients With Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment	Recruiting	No Results Available	Hepatocellular Carcinoma Non-resectable|Metastatic Hepatocellular Carcinoma	Drug: Cabozantinib	Universitätsklinikum Schleswig-Holstein Campus Lübeck, Lübeck, Germany	https://ClinicalTrials.gov/show/NCT04511455
1376	Phase Ⅲ Randomized Trial in Postoperative Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Drug: IFN-α2b	Chang Gung Memorial Hospital, Tao-Yuan, Taiwan	https://ClinicalTrials.gov/show/NCT00149565
1377	Phase 1 Study of SF1126 in Combination With Nivolumab in Patients With Advanced Hepatocellular Carcinoma	Terminated	No Results Available	Advanced Hepatocellular Carcinoma	Drug: SF1126|Drug: Nivolumab	UC San Diego Moores Cancer Center, La Jolla, California, United States	https://ClinicalTrials.gov/show/NCT03059147
1378	RCT of TAE Simultaneously Combined Thermal Ablation for Large Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma, Adult	Drug: Chemotherapy drug|Drug: Embolic agents|Procedure: Simultaneously|Procedure: Sequentially|Device: Ablation	Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT02964260
1379	Efficacy and Safety of Lenvatinib as an Adjuvant Therapy for Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma (HCC)	Drug: Lenvima 4 mg Oral Capsule	Anhui Provincial Hospital, Hefei, Anhui, China|Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China|West China Hospital, Chengdu, Sichuan, China|180 Fenglin Road, Shanghai, China	https://ClinicalTrials.gov/show/NCT04227808
1380	Pilot Clinical Trial to Evaluate the UNI-DEB for Unresectable Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma Non-resectable	Device: UNI-DEB	Catholic University Seoul St. Mary Hospital, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT03564405
1381	Sorafenib With TACE to Treat Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Drug: Sorafenib|Procedure: Transarterial chemoembolisation with doxorubicin	Inselspital, Bern, Switzerland	https://ClinicalTrials.gov/show/NCT00478374
1382	Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)	Terminated	Has Results	Hepatocellular Carcinoma	Drug: PR104 550 mg/m^2 + sorafenib|Drug: PR104 770 mg/m^2 + sorafenib	University of Arizona, Tucson, Arizona, United States|Moores UCSD Cancer Center, La Jolla, California, United States|University of California, Irvine, Orange, California, United States|Sharp Clinical Oncology Research, San Diego, California, United States|Pacific Oncology/Hematology, San Francisco, California, United States|Northwestern University, Chicago, Illinois, United States|Indiana University Simon Cancer Center, Indianapolis, Indiana, United States|Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland, United States|Columbia University Medical Center, New York, New York, United States|Prince of Wales Hospital, Shatin, New Territories, Hong Kong|Singapore General Hospital, Singapore, Singapore|Chang Gung Memorial Hospital, Kaohsiung, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|Chi Mei Medical Center, Liouying, T'ai-nan, Taiwan|China Medical University Hospital, Taichung City, Taiwan|Cathay General Hospital, Taipei City, Taiwan|National Taiwan University Hospital, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT00862082
1383	Study of Sorafenib and Infusional 5-Fluorouracil in Advanced Hepatocellular Carcinoma (HCC)	Completed	No Results Available	Hepatocellular Carcinoma	Drug: Infusional 5-Fluorouracil|Drug: Sorafenib (Bay 43-9006)	Dipartimento di Oncologia, dei Trapianti e delle Nuove Tecnologie in Medicina ... Indirizzo: via Roma, 55 - 56100 Pisa Tel. 050-2218690 - Fax. 050-2218685, Pisa, Italy	https://ClinicalTrials.gov/show/NCT00619541
1384	Stereotactic Body Radiotherapy for Unresectable Hepatocellular Carcinoma	Unknown status	No Results Available	Localized Non-Resectable Adult Hepatocellular Carcinoma	Radiation: Stereotactic body radiotherapy	Samsung Medical Center, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT01910909
1385	Clinical Trial to Evaluate the Efficacy and Safety of UNI-DEB for Unresectable Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma Non-resectable	Device: UNI-DEB	Chonnam National University Hospital, Gwangju, Korea, Republic of|Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of|The Catholic University of Korea, Uijeongbu ST. Mary's Hospital, Gyeonggi-do, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Pusan National University Hospital, Pusan, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT03533920
1386	Multipolar Radiofrequency Ablation for Hepatocellular Carcinoma Using Extra Nodular Versus Intranodular Technique	Completed	No Results Available	Hepatocellular Carcinomas	Procedure: Radiofrequency ablation	Radiology Department, Bondy, France	https://ClinicalTrials.gov/show/NCT01008657
1387	Transarterial Chemoembolisation Plus Bevacizumab for Treatment of Hepatocellular Carcinoma	Terminated	No Results Available	Hepatocellular Carcinoma	Drug: bevacizumab	Medizinische Universität Wien, Vienna, Austria	https://ClinicalTrials.gov/show/NCT00280007
1388	Percutaneous Ethanol Alcohol Injection for the Large and Unresectable Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma Non-resectable	Procedure: Percutaneous ethanol alcohol injection	Ribat University Hospital, Khartoum, Sudan	https://ClinicalTrials.gov/show/NCT03138031
1389	The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) Versus Adjuvant Transarterial Chemoembolization (TACE) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.	Recruiting	No Results Available	Hepatocellular Carcinoma	Procedure: TAI|Procedure: TACE|Drug: epidoxorubicin and cisplatin and lipiodol|Drug: mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)	Cancer Center of Sun Yat-Sen University, Guangzhou, China	https://ClinicalTrials.gov/show/NCT03192644
1390	GH, IGF-I and Somatostatin Analogues in Hepatocellular Carcinoma	Completed	No Results Available	Advanced Hepatocellular Carcinoma	Drug: Octreotide-LAR, Lanreotide Autogel|Other: Locoregional treatments	D. Cotugno Hospital, Naples, Italy	https://ClinicalTrials.gov/show/NCT00495846
1391	Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma|Molecular Targeted Therapy	Drug: Lenvatinib and Gefitinib	Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT04642547
1392	Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma	Withdrawn	No Results Available	Advanced Hepatocellular Carcinoma	Drug: Oprozomib|Drug: Sorafenib	Lahey Hospital & Medical Center, Burlington, California, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|University of Miami Hospital & Clinics, Miami, Florida, United States|The University of Chicago Medical Center, Chicago, Illinois, United States|The Ohio State University, Martha Morehouse Medical Plaza, Columbus, Ohio, United States|University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States	https://ClinicalTrials.gov/show/NCT02227914
1393	Combined Y-90 Selective Internal Radiation Therapy (Y-90 SIRT) and Stereotactic Body Radiation Therapy (SBRT) in Unresectable Hepatocellular Carcinoma (HCC)	Recruiting	No Results Available	Hepatocellular Carcinoma (HCC)|Unresectable Hepatocellular Carcinoma	Drug: Yttrium-90|Device: Selective Internal Radiation Therapy|Radiation: Stereotactic Body Radiation Therapy|Diagnostic Test: PET/CT|Device: Therasphere	University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States	https://ClinicalTrials.gov/show/NCT04518748
1394	Non-invasive Prediction of Microvascular Invasion in Hepatocellular Carcinoma by Blood-Oxygen-Level Dependent Magnetic Resonance Imaging (BOLD MRI)	Completed	No Results Available	Hepatocellular Carcinoma	Procedure: BOLD MRI test	University Health Network, Toronto, Ontario, Canada	https://ClinicalTrials.gov/show/NCT00963612
1395	A Study of LY2181308 in Patients With Advanced Hepatocellular Carcinoma	Withdrawn	No Results Available	Hepatocellular Carcinoma	Drug: LY2181308	For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Los Angeles, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hartford, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Albuquerque, New Mexico, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Stony Brook, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bondy, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Clichy, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Berlin, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hannover, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mannheim, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pamplona, Spain	https://ClinicalTrials.gov/show/NCT00415155
1396	Computed Tomography (CT) - Guided Brachytherapy Versus Transarterial Chemoembolization in Patients With Unresectable Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Radiation: CT-guided brachytherapy|Procedure: transarterial chemoembolization	Clinic of Diagnostic Radiology and Nuclear Medicine, Medical Faculty, University Magdeburg, Magdeburg, Saxony-anhalt, Germany	https://ClinicalTrials.gov/show/NCT00807300
1397	Clinical Study Examining the Safety and Efficacy of Doxorubicin Drug Eluting Microspheres Transarterial Embolization in the Setting of Hepatocellular Carcinoma (HCC)	Completed	No Results Available	Hepatocellular Carcinoma	Drug: doxorubicin, superabsorbent polymer microspheres, embolotherapy	Vancouver General Hospital, Vancouver, British Columbia, Canada	https://ClinicalTrials.gov/show/NCT01116635
1398	Efficacy of Postoperative Adjuvant Treatments for Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis	Unknown status	No Results Available	Hepatocellular Carcinoma	Other: PVIC, TACE	Liver Cancer Insitute, Zhongshan Hospital, Shanghai, China	https://ClinicalTrials.gov/show/NCT01033578
1399	Resection vs. Best Supportive Care for Hepatocellular Carcinoma (HCC) With Portal Venous Thrombus	Terminated	No Results Available	Hepatocellular Carcinoma With Portal Vein Tumor Thrombus	Procedure: Liver resection plus Thrombectomy	Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT01600196
1400	Cabozantinib in Patients With Advanced Hepatocellular Carcinoma With Child Pugh Class B Cirrhosis After First-Line Therapy	Recruiting	No Results Available	Advanced Adult Hepatocellular Carcinoma	Drug: Cabozantinib	University of Chicago, Chicago, Illinois, United States|University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States	https://ClinicalTrials.gov/show/NCT04497038
1401	Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients	Unknown status	No Results Available	Primary Hepatocellular Carcinoma	Drug: TACE|Drug: Arsenic trioxide	Guizhou Cancer Hospital, Guiyang, Guizhou, China|Guizhou Province Tumor Hospital, Guiyang, Guizhou, China|Hunan Provincial People's Hospital, Changsha, Hunan, China|Hunan Cancer Hospital, Changsha, Hunan, China|Xiangya Hospital Central South University, Changsha, Hunan, China|The First Affiliated Hospital of University of South China, Hengyang, Hunan, China|Jiangsu Province Hospital, Nanjing, Jiangsu, China|Xinjiang Medical University Cancer Hospital, Urumqi, Xinjiang, China|The Tumor Hospital of Yunnan Province, Kunming, Yunnan, China	https://ClinicalTrials.gov/show/NCT02956772
1402	Annexin A2 as a Novel Diagnostic Marker in Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma (HCC)	Procedure: blood sample		https://ClinicalTrials.gov/show/NCT02541149
1403	Survival According to the Feeding Artery Obliteration by Chemoembolization for Unresectable Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma|Transarterial Chemoembolization	Procedure: Intermediate embolization|Procedure: Complete embolization	Hallym Sacred Heart Hospital, Anyang, Korea, Republic of|Chuncheon Sacred Heart Hospital, Chuncheon, Korea, Republic of|Kangnam Sacred Heart Hostpita, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT01677468
1404	Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy	Terminated	Has Results	Hepatocellular Carcinoma	Drug: TAC-101|Drug: Placebo	I.R.C.C.S. San Matteo University Hospital, Golgi, Pavia, Italy	https://ClinicalTrials.gov/show/NCT00687596
1405	DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma	Recruiting	No Results Available	Fibrolamellar Hepatocellular Carcinoma (FLC)	Drug: DNAJB1-PRKACA peptide vaccine|Drug: Nivolumab|Drug: Ipilimumab	Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States	https://ClinicalTrials.gov/show/NCT04248569
1406	Autologous Immune Cell Therapy in Primary Hepatocellular Carcinoma Patients Following Resection and TACE Therapy	Completed	No Results Available	Primary Hepatocellular Carcinoma	Biological: DC-TC+GM-CSF	9585 Humin Road,Xuhui district, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT01828762
1407	Cohort of Patients With Hepatocellular Carcinoma or Cholangiocarcinoma	Not yet recruiting	No Results Available	Cholangiocarcinoma|Hepatocellular Carcinoma		Serviec hépatologie-Hôpital Saint Antoine, Paris, France	https://ClinicalTrials.gov/show/NCT04340986
1408	A Phase II Study of a Continuous Hepatic Arterial Infusion Combination Therapy With OPC-18 and 5-FU in Patients With Highly Advanced Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Drug: OPC-18|Drug: cisplatin	Chubu region, Japan|Chugoku region, Japan|Hokkaido region, Japan|Kanto region, Japan|Kinki region, Japan|Kyushu region, Japan|Tohoku region, Japan	https://ClinicalTrials.gov/show/NCT00524498
1409	Transarterial Ethanol Ablation (TEA) Versus Transcatheter Arterial Chemoembolisation (TACE) for Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Procedure: TEA with LEM|Procedure: TACE	Department of Clinical Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong|Department of Diagnostic Radiology and Organ Imaging, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong|Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong	https://ClinicalTrials.gov/show/NCT00467974
1410	The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects	Recruiting	No Results Available	Hepatocellular Carcinoma (HCC)	Drug: Icaritin|Drug: Sorafenib Tosylate Tablets	First Affiliated Hospital Bengbu Medical College, Bengbu, Anhui, China|Anhui Provincial Hospital, Hefei, Anhui, China|The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China|Beijing Hospital, Beijing, Beijing, China|Cancer institute & hospital, chinese academy of medical sciences, Beijing, Beijing, China|Chinese PLA General Hospital, Beijing, Beijing, China|Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Beijing, Beijing, China|Peking University Cancer Hospital, Beijing, Beijing, China|The fifth medical center of PLA General Hospital, Beijing, Beijing, China|The First People's Hospital of Foshan, Foshan, Guangdong, China|Peking University Shenzhen Hospital, Shenzhen, Guangdong, China|First Affiliated Hospital of Harbin Medical University, Ha'erbin, Heilongjiang, China|Henan Cancer Hospital, Zhengzhou, Henan, China|Tongji Hospital, Wuhan, Hubei, China|Hunan Cancer Hospital, Changsha, Hunan, China|Eastern Theater General Hospital,QinHuai District Medical Area, Nanjing, Jiangsu, China|The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China|The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu, China|The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China|First Hospital of Jilin University, Changchun, Jilin, China|Jilin Cancer Hospital, Changchun, Jilin, China|Jinan Central Hospital, Jinan, Shandong, China|Linyi Tumour Hospital, Linyi, Shandong, China|Fudan University Affiliated Zhongshan Hospital, Shanghai, Shanghai, China|Tianjin Medical University Cancer Institution & Hospital, Tianjin, Tianjin, China|Nanfang Hospital of Southern Medical University, Guangzhou, China	https://ClinicalTrials.gov/show/NCT03236649
1411	CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma|Advanced Cancer	Drug: Nivolumab Injection [Opdivo]|Drug: CVM-1118	National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT05257590
1412	Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy	Completed	No Results Available	Unresectable Hepatocellular Carcinoma	Drug: ARQ 197|Drug: Placebo	Los Angeles, California, United States|Tampa, Florida, United States|Galveston, Texas, United States|Brussels, Belgium|Brussels, Belgium|Gent, Belgium|Toronto, Canada|Vancouver, Canada|Essen, Germany|Frankfurt am Main, Germany|Hamburg, Germany|Munchen, Germany|Munchen, Germany|Avellino, Italy|Benevento, Italy|Bologna, Italy|Padova, Italy|Parma, Italy|Pavia, Italy|Pisa, Italy|Reggio Emilia, Italy|Roma, Italy|Rozzano Milano, Italy	https://ClinicalTrials.gov/show/NCT00988741
1413	SIR-Spheres® Microspheres Versus Transarterial Chemoembolisation in Patients With Unresectable Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Device: Radioembolisation (SIR-Spheres® microspheres)|Drug: Transarterial Chemoembolisation	Universitäts-Klinikum München-Grosshadern, Medizinische Klinik und Poliklinik II, München, Germany|Clinica Universitaria de Navarra, Pamplona, Spain	https://ClinicalTrials.gov/show/NCT00867750
1414	Hepatitis B Virus HBeAg-negative Genotype D Patients and Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma|Hepatitis B			https://ClinicalTrials.gov/show/NCT02025842
1415	A Study of Apatinib in Patients With Advanced Hepatocellular Carcinoma	Completed	No Results Available	Advanced Hepatocellular Carcinoma	Drug: Apatinib	Nanjin Military Eighty -one Hosiptal, Nanjin,, Jiangsu, China	https://ClinicalTrials.gov/show/NCT01192971
1416	A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab Versus Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification	Not yet recruiting	No Results Available	C-staged Hepatocellular Carcinoma in BCLC Classification	Combination Product: Hepatic Arterial Infusion combined with Apatinib and Camrelizumab|Combination Product: Apatinib combined with Camrelizumab	Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China|Sun Yat-Sen Memorial Hospital, Guangzhou, Guangdong, China|Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China|The Third Affiliated Hospital of Sun Yat-Sen University, Guanzhou, Guangdong, China|Xiangya Hospital of Central South University, Changsha, Hunan, China	https://ClinicalTrials.gov/show/NCT05313282
1417	Trial of Palliative Chemotherapy With TS-1 and Oxaliplatin for Patients With Advanced Hepatocellular Carcinoma	Unknown status	No Results Available	Advanced Hepatocellular Carcinoma	Drug: SOX	Seoul National University Hospital, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT01429961
1418	COVID-19 Infection in Patients With Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma|COVID-19	Diagnostic Test: nasopharyngeal Covid 19 RT-PCR	CHU Amiens, Amiens, France	https://ClinicalTrials.gov/show/NCT04367805
1419	The Phase II Study of Icaritin in Patients With Advanced Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma (HCC)	Drug: Icaritin	Cancer institute & hospital, chinese academy of medical sciences, Beijing, Beijing, China|Beijing Shenogen Biomedical Co., Ltd, Beijing, Beijing, China|NanJing PLA 81 Hospital, Nanjing, Jiangsu, China	https://ClinicalTrials.gov/show/NCT01972672
1420	A Phase II/III Clinical Study on Inhibitory Effects of E0167 on Recurrence of Hepatocellular Carcinoma	Terminated	No Results Available	Hepatocellular Carcinoma	Drug: Menatetrenone|Drug: Placebo	Fukuoka, Fukuoka-prefecture, Japan|Kurume, Fukuoka-prefecture, Japan|Naka, Hiroshima-prefecture, Japan|Sapporo, Hokkaido-prefecture, Japan|Sapporo, Hokkaido-prefecture, Japan|Hitachi, Ibaraki-prefecture, Japan|Morioka, Iwate-prefecture, Japan|Kawasaki, Kanagawa-prefecture, Japan|Kanazawa, Kanazawa-prefecture, Japan|Senndai, Miyagi-prefecture, Japan|Niigata, Niigata-prefecture, Japan|Oita, Oita-prefecture, Japan|Kurashiki, Okayama-prefecture, Japan|Okayama, Okayama-prefecture, Japan|Okayama, Okayama-prefecture, Japan|Moriguchi, Osaka-prefecture, Japan|Osakasayama, Osaka-prefecture, Japan|Osaka, Osaka-prefecture, Japan|Osaka, Osaka-prefecture, Japan|Osaka, Osaka-prefecture, Japan|Saga, Saga-prefecture, Japan|Saga, Saga-prefecture, Japan|Shizuoka, Shizuoka-prefecture, Japan|Bunkyo-ku, Tokyo, Japan|Chiyoda-ku, Tokyo, Japan|Setagaya-ku, Tokyo, Japan|Shibuya-ku, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan|Wakayama, Wakayama-prefecture, Japan|Ube, Yamaguchi-prefecture, Japan	https://ClinicalTrials.gov/show/NCT00165633
1421	A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation	Recruiting	No Results Available	Hepatocellular Carcinoma (HCC)	Drug: Camrelizumab|Drug: Rivoceranib (Apatinib)	The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China|Guangxi Medical University Affiliated Tumor Hospital, Nanjin, Guangzhou, China|Guizhou Cancer Hospital, Guiyang, Guizhou, China|Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China|Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China|Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China	https://ClinicalTrials.gov/show/NCT04639180
1422	Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction	Withdrawn	No Results Available	Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma|Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma|Metastatic Malignant Solid Neoplasm|Stage III Hepatocellular Carcinoma AJCC v7|Stage IIIA Hepatocellular Carcinoma AJCC v7|Stage IIIB Hepatocellular Carcinoma AJCC v7|Stage IIIC Hepatocellular Carcinoma AJCC v7|Stage IV Hepatocellular Carcinoma AJCC v7|Stage IVA Hepatocellular Carcinoma AJCC v7|Stage IVB Hepatocellular Carcinoma AJCC v7|Unresectable Solid Neoplasm	Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Tazemetostat	Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States	https://ClinicalTrials.gov/show/NCT03217253
1423	A Study of ADH300004 and 5-Fluorouracil in Locally Advanced, Recurrent, or Metastatic Hepatocellular Carcinoma	Terminated	No Results Available	Hepatocellular Carcinoma	Drug: ADH300004	Queens Medical Center, Honolulu, Hawaii, United States|Johns Hopkins Singapore International Medical Center, Singapore, Singapore|Chang Gung Memorial Hospital, Chiayi, Taiwan|Chung-Ho Memorial Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan|National Health Research Institute, Ward Veterans General Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT00319683
1424	A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification	Recruiting	No Results Available	C-staged Hepatocellular Carcinoma in BCLC Classification	Combination Product: Hepatic Arterial Infusion combined with Apatinib and Camrelizumab	Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT04191889
1425	Contrast (Sonazoid)-Enhanced US as a Screening Tool for Hepatocellular Carcinoma in Cirrhosis: An Exploratory Cross-sectional Study	Completed	No Results Available	Hepatocellular Carcinoma (HCC)	Other: Sonazoid-enhanced ultrasonography	Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT02188901
1426	An Individualized Anti-Cancer Vaccine in Advanced Hepatocellular Carcinoma Subjects	Completed	No Results Available	Advanced Adult Hepatocellular Carcinoma	Biological: AlloVax|Biological: AlloStim|Biological: CRCL	National Cancer Institute of Thailand Address: 268/1 Rama Rd. Ratchathewi, Bangkok, Thailand	https://ClinicalTrials.gov/show/NCT02409524
1427	Surufatinib Alone or Combined With Anti-PD-1 mAb in the Treatment of Advanced Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma; Targeted Therapy; Progression-free Survival	Drug: Surufatinib	Zhongnan Hopital of Wuhan University, Wuhan, Hubei, China	https://ClinicalTrials.gov/show/NCT05282433
1428	Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery	Completed	Has Results	Adult Primary Hepatocellular Carcinoma|Advanced Adult Primary Liver Cancer|Localized Unresectable Adult Primary Liver Cancer|Recurrent Adult Primary Liver Cancer|Recurrent Extrahepatic Bile Duct Cancer|Recurrent Gallbladder Cancer|Unresectable Extrahepatic Bile Duct Cancer|Unresectable Gallbladder Cancer	Drug: lapatinib ditosylate|Other: laboratory biomarker analysis	UC Davis Comprehensive Cancer Center, Sacramento, California, United States	https://ClinicalTrials.gov/show/NCT00101036
1429	Phase I/II Study of Z-208 in Advanced Hepatocellular Carcinoma (HCC)	Completed	No Results Available	Advanced Hepatocellular Carcinoma	Drug: Z-208	The University of Tokyo Hospital, Tokyo, Japan	https://ClinicalTrials.gov/show/NCT00731445
1430	A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC)	Terminated	Has Results	Hepatocellular Carcinoma (HCC)	Biological: Pexastimogene Devacirepvec (Pexa Vec)|Drug: Nivolumab	Site No 0102, Nancy, France|Site No 0101, Paris, France	https://ClinicalTrials.gov/show/NCT03071094
1431	Clinical Research of Licartin Combined With TACE in the Treatment of Unresectable Hepatocellular Carcinoma	Completed	No Results Available	Unresectable Hepatocellular Carcinoma	Drug: Licartin|Procedure: Transcatheter arterial chemoembolization		https://ClinicalTrials.gov/show/NCT00829465
1432	CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma	Active, not recruiting	No Results Available	Hepatocellular Carcinoma|Advanced Cancer	Drug: Sorafenib|Drug: CVM-1118	Charleston Hematology Oncology Associates, Charleston, South Carolina, United States|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT03582618
1433	Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)	Completed	No Results Available	Advanced Hepatocellular Carcinoma	Drug: ABT-869	Site Reference ID/Investigator# 7726, Philadelphia, Pennsylvania, United States|Site Reference ID/Investigator# 7169, Toronto, Canada|Site Reference ID/Investigator# 5837, Vancouver, Canada|Site Reference ID/Investigator# 5235, Singapore, Singapore|Site Reference ID/Investigator# 5611, Singapore, Singapore|Site Reference ID/Investigator# 6265, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT00517920
1434	Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma	Completed	Has Results	Advanced Adult Hepatocellular Carcinoma	Drug: Dalantercept plus sorafenib	The University of Chicago Medical Center, Chicago, Illinois, United States|University of Kansas Medical Center (KUMC), Westwood, Kansas, United States|Beth Israel Deaconess Medical Center (BIDMC), Boston, Massachusetts, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|University of Cincinnati Cancer Institute, Cincinnati, Ohio, United States	https://ClinicalTrials.gov/show/NCT02024087
1435	A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)	Enrolling by invitation	No Results Available	Advanced Hepatocellular Carcinoma (HCC)	Drug: camrelizumab；Rivoceranib|Drug: Rivoceranib|Drug: Sorafenib|Drug: Regorafenib	Chinese PLA General Hospital, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT04985136
1436	First Line Hepato Cellular Carcinoma (HCC)	Completed	No Results Available	Hepato Cellular Carcinoma (HCC)	Drug: Brivanib|Drug: Placebo|Drug: Sorafenib	Mayo Clinic Arizona, Scottsdale, Arizona, United States|Univ Of Ark For Med Sci, Little Rock, Arkansas, United States|Agajanian Institute Of Hematology And Oncology, Downey, California, United States|Sharp Clinical Oncology Research, San Diego, California, United States|Va Ct Healthcare System, West Haven, Connecticut, United States|Medical Specialists Of Palm Beaches, Lake Worth, Florida, United States|James Graham Brown Cancer Center, Louisville, Kentucky, United States|3912 Taubman Center, Ann Arbor, Michigan, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Thomas Jefferson Univ., Philadelphia, Pennsylvania, United States|Mcguire Dvamc, Richmond, Virginia, United States|University Of Wisconsin, Madison, Wisconsin, United States|Local Institution, Caba, Buenos Aires, Argentina|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Rosario, Santa Fe, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Camperdown, New South Wales, Australia|Local Institution, Concord, New South Wales, Australia|Local Institution, Westmead Nsw, New South Wales, Australia|Local Institution, Parkville, Victoria, Australia|Local Institution, Prahan, Victoria, Australia|Local Institution, Liege, Belgium|Local Institution, Salvador - Ba, Bahia, Brazil|Local Institution, Salvador, Bahia, Brazil|Local Institution, Fortaleza, Ceara, Brazil|Local Institution, Goiania, Goias, Brazil|Local Institution, Divinopolis, Minas Gerais, Brazil|Local Institution, Curitiba, Parana, Brazil|Local Institution, Porto Alegre, Rio Grande do Sul, Brazil|Local Institution, Porto Alegre, Rio Grande Do Sul, Brazil|Local Institution, Porto Alegre, Rio Grande Do Sul, Brazil|Local Institution, Barretos, Sao Paulo, Brazil|Local Institution, Jau, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Calgary, Alberta, Canada|Local Institution, Vancouver, British Columbia, Canada|Local Institution, London, Ontario, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Chongqing, Chongqing, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Guanzhou, Guangdong, China|Local Institution, Nanning, Guangxi, China|Local Institution, Wuhan, Hubei, China|Local Institution, Changsha, Hunan, China|Local Institution, Changzhou, Jiangsu, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Suzhou, Jiangsu, China|Local Institution, Dalian, Liaoning, China|Local Institution, Xi An, Shaanxi, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Chengdu, Sichuan, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Brno, Czech Republic|Local Institution, Prague 5, Czech Republic|Local Institution, Praha 2, Czech Republic|Local Institution, Bordeaux, France|Local Institution, Clichy Cedex, France|Local Institution, Creteil Cedex, France|Local Institution, Grenoble Cedex 09, France|Local Institution, Lille, France|Local Institution, Lyon Cedex 04, France|Local Institution, Marseille Cedex 05, France|Local Institution, Marseille Cedex 9, France|Local Institution, Paris, France|Local Institution, Paris, France|Local Institution, Paris, France|Local Institution, Rennes, France|Local Institution, Vandoeuvre Cedex, France|Local Institution, Berlin, Germany|Local Institution, Halle, Germany|Local Institution, Hamburg, Germany|Local Institution, Magdeburg, Germany|Local Institution, Ulm, Germany|Local Institution, Hong Kong, Hong Kong|Local Institution, Shatin, Hong Kong|Local Institution, Hyderabad, Andhra Pradesh, India|Local Institution, Kochi, Kerala, India|Local Institution, Trivandrum, Kerala, India|Local Institution, Pune, Maharashtra, India|Local Institution, Ahmedabad, India|Local Institution, Chennai, India|Local Institution, Coimbatore, India|Local Institution, Hyderabad, India|Local Institution, Kolkata, India|Local Institution, Kolkata, India|Local Institution, Mumbai, India|Local Institution, Mumbai, India|Local Institution, New Delhi, India|Local Institution, Milano, Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Pisa, Italy|Local Institution, Roma, Italy|Local Institution, Torrette -Ancona, Italy|Local Institution, Kashiwa-shi, Chiba, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Kanazawa-Shi, Ishikawa, Japan|Local Institution, Kawasaki-shi, Kanagawa, Japan|Local Institution, Yokohama, Kanagawa, Japan|Local Institution, Tsu-shi, MIE, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Higashinari-ku, Osaka, Japan|Local Institution, Osaka-Sayama City, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Sunto-gun, Shizuoka, Japan|Local Institution, Chuo-Ku, Tokyo, Japan|Local Institution, Minato-ku, Tokyo, Japan|Local Institution, Musashino-shi, Tokyo, Japan|Local Institution, Shimonoseki-shi, Yamaguchi, Japan|Local Institution, Nishinomiya-shi, Japan|Local Institution, Busan, Korea, Republic of|Local Institution, Daegu, Korea, Republic of|Local Institution, Gyeonggi-do, Korea, Republic of|Local Institution, Kyunggi-do, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, D.f., Distrito Federal, Mexico|Local Institution, D.f., Distrito Federal, Mexico|Local Institution, Mexico City, Distrito Federal, Mexico|Local Institution, Tlalpan, Distrito Federal, Mexico|Local Institution, Monterrey, Nuevo Leon, Mexico|Local Institution, Aguascalientes, Mexico|Local Institution, Distrito Federal, Mexico|Local Institution, Gdansk, Poland|Local Institution, Gliwice, Poland|Local Institution, Krakow, Poland|Local Institution, Warszawa, Poland|Local Institution, San Juan, Puerto Rico|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Pretoria, Gauteng, South Africa|Local Institution, Durban, Kwa Zulu Natal, South Africa|Local Institution, Cape Town, Western Cape, South Africa|Local Institution, Observatory, Cape Town, Western Cape, South Africa|Local Institution, Rondebosch, Western Cape, South Africa|Local Institution, Santiago De Compostela, A Coruna, Spain|Local Institution, Alicante, Spain|Local Institution, Barcelona, Spain|Local Institution, Stockholm, Sweden|Local Institution, Uppsala, Sweden|Local Institution, Changhua, Taiwan|Local Institution, Kaohsiung, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Tainan R.O.C., Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taoyuan, Taiwan|Local Institution, Bangkok, Thailand|Local Institution, Bangkok, Thailand|Local Institution, Ankara, Turkey|Local Institution, Antalya, Turkey|Local Institution, Istanbul, Turkey|Local Institution, Izmir, Turkey|Local Institution, Kayseri, Turkey|Local Institution, Bristol, Avon, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Birmingham, West Midlands, United Kingdom|Local Institution, Leeds, Yorkshire, United Kingdom	https://ClinicalTrials.gov/show/NCT00858871
1437	A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)	Not yet recruiting	No Results Available	Advanced Hepatocellular Carcinoma (HCC)	Drug: AK105 Injection|Drug: Anlotinib Hydrochloride Capsules|Drug: Sorafenib Tosylate Tablets	The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China|Anhui Provincial Hospital, Hefei, Anhui, China|Anhui Provincial Cancer Hospital, Hefei, Anhui, China|Beijing Ditan Hospital.Capital Medical University, Beijing, Beijing, China|Beijing YouAn Hospital.Capital Medical University, Beijing, Beijing, China|Beijing Cancer Hospital, Beijing, Beijing, China|Peking Union Medical College Hospital, Beijing, Beijing, China|Chinese Pla General Hospital, Beijing, Beijing, China|Beijing Tsinghua Changgung Hospital, Beijing, Beijing, China|Beijing Luhe Hospital.Capital Medical University, Beijing, Beijing, China|The Second Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China|The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China|Fujian Provincial Cancer Hospital, Fuzhou, Fujian, China|The first hospital of Lanzhou University, Lanzhou, Gansu, China|Gansu Wuwei Tumour Hospital, Wuwei, Gansu, China|Sun Yat-sen University Cancar Center, Guangzhou, Guangdong, China|Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China|The First Affiliated Hospital，Sun Yat-sen University, Guangzhou, Guangdong, China|Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China|The First Affiliated Hospital，Sun Yat-sen University, Guangzhou, Guangdong, China|Guangxi Medical University Affiliated Tumor Hospital, Nanning, Guangxi Zhuang Autonomous Region, China|The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China|Hainan General Hospital, Haikou, Hainan, China|Cangzhou Central Hospital, Cangzhou, Hebei, China|The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, China|Affiliated Tumor Hospital of Harbin Medical University, Harbin, Heilongjiang, China|Henan Province People's Hospital, Zhengzhou, Henan, China|Henan Cancer Hospital, Zhengzhou, Henan, China|Xiangya Hospital Central South University, Changsha, Hunan, China|Hunan Cancar Hospital, Changsha, Hunan, China|Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China|Zhongshan Hospital, Fuadn University, Shanghai, Shanghai, China|The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, China|Tangdu Hospital of the Fourth Military Medical University of the People's Liberation Army of China, Xi'an, Shanxi, China|First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, China|Shanxi Provincial Cancer Hospital, Xi'an, Shanxi, China|West China School of Medical Sichuan University, Chengdu, Sichuan, China|Affiliated Hospital of Chengdu University, Chengdu, Sichuan, China|Tianjin Medical University Cancar institute & Hospital, Tianjin, Tianjin, China|Tianjin Third Central Hospital, Tianjin, Tianjin, China|Tianjin First Central Hospital, Tianjin, Tianjin, China|Tianjin Second People's Hospital, Tianjin, Tianjin, China|The First Affiliated Hospital of Xinjiang Medical University, Ürümqi, Xinjiang Uygur Autonomous Region, China	https://ClinicalTrials.gov/show/NCT04344158
1438	Trans-catheter Chemo-embolization Combined With rAd-p53 Gene Injection in Treatment of Advanced Hepatocellular Carcinoma	Unknown status	No Results Available	Advanced Adult Hepatocellular Carcinoma	Drug: TACE plus rAd-p53 artery injection|Drug: TACE	Xijing Hospital of the Fourth Military Medical University, Xi An, Shanxi, China	https://ClinicalTrials.gov/show/NCT02418988
1439	A Single-arm, Open-label, Multi-center Phase II Clinical Study to Evaluate the Safety and Efficacy of Toripalimab Injection (JS001) Combined With Bevacizumab as the First-line Therapy for Advanced Hepatocellular Carcinoma (HCC)	Active, not recruiting	No Results Available	Advanced Hepatocellular Carcinoma (HCC)	Combination Product: Toripalimab combined with Bevacizumab	Beijing Cancer hospital, Beijing, China	https://ClinicalTrials.gov/show/NCT04605796
1440	Safety and Efficacy of GSMs-TACE Combined With Surgical Resection in Treatment of Huge Hepatocellular Carcinoma (HCC) (≥10cm)	Recruiting	No Results Available	Huge Hepatocellular Carcinoma (HCC) (≥10cm)	Device: GSMs-TACE|Procedure: Surgical Resection	Beijing Tsinghua Changgung Hospital, Beijing, China	https://ClinicalTrials.gov/show/NCT04619329
1441	Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Advanced Hepatocellular Carcinoma (HCC)	Completed	No Results Available	ADVANCED HEPATOCELLULAR CARCINOMA (HCC)	Drug: Galunisertib 150mg by mouth twice a day|Radiation: Stereotactic Body Radiotherapy (SBRT)	Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States	https://ClinicalTrials.gov/show/NCT02906397
1442	Tislelizumab Combined With IMRT Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT	Not yet recruiting	No Results Available	Hepatocellular Carcinoma With Portal Vein Tumor Thrombus	Drug: Tislelizumab|Radiation: IMRT	Zhongshan hospital, Fudan University, Shanghai, China	https://ClinicalTrials.gov/show/NCT04850157
1443	HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer	Terminated	Has Results	Hepatocellular Carcinoma	Device: HepaSphere/QuadraSphere Microspheres|Procedure: PVA, lipiodol, doxorubicin	University of Alabama at Birmingham, Birmingham, Alabama, United States|Tuscon Medical Center, Tucson, Arizona, United States|Greater Arkansas Veterans Healthcare, Little Rock, Arkansas, United States|VA Greater Los Angeles Healthcare System, Los Angeles, California, United States|UCLA, Los Angeles, California, United States|Palo Alto Veterans Institute for Research, Palo Alto, California, United States|Stanford University, Stanford, California, United States|Georgetown University Hospital, Washington, District of Columbia, United States|Tampa General Hospital, Tampa, Florida, United States|Northwestern University, Chicago, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Albany Medical Center, Albany, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Albert Einstein Healthcare, Philadelphia, Pennsylvania, United States|VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States|MUSC Medical Center (Medical University of South Carolina), Charleston, South Carolina, United States|UT Health and Science Center, San Antonio, Texas, United States|University Hospitals K.U. Leuven (Dept of Hematology), Leuven, Belgium|Hospital Saint Andre, Bordeaux, France|Hospital Paul Brousse, Villejuif cedex, France|Evgenidion University Hospital, Athens, Greece|S. Croce e Carle Hospital, Cuneo, Italy	https://ClinicalTrials.gov/show/NCT01387932
1444	European Paediatric Non-Alcoholic Fatty Liver Disease Registry (EU-PNAFLD)	Recruiting	No Results Available	Non-Alcoholic Fatty Liver Disease|Non-alcoholic Fatty Liver|Non-alcoholic Steatohepatitis		Maastricht UMC, Maastricht, Netherlands|Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom|Birmingham Children's Hospital, Birmingham, United Kingdom	https://ClinicalTrials.gov/show/NCT04190849
1445	Safety Study of ARQ 197 in Cirrhotic Patients With Hepatocellular Carcinoma (HCC)	Completed	No Results Available	Cirrhosis|Hepatocellular Carcinoma	Drug: ARQ 197	Dallas, Texas, United States|Houston, Texas, United States|Bologna, Italy|Milano, Italy|Barcelona, Spain	https://ClinicalTrials.gov/show/NCT00802555
1446	Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular Carcinoma	Active, not recruiting	No Results Available	Advanced Hepatocellular Carcinoma	Drug: Lenvatinib|Drug: Nivolumab	Hannover Medical School, Hannover, Germany	https://ClinicalTrials.gov/show/NCT03841201
1447	Phase I/II Study of Amplitude-Modulated Electromagnetic Fields in the Treatment of Advanced Hepatocellular Carcinoma	Completed	No Results Available	Advanced Hepatocellular Carcinoma	Device: TheraBionic device	Disciplina de Transplante e Cirurgia do Fígado, São Paulo, Brazil	https://ClinicalTrials.gov/show/NCT00534664
1448	Phase 1b of ASLAN001 (Varlitinib) in Patients With Advanced/ Metastatic Hepatocellular Carcinoma (HCC)	Unknown status	No Results Available	Advanced/ Metastatic Hepatocellular Carcinoma	Drug: ASLAN001	National University Hospital, Singapore, Singapore	https://ClinicalTrials.gov/show/NCT03499626
1449	Trans-catheter Arterial Embolization Combined With p53 Gene Therapy for Treatment of Advanced Hepatocellular Carcinoma	Unknown status	No Results Available	Advanced Hepatocellular Carcinoma (HCC)	Drug: TAE plus P53 gene|Other: TAE	first affiliated hospital in Dalian University, Dalian, Liaoning, China	https://ClinicalTrials.gov/show/NCT02509169
1450	Phase 2 Study of TAC-101 Combined With Transcatheter Arterial Chemoembolization (TACE) Versus TACE Alone in Japanese Patients With Advanced Hepatocellular Carcinoma	Terminated	Has Results	Advanced Hepatocellular Carcinoma	Drug: TAC-101|Drug: Placebo	Aichi Cancer Center Hospital, Nagoya, Aichi, Japan|National hospital organization Shikoku Cancer Center, Matsuyama, Ehime, Japan|Fukuoka University Hospital, Jonan-ku, Fukuoka, Japan|Kurume University Hospital, Kurume, Fukuoka, Japan|Ogaki Municipal Hospital, Oogaki, Gifu, Japan|Fukuyama City Hospital, Fukuyama, Hiroshima, Japan|Asahikawa-Kosei General Hospital, Asahikawa, Hokkaido, Japan|Hokkaido University Hospital, Sapporo, Hokkaido, Japan|The Hospital of Hyogo College of Medicine, Hishinomiya, Hyogo, Japan|Kanazawa University Hospital, Kanazawa, Ishikawa, Japan|Iwate Medical University Hospital, Morioka, Iwate, Japan|Yokohama City University Medical Center, Yokohama, Kanagawa, Japan|Mie University Hospital, Tsu, Mie, Japan|Nara Medical University Hospital, Kashihara, Nara, Japan|Okayama University Hospital, Shikata-cho, Okayama, Japan|Osaka City University Hospital, Abeno-ku, Osaka, Japan|Osaka medical Center for Cancer and Cardiovascular Diseases, Higashinari-ku, Osaka, Japan|Osaka City General Hospital, Miyakojima-ku, Osaka, Japan|Kansai Medical Univesity Takii Hospital, Moriguchi, Osaka, Japan|Kinki University Hospital, Osaka-sayama, Osaka, Japan|Osaka Red Cross Hospital, Tennoji-ku, Osaka, Japan|Shizuoka Cancer Center Hospital, Sunto-gun, Shizuoka, Japan|The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan|Tochigi Cancer Center, Chiyoda-ku, Tokyo, Japan|Kyoundo Hospital, Chiyoda, Tokyo, Japan|National Cancer Center Hospital, Chuo-ku, Tokyo, Japan|Wakayama Medical University Hospital, Kimidera, Wakayama, Japan|Kochi Health Science Center, Kochi, Japan|Kumamoto University Hospital, Kumamoto, Japan	https://ClinicalTrials.gov/show/NCT00667628
1451	Long-term Outcomes of Chronic Hepatitis C Patients Post Sofosbuvir-based Treatment	Recruiting	No Results Available	Liver Fibroses|HepatoCellular Carcinoma|Cryoglobulinemia|Metabolic Disease|Diabetes Mellitus	Other: Observation only	Korea University Ansan Hospital, Ansan, Korea, Republic of|Asan Medical Center, Asan, Korea, Republic of|Soon Chun Hyang University Hospital Bucheon., Bucheon, Korea, Republic of|Dong-A University Hospital, Busan, Korea, Republic of|Inje University Busan Paik Hospital, Busan, Korea, Republic of|Kyungpook National University Hospital, Daegu, Korea, Republic of|Gachon University Gil Hospital, Incheon, Korea, Republic of|Pusan National University Hospital, Pusan, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Bundang Hosptial, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Seoul St. Mary's Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Changhua Christian Hospital, Changhua, Taiwan|Kaoshiung Medical University Hospital, Kaohsiung City, Taiwan|Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan|Keelung Chang Gung Memorial Hospital, Keelung, Taiwan|China Medical University, Taichung, Taiwan|Chi Mei Liouying Hospital, Tainan, Taiwan|MacKay Memorial Hospital, Taipei, Taiwan|National Cheng Kung University Hospital, Taipei, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan	https://ClinicalTrials.gov/show/NCT03042520
1452	Effect of Babaodan on Tumor Recurrence After Curative Resection of Hepatocellular Carcinoma	Not yet recruiting	No Results Available	Hepatocellular Carcinoma|Tumor Recurrence	Drug: Babaodan oral capsule|Drug: Placebo oral capsule		https://ClinicalTrials.gov/show/NCT03515369
1453	Noninvasive Surrogate Marker for Advanced Hepatocellular Carcinoma Response to Concurrent Chemoradiotherapy: MR Perfusion, Contrast Enhanced Ultrasound and Biomarkers	Unknown status	No Results Available	Advanced Adult Hepatocellular Carcinoma	Radiation: DCE MRI	Severance Hospital, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT01336452
1454	The Mechanism of Sox4 Transcription in Regulation of Angiogenesis in Hepatocellular Carcinoma	Completed	No Results Available	Translational Research of SOX4 in Hepatocellular Carcinoma	Other: microvessel density		https://ClinicalTrials.gov/show/NCT04296058
1455	Safety and Efficacy of Photodynamic Therapy for Bile Duct Invasion of Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma|Obstructive Jaundice	Drug: Photofrin	Samsung Medical Center 81 Irwon-Ro Gangnamgu, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT01506115
1456	Safety and Efficacy of GSMs-TACE Combined With Surgical Resection in the Treatment of Hepatocellular Carcinoma (HCC) With Type III Portal Vein Tumor Thrombus (PVTT)	Recruiting	No Results Available	Hepatocellular Carcinoma (HCC) With Type III Portal Vein Tumor Thrombus (PVTT)	Device: GSMs-TACE|Procedure: Surgical Resection	Beijing Changgung Hospital, Beijing, China	https://ClinicalTrials.gov/show/NCT04619342
1457	The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma Subjects	Recruiting	No Results Available	Advanced HBV-Related Hepatocellular Carcinoma (HCC)	Drug: Icaritin|Drug: HUACHANSU PIAN	Anhui Provincial Hospital, Hefei, Anhui, China|The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China|Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China|Beijing Hospital, Beijing, Beijing, China|General Hospital of Chinese Armed Police Forces, Beijing, Beijing, China|Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Beijing, Beijing, China|Peking University Cancer Hospital, Beijing, Beijing, China|Chongqing Traditional Chinese Medicine Hospital, Chongqing, Chongqing, China|The First People's Hospital of Foshan, Foshan, Guangdong, China|Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, China|Guangxi Medical University Affiliated Tumor Hospital, Nanning, Guangxi, China|Haikou People's Hospital, Haikou, Hainan, China|The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China|The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China|The Third Xiangya Hospital of Central South University, Changsha, Hunan, China|Eastern Theater General Hospital,QinHuai District Medical Area, Nanjing, Jiangsu, China|The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China|The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu, China|First Hospital of Jilin University, Changchun, Jilin, China|The Sixth People's Hospital in Shenyang, Shenyang, Liaoning, China|Chifeng Municipal Hospital, Chifeng, Neimenggu, China|Jinan Central Hospital, Jinan, Shandong, China|Linyi Cancer Hospital, Linyi, Shandong, China|Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China|West China Hospital of Sichuan University, Chengdu, Sichuan, China|Yunnan Provincial Hospital of Traditional Chinese Medicine, Kunming, Yunnan, China|The Affiliated Hospital of Hangzhou Normal University, Hangzhou, Zhejiang, China|Nanfang Hospital of Southern Medical University, Guangzhou, China	https://ClinicalTrials.gov/show/NCT03236636
1458	A Clinical Study of GP73 as a Hepatocellular Carcinoma (HCC) Tumor Mark	Unknown status	No Results Available	Hepatocellular Carcinoma		The University of Chicago, Chicago, Illinois, United States	https://ClinicalTrials.gov/show/NCT00902902
1459	A Study of LY2157299 in Participants With Unresectable Hepatocellular Cancer (HCC)	Completed	No Results Available	Hepatocellular Carcinoma	Drug: LY2157299|Drug: Sorafenib	For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chiba, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kanagawa, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Suita-shi, Japan	https://ClinicalTrials.gov/show/NCT02240433
1460	Hepatocellular Carcinoma Surveillance in Cirrhotics	Active, not recruiting	No Results Available	Hepatocellular Carcinoma|Cirrhosis	Behavioral: Usual care|Behavioral: Opt-out|Behavioral: Opt-out + Incentive	University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States	https://ClinicalTrials.gov/show/NCT04248816
1461	A Study on Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Patients With Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma	Unknown status	No Results Available	Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma	Drug: TQB2450 injection|Drug: Anlotinib	Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT03825705
1462	Chemoembolization of Non-resectable Non-metastatic Hepatocellular Carcinoma Using Embolization Microspheres	Completed	No Results Available	Localized Non-Resectable Adult Hepatocellular Carcinoma	Biological: blood samples (5 ml) will be taken|Radiation: Chemoembolization	CHU de DIJON, Dijon, France	https://ClinicalTrials.gov/show/NCT02870010
1463	Randomized Control Trial (RCT) of Early Palliative Care for HCC	Recruiting	No Results Available	Carcinoma, Hepatocellular	Behavioral: Early Palliative Care/Symptom Control	Lyndon Baines Johnson (LBJ) General Hospital, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT02556619
1464	Sorafenib Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection	Terminated	No Results Available	Hepatocellular Carcinoma|Recurrence	Drug: Sorafenib	Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT02867280
1465	The Efficacy of 5-fluorouracil/Mitomycin for the Patients With Pulmonary Metastasis of Hepatocellular Carcinoma	Withdrawn	No Results Available	Hepatocellular Carcinoma|Lung Metastasis	Drug: 5-fluorouracil|Drug: Mitomycin	Seoul National University Hospital, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT01953406
1466	SynOV1.1 Intratumoral Injection Study	Not yet recruiting	No Results Available	Hepatocellular Carcinoma	Biological: SynOV1.1|Drug: Atezolizumab		https://ClinicalTrials.gov/show/NCT04612504
1467	Stereotactic Ablative Radiotherapy for Hepatocellular Carcinoma With Major Portal Vein Invasion	Completed	No Results Available	Hepatocellular Carcinoma|Portal Vein Tumor Thrombus	Radiation: Stereotactic ablative radiotherapy	Gyeongsang National University Hospital, Jinju, Gyeongsang-nam-do, Korea, Republic of|Dongnam Institute of Radiological & Medical Sciences, Busan, Korea, Republic of|Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of|Catholic University Incheon St. Mary's Hospital, Incheon, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Korea, Republic of|Soon Chun Hyang University Hospital Seoul, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT01850368
1468	Comprehensive Treatment for Different Types of Tumor Thrombi in the Portal Vein for Hepatocellular Carcinoma Patients	Completed	No Results Available	Hepatocellular Carcinoma|Portal Vein Tumor Thrombus	Drug: chemotherapy with endostar|Drug: treatment with CBP and 5-FU|Drug: treatment with endostar, CBP and 5-FU	Eastern hepatobilliary surgery hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT00849264
1469	Effect of Intraoperative Controlled Release 5-Fluorouracil Therapy on Recurrence in Hepatocellular Carcinoma Patients	Unknown status	No Results Available	Hepatocellular Carcinoma|Recurrence	Procedure: Hepatectomy|Drug: 5-Fluorouracil	Eastern hepatobilliary surgery hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT02523053
1470	Hepatic IA Therapy in Stage B or Limited Stage C Hepatoma (HCC)	Recruiting	No Results Available	Hepatocellular Carcinoma (HCC)	Biological: IA therapy of HCC with CSR02-Fab-TF	Washington University School of Medicine, Mallinckrodt Institute of Radiology, Saint Louis, Missouri, United States|UT Southwestern Medical Center, Dallas, Texas, United States|University of Washington, Seattle, Washington, United States|National Cheng Kung University Hospital (NCKUH), Tainan City, North Dist., Taiwan|Koo Foundation Sun Yat-Sen Cancer Center (KFSYSCC), Taipei, Pei-Tou Dist., Taiwan|National Taiwan University Hospital (NTUH), Taipei city, Zhongzheng Dist., Taiwan|KFSYSCC, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT04601428
1471	Transarterial RAdioembolization Versus ChemoEmbolization for the Treatment of Hepatocellular Carcinoma (HCC)	Suspended	No Results Available	Hepatocellular Carcinoma	Drug: TACE-DEB|Drug: 90Y-RE	University Hospital Ghent, Ghent, Belgium	https://ClinicalTrials.gov/show/NCT01381211
1472	By Using Adoptive Transfer of Autologous NK Cells to Prevent Recurrence of Hepatocellular Carcinoma After Curative Therapy	Unknown status	No Results Available	Hepatocellular Carcinoma	Biological: NK cells|Other: Curative therapy	Southwest Hospital of Third Millitary Medical University, Chongqing, Chongqing, China	https://ClinicalTrials.gov/show/NCT02725996
1473	Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma|HCC	Drug: Nivolumab|Drug: Ipilimumab|Drug: Cabozantinib|Procedure: Transarterial Chemoembolization	Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California, United States	https://ClinicalTrials.gov/show/NCT04472767
1474	Effects of TIVA Versus Inhalational Anaesthesia on Circulating Tumour Cells in Hepatocellular Carcinoma Patients	Recruiting	No Results Available	Circulating Tumor Cell|Hepatocellular Carcinoma	Drug: Propofol|Drug: Sevoflurane	HKU Li Ka Shing Faculty of Medicine, Hong Kong, Guangdong, China	https://ClinicalTrials.gov/show/NCT04601961
1475	SBRT With DIBH for HCC After TACE and Lipiodol Marking	Recruiting	No Results Available	Hepatocellular Carcinoma	Procedure: Lipiodol marking	Bo Chen, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT05021250
1476	Albumin for Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma|Hypoproteinemia	Drug: Albumin infusion	Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi, China|Jian-Hong Zhong, Nanning, Guangxi, China	https://ClinicalTrials.gov/show/NCT03974074
1477	Non-selective Beta Blockers Versus EVL for Primary Prophylaxis of Esophageal Variceal Bleeding in Patients With Hepatocellular Carcinoma With Portal Vein Tumour Thrombosis.	Withdrawn	No Results Available	Hepatocellular Carcinoma With Portal Vein Thrombosis	Procedure: Endoscopic Variceal Ligation|Drug: Carvedilol	Institute of Liver and Biliary Sciences, New Delhi, Delhi, India	https://ClinicalTrials.gov/show/NCT01659346
1478	Lipotecan Based Concurrent Chemoradiotherapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis	Terminated	No Results Available	HepatoCellular Carcinoma|Portal Vein Tumor Thrombosis	Drug: Lipotecan	China Medical University Hospital, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Taiwan University Hosipital, Taipei, Taiwan|Taipei Veteran General Hospital, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT03035006
1479	Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment	Unknown status	No Results Available	Hepatocellular Carcinoma|Cirrhosis	Biological: Blood test	UH Montpellier, Montpellier, France	https://ClinicalTrials.gov/show/NCT01492127
1480	DEB-TACE for Hepatocellular Carcinoma	Terminated	No Results Available	Hepatocellular Carcinoma	Procedure: DEB-TACE	University of Alabama at Birmingham, Birmingham, Alabama, United States|University of Arizona, Phoenix, Arizona, United States|UCLA, Los Angeles, California, United States|USC, Los Angeles, California, United States|Radiology Imaging Associates, Denver, Colorado, United States|Georgetown University, Washington, District of Columbia, United States|University of Maryland, Baltimore, Maryland, United States|New York University, New York, New York, United States|Cleveland Clinical Foundation, Cleveland, Ohio, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|University of Utah, Salt Lake City, Utah, United States	https://ClinicalTrials.gov/show/NCT02748161
1481	Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial	Recruiting	No Results Available	Hepatocellular Carcinoma	Procedure: FOLFOX-HAIC|Drug: Camrelizumab|Drug: Apatinib	Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT05198609
1482	SBRT + Atezolizumab + Bevacizumab in Resectable HCC	Recruiting	No Results Available	Hepatocellular Carcinoma|Resectable Hepatocellular Carcinoma	Drug: Atezolizumab|Drug: Bevacizumab|Radiation: Stereotactic Beam Radiation Therapy (SBRT)	Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States	https://ClinicalTrials.gov/show/NCT04857684
1483	Nurse-led Decision Counseling on Hepatocellular Carcinoma Screening	Completed	No Results Available	Hepatitis B|Hepatocellular Carcinoma	Other: Nurse-led decision counseling|Other: Usual care	Henan Provincial People's Hospital, Zhengzhou, Henan, China|The Nethersole School of Nursing, The Chinese University of Hong Kong, Hong Kong, Hong Kong, China	https://ClinicalTrials.gov/show/NCT04659005
1484	Palliative Treatment of Hepatocellular Carcinoma in Patient With CHILD B Cirrhosis	Completed	No Results Available	Hepatocellular Carcinoma|CHILD B	Drug: sorafenib|Drug: Pravastatin|Drug: Sorafenib + Pravastatin|Other: patients receiving best supportive care	CH d'Abbeville, Abbeville, France|CH Pays d'Aix, Aix-en-provence, France|CH d'Auxerre, Auxerre, France|CH de la Côte Basque, Bayonne, France|AP-HP- Hôpital Jean-Verdier, Bondy, France|CHU de Bordeaux, Bordeaux, France|CH Duchenne, Boulogne Sur Mer, France|CH de Béziers, Béziers, France|AP-HP Hôpital Henri Mondor, Creteil, France|CHU Le Bocage, Dijon, France|CH Départemental Vendée, La Roche-sur-yon, France|CH Le Mans, Le Mans, France|CH de Bretagne Sud, Lorient, France|Hôpital privé Jean Mermoz, Lyon, France|AP-HM Hôpital de la Timone, Marseille, France|CH de Meaux, Meaux, France|CH Mont de Marsan, Mont-de-marsan, France|CHU de Nancy Hôpital Brabois, Nancy, France|CHU de Nantes Hôpital de l'Hotel Dieu, Nantes, France|CHU Nîmes, Nimes, France|CHR d'Orléans - Hôpital La Source, Orleans, France|Groupe Hospitalier Paris Saint Joseph, Paris, France|CH Perpignan, Perpignan, France|CHU de Bordeaux, Hôpital du Haut Lévèque, Pessac, France|CH de la Région d'Annecy, Pringy, France|Centre Eugène Marquis, Rennes, France|Clinique Mathilde, Rouen, France|Clinique Armoricaine de Radiologie, Saint Brieuc, France|CH Saint-Malo, Saint Malo, France|Centre René Gauducheau CLCC Nantes Atlantique, Saint-herblain, France|CH Gaston Ramon, Sens, France|Centre Régional de Lutte contre le Cancer Centre Paul Strauss, Strasbourg, France|Hôpitaux Universitaires de Strasbourg Hôpital civil, Strasbourg, France|Hôpitaux Universitaires de Strasbourg, Hôpital Hautepierre, Strasbourg, France|CHRU de Tours, Tours, France	https://ClinicalTrials.gov/show/NCT01357486
1485	A TheraSphere® Advanced Dosimetry Retrospective Global Study in HCC	Completed	No Results Available	Hepatocellular Carcinoma	Device: TheraSphere	Stanford University Medical Center, Stanford, California, United States|University of Florida College of Medicine, Gainesville, Florida, United States|Northwestern Memorial Hospital, Robert H Lurie Comprehensive Cancer Center, Chicago, Illinois, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|Washington University in St. Louis, School of Medicine, Saint Louis, Louisiana, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Centre Eugene Marquis, Rennes, France|Universitätsklinikum Essen, Essen, Germany|Foundation IRCCS Istituto Nazionale Tumori, Milan, Italy|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|King Faisal Hospital, Riyad, Saudi Arabia|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland|Istanbul university Istanbul medical school, Fatih, Turkey|Florence Nightingale, Şişli, Turkey	https://ClinicalTrials.gov/show/NCT03295006
1486	Mutational Landscape in Hepatocellular Carcinoma	Completed	No Results Available	HepatoCellular Carcinoma|Cirrhosis		INSERM, Paris, France	https://ClinicalTrials.gov/show/NCT03071458
1487	Liquid Biopsy in Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatic Carcinoma Malignant Primary Non-Resectable	Diagnostic Test: Cell Free DNA	Postgraduate Institute of Medical Education and Research, Chandigarh, Choose Any State/Province, India	https://ClinicalTrials.gov/show/NCT04111029
1488	24hr Imaging Of HCC After EOVIST	Withdrawn	No Results Available	Hepatocellular Carcinoma	Drug: Eovist	Massachusetts General Hospital, Boston, Massachusetts, United States	https://ClinicalTrials.gov/show/NCT01968629
1489	Efficacy of TACE With Endoscopic Therapy for Unresectable Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma|Esophagogastric Varices	Procedure: transarterial chemoembolization combined with endoscopic therapy	Qilu Hospital , Shandong University, Jinan, Shandong, China	https://ClinicalTrials.gov/show/NCT05017922
1490	BMS-247550 in Treating Patients With Liver or Gallbladder Cancer	Terminated	No Results Available	Adult Primary Cholangiocellular Carcinoma|Adult Primary Hepatocellular Carcinoma|Advanced Adult Primary Liver Cancer|Cholangiocarcinoma of the Extrahepatic Bile Duct|Cholangiocarcinoma of the Gallbladder|Localized Extrahepatic Bile Duct Cancer|Localized Gallbladder Cancer|Localized Resectable Adult Primary Liver Cancer|Localized Unresectable Adult Primary Liver Cancer|Recurrent Adult Primary Liver Cancer|Recurrent Extrahepatic Bile Duct Cancer|Recurrent Gallbladder Cancer|Unresectable Extrahepatic Bile Duct Cancer|Unresectable Gallbladder Cancer	Drug: ixabepilone|Other: laboratory biomarker analysis	University of Chicago, Chicago, Illinois, United States	https://ClinicalTrials.gov/show/NCT00023946
1491	GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma|HCC	Drug: Nivolumab|Drug: GT90001	City of Hope National Medical Center, Duarte, California, United States|Los Angeles Hematology Oncology Medical Group, Los Angeles, California, United States|NYU Langone Health, New York, New York, United States|Renovatio Clinical, Houston, Texas, United States|Medical Oncology Associates, Spokane, Washington, United States	https://ClinicalTrials.gov/show/NCT05178043
1492	TQB2450 Combined With Anlotinib Hydrochloride in the Perioperative Treatment of Hepatocellular Carcinoma Hydrochloride Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With a High Risk of Recurrence or Metastasis	Recruiting	No Results Available	Patients With Resectable Hepatocellular Carcinoma Who Are at High Risk of Recurrence or Metastasi	Drug: Anlotinib hydrochloride capsules＋ TQB2450 injection	Chinese Academy of Medical Sciences, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT04888546
1493	Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab Therapy	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Pembrolizumab|Drug: Lenvatinib Capsules	Charité-Universitätsmedizin Berlin, Berlin, Germany|Medizinische Hochschule Hannover, Hannover, Germany	https://ClinicalTrials.gov/show/NCT05101629
1494	Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma|Immunotherapy|Molecular Targeted Therapy	Drug: Camrelizumab|Drug: Apatinib Mesylate|Procedure: TACE treatment|Procedure: Radical surgery	180 Fenglin Road, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT04521153
1495	Atezolizumab+Bevacizumab+SBRT in Unresectable HCC	Not yet recruiting	No Results Available	Unresectable Hepatocellular Carcinoma	Drug: Atezolizumab|Drug: Bevacizumab|Radiation: Stereotactic body radiation therapy (SBRT)	Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States	https://ClinicalTrials.gov/show/NCT05096715
1496	Redirected HBV-Specific T Cells in Patients With HBV-related HCC (SAFE-T-HBV)	Not yet recruiting	No Results Available	Hepatocellular Carcinoma	Drug: mRNA HBV/TCR T-cells	Singapore General Hospital, Singapore, Singapore	https://ClinicalTrials.gov/show/NCT04745403
1497	A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation	Not yet recruiting	No Results Available	Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation	Drug: Camrelizumab、Rivoceranib|Drug: Camrelizumab		https://ClinicalTrials.gov/show/NCT05367687
1498	Radiomics of Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma		Key Laboratory of Molecular Imaging, Chinese Academy of Sciences, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT02757846
1499	Himalaya Early Access Program	Available	No Results Available	Unresectable Hepatocellular Carcinoma	Drug: Durvalumab|Drug: Tremelimumab		https://ClinicalTrials.gov/show/NCT05345678
1500	Decrease in Circulating Tumour Cell Count Reflects the Effectiveness of Postoperative Adjuvant Transarterial Chemoembolization (TACE) in Preventing Hepatocellular Carcinoma Recurrence	Completed	No Results Available	Circulating Tumor Cell;|Hepatocellular Carcinoma	Procedure: transarterial chemoembolization (TACE)	Department of Interventional Radiology; Cancer Center; Guangdong General Hospital, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT02032368
1501	Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma|Unresectable Hepatocellular Carcinoma|Metastatic Hepatocellular Carcinoma	Drug: Lenvatinib|Drug: Tislelizumab	Anhui Provincial Hospital, Hefei, Anhui, China|Peking Union Medical College Hospital, Beijing, Beijing, China|Nanfang Hospital, Guangzhou, Guangdong, China|Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China|Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China|Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China|The First Affiliated Hospital of Xi 'an Jiaotong University, Xi'an, Shanxi, China|West China Hospital ,Sichuan University, Chengdu, Sichuan, China|The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China|Sun Yat-sen University - Cancer Center (SYSUCC), Guangzhou, China	https://ClinicalTrials.gov/show/NCT04401800
1502	Chimeric Antigen Receptor T Cells Targeting Glypican-3	Completed	No Results Available	Hepatocellular Carcinoma	Biological: CAR-GPC3 T Cells	Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China|The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China|The 81st Hospital of Chinese PLA, Nanjing, Jiangsu, China|Renji Hospital Shang Hai Jiaotong Unversity of Medicine, Shanghai, Shanghai, China|Zhongshan Hospital of Fudan University, Shanghai, Shanghai, China|The First Affiliated Hospital Zhejiang University, Hangzhou, Zhejiang, China	https://ClinicalTrials.gov/show/NCT03884751
1503	A Single Center Real-world Study of Donafenib in the Treatment of Hepatocellular Carcinoma in Routine Clinical Practice	Recruiting	No Results Available	Donafenib|Hepatocellular Carcinoma		Zhongshan Hospital, Fudan University,, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT05200221
1504	A Study of Camrelizumab Combined Apatinib in Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors (ICIs).	Recruiting	No Results Available	Hepatocellular Carcinoma|Immune Checkpoint Inhibitors	Drug: Camrelizumab combined Apatinib regimen	Hunan Cancer Hospital, Changsha, Hunan, China	https://ClinicalTrials.gov/show/NCT04826406
1505	Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCC	Recruiting	No Results Available	Advanced Hepatocellular Carcinoma	Drug: Atezolizumab plus bevacizumab	Cha Medical Center, Seongnam-si, Gyeonggi-do, Korea, Republic of	https://ClinicalTrials.gov/show/NCT04862949
1506	TACE+RFA Versus TACE Alone for Intermediate-stage Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma|Chemoembolization, Therapeutic|Ablation Techniques, RFA	Procedure: TACE|Procedure: RFA	Minimally Invasive Interventional Division, Medical Imaging Center, Sun Yat-sen University Cancer Center,, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT02435953
1507	The Risk of Exacerbation of Chronic Hepatitis B After Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatitis B|Hepatocellular Carcinoma	Procedure: radiofrequency ablation	Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT00720668
1508	Impact of Hepatitis B Immunoglobulins in Patients With Chronic Hepatitis B on Hepatocellular Carcinoma - a Proof of Concept Study	Not yet recruiting	No Results Available	Hepatocellular Carcinoma|HBV	Drug: Hepatect CP 50 I.E./ml infusion solution		https://ClinicalTrials.gov/show/NCT05293158
1509	Cohort Study of Patients With Hepatocellular Carcinoma and Circulating Tumor DNA Monitoring of Chemoembolization	Recruiting	No Results Available	Circulating Tumor DNA|Hepatocellular Carcinoma Non-resectable|Transarterial Chemoembolization	Biological: DNA	CHU de Rouen, Rouen, France	https://ClinicalTrials.gov/show/NCT05390112
1510	VG161 in the Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma	Not yet recruiting	No Results Available	Hepatocellular Carcinoma|Intrahepatic Cholangiocarcinoma	Drug: VG161		https://ClinicalTrials.gov/show/NCT05223816
1511	Primary Prevention of Patients With Hepatocellular Carcinoma and Concomitant Esophageal Varices	Recruiting	No Results Available	Bleeding Esophageal Varices|Hepatocellular Carcinoma	Drug: Propranolol|Procedure: Esophageal variceal ligation	Taipei Veterans General Hospital, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT01970748
1512	Radiofrequency Ablation Using Octopus Electrodes for Small Hepatocellular Carcinoma With No-touch Technique	Completed	No Results Available	Hepatocellular Carcinoma|Radiofrequency Ablation	Procedure: RFA	Asan medical Center, Seoul, Korea, Republic of|Samsung medical center, Seoul, Korea, Republic of|KonKuk university hospital, Seoul, Korea, Republic of|Saint Mary Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT03375281
1513	Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery	Active, not recruiting	No Results Available	Liver Cancer	Biological: bevacizumab|Drug: dexamethasone|Drug: floxuridine|Genetic: protein expression analysis|Other: flow cytometry|Other: immunoenzyme technique|Other: immunohistochemistry staining method|Other: immunologic technique|Other: laboratory biomarker analysis|Procedure: dynamic contrast-enhanced magnetic resonance imaging	New York Weill Cornell Cancer Center at Cornell University, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States	https://ClinicalTrials.gov/show/NCT00410956
1514	The Effect of Mobile Health-based Exercise on Hepatocellular Carcinoma Patients With Insulin Resistance	Recruiting	No Results Available	Hepatocellular Carcinoma|Insulin Resistance	Behavioral: Mobile health	Moon Seok Choi, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT04649671
1515	PENS or TENS for Pain in Liver Cancer	Completed	No Results Available	Pain|Cancer Pain|Liver Neoplasms	Device: PENS|Device: TENS	Fuda Cancer Hospital, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT03338543
1516	Cryoablation Combined With Camrelizumab and Apatinib in Advanced Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Camrelizumab; Apatinib	Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT04724226
1517	Combination of Regorafenib and Nivolumab in Unresectable Hepatocellular Carcinoma	Recruiting	No Results Available	Carcinoma, Hepatocellular|Hepatoma	Drug: Regorafenib/Nivolumab	Bundang CHA Hospital, Seongnam, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT04310709
1518	Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma	Active, not recruiting	No Results Available	Gastric Cancer|Hepatocellular Carcinoma	Drug: Telatinib|Drug: Keytruda	Tower Hematology Oncology Medical Group, Beverly Hills, California, United States|The Angeles Clinic and Research Institute, Los Angeles, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|Torrance Memorial Physician Network Cancer Care Physicians, Torrance, California, United States	https://ClinicalTrials.gov/show/NCT04798781
1519	A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area	Completed	No Results Available	Carcinoma, Hepatocellular|Liver Cirrhosis, Alcoholic|Hepatitis, Alcoholic|Hepatitis, Chronic|Hepatitis, Viral, Human		University of Maryland Medical Center, Baltimore, Maryland, United States|Veterans Affairs Medical Center, Baltimore, Maryland, United States	https://ClinicalTrials.gov/show/NCT00913757
1520	Circulating Tumor Cell Capture for Early Diagnosis and Postoperative Tumor Recurrence Monitoring of Liver Cancer	Unknown status	No Results Available	Circulating Tumor Cell	Diagnostic Test: Circulating tumor cell capture technology	Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China	https://ClinicalTrials.gov/show/NCT04688606
1521	P1101 and Anti-PD1 for After Curative Surgery of Hepatitis B-related Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: P1101 (Ropeginterferon alfa-2b)|Drug: Nivolumab	National Taiwan university Hospital, Taipei city, Taiwan	https://ClinicalTrials.gov/show/NCT04233840
1522	Contribution of the Perfusion Scanner in the Prediction of the Tumor Control of Patients With Hepatocellular Carcinoma Treated With Sorafenib.	Completed	No Results Available	Hepatocellular Carcinoma|Perfusion Scanner	Other: Scannographic evaluation of the tumor response performed with mRECIST criteria after 3 months of treatment with sorafenib	CHU Amiens Picardie, Amiens, Picardie, France	https://ClinicalTrials.gov/show/NCT03140332
1523	Prospective Study to Evaluate Safety of Deb-TACE With 100µ Beads in Patients With Non Resectable HCC	Completed	Has Results	Hepatocellular Carcinoma	Device: DEB-TACE	Hospital Ramón y Cajal, Madrid, Spain	https://ClinicalTrials.gov/show/NCT02670122
1524	Genome Studies of Hepatocellular Carcinoma Developed in Hepatitis C Patients With Sustained Virological Response	Completed	No Results Available	Hepatocellular Carcinoma|Hepatitis C		Karolinska Institutet, Stockholm, Sweden	https://ClinicalTrials.gov/show/NCT03254121
1525	TACE Combined With Sintilimab Plus Bevacizumab Biosimilar in Hepatocellular Carcinoma (BCLC-C Stage ): a Prospective Single-arm Phase II Clinical Study	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Sintilimab; Bevacizumab Biosimilar	Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT04796025
1526	Palliative Treatments for Patients With Advanced Hepatocellular Carcinoma (HCC)	Completed	No Results Available	Hepatectomy|Hepatocellular Carcinoma|Sorafenib	Procedure: hepatic resection|Procedure: transcatheter hepatic arterial chemoembolization|Drug: sorafenib	Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT01409499
1527	A RCT of TNF and ENT in the Treatment of Long-term Prognosis With Hepatitis B-related HCC After Curative Resection	Recruiting	No Results Available	Hepatocellular Carcinoma Recurrent	Drug: Tenofovir disoproxil fumarate 300mg|Drug: Entecavir 0.5 mg	Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT04392700
1528	Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma|Face Cancer	Procedure: TACE-Sorafenib group|Procedure: TACE	Cancer Centre of Sun Yat-Sen University, Guangzhou, China	https://ClinicalTrials.gov/show/NCT01833299
1529	A Trial of Adjuvant Therapy After Hepatocarcinoma Resection Based on Folate Receptor-positive Circulating Tumor Cells	Not yet recruiting	No Results Available	Hepatocellular Carcinoma	Drug: FOLFOX4(infusional fluorouracil [FU], leucovorin [LV], and oxaliplatin [OXA]).	Eastern hepatobilliary surgery hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT04521491
1530	Recurrence Rate of Hepatocellular Carcinoma After Treatment of Chronic Hepatits C Patients With Direct Acting Antivirals: Randomized Controlled Phase 3 Trial	Unknown status	No Results Available	Hepatocellular Carcinoma|Hepatitis C, Chronic	Drug: Administration of DAA-based treatment	Ain Shams University, Cairo, Egypt	https://ClinicalTrials.gov/show/NCT03551444
1531	A Study of BBI503 in Advanced Solid Tumors, or BBI503/ Sorafenib in Advanced Hepatocellular Carcinoma	Completed	No Results Available	Advanced Solid Tumors|Hepatocellular Carcinoma	Drug: BBI503|Drug: Sorafenib	5 Sites, Chiba, Etc., Japan	https://ClinicalTrials.gov/show/NCT02354898
1532	A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellular Cancer	Completed	No Results Available	Advanced Hepatocellular Carcinoma|Inoperable Hepatocellular Carcinoma	Drug: AMG 386|Drug: Sorafenib		https://ClinicalTrials.gov/show/NCT00872014
1533	Phase II of Lenvatinib Plus Toripalimab for Advanced HCC	Withdrawn	No Results Available	Hepatocellular Carcinoma	Drug: Lenvatinib|Drug: Toripalimab	Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT03919383
1534	Phase II of Lenvatinib Plus PD-1 Antibody for Advanced HCC	Withdrawn	No Results Available	Hepatocellular Carcinoma	Drug: Lenvatinib|Drug: PD-1 antibody	Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT03746249
1535	Neoadjuvant Regorafenib Plus Durvalumab (MEDI4736) in Patients With High-risk Hepatocellular Carcinoma	Not yet recruiting	No Results Available	Stage IB Hepatocellular Carcinoma AJCC v8|Stage II Hepatocellular Carcinoma AJCC v8|Stage IIIA Hepatocellular Carcinoma AJCC v8	Biological: Durvalumab|Drug: Regorafenib	University of Florida Health Science Center - Gainesville, Gainesville, Florida, United States|Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States|Carle Cancer Center NCI Community Oncology Research Program, Urbana, Illinois, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States	https://ClinicalTrials.gov/show/NCT05194293
1536	Adjuvant Therapy With Thalidomide After Curative Resection of Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma|Recurrence	Drug: Thalidomide	First affiliated Hospital of Xiamen University, Xiamen, Fujian, China	https://ClinicalTrials.gov/show/NCT01924624
1537	Study of Tranexamic Acid for Reducing Blood Requirement in Patients Undergoing Major Gastro-intestinal Surgery	Unknown status	No Results Available	Gastric Cancer|Pancreatic Cancer|Hepatocellular Cancer|Colon Cancer	Drug: Tranexamic acid|Other: Standard of care	Tribhuvan University Teaching Hospital, Kathmandu, Kathmandy, Nepal	https://ClinicalTrials.gov/show/NCT01655641
1538	Genome-wide Association Study to Predict Treatment Response for Molecular Targeted Therapy in Hepatocellular Carcinoma and Renal Cell Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma|Renal Cell Carcinoma		Samsung Medical Center, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT01482520
1539	Drug-eluting Bead Transarterial Chemoembolisation (DEB-TACE) Versus (VS) Conventional Transarterial Chemoembolisation (cTACE) for Unresectable Hepatocellualr Carcinoma (HCC)	Not yet recruiting	No Results Available	Hepatocellular Carcinoma	Procedure: DEB-TACE|Procedure: cTACE	Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, Shaanxi, China	https://ClinicalTrials.gov/show/NCT03969576
1540	Safety and Efficacy of Doxorubicin-eluting-bead Embolization in Patients With Advanced Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma	Procedure: Device(DC Bead)	Seoul National University, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT02525380
1541	Transarterial Chemoembolization (TACE) With Radiation Therapy (RT) in Advanced Hepatocellular Carcinoma (HCC)	Unknown status	No Results Available	Hepatocellular Carcinoma|Portal Vein Tumor Thrombosis	Radiation: Scheduled interval TACE - RT	Samsung Medical Center, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT02290977
1542	TACE Plus PD-1 Antibody vs TACE Alone for Unresectable HCC	Withdrawn	No Results Available	Hepatocellular Carcinoma	Procedure: TACE|Drug: PD-1 antibody|Drug: Placebos	Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China|Guangzhou Twelfth People's Hospital, Guangzhou, Guangdong, China|Kaiping Central Hospital, Kaiping, Guangdong, China	https://ClinicalTrials.gov/show/NCT03782831
1543	Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCC	Withdrawn	No Results Available	Hepatocellular Carcinoma	Drug: Lenvatinib|Drug: PD-1 antibody|Drug: Placebo	Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China|The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China|Guangzhou Twelfth People 's Hospita, Guangzhou, Guangdong, China|Kaiping Central Hospital, Kaiping, Guangdong, China|First Affiliated Hospital of University Of South China, Hengyang, Hunan, China	https://ClinicalTrials.gov/show/NCT03744247
1544	GPC3-targeted CAR-T Cell for Treating GPC3 Positive Advanced HCC	Recruiting	No Results Available	Hepatocellular Carcinoma	Biological: CAR-T cell immunotherapy	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China	https://ClinicalTrials.gov/show/NCT04121273
1545	Early Screening of Hepatocellular Carcinoma in Cirrhotic Patients: a Prospective Study	Completed	No Results Available	Cirrhosis|Hepatocellular Carcinoma		Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan	https://ClinicalTrials.gov/show/NCT00629421
1546	Impact of Y90 Radiation Segmentectomy on HCC	Completed	No Results Available	Hepatocellular Carcinoma	Radiation: Radiation Segmentectomy	Icahn School of Medicine at Mount Sinai, New York, New York, United States	https://ClinicalTrials.gov/show/NCT03248375
1547	HAIC Combined With PD-1 Inhibitor in Potentially Resectable Locally Advanced HCC	Active, not recruiting	No Results Available	Hepatocellular Carcinoma	Combination Product: HAIC+PD1|Drug: HAIC	Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT03869034
1548	RFA vs. SBRT for Small HCC	Recruiting	No Results Available	Hepatocellular Carcinoma	Radiation: stereotactic body radiotherapy (SBRT)|Procedure: Radiofrequency ablation (RFA)	Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT03898921
1549	Safety and Efficacy of dRug-ElutiNg beADs Trans-arterial chemoEmbolization for Hepatocellular Carcinoma in Taiwan	Unknown status	No Results Available	Hepatocellular Carcinoma Non-resectable|Chemoembolization, Therapeutic	Device: Patient records	National Taiwan University Hospital, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT03283956
1550	Trial of Ablation of Small Hepatocellular Carcinomas in Patients of Cirrhosis	Unknown status	No Results Available	Hepatocellular Carcinoma	Procedure: PAI|Procedure: RFA	AIIMS, New Delhi, Delhi, India	https://ClinicalTrials.gov/show/NCT01438437
1551	Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma	Suspended	No Results Available	Hepatocellular Carcinoma|Intrahepatic Cholangiocarcinoma	Device: Delcath Hepatic Delivery System|Drug: Melphalan	Universitätsklinikum Frankfurt, Frankfurt, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitätsklinikum Jena, Jena, Germany	https://ClinicalTrials.gov/show/NCT02415036
1552	Capecitabine to Prevent Recurrence of Hepatocellular Carcinoma After Curative Resection	Unknown status	No Results Available	Hepatocellular Carcinoma|Neoplasm Metastasis	Drug: Capecitabine|Other: No other preventive treatment	Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT00561522
1553	RFA Versus SBRT for Recurrent Small HCC	Recruiting	No Results Available	Hepatocellular Carcinoma	Radiation: stereotactic body radiotherapy (SBRT)|Procedure: Radiofrequency ablation (RFA)	Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT04047173
1554	Effect of Colchicine for the Palliative Management of Hepatocellular Carcinoma	Completed	Has Results	Hepatocellular Carcinoma|Metastasis|Invasion	Drug: Colchicine	Kaohsiung Medical University Hospital, Kaohsiung, Taiwan	https://ClinicalTrials.gov/show/NCT01935700
1555	Efficacy and Safety of 'Immuncell-LC Group' and 'Non-treatment Group' in Nexavar Treated Patients for Advanced HCC	Completed	No Results Available	Advanced Hepatocellular Carcinoma	Drug: Immuncell-LC	Inha University Hospital, Incheon, Korea, Republic of|Yonsei University Health System, Seoul, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT01897610
1556	Prophylactic Antibiotics Before RFA for HCC	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: Cefazolin	Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT02534961
1557	Anti-CTLA-4 Human Monoclonal Antibody CP-675,206 in Patients With Advanced Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma|Hepatitis C Virus Chronic Infection	Biological: CP 675,206	Hospital Universitario Reina Sofía, Córdoba, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Clinica Universitaria de Navarra, Pamplona, Spain	https://ClinicalTrials.gov/show/NCT01008358
1558	The Effect of Telephone Counseling on the Compliance and Satisfaction for Advanced HCC Patients Receiving Sorafenib	Unknown status	No Results Available	Hepatocellular Carcinoma	Other: telephone counseling	Asan Medical Center, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT02564666
1559	Optimal Treatment on Hepatocellular Carcinoma (HCC) With Cirrhotic Portal Hypertension	Completed	No Results Available	Hepatocellular Carcinoma(HCC)|Cirrhotic Portal Hypertension	Procedure: Precise hepatectomy|Other: Combined intervention (chemoembolization/ablation)	Sun Yat-sen University Cancer Center, GuangZhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT01642446
1560	TACE Combined With Penpulimab and Anlotinib for Advanced HCC	Not yet recruiting	No Results Available	Hepatocellular Carcinoma	Drug: TACE+penpulimab+anlotinib vs. penpulimab+anlotinib		https://ClinicalTrials.gov/show/NCT05344924
1561	Camrelizumab in Combination With Apatinib Plus NK Cell for Advanced HCC	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Apatinib|Drug: Camrelizumab|Drug: NK cell	Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT05171309
1562	Pretreatment MRI Predicting Outcome After Radio-frequency Ablation of HCC	Unknown status	No Results Available	Hepatocellular Carcinoma	Other: RFA	University Hospitals UZ Leuven, Gasthuisberg, Leuven, Vlaams-Brabant, Belgium	https://ClinicalTrials.gov/show/NCT02051283
1563	Ablation Combined With PD-1 in HCC: Phase II Study	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: PD-1 monoclonal antibody|Procedure: Radiofequencey or microwave ablation	Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT04652440
1564	Identification of Specific Modulation Frequencies in Hepatitis B Carriers With and Without Hepatocellular Carcinoma	Completed	No Results Available	Hepatitis|Hepatocellular Carcinomas	Device: Low intensity amplitude-moduled electromagnetic fields	Hospital Sírio Libanês, São Paulo, Brazil	https://ClinicalTrials.gov/show/NCT01641276
1565	Adjuvant Therapy With Anlotinib for HCC	Withdrawn	No Results Available	Hepatocellular Carcinoma	Drug: Anlotinib Hydrochloride	Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT04947371
1566	A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer	Completed	No Results Available	Hepatocellular Carcinoma (HCC)	Drug: brivanib (active)	City Of Hope National Medical Center, Duarte, California, United States|Harbor-Ucla Medical Center, Los Angeles, California, United States|Christiana Care Health Services, Newark, Delaware, United States|University Of Miami Miller School Of Medicine, Miami, Florida, United States|Northwestern University Feinberg School Of Medicine, Chicago, Illinois, United States|University Of Chicago, Chicago, Illinois, United States|University Of Iowa Hospitals And Clinics, Iowa City, Iowa, United States|Wayne State University, Detroit, Michigan, United States|The Cancer Center At Hackensack University Medical Center, Hackensack, New Jersey, United States|Duke University Medical Center, Durham, North Carolina, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Albert Einstein Cancer Center, Philadelphia, Pennsylvania, United States|Univ Of Texas Southwestern, Dallas, Texas, United States|Md Anderson Cancer Center, Houston, Texas, United States|Medical College Of Wisconsin, Milwaukee, Wisconsin, United States|Local Institution, Marseille, France|Local Institution, Reims Cedex, France|Local Institution, Rennes, France|Local Institution, Villejuif, France|Local Institution, Shatin, Nt.,, Hong Kong|Local Institution, Gyeonggi-Do, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Nilai, Negeri Sembilan, Malaysia|Local Institution, Kuala Lumpur, Malaysia|Local Institution, Cebu City, Philippines|Local Institution, Davao City, Philippines|Local Institution, Quezon, Philippines|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Local Institution, Tainan, Taiwan|Local Institution, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT00355238
1567	Anti-PD-1/PD-L1 Antibodies Plus Pegylated Interferon Alfa-2b Treatment in Patients With Advanced-Stage HCC	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Anti-PD-1/PD-L1|Drug: PEG-Interferon Alfa	Zhongshan Hospital, Fudan University, Shanghai, China	https://ClinicalTrials.gov/show/NCT04943679
1568	Efficacy and Safety of TACE in Combination With ICIs for HCC: a Real-world Study	Recruiting	No Results Available	Hepatocellular Carcinoma	Other: TACE+ICIs|Procedure: TACE	Gao-Jun Teng, Nanjing, China	https://ClinicalTrials.gov/show/NCT04975932
1569	RFA for Treatment of Intermediate Stage HCC	Completed	No Results Available	Hepatocellular Carcinoma	Device: percutaneous radiofrequency ablation (RFA)	Interventional Ultrasonography Unit, Tropical Medicine Department, Beni-Suef University Hospitals, Banī Suwayf, Egypt	https://ClinicalTrials.gov/show/NCT05281783
1570	Tenofovir Antiviral Therapy Following Transarterial Chemoembolization for HBV Related Hepatocellular Carcinoma	Terminated	No Results Available	Chronic Hepatitis B|Hepatocellular Carcinoma	Drug: Tenofovir|Drug: Placebo	Chia-Yi Christine Hospital, Chia-Yi, Taiwan|E-Da Hospital, Kaohsiung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|Mackay Memorial Hosp, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT01872988
1571	Sorafenib Chemoembolization Evaluation Controlled Trial	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: Sorafenib|Procedure: TACE	Xijing Hospital of Digestive Disease, Xi'an, Shaanxi, China	https://ClinicalTrials.gov/show/NCT01906216
1572	Assessing the Prognosis of TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for HCC by Using Clinical and Imaging Biomarkers	Recruiting	No Results Available	Hepatocellular Carcinoma		Zhongda Hospital, Southeast University, Nanjing, Jiangsu, China	https://ClinicalTrials.gov/show/NCT05278195
1573	HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Advanced Unresectable HCC	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: HAIC|Drug: Sintilimab|Drug: Bevacizumab Biosimilar	Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China	https://ClinicalTrials.gov/show/NCT05029973
1574	Adjuvant Immunotherapy With Toripalimab Following Curative-intent Ablation for Recurrent Hepatocarcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Toripalimab|Procedure: Thermal ablation	Xiangya Hospital, Central South University, Changsha, Hunan, China	https://ClinicalTrials.gov/show/NCT05240404
1575	Body Composition Analysis in Patients Undergoing Chemoembolization	Completed	No Results Available	Hepatocellular Carcinoma		Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Mexico city, Mexico	https://ClinicalTrials.gov/show/NCT01777698
1576	Toripalimab Plus Stereotactic Body Radiotherapy for HCC With PVTT	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: Toripalimab|Radiation: Stereotactic body radiotherapy	Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT04169399
1577	Combination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma(HCC)	Active, not recruiting	No Results Available	Metastatic Hepatocellular Carcinoma|HCC|Combinations of Drugs; Dependence	Drug: GT90001 and Nivolumab	National Cheng Kung University Hospital, Tainan, Taiwan|MacKay Memorial Hospital, Taipei, Taiwan|National TaiWan University Hospital, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT03893695
1578	RCT on Adjuvant TACE After Hepatectomy for HCC	Completed	No Results Available	Hepatocellular Carcinoma	Procedure: Transarterial chemoembolisation using cisplatin-lipiodol mixture	Prince of Wales Hospital, Hong Kong, China	https://ClinicalTrials.gov/show/NCT01512407
1579	Study of Thymopentin in Patients After Curative Resection of Small Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: Thymopentin	Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT00460681
1580	Adjuvant IFN-α for Patients Underwent Curative Surgery for HCC With a Low miR-26 Expression	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: interferon-alpha (IFN-alpha)	The Mengchao hepatobiliary hospital，Fujian Medical University，and Liver disease research center of Fujian province, Fuzhou, Fujian, China|Zhongshan Hospital, Xiamen University, Xiamen, Fujian, China|Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China|ShanghaiBio Coorperation, Shanghai, Shanghai, China|Tumor Hospital, Tianjin Medical University, Tianjin, Tianjin, China	https://ClinicalTrials.gov/show/NCT01681446
1581	HAIC Plus Lenvatinib vs HAIC Plus Sorafenib for Advanced HCC	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: Lenvatinib|Drug: Sorafenib|Procedure: Hepatic arterial infusion chemotherapy	Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT03775395
1582	Etoposide, Oxaliplatin and Capecitabine in Advanced Hepatocellular Carcinoma (HCC)	Terminated	No Results Available	Hepatocellular Carcinoma	Drug: Etoposide|Drug: Oxaliplatin|Drug: Capecitabine	Århus Sygehus, Dept. of Oncology, Århus, Denmark	https://ClinicalTrials.gov/show/NCT00351195
1583	A Clinical Study in Patients With High-risk Recurrent Primary Hepatocellular Carcinoma Using Autologous TILs	Active, not recruiting	No Results Available	Hepatic Carcinoma	Drug: Tumor infiltrating lymphocyte	Eastern Hepatobiliary Surgery Hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT04538313
1584	Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria	Withdrawn	No Results Available	Hepatocellular Carcinoma	Drug: Lenvatinib|Drug: PD-1 antibody|Procedure: TACE|Drug: TACE Drug Protocol	Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China|Guangzhou Twelfth People 's Hospita, Guangzhou, Guangdong, China|Kaiping Central Hospital, Kaiping, Guangdong, China	https://ClinicalTrials.gov/show/NCT03791918
1585	HAIC Plus PD-1 Antibody vs HAIC Plus Sorafenib for Advanced HCC	Withdrawn	No Results Available	Hepatocellular Carcinoma	Procedure: HAIC|Drug: PD-1 antibody|Drug: Sorafenib	Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China|Guangzhou Twelfth People 's Hospital, Guangzhou, Guangdong, China|Kaiping Central Hospital, Kaiping, Guangdong, China	https://ClinicalTrials.gov/show/NCT03780634
1586	DEB-TACE+HAIC vs. HAIC for Large HCC	Recruiting	No Results Available	Unresectable Hepatocellular Carcinoma	Procedure: dTACE-HAIC|Procedure: HAIC|Drug: dTACE-HAIC protocol|Drug: HAIC protocol	the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT05263219
1587	Entecavir for Chronic Hepatitis B in Hepatocellular Carcinoma Patients Underwent Radiofrequency Ablation Therapy	Unknown status	No Results Available	Chronic Hepatitis B|Hepatocellular Carcinoma	Drug: Entecavir	Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT01270178
1588	Arabinoxylan Rice Bran (MGN-3/Biobran) for the Treatment of Hepatocellular Carcinoma and Hepatitis B and C Infection	Completed	No Results Available	Hepatocellular Carcinoma|Hepatitis B	Procedure: PEIT|Procedure: TOCE|Procedure: TOCE plus PEIT|Procedure: TOCE plus RFA|Dietary Supplement: MGN-3|Drug: Entecavir	The 108 Military Central Hospital, Hanoi, Vietnam	https://ClinicalTrials.gov/show/NCT01018381
1589	Hepatocellular Carcinoma Recurrence and Anesthesia	Completed	No Results Available	Hepatocellular Carcinoma	Other: Volatile anesthetics|Other: Intravenous anesthetics	Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Korea, Republic of	https://ClinicalTrials.gov/show/NCT02643173
1590	Stereotactic Body Radiotherapy Based Treatment for Hepatocellular Carcinoma With Extensive Portal Vein Tumor Thrombosis	Completed	No Results Available	Hepatocellular Carcinoma Non-resectable|Portal Vein Tumor Thrombosis|Stereotactic Body Radiotherapy	Radiation: stereotactic body raiotherapy	the second affiliated hospital of Zhejiang University, Hangzhou, Zhejiang, China	https://ClinicalTrials.gov/show/NCT04966195
1591	A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC	Withdrawn	No Results Available	Hepatocellular Carcinoma (HCC)	Drug: HLX10|Drug: HLX04|Drug: Sorafenib	Ethics committee of zhongshan hospital affiliated to fudan university, Shanghai, China	https://ClinicalTrials.gov/show/NCT04465734
1592	TACE and Adefovir Compared With Transarterial Chemoembolization (TACE) Alone for Hepatitis B Virus (HBV)-Related Unresectable Hepatocellular Carcinoma (HCC)	Unknown status	No Results Available	Hepatitis B Virus|Hepatocellular Carcinoma	Drug: adefovir|Procedure: TACE	The Fourth Affiliated Hospital of Haerbin Medical University, Ha'er'bin, Heilongjiang, China|Shanghai 10th Hospital of Tongji University, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT00960518
1593	Ablation Plus Tislelizumab Versus Ablation Alone for Intrahepatic Recurrent Early Stage HCC	Recruiting	No Results Available	Recurrent Hepatocellular Carcinoma	Drug: Tislelizumab|Procedure: Ablation	Department of Minimally Invasive and Interventional Radiology, Liver Cancer Study and Service Group, Sun Yat-sen University Cancer Center,, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT04663035
1594	Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC	Recruiting	No Results Available	Recurrent Hepatocellular Carcinoma	Drug: Tislelizumab|Drug: Tislelizumab combined with Levatinib	The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT04615143
1595	Yliver as a Test to Early Diagnose HCC	Completed	No Results Available	Hepatocellular Carcinoma	Diagnostic Test: Test Yliver	Corporacion Parc Taulí, Sabadell, Barcelona, Spain	https://ClinicalTrials.gov/show/NCT03767764
1596	Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular Carcinoma	Unknown status	No Results Available	Chronic Hepatitis C|Hepatocellular Carcinoma	Drug: peginterferon alpha-2a and ribavirin	Kaohsiung Medical University Hospital, Kaohsiung, Taiwan	https://ClinicalTrials.gov/show/NCT00834860
1597	Adjuvant Entecavir or Tenofovir for Postoperative HBV-HCC	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Entecavir|Drug: Tenofovir	Department of Hepatobilliary Surgery, Affiliated Tumor of Guangxi University, Nanning, Guangxi, China	https://ClinicalTrials.gov/show/NCT02650271
1598	4th Generation Chimeric Antigen Receptor T Cells Targeting Glypican-3	Completed	No Results Available	Advanced Hepatocellular Carcinoma	Drug: CAR-GPC3 T Cells	First affiliated hospital, Zhejiang University, Hangzhou, Zhejiang, China	https://ClinicalTrials.gov/show/NCT03980288
1599	Post-marketing Surveillance of DC Bead in Patients With Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma	Device: E7040	Multiple Locations, Japan	https://ClinicalTrials.gov/show/NCT02269995
1600	HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure	Not yet recruiting	No Results Available	Hepatocellular Carcinoma	Procedure: Hepatic Artery Infusion Chemotherapy|Procedure: Transarterial Chemoembolization|Drug: Regorafenib|Drug: Immune Checkpoint Inhibitors		https://ClinicalTrials.gov/show/NCT05233358
1601	Radiofrequency Ablation Combined With Transcatheter Arterial Chemoembolization Versus Radiofrequency Ablation Alone for Recurrent Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma|RFA|TACE	Procedure: RFA|Procedure: TACE-RFA	Cancer Center, Sun Yat-set University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT01415063
1602	Thermal Ablation Followed by Immunotherapy for HCC	Active, not recruiting	No Results Available	Hepatocellular Carcinoma Non-resectable	Procedure: Thermal ablation|Drug: Toripalimab	Xiangya Hospital, Central South University, Changsha, Hunan, China	https://ClinicalTrials.gov/show/NCT03864211
1603	LiverMultiScan Analysis of MRI Scans in HCC	Recruiting	No Results Available	Hepatocellular Carcinoma	Procedure: Surgery|Radiation: Radiation therapy|Drug: Drug treatment	National Cancer Center Singapore, Singapore, Singapore	https://ClinicalTrials.gov/show/NCT04451603
1604	Hepatic Artery Infusion Chemotherapy (HAIC) Plus Durvalumab for Advanced Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Procedure: Hepatic artery infusion chemotherapy（HAIC）|Drug: Durvalumab	Department of Minimally Invasive and Interventional Radiology, Liver Cancer Study and Service Group, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT04945720
1605	DEB-TACE vs. cTACE as Conversion Therapy for Unresectable Large HCC	Recruiting	No Results Available	Hepatocellular Carcinoma Non-resectable	Procedure: Drug-eluting bead transarterial chemoembolization (DEB-TACE)|Procedure: Conventional transarterial chemoembolization (cTACE)	the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT04967482
1606	HAIC Plus Lenvatinib and Toripalimab for Advanced HCC	Unknown status	No Results Available	Hepatocellular Carcinoma	Procedure: Hepatic arterial infusion chemotherapy|Drug: Lenvatinib|Drug: Toripalimab	Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT04044313
1607	Concurrent Nivolumab and External Beam Radiation Therapy for Patients With Advanced HCC	Enrolling by invitation	No Results Available	Advanced Hepatocellular Carcinoma	Drug: Nivolumab	National Cancer Center, Korea, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT04611165
1608	Comparison of Hepatic Intraarterial Versus Systemic Intravenous 68Ga-PSMA PET/CT for Detection of Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma	Radiation: Gallium Ga 68 Gozetotide|Procedure: Hepatic Artery Embolization|Procedure: Positron Emission Tomography and Computed Tomography Scan	Mayo Clinic in Rochester, Rochester, Minnesota, United States	https://ClinicalTrials.gov/show/NCT05111314
1609	Lenvatinib Plus PD-1 Antibody for Intermediate-stage HCC Beyond Up-to-seven Criteria	Withdrawn	No Results Available	Hepatocellular Carcinoma	Drug: Lenvatinib|Drug: PD-1 antibody	Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT03775707
1610	Prognostic Value Related to the Presence of Thrombosis or Portal Vein Invasion in Patients With Hepatocellular Carcinoma Submitted to Surgery	Suspended	No Results Available	Hepatocellular Carcinoma|Portal Vein Thrombosis|Hepatic Portal Vein Tumor Invasion		Hospital Sírio-Libanês, São Paulo, Brazil	https://ClinicalTrials.gov/show/NCT01690715
1611	Hepatic Xenetix-CT Perfusion	Completed	Has Results	Hepatocellular Carcinoma	Drug: Xenetix-CT perfusion imaging	AKH, Vienna, Austria|Universitätsklinikum Erlangen, Erlangen, Germany|SMC, Seoul, Korea, Republic of|SNUH, Seoul, Korea, Republic of|Zurich University Hospital, Zurich, Switzerland	https://ClinicalTrials.gov/show/NCT01639703
1612	Pembrolizumab as Neoadjuvant Treatment in HCC	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: Pembrolizumab		https://ClinicalTrials.gov/show/NCT03337841
1613	A RCT of Oral S-1 in Combination With Sequential HAIC of Oxaliplatin After TACE in Patients With Advanced HCC	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: S-1	Beijing Cancer Hospital, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT01997957
1614	HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized Trial	Unknown status	No Results Available	Hepatocellular Carcinoma	Procedure: Hepatic arterial infusion chemotherapy|Drug: Toripalimab|Drug: Sorafenib	Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT04135690
1615	HAIC Plus Lenvatinib and PD-1 Antibody Versus HAIC Plus Lenvatinib for Advanced HCC	Withdrawn	No Results Available	Hepatocellular Carcinoma	Procedure: Hepatic arterial infusion chemotherapy|Drug: Folfox Protocol|Drug: Lenvatinib|Drug: PD-1 antibody	Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China|Guangzhou Twelfth People 's Hospita, Guangzhou, Guangdong, China|Kaiping Central Hospital, Kaiping, Guangdong, China	https://ClinicalTrials.gov/show/NCT03803254
1616	Phase 2 Study of Sorafenib Plus HAIC of FOLFOX vs. Sorafenib Plus HAIC of OXA for Advanced HCC	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: Sorafenib|Drug: HAIC of FOLFOX|Drug: HAIC of OXA	Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China|Guangzhou Twelfth People 's Hospita, Guangzhou, Guangdong, China|Kaiping Central Hospital, Kaiping, Guangdong, China	https://ClinicalTrials.gov/show/NCT03812770
1617	TACE+RFA Versus Re-resection for Recurrent Small Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma|Surgery|Ablation	Procedure: TACE+RFA|Procedure: re-resection	Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT01833286
1618	Combined Radiotherapy and Sorafenib in Patients With Hepatoma	Unknown status	No Results Available	Hepatocellular Carcinoma	Other: Radiotherapy combined with sorafenib	Chi-Mei Hospital, Tainan, Taiwan|Taipei Medical University Hospital, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT01319942
1619	HAIC of FOLFOX Plus Sorafenib vs HAIC of FOLFIRINOX Plus Sorafenib for Advcanced HCC	Unknown status	No Results Available	Hepatocellular Carcinoma	Procedure: Hepatic arterial infusion chemotherapy|Drug: Folfox Protocol|Drug: Sorafenib|Drug: FOLFIRINOX	Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT03812783
1620	Pembrolizumab in Advanced Hepatocellular Carcinoma as Second-line Treatment After Failure of Sorafenib	Completed	No Results Available	Hepatocellular Carcinoma	Drug: Pembrolizumab	Samsung Medical Center, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT03163992
1621	HAIC of FOLFOX vs. HAIC of OXA for Advanced HCC	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: Sorafenib|Drug: HAIC of FOLFOX|Drug: HAIC of OXA	Dongguan People's Hospital, Dongguan, Guangdong, China|Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China|The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China|Guangzhou Twelfth People 's Hospital, Guangzhou, Guangdong, China|Kaiping Central Hospital, Kaiping, Guangdong, China|First Affiliated Hospital of University Of South China, Hengyang, Hunan, China|The First Affiliated Hospital Of Xi'an Jiaotong University, Xi'an, Shanxi, China	https://ClinicalTrials.gov/show/NCT03468231
1622	A Novel Immunotherapy PD-1 Antiboty to Suppress Recurrence of HCC Combined With PVTT After Hepatic Resection	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: PD-1 antibody|Procedure: TACE	Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi, China	https://ClinicalTrials.gov/show/NCT03914352
1623	Hyperbaric Oxygen Therapy Combined Camrelizumab in Patients With Advanced/Metastatic Hepatocellular Carcinoma	Recruiting	No Results Available	Combinational Immunotherapy|Hepatocellular Carcinoma Non-Resectable|Hyperbaric Oxygen Therapy	Combination Product: hyperbaric oxygen therapy plus Camrelizumab	Hepatic Surgery Center, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei, China	https://ClinicalTrials.gov/show/NCT05031949
1624	Radiotherapy in Hepatocellular Carcinomas After Hepatectomy With Narrow Margin (<1 cm) or Portal Vein Thrombosis	Unknown status	No Results Available	HepatoCellular Carcinoma		TaoBai, Nanning, Guangxi, China	https://ClinicalTrials.gov/show/NCT02309788
1625	A Multicenter Study of Anlotinib in Hepatocellular Carcinoma (HCC) Patients at High Risk of Post Surgery Recurrence	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Anlotinib Hydrochloride	The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, Zhejiang, China	https://ClinicalTrials.gov/show/NCT03945799
1626	Comparing Re-TACE Versus SABR for Post-prior-TACE Incompletely Regressed HCC: a Randomized Controlled Trial (TASABR)	Recruiting	No Results Available	Hepatocellular Carcinoma(HCC)	Radiation: Stereotactic ablative radiotherapy (SABR)|Procedure: Re-Transcatheter arterial chemoembolization (re-TACE)	Dalin Tzu Chi Hospital, Chiayi City, Taiwan	https://ClinicalTrials.gov/show/NCT02921139
1627	Efficacy and Safety of Cabozantinib in Patients With Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocarcinoma	Drug: Cabozantinib 60 MG	Istituto Clinico Humanitas, Rozzano, Milano, Italy	https://ClinicalTrials.gov/show/NCT04435977
1628	Hepatic Artery Infusion Chemotherapy for Unresectable Hepatocelluar Carcinoma Who Failed to Systemic Therapy	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Hepatic artery infusion chemotherapy with FOLFOX regimens (oxaliplatin, fluorouracil, and leucovorin)	Zhongshan Hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT04994236
1629	A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC	Completed	No Results Available	Hepatocellular Carcinoma (HCC)	Drug: Brivanib 800 mg, QD|Drug: Brivanib 400 mg, BID	Anhui Provincial Hospital, Hefei, Anhui, China|Nanfang Hospital, Guangzhou, Guangdong, China|Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China|Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China|Henan Cancer Hospital, Zhengzhou, Henan, China|Hunan Cancer Hospital, Changsha, Hunan, China|China PLA 81st hospital, Nanjing, Jiangsu, China|The first Hospital of Jilin University, Changchun, Jilin, China|Army General Hospital of Shenyang military region, Shenyang, Liaoning, China|Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China|Zhongshan Hospital, Shanghai, Shanghai, China|Tangdu Hospital, Xi'an, Shanxi, China|West China Hospital West China School of Medicine Sichuan University, Chengdu, Sichuan, China|Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China	https://ClinicalTrials.gov/show/NCT03516071
1630	Evaluation of Diagnostic Efficiency of PIVKA-II and Other Tumor Markers in HCC	Unknown status	No Results Available	Hepatocellular Carcinoma	Diagnostic Test: PIVKA-II	Eastern hepatobiliary surgery hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT03047603
1631	Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCC	Recruiting	No Results Available	Hepatocellular Carcinoma Non-resectable	Drug: Regorafenib + sintilimab|Drug: Regorafenib	the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT04718909
1632	CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab	Recruiting	No Results Available	Intermediate Stage of Hepatocellular Carcinoma|Hepatocellular Carcinoma	Drug: Durvalumab|Drug: Tremelimumab (Cohort A dose)|Drug: Tremelimumab (Cohort B dose)	Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States	https://ClinicalTrials.gov/show/NCT03638141
1633	To Explore the Diversity of Intestinal Flora in Patients With Advanced HCC Combin ed With Anti-PD-1 and Targeted Drug Therapy and the Correlation Between Metabolites and Therapeutic Effect	Not yet recruiting	No Results Available	Advanced Hepatocellular Carcinoma			https://ClinicalTrials.gov/show/NCT04101747
1634	Risk Factors for the Leakage of Anticancer Drugs to Systemic Circulation by Transcatheter Arterial Chemoembolization	Completed	No Results Available	Hepatocellular Carcinoma		Division of Hepatobiliary Medicine, Department of Internal Medicine, Kaohsiung Medical University Hospital, No. 100 Tzyou 1st Road, Kaohsiung, Taiwan	https://ClinicalTrials.gov/show/NCT00630240
1635	Preventive Effects of Parecoxib on Postoperative Complications in Hepatocellular Carcinoma Patients Undergoing Hepatic Transcatheter Arterial Chemoembolization	Completed	No Results Available	Hepatocellular Carcinoma	Drug: parecoxib sodium		https://ClinicalTrials.gov/show/NCT02552745
1636	TACE Plus Multikinase Inhibitor and I-125 Seeds Brachytherapy for HCC With Branch PVTT	Recruiting	No Results Available	Hepatocellular Carcinoma Non-resectable	Procedure: TACE combined with sorafenib/lenvatinib and iodion-125 seeds brachytherapy|Procedure: TACE combined with sorafenib/lenvatinib	the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT04967495
1637	PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of HCC	Unknown status	No Results Available	Hepatocellular Carcinoma Non-resectable	Combination Product: PD-1 mAb combined with TACE and lenvatinib	Tianjin Medical University Cancer Hospital, Tianjin, Tianjin, China	https://ClinicalTrials.gov/show/NCT04273100
1638	The Impact on Therapeutic Effect and Tolerance of Treatment for Patients With Hepatocellular Carcinoma in Transcatheter Arterial Chemoembolization (TACE) of Dexamethasone Application: A Random, Double-blind, Controlled, Clinical Trial.	Unknown status	No Results Available	HepatoCellular Carcinoma	Drug: Dexamethasone|Drug: Normal Saline	Cancer Center of Sun Yat-Sen University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT02987907
1639	Preoperative Transarterial Chemoembolization for Resectable HCC With Portal Venous Invasion	Completed	No Results Available	Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus	Procedure: Preoprative TACE|Procedure: Liver resection plus Thrombectomy	SunYat-sen University cancer center, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT01952353
1640	Study of ADI-PEG 20 Versus Placebo in Subjects With Genotype WWOX-GG, Unresectable HCC	Recruiting	No Results Available	Hepatocellular Carcinoma|Advanced Hepatocellular Carcinoma	Drug: ADI-PEG20|Other: Placebo	Changhua Christian Hospital (CCH), Changhua, Taiwan|Ditmanson Medical Foundation Chiayi Christian Hospital (CYCH), Chiayi City, Taiwan|Chang Gung Medical Foundation-Chia-Yi (CGMF-CY), Chiayi City, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH), Kaohsiung, Taiwan|Chang Gung Medical Foundation-Kaohsiung(CGMF-KS), Kaohsiung, Taiwan|Chi Mei Medical Center (CMMC-YK), Tainan, Taiwan|Chi Mei Hospital, Liouying (CMMC-LY), Tainan, Taiwan|Taipei Veterans General Hospital (TPVGH), Taipei, Taiwan|Chang Gung Medical Foundation-Linkou (CGMF-LK), Taoyuan, Taiwan	https://ClinicalTrials.gov/show/NCT05317819
1641	Systemic Chemotherapy Plus Lenvatinib and Toripalimab for HCC With Extrahepatic Metastasis	Recruiting	No Results Available	Hepatocellular Carcinoma	Procedure: Systemic chemotherapy|Drug: Lenvatinib|Drug: Toripalimab	Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT04170179
1642	Sorafenib and LBH589 in Hepatocellular Carcinoma (HCC)	Terminated	No Results Available	Hepatocellular Carcinoma	Drug: Sorafenib + LBH589	Department of Medicine 1, University Hospital Erlangen, Erlangen, Germany	https://ClinicalTrials.gov/show/NCT00823290
1643	Pegylated Recombinant Human Arginase 1 in Combination With Oxaliplatin and Capecitabine for the Treatment of HCC	Completed	No Results Available	Hepatocellular Carcinoma	Biological: PACOX	The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong	https://ClinicalTrials.gov/show/NCT02089633
1644	Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC	Not yet recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Hepatectomy Combined With Camrelizumab and Apatinib		https://ClinicalTrials.gov/show/NCT05062837
1645	PD-1 Antibody and Lenvatinib Plus TACE on Downstaging BCLC B/C HCC	Recruiting	No Results Available	Hepatocellular Carcinoma	Combination Product: PD-1 and Lenvatinib Plus TACE	Huashan hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT04974281
1646	Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.	Recruiting	No Results Available	Hepatocellular Carcinoma	Procedure: HAIC|Procedure: TACE|Drug: FOLFOX|Drug: cTACE or DEB-TACE|Drug: Donafenib	Peking University Cancer Hospital, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT05171166
1647	Role of DEB-TACE Versus c-TACE in Treatment of HCC	Active, not recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Doxorubicin-Eluting Beads	Sohag University Hospital, Sohag, Egypt	https://ClinicalTrials.gov/show/NCT05093920
1648	Multi-Detector CT Angiography With 3D Reconstruction Versus Digital Subtraction Angiography	Not yet recruiting	No Results Available	Hepatocellular Carcinoma	Diagnostic Test: Multi-Detector CT angiography|Procedure: Trans-arterial chemoembolization and DSA		https://ClinicalTrials.gov/show/NCT05304572
1649	Personalized Cancer Vaccine in Egyptian Cancer Patients	Recruiting	No Results Available	Hepatocellular Carcinoma	Biological: Peptide cancer vaccine	Faculty of Medicine Ain Shams Research Institute- Clinical Research Center (MASRI-CRC), Cairo, Egypt	https://ClinicalTrials.gov/show/NCT05059821
1650	OREIOS International Study	Recruiting	No Results Available	Hepatocellular Carcinoma		Research Site, Alexandira, Egypt|Research Site, Cairo, Egypt|Research Site, Menufia, Egypt|Research Site, Faridabad, India|Research Site, Howrah, India|Research Site, Kolkata, India|Research Site, Kolkata, India|Research Site, Mumbai, India|Research Site, New Delhi, India|Research Site, New Delhi, India|Research Site, Chelyabinsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Makkah, Saudi Arabia	https://ClinicalTrials.gov/show/NCT05239507
1651	Carelizumab Combined With Regorafenib in the Treatment of HCC（CARE-2020）	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Regorafenib Pill&Camrelizumab	NanFang Hospital of Southern Medical University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT04806243
1652	Efficacy and Safety of T+A+RAD in HCC	Recruiting	No Results Available	Hepatocellular Carcinoma	Radiation: Multifocal Stereotactic Radiotherapy|Drug: Atezolizumab Injection [Tecentriq]|Drug: Bevacizumab	Fudan University Shanghai Cancer Center, Shanghai, China	https://ClinicalTrials.gov/show/NCT05396937
1653	RT+ Anti-PD-1 for Patients With Advanced HCC (RT+PD-1-HCC)	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: Radiation therapy and systemic anti-PD-1 immunotherapy for patients with advanced hepatocellular carcinoma		https://ClinicalTrials.gov/show/NCT04193696
1654	Anti-angiogenic Agents Plus Anti-PD-1 Antibodies for uHCC	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Anti-angiogenic agents plus anti-PD-1/PD-L1 antibodies	Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT04639284
1655	Study of TACE Combined With Camrelizumab in the Treatment of HCC Patients	Enrolling by invitation	No Results Available	Hepatocellular Carcinoma	Drug: TACE combined with Camrelizumab|Procedure: TACE plus Camrelizumab	Department of Interventional Radiology, Zhongshan Hospital, Fudan University., Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT04483284
1656	Role of CEUS as a Secondary Diagnostic Modality	Recruiting	No Results Available	Hepatocellular Carcinoma	Diagnostic Test: contrast enhanced ultrasound	Seoul National University Hospital, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT04494022
1657	Neoadjuvant Radiotherapy for HCC Involving Type I PVTT	Unknown status	No Results Available	Hepatocellular Carcinoma	Procedure: Hepatectomy alone|Radiation: Neoadjuvant radiotherapy	Department of Hepatobilliary Surgery, Affiliated Tumor of Guangxi University, Nanning, Guangxi, China	https://ClinicalTrials.gov/show/NCT04025437
1658	Observational Study of Factors Predicting Therapeutic Effects and Clinical Prognosis After HAIC for Locally Advanced HCC	Not yet recruiting	No Results Available	Hepatocellular Carcinoma	Other: Search of factors predicting therapeutic effects and prognosis	Department of Minimally Invasive and Interventional Radiology, Liver Cancer Study and Service Group, Sun Yat-sen University Cancer Center,, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT05002452
1659	Neoadjuvant and Adjuvant Lenvatinib in HCC Patients Treated by Percutaneous Ablative	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Lenvatinib Pill	NAHON, Bobigny, France	https://ClinicalTrials.gov/show/NCT05113186
1660	Prevention of Hand-foot Skin Reaction	Completed	No Results Available	Hepatocellular Carcinoma	Other: best support care|Other: moisture cream|Other: 10% urea-based cream		https://ClinicalTrials.gov/show/NCT04568330
1661	Effect and Safety of Recombinant Human Adenovirus Type 5 in Advanced HCC With Stable Disease After Sorafenib Treatment	Active, not recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Recombinant Human Adenovirus Type 5 injection|Drug: Sorafenib	Shaanxi Provincial People's Hospital, Xi'an, Shaanxi, China|Tangdu Hospital, Xi'an, Shaanxi, China|The First Affiliated Hospital of Xi 'an Jiaotong University, Xi'an, Shaanxi, China|The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China	https://ClinicalTrials.gov/show/NCT05113290
1662	R1vascular Hepatectomy for HCC Patients	Completed	No Results Available	Hepatocellular Carcinoma	Procedure: Hepatic resection		https://ClinicalTrials.gov/show/NCT03476421
1663	Toripalimab in Combination With Lenvatinib and TACE for Conversion Therapy in Patients With Potentially Resectable HCC	Enrolling by invitation	No Results Available	Hepatocellular Carcinoma	Drug: Lenvatinib 4 MG Oral Capsule [Lenvima]|Drug: Toripalimab|Procedure: TACE	Fudan University Zhongshan Hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT05056337
1664	Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients	Not yet recruiting	No Results Available	Locally Advanced Hepatocellular Carcinoma	Combination Product: SIRT-Y90 with Atezolizumab + Bevacizumab|Combination Product: SIRT-Y90 with Placebo (IV)	National University Hospital, Singapore, Singapore|National Cancer Centre Singapore, Singapore, Singapore	https://ClinicalTrials.gov/show/NCT05377034
1665	Comparison Study of Operation and PEIT for Small, Solitary Hepatocellular Carcinoma (HCC)	Completed	No Results Available	Hepatocellular Carcinoma	Procedure: Operation|Procedure: Percutaneous ethanol injection therapy	Seoul NUH, Seoul, Chongno-gu, Korea, Republic of	https://ClinicalTrials.gov/show/NCT00357422
1666	Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib	Recruiting	No Results Available	Hepatocellular Carcinoma	Device: TheraBionic|Drug: Regorafenib	Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States	https://ClinicalTrials.gov/show/NCT04327700
1667	Nivolumab Combined With BMS-986253 in HCC Patients	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Nivolumab 240 mg IV every 2 weeks + Cabiralizumab 4 mg/kg IV every 2 weeks|Drug: Nivolumab 240 mg IV every 2 weeks + BMS-986253 1200 mg IV every 2 weeks|Drug: Nivolumab 240 mg IV every 2 weeks	NYU Langone Health, New York, New York, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States	https://ClinicalTrials.gov/show/NCT04050462
1668	Hepatectomy With or Without Transcatheter Arterial Chemoembolization for Stage IIIA Hepatocellular Carcinoma	Completed	No Results Available	Hepatocellular Carcinoma|Hepatectomy|Chemoembolization	Procedure: hepatectomy and transcatheter arterial chemoembolization|Procedure: hepatectomy	Department of Hepatobilliary Surgery, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT00652587
1669	Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced HCC	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Camrelizumab|Drug: Lenvatinib	Chinese Academy of Medical Sciences & Peking Union Medical College Hospital, Beijing, Please Select, China	https://ClinicalTrials.gov/show/NCT04443309
1670	NewishT Cell Therapy for HCC With High Risk of Recurrence After Radical Resection	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Autologous memory lymphocyte Injection (NewishT), low-dose group|Drug: Autologous memory lymphocyte Injection (NewishT), high-dose group	Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China	https://ClinicalTrials.gov/show/NCT05352646
1671	Interest of the Intervention of a Nurse Coordinator in Complex Care Pathway	Unknown status	No Results Available	Hepatocellular Carcinoma		BEAUJON Hospital, Clichy-sous-Bois, France	https://ClinicalTrials.gov/show/NCT04209491
1672	Substudy: Interconnection of Arterial Tumor Feeders Through Tumor Sinusoid in HCC	Recruiting	No Results Available	Hepatocellular Carcinoma	Procedure: TACE	Department of Imaging and Interventional Radiology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong	https://ClinicalTrials.gov/show/NCT04641637
1673	A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: IBI310|Drug: Sintilimab|Drug: Sorafenib	Fudan Universtiy Zhongshan Hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT04720716
1674	The AI Prognostic Assessment and Pathological Basis Research of Early HCC After Minimally Invasive Treatment	Active, not recruiting	No Results Available	Hepatocellular Carcinoma	Procedure: Minimally invasive treatment|Procedure: Hepatectomy	The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China	https://ClinicalTrials.gov/show/NCT04299919
1675	Combination PET With 18F-fluorodeoxyglucose (18F-FDG) and 18 F-choline in Patient With HCC	Recruiting	No Results Available	Hepatocellular Carcinoma	Radiation: PET-TDM with 18F-FDG + PET-TDM with 18F-fluorocholine	NAULT, Bobigny, France	https://ClinicalTrials.gov/show/NCT04391348
1676	HAIC of Oxaliplatin, and 2400 mg/m² 5-fu vs HAIC of Oxaliplatin, and 1200 mg/m² 5-fu for Unresectable HCC: a Randomised Phase 3 Non-inferiority Trial	Recruiting	No Results Available	HepatoCellular Carcinoma	Drug: 2400 mg/m² 5-fu|Drug: 1200 mg/m² 5-fu	Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China|Guangzhou Twelfth People 's Hospita, Guangzhou, Guangdong, China|Kaiping Central Hospital, Kaiping, Guangdong, China	https://ClinicalTrials.gov/show/NCT04667351
1677	Microwave Ablation Combined With TACE in the Treatment of Unresectable Huge Hepatocellular Carcinoma Huge	Unknown status	No Results Available	Hepatocellular Carcinoma Non-resectable|Transarterial Chemoembolization|Microwave Ablation	Procedure: TACE|Procedure: MWA|Device: MWA system|Drug: Chemoembolization	Cancer Institute &Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China|The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China|The tumor hospital of Fujian Province, Fuzhou, Fujian, China|the First Affiliated Hospital of SunYat-senUniversity, Guangzhou, Guangdong, China|Shenzhen People's Hospital, Shenzhen, Guangdong, China|Peking University Hospital of Shenzhen, Shenzhen, Guangdong, China|The Second Affiliated Hospital of Shandong University, Jinan, Shandong, China|Shandong Province Hospital, Jinan, Shandong, China|the Affiliated Hospital of Medical College Qingdao University, Qingdao, Shandong, China|The First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China	https://ClinicalTrials.gov/show/NCT03277716
1678	The Overall Survival of Patients With Unresectable HCC in Real-life	Recruiting	No Results Available	Hepatocellular Carcinoma		Beijing 302 Hospital, Beijing, China|Humanity & Health Medical Group Limited, Hong Kong, Hong Kong|Tokyo University, Tokyo, Japan	https://ClinicalTrials.gov/show/NCT03612726
1679	Randomized Control Trial (RCT) of Transarterial Chemoembolization (TACE) Versus TACE and Oral Drug Therapy in the Treatment of Unresectable Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma	Procedure: TACE	All India Institute of Medical Sciences, New Delhi, Delhi, India	https://ClinicalTrials.gov/show/NCT00522405
1680	Adoptive Transfer of iNKT Cells for Treating Patients With Relapsed/Advanced HCC	Unknown status	No Results Available	Hepatocellular Carcinoma	Biological: iNKT cells|Drug: IL-2|Drug: Tegafur	Beijing Youan Hospital,Capital Medical University, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT03175679
1681	The Impact on Hepatic Recurrence After Adjuvant Chemotherapy With Intraarterial Infusion of Idarubicin-Lipiodol	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: percutaneous destruction of the tumor + Idarubicin-Lipiodol treatment|Procedure: Percutaneous destruction of the tumor	UH Montpellier, Montpellier, France	https://ClinicalTrials.gov/show/NCT04178642
1682	Metabolic Signature of Healthy Lifestyle and HCC	Completed	No Results Available	Hepatocellular Carcinoma			https://ClinicalTrials.gov/show/NCT03356535
1683	Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCC	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Anlotinib|Device: TACE+RFA	Beijing Ditan Hospital, Capital Medical University, Beijing, Beijing, China|The First Affiliated Hospital of Dalian Medical University, Dalian, China|Shengjing Hospital Of China Medical University, Shenyang, China	https://ClinicalTrials.gov/show/NCT04157140
1684	Sorafenib Plus TACE Versus Sorafenib Alone as Postoperative Adjuvant Treatment for Resectable Primary Advanced HCC	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Sorafenib|Procedure: Transarterial chemoembolization	The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT04143191
1685	Study of Adoptive Transfer of iNKT Cells Combined With TACE to Treat Advanced HCC	Unknown status	No Results Available	Hepatocellular Carcinoma	Biological: iNKT cells|Drug: Cyclophosphamide|Drug: Human recombinated Interleukin-2|Procedure: TACE	Beijing Youan Hospital,Capital Medical University, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT04011033
1686	A Trial of SHR-1210 in Combination With Apatinib in Patients With Unresectable HCC	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: SHR1210|Drug: Apatinib		https://ClinicalTrials.gov/show/NCT03793725
1687	HCC Screening Using DNA Methylation Changes in ctDNA	Completed	No Results Available	Hepatocellular Carcinoma	Diagnostic Test: ctDNA methylation in and it's Correlation wth Development and prediction of HCC	Infectious Diseases Division, Dhaka, Bangladesh	https://ClinicalTrials.gov/show/NCT03483922
1688	Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma	Recruiting	No Results Available	Hepatocellular Carcinoma|Regorafenib|PD-1 Inhibitor	Drug: Regorafenib|Drug: PD-1 inhibitor	Hai-Tao Zhao, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT05048017
1689	Safety and Efficacy Study of Radioembolization in Combination With Durvalumab in Locally Advanced and Unresectable HCC	Active, not recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Durvalumab|Radiation: Radioembolization	Seoul National University Hospital, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT04124991
1690	SBRT or TACE for Advanced HCC	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: DEB|Radiation: SBRT	Medanta, Delhi, NCT, India	https://ClinicalTrials.gov/show/NCT03338647
1691	Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Durvalumab|Drug: Sorafenib|Drug: Lenvatinib|Drug: Regorafenib|Drug: Cabozantinib	Humanity & Health Research Centre, Hong Kong, Hong Kong SAR, Hong Kong	https://ClinicalTrials.gov/show/NCT03899428
1692	SECOX as Neoadjuvant Therapy in Patients With Locally Advanced HCC	Completed	No Results Available	Hepatocellular Carcinoma	Drug: Sorafenib|Drug: Capecitabine|Drug: Oxaliplatin	Queen Mary Hospital, Hong Kong, Hong Kong	https://ClinicalTrials.gov/show/NCT03578874
1693	Sorafenib or Lenvatinib Plus HAIC of 130 mg/m² Oxaliplatin, and 5-fu vs Sorafenib or Lenvatinib Plus HAIC of 85mg/m² Oxaliplatin, and 5-fu for Unresectable Advanced HCC: a Randomised Phase 3 Trial	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: HAIC of 130 mg/m² Oxaliplatin, and 5-fu|Drug: HAIC of 85 mg/m² Oxaliplatin, and 5-fu|Drug: TKI	Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China|Guangzhou Twelfth People 's Hospita, Guangzhou, Guangdong, China|Kaiping Central Hospital, Kaiping, Guangdong, China	https://ClinicalTrials.gov/show/NCT04687163
1694	Adoptive Transfer of Specific HCC Antigens CD8+ T Cells for Treating Patients With Relapsed/Advanced HCC	Unknown status	No Results Available	Hepatocellular Carcinoma	Biological: HCC antigens-specific CD8+ T lymphocytes|Drug: IL-2|Drug: Tegafur	Beijing Youan Hospital,Capital Medical University, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT03175705
1695	Bipolar RFA Using Twin ICW Electrodes vs. Switching Monopolar RFA for Recurrent HCC	Completed	No Results Available	Hepatocellular Carcinoma	Device: Bipolar RFA|Device: SM-RFA|Device: Twin internally cooled-wet electrodes|Device: Separable clustered electrodes	Seoul National University Hospital, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT03806218
1696	Short-term MRI for Treatment Response Evaluation/Prediction of HCC Treated With TARE	Recruiting	No Results Available	Hepatocellular Carcinoma	Diagnostic Test: MRI	Seoul National University Hospital, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT03731910
1697	A Study of PTS100 in Primary HCC Patients	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Para-Toluenesulfonamide	Taipei Medical University Hospital, Taipei City, Taiwan|Taipei Veterans General Hospital, Taipei City, Taiwan|National Taiwan University Hospital, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT03447951
1698	Laparoscopic Surgery VS RFA for Recurrent HCC	Not yet recruiting	No Results Available	Hepatocellular Carcinoma	Procedure: laparoscopic surgery(LS)|Procedure: RFA		https://ClinicalTrials.gov/show/NCT02785380
1699	Adagloxad Simolenin/OBI-821 in Combination With TACE Therapy in HCC Patients With GALNT14-rs9679162-non-TT Genotype	Terminated	No Results Available	Hepatocellular Carcinoma	Biological: adagloxad simolenin/OBI-821|Procedure: TACE	Linkou Chang Gung Memorial Hospital, Taoyuan City, Taoyuan, Taiwan	https://ClinicalTrials.gov/show/NCT03608878
1700	Targeted and Staged Cyber Knife Combined With Interventional Therapy in the Treatment of MHCC	Unknown status	No Results Available	Hepatocellular Carcinoma	Radiation: TACE plus Cyber knife	Chinese PLA Gereral Hospital, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT03243916
1701	Dual and Single Switching Monopolar RFA Using Separable Clustered Electrode for Treatment of HCC	Completed	No Results Available	Hepatocellular Carcinoma	Device: DSM|Device: SSM|Device: Separable clustered electrodes	Seoul National University Hospital, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT03699657
1702	Trial of TRC105 and Sorafenib in Patients With HCC	Completed	Has Results	Hepatocellular Carcinoma	Drug: Carotuximab (TRC105)|Drug: Sorafenib	University of Alabama, Birmingham, Alabama, United States|University Hospitals, Cleveland, Ohio, United States|MD Anderson, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT02560779
1703	Phase Ⅱ Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACE	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: HAIC of FOLFOX|Drug: Sorafenib	Guangzhou Twelfth People 's Hospital, Guangzhou, Guangdong, China|Ming Shi, Guangzhou, Guangdong, China|Kaiping Central Hospital, Kaiping, Guangdong, China	https://ClinicalTrials.gov/show/NCT03722498
1704	Trial Comparing PLA to HIGRT (PROVE-HCC)	Terminated	Has Results	Hepatocellular Carcinoma	Procedure: Percutaneous Local Abalation|Radiation: Hypofractionated Image Guided Radiation Therapy	Durham Veterans Administration Medical Center (DVAMC), Durham, North Carolina, United States|Duke Cancer Center, Durham, North Carolina, United States	https://ClinicalTrials.gov/show/NCT03402607
1705	Expanding Phase III Study of Tyroserleutide for Injection	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: Gan Fu Le Tablets|Drug: Tyroserleutide for injection|Drug: Placebo		https://ClinicalTrials.gov/show/NCT03516448
1706	TACE Emulsion Versus Suspension	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Cisplatin	Department of Imaging and Interventional Radiology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong	https://ClinicalTrials.gov/show/NCT03268499
1707	The Effect of Urea Cream on Sorafenib-associated Hand-Foot Skin Reaction	Completed	No Results Available	Hepatocellular Carcinoma	Drug: Urea Cream 20%|Drug: Placebos	Korea University Guro Hospital, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT03212625
1708	Comparison of SBRTand Repeat TACE for HCC	Unknown status	No Results Available	HepatoCellular Carcinoma	Radiation: SBRT	Gangneung Asan Hospital, Wŏnju, Gangwondo, Korea, Republic of	https://ClinicalTrials.gov/show/NCT03326375
1709	Study of T900607-Sodium in Chemotherapy Naive Patients With Hepatocellular Carcinoma.	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: intravenous T900607-sodium	Scripps Health Center, La Jolla, California, United States|University of California San Diego, La Jolla, California, United States|George Washington University, Washington, District of Columbia, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Ellis Fischel Cancer Center, Columbia, Missouri, United States|University of New Mexico, Albuquerque, New Mexico, United States|University of Rochester, Rochester, New York, United States|Ireland Cancer Center, Cleveland, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Queen Mary Hospital, Hong Kong, China	https://ClinicalTrials.gov/show/NCT00043433
1710	11C-acetate for Treatment Response After Radiotherapy for HCC	Terminated	Has Results	Hepatocellular Carcinoma	Drug: 11C-Acetate	Indiana University, Indianapolis, Indiana, United States	https://ClinicalTrials.gov/show/NCT02549755
1711	Central Obesity and Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma|Obesity|Microwave Ablation		Chinese PLA General Hospital, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT03082378
1712	TACE Plus Sorafenib Versus TACE Alone for Recurrent Unresectable Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma|Sorafenib|Transarterial Chemoembolization	Combination Product: TACE+sorafenib|Procedure: TACE	The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT04103398
1713	Metformin Plus Sorafenib for Advanced HCC	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: Sorafenib|Drug: Metformin	Tianjin Medical University Cancer Institute and Hospital, Tianjin, China	https://ClinicalTrials.gov/show/NCT02672488
1714	Adjuvant Therapies for Patients With HCC and MVI	Recruiting	No Results Available	Hepatocellular Carcinoma	Procedure: TACE|Drug: Sorafenib|Drug: TACE plus sorafenib|Other: empty control	Department of Hepatobilliary Surgery, Affiliated Tumor of Guangxi University, Nanning, Guangxi, China	https://ClinicalTrials.gov/show/NCT02436902
1715	Laparoscopic Surgery Versus Radiofrequency Ablation for Recurrent HCC	Unknown status	No Results Available	Hepatocellular Carcinoma	Procedure: Laparoscopic Surgery(LS)|Procedure: RFA		https://ClinicalTrials.gov/show/NCT02535117
1716	HAIC Plus Sorafenib Versus TACE Plus Sorafenibfor Advanced HCC	Unknown status	No Results Available	Hepatocellular Carcinoma	Procedure: Hepatic arterial infusion chemotherapy|Procedure: Transarterial chemoembolization|Drug: TACE regimen|Drug: HAIC Regimen|Drug: Oral Sorafenib	Dongguan People's Hospital, Dongguan, Guangdong, China|Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China|The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China|Guangzhou Twelfth People 's Hospital, Guangzhou, Guangdong, China|Kaiping Central Hospital, Kaiping, Guangdong, China|The First Affiliated Hospital of University Of South China, Hengyang, Hunan, China|The First Affiliated Hospital Of Xi'an Jiaotong University, Xi'an, Shanxi, China	https://ClinicalTrials.gov/show/NCT02856126
1717	Efficacy of Sequential TACE and PVE on the Resectability of Hepatitis B Related HCC	Completed	No Results Available	Hepatocellular Carcinoma	Procedure: TACE|Procedure: PVE	Eastern Hepatobiliary Surgery Hospital, Shanghai, China	https://ClinicalTrials.gov/show/NCT00834158
1718	Efficacy of Antiviral Therapy After Radical Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma|Hepatitis B Virus|Recurrence	Drug: antiviral treatment (lamivudine or entecavir)|Procedure: radical resection of HBV-related HCC	Xiang-Ming Lao, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT00768157
1719	QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine	Withdrawn	No Results Available	Hepatocellular Carcinoma Non-resectable|Hepatocellular Carcinoma Recurrent	Biological: ETBX-011|Biological: GI-4000|Biological: haNK for infusion|Biological: avelumab|Drug: Capecitabine|Drug: Cyclophosphamide|Drug: 5-Fluorouracil|Drug: Leucovorin|Drug: nab-Paclitaxel|Drug: Sorafenib|Procedure: SBRT|Biological: Aldoxorubicin hydrochloride|Biological: ETBX-051|Biological: ETBX-061|Biological: GI-6207|Biological: GI-6301|Drug: Cetuximab|Biological: N-803	Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States	https://ClinicalTrials.gov/show/NCT03563170
1720	HR Combined With FOLFOX4 for HCC With PVTT	Unknown status	No Results Available	Hepatocellular Carcinoma	Procedure: HR|Drug: FOLFOX4		https://ClinicalTrials.gov/show/NCT02452853
1721	Plan for Microwave Thermal Field	Active, not recruiting	No Results Available	Hepatocellular Carcinoma|Ablation	Procedure: Microwave Thermal guided by Plan for Microwave Thermal Field system	Chinese PLA General Hospital, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT05270642
1722	Correlation Between CT Perfusion and Post Y-90 TARE PET/CT Dosimetry	Withdrawn	No Results Available	Hepatocellular Carcinoma	Radiation: CT Liver Perfusion|Radiation: PET/CT of liver	Rush University Medical Center, Chicago, Illinois, United States	https://ClinicalTrials.gov/show/NCT02558205
1723	A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC	Terminated	No Results Available	Advanced Hepatocellular Carcinoma (HCC)	Drug: OSI-906|Drug: Placebo	University of California - Los Angeles, Los Angeles, California, United States|Tulane University Health Services Center, New Orleans, Louisiana, United States|Oregon Health & Science University, Portland, Oregon, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Seattle Cancer Care Alliance University of Washington, Seattle, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Cliniques Universitaires Saint-Luc, Brussells, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|Hopital Jean Verdier - Dervice d'Hepato-Gastroenterologie, Bondy Cedex, France|Hôpital Henri Mondor, Creteil cedex, France|Hopital de la Timone, Marseille Cedex 5, France|Hopital l'Archet 2, Nice cedex 03, France|Hôpital Saint-Antoine, Paris cedex 12, France|Hôpital de Tenon, Paris cedex 12, France|Centre Rene Gauducheau, Saint Herblain cedex, France|Universitatsklinikum Essen, Essen, Germany|Universitätsklinikum Halle, Halle, Germany|Universitatsklinikum des Saarlandes, Homburg, Germany|Universitätsklinikum Magdeburg A.ö.R., Magdeburg, Germany|Queen Mary Hospital, Hong Kong, Hong Kong|Fondazione Ca' Granda Ospedale Maggiore Policlinico, Divisione di Gastroenterologia I, Milano, Italy|Ospedale Fatebenefratelli, Dipartimento Medicina Interna, Napoli, Italy|IRCCS Istituto Nazionale per lo studio e la cura dei tumori Fondazione G. Pascale-SSD Epatobiliare, Napoli, Italy|Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione ISMETT-Dipartimento di Epatologia e Gastroenterologia, Palermo, Italy|Pusan National University Hospital, Busan, Korea, Republic of|Kyungpook National University Hospital, Daegu, Korea, Republic of|National Cancer Center, Goyang-si, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Singapore General Hospital, Singapore, Singapore|Johns Hopkins Singapore International Medical Centre, Singapore, Singapore|Hospital Clinico Universitario de Santiago de Compostela, Santiago de Compostela, Coruna, Spain|Hospital Clinic Provincial, Barcelona, Spain|Hospital Puerta de Hierro Majadahonda, Madrid, Spain|Clinica Universitaria de Navarra, Pamplona, Spain|Changhua Christian Hospital, Changhua, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|China Medical University Hospital, Taichung, Taiwan|Chang Gung Medical Foundation LinKou Branch, TaoYuan, Taiwan	https://ClinicalTrials.gov/show/NCT01101906
1724	TACE as an Adjuvant Therapy After Hepatectomy for HCC	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: Ethiodized Oil + Doxorubicin	Zhongshan Hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT01966133
1725	Combine TACE and RFA Versus TACE Alone for HCC With PVTT	Unknown status	No Results Available	Hepatocellular Carcinoma	Procedure: TACE|Procedure: RFA|Drug: pirarubicin,mitomycin and lobaplatin	Minimally Invasive Interventional Division, Medical Imaging Center, Sun Yat-sen University Cancer Center,, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT02301091
1726	Combine Apatinib Mesylate With PD-1 Antibody SHR-1210 for HCC With High Risk of Recurrence After Radical Resection	Not yet recruiting	No Results Available	Hepatocellular Carcinoma	Combination Product: Apatinib Mesylate +SHR-1210|Procedure: Hepatic Arterial Infusion(HAI)	Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT03839550
1727	Efficacy and Safety of Immuncell-LC Group and Non-treatment Group in Hepatocelluar Carcinoma Patients	Completed	Has Results	Hepatocellular Carcinoma	Biological: Immuncell-LC	Korea University Guro Hospital, Seoul, Guro 2-Dong, Guro-Gu, Korea, Republic of|Samsung Medical Center, Seoul, Ilwon-dong/Gangnam-gu, Korea, Republic of|Korea University Ansan Hospital, Gojan1-dong, Danwon-gu, Ansan-si, Kyoungi-do, Seoul, Seoul, Korea, Republic of|Seoul Asan Medical center, Pungnab2-dong, Songpa-gu, Seoul, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Yeongun-dong/Jongro-gu, Korea, Republic of	https://ClinicalTrials.gov/show/NCT00699816
1728	Temsirolimus as Second-line Therapy in HCC	Unknown status	No Results Available	Unresectable or Metastatic Hepatocellular Carcinoma	Drug: Temsirolimus	Boston Baskin Cancer Foundation, Memphis, Tennessee, United States	https://ClinicalTrials.gov/show/NCT01567930
1729	Different Genetic Features Associated With Hepatic Carcinogenesis	Unknown status	No Results Available	Hepatocellular Carcinoma		National Taiwan University Hospital, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT01247506
1730	Outcome of Transarterial Chemo-embolization (TACE) in Hepatocellular Carcinoma Patients With Partial Portal Vein Thrombosis	Completed	No Results Available	Hepatocellular Carcinoma (HCC)	Procedure: transarterial chemoembolization versus the standard treatment with sorafinib		https://ClinicalTrials.gov/show/NCT03007212
1731	Phase 1-2 Trial HCQ Plus TACE in Unresectable HCC	Terminated	Has Results	Hepatocellular Carcinoma	Drug: HCQ	Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States	https://ClinicalTrials.gov/show/NCT02013778
1732	A Trial on SBRT After Incomplete TAE or TACE Versus Exclusive TAE or TACE For Treatment of Inoperable HCC	Terminated	No Results Available	Hepatocellular Carcinoma	Radiation: SBRT|Procedure: TACE	Humanitas Research Hospital, Rozzano, Milan, Italy	https://ClinicalTrials.gov/show/NCT02323360
1733	Direct-acting Antivirals and Hepatocellular Carcinoma Recurrence	Completed	No Results Available	Hepatocellular Carcinoma|Hepatitis C|Direct Acting Antivirals	Drug: Direct Acting Antivirals against hepatitis C virus infection		https://ClinicalTrials.gov/show/NCT03197155
1734	A Phase I, Open Label, Non Randomized, Multicenter, Dose Escalation Clinical Study to Investigate Safety and Tolerability of OPB(Otsuka Pharmaceutical Biwa)-111077 in Subjects With Advanced HCC(Hepatocellular Carcinoma)	Terminated	No Results Available	Advanced Hepatocellular Carcinoma	Drug: OPB-111077	Seoul & Gyeonggi-Do, Korea, Republic of	https://ClinicalTrials.gov/show/NCT01942083
1735	to Evaluate the Efficacy and Safety of MG4101(Ex Vivo Expanded Allogeneic NK Cell)	Completed	No Results Available	Hepatocellular Carcinoma	Biological: MG4101	Samsung Medical Center, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT02008929
1736	Urea Cream Treatment Sorafenib-Associated HSFR in HCC	Completed	No Results Available	Hepatocellular Carcinoma	Drug: urea-based cream	301 Military Hospital, Beijing, China, Beijing, Beijing, China|302 Military Hospital, Beijing, China, Beijing, Beijing, China|Union Hospital of Fujian Medical University, Fujian, China, Fuzhou, Fujian, China|Guangdong Provincial People's Hospital, Guangdong, China, Guangzhou, Guangdong, China|The Third Affiliated Hospital of Sun Yat-sen University, Guangdong, China, Guangzhou, Guangdong, China|Heilongjiang Provincial Cancer Hospital, Heilongjiang, China, Haerbin, Heilongjiang, China|The 81 Hospital of the Chinese People's Liberation Army, Nanjing, China, Nanjing, Jiangsu, China|Jilin Provincial Tumor Hospital, Jilin, China, Changchun, Jilin, China|Zhongshan Hospital, Fudan University, Shanghai, Shanghai, Shanghai, China|Eastern Hepatobiliary Surgery Hospital of the Second Military Medical University, Shanghai, China, Shanghai, Shanghai, China|Tianjin Cancer Hospital, Tianjin, China, Tianjin, Tianjin, China	https://ClinicalTrials.gov/show/NCT01934829
1737	Sorafenib VS TACE in HCC Patients With Portal Vein Invasion	Terminated	No Results Available	Hepatocellular Carcinoma	Drug: Sorafenib|Procedure: TACE for HCC with portal vein invasion	Seoul National University Hospital, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT01480817
1738	Anlotinib Combined With TACE in Hepatocellular Carcinoma Patients at High Risk of Post Surgery Recurrence	Recruiting	No Results Available	Hepatocellular Carcinoma|TACE|Anlotinib	Drug: Anlotinib Hydrochloride|Procedure: TACE	The First Hospital of Lanzhou University, Lanzhou, Gansu, China|Tangdu Hospital of The Fourth Military Medical University, Xi'an, Shaanxi, China|The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China	https://ClinicalTrials.gov/show/NCT04213118
1739	Clinical Study of MAK Immune Cells in the Treatment of PHC	Recruiting	No Results Available	Primary Hepatocellular Carcinoma	Other: Mixed-activated Killer Immune Cells	Zhongnan Hospital of Wuhan University, Hubei, Wuhan, China	https://ClinicalTrials.gov/show/NCT05242757
1740	Anti-recurrence Treatment of Postresection on HCC Patients With MVI Presence and Over-expression of ASPH	Unknown status	No Results Available	Hepatocellular Carcinoma	Procedure: TACE	Eastern hepatobilliary surgery hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT02587884
1741	Hypermethylation of VTRNA2-1 Promoter in HCC Outcome	Completed	No Results Available	Hepatocellular Carcinoma Resectable		Ming-Chin Yu, Taoyuan, Taiwan	https://ClinicalTrials.gov/show/NCT04177316
1742	DC-CIK Combined With TACE in the Treatment of Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma|Neoplasms|Digestive System Neoplasms	Procedure: Transcatheter Arterial Chemoembolization (TACE)|Biological: DC-CIK	Yantai City Hospital for Infectious Diseases, Yantai, Shandong, China	https://ClinicalTrials.gov/show/NCT02487017
1743	Laser Ablation for Intermediate and Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus	Completed	No Results Available	Hepatocellular Carcinoma|Laser Ablation|Portal Vein Tumor Thrombus	Procedure: LA|Procedure: 3D-CRT	Eastern hepatobilliary surgery hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT02724475
1744	Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma With PVTT	Recruiting	No Results Available	Radiotherapy|Toripalimab|Sorafenib|Advanced Hepatocellular Carcinoma	Other: Radiotherapy plus Toripalimab|Drug: Sorafenib	Bo Chen, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT04709380
1745	Study in Asia of the Combination of TACE With Sorafenib in HCC Patients	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: doxorubicin|Procedure: TACE (Transcatheter arterial chemoembolization)	E-Da hospital, Kaohsiung, Taiwan|Veterans General Hospital- Kaochiung, Kaoshiung, Taiwan|Veterans General Hospital- Taichung, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|Mackay Memorial Hospital, Taipei, Taiwan|Tri- Service General Hospital, Taipei, Taiwan|Veterans General Hospital- Taipei, Taipei, Taiwan|Chang-Gung Memorial Hospital- LinKou, TaoYuan Hsien, Taiwan	https://ClinicalTrials.gov/show/NCT00990860
1746	Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCC	Terminated	Has Results	Hepatocellular Carcinoma	Drug: everolimus|Drug: everolimus placebo	Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, Kaohsiung, Taiwan|Novartis Investigative Site, Kaohsiung, Taiwan|Novartis Investigative Site, Lin-Kou, Taiwan|Novartis Investigative Site, Chiang Mai, Thailand	https://ClinicalTrials.gov/show/NCT01379521
1747	Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction	Completed	No Results Available	Adult Anaplastic Astrocytoma|Adult Anaplastic Ependymoma|Adult Anaplastic Oligodendroglioma|Adult Brain Stem Glioma|Adult Diffuse Astrocytoma|Adult Ependymoblastoma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Adult Mixed Glioma|Adult Myxopapillary Ependymoma|Adult Oligodendroglioma|Adult Pilocytic Astrocytoma|Adult Primary Hepatocellular Carcinoma|Adult Subependymoma|Advanced Adult Primary Liver Cancer|Advanced Malignant Mesothelioma|Male Breast Cancer|Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Adult Brain Tumor|Recurrent Adult Primary Liver Cancer|Recurrent Anal Cancer|Recurrent Basal Cell Carcinoma of the Lip|Recurrent Bladder Cancer|Recurrent Breast Cancer|Recurrent Cervical Cancer|Recurrent Colon Cancer|Recurrent Esophageal Cancer|Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Recurrent Lymphoepithelioma of the Nasopharynx|Recurrent Lymphoepithelioma of the Oropharynx|Recurrent Malignant Mesothelioma|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Non-small Cell Lung Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Pancreatic Cancer|Recurrent Prostate Cancer|Recurrent Rectal Cancer|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Verrucous Carcinoma of the Larynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Stage II Esophageal Cancer|Stage II Pancreatic Cancer|Stage III Esophageal Cancer|Stage III Pancreatic Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Adenoid Cystic Carcinoma of the Oral Cavity|Stage IV Anal Cancer|Stage IV Basal Cell Carcinoma of the Lip|Stage IV Bladder Cancer|Stage IV Breast Cancer|Stage IV Colon Cancer|Stage IV Esophageal Cancer|Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IV Lymphoepithelioma of the Nasopharynx|Stage IV Lymphoepithelioma of the Oropharynx|Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IV Mucoepidermoid Carcinoma of the Oral Cavity|Stage IV Non-small Cell Lung Cancer|Stage IV Ovarian Epithelial Cancer|Stage IV Pancreatic Cancer|Stage IV Prostate Cancer|Stage IV Rectal Cancer|Stage IV Salivary Gland Cancer|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Larynx|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IV Squamous Cell Carcinoma of the Oropharynx|Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IV Verrucous Carcinoma of the Larynx|Stage IV Verrucous Carcinoma of the Oral Cavity|Stage IVA Cervical Cancer|Stage IVB Cervical Cancer|Unspecified Adult Solid Tumor, Protocol Specific|Untreated Metastatic Squamous Neck Cancer With Occult Primary	Drug: erlotinib hydrochloride|Other: laboratory biomarker analysis	Cancer and Leukemia Group B, Chicago, Illinois, United States	https://ClinicalTrials.gov/show/NCT00030498
1748	Chemoembolization With or Without Antiviral Therapy for Unresectable HBV-related HCC With Low HBV DNA Replication	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: Lamivudine 100mg once daily; or Entecavir 0.5mg once daily.	Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT01894269
1749	HDE Use Protocol of TheraSphere for Treatment of Unresectable HCC	Completed	Has Results	Hepatocellular Carcinoma	Radiation: TheraSphere-Yttrium 90 microsphere		https://ClinicalTrials.gov/show/NCT00605150
1750	A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC	Recruiting	No Results Available	Advanced Hepatocellular Carcinoma	Drug: Ociperlimab|Drug: Tislelizumab|Drug: BAT1706	Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China|Beijing Cancer Hospital, Beijing, Beijing, China|Chongqing University Three Gorges Hospital, Chongqing, Chongqing, China|Fujian Cancer Hospital, Fuzhou, Fujian, China|Mengchao Hepatobiliary Hospital of Fujian Medical University, Gulou, Fuzhou, China|Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China|The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China|Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China|Hubei Cancer Hospital, Wuhan, Hubei, China|Hunan Cancer Hospital, Changsha, Hunan, China|The First Hospital of China Medical University, Shenyang, Liaoning, China|Shengjing Hospital of China Medical University, Shenyang, Liaoning, China|Fudan University Zhongshan Hospital, Shanghai, Shanghai, China|West China Hospital Sichuan University, Chengdu, Sichuan, China|Tianjin Medical University Cancer institute & Hospital, Tianjin, Tianjin, China|Tianjin Third Central Hospital, Tianjin, Tianjin, China|The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China|Nanfang Hospital of Southern Medical University, Guangdong, China|The Second Affiliated Hospital of Nanchang University, Jiangxi, China|Hwa Mei Hospital, University of Chinese Academy of Sciences, Zhejiang, China|National Cheng Kung University Hospital, Tainan, Taiwan|Chi Mei Medical Center, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Chang Gung Medical Foundation (CGMF) - Linkou Branch, Taoyuan, Taiwan	https://ClinicalTrials.gov/show/NCT04948697
1751	A Study to Evaluate the Safety and Efficacy of PLM60 in Advanced HCC	Not yet recruiting	No Results Available	Advanced Hepatocellular Carcinoma	Drug: Liposome-entrapped Mitoxantrone Hydrochloride Injection		https://ClinicalTrials.gov/show/NCT04331743
1752	Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC	Completed	No Results Available	Hepatocellular Carcinoma	Drug: Brivanib|Other: Brivanib Placebo|Procedure: TACE Therapy	Richard Finn, M.D., Los Angeles, California, United States|Sharp Clinical Oncology Research, San Diego, California, United States|Montefiore Medical Center, Bronx, New York, United States|Rhode Island Hospital, Providence, Rhode Island, United States|The University Of Texas MD Anderson Cancer Center, Houston, Texas, United States|University Of Virginia Health System, Charlottesville, Virginia, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Parkville, Victoria, Australia|Local Institution, Vancouver, British Columbia, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Beijing, Beijing, China|Local Institution, Guanzhou, Guangdong, China|Local Institution, Nanning, Guangxi, China|Local Institution, Harbin, Heilongjiang, China|Local Institution, Changsha, Hunan, China|Local Institution, Changzhou, Jiangsu, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Suzhou, Jiangsu, China|Local Institution, Changchun, Jilin, China|Local Institution, Xi'an, Shan3xi, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Chengdu, Sichuan, China|Local Institution, Tianjing, Tianjin, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Angers, France|Local Institution, Bondy, France|Local Institution, Bordeaux, France|Local Institution, Clichy Cedex, France|Local Institution, Creteil Cedex, France|Local Institution, Grenoble, France|Local Institution, Lille Cedex, France|Local Institution, Lyon Cedex 04, France|Local Institution, Marseille Cedex 05, France|Local Institution, Paris Cedex, France|Local Institution, Paris, France|Local Institution, Toulouse Cedex 09, France|Local Institution, Hong Kong, Hong Kong|Local Institution, New Territories, Hong Kong|Local Institution, Genova, Italy|Local Institution, Padova, Italy|Local Institution, Pisa, Italy|Local Institution, Roma, Italy|Local Institution, Toyoake City, Aichi, Japan|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Kashiwa-shi, Chiba, Japan|Local Institution, Ogaki-shi, Gifu, Japan|Local Institution, Hiroshima City, Hiroshima, Japan|Local Institution, Kure-shi, Hiroshima, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Kanazawa-shi, Ishikawa, Japan|Local Institution, Kawasaki-shi, Kanagawa, Japan|Local Institution, Yokohama, Kanagawa, Japan|Local Institution, Kochi-shi, Kochi, Japan|Local Institution, Kumamoto-shi, Kumamoto, Japan|Local Institution, Kyoto-shi, Kyoto, Japan|Local Institution, Tsu-shi, MIE, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Higashinari-ku, Osaka, Japan|Local Institution, Osaka-sayama City, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Sunto-gun, Shizuoka, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Minato-ku, Tokyo, Japan|Local Institution, Musashino-shi, Tokyo, Japan|Local Institution, Toyama City, Toyama, Japan|Local Institution, Nishinomiya-shi, Japan|Local Institution, Busan, Korea, Republic of|Local Institution, Kyunggi-do, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Suwon, Korea, Republic of|Local Institution, Taegu, Korea, Republic of|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Valencia, Spain|Local Institution, Valencia, Spain|Local Institution, Kaohsiung, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Tainan, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taoyuan, Taiwan|Local Institution, Bangkok, Thailand|Local Institution, Bangkok, Thailand	https://ClinicalTrials.gov/show/NCT00908752
1753	MANDARIN (S6371)	Recruiting	No Results Available	Inoperable Hepatocellular Carcinoma	Combination Product: TheraSphere™ Yttrium-90 Glass Microspheres|Procedure: conventional Transarterial Chemoembolization(cTACE)	Zhongda Hospital Southeast University, Nanjing, Jiangsu, China	https://ClinicalTrials.gov/show/NCT05016245
1754	Clinical Study on the Efficacy and Safety of c-Met/PD-L1 CAR-T Cell Injection in the Treatment of HCC	Unknown status	No Results Available	Primary Hepatocellular Carcinoma	Biological: c-Met/PD-L1 CAR-T cell injection		https://ClinicalTrials.gov/show/NCT03672305
1755	TACE With Lenvatinib Versus Lenvatinib Alone in in First-line Treatment of Advanced HCC	Recruiting	No Results Available	Advanced Hepatocellular Carcinoma	Procedure: TACE|Drug: Lenvatinib	The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT03905967
1756	HAIC Combine With Lenvatinib and Camrelizumab for Advanced HCC With PVTT	Recruiting	No Results Available	Hepatocellular Carcinoma|Portal Vein Thrombosis	Procedure: HAIC|Drug: Lenvatinib 1|Drug: Camrelizumab 1|Drug: Lenvatinib 2|Drug: Camrelizumab 2	Peking Univerisity Cancer Hospital, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT05166239
1757	A Study of Individualized Radiotherapy Based on a Prediction Model of Lymph Node Metastasis in Hepatocellular Carcinoma	Unknown status	No Results Available	Lymph Node Metastasis|Hepatocellular Carcinoma|Radiotherapy	Radiation: Radiotherapy	180 Fenglin Road, Shanghai, China	https://ClinicalTrials.gov/show/NCT03416803
1758	Lenvatinib Plus HAIC of Modified FOLFOX Regime vs Lenvatinib Plus HAIC of ROX Regime in Patients With Advanced HCC	Enrolling by invitation	No Results Available	Hepatocellular Carcinoma Stage IIIa	Drug: Lenvatinib|Drug: mFOLFOX regimen|Drug: ROX regimen	The Cancer Hospital of the University of Chinese Academy of Sciences（Zhejiang Cancer Hospital）, Hangzhou, Zhejiang, China	https://ClinicalTrials.gov/show/NCT05007587
1759	Comparison Study of Transarterial Chemoembolization and Percutaneous Ethanol Injection for Multiple, Small HCCs	Completed	No Results Available	Hepatocellular Carcinoma	Procedure: Transarterial chemoembolization|Procedure: Percutaneous ethanol injection therapy	Seoul NUH, Seoul, Chongno-gu, Korea, Republic of	https://ClinicalTrials.gov/show/NCT00357474
1760	Performance Evaluation (Sensitivity/Specificity) of HelioLiver Test for Detection of HCC	Completed	No Results Available	Hepatocellular Carcinoma by AJCC Stage	Diagnostic Test: Helio Liver Test	The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China|The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT05059665
1761	A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With FOLFOX4 in Subjects With Advanced HCC Who Have Never Received Prior Systemic Treatment.	Recruiting	No Results Available	Advanced Hepatocellular Carcinoma	Drug: SHR-1210|Drug: FOLFOX4|Drug: Placebo	81 Hospital Nanjing, Nanjing, Jiangsu, China	https://ClinicalTrials.gov/show/NCT03605706
1762	TACE Combined With Sintilimab and Bevacizumab for Unresectable HCC	Active, not recruiting	No Results Available	Hepatocellular Carcinoma Non-resectable	Drug: TACE combined with sintilimab and bevacizumab	The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT04592029
1763	TACE Combined With Sorafenib and Tislelizumab for Advanced HCC	Active, not recruiting	No Results Available	Hepatocellular Carcinoma Non-resectable	Drug: TACE combined with sorafenib and tislelizumab	The 2nd Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China|the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT04599777
1764	TACE Combined With Lenvatinib and Sintilimab for Advanced HCC	Active, not recruiting	No Results Available	Hepatocellular Carcinoma Non-resectable	Drug: TACE combined with lenvatinib and sintilimab	The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT04599790
1765	Y90 Radiation Segmentectomy vs SBRT for HCC	Recruiting	No Results Available	Hepatocellular Carcinoma (HCC)	Radiation: Yttrium-90 Radiation Segmentectomy|Radiation: Stereotactic Body Radiation Therapy	Indiana University, Indianapolis, Indiana, United States	https://ClinicalTrials.gov/show/NCT04235660
1766	Efficacy and Safety of Lenvatinib as a Conversion Therapy for HCC	Unknown status	No Results Available	Hepatocellular Carcinoma (HCC)	Drug: Lenvatinib 4 mg Oral	Anhui Provincial Hospital, Hefei, Anhui, China|Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China|West China Hospital, Chengdu, Sichuan, China|180 Fenglin Road, Shanghai, China	https://ClinicalTrials.gov/show/NCT04241523
1767	Atezolizumab/Bevacizumab Followed by On-demand TACE or Initial Synchronous Treatment With TACE and Atezolizumab/Bevacizumab	Recruiting	No Results Available	Hepatocellular Carcinoma Non-resectable	Combination Product: Atezolizumab Injection, Bevacizumab Injection	KEM Evang. Kliniken Essen Mitte, Essen, Germany|University Hospital Jena, Jena, Germany|University Hospital Cologne, Köln, Germany|Hospital of the University of Munich, Munich, Germany|Klinikum Rechts der Isar of the Technical University Munich, Munich, Germany|University Hospital Regensburg, Regensburg, Germany|University Hospital Tübingen, Tübingen, Germany	https://ClinicalTrials.gov/show/NCT04224636
1768	Randomized Trial Sorafenib-Pravastatin Versus Sorafenib Alone for the Palliative Treatment of Child-Pugh A Hepatocellular Carcinoma	Completed	No Results Available	Child-Pugh A Hepatocellular Carcinoma	Drug: Sorafenib + Pravastatin|Drug: Sorafenib	CHU de Dijon, Dijon, France	https://ClinicalTrials.gov/show/NCT01903694
1769	Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrence	Completed	No Results Available	Adult Hepatocellular Carcinoma|Recurrent Hepatocellular Carcinoma|Adverse Reaction to Drug|Vascular Endothelial Growth Factor Overexpression	Drug: thalidomine|Drug: tegafur-uracil	Chang Gung Memorial Hospital, Taoyuan, Taiwan	https://ClinicalTrials.gov/show/NCT02447679
1770	A Study to Evaluate SHR-1210 in Subjects With Advanced HCC	Unknown status	No Results Available	Hepatocellular Carcinoma Non-Resectable	Biological: SHR-1210	The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China|The Second Hospital of Anhui Medical University, Hefei, Anhui, China|Cancer Hospital Chinese Academy of Medical Science, Beijing, Beijing, China|Fujian Medical University Union Hospital, Fuzhou, Fujian, China|Guangdong General Hospital, Guangzhou, Guangdong, China|Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, China|Haerbin Medical University Cancer Hospital, Haerbin, Heilongjiang, China|Xiangya Hospital Central South University, Changsha, Hunan, China|Hunan Cancer Hospital, Changsha, Hunan, China|81 Hospital Nanjing, Nanjing, Jiangsu, China|The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China|Jilin Cancer Hospital, Changchun, Jilin, China|Zhangshan Hospital Fudan University, Shanghai, Shanghai, China|The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, China|West China Hospital, Chengdu, Sichuan, China|The First Affiliated Hospital Zhejiang University, Hangzhou, Zhejiang, China|Fudan University Shanghai Cancer Center, Shanghai, China	https://ClinicalTrials.gov/show/NCT02989922
1771	Impact of Three-dimensional Visualization on Operation Strategy and Complications for Complex Hepatic Carcinoma	Unknown status	No Results Available	Hepatic Carcinoma		Zhujiang Hospital of The Southern Medical University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT03132740
1772	Natural Killer (NK) Cell Therapy in Locally Advanced HCC	Recruiting	No Results Available	Locally Advanced Hepatocellular Carcinoma	Biological: Vax-NK/HCC	Seon-Ah Ha, Hwasun, Jeollanam-do, Korea, Republic of	https://ClinicalTrials.gov/show/NCT05040438
1773	Evaluation of Hepatic Arterial Infusion of Cisplatin and 5-FU in Biomarker Stratified HCC	Unknown status	No Results Available	Hepatocellular Carcinoma Non-Resectable	Drug: cisplatin and 5-fluorouracil	Korea University Ansan Hospital, Ansan, Korea, Republic of|Sooncheonhyang University Hospital Bucheon, Bucheon, Korea, Republic of|The Catholic University of Korea Bucheon ST. Mary's Hospital, Bucheon, Korea, Republic of|Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of|The Catholic University of Korea Daejeon ST. Mary's Hospital, Daejeon, Korea, Republic of|Chonnam National University Hwasun Hospital, Hwasun, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Sooncheonhyang University Hospital Seoul, Seoul, Korea, Republic of|The Catholic University of korea, Seoul ST. Mary's Hospital, Seoul, Korea, Republic of|Ajou University Hospital, Suwon, Korea, Republic of|The Catholic University of Korea ST. Vincent's Hospital, Suwon, Korea, Republic of	https://ClinicalTrials.gov/show/NCT02967887
1774	Expanded Activated Lymphocytes (EAL) as Adjuvant Therapy in Patients With HCC at High Risk of Recurrence After Radical Resection	Recruiting	No Results Available	Hepatocellular Carcinoma (HCC)	Biological: Expanded Activated Lymphocytes (EAL)|Procedure: transarterial chemoembolization (TACE)	Chinese PLA General Hospital, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT05213637
1775	The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein 1 (PD-1) Antibody of Advanced Unresectable Hepatocellular Carcinoma	Enrolling by invitation	No Results Available	Hepatocellular Carcinoma Non-resectable|Transarterial Chemoembolization|Tyrosine Kinase Inhibitor|Immune Checkpoint Blockade	Drug: lenvatinib + sindilimab/carrelizumab|Procedure: TACE	West China Hospital of Sichuan University, Chengdu, Sichuan, China	https://ClinicalTrials.gov/show/NCT04997850
1776	Identification of Biomarkers Associated With Human Hepatocellular Carcinoma by SELDI	Unknown status	No Results Available	Hepatocellular Carcinoma|Hepatitis B|Hepatitis C		National Taiwan University Hospital, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT00154531
1777	Circulating Cell-free DNA as a Predictive Biomarker for Hepatocelluar Carcinoma.	Unknown status	No Results Available	Hepatocellular Carcinoma		Stanford Genome Technology Center, Stanford, California, United States|Department of liver surgery; Peking Union Medical College Hospital；, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT02036216
1778	Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC	Withdrawn	No Results Available	Hepatocellular Carcinoma (HCC)	Device: Melphalan/HDS|Drug: Sorafenib	H. Lee Moffitt Cancer Center and Research Institute at University of South Florida, Tampa, Florida, United States|Montefiore Medical Center, New York, New York, United States	https://ClinicalTrials.gov/show/NCT02406508
1779	Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC	Recruiting	No Results Available	Advanced Hepatocellular Carcinoma (HCC)	Combination Product: Toripalimab combined with Bevacizumab|Drug: Sorafenib	Jia Fan, Shanghai, China	https://ClinicalTrials.gov/show/NCT04723004
1780	SBRT+TACE+Sorafenib Vs Sorafenib in the Treatment of uHCC With PVTT	Recruiting	No Results Available	Unresectable Hepatocellular Carcinoma|Portal Vein Thrombosis	Radiation: SBRT+TACE+Sorafenib|Drug: Sorafenib	The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China	https://ClinicalTrials.gov/show/NCT04387695
1781	Comparison Between Radiofrequency Ablation and Hypofractionated Proton Beam Radiation for Recurrent/Residual HCC	Completed	No Results Available	Recurrent Small Hepatocellular Carcinoma|Residual Small Hepatocellular Carcinoma	Procedure: radiofrequency ablation|Radiation: Proton beam therapy	National Cancer Center, Korea, Goyang-si, Gyeonggi-do, Korea, Republic of	https://ClinicalTrials.gov/show/NCT01963429
1782	A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma	Completed	Has Results	Solid Tumor|Non-Small Cell Lung Cancer Recurrent|Hepatocellular Carcinoma Recurrent	Drug: Galunisertib|Drug: Nivolumab	University of Alabama at Birmingham Medical Center, Birmingham, Alabama, United States|University of California - San Diego, La Jolla, California, United States|H Lee Moffitt Cancer Center, Tampa, Florida, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Institut Catala d'Oncologia, Barcelona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Regional Universitario de Málaga, Malaga, Spain	https://ClinicalTrials.gov/show/NCT02423343
1783	A Randomized, Controlled Phase III Trial of Sorafenib With or Without cTACE in Patients With Advanced HCC	Completed	No Results Available	Advanced Adult Hepatocellular Carcinoma	Other: Conventional Transarterial Chemoembolization (cTACE)	National Cancer Center, Korea, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT01829035
1784	IIT Study of M1-c6v1 Combined With SHR-1210 and Apatinib in Patients With HCC	Not yet recruiting	No Results Available	Advanced/Metastatic Hepatocellular Carcinoma	Drug: Recombinant oncolytic virus M1, anti PD-1 antibody, Apatinib		https://ClinicalTrials.gov/show/NCT04665362
1785	The Safety and Maximum Tolerated Dose of Axitinib in Combination With Radiotherapy for HCC	Completed	No Results Available	Advanced Hepatocellular Carcinoma (HCC)	Drug: Axitinib|Radiation: Radiation	Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT02814461
1786	Contrast Enhanced (CE) Ultrasound and CE Computed Tomography or CE Magnetic Resonance Imaging in Liver Masses	Completed	No Results Available	Liver Tumors		Vancouver General Hospital, Vancouver, British Columbia, Canada|London Health Sciences Centre, University Hospital, London, Ontario, Canada|Sunnybrook Medical centre, Toronto, Ontario, Canada|Centre Hospitalier de l'Université de Montréal, Hôpital Saint-Luc, Montréal, Quebec, Canada	https://ClinicalTrials.gov/show/NCT00828607
1787	Residual Plasma Concentration of Sorafenib and Adverse Events in CHC	Unknown status	No Results Available	Advanced or Metastatic Hepatocellular Carcinoma		Caen University Hospital, Caen, France	https://ClinicalTrials.gov/show/NCT03340636
1788	A Study of Laparoscopic Middle Hepatic Vein Guidance and Traditional Anatomic Hemihepatectomy	Recruiting	No Results Available	Hepatocellular Carcinoma	Procedure: laparoscopic middle hepatic vein guidance anatomic hemihepatectomy	Southwest Hospital, Chongqing, Chongqing, China	https://ClinicalTrials.gov/show/NCT04422249
1789	A Study of Changes in Hepatic Function During Radiation Therapy Using Hepatobiliary Single Photon Emission Tomography (SPECT)	Completed	No Results Available	Hepatocellular Carcinoma	Radiation: Liver Irradiation	University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States	https://ClinicalTrials.gov/show/NCT01519232
1790	A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC	Not yet recruiting	No Results Available	Unresectable, Non-metastatic Hepatocellular Carcinoma	Biological: AK104|Drug: Lenvatinib|Procedure: TACE	The First Hospital of Beijing University, Beijing, Beijing, China|Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China|Henan Cancer Hospital, Zhengzhou, Henan, China|Hunan Cancer Hospital, Changsha, Hunan, China|Shandong Cancer Hospital, Jinan, Shandong, China	https://ClinicalTrials.gov/show/NCT05319431
1791	Combination Therapy of HAIC and HLX10 and HLX04 in HCC With Major Portal Vein Tumor Thrombosis	Not yet recruiting	No Results Available	Hepatocellular Carcinoma With Major Portal Vein Thrombosis	Procedure: HAIC (Hepatic arterial infusion chemotherapy)|Drug: HLX10 (PD-1 antibody)|Drug: HLX04 (VEGF antibody)|Drug: Placebo		https://ClinicalTrials.gov/show/NCT04947826
1792	Thymalfasin Adjuvant Therapy in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) After Curative Resection	Unknown status	No Results Available	Curable Hepatitis B Virus-Related Hepatocellular Carcinoma	Procedure: curative resection|Drug: thymalfasin|Drug: nucleoside analog (suggest to use entecavir)	Zhongshan Hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT02281266
1793	Sorafenib Plus Hepatic Arterial Infusion Versus Sorafenib for HCC With Major Portal Vein Tumor Thrombosis	Completed	No Results Available	HepatoCellular Carcinoma|Portal Vein Thrombosis	Procedure: HAIC|Drug: Sorafenib	Peking University Cancer Hospital, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT03009461
1794	Hepatocellular Carcinoma in HIV-infected Individuals in Asian Population	Recruiting	No Results Available	HIV Infections|Hepatitis B|Hepatitis C|Hepatocellular Carcinoma		Prince of Wales Hospital, Sha Tin, Hong Kong	https://ClinicalTrials.gov/show/NCT03702998
1795	Post Sustained Virological Response (SVR) Hepatocellular Carcinoma (HCC) Screening	Completed	No Results Available	Hepatocellular Carcinoma|HCC|Hepatitis C|HCV	Behavioral: Automated reminders|Behavioral: Patient navigation	Icahn School of Medicine at Mount Sinai, New York, New York, United States	https://ClinicalTrials.gov/show/NCT02833298
1796	HCV Related Hepatocellular Carcinoma Recurrence After Directly Acting Antivirals: A Randomized Controlled Trial	Active, not recruiting	No Results Available	Hepatocellular Carcinoma|Hepatitis C|Neoplasm Recurrence|Treatment Complication	Drug: Velpatasvir/Sofosbuvir	Alexandria University, Faculty of Medicine, Alexandria, Egypt	https://ClinicalTrials.gov/show/NCT04653818
1797	Surefire Precision Infusion System Registry	Terminated	No Results Available	Hepatocellular Carcinoma	Device: DEB-TACE with Surefire Precision Infusion System	UCLA, Los Angeles, California, United States|USC, Los Angeles, California, United States|UCSD, San Diego, California, United States|Medstar Georgetown University Hospital, Washington, District of Columbia, United States|Florida Hospital, Orlando, Florida, United States|Sarasota Memorial Hospital, Sarasota, Florida, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|University of Utah, Salt Lake City, Utah, United States	https://ClinicalTrials.gov/show/NCT02967523
1798	TACE Plus HAIC With Oxaliplatin and Raltitrexed for BCLC Stage C HCC	Not yet recruiting	No Results Available	Transarterial Chemoembolization|Hepatocellular Carcinoma	Drug: cTACE-HAIC		https://ClinicalTrials.gov/show/NCT04597970
1799	Prompt Or Watchful Monitoring for Hepatitis B Virus Related Hepatocellular Carcinoma Without Elevated viRal Load	Unknown status	No Results Available	Carcinoma, Hepatocellular	Drug: Tenofovir disoproxil fumarate		https://ClinicalTrials.gov/show/NCT02308319
1800	A Study With Clevudine Monotherapy or Adefovir and Clevudine Combination in Proportion to Roadmap Concept in Patients With HBV Associated-HCC	Completed	No Results Available	Hepatitis B Associated Hepatocellular Carcinoma	Drug: clevudine, Adefovir	Seoul National University Hospital, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT01263002
1801	Determination of Autonomic Responses to Exposure to Electromagnetic Fields With Low Energy Modulated Frequency	Completed	No Results Available	Hepatocellular Carcinoma|Breast Cancer	Device: Electromagnetic Fields of Low Energy (EEFLE)	Hospital Sírio-Libanês, Sao Paulo, Brazil	https://ClinicalTrials.gov/show/NCT01686412
1802	Efficacy and Safety of Sorafenib (Nexavar) in Combination With Gemcitabine in Advanced Hepatocellular Carcinoma (HCC)	Completed	No Results Available	Carcinoma, Hepatocellular	Drug: Sorafenib and Gemcitabine	Department of Medicine, Siriraj Hospital, Bangkoknoi, Bangkok, Thailand|Medical Oncology Unit, Chulalongkorn Hospital, Patumwan, Bangkok, Thailand|Horizon Regional Cancer Center, Bamrungrad Hospital, Sukhumvit 3, Bangkok, Thailand	https://ClinicalTrials.gov/show/NCT00703365
1803	HAIC Using Oxaliplatin Plus Fluorouracil/Leucovorin for Patients With Locally Advanced HCC	Approved for marketing	No Results Available	Hepatocellular Carcinoma|Injury; Blood Vessel, Hepatic, Artery	Procedure: HAIC using oxaliplatin plus fluorouracil/leucovorin|Drug: Oxaliplatin|Drug: Fluorouracil|Drug: Leucovorin	Minimally Invasive Interventional Division, Medical Imaging Center, Sun Yat-sen University Cancer Center,, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT02436044
1804	A Post-marketing Observational Study on Risk Factors for Hepatic Encephalopathy in Participants With Unresectable Hepatocellular Carcinoma	Completed	No Results Available	Carcinoma, Hepatocellular	Drug: Lenvatinib	Eisai trial site 1, Osaka, Japan|Eisai trial site 2, Tokyo, Japan	https://ClinicalTrials.gov/show/NCT03663114
1805	Postoperative TACE(Transhepatic Arterial Chemotherapy And Embolization) for Patients With Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma|Transcatheter Arterial Chemoembolization	Drug: Transcatheter Arterial Chemoembolization|Other: No intervention No Transcatheter Arterial Chemoembolization	The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China	https://ClinicalTrials.gov/show/NCT02109146
1806	Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms	Completed	No Results Available	Hepatocellular Carcinoma|Primary Liver Cancer|Bile Duct Cancer|Pancreatic Cancer|Gallbladder Cancer|Colorectal Carcinoma|Liver Metastases	Other: Collaborative Care|Other: Enhanced usual Care	University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States	https://ClinicalTrials.gov/show/NCT01640522
1807	CAR-T Cell Immunotherapy for HCC Targeting GPC3	Withdrawn	No Results Available	GPC3 Positive Hepatocellular Carcinoma|CAR-T Cell Immunotherapy	Biological: CAR-T cell immunotherapy	Central laboratory in Fuda cancer hospital, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT02723942
1808	Efficacy and Safety of Concurrent TACE and Sorafenib in Patients With HCC and Extrahepatic Metastasis (COTSOM Study)	Unknown status	No Results Available	Hepatocellular Carcinoma|Metastasis	Procedure: Conventional Transarterial Chemoembolization (TACE)|Drug: sorafenib	Asan Medical Center, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT02311205
1809	A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection	Recruiting	No Results Available	Hepatocellular Carcinoma|Adjuvant Therapy	Drug: Tislelizumab|Drug: TACE	the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China	https://ClinicalTrials.gov/show/NCT04981665
1810	Nexavar Post-marketing Surveillance for Hepatocellular Carcinoma in Japan	Completed	No Results Available	Carcinoma, Hepatocellular	Drug: Sorafenib (Nexavar, BAY43-9006)	Many locations, Japan	https://ClinicalTrials.gov/show/NCT01411436
1811	Hector-Study to Evaluate the Efficacy of Octreotide in Patients With Inoperable Hepatocellular Carcinoma	Completed	No Results Available	Carcinoma, Hepatocellular	Drug: Somatostatin (octreotide)	University Medical Center Freiburg, Freiburg, Baden-Württemberg, Germany	https://ClinicalTrials.gov/show/NCT00386984
1812	Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma	Terminated	No Results Available	Advanced Gastrointestinal (GI) Malignancies|Hepatocellular Carcinoma|Gastric Cancer|Colorectal Cancer	Drug: ADI-PEG 20 plus modified FOLFOX6	California Pacific Medical Center, San Francisco, California, United States|Emory University, Atlanta, Georgia, United States|The University of Chicago Medical Center, Chicago, Illinois, United States|The University of Kansas Cancer Center, Westwood, Kansas, United States|Masonic Cancer Center, Minneapolis, Minnesota, United States|Washington University, Saint Louis, Missouri, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Oregon Health and Science University, Portland, Oregon, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|University of Washington, Seattle, Washington, United States|The Chinese People's Liberation Army 81 Hospital, Nanjing, Jiangsu, China|West China Hospital, Sichuan University, Chengdu, Sichuan, China|IRCCS Ca Granda Ospedale Maggiore Policlinico, Milano, Lombardia, Italy|National Cancer Institute of Napoli IRCCS G. Pascale, Napoli, Italy|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of|Pusan National University Hospital, Busan, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul, Korea, Republic of|Changhua Christian Hospital, Changhua, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|Chang Gung Medical Foundation - Kaohsiung, Kaohsiung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|Chi Mei Medical Center, Tainan, Taiwan|Chi Mei Hospital, Liouying, Tainan, Taiwan|Mackay Memorial Hospital, Taipei, Taiwan|Taipei Medical University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan|Chang Gung Medical Foundation - Linkou, Taoyuan, Taiwan|The Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, Wirral, United Kingdom|Royal Free Hospital, London, United Kingdom|Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom	https://ClinicalTrials.gov/show/NCT02102022
1813	The Effect of Ultrasound-guided Erector Spinae Plane Block on Postoperative Analgesia in Radiofrequency Ablation Therapy	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: ESPB group|Drug: Control group	National Taiwan University Hospital, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT04837742
1814	Clinical Study of the Efficacy and Safety of Transhepatic Arterial Chemoembolization Combined With Tislelizumab and Lenvatinib in Patients With Advanced Unresectable Hepatocellular Carcinoma	Active, not recruiting	No Results Available	Tislelizumab|Lenvatinib|TACE|Advanced Unresectable Hepatocellular Carcinoma	Combination Product: Tislelizumab and Lenvatinib	The Affiliated Cancer Hospital of Guangxi Medical University, Nanning, Guangxi, China	https://ClinicalTrials.gov/show/NCT05131698
1815	Songyou Granule and Transarterial Chemoembolization for Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatocellular Carcinoma|Unresectable	Drug: Songyou|Drug: placebo	Cancer Hospital of Fudan University, Shanghai, Shanghai, China|Liver Cancer Institute and Zhongshan Hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT00805896
1816	Study on the Safety and Efficacy of Donafinib Combined With Anti-PD-1 Antibody as Adjuvant Therapy for HCC Patients	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Donafenib and anti-PD-1 antibody	the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China	https://ClinicalTrials.gov/show/NCT04418401
1817	Huaier Granule for Prevention of Disease Progression of Hepatocarcinoma After Non-radical Hepatectomy	Terminated	No Results Available	Hepatic Carcinoma	Drug: Huaier Granule	Tongji Hospital Affiliated to Tongji Medical College, Huazhong, Wuhan, Hubei, China	https://ClinicalTrials.gov/show/NCT01760616
1818	Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)	Recruiting	No Results Available	Non-small Cell Lung Cancer|Hepatocellular Carcinoma	Drug: Nivolumab|Drug: BMS-813160|Drug: BMS-986253	Icahn School of Medicine at Mount Sinai, New York, New York, United States	https://ClinicalTrials.gov/show/NCT04123379
1819	Benefit of the Use of 3D Models and Tools in Hepatectomy Planning for Hepatocarcinomas	Completed	No Results Available	Hepatocarcinoma	Procedure: Surgical planning	Service de Chirurgie Digestive - Hôpital Beaujon, Clichy, France|Hôpital Henri Mondor - Service de Chirurgie Digestive et Hépatobiliaire -, Créteil, France|Service de Chirurgie Digestive et Transplantation - Hôpital Claude Huriez, Lille, France|Service de Chirurgie Digestive et Transplantation Hépatique - Hôpital universitaire de la Croix-Rousse, Lyon, France|Service de Chirurgie Digestive - CH Emile Muller, Mulhouse, France|Chirurgie Viscérale et Digestive - Polyclinique de Gentilly, Nancy, France|Chirurgie Digestive, Hépato-bilio-pancréatique et Transplantation - La Pitié Sâlpêtrière, Paris, France|Service de Chirurgie Digestive - CHU Robert Debré, Reims, France|Service de Chirurgie Digestive Hôpital Charles Nicolle - CHU Rouen, Rouen, France|Institut de Chirurgie Viscérale - Clinique de l'Orangerie, Strasbourg, France|Service de Chirurgie Digestive et Endocrinienne - Nouvel Hôpital Civil, Strasbourg, France|Centre Hépato-Biliaire - Hôpital Paul Brousse, Villejuif, France	https://ClinicalTrials.gov/show/NCT03382327
1820	Qidong Hepatitis B Intervention Study	Completed	No Results Available	Hepatitis B|Liver Neoplasms|Liver Diseases	Biological: Hep-V Vax	Qidong Liver Cancer Institute, Qidong, Jiangsu, China|Cancer Institute, Chinese Academy of Medical Sciences, Beijing, China|Clinical Trial Service Unit and Epidemiological Studies Unit, Oxford, United Kingdom	https://ClinicalTrials.gov/show/NCT00222664
1821	Diagnostic Value of AFP-L3 and PIVKA-II in HCC	Unknown status	No Results Available	Hepatocellular Carcinoma	Diagnostic Test: AFP-L3 and PIVKA-II in HCC	Hanoi Medical University, Hanoi, Vietnam	https://ClinicalTrials.gov/show/NCT03460080
1822	REgistry of Selective Internal Radiation Therapy in TaiwaN (RESIN)	Unknown status	No Results Available	Hepatocellular Carcinoma		Taipei Veterans General Hospital, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT03292991
1823	Phase II Study of HAIC Using Cisplatin,Leucovorin and 5-Fluorouracil	Unknown status	No Results Available	HepatoCellular Carcinoma	Drug: 5-Fu, oxaliplatin , leucovorin	Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT02987699
1824	Sorafenib Alone Versus Sorafenib Combined With HAIC for Advanced HCC	Completed	No Results Available	Hepatocellular Carcinoma	Drug: Sorafenib|Procedure: Hepatic arterial infusion chemotherapy|Drug: Folfox Protocol	Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China|The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China|Guangzhou Twelfth People 's Hospita, Guangzhou, Guangdong, China|The Kaiping Center's Hospital, Kaiping, Guangdong, China|First Affiliated Hospital of University Of South China, Hengyang, Hunan, China	https://ClinicalTrials.gov/show/NCT02774187
1825	A Real-world Study of Donafenib Combined With TACE-based Treatment in Patients With Unresectable HCC	Recruiting	No Results Available	Hepatocellular Carcinoma|Donafenib	Drug: Donafenib combined with TACE	Fudan University, Shanghai, China	https://ClinicalTrials.gov/show/NCT05205629
1826	Effect of Tumor Micronecrosis on Postoperative Transcatheter Arterial Chemoembolization in Patients With Hepatocellular Carcinomas	Completed	No Results Available	Carcinoma, Hepatocellular	Procedure: transcatheter arterial chemoembolization	the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China	https://ClinicalTrials.gov/show/NCT05352204
1827	Evaluation of Liver Regeneration With Autologous Peripheral Stem Cells	Unknown status	No Results Available	Liver Cirrhosis	Procedure: Plasma pheresis, Right portal vein embolization	Ho-Seong Han, Seongnam, Gyeonggi-do, Korea, Republic of	https://ClinicalTrials.gov/show/NCT01108380
1828	Surgical Therapy and Survival in HCC/ C.F. Zhang et al.	Completed	No Results Available	Hepatocellular Carcinoma|Surgery		linzhu Zhai, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT04820712
1829	Study of PolyIC and PD-1 mAb in Subjects With Unresectable Hepatocellular Carcinoma	Recruiting	No Results Available	Carcinoma, Hepatocellular	Drug: PD-1 mAb|Drug: PolyIC	The second affiliated hospital of Zhejiang University, Hangzhou, Zhejiang, China	https://ClinicalTrials.gov/show/NCT03732547
1830	Preventive Effect of Celecoxib on Sorafenib-related Hand Foot Syndrome, a Single Center, Randomized Controlled Clinical Trail	Completed	No Results Available	Hepatocellular Carcinoma	Drug: Celecoxib|Drug: Sorafenib		https://ClinicalTrials.gov/show/NCT02961998
1831	A Trial of EVL\GVS Alone vs. EVL\GVS Combined Propranolol (S-HCC)	Unknown status	No Results Available	Gastroesophageal Varices Hemorrhage|Hepatocellular Carcinoma	Drug: propranolol	Veteran General Hospital-Taipei, Taipei, Ming-Chih Hou, MD, Taiwan	https://ClinicalTrials.gov/show/NCT01451658
1832	Role of Perfluorobutane in Lesion Detection, Targeting and Response Assessment for Ablation of HCC	Completed	No Results Available	Hepatocellular Carcinoma|Microwave Ablation	Drug: Perfluorobutane	Institute of Liver & Biliary Sciences, New Delhi, Delhi, India	https://ClinicalTrials.gov/show/NCT05068076
1833	Phase II Study of Best Support Care (BSC) Plus ZD6474(Vandetanib) in Patients With Inoperable Hepatocellular Carcinoma (HCC)	Completed	Has Results	Carcinoma, Hepatocellular	Drug: Vandetanib|Drug: Best Supportive Care	Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan, Taiwan	https://ClinicalTrials.gov/show/NCT00508001
1834	Contrast-enhanced Ultrasound Evaluation of Chemoembolization	Recruiting	No Results Available	Hepatocellular Carcinoma|Chemoembolization, Therapeutic	Drug: Ultrasound contrast agent (Contrast-enhanced ultrasound)|Device: Logiq E9 Scanner (Contrast-enhanced ultrasound)	University of California, San Diego, La Jolla, California, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Vanderbilt University, Nashville, Tennessee, United States	https://ClinicalTrials.gov/show/NCT02764801
1835	Clinical Decision and Prognosis Prediction of Hepatocellular Carcinoma by Deep Learning	Recruiting	No Results Available	Hepatocellular Carcinoma|Contrast-enhanced Ultrasound|Prognosis|Surgery|Ablation	Procedure: Surgery|Procedure: Ablation (Microwave ablation or Radiofrequency ablation)	Chinese PLA General Hospital, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT05257694
1836	Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma	Completed	Has Results	Carcinoma, Hepatocellular	Drug: Doxorubicin 20 mg/m2|Drug: Doxorubicin 30 mg/m2|Drug: Best Standard of Care	Gabrail Cancer Center, Canton, Ohio, United States|Penn State Hershey Cancer Institute, Hershey, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|Krankenhaus der Elisabethinen Linz GmbH, Linz, Austria|Medical University Vienna, Vienna, Austria|CHU Brugmann, Brussels, Belgium|UCL Saint-Luc, Brussels, Belgium|CHU Sart Tilman, Liège, Belgium|CHU UCL Mont-Godinne Dinant, Yvoir, Belgium|Clinical Research Center/ Alexandria university hospital, Alexandria, Egypt|Oncology Department, Medical Research Institute, Alexandria University, Alexandria, Egypt|Medical Oncology department /Ain Shams University Hospitals, Cairo, Egypt|National hepatology and tropical medicine research institute, Cairo, Egypt|Medical Oncology department /Mansoura University Hospitals, Mansoura, Egypt|National Liver Institute / Menoufyia University, Menofia, Egypt|Hospital Amiens, Amiens, France|Hospital Jean Minjoz, Besançon, France|Hospital Saint André, Bordeaux, France|Centre hospitalier P Oudot, Bourgoin-Jallieu, France|Hospital Estaing, Clermont-Ferrand, France|Centre Hospitalier Beaujon, Clichy, France|Hospital Henri-Mondor, Creteil, France|Centre Jean-François Leclerc, Dijon, France|CHU, Dijon, France|Hospital Grenoble, La Tronche, France|CHU Dupuytren, Limoges, France|Hospital Croix Rousse, Lyon, France|Hospital La Timone, Marseille, France|Hospital Saint Eloi, Montpellier, France|Hospital Brabois, Nancy, France|Hospital Hotel Dieu, Nantes, France|CHU - Hôpital Archet, Nice, France|Hospital La Source, Orleans, France|Hospital Pitié-Salpetriere, Paris, France|Hospital Tenon, Paris, France|Hospital Saint Jean, Perpignan, France|CHU de Rouen- Hôpital Charles Nicolle, Rouen, France|IC LOIRE, Saint-Etienne, France|Hospital Civil, Strasbourg, France|Hospital Paul Brousse, Villejuif, France|Universitätsklinikum Freiburg, Freiburg, Germany|Universitätsklinikum Halle (Saale), Halle An Der Saale, Germany|Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany|Universität Leipzig AöR, Leipzig, Germany|Klinikum rechts der Isar der TU Munchen II, Munchen, Germany|Semmelweis Egyetem Radiológiai és Onkoterápiás Klinika, Budapest, Hungary|Egyesített Szent István és Szent László Kórház - Rendelőintézet, Budapest, Hungary|Debreceni Egyetem Orvos- és Egészségtudományi Centrum Onkológiai Intézet, Debrecen, Hungary|Szegedi Tudományegyetem Onkoterápiás Klinika, Szeged, Hungary|Irccs Centro Di Riferimento Oncologico (Cro), Aviano, Italy|Ospedale Civile e degli Infermi, Faenza, Italy|Ausl 12 Livorno Ospedale Unico della Versilia, Lido di Camaiore, Italy|IRST Istituto Romagnolo Ricerca e Cura dei Tumori, Meldola, Italy|Granda Osp. Magg. Policlinico, Milano, Italy|Azienda Ospedaliera Policlinico di Modena, Modena, Italy|A.O. Ospedale Maggiore della Carità, Novara, Italy|Rimini, Italy|Ain Wazein Hospital, El Chouf, Lebanon|Hospital General Universitario de Alicante, Alicante, Spain|Hospital Universitario Virgen de la Arrixaca, El Palmar Murcia, Spain|Complejo Hospitalario de Jaen, Jaen, Spain|Hospital General Universario Gregorio Maranon, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Universitario Madrid Sanchinarro, Madrid, Spain|Hospital Carlos Haya, Malaga, Spain|Hospital Universario Son Espaces, Palma De Mallorca, Spain|Hospital Universitario Marques de Valdecilla, Santander, Spain|Hospital Universitario Río Hortega, Valladolid, Spain|Hacettepe University Medical Faculty, Ankara, Turkey|Ege Univeristy Medical Faculty,, İzmir, Turkey	https://ClinicalTrials.gov/show/NCT01655693
1837	Combine TACE and Autologous Tcm Immunotherapy Versus TACE Alone for HCC With MVI After Radical Resection	Completed	Has Results	Hepatocellular Carcinoma|Malignant Neoplasm	Combination Product: TACE plus autologous Tcm immunotherapy|Procedure: TACE	Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT03575806
1838	Neoadjuvant Combination of Atezolizumab/Bevacizumab Versus Neoadjuvant Radiation Therapy	Not yet recruiting	No Results Available	Hepatocellular Carcinoma|Portal Vein Tumour Thrombosis	Combination Product: Neoadjuvant	Tom Baker Cancer Centre, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|Nova Scotia Cancer Centre, Halifax, Nova Scotia, Canada|Juravinski Cancer Centre, Hamilton, Ontario, Canada|London Health Sciences, London, Ontario, Canada|Ottawa Regional Cancer Centre, Ottawa, Ontario, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|8. Centre the recherche du Centre hospitalier de l'Université de Montréal - CHUM, Montreal, Quebec, Canada|McGill Cedars Cancer Centre, Montréal, Quebec, Canada	https://ClinicalTrials.gov/show/NCT05137899
1839	Pembrolizumab and Lenvatinib for Resectable Hepatocellular Carcinoma	Not yet recruiting	No Results Available	Carcinoma, Hepatocellular	Drug: Pembrolizumab+Lenvatinib	Zhongshan hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT05389527
1840	Electromagnetic Tracking and Optical Imaging With ICG for Hepatic Biopsies	Enrolling by invitation	No Results Available	Hepatocellular Carcinoma	Device: Optical Molecular Imaging|Radiation: Indocyanine Green	National Institutes of Health Clinical Center, Bethesda, Maryland, United States	https://ClinicalTrials.gov/show/NCT04258566
1841	Safety and Efficacy of Radiotherapy Plus Sintilimab for HCC With Portal Vein Tumor Thrombosis	Recruiting	No Results Available	Hepatocellular Carcinoma|Portal Vein Tumor Thrombosis	Radiation: Radiotherapy|Drug: Sintilimab	Beijing Tsinghua Changgung Hospital, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT04104074
1842	Post Marketing Surveillance to Observe Safety and Effectiveness of CABOMETYX™ in Korea.	Recruiting	No Results Available	Renal Cell Carcinoma|Hepatocellular Carcinoma		Korea University Ansan Hospital, Ansan, Korea, Republic of|Hallym University Sacred Heart Hospital, Anyang, Korea, Republic of|DONG-A University Hospital (Site A), Busan, Korea, Republic of|DONG-A University Hospital (Site B), Busan, Korea, Republic of|Chungbuk National University Hospital, Chungbuk, Korea, Republic of|Kyungpook National University Chilgok Hospital, Daegu, Korea, Republic of|Daegu Catholic University Medical Center, Daegu, Korea, Republic of|Keimyung University Dongsan Hospital (Site A), Daegu, Korea, Republic of|Keimyung University Dongsan Hospital (Site B), Daegu, Korea, Republic of|The Catholic University of Korea, Daejeon ST.Mary's Hospital, Daejeon, Korea, Republic of|Chungnam National University Hospital, Daejeon, Korea, Republic of|Daejeon Eulji Medical center, Eulji University, Daejeon, Korea, Republic of|Konyang University Hospital, Daejeon, Korea, Republic of|Uijeongbu Eulji Medical Center, Eulji University, Gyeonggi-do, Korea, Republic of|The Catholic University of Korea, Uijeongbu ST. Mary's Hospital (site A), Gyeonggi-do, Korea, Republic of|The Catholic University of Korea, Uijeongbu ST. Mary's Hospital (Site B), Gyeonggi-do, Korea, Republic of|Chonnam National University Hwasun Hospital, Hwasun, Korea, Republic of|Wonkwang University Hospital, Iksan, Korea, Republic of|The Catholic University of Korea, St. Mary's Hospital, Incheon, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Inje University Busan Paik Hospital, Pusan, Korea, Republic of|Inje University Haeundae Paik Hospital, Pusan, Korea, Republic of|Pusan National University Hospital (Site A), Pusan, Korea, Republic of|Pusan National University Hospital (Site B), Pusan, Korea, Republic of|Kosin University Gospel Hospital, Pusan, Korea, Republic of|CHA Bundang Medical Center, CHA University, Seongnam, Korea, Republic of|Inje University Sanggye Paik Hospital (Site A), Seoul, Korea, Republic of|Inje University Sanggye Paik Hospital (Site B), Seoul, Korea, Republic of|Korea University Anam Hospital (Site A), Seoul, Korea, Republic of|Korea University Anam Hospital (Site B), Seoul, Korea, Republic of|Severance Hospital, Yonsei University (Site A), Seoul, Korea, Republic of|Severance Hospital, Yonsei University (Site B), Seoul, Korea, Republic of|Hanyang University Seoul Hospital, Seoul, Korea, Republic of|Asan Medical Center (Site A), Seoul, Korea, Republic of|Asan Medical Center (Site B), Seoul, Korea, Republic of|Gangnam Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Samsung medical center (Site B), Seoul, Korea, Republic of|Samsung Medical Center (Site C), Seoul, Korea, Republic of|Samsung Medical Centre (Site A), Seoul, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea, Republic of|Chung-Ang University Hospital, Seoul, Korea, Republic of|The Catholic University of Korea, Yeouido St. Mary's Hospital, Seoul, Korea, Republic of|The Catholic University of Korea, St. Vincent's Hospital, Suwon, Korea, Republic of|Ulsan University Hospital, Ulsan, Korea, Republic of	https://ClinicalTrials.gov/show/NCT03776123
1843	Irradiation Stent Placement Plus TACE for HCC and PVTT	Unknown status	No Results Available	Hepatocellular Carcinoma|Portal Vein Tumor Thrombosis	Procedure: Portal irradiation stent placement|Procedure: TACE|Drug: Sorafenib	Zhong-da Hospital, Southeast University, Nanjing, Jiangsu, China	https://ClinicalTrials.gov/show/NCT03730675
1844	Neo-TACE-HAIC for PVTT-HCC	Recruiting	No Results Available	Hepatocellular Carcinoma|Portal Vein Thrombosis	Procedure: neo-TACE-HAIC+Surgery|Procedure: Surgery alone	Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China|Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT04181931
1845	Investigating Patient Characteristics of Intermediate Stage Hepatocellular Carcinoma Patients Treated With Nexavar and Their Distribution to Different Treatment Groups as Well as Determining Effectiveness and Safety	Completed	No Results Available	Carcinoma, Hepatocellular	Drug: Sorafenib (Nexavar, BAY43-9006)	Many Locations, Germany	https://ClinicalTrials.gov/show/NCT01908322
1846	Auxiliary Diagnosis of Liver Nodules Using cfDNA Whole-genome Signatures	Not yet recruiting	No Results Available	Focal Liver Lesions	Other: No interventions	The 2nd affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China|Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China|Eastern Hepatobiliary Surgery Hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT05393102
1847	LifePearl-Doxo Pharmacokinetic (PK) Study	Completed	No Results Available	HCC|Hepatocellular Carcinoma	Device: Chemoembolization|Other: Pharmacokinetics	Evgenidio Therapeftirio "Agia Trias", Athens, Greece|Hospital Clínic i provincial de Barcelona, Barcelona, Spain|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland	https://ClinicalTrials.gov/show/NCT02548780
1848	High Dose Vitamin C Combined With Metformin in the Treatment of Malignant Tumors	Recruiting	No Results Available	Hepatocellular Cancer|Pancreatic Cancer|Gastric Cancer|Colorectal Cancer	Drug: Vitamin C|Drug: Metformin	Zhongnan Hopital of Wuhan University, Wuhan, Hubei, China	https://ClinicalTrials.gov/show/NCT04033107
1849	Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC)	Terminated	Has Results	Carcinoma, Hepatocellular	Drug: Lenvatinib	California Liver Research Institute, Pasadena, California, United States|University of Florida, Gainesville, Florida, United States|University of Louisville, Louisville, Kentucky, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States	https://ClinicalTrials.gov/show/NCT03433703
1850	Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma Following Local Ablation	Recruiting	No Results Available	Hepatocarcinoma		The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China|Shijiazhuang Fifth Hospital, Shijiazhuang, Hebei, China|Affiliated Cancer Hospital of Harbin Medical University, Harbin, Heilongjiang, China|Henan Cancer Hospital, Zhengzhou, Henan, China|Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China|The Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning, China|The Second Hospital of Dalian Medical University, Dalian, Liaoning, China|Shandong Provincial Hospital, Jinan, Shandong, China|The Second Hospital of Shandong University, Jinan, Shandong, China|The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China|First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, China|the Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China|Beijing You 'an Hospital, Capital Medical University, Beijing, China|Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China|Chinese PLA General Hospital, Beijing, China|Chongqing Cancer Hospital, Chongqing, China|Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China	https://ClinicalTrials.gov/show/NCT03356236
1851	Primary Culture of Residual Specimens Obtained From Aspiration of Hepatic Tumor to Predict the Prognosis of the Patients	Completed	No Results Available	Hepatocellular Carcinoma	Other: not interventional study	Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|Chang Gung Memorial Hospital, Kaohsiung, Taiwan	https://ClinicalTrials.gov/show/NCT02587793
1852	Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib	Completed	No Results Available	Carcinoma, Hepatocellular	Drug: Sorafenib (Nexavar, BAY43-9006)	Many Locations, Alabama, United States|Many Locations, Arizona, United States|Many Locations, Arkansas, United States|Many Locations, California, United States|Many Locations, Colorado, United States|Many Locations, Connecticut, United States|Many Locations, Florida, United States|Many Locations, Georgia, United States|Many Locations, Hawaii, United States|Many Locations, Illinois, United States|Many Locations, Indiana, United States|Many Locations, Iowa, United States|Many Locations, Kansas, United States|Many Locations, Kentucky, United States|Many Locations, Louisiana, United States|Many Locations, Maryland, United States|Many Locations, Massachusetts, United States|Many Locations, Michigan, United States|Many Locations, Minnesota, United States|Many Locations, Missouri, United States|Many Locations, Nebraska, United States|Many Locations, Nevada, United States|Many Locations, New Hampshire, United States|Many Locations, New Jersey, United States|Many Locations, New York, United States|Many Locations, North Carolina, United States|Many Locations, Ohio, United States|Many Locations, Oklahoma, United States|Many Locations, Oregon, United States|Many Locations, Pennsylvania, United States|Many Locations, South Carolina, United States|Many Locations, Tennessee, United States|Many Locations, Texas, United States|Many Locations, Utah, United States|Many Locations, Virginia, United States|Many Locations, Washington, United States|Many Locations, Wisconsin, United States|Many Locations, Canada|Many Locations, China|Many Locations, Colombia|Many Locations, Croatia|Many Locations, Czech Republic|Many Locations, Finland|Many Locations, France|Many Locations, Greece|Many Locations, Hong Kong|Many Locations, Hungary|Many Locations, India|Many Locations, Indonesia|Many Locations, Israel|Many Locations, Italy|Many Locations, Japan|Many Locations, Kazakhstan|Many Locations, Korea, Republic of|Many Locations, Libyan Arab Jamahiriya|Many Locations, Malaysia|Many Locations, Mexico|Many Locations, Norway|Many Locations, Pakistan|Many Locations, Philippines|Many Locations, Portugal|Many Locations, Qatar|Many Locations, Romania|Many Locations, Russian Federation|Many Locations, Singapore|Many Locations, Slovakia|Many Locations, Spain|Many Locations, Sweden|Many Locations, Syrian Arab Republic|Many Locations, Thailand|Many Locations, Ukraine|Many Locations, United Arab Emirates|Many Locations, Uruguay|Many Locations, Venezuela|Many Locations, Vietnam	https://ClinicalTrials.gov/show/NCT00812175
1853	The HistoSonics System for Treatment of Primary and Metastatic Liver Tumors Using Histotripsy	Recruiting	No Results Available	Liver Tumor|HCC|Metastasis	Device: HistoSonics Histotripsy	Miami Cancer Institute, Miami, Florida, United States|Tampa General Hospital, Tampa, Florida, United States|University of Chicago, Chicago, Illinois, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|University of Michigan Hospital, Ann Arbor, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|University Hospital - UW Health, Madison, Wisconsin, United States|Medical College of Wisconsin/Froedtert Hospital, Milwaukee, Wisconsin, United States	https://ClinicalTrials.gov/show/NCT04572633
1854	Sorafenib Monotherapy vs. TACE-sorafenib Sequential Therapy for HCC With Metastasis	Unknown status	No Results Available	Hepatocellular Carcinoma|Metastasis	Procedure: transarterial chemoembolization (TACE)|Drug: Sorafenib	Korea University Ansan Hospital, Ansan, Gyeonggi-do, Korea, Republic of|Soonchunghyang University Bucheon Hospital, Bucheon, Gyeonggi-do, Korea, Republic of|Keimyung University Dongsan Hospital, Daegu, Korea, Republic of|Chonnam National University Hwasoon Hospital, Gwangju, Korea, Republic of|Seoul Saint Marry Hospital, the Catholic University of Korea, Seoul, Korea, Republic of|Severance Hospital, Yonsei University, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT03518502
1855	Sorafenib and TACE as Adjuvant Therapy for MVI in HCC Patients After Radical Resection	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: Sorafenib|Procedure: TACE	Cancer Hospital and Institute, Chinese Academy of Medical Sciences, Bei jing, China	https://ClinicalTrials.gov/show/NCT02537158
1856	Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma After Radical Hepatectomy	Completed	Has Results	Hepatic Carcinoma	Drug: Huaier Granule	Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China	https://ClinicalTrials.gov/show/NCT01770431
1857	TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCC	Not yet recruiting	No Results Available	Hepatocellular Carcinoma	Drug: PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab|Procedure: TACE		https://ClinicalTrials.gov/show/NCT05332821
1858	TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC	Not yet recruiting	No Results Available	Hepatocellular Carcinoma	Drug: PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab|Procedure: TACE		https://ClinicalTrials.gov/show/NCT05332496
1859	Postoperative Adjuvant TACE Treatment in CK18 Positive Patients	Completed	No Results Available	Postoperative Adjuvant TACE|Hepatocellular Carcinoma.		Eastern hepatobilliary surgery hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT02724345
1860	Donafenib Plus Sintilimab for Advanced HCC	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Donafenib+sintilimab	The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT05162352
1861	The Efficacy and Safety of HAIC With FOLFOX vs Sorafenib for Patients Who Showed TACE-resistant: a Retrospective Study	Completed	No Results Available	Hepatocellular Carcinoma	Procedure: HAIC|Drug: Sorafenib	Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT05121571
1862	PLA for HCC and Esophageal ca Serum	Unknown status	No Results Available	Hepatocellular Carcinoma|Esophageal Cancer		National Taiwan University Hospital, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT01957241
1863	DAA in the Risk of Recurrence After Curative Treatment of HCC	Withdrawn	No Results Available	Hepatocellular Carcinoma	Drug: Ledipasvir 90mg/Sofosbuvir 400 mg|Drug: Ribavirin		https://ClinicalTrials.gov/show/NCT02959359
1864	TACE Combinated With Sorafenib in Treating Patients With Unresectable Hepatocellular Carcinoma	Unknown status	No Results Available	PHENYTOIN/SORAFENIB [VA Drug Interaction]|Carcinoma, Hepatocellular	Procedure: TACE|Drug: sorafenib combined with TACE	Shandong Medical Imaging Research Institute, Jinan, Shandong, China|Qilu Hospital of Shandong University, Jinan, Shandong, China|Shandong Cancer Hospital and Institute, Jinan, Shandong, China|the Affiliated Hospital of Medical College Qingdao University, Qingdao, Shandong, China|Yantai Yuhuangding Hospital, Yantai, Shandong, China	https://ClinicalTrials.gov/show/NCT01605734
1865	Profile of Soluble and Cellular Biomarkers and of Functional Imaging During Antiangiogenic Therapies in Cancer Patients	Terminated	No Results Available	Hepatocellular Cancer|Non-small Cell Lung Cancer|Renal Cell Cancer|Colorectal Cancer	Drug: Avastin|Drug: Suntent|Drug: Nexavar	University Hospital Innsbruck, Internal Medicine V, Hematology Oncology, Innsbruck, Austria	https://ClinicalTrials.gov/show/NCT01507740
1866	The Short-term Efficacy of Novel NTDP-RFA in the Treatment of Small HCC With Cirrhosis.	Recruiting	No Results Available	Hepatocellular Carcinoma Stage I|Radiofrequency Ablation		Institute of hepatobiliary surgery,Southwest Hospital, Chongqing, Chongqing, China|Institute of hepatobiliary surgery,Southwest Hospital, Chongqing, Chongqing, China	https://ClinicalTrials.gov/show/NCT04513119
1867	Diffusion-Weighted Magnetic Resonance Imaging	Unknown status	No Results Available	Hepatocellular Carcinoma|Spine Metastasis	Radiation: External beam radiation therapy	Samsung Medical Center, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT02242786
1868	Clinical Study of Sorafenib and Zoledronic Acid to Treat Advanced HCC	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: Sorafenib and Zoledronic Acid	Liver Cancer Institute, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT01259193
1869	Comparison of Treatment of Recurrent HCC With Repeat Hepatectomy,and TACE With AFP Conversion	Completed	No Results Available	Recurrent Hepatocellular Carcinoma	Procedure: TACE|Procedure: Hepatectomy	Eastern hepatobilliary surgery hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT02728219
1870	A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC	Terminated	No Results Available	Triple Negative Breast Cancer|Hepatocellular Carcinoma	Drug: eFT508	City of Hope, Duarte, California, United States|Kansas City Research Institute, Kansas City, Missouri, United States	https://ClinicalTrials.gov/show/NCT03318562
1871	A Study to Evaluate the Safety and Tolerability of Lenvatinib in Participants With Advanced or Unresectable Hepatocellular Carcinoma	Recruiting	No Results Available	Carcinoma, Hepatocellular	Drug: Lenvatinib|Drug: Sorafenib	UCSF Fresno, Fresno, California, United States|California Liver Research Institute, Pasadena, California, United States|Mercy Medical Center (Baltimore), Baltimore, Maryland, United States|Montefiore Medical Center, Bronx, New York, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|Monash Health, Monash Medical Centre, Clayton, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Universitätsklinikum St. Pölten, St. Polten, Niederösterreich, Austria|Klinikum Klagenfurt Am Woerthersee, Klagenfurt Am Woerthersee, Austria|Medizinische Universitat Wien (Medical University of Vienna), Vienna, Austria|Eisai Trial Site #5, Mainz, Rheinland-Pfalz, Germany|Eisai Trial Site #2, Berlin, Germany|Eisai Trial Site #6, Munich, Germany|Eisai Trial Site #1, Ulm, Germany|Ospedale del Mare, Napoli, Campania, Italy|Fondazione Policlinico Universitario A Gemelli, Roma, Lazio, Italy|Fondazione PTV Policlinico Tor Vergata, Roma, Lazio, Italy|Azienda Ospedaliera San Camillo Forlanini, Roma, Lazio, Italy|Azienda Ospedaliero Universitaria Di Cagliari, Monserrato, Sardegna, Italy|Azienda Ospedaliero Universitaria Di Bologna - Policlinico S Orsola Malpighi, Bologna, Italy|Hospital Garcia de Orta, Almada, Setúbal, Portugal|Centro Hospitalar Lisboa Norte, E.P.E. - Hospital de Santa Maria, Lisboa, Portugal|Centro Hospitalar Trás Os Montes E Alto Douro EPE, Vila Real, Portugal|Budgetary Institution of the Chuvash Republic-The Republican Clinical Oncologic Dispensary-Cheboksar, Cheboksary, Chuvashskaya Respublika, Russian Federation|Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain|Hospital General Universitario de Alicante, Alicante, Spain|C.H. Regional Reina Sofia - PPDS, Cordoba, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|CHUS - H. Clinico U. de Santiago, Santiago de Compostela, Spain|Hospital Universitari i Politecnic La Fe de Valencia, Valencia, Spain|Karolinska Universitetssjukhuset Huddinge, Stockholm, Sweden|University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom|Barts Health NHS Trust - Charterhouse Square, London, United Kingdom|Royal Free London NHS Foundation Trust, London, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom	https://ClinicalTrials.gov/show/NCT04763408
1872	Observation Study: Superselective Drug-Eluting Chemoembolization in Unresectable Intermediate and Advanced HCC Patients	Unknown status	No Results Available	Hepatocellular Carcinoma		Taipei Veterans General Hospital, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT03273608
1873	Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)	Completed	No Results Available	Carcinoma, Hepatocellular	Drug: Refametinib (BAY86-9766)	Washington, District of Columbia, United States|Miami, Florida, United States|Tampa, Florida, United States|New York, New York, United States|Rochester, New York, United States|Graz, Austria|Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Charleroi, Belgium|Gent, Belgium|Leuven, Belgium|Praha 2, Czechia|CLERMONT-FERRAND Cedex 1, France|Creteil, France|Lille, France|Marseille, France|Montpellier Cedex, France|Vandoeuvre-les-nancy, France|Heidelberg, Baden-Württemberg, Germany|München, Bayern, Germany|Hannover, Niedersachsen, Germany|Essen, Nordrhein-Westfalen, Germany|Mainz, Rheinland-Pfalz, Germany|Berlin, Germany|Shatin, Hong Kong|Budapest, Hungary|Debrecen, Hungary|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Kashiwa-shi, Chiba, Japan|Kobe, Hyogo, Japan|Moriguchi, Osaka, Japan|Osaka-shi, Osaka, Japan|Osakasayama-shi, Osaka, Japan|Sunto, Shizuoka, Japan|Shimotsuke, Tochigi, Japan|Chuo-ku, Tokyo, Japan|Osaka, Japan|Shizuoka, Japan|Busan, Korea, Republic of|Daegu, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Auckland, New Zealand|Santiago de Compostela, A Coruña, Spain|Barcelona, Catalunya, Spain|Alicante, Spain|Pontevedra, Spain|Valencia, Spain|Genève 14, Genève, Switzerland|Bern, Switzerland|Kaohsiung City, Taiwan|Tainan, Taiwan|Bangkok, Thailand|Bangkok, Thailand|Bangkok, Thailand|Birmingham, West Midlands, United Kingdom	https://ClinicalTrials.gov/show/NCT01915589
1874	Direct Acting Antiviral-Post Authorization Safety Study	Completed	No Results Available	Hepatitis C|Hepatocellular Carcinoma		Banner University Medical Center, Phoenix, Arizona, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Norris Comprehensive Cancer Center, Los Angeles, California, United States|Stanford University, Palo Alto, California, United States|California Liver Research Institute, Pasadena, California, United States|University of California - Davis Clinical Trials, Sacramento, California, United States|University of California - San Francisco, San Francisco, California, United States|Georgetown University, Washington, District of Columbia, United States|Gastro Florida, Clearwater, Florida, United States|University of Florida Hepatology Research at CTRB, Gainesville, Florida, United States|University of Florida - Health Gastroenerology, Jacksonville, Florida, United States|Schiff Center for Liver Diseases, Miami, Florida, United States|Tampa General Medical Group, Tampa, Florida, United States|Piedmont Atlanta Hospital, Atlanta, Georgia, United States|Emory University Hospital, Atlanta, Georgia, United States|Northwestern University Division of Gastroenterology and Hepatology, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Tulane University School of Medicine, New Orleans, Louisiana, United States|Mercy Medical Center, Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Southern Therapy and Advanced Research LLC, Jackson, Mississippi, United States|Saint Louis University, Saint Louis, Missouri, United States|Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States|Northwell Health - Center for Liver Disease, Manhasset, New York, United States|New York University Langone Health, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Carolinas HealthCare System Center for Liver Disease, Charlotte, North Carolina, United States|Providence Health & Services Cancer Clinical Trials, Portland, Oregon, United States|Penn State Hershey Medical Center, Hershey, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Vanderbilt University Medical Center - GI Research Office, Nashville, Tennessee, United States|Clinical Research Institute@ Methodist Dallas Medical Center, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor Scott & White All Saints, Fort Worth, Texas, United States|Research Specialists of Texas, Houston, Texas, United States|Research Specialists of Texas, Houston, Texas, United States|University of Virginia Transplant Center, Charlottesville, Virginia, United States|Bon Secours Liver Institute of Virginia, Richmond, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Harborview Medical Center, Seattle, Washington, United States|Wenatchee Valley Hospital & Clinics, Wenatchee, Washington, United States|CHU de Nice - Hôpital L'Archet 2, Nice, France|Hôpitaux Universitaires Paris Centre, Paris, France|Charité - Universitätsmedizin Berlin, Berlin, Germany|Universitätsklinikum Frankfurt, Frankfurt, Germany|Universitätsklinikum Leipzig, Leipzig, Germany|Universitätsklinikum Magdeburg, Magdeburg, Germany|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy|A.O.U.P. di Palermo, Palermo, Italy|Humanitas Mirasole IRCCS, Rozzano, Italy|IRCCS "Casa Sollievo della Sofferenza", San Giovanni Rotondo, Italy|Hospital Puerta de Hierro Majadahonda, Madrid, Spain|Clínica Universidad de Navarra, Pamplona, Spain|Hospital Universitario Marques de Valdecilla, Santander, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Hospital Universitario Politècnic La Fe, Valencia, Spain	https://ClinicalTrials.gov/show/NCT03707080
1875	Hepatocellular Carcinoma and Rheumatoid Arthritis	Completed	No Results Available	Carcinoma, Hepatocellular	Other: RA		https://ClinicalTrials.gov/show/NCT02880306
1876	Proton Radiotherapy Versus Radiofrequency Ablation for Patients With Medium or Large Hepatocellular Carcinoma	Unknown status	No Results Available	Carcinoma, Hepatocellular	Radiation: Proton radiotherapy|Procedure: Radiofrequency Ablation	Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan	https://ClinicalTrials.gov/show/NCT02640924
1877	11C-Choline PET/CT and DWI MRI for Response Assessment of HCC Candidate to TARE	Completed	No Results Available	Hepatocarcinoma	Other: No intervention	Istituto Clinico Humanitas, Rozzano, Milano, Italy	https://ClinicalTrials.gov/show/NCT02519075
1878	Italian Study Of Validation Of Angiogenesis Polymorphisms In HCC Patients Treated With Sorafenib	Active, not recruiting	No Results Available	Hepatocellular Carcinoma	Procedure: blood sample collection	IRCCS Istituto Tumori Giovanni Paolo II, Bari, BA, Italy|AOU di Cagliari - PO San Giovanni di Dio, Cagliari, CA, Italy|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, FC, Italy|Istituto Oncologico Veneto, Padova, PD, Italy|Azienda Ospedaliera Universitaria Pisana, Pisa, PI, Italy|Oncologia medica - AOU di Parma, Parma, PR, Italy|Oncologia medica , PO FAENZA, Ausl della Romagna, Faenza, RA, Italy|Ospedale Civile degli Infermi, Rimini, RM, Italy|Azienda Sanitaria Universitaria Integrata di Udine S. Maria della Misericordia, Udine, UD, Italy|policlinico universitario Campus Bio-medico, Roma, Italy	https://ClinicalTrials.gov/show/NCT02786342
1879	Targeted Internal Radiation Therapy in Advanced HCC Patients.	Completed	No Results Available	Internal Radiation|Advanced Hepatocellular Carcinoma	Biological: 131I-chTNT-1/B	Eastern hepatobilliary surgery hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT02724267
1880	Metabolic Syndrome, Bile Acids, Hepatocellular Carcinoma and Cholangiocarcinoma	Completed	No Results Available	Morbid Obesity|Vertical Sleeve Gastrectomy|Metabolic Syndrome|Hepatocellular Carcinoma|Cholangiocarcinoma|Disorder of Bile Acid and Cholesterol Metabolism		AP-HP, Antoine Béclère Hospital, Clamart, France	https://ClinicalTrials.gov/show/NCT02730611
1881	Laparoscope Anatomical and Aon-anatomical Hepatectomy	Recruiting	No Results Available	Hepatocellular Carcinoma	Procedure: Laparoscopic Anatomical Hepatectomy|Procedure: Laparoscopic Aon-anatomical Hepatectomy	Southwest Hospital, Chongqing, Chongqing, China	https://ClinicalTrials.gov/show/NCT02009176
1882	The Clinical Validity and Safety of IOP Injection MRI Contrast Agent in Hepatocellular Carcinoma	Completed	No Results Available	Magnetic Resonance Imaging	Drug: IOP Injection (MPB-1523)	Chang Gung Medical Foundation, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT03407495
1883	Yttrium Y 90 Glass Microspheres in Treating Patients With Unresectable Hepatocellular Carcinoma	Recruiting	No Results Available	Stage III Hepatocellular Carcinoma AJCC v8|Stage IIIA Hepatocellular Carcinoma AJCC v8|Stage IIIB Hepatocellular Carcinoma AJCC v8|Stage IV Hepatocellular Carcinoma AJCC v8|Stage IVA Hepatocellular Carcinoma AJCC v8|Stage IVB Hepatocellular Carcinoma AJCC v8|Unresectable Hepatocellular Carcinoma	Radiation: Yttrium Y 90 Glass Microspheres	M D Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT01176604
1884	Efficacy and Safety Study of Sorafenib Plus Pravastatin to Treat Advanced Hepatocarcinoma	Completed	No Results Available	Advanced Hepatocarcinoma	Drug: Pravastatin	Hospital Donostia, Instituto Biodonostia, San Sebastian, Gipuzkoa, Spain	https://ClinicalTrials.gov/show/NCT01418729
1885	Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC	Completed	No Results Available	Hepatitis C, Chronic	Drug: interferon-alfa-2b and ribavirin	Department of Gastroenterology and Hepatology, Kyoto University Hospital, Kyoto, Japan|Osaka Red Cross Hospital, Osaka, Japan	https://ClinicalTrials.gov/show/NCT00375661
1886	The Effectiveness and Safety of Camrelizumab/Lenvatinib Combined With TACE in Patients With Borderline Resectable HCC	Not yet recruiting	No Results Available	Carrelizumab Plus Lenvatinib Combined With TACE|Borderline Resectable Hepatocellular Carcinoma	Drug: camrelizumab/lenvatinib combined with TACE	West China Hospital, Sichuan University, Chengdu, Sichuan, China	https://ClinicalTrials.gov/show/NCT05042336
1887	Liver MRI With Primovist/Eovist in Pediatric Subjects Who Are Suspected or Have Focal Liver Lesions.	Completed	Has Results	Liver Neoplasms|Adenoma|Carcinoma|Liver Abscess	Drug: Gadoxetic Acid Disodium (Eovist, BAY86-4873)	Palo Alto, California, United States|New York, New York, United States|Durham, North Carolina, United States|Cinncinati, Ohio, United States|Hershey, Pennsylvania, United States|Many Locations, Italy|Many Locations, Japan|Many Locations, Singapore|Many Locations, Taiwan	https://ClinicalTrials.gov/show/NCT01043523
1888	Phase II Trial of Capecitabine for the Treatment of Unresectable/ Metastatic or Advanced Hepatocellular Carcinoma(HCC)	Completed	No Results Available	Carcinoma, Hepatocellular	Drug: Capecitabine in HCC	Aga Khan University, Karachi, Sind, Pakistan	https://ClinicalTrials.gov/show/NCT00464295
1889	FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression	Completed	Has Results	Hepatocellular Carcinoma (HCC)|Solid Malignancies	Drug: FGF401|Biological: PDR001	University of California at Los Angeles Santa Monica Location, Los Angeles, California, United States|Massachusetts General Hospital Oncology Dept, Boston, Massachusetts, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Novartis Investigative Site, Shanghai, Shanghai, China|Novartis Investigative Site, Rennes Cedex, Ille Et Vilaine, France|Novartis Investigative Site, Lille Cedex, France|Novartis Investigative Site, Montpellier cedex 5, France|Novartis Investigative Site, Pessac Cedex, France|Novartis Investigative Site, Toulouse Cedex 9, France|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Wuerzburg, Germany|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Modena, MO, Italy|Novartis Investigative Site, Osaka Sayama, Osaka, Japan|Novartis Investigative Site, Chuo ku, Tokyo, Japan|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Tainan, Taiwan ROC, Taiwan|Novartis Investigative Site, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT02325739
1890	Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma	Completed	Has Results	Carcinoma, Hepatocellular	Drug: Mapatumumab|Drug: Placebo|Drug: Sorafenib	GSK Investigational Site, Aurora, Colorado, United States|GSK Investigational Site, Shreveport, Louisiana, United States|GSK Investigational Site, Rochester, Minnesota, United States|GSK Investigational Site, Tupelo, Mississippi, United States|GSK Investigational Site, Newark, New Jersey, United States|GSK Investigational Site, Hershey, Pennsylvania, United States|GSK Investigational Site, Hershey, Pennsylvania, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, United States|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Frankfurt, Hessen, Germany|GSK Investigational Site, Hannover, Niedersachsen, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Gdansk, Poland|GSK Investigational Site, Olsztyn, Poland|GSK Investigational Site, Poznan, Poland|GSK Investigational Site, Szczecin, Poland|GSK Investigational Site, Warszawa, Poland|GSK Investigational Site, Warszawa, Poland|GSK Investigational Site, San Juan, Puerto Rico|GSK Investigational Site, Bucuresti, Romania|GSK Investigational Site, Cluj-Napoca, Romania|GSK Investigational Site, Craiova, Romania|GSK Investigational Site, Iasi, Romania|GSK Investigational Site, Ekaterinburg, Russian Federation|GSK Investigational Site, Kazan, Russian Federation|GSK Investigational Site, Krasnoyarsk, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Pyatigorsk, Russian Federation|GSK Investigational Site, St-Petersburg, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, Tomsk, Russian Federation|GSK Investigational Site, Yaroslavl, Russian Federation|GSK Investigational Site, Dnipropetrovsk, Ukraine|GSK Investigational Site, Donetsk, Ukraine|GSK Investigational Site, Kharkiv, Ukraine|GSK Investigational Site, Kyiv, Ukraine|GSK Investigational Site, Kyiv, Ukraine|GSK Investigational Site, Lviv, Ukraine|GSK Investigational Site, Uzhhorod, Ukraine|GSK Investigational Site, Zaporizhia, Ukraine	https://ClinicalTrials.gov/show/NCT01258608
1891	The Efficacy and Safety of Retreatment With TAI for Patients Who Showed TACE-resistant: a Randomized Controlled Trial	Terminated	No Results Available	Hepatocellular Carcinoma	Procedure: TAI of FOLFOX|Drug: Sorafenib	Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT02220088
1892	SNMC (Stronger Neo-Minophagen C ) for Acute Hepatitis Post Transarterial Chemoembolization Therapy	Completed	No Results Available	Hepatocellular Carcinoma	Drug: Stronger Neo-Minophagen C	ChiMei Medical Center, Tainan, Taiwan	https://ClinicalTrials.gov/show/NCT04015245
1893	Harms of Hepatocellular Carcinoma Surveillance	Active, not recruiting	No Results Available	Carcinoma, Hepatocellular	Other: Prospective Longitudinal Data|Other: Surveys and Semi-structured Interviews	University of Texas Southwestern Medical Center, Dallas, Texas, United States	https://ClinicalTrials.gov/show/NCT03756051
1894	Coriolus Versicolor as Palliative Therapy Compared to Placebo in Patients With Child-Pugh C Unresectable Hepatocellular Carcinoma	Terminated	No Results Available	Carcinoma|Therapy	Drug: Coriolus Versicolor	National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|National Cancer Centre, Singapore, Singapore	https://ClinicalTrials.gov/show/NCT01097083
1895	Enumeration and Function Analysis of Treg Cells in Peripheral Blood of HCC Patients Before and After Ablation Therapy	Unknown status	No Results Available	Hepatocellular Carcinoma	Procedure: radiofrequency ablation	Sun Yat-Sen University,First Affiliated Hospital, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT01668381
1896	Comparison of Hydro-dissection Versus Ultrasonic Aspirator in Division of Liver Parenchyma in Laparoscopic Resection	Completed	Has Results	Liver Transection During Laparoscopic Liver Resection	Procedure: liver transection during laparoscopic liver resection	Moscow Clinical scientific Center, Moscow, Entuziastov Shosse,86, Russian Federation	https://ClinicalTrials.gov/show/NCT03208192
1897	Transarterial Chemoembolization (TACE) With or Without Stereotactic Body Radiotherapy (SBRT) in Hepatocellular Carinoma	Withdrawn	No Results Available	Hepatocellular Carcinoma	Procedure: transarterial chemoembolization|Radiation: TACE plus RT		https://ClinicalTrials.gov/show/NCT03079778
1898	Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)	Completed	No Results Available	Carcinoma, Hepatocellular	Drug: Refametinib (BAY86-9766)|Drug: Sorafenib (BAY43-9006)	Louisville, Kentucky, United States|Wien, Austria|Bruxelles - Brussel, Belgium|Edegem, Belgium|Leuven, Belgium|Liege, Belgium|Guangzhou, Guangdong, China|Beijing, China|Shanghai, China|Hradec Kralove, Czechia|Olomouc, Czechia|Bordeaux, France|Caen Cedex, France|Lyon, France|Marseille, France|Nice Cedex 3, France|Paris, France|Saint-priest-en-jarez, France|Vandoeuvre-les-nancy, France|Heidelberg, Baden-Württemberg, Germany|Tübingen, Baden-Württemberg, Germany|Frankfurt, Hessen, Germany|Essen, Nordrhein-Westfalen, Germany|Essen, Nordrhein-Westfalen, Germany|Magdeburg, Sachsen-Anhalt, Germany|Berlin, Germany|Hamburg, Germany|Hong Kong, Hong Kong|Budapest, Hungary|Debrecen, Hungary|Pecs, Hungary|Zalaegerszeg, Hungary|Haifa, Israel|Jerusalem, Israel|Petach Tikva, Israel|Tel Aviv, Israel|Bologna, Emilia-Romagna, Italy|Roma, Lazio, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Nagoya, Aichi, Japan|Chiba-shi, Chiba, Japan|Fukuoka-shi, Fukuoka, Japan|Yokohama, Kanagawa, Japan|Osakasayama-shi, Osaka, Japan|Irima-gun, Saitama, Japan|Bunkyo-ku, Tokyo, Japan|Itabashi-ku, Tokyo, Japan|Kyoto, Japan|Osaka, Japan|Osaka, Japan|Seoul, Seoul Teugbyeolsi, Korea, Republic of|Daegu, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Auckland, New Zealand|Singapore, Singapore|Santiago de Compostela, A Coruña, Spain|Oviedo, Asturias, Spain|Hospitalet de Llobregat, Barcelona, Spain|Vigo, Pontevedra, Spain|Madrid, Spain|Madrid, Spain|Bern, Switzerland|Tainan, Taiwan|Tainan, Taiwan|Taipei, Taiwan|Chiang Mai, Thailand|Khon Kaen, Thailand|Songkhla, Thailand|Istanbul, Turkey|Istanbul, Turkey|Istanbul, Turkey|Mersin, Turkey|Birmingham, United Kingdom|London, United Kingdom	https://ClinicalTrials.gov/show/NCT01915602
1899	An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies	Terminated	No Results Available	Hepatocellular Carcinoma (HCC)|Cholangiocarcinoma|Esophageal Cancer|Nasopharyngeal Cancer|Ovarian Cancer|Solid Tumors	Drug: INCB062079	University of Alabama, Birmingham, Alabama, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University of Toledo Medical Center, Toledo, Ohio, United States|Institut Jules Bordet, Brussels, Belgium|Cliniques Universitaires Saint-Luc, Brussels, Belgium|University Hospital (UZ) Leuven, Leuven, Belgium	https://ClinicalTrials.gov/show/NCT03144661
1900	A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors	Completed	No Results Available	Hepatocellular Carcinoma	Drug: MM-141	Marietta, Georgia, United States|Boston, Massachusetts, United States|Detroit, Michigan, United States|Villejuif, France	https://ClinicalTrials.gov/show/NCT01733004
1901	Pringle's Maneuver Versus Selective Hepatic Vascular Exclusion in Hepatectomy	Completed	No Results Available	Hepatocellular Carcinoma	Procedure: Selective Hepatic Vascular Exclusion|Procedure: Pringle's Maneuver	Eastern hepatobilliary surgery hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT00820339
1902	A Study of Overall Survival in Participants With Unresectable Hepatocellular Carcinoma	Completed	No Results Available	Carcinoma, Hepatocellular|Carcinoma|Neoplasms, Glandular and Epithelial|Neoplasms	Drug: Lenvatinib	Eisai Trial Site #1, Osaka, Japan|Eisai Trial Site #2, Tokyo, Japan	https://ClinicalTrials.gov/show/NCT04008082
1903	PI-88 in Hepatocellular Carcinoma After Hepatectomy	Completed	Has Results	Carcinoma, Hepatocellular	Drug: PI-88	Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital-Linkou Medical Centre, Taoyuan, Taiwan	https://ClinicalTrials.gov/show/NCT00247728
1904	Prospective Liver Study	Completed	No Results Available	Liver Cancer		Emory University, Atlanta, Georgia, United States	https://ClinicalTrials.gov/show/NCT01539993
1905	Resection Versus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma With Solitary Huge Tumor	Unknown status	No Results Available	Carcinoma, Hepatocellular|Survival Rate	Procedure: hepatic resection|Procedure: TACE	Hepatic surgery center, Tong ji Hospital, Wuhan, Hubei, China	https://ClinicalTrials.gov/show/NCT03191123
1906	Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery	Completed	Has Results	Adult Cholangiocarcinoma|Advanced Adult Hepatocellular Carcinoma|BCLC Stage C Adult Hepatocellular Carcinoma|BCLC Stage D Adult Hepatocellular Carcinoma|Hilar Cholangiocarcinoma|Localized Non-Resectable Adult Liver Carcinoma|Recurrent Adult Liver Carcinoma|Recurrent Childhood Liver Cancer|Recurrent Extrahepatic Bile Duct Carcinoma|Recurrent Gallbladder Carcinoma|Stage II Gallbladder Cancer|Stage III Childhood Hepatocellular Carcinoma|Stage IIIA Gallbladder Cancer|Stage IIIB Gallbladder Cancer|Stage IV Childhood Hepatocellular Carcinoma|Stage IV Distal Bile Duct Cancer|Stage IVA Gallbladder Cancer|Stage IVB Gallbladder Cancer|Unresectable Extrahepatic Bile Duct Carcinoma	Drug: Capecitabine|Drug: Fluorouracil|Other: Laboratory Biomarker Analysis|Drug: Leucovorin Calcium|Drug: Trametinib	Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States|Alaska Women's Cancer Care, Anchorage, Alaska, United States|Anchorage Oncology Centre, Anchorage, Alaska, United States|Katmai Oncology Group, Anchorage, Alaska, United States|Providence Alaska Medical Center, Anchorage, Alaska, United States|Kaiser Permanente-Anaheim, Anaheim, California, United States|Sutter Auburn Faith Hospital, Auburn, California, United States|Kaiser Permanente-Baldwin Park, Baldwin Park, California, United States|Kaiser Permanente-Bellflower, Bellflower, California, United States|Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States|Mills - Peninsula Hospitals, Burlingame, California, United States|Sutter Davis Hospital, Davis, California, United States|City of Hope Comprehensive Cancer Center, Duarte, California, United States|Kaiser Permanente Hospital, Fontana, California, United States|Kaiser Permanente - Harbor City, Harbor City, California, United States|Kaiser Permanente-Irvine, Irvine, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Los Angeles County-USC Medical Center, Los Angeles, California, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|Kaiser Permanente-Cadillac, Los Angeles, California, United States|Fremont - Rideout Cancer Center, Marysville, California, United States|Memorial Medical Center, Modesto, California, United States|Palo Alto Medical Foundation-Camino Division, Mountain View, California, United States|Palo Alto Medical Foundation-Gynecologic Oncology, Mountain View, California, United States|Sutter Cancer Research Consortium, Novato, California, United States|UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States|Palo Alto Medical Foundation Health Care, Palo Alto, California, United States|Kaiser Permanente - Panorama City, Panorama City, California, United States|Kaiser Permanente-Riverside, Riverside, California, United States|Sutter Roseville Medical Center, Roseville, California, United States|Sutter General Hospital, Sacramento, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|Kaiser Permanente-San Diego Mission, San Diego, California, United States|Kaiser Permanente-San Diego Zion, San Diego, California, United States|California Pacific Medical Center-Pacific Campus, San Francisco, California, United States|Kaiser Permanente-San Marcos, San Marcos, California, United States|Palo Alto Medical Foundation-Santa Cruz, Santa Cruz, California, United States|Sutter Pacific Medical Foundation, Santa Rosa, California, United States|Palo Alto Medical Foundation-Sunnyvale, Sunnyvale, California, United States|Sutter Solano Medical Center/Cancer Center, Vallejo, California, United States|Kaiser Permanente, Woodland Hills, California, United States|University of Colorado Cancer Center - Anschutz Cancer Pavilion, Aurora, Colorado, United States|Memorial Hospital Colorado Springs, Colorado Springs, Colorado, United States|Smilow Cancer Hospital-Derby Care Center, Derby, Connecticut, United States|Medical Oncology and Hematology Group PC-Guilford, Guilford, Connecticut, United States|Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut, United States|Yale University, New Haven, Connecticut, United States|Yale-New Haven Hospital North Haven Medical Center, North Haven, Connecticut, United States|Smilow Cancer Hospital-Orange Care Center, Orange, Connecticut, United States|Charlotte Hungerford Hospital Center for Cancer Care, Torrington, Connecticut, United States|Smilow Cancer Hospital-Waterbury Care Center, Waterbury, Connecticut, United States|University of Florida, Gainesville, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States|Kootenai Medical Center, Coeur d'Alene, Idaho, United States|Kootenai Cancer Center, Post Falls, Idaho, United States|Kootenai Cancer Clinic, Sandpoint, Idaho, United States|Saint Joseph Medical Center, Bloomington, Illinois, United States|Illinois CancerCare-Bloomington, Bloomington, Illinois, United States|Illinois CancerCare-Canton, Canton, Illinois, United States|Memorial Hospital of Carbondale, Carbondale, Illinois, United States|Illinois CancerCare-Carthage, Carthage, Illinois, United States|Centralia Oncology Clinic, Centralia, Illinois, United States|Cancer Care Center of Decatur, Decatur, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|Illinois CancerCare-Eureka, Eureka, Illinois, United States|Illinois CancerCare-Galesburg, Galesburg, Illinois, United States|Western Illinois Cancer Treatment Center, Galesburg, Illinois, United States|Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States|Illinois CancerCare-Macomb, Macomb, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Good Samaritan Regional Health Center, Mount Vernon, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Radiation Oncology of Northern Illinois, Ottawa, Illinois, United States|Illinois CancerCare-Pekin, Pekin, Illinois, United States|OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center, Pekin, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|OSF Saint Francis Radiation Oncology at Peoria Cancer Center, Peoria, Illinois, United States|OSF Saint Francis Medical Center, Peoria, Illinois, United States|Illinois CancerCare-Peru, Peru, Illinois, United States|Valley Radiation Oncology, Peru, Illinois, United States|Illinois CancerCare-Princeton, Princeton, Illinois, United States|Central Illinois Hematology Oncology Center, Springfield, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Springfield Clinic, Springfield, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|Reid Health, Richmond, Indiana, United States|Cancer Center of Kansas - Chanute, Chanute, Kansas, United States|Cancer Center of Kansas - Dodge City, Dodge City, Kansas, United States|Cancer Center of Kansas - El Dorado, El Dorado, Kansas, United States|Newman Regional Health, Emporia, Kansas, United States|Cancer Center of Kansas - Fort Scott, Fort Scott, Kansas, United States|Saint Catherine Hospital, Garden City, Kansas, United States|Saint Rose Ambulatory and Surgery Center, Great Bend, Kansas, United States|Hays Medical Center, Hays, Kansas, United States|Cancer Center of Kansas-Independence, Independence, Kansas, United States|University of Kansas Cancer Center-West, Kansas City, Kansas, United States|University of Kansas Cancer Center, Kansas City, Kansas, United States|Cancer Center of Kansas-Kingman, Kingman, Kansas, United States|Lawrence Memorial Hospital, Lawrence, Kansas, United States|Cancer Center of Kansas-Liberal, Liberal, Kansas, United States|Cancer Center of Kansas-Manhattan, Manhattan, Kansas, United States|Cancer Center of Kansas - McPherson, McPherson, Kansas, United States|Cancer Center of Kansas - Newton, Newton, Kansas, United States|Olathe Medical Center, Olathe, Kansas, United States|University of Kansas Cancer Center-Overland Park, Overland Park, Kansas, United States|Cancer Center of Kansas - Parsons, Parsons, Kansas, United States|Via Christi Hospital-Pittsburg, Pittsburg, Kansas, United States|Cancer Center of Kansas - Pratt, Pratt, Kansas, United States|Cancer Center of Kansas - Salina, Salina, Kansas, United States|Salina Regional Health Center, Salina, Kansas, United States|Saint Francis Hospital and Medical Center - Topeka, Topeka, Kansas, United States|Cancer Center of Kansas - Wellington, Wellington, Kansas, United States|Associates In Womens Health, Wichita, Kansas, United States|Cancer Center of Kansas-Wichita Medical Arts Tower, Wichita, Kansas, United States|Cancer Center of Kansas - Wichita, Wichita, Kansas, United States|Via Christi Regional Medical Center, Wichita, Kansas, United States|Wichita NCI Community Oncology Research Program, Wichita, Kansas, United States|Cancer Center of Kansas - Winfield, Winfield, Kansas, United States|Oncology Hematology Care Inc-Crestview, Crestview Hills, Kentucky, United States|Boston Medical Center, Boston, Massachusetts, United States|Lahey Hospital and Medical Center, Burlington, Massachusetts, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|Michigan Cancer Research Consortium NCORP, Ann Arbor, Michigan, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Bronson Battle Creek, Battle Creek, Michigan, United States|Beaumont Hospital-Dearborn, Dearborn, Michigan, United States|Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States|Saint John Hospital and Medical Center, Detroit, Michigan, United States|Weisberg Cancer Treatment Center, Farmington Hills, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Mercy Health Saint Mary's, Grand Rapids, Michigan, United States|Spectrum Health at Butterworth Campus, Grand Rapids, Michigan, United States|Allegiance Health, Jackson, Michigan, United States|Sparrow Hospital, Lansing, Michigan, United States|Saint Mary Mercy Hospital, Livonia, Michigan, United States|Mercy Health Mercy Campus, Muskegon, Michigan, United States|Lakeland Community Hospital, Niles, Michigan, United States|Saint Joseph Mercy Oakland, Pontiac, Michigan, United States|Lake Huron Medical Center, Port Huron, Michigan, United States|Spectrum Health Reed City Hospital, Reed City, Michigan, United States|Saint Mary's of Michigan, Saginaw, Michigan, United States|Lakeland Hospital, Saint Joseph, Michigan, United States|Marie Yeager Cancer Center, Saint Joseph, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|Saint John Macomb-Oakland Hospital, Warren, Michigan, United States|Parkland Health Center-Bonne Terre, Bonne Terre, Missouri, United States|Saint Francis Medical Center, Cape Girardeau, Missouri, United States|Southeast Cancer Center, Cape Girardeau, Missouri, United States|Capital Region Medical Center-Goldschmidt Cancer Center, Jefferson City, Missouri, United States|Truman Medical Center, Kansas City, Missouri, United States|The University of Kansas Cancer Center-South, Kansas City, Missouri, United States|The University of Kansas Cancer Center-North, Kansas City, Missouri, United States|The University of Kansas Cancer Center-Lee's Summit, Lee's Summit, Missouri, United States|Phelps County Regional Medical Center, Rolla, Missouri, United States|Saint John's Clinic-Rolla-Cancer and Hematology, Rolla, Missouri, United States|Saint Louis Cancer and Breast Institute-South City, Saint Louis, Missouri, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, United States|Mercy Hospital Saint Louis, Saint Louis, Missouri, United States|Sainte Genevieve County Memorial Hospital, Sainte Genevieve, Missouri, United States|Cancer Research for the Ozarks NCORP, Springfield, Missouri, United States|Mercy Hospital Springfield, Springfield, Missouri, United States|CoxHealth South Hospital, Springfield, Missouri, United States|Missouri Baptist Sullivan Hospital, Sullivan, Missouri, United States|Missouri Baptist Outpatient Center-Sunset Hills, Sunset Hills, Missouri, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Montana Cancer Consortium NCORP, Billings, Montana, United States|Saint Vincent Healthcare, Billings, Montana, United States|Bozeman Deaconess Hospital, Bozeman, Montana, United States|Saint James Community Hospital and Cancer Treatment Center, Butte, Montana, United States|Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana, United States|Saint Peter's Community Hospital, Helena, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Saint Patrick Hospital - Community Hospital, Missoula, Montana, United States|Community Medical Hospital, Missoula, Montana, United States|Cancer and Blood Specialists-Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada - Henderson, Henderson, Nevada, United States|Las Vegas Cancer Center-Henderson, Henderson, Nevada, United States|21st Century Oncology - Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada-Southeast Henderson, Henderson, Nevada, United States|University Medical Center of Southern Nevada, Las Vegas, Nevada, United States|Cancer and Blood Specialists-Shadow, Las Vegas, Nevada, United States|Nevada Cancer Research Foundation CCOP, Las Vegas, Nevada, United States|Radiation Oncology Centers of Nevada Central, Las Vegas, Nevada, United States|21st Century Oncology, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-San Martin, Las Vegas, Nevada, United States|Radiation Oncology Centers of Nevada Southeast, Las Vegas, Nevada, United States|Cancer Therapy and Integrative Medicine, Las Vegas, Nevada, United States|Cancer and Blood Specialists-Tenaya, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada - Northwest, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Tenaya, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada-Summerlin, Las Vegas, Nevada, United States|Las Vegas Cancer Center-Medical Center, Las Vegas, Nevada, United States|21st Century Oncology - Fort Apache, Las Vegas, Nevada, United States|Cancer and Blood Specialists-Fort Apache, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada - Central Valley, Las Vegas, Nevada, United States|21st Century Oncology - Vegas Tenaya, Las Vegas, Nevada, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Christus Saint Vincent Regional Cancer Center, Santa Fe, New Mexico, United States|Columbia University/Herbert Irving Cancer Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|Cancer Care of Western North Carolina, Asheville, North Carolina, United States|Mission Hospital-Memorial Campus, Asheville, North Carolina, United States|Asheville Hematology-Oncology Associates, Asheville, North Carolina, United States|Southeastern Medical Oncology Center-Clinton, Clinton, North Carolina, United States|Southeastern Medical Oncology Center-Goldsboro, Goldsboro, North Carolina, United States|Wayne Memorial Hospital, Goldsboro, North Carolina, United States|Southeastern Medical Oncology Center-Jacksonville, Jacksonville, North Carolina, United States|Iredell Memorial Hospital, Statesville, North Carolina, United States|Southeastern Medical Oncology Center-Wilson, Wilson, North Carolina, United States|Southeast Clinical Oncology Research (SCOR) Consortium NCORP, Winston-Salem, North Carolina, United States|Strecker Cancer Center-Belpre, Belpre, Ohio, United States|Adena Regional Medical Center, Chillicothe, Ohio, United States|Oncology Hematology Care Inc-Eden Park, Cincinnati, Ohio, United States|Oncology Hematology Care Inc-Mercy West, Cincinnati, Ohio, United States|Oncology Hematology Care Inc - Anderson, Cincinnati, Ohio, United States|Oncology Hematology Care Inc-Kenwood, Cincinnati, Ohio, United States|Oncology Hematology Care Inc-Blue Ash, Cincinnati, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Columbus Oncology and Hematology Associates Inc, Columbus, Ohio, United States|Riverside Methodist Hospital, Columbus, Ohio, United States|Columbus NCI Community Oncology Research Program, Columbus, Ohio, United States|Grant Medical Center, Columbus, Ohio, United States|The Mark H Zangmeister Center, Columbus, Ohio, United States|Mount Carmel Health Center West, Columbus, Ohio, United States|Doctors Hospital, Columbus, Ohio, United States|Good Samaritan Hospital - Dayton, Dayton, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|Samaritan North Health Center, Dayton, Ohio, United States|Dayton NCI Community Oncology Research Program, Dayton, Ohio, United States|Delaware Health Center-Grady Cancer Center, Delaware, Ohio, United States|Delaware Radiation Oncology, Delaware, Ohio, United States|Grady Memorial Hospital, Delaware, Ohio, United States|Oncology Hematology Care Inc-Healthplex, Fairfield, Ohio, United States|Blanchard Valley Hospital, Findlay, Ohio, United States|Atrium Medical Center-Middletown Regional Hospital, Franklin, Ohio, United States|Wayne Hospital, Greenville, Ohio, United States|Kettering Medical Center, Kettering, Ohio, United States|Fairfield Medical Center, Lancaster, Ohio, United States|Marietta Memorial Hospital, Marietta, Ohio, United States|Knox Community Hospital, Mount Vernon, Ohio, United States|Licking Memorial Hospital, Newark, Ohio, United States|Newark Radiation Oncology, Newark, Ohio, United States|Southern Ohio Medical Center, Portsmouth, Ohio, United States|Springfield Regional Medical Center, Springfield, Ohio, United States|Upper Valley Medical Center, Troy, Ohio, United States|Saint Ann's Hospital, Westerville, Ohio, United States|Genesis Healthcare System Cancer Care Center, Zanesville, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Clackamas Radiation Oncology Center, Clackamas, Oregon, United States|Providence Milwaukie Hospital, Milwaukie, Oregon, United States|Providence Newberg Medical Center, Newberg, Oregon, United States|Providence Willamette Falls Medical Center, Oregon City, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence Saint Vincent Medical Center, Portland, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States|Roper Hospital, Charleston, South Carolina, United States|Charleston Hematology Oncology Associates-Roper, Charleston, South Carolina, United States|Lowcountry Hematology Oncology PA-North Charleston, Charleston, South Carolina, United States|Charleston Hematology Oncology Associates PA-St. Francis, Charleston, South Carolina, United States|Lowcountry Hematology Oncology PA-West Ashley, Charleston, South Carolina, United States|Greenville Health System Cancer Institute-Easley, Easley, South Carolina, United States|Saint Francis Hospital, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Andrews, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Butternut, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Faris, Greenville, South Carolina, United States|Greenville Memorial Hospital, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Eastside, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Greer, Greer, South Carolina, United States|Gibbs Cancer Center-Pelham, Greer, South Carolina, United States|Lowcountry Hematology Oncology PA-Mount Pleasant, Mount Pleasant, South Carolina, United States|Greenville Health System Cancer Institute-Seneca, Seneca, South Carolina, United States|Spartanburg Medical Center, Spartanburg, South Carolina, United States|Greenville Health System Cancer Institute-Spartanburg, Spartanburg, South Carolina, United States|Wellmont Bristol Regional Medical Center, Bristol, Tennessee, United States|Wellmont Medical Associates Oncology and Hematology-Johnson City, Johnson City, Tennessee, United States|Wellmont Holston Valley Hospital and Medical Center, Kingsport, Tennessee, United States|Wellmont Medical Associates Oncology and Hematology-Kingsport, Kingsport, Tennessee, United States|The Don and Sybil Harrington Cancer Center, Amarillo, Texas, United States|The Methodist Hospital System, Houston, Texas, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States|Southwest VA Regional Cancer Center, Norton, Virginia, United States|PeaceHealth Saint John Medical Center, Longview, Washington, United States|Swedish Medical Center-First Hill, Seattle, Washington, United States|PeaceHealth Southwest Medical Center, Vancouver, Washington, United States|Rocky Mountain Oncology, Casper, Wyoming, United States|Big Horn Basin Cancer Center, Cody, Wyoming, United States|Billings Clinic-Cody, Cody, Wyoming, United States|Welch Cancer Center, Sheridan, Wyoming, United States	https://ClinicalTrials.gov/show/NCT02042443
1907	East-West Hepatocellular Carcinoma Study Group	Completed	No Results Available	Carcinoma, Hepatocellular			https://ClinicalTrials.gov/show/NCT01237132
1908	Safety and Effectiveness of BioTraceIO Lite for Tissue Damage Assessment Following Liver Tissue Ablation Procedures	Recruiting	No Results Available	Carcinoma, Hepatocellular|Metastatic Liver Cancer	Device: BioTraceIO Lite	Mayo Clinic, Phoenix, Arizona, United States|Stanford Medicine, Stanford, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|University Hospitals Cleveland, Cleveland, Ohio, United States|Houston Methodist Hospital, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT04970212
1909	The Efficacy of Hepatectomy or TILA-TACE in Patients With Resectable Hepatocellular Carcinoma	Not yet recruiting	No Results Available	Surgical Resection|HCC	Procedure: TILA-TACE	The Second Affiliated Hospital Zhejiang University School of Medicine, Hanzhou, Zhejiang, China	https://ClinicalTrials.gov/show/NCT03314532
1910	Autologous HBV-specific T Cell Receptor Engineered T Cells (TCR-T) in Patients With HBV-related Advanced HCC	Recruiting	No Results Available	Hepatocellular Carcinoma	Genetic: SCG101|Biological: PD1/PD-L1 checkpoint inhibitor	Peking Union Medical College Hospital, Beijing, China|Zhongshan Hospital, Fudan University, Shanghai, China|The First Hospital of China Medical University, Shenyang, China|The Sixth People's Hospital of Shenyang, Shenyang, China	https://ClinicalTrials.gov/show/NCT05339321
1911	A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers	Completed	No Results Available	Hepatocellular Carcinoma	Drug: BR2008-1 (R)|Drug: BR2008 (T)	Bestian Hospital, Osong, Korea, Republic of	https://ClinicalTrials.gov/show/NCT05068193
1912	DYNAmic Immune Microenvironment of HCC Treated With atezolIzumab Plus bevaCizumab	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Aatezolizumab plus Bevacizumab	Asan Medical Center, Seoul, Songpa, Korea, Republic of	https://ClinicalTrials.gov/show/NCT04954339
1913	Evaluating the Effects of Selective Treatment Utilizing Flex-dosing for Unresectable HCC With Y90 SIR-Spheres	Recruiting	No Results Available	Hepatocellular Carcinoma	Procedure: SIRT with Y-90 resin microspheres	Methodist Dallas Medical Center, Dallas, Texas, United States	https://ClinicalTrials.gov/show/NCT04903548
1914	CT/MR-US Automatic Fusion System in Pre-procedure Planning for Radiofrequency Ablation	Completed	No Results Available	Hepatocellular Carcinoma	Procedure: automatic CT/MRI-US fusion system guided radiofrequency ablation		https://ClinicalTrials.gov/show/NCT04844112
1915	Sintilimab Combined With Bevacizumab Biosimilar for Potentially Resectable Intermediate HCC	Not yet recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Sintilimab|Drug: Bevacizumab Biosimilar		https://ClinicalTrials.gov/show/NCT04843943
1916	cTACE Plus Sintilimab for Unresectable Intermediate-stage HCC With Beyond Up-to-seven Criteria	Not yet recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Sintilimab|Device: TACE		https://ClinicalTrials.gov/show/NCT04842565
1917	PD-1 Antibody and Lenvatinib Plus TACE-HAIC for Potential Resectable HCC: a Single-arm, Phase 2 Clinical Trial	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: PD-1 inhibitor	Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT04814043
1918	Transarterial Infusion of PD-1 Antibody Plus TACE-HAIC for Unresectable HCC: a Single-arm, Phase 2 Clinical Trial	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: PD-1 inhibitor	Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT04814030
1919	A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Atezolizumab|Drug: Becavizumab|Device: Transarterial chemoembolization (TACE)	Peking University First Hospital, Beijing City, China|Beijing You An Hospital; Digestive Dept, Beijing City, China|Beijing Tsinghua Changgung Hospital, Beijing City, China|Hunan Cancer Hospital, Changsha City, China|Sichuan Cancer Hospital, Chengdu City, China|West China Hospital, Sichuan University; Surgical Oncology, Chengdu City, China|The First Affiliated Hospital, Chongqing Medical University, Chongqing, China|The First Affiliated Hospital Of Fujian Medical University, Fuzhou City, China|The 900th Hospital of PLA joint service support force, Fuzhou, China|Fujian Cancer Hospital, Fuzhou, China|Sun Yet-sen University Cancer Center, Guangzhou, China|Nanfang Hospital, Southern Medical University, Guangzhou, China|Harbin Medical University Cancer Hospital; internal medicine, Harbin City, China|Anhui Provincial Hospital, Hefei, China|Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University), Nanjing City, China|Jiangsu Cancer Hospital, Nanjing City, China|Guangxi Cancer Hospital of Guangxi Medical University, Nanning, China|Zhongshan Hospital Fudan Unvierstiy, Shanghai City, China|Fudan University Shanghai Cancer Center, Shanghai City, China|Shengjing Hospital of China Medical University, ShenYang, China|Tianjin Cancer Hospital; Surgical Department, Tianjin City, China|Hubei Cancer Hospital, Wuhan, China|The First Affiliated Hospital of Xi'an Jiaotong University; Hepatobiliary surgery Department, Xi'an, China|Zhejiang Cancer Hospital, Zhejiang, China|Henan Cancer Hospital, Zhengzhou, China|Zhuhai People's Hospital, Zhuhai, China|Aichi Cancer Center, Aichi, Japan|Chiba University Hospital, Chiba, Japan|Kurume University Hospital, Fukuoka, Japan|Hiroshima University Hospital, Hiroshima, Japan|Yokohama City University Medical Center, Kanagawa, Japan|Kanagawa Cancer Center, Kanagawa, Japan|Kitasato University Hospital, Kanagawa, Japan|Osaka University Hospital, Osaka, Japan|Kindai University Hospital, Osaka, Japan|Toranomon Hospital, Tokyo, Japan	https://ClinicalTrials.gov/show/NCT04712643
1920	Comparison of Multiphase and Monophasic Arterial Hepatic MRI in the Detection of Arterial Enhancement of CHC Nodules	Completed	No Results Available	Hepatocellular Carcinoma	Other: non interventional		https://ClinicalTrials.gov/show/NCT04687280
1921	Comparison of HBV Reactivation Between Patients With High HBV-DNA and Low HBV-DNA Loads Undergoing ICI and Concurrent Antiviral Prophylaxis: a Prospective Observational Study	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: ICI|Drug: Antiviral Prophylaxis	Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China|Guangzhou Twelfth People 's Hospital, Guangzhou, Guangdong, China|Kaiping Central Hospital, Kaiping, Guangdong, China|ZhongShan People 's Hospital, Zhongshan, China	https://ClinicalTrials.gov/show/NCT04680598
1922	MR Quality + Diagnostic Performance for CHC Diagnosis - Gadoxetic Acid, Gadoteric Acid and P03277 Comparison	Completed	No Results Available	Hepatocellular Carcinoma	Diagnostic Test: MRI diagnostic		https://ClinicalTrials.gov/show/NCT04652947
1923	The European NAFLD Registry	Recruiting	No Results Available	NAFLD|NASH|NASH - Nonalcoholic Steatohepatitis|Fibrosis, Liver|Steatosis of Liver|Hepatocellular Carcinoma|Cardiovascular Diseases|Type 2 Diabetes|Dyslipidaemia|Hypertension|Obesity|Other Associated Comorbidities		Universitair Ziekenhuis Antwerpen, Antwerp, Belgium|Helsinki University Hospital, Helsinki, Finland|Le Centre de Recherche Clinique (CRC) du CHU d'Angers, Angers, France|Institut ICAN - Institute of Cardiometabolism And Nutrition Hôpital de la Pitié Salpêtrière, Paris, France|UNIVERSITÄTSKLINIKUM der RWTH Aachen, Aachen, Germany|Charité University Hospital Berlin, Berlin, Germany|Universitätsklinikum Freiburg, Freiburg, Germany|UNIVERSITÄTSMEDIZIN der Johannes Gutenberg Universität Mainz, Mainz, Germany|Universitätsklinikums Würzburg, Würzburg, Germany|Laiko General Hospital of Athens, Athens, Greece|Polytechnic University of Marche, Ancona, Italy|Università degli Studi Milano, Milan, Italy|Università di Palermo, Palermo, Italy|Università Cattolica del Sacro Cuore, Rome, Italy|Department of Medical Sciences University of Torino, Turin, Italy|Amsterdam UMC, Amsterdam, Netherlands|Hospital de Santa Maria, Lisboa, Portugal|Vall d'Hebron University Hospital, Barcelona, Spain|Biodonostia Health Research Institute, Donostia, Spain|Puerta de Hierro University Hospital, Majadahonda, Spain|Marqués de Valdecilla University Hospital, Santander, Spain|Institute of Biomedicine of Sevilla (IBiS), Virgen del Rocío University Hospital, Sevilla, Spain|HU Clínico de Valladolid, Valladolid, Spain|Karolinska Universitetssjukhuset, Huddinge, Sweden|Linköping University Hospital, Linköping, Sweden|Inselspital, University Hospital, Bern, Switzerland|University Hospitals Birmingham Nhs Foundation Trust, Birmingham, United Kingdom|Addenbrooke'S Hospital, Cambridge, United Kingdom|Queen Elizabeth Hospital, Gateshead, United Kingdom|Hull Royal Infirmary, Hull, United Kingdom|Royal London Hospital, Barts Health NHS Trust, London, United Kingdom|St George's University Hospitals, London, United Kingdom|The Newcastle Upon Tyne Hospitals Nhs Foundation Trust, Newcastle-upon Tyne, United Kingdom|Queen'S Medical Centre, Nottingham, United Kingdom|Oxford University Hospitals Nhs Foundation Trust, Oxford, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Queen Alexandra Hospital, Portsmouth, United Kingdom	https://ClinicalTrials.gov/show/NCT04442334
1924	Identify Proteomic Biomarkers for Outcome Prediction of Lipiodol TACE Treatment	Not yet recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Lipiodol	UT Southwestern Medical Center, Dallas, Texas, United States	https://ClinicalTrials.gov/show/NCT04459468
1925	Safety and Efficacy of Lenvatinib in Subjects With HCC Progression After First Line Treatment With Checkpoint Inhibitors	Not yet recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Lenvatinib	Humanity & Health Clinical Trial Centre, Hong Kong, Hong Kong SAR, Hong Kong	https://ClinicalTrials.gov/show/NCT04428437
1926	Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCC	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Nivolumab and TACE/TAE|Procedure: TACE/TAE	University of Liverpool, Liverpool, United Kingdom	https://ClinicalTrials.gov/show/NCT04268888
1927	BioPearl™ Microspheres Loaded With Doxorubicin: Prospective, Single Arm, Multi-centre Post-market Follow-up Study.	Withdrawn	No Results Available	Hepatocellular Carcinoma	Device: Chemoembolization	CUB Hôpital Erasme, Brussels, Belgium|UZ Gent, Gent, Belgium|University Hospital Leuven, Leuven, Belgium	https://ClinicalTrials.gov/show/NCT04231929
1928	Longitudinal Immune-phenotyping of HCC Following MK-3475	Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Pembrolizumab	National Cancer Centre Singapore, Singapore, Singapore	https://ClinicalTrials.gov/show/NCT04224480
1929	SBRT for Hepatocellular Carcinoma Patients With Partial Response to TACE	Active, not recruiting	No Results Available	Carcinoma, Hepatocellular	Radiation: SBRT	Instituto do Cancer do Estado de Sao Paulo, Hospital das Clinicas da Faculdade de Medicina da USP, Sao Paulo, Brazil	https://ClinicalTrials.gov/show/NCT02221778
1930	An Intraoperative Guidance Platform for Radio Frequency Ablation	Active, not recruiting	No Results Available	Hepatocellular Carcinoma	Device: RFA Physics Library -- a Planning and Guidance Platform (PGP)	Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States	https://ClinicalTrials.gov/show/NCT04152343
1931	TCR-Redirected T Cells Therapy in Patient With HBV Related HCC	Recruiting	No Results Available	Hepatocellular Carcinoma	Biological: TCR redirected T cells	Beijing 302 Hospital of China, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT03899415
1932	Pretreatment Lymphocyte Monocyte Ratio on Outcome HCC Patients	Unknown status	No Results Available	Hepatocellular Carcinoma	Diagnostic Test: CBC		https://ClinicalTrials.gov/show/NCT03869151
1933	A Study on the Angioarchitecture of Hepatocellular Carcinoma	Recruiting	No Results Available	Carcinoma, Hepatocellular	Other: embolization	Department of Imaging and Interventional Radiology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong	https://ClinicalTrials.gov/show/NCT03808766
1934	Use of TheraSphere® Yttrium-90 Glass Microspheres for Primary and Metastatic Liver Tumors	Completed	No Results Available	Carcinoma, Hepatocellular|Liver Neoplasms	Device: yttrium Y 90 microspheres (TheraSphere®)	Cancer Treatment Centers of America at Southwestern Regional Medical Center, Tulsa, Oklahoma, United States	https://ClinicalTrials.gov/show/NCT00493883
1935	Phase II Study of Concurrent Lenvatinib and Radiotherapy for Advanced HCC	Recruiting	No Results Available	Hepatocellular Carcinoma|Radiotherapy|Lenvatinib	Radiation: concurrent lenvatinib and Radiotherapy, followed lenvatinib maintenance	Bo Chen, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT04791176
1936	Neoadjuvant and Adjuvant Nivolumab in HCC Patients Treated by Electroporation	Active, not recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Nivolumab Injection [Opdivo]	Hôpital Jean Verdier, Bondy, France	https://ClinicalTrials.gov/show/NCT03630640
1937	Proteomic Analysis of Human Hepatocellular Carcinoma	Completed	No Results Available	Carcinoma, Hepatocellular	Procedure: Operation	Far Eastern Memorial Hospital, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT01177631
1938	TACE Combined With Iodine-125 Seeds Implantation for HCC	Active, not recruiting	No Results Available	Hepatocellular Carcinoma|Portal Vein Occlusion|Tumor Thrombus	Procedure: TACE combined with iodine-125 seeds implantation|Procedure: TACE	The 2nd Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT03322280
1939	TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma (Prolong)	Not yet recruiting	No Results Available	Carcinoma, Hepatocellular	Drug: Lenvatinib|Procedure: TACE		https://ClinicalTrials.gov/show/NCT04560751
1940	Incidence of de Novo Hepatocellular Carcinoma After Antiviral Agents for HCV.	Unknown status	No Results Available	Hepatitis C|Cirrhosis|Antiviral Drug Adverse Reaction	Drug: Direct antiviral agents for hepatitis C	Universidad Austral, Pilar, Buenos Aires, Argentina	https://ClinicalTrials.gov/show/NCT03775798
1941	A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced HCC(RESCUE)	Unknown status	No Results Available	Hepatocellular Carcinoma	Drug: SHR 1210+apatinib	The Affiliated Hospital of the Chinese Academy of Military Medical Sciences, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT03463876
1942	Safety and Efficacy of Oncoxin Plus Surafineb in Hepatocellular Carcinoma	Unknown status	No Results Available	Quality of Life	Dietary Supplement: Oncoxin|Drug: Suranix	Farabi General Hospital, Dhaka, Bangladesh	https://ClinicalTrials.gov/show/NCT01747642
1943	Surefire Institutional DEB-TACE	Unknown status	No Results Available	Hepatocellular Carcinoma	Procedure: TACE with Surefire	Medstar Georgetown University Hospital, Washington, District of Columbia, United States	https://ClinicalTrials.gov/show/NCT03211598
1944	Kinectics of Distribution of Doxorubicin-Lipiodol Emulsion in c-TACE	Completed	No Results Available	Hepato Cellular Carcinoma	Drug: Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc iso-osmolar ionic iodinated contrast media|Drug: Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc normal saline	University Hospital, Strasbourg, france, Strasbourg, France	https://ClinicalTrials.gov/show/NCT03706157
1945	Predictive Power of Share Wave Fibro Scan in HCC After HCV Infection	Completed	No Results Available	Hepatocellular Carcinoma	Diagnostic Test: Share wave fibro scan	Assiut University, Assiut, Egypt	https://ClinicalTrials.gov/show/NCT05105828
1946	FLNA in HCC Patients	Completed	No Results Available	Hepatocellular Carcinoma			https://ClinicalTrials.gov/show/NCT03081637
1947	Efficacy and Safety of Drug Eluting Beads TACE in Treatment of HCC in Egyptian Patients	Completed	Has Results	HepatoCellular Carcinoma	Drug: Trans-arterial chemoembolization (TACE)|Drug: TACE with Drug Eluting Beads procedure		https://ClinicalTrials.gov/show/NCT03007225
1948	Analysis of cfDNA in Patients With Hepatocarcinoma and Treated by Sorafenib or Regorafenib	Active, not recruiting	No Results Available	Hepatocarcinoma	Device: Intplex test	Hôpital Saint-Eloi, Montpellier, Hérault, France|CHU Grenoble - Hôpital Michalon, Grenoble, Isère, France|Hôpital Hôtel Dieu, Nantes, Loire-Atlantique, France|CHRU Nancy - Hôpital Brabois, Vandœuvre-lès-Nancy, Meurthe Et Moselle, France|CHRU de Lille - Hôpital Claude Duriez, Lille, Nord, France|Hôpital Beaujon, Clichy, Seine-Saint-Denis, France	https://ClinicalTrials.gov/show/NCT03956940
1949	Treatment of Avatrombopag for Thrombocytopenia in Patients Undergoing Selective Resection of Hepatocellular Carcinoma	Recruiting	No Results Available	Thrombocytopenia	Drug: Avatrombopag	Zhongshan hospital, Fudan University, Shanghai, China	https://ClinicalTrials.gov/show/NCT05087459
1950	Randomized Phase II Trial of Chemoembolization and Sorafenib	Withdrawn	No Results Available	Hepatocellular Carcinoma	Drug: conventional TACE in combination with sorafenib, administered on a continuous schedule|Drug: conventional TACE in combination with sorafenib, administered on a sequential schedule	Smilow Cancer Center, New Haven, Connecticut, United States	https://ClinicalTrials.gov/show/NCT02908165
1951	Anti-angiogenesis Combined With PD-1/PD-L1 Therapy in Patients With Advanced Liver Cancer	Not yet recruiting	No Results Available	Carcinoma, Hepatocellular			https://ClinicalTrials.gov/show/NCT05383066
1952	The Combination Effect of Statin Plus Metformin on Relapse-free	Terminated	No Results Available	Hepatocellular Carcinoma	Drug: Statin and Metformin use	Taipei Medical University - WanFang Hospital, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT02819869
1953	A Novel Laparoscopic Hepatectomy Posture, Left Lateral Position Plus Jackknife Position	Completed	No Results Available	Hepatocellular Carcinoma	Procedure: Jackknife posture		https://ClinicalTrials.gov/show/NCT02809287
1954	HepaSphere Chemoembolization in Advanced HCC Patients: Safety & Efficacy Registry in China	Unknown status	No Results Available	Hepatocellular Carcinoma	Device: HepaSphere with 50-75mg Doxorubicin	Cancer Hospital Chinese Academy of Medical Science, Beijing, China|Peking Union Medical College Hospital, Beijing, China|Fifth Affiliated Hospiatl, Sun Yet-Sen University, Guangzhou, China|Nanfang Hospital, Southern Medical University, Guangzhou, China|Third Affiliated Hospiatl, Sun Yet-Sen Hospital, Guangzhou, China|Zhongshan Hospital, Fudan University, Shanghai, China	https://ClinicalTrials.gov/show/NCT02743065
1955	Prospective, Multicenter HCCIS Evaluation Study	Unknown status	No Results Available	Hepatocellular Carcinoma	Other: Overall survival		https://ClinicalTrials.gov/show/NCT02718235
1956	Resection+Highly Purified CTL Versus Resection Alone for HCC	Unknown status	No Results Available	Hepatocellular Carcinoma	Procedure: resection|Procedure: highly-purified CTL		https://ClinicalTrials.gov/show/NCT02709070
1957	RFA+Highly-purified CTL vs. RFA Alone for Recurrent HCC	Unknown status	No Results Available	Hepatocellular Carcinoma	Procedure: RFA|Procedure: RFA+highly-purified CTL	Zhen-Wei Peng, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT02678013
1958	Prospective Surveillance for Very Early Hepatocellular Carcinoma	Recruiting	No Results Available	Carcinoma, Hepatocellular		The First Hospital Affiliated to AMU (Southwest Hospital), Chongqing, Chongqing, China|Mengchao Hepatobiliary Surgery Hospital of Fujian Medical University, Fuzhou, Fujian, China|Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China|The Central Hospital of Wuhan, Wuhan, Hubei, China|Chifeng Municipal Hospital, Chifeng, Inner Mongolia, China|Xuzhou No.1 People's Hospital, Xuzhou, Jiangsu, China|Xuzhou Infectious Disease Hospital, Xuzhou, Jiangsu, China|The First Bethune of Jilin University, Changchun, Jilin, China|The Second Hospital of Shandong University, Jinan, Shandong, China|Shanghai Public Health Clinical Center, Shanghai, Shanghai, China|Shanghai Oriental Hepatobiliary Surgery Hospital, Shanghai, Shanghai, China|First Affiliated Hospital, Xinjiang Medical University, Ürümqi, Xinjiang, China|HwaMei Hospital, University of Chinese Academy of Sciences, Ningbo, Zhejiang, China	https://ClinicalTrials.gov/show/NCT03588442
1959	Sorafenib Concomitantly Used With TACE (Transarterial Chemoembolization) in uHCC (Unresectable Hepatocellular Carcinoma) Patients in China	Completed	No Results Available	Carcinoma, Hepatocellular	Drug: Sorafenib (Nexavar, BAY43-9006)	Multiple Locations, China	https://ClinicalTrials.gov/show/NCT01839630
1960	Circulating Tumor Cell Genome in Peripheral Blood From Hepatocellular Carcinoma Patients Under Radiotherapy	Unknown status	No Results Available	Circulating Neoplastic Cells|Adverse Effect of Radiation Therapy|Fatal Outcome	Genetic: hepatoma requiring radiotherapy	China Medical University Hospital, Taichung, Taiwan	https://ClinicalTrials.gov/show/NCT02066974
1961	Surefire Catheter Versus Standard End-hole Microcatheter: A Pilot Study	Suspended	No Results Available	Hepatocellular Carcinoma	Device: Surefire® Infusion System|Device: Standard End-hole catheter		https://ClinicalTrials.gov/show/NCT02446925
1962	Simo Decoction and Gum Chewing for Bowel Activity	Completed	No Results Available	Hepatocellular Carcinoma	Dietary Supplement: simo decoction|Other: gum chewing	Department of Hepatobilliary Surgery, Affiliated Tumor of Guangxi University, Nanning, Guangxi, China	https://ClinicalTrials.gov/show/NCT02438436
1963	RFA Combined With Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) for Recurrent HCC	Unknown status	No Results Available	Hepatocellular Carcinoma	Procedure: RFA|Drug: Oxaliplatin|Drug: 5-Fluorouracil/Leucovorin	Zhen-Wei Peng, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT02426450
1964	Anti-GPC3 CAR T for Treating Patients With Advanced HCC	Completed	No Results Available	Hepatocellular Carcinoma	Biological: anti-GPC3 CAR T	Shanghai Cancer Institute, Xuhui, Shanghai, China	https://ClinicalTrials.gov/show/NCT02395250
1965	Ablative Chemoembolization for Unresectable and Large Hepatocellular Carcinoma	Recruiting	No Results Available	Carcinoma, Hepatocellular	Procedure: Ablative chemoembolization (ACE)	Department of Imaging and Interventional Radiology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong	https://ClinicalTrials.gov/show/NCT03662841
1966	Clinical Outcome and Future Liver Remnant Regenerative Response in Laparoscopic Versus Open ALPPS	Recruiting	No Results Available	Liver Cancer	Procedure: Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS)	The University of Hong Kong, Hong Kong, Hong Kong	https://ClinicalTrials.gov/show/NCT04868149
1967	ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma	Recruiting	No Results Available	Carcinoma, Hepatocellular	Drug: ABX196	Scripps Clinic Torrey Pines, La Jolla, California, United States|MD Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT03897543
1968	A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma	Active, not recruiting	No Results Available	Carcinoma, Hepatocellular	Drug: Lenvatinib|Drug: Nivolumab	Eisai Trial Site 1, Kashiwa, Chiba, Japan|Eisai Trial Site 6, Iizuka, Fukuoka, Japan|Eisai Trial Site 3, Kawasaki, Kanagawa, Japan|Eisai Trial Site 4, Osakasayama, Osaka, Japan|Eisai Trial Site 2, Chuo-ku, Tokyo, Japan|Eisai Trial Site 5, Chiba, Japan	https://ClinicalTrials.gov/show/NCT03418922
1969	DCE-MRI Using Dotarem® in Evaluation of Therapeutic Response to Sorafenib in Patients With Advanced Stage HCC	Terminated	Has Results	Hepatocellular Carcinoma	Drug: Gadoterate meglumine	Guerbet Korea, Seoul, Gangnam Gu, Korea, Republic of	https://ClinicalTrials.gov/show/NCT01806740
1970	Primary Cell Culture of Hepatic Tumorous Cells From Routine Fine-needle Aspiration	Completed	Has Results	Hepatocellular Carcinoma		Kaohsiung Medical University Hospital, Kaohsiung, Taiwan	https://ClinicalTrials.gov/show/NCT01549275
1971	Study of Guanábana Leaves for The Treatment of Patients With Gastric, Gastroesophageal Junction, Pancreatic and Colorectal Adenocarcinomas; Hepatocellular Carcinoma, and Low Grade Lymphomas	Recruiting	No Results Available	Gastric Adenocarcinoma|Adenocarcinoma of the Gastroesophageal Junction|Hepatocellular Carcinoma|Pancreatic Adenocarcinoma|Low Grade Lymphoma|Colorectal Adenocarcinoma	Dietary Supplement: Tea Made of Graviola Leaves	Auxilio Mutuo Cancer Center, San Juan, Puerto Rico	https://ClinicalTrials.gov/show/NCT04773769
1972	Study of Tyroserleutide for Injection in Hepatocellular Carcinoma (HCC) Patients	Unknown status	No Results Available	Hepatocellular,Carcinoma	Drug: Tyroserleutide for injection ,chemotherapy(mitomycin, and Fluorouracil )|Drug: the placebo ,chemotherapy(mitomycin, and Fluorouracil )	Fudan University Zhongshan Hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT01489566
1973	Measuring and Improving the Safety of Test Result Follow-Up	Active, not recruiting	No Results Available	Lung Cancer|Breast Cancer|Colon Cancer|Bladder Cancer|Hepatocellular Cancer	Behavioral: SAFER TRACKS Intervention	Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas, United States|White River Junction VA Medical Center, White River Junction, VT, White River Junction, Vermont, United States	https://ClinicalTrials.gov/show/NCT04166240
1974	Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma	Recruiting	No Results Available	Carcinoma, Hepatocellular	Other: Comprehensive Geriatric Assessment (CGA)	Mays Cancer Center, San Antonio, Texas, United States	https://ClinicalTrials.gov/show/NCT03894917
1975	Arsenic Trioxide TACE and Intravenous Administration in Unresectable Hepatocellular Carcinoma	Unknown status	No Results Available	Carcinoma, Hepatocellular	Device: Arsenic trioxide TACE|Drug: Arsenic trioxide intravenous infusion|Drug: lipiodol|Drug: NaCl solution		https://ClinicalTrials.gov/show/NCT01861912
1976	Oxaliplatin in Unresectable Hepatocellular Carcinoma	Completed	No Results Available	Carcinoma, Hepatocellular	Drug: Oxaliplatin		https://ClinicalTrials.gov/show/NCT00280618
1977	Phase II Study of Avelumab in Patients With Advanced Hepatocellular Carcinoma After Prior Sorafenib Treatment	Completed	No Results Available	Carcinoma, Hepatocellular	Drug: Avelumab	Seoul National University Hospital, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT03389126
1978	Study of Sorafenib In Combination With Low-dose 5-fluorouracil/Cisplatin (FP) Intraarterial Infusion Chemotherapy	Completed	No Results Available	Hepatocellular Carcinoma	Drug: sorafenib, cisplatin, fluorouracil	Kurume University Medical Center, Kurume, Fukuoka, Japan|Ogaki Municipal Hospital, Oogaki, Gifu, Japan|Kinki University School of Medicine, Osaka-Sayama, Osaka, Japan	https://ClinicalTrials.gov/show/NCT00933816
1979	A Study of LY2157299 in Participants With Hepatocellular Carcinoma	Completed	Has Results	Carcinoma, Hepatocellular	Drug: LY2157299|Drug: Sorafenib|Drug: Ramucirumab	Highlands Oncology Group, Fayetteville, Arkansas, United States|University of California, San Francisco, San Francisco, California, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|MD Anderson Cancer Center Orlando, Orlando, Florida, United States|Northwestern University, Chicago, Illinois, United States|Indiana Univ Melvin & Bren Simon Cancer Center, Indianapolis, Indiana, United States|Lahey Clinic Medical Center, Burlington, Massachusetts, United States|Weill Cornell Medical College, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nedlands, Western Australia, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Greenslopes, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Heidelberg, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St. Leonards, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brest, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Caen, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Clichy, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Creteil, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lille, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lyon, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Marseille, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Montpellier, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pessac, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Saint Etienne, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Herblain, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Strasbourg, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vandoeuvre Les Nancy, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Berlin, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Erlangen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Göttingen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Köln, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mainz, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Münster, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bari, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rome, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rozzano, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Auckland, New Zealand|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain	https://ClinicalTrials.gov/show/NCT01246986
1980	Endoarterial Treatment in Combination With Percutaneous Thermoablation for Medium-sized and Oligonodular Hepatocellular Carcinomas	Completed	No Results Available	Carcinoma, Hepatocellular		Nice Hospital, Nice, France	https://ClinicalTrials.gov/show/NCT04172194
1981	TACE Combined With Anlotinib Treatment of Middle-advanced Hepatocellular Carcinoma (HCC) Patients	Unknown status	No Results Available	Carcinoma, Hepatocellular	Device: TACE|Drug: Anlotinib Hydrochloride	Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China	https://ClinicalTrials.gov/show/NCT04066543
1982	A Phase II, Open-Label Trial Evaluating GV1001 in Advanced Hepatocellular Carcinoma.	Completed	No Results Available	Carcinoma, Hepatocellular	Biological: GV1001	Michel Beaugrand, Bondy, France|Tim F. Greten, Hannover, Germany|Jordi Bruix, Barcelona, Spain	https://ClinicalTrials.gov/show/NCT00444782
1983	A Trial of Complete Versus Selective HepaticVascular Clamping in Hepatectomy	Completed	No Results Available	Hepatocellular Carcinoma	Procedure: Pringle's Maneuver|Procedure: Hemihepatic vascular Clamping|Procedure: Portal vein occlusion	Eastern Hepatobiliary Surgery Hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT00851968
1984	A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With or Without Dasabuvir and With or Without Ribavirin in Chronic Hepatitis C Virus Genotype 1 or 4 Infected Adults With Successfully Treated Early Stage Hepatocellular Carcinoma	Terminated	Has Results	Chronic Hepatitis C Infection	Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir|Drug: ombitasvir/paritaprevir/ritonavir|Drug: ribavirin		https://ClinicalTrials.gov/show/NCT02504099
1985	Trial of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma	Unknown status	No Results Available	Carcinoma, Hepatocellular	Drug: epirubicin|Drug: Cisplatin	Department of Digestive Surgery, Nihon University School of Medicine, Itabashi, Tokyo, Japan	https://ClinicalTrials.gov/show/NCT00843934
1986	Testing of ADI-PEG in Hepatocellular Carcinoma	Completed	No Results Available	Carcinoma, Hepatocellular	Drug: ADI-PEG 20	MD Anderson Cancer center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT00056992
1987	Phase I Study of Image-Guided Radiation Concurrent With Double-Agent Chemotherapy for Hepatocellular Carcinoma	Unknown status	No Results Available	Carcinoma, Hepatocellular	Radiation: IGRT|Drug: Capecitabine|Drug: Oxaliplatin	Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT02403544
1988	TACE+Tilelizumab+Sorafenib in the Treatment of BCLC Stage C HCC	Not yet recruiting	No Results Available	BCLC Stage C Hepatocellular Carcinoma	Procedure: TACE|Drug: Tilelizumab|Drug: Sorafenib	The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China	https://ClinicalTrials.gov/show/NCT04992143
1989	Identification of Image Phenotypes to Predict Recurrence After Resection of Hepatocellular Carcinoma	Completed	No Results Available	CT Scans Prior to Surgery With a Least 2 Years of Follow-up	Other: Non intervention	Paul Brousse Hospital, Villejuif, France	https://ClinicalTrials.gov/show/NCT05235490
1990	A Study Comparing Radiofrequency Ablation and Hepatic Resection for Hepatocellular Carcinoma	Terminated	No Results Available	Carcinoma, Hepatocellular	Procedure: Hepatic resection|Procedure: Radiofrequency ablation		https://ClinicalTrials.gov/show/NCT02482909
1991	Role of Huachansu in Treating Hepatocellular Carcinoma and the Correlation With Na+/K+-ATPase	Unknown status	No Results Available	Carcinoma, Hepatocellular	Drug: Huachansu|Other: TACE	Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT01715532
1992	Phase I Study to Evaluate the Safety and Efficacy of Telomelysin (OBP-301) in Patients With Hepatocellular Carcinoma	Unknown status	No Results Available	Carcinoma, Hepatocellular	Biological: OBP-301	Pusan National University Hospital, Busan, Korea, Republic of|National Taiwan University Hospital, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT02293850
1993	Transarterial Embolization Alone Versus Drug-Eluting Beads Chemoembolization for Hepatocellular Carcinoma	Recruiting	No Results Available	Carcinoma, Hepatocellular	Combination Product: DEB-TACE|Device: TAE	IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy	https://ClinicalTrials.gov/show/NCT04803019
1994	Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular Carcinoma	Completed	No Results Available	Carcinoma, Hepatocellular	Drug: JNJ-42756493 (erdafitinib)	Changchun, China|Guangzhou, China|Hangzhou, China|Harbin, China|Nanjing, China|Shanghai, China|Seoul, Korea, Republic of|Kaohsiung, Taiwan|Tainan, Taiwan|Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT02421185
1995	A Study to Evaluate Efficacy and Safety of TheraSphere and Resection Combination Therapy in Patients With Single Large ((> 5cm, Long Diameter ) Hepatocellular Carcinoma : Exploratory Trial	Completed	No Results Available	Carcinoma, Hepatocellular	Device: Theraspere	Seoul National University Hospital, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT05038397
1996	MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery	Completed	Has Results	Advanced Adult Hepatocellular Carcinoma|Localized Non-Resectable Adult Liver Carcinoma|Recurrent Adult Liver Carcinoma|Recurrent Gallbladder Carcinoma|Stage IV Distal Bile Duct Cancer|Stage IV Gallbladder Cancer|Unresectable Extrahepatic Bile Duct Carcinoma|Unresectable Gallbladder Carcinoma	Drug: Akt Inhibitor MK2206|Other: Diagnostic Laboratory Biomarker Analysis|Other: Pharmacological Study	USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|Emory University/Winship Cancer Institute, Atlanta, Georgia, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Seidman Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|M D Anderson Cancer Center, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT01425879
1997	Randomized Trial Comparing Stereotactic Body Radiation Therapy to Microwave Ablation for the Treatment of Localized Hepatocellular Carcinoma	Withdrawn	No Results Available	Carcinoma, Hepatocellular	Radiation: Microwave Ablation (MWA)|Radiation: Stereotactic Body Radiation Therapy (SBRT)	The University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States	https://ClinicalTrials.gov/show/NCT03168152
1998	A National Registry of Patients With Hepatocellular Carcinoma	Completed	No Results Available	Carcinoma, Hepatocellular		Vanderbilt University, Nashville, Tennessee, United States	https://ClinicalTrials.gov/show/NCT00178867
1999	Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma	Completed	Has Results	Carcinoma, Hepatocellular	Drug: Regorafenib (Stivarga, BAY73-4506)|Drug: Placebo	Los Angeles, California, United States|Los Angeles, California, United States|Orange, California, United States|Aurora, Colorado, United States|Washington, District of Columbia, United States|Gainesville, Florida, United States|Tampa, Florida, United States|Chicago, Illinois, United States|Louisville, Kentucky, United States|Worcester, Massachusetts, United States|Minneapolis, Minnesota, United States|Saint Louis, Missouri, United States|New York, New York, United States|Rochester, New York, United States|Pittsburgh, Pennsylvania, United States|Richmond, Virginia, United States|Seattle, Washington, United States|Pilar, Buenos Aires, Argentina|Camperdown, New South Wales, Australia|Liverpool, New South Wales, Australia|Herston, Queensland, Australia|Clayton, Victoria, Australia|Box Hill, Australia|Linz, Oberösterreich, Austria|Graz, Steiermark, Austria|Wien, Austria|Bruxelles - Brussel, Belgium|La Louviere, Belgium|Salvador, Bahia, Brazil|Sao Paulo, Brazil|Hefei, Anhui, China|Fuzhou, Fujian, China|Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Nanning, Guangxi, China|Harbin, Heilongjiang, China|Wuhan, Hubei, China|Changsha, Hunan, China|Nanjing, Jiangsu, China|Suzhou, Jiangsu, China|Dalian, Liaoning, China|Xi'an, Shaanxi, China|Xi'an, Shaanxi, China|Xi'an, Shaanxi, China|Chengdu, Sichuan, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Chongqing, China|Shanghai, China|Shanghai, China|Shanghai, China|Tianjin, China|Hradec Kralove, Czechia|Olomouc, Czechia|Praha 2, Czechia|Angers, France|Caen, France|Clichy, France|Creteil, France|Dijon, France|La Tronche, France|Lille, France|Lyon, France|Marseille, France|Montpellier Cedex, France|Nice Cedex 3, France|Paris, France|Paris, France|Perpignan, France|Reims Cedex, France|Rennes Cedex, France|Toulouse, France|Vandoeuvre les Nancy, France|Villejuif Cedex, France|Heidelberg, Baden-Württemberg, Germany|München, Bayern, Germany|Frankfurt, Hessen, Germany|Hannover, Niedersachsen, Germany|Aachen, Nordrhein-Westfalen, Germany|Essen, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Mainz, Rheinland-Pfalz, Germany|Magdeburg, Sachsen-Anhalt, Germany|Berlin, Germany|Hamburg, Germany|Budapest, Hungary|Debrecen, Hungary|Kaposvar, Hungary|Napoli, Campania, Italy|Bologna, Emilia-Romagna, Italy|Modena, Emilia-Romagna, Italy|Roma, Lazio, Italy|Genova, Liguria, Italy|Bergamo, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Novara, Piemonte, Italy|Torino, Piemonte, Italy|Foggia, Puglia, Italy|Cagliari, Sardegna, Italy|Pisa, Toscana, Italy|Padova, Veneto, Italy|Chiba-shi, Chiba, Japan|Kashiwa-shi, Chiba, Japan|Fukuoka-shi, Fukuoka, Japan|Iizuka-shi, Fukuoka, Japan|Yokohama-shi, Kanagawa, Japan|Kumamoto-shi, Kumamoto, Japan|Osaka-shi, Osaka, Japan|Osakasayama-shi, Osaka, Japan|Utsunomiya-shi, Tochigi, Japan|Chiyoda-ku, Tokyo, Japan|Chuo-ku, Tokyo, Japan|Musashino-shi, Tokyo, Japan|Busan, Busan Gwang''yeogsi, Korea, Republic of|Daegu, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Amsterdam, Netherlands|Leiden, Netherlands|Barnaul, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Singapore, Singapore|Oviedo, Asturias, Spain|Alicante, Spain|Barcelona, Spain|Barcelona, Spain|Córdoba, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Zaragoza, Spain|Bellinzona, Ticino, Switzerland|Bern, Switzerland|Kaohsiung City, Kaohsiung, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan|Birmingham, West Midlands, United Kingdom|Leeds, West Yorkshire, United Kingdom|Bristol, United Kingdom|London, United Kingdom|London, United Kingdom	https://ClinicalTrials.gov/show/NCT01774344
2000	Needle Guiding Robot for Radiofrequency Ablation: Safety and Efficacy Study on Hepatocellular Carcinoma Patients	Unknown status	No Results Available	Carcinoma, Hepatocellular	Device: Needle guiding robot	Asan Medical Center, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT03005756
2001	Transarterial Chemoembolization Versus Proton Beam Radiotherapy for the Treatment of Hepatocellular Carcinoma	Completed	No Results Available	Carcinoma, Hepatocellular	Procedure: Transarterial Chemoembolization|Radiation: Proton Beam Radiotherapy	Loma Linda University Medical Center, Loma Linda, California, United States	https://ClinicalTrials.gov/show/NCT00857805
2002	TACE Combined With Synchronous Radiofrequency /Microwave Ablation to Treat Large and Huge Hepatocellular Carcinoma	Unknown status	No Results Available	Carcinoma, Hepatocellular	Procedure: Thermal Ablation|Drug: EADM|Drug: Ultra-fluid lipiodol|Other: Gelatin sponge articles	Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT02630108
2003	Freehand Ultrasound Elasticity Imaging in Liver Surgery	Terminated	No Results Available	Liver Tumors		SKCCC, Baltimore, Maryland, United States	https://ClinicalTrials.gov/show/NCT00942383
2004	Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP)	Completed	No Results Available	Carcinoma, Hepatocellular	Drug: Apatinib|Drug: Placebo	Jiangsu hengrui medicine CO. LTD, Lianyungang, Jiangsu, China	https://ClinicalTrials.gov/show/NCT02329860
2005	Safety Study of BAY73-4506 in Patients With Hepatocellular Carcinoma	Completed	No Results Available	Carcinoma, Hepatocellular	Drug: BAY73-4506	Regensburg, Bayern, Germany|Frankfurt, Hessen, Germany|Essen, Nordrhein-Westfalen, Germany|Mainz, Rheinland-Pfalz, Germany|Magdeburg, Sachsen-Anhalt, Germany|Rozzano, Milano, Italy|Bologna, Italy|Milano, Italy|Milano, Italy|Roma, Italy|Daegu, Korea, Republic of|Seoul, Korea, Republic of|Barcelona, Spain	https://ClinicalTrials.gov/show/NCT01003015
2006	Study on Therapeutic Effect of Combination of Envafolimab, Lenavatinib and TACE in Advanced HCC Patients	Recruiting	No Results Available	Advanced Hepatocellular Carcinoma	Drug: Envafolimab|Procedure: TACE|Drug: Lenvatinib	the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China	https://ClinicalTrials.gov/show/NCT05213221
2007	Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma	Withdrawn	No Results Available	Carcinoma, Hepatocellular	Device: CyberKnife|Procedure: TACE|Drug: CT Contrast|Drug: doxorubicin|Drug: Epirubicin|Drug: 5-fluorouracil|Drug: Mitomycin C|Drug: Gemcitabine|Drug: Cisplatin|Device: SMANCS	Stanford University School of Medicine, Stanford, California, United States	https://ClinicalTrials.gov/show/NCT01327521
2008	MiRNA as a Diagnostic and Prognostic Biomarker of Hepatocellular Carcinoma	Not yet recruiting	No Results Available	Carcinoma, Hepatocellular|Marker, Biological		National Taiwn University Hospital, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT02448056
2009	A Study of Laparoscopic Hepatectomy Versus RFA in the Treatment of Recurrent HCC	Unknown status	No Results Available	Hepatocellular Carcinoma Recurrent	Procedure: Laparoscopic Hepatectomy|Procedure: Radiofrequency Ablation	Southwest Hospital, Chongqing, Chongqing, China	https://ClinicalTrials.gov/show/NCT03313648
2010	Treatment of Hepatocellular Carcinoma: Long-Acting Somatostatin Plus Percutaneous Ethanol Instillation (PEI) Versus Long-Acting Somatostatin Alone	Unknown status	No Results Available	Carcinoma, Hepatocellular	Procedure: percutaneous ethanol instillation (PEI)	Universitaetsklinik fuer Innere Medizin IV / Gastroenterologie und Hepatologie, Vienna, Austria	https://ClinicalTrials.gov/show/NCT00121914
2011	A Dose-escalation Study of Lipotecan® Plus Radiotherapy in Locally Advanced Hepatocellular Carcinoma	Terminated	No Results Available	Carcinoma, Hepatocellular	Drug: Lipotecan® (TLC388)	Mackay Memorial Hospital, Taipei, Taiwan|Taipei Veteran General Hospital, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT01425996
2012	A Prospective, Randomized, Multicenter Study of Comparison of TACE Combination With and Without EBRT for Hepatocellular Carcinoma With Portal Vein Tumor Thrombi	Unknown status	No Results Available	Carcinoma, Hepatocellular	Radiation: RT|Procedure: TACE	Zhongshan Hosptial, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT03939845
2013	Dose Escalation Study Using Proton Beam Radiotherapy for Hepatocellular Carcinoma	Completed	No Results Available	Carcinoma, Hepatocellular	Radiation: respiratory gated proton beam radiotherapy	National Cancer Center Korea, Goyang, Gyeonggi, Korea, Republic of	https://ClinicalTrials.gov/show/NCT00662246
2014	A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma	Active, not recruiting	Has Results	Carcinoma, Hepatocellular	Drug: Atezolizumab|Drug: Bevacizumab|Drug: Sorafenib	St. Josephs Hospital and Medical Center, Phoenix, Arizona, United States|City of Hope, Duarte, California, United States|Uni of California - San Diego; Cancer Center & Dept of Medicine, La Jolla, California, United States|Kaiser Permanente Northern California, Novato, California, United States|University of California Irvine Medical Center, Orange, California, United States|Kaiser Permanente Sacramento Medical Center, Sacramento, California, United States|California Pacific Medical Center, San Francisco, California, United States|Kaiser Permanente - San Francisco Medical Center, San Francisco, California, United States|University of California Los Angeles, Santa Monica, California, United States|Kaiser Permanente - Walnut Creek, Walnut Creek, California, United States|Banner MD Anderson Cancer Center, Greeley, Colorado, United States|Georgetown University, Washington, District of Columbia, United States|Moffitt Cancer Center, Tampa, Florida, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Washington University; Wash Uni. Sch. Of Med, Saint Louis, Missouri, United States|University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico, United States|Laura and ISAAC Perlmutter Cancer Center at NYU Langone., New York, New York, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|M.D Anderson Cancer Center; Uni of Texas At Houston, Houston, Texas, United States|Swedish Cancer Inst., Seattle, Washington, United States|Bankstown-Lidcombe Hospital, Bankstown, New South Wales, Australia|St George Hospital, Kogarah, New South Wales, Australia|The Queen Elizabeth Hospital, Woodville, South Australia, Australia|Sunshine Hospital, St Albans, Victoria, Australia|Ottawa Hospital Research Institute, Ottawa, Ontario, Canada|Centre hospitalier de l'Universite de Montreal (CHUM), Montreal, Quebec, Canada|Jewish General Hospital, Montreal, Quebec, Canada|McGill University Health Centre - Glen Site, Montreal, Quebec, Canada|Peking Union Medical College Hospital, Beijing City, China|Beijing Friendship Hospital, Beijing, China|Beijing Cancer Hospital, Beijing, China|the First Hospital of Jilin University, Changchun, China|Jilin Cancer Hospital, Changchun, China|Hunan Cancer Hospital, Changsha City, China|The First People's Hospital of Foshan, Foshan, China|The 900th Hospital of PLA joint service support force, Fuzhou, China|Sun Yet-sen University Cancer Center, Guangzhou, China|Nanfang Hospital, Southern Medical University, Guangzhou, China|Zhejiang Cancer Hospital; Zhejiang Cancer Hospital cancer department, Hangzhou City, China|The First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, China|Sir Run Run Shaw Hospital, Hangzhou, China|Harbin Medical University Cancer Hospital, Harbin, China|Anhui Province Cancer Hospital, Hefei, China|The First Affiliated Hospital of Anhui Medical University, Hefei, China|General Hospital of Jinan Military Command of PLA, Jinan, China|The 81st Hospital of P.L.A., Nanjing City, China|Fudan University Shanghai Cancer Center, Shanghai City, China|Zhongshan Hospital Fudan University, Shanghai, China|Tongji Hosp, Tongji Med. Col, Huazhong Univ. of Sci. & Tech, Wuhan, China|Masarykuv onkologicky ustav, Brno, Czechia|Fakultni nemocnice Olomouc; Onkologicka klinika, Olomouc, Czechia|Hopital Claude Huriez;Gastro Enterologie, Lille, France|Hopital De La Croix Rousse; Hepatologie Gastro Enterologie, Lyon, France|Hopital Timone Adultes; Gastro Enterologie, Marseille, France|Hopital Saint-Eloi; Hepatologie-Gastro-Enterologie, Montpellier, France|Hopital Hotel Dieu Et Hme; Hepatologie Gastro Enterologie, Nantes, France|CHU Nice - Hôpital de l'Archet 2; service Hepato gastro enterologie, Nice Cedex, France|Hopital Charles Nicolle; Gastroenterologie, Rouen, France|Hopital Hautepierre; Gastro Enterologie, Strasbourg, France|Hôpital d'Adultes; Service hépato-gastro-entérologie, Vandoeuvre-les-nancy, France|Institut Gustave Roussy; Gastro-Enterologie, Villejuif, France|Campus Virchow-Klinikum Charité Centrum 13; Medizinische Klinik; Abt.Hepatologie u.Gastroenterologie, Berlin, Germany|Klinik Johann Wolfgang von Goethe Uni; Zentrum der Inneren Medizin; Medizinische Klinik I, Frankfurt, Germany|Universitaetsklinikum Hamburg-Eppendorf; I. Medizinische Klinik - Gastroenterologie, Hamburg, Germany|Med. Hochschule Hannover; Gastroenterologie, Hannover, Germany|Universitätsklinikum Leipzig Medizinische Klinik II Gastroenterolog. u. Hepatolog., Leipzig, Germany|Uniklinik Mainz; I. Medizinische Klinik, Mainz, Germany|Klinikum der Uni Regensburg; Klinik f.Innere Medizin I Abt. Hämatologie und Internistische Onkologie, Regensburg, Germany|Queen Mary Hospital; Dept. Of Haematology & Oncology, Hong Kong, Hong Kong|Prince of Wales Hosp; Dept. Of Clinical Onc, Shatin, Hong Kong|Az. Osp. Rummo; Oncologia Medica, Benevento, Campania, Italy|IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica, Meldola, Emilia-Romagna, Italy|Az. Osp. S. Luigi Gonzaga; Divisione Di Oncologia Medica, Orbassano, Piemonte, Italy|A.O.U. Cagliari-P.O. Monserrato;U.O. Oncologia, Cagliari, Sardegna, Italy|Azienda Ospedaliero - Universitaria Pisana U.O. Oncologia Medica 2 Universitaria - Polo Oncologico, Pisa, Toscana, Italy|IRCCS Istituto Oncologico Veneto (IOV); Oncologia Medica Prima, Padova, Veneto, Italy|Chiba University Hospital, Chiba, Japan|National Cancer Center Hospital East, Chiba, Japan|Kurume University Hospital, Fukuoka, Japan|Sapporo Kosei General Hosopital, Hokkaido, Japan|Hokkaido University Hospital, Hokkaido, Japan|Kanazawa University Hospital, Ishikawa, Japan|Kitasato University Hospital, Kanagawa, Japan|Kumamoto University Hospital, Kumamoto, Japan|Osaka City University Hospital, Osaka, Japan|Kindai University Hospital, Osaka, Japan|Saga-ken Medical Centre Koseikan, Saga, Japan|Shizuoka Cancer Center, Shizuoka, Japan|Japanese Red Cross Musashino Hospital, Tokyo, Japan|Chonnam National University Hwasun Hospital, Jeollanam-do, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Ulsan University Hosiptal, Ulsan, Korea, Republic of|Copernicus Podmiot Medyczny Sp. z o.o. Wojewodzkie Centrum Onkologii, Gdansk, Poland|ID Clinic, Myslowice, Poland|SP ZOZ MSWiA z WARMINSKO-MAZURSKIM CENTRUM ONKOLOGII; CLINICAL ONCOLOGY, CLINICAL IMMUNOLOGY, Olsztyn, Poland|Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy, Warszawa, Poland|Dolnośląskie Centrum Onkologii; Oddział Onkologii Klinicznej i Chemioterapii, Wrocław, Poland|FSBI "National Medical Research Center of Oncology N.N. Blokhin"; Clinical Biotechnologies, Moscow, Moskovskaja Oblast, Russian Federation|GBUZ Saint Petersburg Clinical Research Center of Specialized Types of Care (Oncology), Saint Petersburg, Russian Federation|National Cancer Centre, Singapore, Singapore|Tan Tock Seng Hospital; Oncology, Singapore, Singapore|Hospital Universitari Vall d'Hebron; Oncology, Barcelona, Spain|Hospital Clinico San Carlos; Servicio de Oncologia, Madrid, Spain|Hospital Universitario La Paz; Servicio de Oncologia, Madrid, Spain|Centro Integral Oncologico Clara Campal; Servicio de Oncología, Madrid, Spain|Hospital Universitario Miguel Servet; Servicio de Oncologia Medica, Zaragoza, Spain|National Cheng Kung University Hospital; Oncology, Tainan, Taiwan|Chi-Mei Medical Centre; Hematology & Oncology, Tainan, Taiwan|Veterans General Hospital; Cancer Center, Taipei, Taiwan|National Taiwan Uni Hospital; Dept of Oncology, Taipei, Taiwan|Chang Gung Memorial Hospital-Linkou; Dept of Oncology, Taoyuan County, Taiwan|Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|Royal Free Hospital; Dept of Oncology, London, United Kingdom|King'S College Hospital, London, United Kingdom|Christie Hospital Nhs Trust; Medical Oncology, Manchester, United Kingdom	https://ClinicalTrials.gov/show/NCT03434379
2015	Chemoembolisation of Non Resectable, Non Metastatic Hepatocellular Carcinomas	Completed	No Results Available	Carcinoma, Hepatocellular	Drug: idarubicin	Centre Hospitalier Universitaire de DIJON, Dijon, Burgundy, France	https://ClinicalTrials.gov/show/NCT01040559
2016	Comparison Study of Sorafenib and 5-fluorouracil/Mitomycin for Metastatic Hepatocellular Carcinoma	Terminated	No Results Available	Carcinoma, Hepatocellular	Drug: 5-FU|Drug: Mitomycin|Drug: sorafenib	Seoul National University Hospital, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT01171482
2017	A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy	Active, not recruiting	No Results Available	Carcinoma, Hepatocellular	Drug: Atezolizumab|Drug: Bevacizumab	Hospital General Universitario de Elche; Servicio de Oncologia, Elche, Alicante, Spain|Hospital Univ. Central de Asturias; servicio de Digestivo, Oviedo, Asturias, Spain|Corporacio Sanitaria Parc Tauli; Servicio de Hepatologia, Sabadell, Barcelona, Spain|Hospital Universitario Marques de Valdecilla; Servicio de Oncologia, Santander, Cantabria, Spain|Hospital Provincial de Castellon; Servicio de Oncologia, Castellon de La Plana, Castellon, Spain|Hospital Son Llatzer; Servicio de Oncologia, Palma de Mallorca, Islas Baleares, Spain|Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Oncologia, Santiago de Compostela, LA Coruña, Spain|Hospital de Gran Canaria Dr. Negrin; Servicio de Aparato Digestivo, Las Palmas de Gran Canaria, LAS Palmas, Spain|Hospital Universitario de Torrejon; Servicio de Oncología, Torrejón de Ardoz, Madrid, Spain|Clinica Universitaria de Navarra; Servicio de Hepatologia, Pamplona/iruña, Navarra, Spain|Hospital de Basurto; Servicio de Oncologia, Bilbao, Vizcaya, Spain|Complejo Hospitalario Universitario de Albacete; Servicio de Oncologia, Albacete, Spain|Hospital General Univ. de Alicante; Servicio de Hepatologia, Alicante, Spain|Complejo Hospitalario Torrecardenas; Servicio de Hepatologia, Almeria, Spain|Hospital Universitari Vall d'Hebron; Servicio de Hepatologia, Barcelona, Spain|Hospital Clinic i Provincial; Servicio de Hepatología, Barcelona, Spain|Hospital Universitario Reina Sofia; Servicio de Hepatologia, Cordoba, Spain|Complejo Hospitalario de Jaen-Hospital Universitario Medico Quirurgico; Servicio de Oncologia, Jaen, Spain|Hospital Lucus Augusti; Servicio de Oncologia, Lugo, Spain|Hospital General Univ. Gregorio Maranon, Madrid, Spain|Clinica Universidad de Navarra Madrid; Servicio de Oncología, Madrid, Spain|Hospital Universitario Ramón y Cajal; Servicio de Digestivo, Madrid, Spain|Hospital Clinico San Carlos; Servicio de Oncologia, Madrid, Spain|Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain|Hospital Univ. Nuestra Señora de Valme; Servicio de Oncologia, Sevilla, Spain|Hospital Universitari i Politecnic La Fe; Oncologia, Valencia, Spain|Hospital Universitario Miguel Servet; Servicio Oncologia, Zaragoza, Spain	https://ClinicalTrials.gov/show/NCT04732286
2018	A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista	Active, not recruiting	No Results Available	Carcinoma, Hepatocellular	Drug: Atezolizumab|Drug: Bevacizumab	Fondazione Pascale; U.O. Sperimentazioni Cliniche, Napoli, Campania, Italy|Azienda Osp Uni Seconda Università Degli Studi Di Napoli; Unità Operativa Oncologia Medica, Napoli, Campania, Italy|Ospedale del Mare; UOC di Oncologia, Napoli, Campania, Italy|A.O. S. Orsola Malpighi; Ambulatorio Epatocarcinoma (Bolondi), Bologna, Emilia-Romagna, Italy|Arcispedale Santa Maria Nuova; Oncologia, Reggio Emilia, Emilia-Romagna, Italy|Azienda Ospedaliera San Camillo Forlanini, Roma, Lazio, Italy|Policlinico Universitario Agostino Gemelli, Roma, Lazio, Italy|A.O. Universitaria S. Martino Di Genova, Genova, Liguria, Italy|Ospedali Riuniti - Bergamo; Gastroenterologia, Bergamo, Lombardia, Italy|Fondazione IRCCS Ospedale Maggiore Policlinico; Gastroenterologia, Milano, Lombardia, Italy|Istituto Nazionale Dei Tumori; Dipartimento Chirurgia Generale - Unita' Trapianti Fegato, Milano, Lombardia, Italy|Istituto Clinico Humanitas;U.O. Oncologia Medica Ed Ematologia, Rozzano, Lombardia, Italy|Azienda Ospedaliera Ordine Mauriziano di Torino, Torino, Piemonte, Italy|IRCCS Ospedale Casa Sollievo Della Sofferenza; Oncologia, San Giovanni Rotondo, Puglia, Italy|A.O.U. Cagliari-P.O. Monserrato;U.O. Oncologia, Cagliari, Sardegna, Italy|A.O.U. Policlinico Paolo Giaccone; Gastroenterologia ed Epatologia, Palermo, Sicilia, Italy|Azienda Ospedaliera Di Rilievo Nazionale E Di Alta Specializzazione Garibaldi, Palermo, Sicilia, Italy|A.O.U Careggi, Florence, Toscana, Italy|Azlenda Ospendaliero-Universitaria Pisana; C.O. Oncologia 2, Pisa, Toscana, Italy|Clinica Oncologica-Ospedali Riuniti Ancona, Torrette, Toscana, Italy|IOV - Istituto Oncologico Veneto - IRCCS; Oncologia Medica II, Padova, Veneto, Italy	https://ClinicalTrials.gov/show/NCT04487067
2019	Dose Escalation Study for Primary Hepatocellular Carcinoma	Completed	Has Results	Carcinoma, Hepatocellular	Radiation: Stereotactic Body Radiation	Indiana University Department of Radiation Oncology, Indianapolis, Indiana, United States	https://ClinicalTrials.gov/show/NCT00243841
2020	Trial for Hepatocellular Carcinoma Adjuvant Treatment by Lipiocis	Completed	No Results Available	Carcinoma, Hepatocellular|Hepatitis, Viral, Human	Drug: 131 I-lipiodol	Service d'Hépatologie Hôpital Saint Antoine, Paris, France	https://ClinicalTrials.gov/show/NCT00116454
2021	Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular Carcinoma	Completed	Has Results	Carcinoma, Hepatocellular	Drug: Nintedanib high dose|Drug: Nintedanib low dose|Drug: Nintedanib medium dose	1199.120.001 Boehringer Ingelheim Investigational Site, Chuo-ku, Tokyo, Japan|1199.120.005 Boehringer Ingelheim Investigational Site, Fukuoka, Fukuoka, Japan|1199.120.002 Boehringer Ingelheim Investigational Site, Kashiwa, Chiba, Japan|1199.120.003 Boehringer Ingelheim Investigational Site, Nagoya, Aichi, Japan|1199.120.004 Boehringer Ingelheim Investigational Site, Saga, Saga, Japan	https://ClinicalTrials.gov/show/NCT01594125
2022	Intra-tumor Injection of Drug-eluting Microspheres	Recruiting	No Results Available	Hepatocellular Carcinoma|Solid Tumor, Adult	Drug: Injection of drug-eluting microspheres into malignant tumors	The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT04770207
2023	A Study of GC33 (RO5137382) in Patients With Advanced or Metastatic Hepatocellular Carcinoma	Completed	No Results Available	Carcinoma, Hepatocellular	Drug: Placebo|Drug: GC33	UCLA Medical Center, Los Angeles, California, United States|National Cancer Institute; Ctr for Cancer Research, Bethesda, Maryland, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Washington Univ School of Med; Barnes-Jewish Hospital; Siteman Cancer Center, Saint Louis, Missouri, United States|Columbia University Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Vanderbilt Medical Center, Nashville, Tennessee, United States|Swedish Cancer Inst., Seattle, Washington, United States|Hospital Erasme, Bruxelles, Belgium|UZ Gent, Gent, Belgium|Hotel Dieu; Medecine A, Angers, France|CHU de GRENOBLE; UF de Cancérologie, Grenoble, France|Aphm; Hopital De La Conception, Marseille, France|Hopital de L'Archet; Pole de Reference Hepatite C, Nice, France|Hôpital Saint Antoine; Service Hépathologie, Paris, France|Hopital Purpan;Gastro Enterologie Hepatologie, Toulouse, France|Hôpital d'Adultes; Service hépato-gastro-entérologie, Vandoeuvre-les-nancy, France|Charité Uni.-medizin Berlin, Campus Virchow-Klinikum; Med. Klinik m.S. Hepatologie Gastroenterologie, Berlin, Germany|Klinik Johann Wolfgang von Goethe Uni; Zentrum der Inneren Medizin; Medizinische Klinik I, Frankfurt Am Main, Germany|Uni Heidelberg Med. Klinik; Innere Medizin IV, Heidelberg, Germany|Universitätsklinikum Leipzig, Leipzig, Germany|Klinikum rechts der Isar der TU München; Klinikapotheke, Muenchen, Germany|Queen Mary Hospital; Dept of Surgery, Pokfulam, Hong Kong|Prince of Wales Hosp; Dept. Of Clinical Onc, Shatin, Hong Kong|Azienda Ospedaliera G. Rummo; Unità Operativa di Oncologia Medica 1, Benevento, Campania, Italy|Policlinico Universitario Agostino Gemelli, Roma, Lazio, Italy|Fondazione IRCCS Ospedale Maggiore Policlinico; Gastroenterologia, Milano, Lombardia, Italy|National Cancer Center Hospital East, Chiba, Japan|Kanazawa University Hospital, Ishikawa, Japan|Kanagawa Cancer Center, Kanagawa, Japan|Kindai University Hospital, Osaka, Japan|National Cancer Center Hospital, Tokyo, Japan|Kyorin University Hospital, Tokyo, Japan|Pusan University Hospital, Busan, Korea, Republic of|National Cancer Center, Gyeonggi-do, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul St Mary's Hospital, Seoul, Korea, Republic of|Auckland Hospital; New Zealand Liver Transplant Unit, Auckland, New Zealand|National Cancer Centre; Medical Oncology, Singapore, Singapore|Hospital Universitario Marques de Valdecilla; Servicio de Oncologia, Santander, Cantabria, Spain|Hospital Universitari Vall d'Hebron; Servicio de Hepatologia, Barcelona, Spain|Hospital Clínic i Provincial; Servicio de Hematología y Oncología, Barcelona, Spain|Hospital General Universitario Gregorio Marañon; Servicio de Oncologia, Madrid, Spain|Hospital General Universitario Gregorio Marañon, Madrid, Spain|Hospital Universitario Clínico San Carlos; Servicio de Oncologia, Madrid, Spain|Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain|Hospital Universitario Miguel Servet; Servicio Hematologia, Zaragoza, Spain|Chang Gung Memorial Foundation - Kaohsiung, Kaohsiung, Taiwan|Taichung Veterans Gen Hosp, Taichung, Taiwan|National Cheng Kung Univ Hosp, Tainan, Taiwan|Taipei Veterans General Hospital, Taipei City, Taiwan|National Taiwan Uni Hospital; Dept of Oncology, Taipei, Taiwan|The Clatterbridge Cancer Ctr NHS Foundation Trust, Bebington, United Kingdom|Royal Free Hospital; Dept of Oncology, London, United Kingdom|King'S College Hospital; Haematology, London, United Kingdom	https://ClinicalTrials.gov/show/NCT01507168
2024	A Phase I Study of AZD1480 in Patients With Advanced Solid Malignancies and Advanced Hepatocellular Carcinoma in the Escalation Phase,Non-Small Cell Lung Cancer(NSCLC) and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour in the Expansion Phase.	Terminated	No Results Available	Solid Tumour|Advanced Solid Malignancies|Child-Pugh A to B7 Advanced Hepatocellular Carcinoma|EGFR and/or ROS Mutant NSCLC|Lung Metastasis Carcinoma|Gastric Cancer	Drug: AZD1480 Daily|Drug: AZD1480 BID	Research Site, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT01219543
2025	Circulating Tumor Cells for Hepatocellular Carcinoma	Unknown status	No Results Available	Carcinoma, Hepatocellular|Neoplasm Circulating Cells		National Taiwan University Hospital, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT01930383
2026	A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients	Completed	Has Results	Carcinoma, Hepatocellular	Drug: Sorafenib|Drug: BIBF 1120	1199.39.82001 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of|1199.39.82002 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of|1199.39.82003 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of|1199.39.82004 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of|1199.39.82005 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of|1199.39.82006 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of|1199.39.88606 Boehringer Ingelheim Investigational Site, Changhua, Taiwan|1199.39.88609 Boehringer Ingelheim Investigational Site, Kaohsiung, Taiwan|1199.39.88610 Boehringer Ingelheim Investigational Site, Kaohsiung, Taiwan|1199.39.88605 Boehringer Ingelheim Investigational Site, Taichung, Taiwan|1199.39.88608 Boehringer Ingelheim Investigational Site, Tainan City, Taiwan|1199.39.88602 Boehringer Ingelheim Investigational Site, Tainan, Taiwan|1199.39.88601 Boehringer Ingelheim Investigational Site, Taipei, Taiwan|1199.39.88603 Boehringer Ingelheim Investigational Site, Taipei, Taiwan|1199.39.88604 Boehringer Ingelheim Investigational Site, Taoyuan County, Taiwan|1199.39.88607 Boehringer Ingelheim Investigational Site, Yunlin County, Taiwan	https://ClinicalTrials.gov/show/NCT00987935
2027	Phase II Study of Eloxatin+5-FU/LV in Patients With Unresectable Hepatocellular Carcinoma	Completed	No Results Available	Carcinoma, Hepatocellular	Drug: Oxaliplatin|Drug: Fluorouracil|Drug: Leucovorin	Sanofi-Aventis Administrative Office, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT00559455
2028	Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)	Active, not recruiting	No Results Available	Carcinoma, Hepatocellular	Biological: pembrolizumab|Drug: placebo|Other: best supportive care (BSC)	Anhui Provincial Hospital ( Site 0032), Hefei, Anhui, China|The First Affiliated Hospital of Anhui Medical University ( Site 0005), Hefei, Anhui, China|Fuzhou General Hospital of Nanjing Military Command ( Site 0019), Fuzhou, Fujian, China|The First People s Hospital of Foshan ( Site 0033), Foshan, Guangdong, China|Guangdong General Hospital ( Site 0015), Guangzhou, Guangdong, China|Harbin Medical University Cancer Hospital ( Site 0007), Harbin, Heilongjiang, China|Wuhan Tongji Hospital ( Site 0021), Wuhan, Hubei, China|Hubei Cancer Hospital ( Site 0035), Wuhan, Hubei, China|Hunan Cancer Hospital ( Site 0027), Changsha, Hunan, China|The Third Xiangya Hospital of Central South University ( Site 0026), Changsha, Hunan, China|Jiangsu Cancer Hospital ( Site 0003), Nanjing, Jiangsu, China|The 81st Hospital of PLA ( Site 0016), Nanjing, Jiangsu, China|Nantong Tumor Hospital ( Site 0028), Nantong, Jiangsu, China|The First Affiliated Hospital of Soochow University ( Site 0025), Suzhou, Jiangsu, China|Yangzhou No.1 People's Hospital ( Site 0023), Yangzhou, Jiangsu, China|The First Hospital Of Jilin University ( Site 0001), Chang Chun, Jilin, China|Jilin Province Cancer Hospital, Department of Chemotherapy ( Site 0002), Changchun, Jilin, China|The First Affiliated Hospital of Dalian Medical University ( Site 0022), Dalian, Liaoning, China|Fudan University Shanghai Cancer Center ( Site 0024), Shanghai, Shanghai, China|The first affiliated Hospital of Xi an Jiaotong University ( Site 0014), XI An, Shanxi, China|West China Hospital of Sichuan University ( Site 0030), Chengdu, Sichuan, China|The First affiliated Hospital Zhejing University ( Site 0034), Hangzhou, Zhejiang, China|Zhejiang Cancer Hospital ( Site 0011), Hangzhou, Zhejiang, China|Beijing Cancer Hospital ( Site 0010), Beijing, China|Bengbu Medical College First Affiliated Hospital ( Site 0020), Bengbu, China|The Second Affiliated Hospital of Anhui Medical University ( Site 0008), Hefei, China|Zhongshan Hospital Fudan University ( Site 0012), Shanghai, China|Renji Hosp,Shanghai Jiao Tong University School of Medicine ( Site 0017), Shanghai, China|Hong Kong Sanatorium Hospital ( Site 0053), Hong Kong, Hong Kong|Pamela Youde Nethersole Eastern Hospital ( Site 0052), Hong Kong, Hong Kong|Princess Margaret Hospital. ( Site 0051), Hong Kong, Hong Kong|Asan Medical Center ( Site 0072), Seoul., Korea, Republic of|Seoul National University Hospital ( Site 0074), Seoul, Korea, Republic of|Severance Hospital Yonsei University Health System ( Site 0073), Seoul, Korea, Republic of|Samsung Medical Center ( Site 0071), Seoul, Korea, Republic of|Beacon Hospital Sdn Bhd ( Site 0092), Petaling Jaya, Selangor, Malaysia|University Malaya Medical Centre ( Site 0091), Kuala Lumpur, Wilayah Persekutuan, Malaysia|Hospital Universiti Kebangsaan Malaysia ( Site 0093), Cheras, Malaysia|Chia-Yi Chang Gung Memorial Hospital ( Site 0133), Chiayi, Taiwan|China Medical University Hospital ( Site 0131), Taichung, Taiwan|National Cheng Kung University Hospital ( Site 0132), Tainan, Taiwan	https://ClinicalTrials.gov/show/NCT03062358
2029	Prognostic Performance of Preoperative and Follow by Gadoxetic Enhanced MRI in HCC Patients After TACE	Not yet recruiting	No Results Available	Hepatocellular Carcinoma Stage III	Device: TACE,Ablation		https://ClinicalTrials.gov/show/NCT05125094
2030	Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Surgery or Biopsy	Recruiting	No Results Available	Gastric Cancers		The University of Chicago, Chicago, Illinois, United States	https://ClinicalTrials.gov/show/NCT01416714
2031	Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.	Completed	Has Results	Carcinoma	Drug: Everolimus|Drug: Everolimus Placebo|Other: Best Supportive Care (BSC)	Highlands Oncology Group Dept of Highlands Oncology Grp, Fayetteville, Arkansas, United States|Compassionate Cancer Care Medical Group CCCMG, Fountain Valley, California, United States|University of California San Diego - Moores Cancer Center SC - 3, La Jolla, California, United States|California Pacific Medical Center California Pacific Med, San Francisco, California, United States|Rocky Mountain Cancer Centers RMCC - Denver-Midtown (4), Greenwood Village, Colorado, United States|Queen's Medical Center Queens Cancer Center, Honolulu, Hawaii, United States|The Sidney Kimmel Cancer Center at Johns Hopkins Hospital Dept. of SKCC @ JHU, Baltimore, Maryland, United States|Massachusetts General Hospital Dept. of Mass General Hospital, Boston, Massachusetts, United States|Midwest Cancer Care Physicians Research Medical Center, Kansas City, Missouri, United States|VA Sierra Nevada Health Care System Dept. of VA Sierra Nevada HCS, Reno, Nevada, United States|University of Rochester Medical Center Rochester, Rochester, New York, United States|Northwest Cancer Specialists Rose Quarter Cancer Center, Portland, Oregon, United States|St. Luke's Hospital and Health Network St. Luke's Cancer Network (2), Bethlehem, Pennsylvania, United States|Texas Cancer Center - Abilene, Abilene, Texas, United States|Methodist Charlton Cancer Center Methodist, Dallas, Texas, United States|University of Texas Southwestern Medical Center DeptofSimmons Cancer Center(3), Dallas, Texas, United States|Cancer Care Centers of South Texas / HOAST CCC of So. TX- San Antonio, San Antonio, Texas, United States|Blue Ridge Research Center at Roanoke Neurological Center Blue Ridge Cancer Care, Roanoke, Virginia, United States|University of Washington Cancer Care SC, Seattle, Washington, United States|Novartis Investigative Site, Camperdown, New South Wales, Australia|Novartis Investigative Site, Kogarah, New South Wales, Australia|Novartis Investigative Site, Westmead, New South Wales, Australia|Novartis Investigative Site, Heidelberg, Victoria, Australia|Novartis Investigative Site, Parkville, Victoria, Australia|Novartis Investigative Site, Graz, Austria|Novartis Investigative Site, Innsbruck, Austria|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Edegem, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, London, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Nanjing, Jiangsu, China|Novartis Investigative Site, Xi'an, Shanxi, China|Novartis Investigative Site, Chengdu, Sichuan, China|Novartis Investigative Site, Hangzhou, Zhejiang, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Guangzhou, China|Novartis Investigative Site, Amiens cedex 1, France|Novartis Investigative Site, Avignon Cedex, France|Novartis Investigative Site, Bordeaux Cedex, France|Novartis Investigative Site, Caen Cedex9, France|Novartis Investigative Site, Chambray-lès-Tours, France|Novartis Investigative Site, Clermont Ferrand cedex 1, France|Novartis Investigative Site, Clichy, France|Novartis Investigative Site, Dijon, France|Novartis Investigative Site, Lille Cedex, France|Novartis Investigative Site, Lyon Cedex 04, France|Novartis Investigative Site, Marseille Cédex 5, France|Novartis Investigative Site, Montpellier Cedex 5, France|Novartis Investigative Site, Nantes Cedex 1, France|Novartis Investigative Site, Nice Cedex 3, France|Novartis Investigative Site, Reims, France|Novartis Investigative Site, Rouen Cedex, France|Novartis Investigative Site, St Priest en Jarez Cedex, France|Novartis Investigative Site, Strasbourg, France|Novartis Investigative Site, Mannheim, Baden-Württemberg, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Esslingen, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Goettingen, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Würzburg, Germany|Novartis Investigative Site, Athens, GR, Greece|Novartis Investigative Site, Larissa, GR, Greece|Novartis Investigative Site, Thessaloniki, Greece|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Debrecen, Hungary|Novartis Investigative Site, Szeged, Hungary|Novartis Investigative Site, Szombathely, Hungary|Novartis Investigative Site, Petach Tikva, Israel|Novartis Investigative Site, Ramat Gan, Israel|Novartis Investigative Site, Benevento, BN, Italy|Novartis Investigative Site, Bologna, BO, Italy|Novartis Investigative Site, Foggia, FG, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Rozzano, MI, Italy|Novartis Investigative Site, Modena, MO, Italy|Novartis Investigative Site, Palermo, PA, Italy|Novartis Investigative Site, Padova, PD, Italy|Novartis Investigative Site, Aviano, PN, Italy|Novartis Investigative Site, Pavia, PV, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Frattamaggiore, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Nagoya, Aichi, Japan|Novartis Investigative Site, Chiba-city, Chiba, Japan|Novartis Investigative Site, Kashiwa, Chiba, Japan|Novartis Investigative Site, Matsuyama, Ehime, Japan|Novartis Investigative Site, Iizuka-city, Fukuoka, Japan|Novartis Investigative Site, Gifu-shi, Gifu, Japan|Novartis Investigative Site, Ogaki-city, Gifu, Japan|Novartis Investigative Site, Kanazawa-city, Ishikawa, Japan|Novartis Investigative Site, Yokohama-city, Kanagawa, Japan|Novartis Investigative Site, Kumamoto City, Kumamoto, Japan|Novartis Investigative Site, Sendai-city, Miyagi, Japan|Novartis Investigative Site, OsakaSayama, Osaka, Japan|Novartis Investigative Site, Chuo-ku, Tokyo, Japan|Novartis Investigative Site, Mitaka-city, Tokyo, Japan|Novartis Investigative Site, Shinagawa-ku, Tokyo, Japan|Novartis Investigative Site, Fukuoka, Japan|Novartis Investigative Site, Fukuoka, Japan|Novartis Investigative Site, Osaka, Japan|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Cordoba, Andalucia, Spain|Novartis Investigative Site, Sabadell, Barcelona, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Pamplona, Navarra, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Taipei, Taiwan, ROC, Taiwan|Novartis Investigative Site, Lin-Kou, Taiwan|Novartis Investigative Site, Liouying Township, Taiwan|Novartis Investigative Site, Niaosong Township, Taiwan|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Tainan, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand	https://ClinicalTrials.gov/show/NCT01035229
2032	Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)	Active, not recruiting	No Results Available	Carcinoma, Hepatocellular	Drug: lenvatinib|Biological: pembrolizumab|Drug: saline placebo	The University of Arizona Cancer Center - North Campus ( Site 0621), Tucson, Arizona, United States|City of Hope Comprehensive Cancer Center ( Site 0587), Duarte, California, United States|Scripps Health ( Site 0644), La Jolla, California, United States|Pacific Hematology Oncology Associates ( Site 0588), San Francisco, California, United States|UCLA ( Site 0589), Santa Monica, California, United States|Georgetown University ( Site 0594), Washington, District of Columbia, United States|University of Miami, Sylvester Comprehensive Cancer Center ( Site 0596), Miami, Florida, United States|Advent Health ( Site 0595), Orlando, Florida, United States|Tampa General Medical Group ( Site 0629), Tampa, Florida, United States|Emory University Winship Cancer Institute ( Site 0639), Atlanta, Georgia, United States|University of Kansas Cancer Center ( Site 0600), Westwood, Kansas, United States|Massachusetts General Hospital ( Site 0603), Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center ( Site 0716), Boston, Massachusetts, United States|Icahn School of Medicine at Mount Sinai ( Site 0611), New York, New York, United States|University of Rochester ( Site 0613), Rochester, New York, United States|Stony Brook University Medical Center - Cancer Center ( Site 0612), Stony Brook, New York, United States|University of Oklahoma Health Science Center ( Site 0625), Oklahoma City, Oklahoma, United States|Oregon Health & Science University ( Site 0645), Portland, Oregon, United States|Eastern Regional Medical Center, Inc. ( Site 0626), Philadelphia, Pennsylvania, United States|Central Texas Veterans Healthcare System ( Site 0617), Temple, Texas, United States|Cancer Care Northwest ( Site 0636), Spokane, Washington, United States|Royal Prince Alfred Hospital ( Site 0001), Camperdown, New South Wales, Australia|Princess Alexandra Hospital ( Site 0007), Wooloongabba, Queensland, Australia|Monash Health-Monash Medical Centre ( Site 0004), Clayton, Victoria, Australia|St Vincents Hospital Melbourne ( Site 0003), Fitzroy, Victoria, Australia|Liverpool Hospital. ( Site 0002), Liverpool, Australia|BC Cancer-Vancouver Center ( Site 0056), Vancouver, British Columbia, Canada|London Health Sciences Centre ( Site 0053), London, Ontario, Canada|Sunnybrook Research Institute ( Site 0055), Toronto, Ontario, Canada|Princess Margaret Cancer Centre ( Site 0050), Toronto, Ontario, Canada|McGill University Health Centre ( Site 0052), Montreal, Quebec, Canada|Clinica Universidad Catolica del Maule ( Site 0065), Talca, Region Del Maule, Chile|Fundacion Arturo Lopez Perez ( Site 0064), Santiago, Region Metropolitana De Santiago, Chile|Pontificia Universidad Catolica de Chile ( Site 0070), Santiago, Region Metropolitana De Santiago, Chile|Instituto Clinico Oncologico del Sur ( Site 0067), Temuco, Chile|First Affiliated Hospital of Anhui Medical University ( Site 0095), Hefei, Anhui, China|Cancer Hospital Chinese Academy of Medical Sciences ( Site 0100), Beijing, Beijing, China|Beijing Cancer Hospital ( Site 0088), Beijing, Beijing, China|900 Hospital of the Joint ( Site 0091), Fuzhou, Fujian, China|Guangdong General Hospital ( Site 0092), Guangzhou, Guangdong, China|Southern Medical University Nanfang Hospital ( Site 0102), Guangzhou, Guangdong, China|Harbin Medical University Cancer Hospital ( Site 0089), Harbin, Heilongjiang, China|Wuhan Union hospital Cancer Center ( Site 0105), Wuhan, Hubei, China|Hunan Cancer Hospital ( Site 0094), Changsha, Hunan, China|The Third Xiangya Hospital of Central South University ( Site 0093), Changsha, Hunan, China|The 81st Hospital of PLA ( Site 0085), Nanjing, Jiangsu, China|Fudan University Shanghai Cancer Center ( Site 0086), Shanghai, Shanghai, China|The First Affiliated Hospital of Xi an Jiaotong University ( Site 0090), XI An, Shanxi, China|West China Hospital of Sichuan University ( Site 0087), Chengdu, Sichuan, China|Affiliated Tumor Hospital of Xinjiang Medical University ( Site 0109), Urumqi, Xinjiang, China|The First Affiliated Hospital of Zhejiang University ( Site 0097), Hangzhou, Zhejiang, China|Sir Run Run Shaw Hospital ( Site 0110), Hangzhou, Zhejiang, China|Zhejiang Cancer Hospital ( Site 0101), Hangzhou, Zhejiang, China|Zhongshan Hospital Fudan University ( Site 0096), Shanghai, China|Fundacion Centro de Investigacion Clinica CIC ( Site 0141), Medellin, Antioquia, Colombia|Hospital Pablo Tobon Uribe ( Site 0144), Medellin, Antioquia, Colombia|Hospital General de Medellin Luz Castro de Gutierrez ( Site 0137), Medellin, Antioquia, Colombia|Biomelab S A S ( Site 0145), Barranquilla, Atlantico, Colombia|Administradora Country SA - Clinica del Country ( Site 0146), Bogota, Distrito Capital De Bogota, Colombia|Instituto Nacional de Cancerologia E.S.E ( Site 0142), Bogota, Distrito Capital De Bogota, Colombia|Fundacion Valle del Lili ( Site 0140), Cali, Valle Del Cauca, Colombia|Centro Medico Imbanaco de Cali S.A ( Site 0139), Cali, Valle Del Cauca, Colombia|Institut Sainte Catherine ( Site 0167), Avignon, France|Hopital Beaujon ( Site 0160), Clichy, France|CHU Henri Mondor ( Site 0162), Creteil, France|CHRU de Lille - Hopital Claude Huriez ( Site 0159), Lille, France|Hopital de la Croix Rousse ( Site 0157), Lyon, France|Hopital Saint Joseph ( Site 0166), Marseille, France|Centre Hospitalier Regional du Orleans ( Site 0169), Orleans, France|Centre Eugene Marquis ( Site 0158), Rennes, France|CHU de Nancy Hopital Brabois Adultes ( Site 0164), Vandoeuvre les Nancy, France|Klinikum der Universitaet Aachen - RWTH ( Site 0185), Aachen, Germany|Universitaetsklinikum Carl Gustav Carus der TU Dresden ( Site 0178), Dresden, Germany|Universitaetsklinikum Essen ( Site 0188), Essen, Germany|Universitaetsklinikum Frankfurt ( Site 0180), Frankfurt am Main, Germany|Universitaetsklinikum Hamburg-Eppendorf ( Site 0184), Hamburg, Germany|Universitaetsklinik Koeln ( Site 0189), Koeln, Germany|Universitaetsklinikum Leipzig ( Site 0187), Leipzig, Germany|Otto-Von-Guericke-Universitaet Magdeburg ( Site 0182), Magdeburg, Germany|Universitaetsklinikum Tuebingen ( Site 0179), Tuebingen, Germany|Universitaetsklinikum Wuerzburg ( Site 0186), Wuerzburg, Germany|St Vincents University Hospital ( Site 0242), Dublin, Ireland|Mater Misericordiae University Hospital ( Site 0241), Dublin, Ireland|Ospedale Sacro Cuore - Don Calabria ( Site 0289), Negrar, VR, Italy|Centro di Riferimento Oncologico de Aviano Istituto Nazionale Tumori ( Site 0292), Aviano, Italy|Policlinico S. Orsola-Malpighi ( Site 0286), Bologna, Italy|Istituto Oncologico Veneto ( Site 0287), Padova, Italy|Az Osp Univ Policlin Paolo Giaccone ( Site 0284), Palermo, Italy|Fondazione Salvatore Maugeri IRCCS. ( Site 0290), Pavia, Italy|Azienda Ospedaliero-Univers. Pisana Ospedale S. Chiara ( Site 0291), Pisa, Italy|Policlinico Universitario Campus Biomedico ( Site 0288), Roma, Italy|Aichi Cancer Center Hospital ( Site 0316), Nagoya, Aichi, Japan|National Cancer Center Hospital East ( Site 0306), Kashiwa, Chiba, Japan|Kurume University Hospital ( Site 0322), Kurume, Fukuoka, Japan|Hokkaido P.W.F.A.C Sapporo-Kosei General Hospital ( Site 0304), Sapporo, Hokkaido, Japan|Kanazawa University Hospital ( Site 0315), Kanazawa, Ishikawa, Japan|Kagawa University Hospital ( Site 0324), Kita-gun, Kagawa, Japan|Kagawa Prefectural Central Hospital ( Site 0325), Takamatsu, Kagawa, Japan|Toranomon Hospital Kajigaya ( Site 0312), Kawasaki, Kanagawa, Japan|Yokohama City University Medical Center ( Site 0313), Yokohama, Kanagawa, Japan|Kanagawa Cancer Center ( Site 0314), Yokohama, Kanagawa, Japan|Kindai University Hospital ( Site 0319), Osakasayama, Osaka, Japan|Kyorin University Hospital ( Site 0309), Mitaka, Tokyo, Japan|Musashino Red Cross Hospital ( Site 0310), Musashino, Tokyo, Japan|Chiba University Hospital ( Site 0305), Chiba, Japan|National Hospital Organization Kyushu Medical Center ( Site 0321), Fukuoka, Japan|Hiroshima University Hospital ( Site 0320), Hiroshima, Japan|Osaka Red Cross Hospital ( Site 0317), Osaka, Japan|Saga-Ken Medical Centre Koseikan ( Site 0323), Saga, Japan|National Cancer Center Hospital ( Site 0307), Tokyo, Japan|Toranomon Hospital ( Site 0311), Tokyo, Japan|The University of Tokyo Hospital ( Site 0308), Tokyo, Japan|Wakayama Medical University Hospital ( Site 0318), Wakayama, Japan|Seoul National University Bundang Hospital ( Site 0464), Seongnam-si, Kyonggi-do, Korea, Republic of|Seoul National University Hospital ( Site 0462), Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of|Yonsei University Severance Hospital ( Site 0463), Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of|Asan Medical Center ( Site 0460), Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of|Samsung Medical Center ( Site 0461), Seoul, Korea, Republic of|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran ( Site 0363), Ciudad de Mexico, Cdmx, Mexico|Hospital Civil de Guadalajara Fray Antonio Alcalde ( Site 0365), Guadalajara, Jalisco, Mexico|Centro de Investigacion Medica Aguascalientes ( Site 0355), Aguascalientes, Mexico|Medical Care and Research S.A. de C.V. ( Site 0359), Merida, Mexico|CRYPTEX Investigacion Clinica S.A. de C.V. ( Site 0362), Mexico City, Mexico|Oaxaca Site Management Organization S.C. ( Site 0366), Oaxaca, Mexico|Unidad Medica Oncologica ( Site 0369), Puebla, Mexico|Auckland City Hospital ( Site 0376), Auckland, New Zealand|Christchurch Hospital ( Site 0377), Christchurch, New Zealand|Wojewodzki Szpital Specjalistyczny nr 4 w Bytomiu ( Site 0419), Bytom, Slaskie, Poland|Szpital Wojewodzki w Koszalinie im. Mikolaja Kopernika ( Site 0421), Koszalin, Zachodniopomorskie, Poland|ID Clinic ( Site 0431), Myslowice, Poland|Ars Medical Sp. z o.o. ( Site 0433), Pila, Poland|MTZ Clinical Research Sp. z o. o. ( Site 0427), Warsaw, Poland|Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 0418), Warszawa, Poland|N.N. Blokhin NMRCO ( Site 0439), Moscow, Moskva, Russian Federation|First Moscow State Medical University n.a. I.M.Sechenov ( Site 0453), Moscow, Moskva, Russian Federation|Railway Hospital of OJSC ( Site 0447), Saint Petersburg, Sankt-Peterburg, Russian Federation|City Clinical Oncology Center ( Site 0446), Saint Petersburg, Sankt-Peterburg, Russian Federation|Krasnoyarsk Regional Clinical Oncological Dispensary ( Site 0450), Krasnoyarsk, Russian Federation|Pyatigorsk Oncology Dispensary ( Site 0441), Pyatigorsk, Russian Federation|Hospital Universitari Vall d Hebron ( Site 0508), Barcelona, Barcelona [Barcelona], Spain|Hospital Universitario Puerta de Hierro ( Site 0513), Majadahonda, Madrid, Spain|Hospital General Universitario Gregorio Maranon ( Site 0504), Madrid, Spain|Hospital Universitario Ramon y Cajal ( Site 0514), Madrid, Spain|Hospital Universitario La Paz ( Site 0510), Madrid, Spain|Complejo Hospitalario Universitario de Santiago ( Site 0506), Santiago de Compostela, Spain|Hospital Universitario Virgen del Rocio ( Site 0509), Sevilla, Spain|Hospital Universitario y Politecnico La Fe de Valencia ( Site 0505), Valencia, Spain|Kaohsiung Medical University Chung-Ho Memorial Hospital ( Site 0529), Kaoshiung, Taiwan|China Medical University Hospital ( Site 0527), Taichung, Taiwan|Taichung Veterans General Hospital ( Site 0526), Taichung, Taiwan|National Cheng Kung University Hospital ( Site 0528), Tainan, Taiwan|National Taiwan University Hospital ( Site 0523), Taipei, Taiwan|Taipei Veterans General Hospital ( Site 0524), Taipei, Taiwan|Chang Gung Medical Foundation. Linkou ( Site 0525), Taoyuan, Taiwan|Siriraj Hospital. Mahidol Univerisity ( Site 0213), Bangkok Noi, Bangkok, Thailand|Songklanagarind Hospital ( Site 0214), HatYai, Songkhla, Thailand|Chiang Mai University Maharaj Nakorn Chiang Mai Hospital ( Site 0211), Chiang Mai, Thailand|Adana Sehir Hastanesi ( Site 0549), Adana, Turkey|Hacettepe Uni. Tip Fakultesi ( Site 0553), Ankara, Turkey|Abdurrahman Yurtaslan Onkoloji Hastanesi ( Site 0551), Ankara, Turkey|Akdeniz Universitesi Tip Fakultesi ( Site 0548), Antalya, Turkey|Trakya Universitesi Tip Fakultesi ( Site 0544), Edirne, Turkey|Erzurum Ataturk University Faculty of Medicine ( Site 0546), Erzurum, Turkey|Bezmi Alem Universitesi Tıp Fakultesi ( Site 0547), İstanbul, Turkey|Necmettin Erbakan Universitesi Meram Tip Fakultesi ( Site 0550), Konya, Turkey|Inonu Universitesi Medical Fakultesi ( Site 0545), Malatya, Turkey|Royal Free London NHS Foundation Trust ( Site 0567), London, London, City Of, United Kingdom|Kings College Hospital NHS Foundation Trust ( Site 0565), London, London, City Of, United Kingdom|The Clatterbridge Cancer Centre NHS Foundation Trust ( Site 0573), Birkenhead, United Kingdom|The Beatson West of Scotland Cancer Centre ( Site 0566), Glasgow, United Kingdom|The Christie NHS Foundation Trust ( Site 0575), Manchester, United Kingdom|Nottingham University Hospitals NHS Trust ( Site 0569), Nottingham, United Kingdom	https://ClinicalTrials.gov/show/NCT03713593
2033	Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)	Recruiting	No Results Available	Carcinoma, Hepatocellular	Drug: Lenvatinib|Biological: Pembrolizumab|Drug: Oral Placebo|Drug: IV Placebo|Procedure: TACE	Arizona Oncology Associates PC- HOPE ( Site 0770), Tucson, Arizona, United States|Scripps Clinic Torrey Pines ( Site 0714), La Jolla, California, United States|USC Norris Comprehensive Cancer Center ( Site 0717), Los Angeles, California, United States|UCLA Hematology/Oncology - Santa Monica ( Site 0720), Los Angeles, California, United States|UC Irvine Health ( Site 0718), Orange, California, United States|Yale Cancer Center ( Site 0724), New Haven, Connecticut, United States|Tampa General Hospital ( Site 0764), Tampa, Florida, United States|Mountain States Tumor Institute ( Site 0773), Boise, Idaho, United States|University of Iowa Hospital and Clinics ( Site 0729), Iowa City, Iowa, United States|University of Kansas Cancer Center ( Site 0731), Westwood, Kansas, United States|University of Louisville ( Site 0757), Louisville, Kentucky, United States|Tulane Medical Center ( Site 0787), New Orleans, Louisiana, United States|University Medical Center New Orleans ( Site 0733), New Orleans, Louisiana, United States|Henry Ford Hospital-GI/Hepatology Research ( Site 0735), Detroit, Michigan, United States|Saint Louis University ( Site 0769), Saint Louis, Missouri, United States|Monter Cancer Center ( Site 0780), Lake Success, New York, United States|Icahn School of Medicine at Mount Sinai ( Site 0744), New York, New York, United States|Wake Forest Baptist Health ( Site 0741), Winston-Salem, North Carolina, United States|University of Cincinnati Medical Center ( Site 0791), Cincinnati, Ohio, United States|The Ohio State University Wexner Medical Center ( Site 0759), Columbus, Ohio, United States|ProMedica Flower Hospital ( Site 0796), Sylvania, Ohio, United States|Stephenson Cancer Center ( Site 0745), Oklahoma City, Oklahoma, United States|OHSU Center for Health & Healing ( Site 0746), Portland, Oregon, United States|Penn State Hershey Medical Center ( Site 0766), Hershey, Pennsylvania, United States|Houston Methodist Research Institute ( Site 0784), Houston, Texas, United States|Edwards Comprehensive Cancer Center ( Site 0786), Huntington, West Virginia, United States|St George Hospital ( Site 0005), Kogarah, New South Wales, Australia|Princess Alexandra Hospital ( Site 0006), Brisbane, Queensland, Australia|Austin Health ( Site 0008), Heidelberg, Victoria, Australia|Alfred Health ( Site 0004), Melbourne, Victoria, Australia|Royal Perth Hospital ( Site 0002), Perth, Western Australia, Australia|Clinica de Oncologia Reichow ( Site 0052), Blumenau, Santa Catarina, Brazil|Fundacao Dr Amaral Carvalho ( Site 0050), Jau, Sao Paulo, Brazil|Hospital de Base de Sao Jose de Rio Preto ( Site 0043), Sao Jose do Rio Preto, Sao Paulo, Brazil|BP - A Beneficencia Portuguesa de São Paulo ( Site 0046), São Paulo, Sao Paulo, Brazil|A.C. Camargo Cancer Center ( Site 0054), Sao Paulo, Brazil|Centro Investigación del Cáncer James Lind ( Site 0064), Temuco, Araucania, Chile|Centro de Cancer Nuestra Senora de la Esperanza ( Site 0065), Santiago, Region M. De Santiago, Chile|Bradfordhill ( Site 0066), Santiago, Region M. De Santiago, Chile|Anhui Provincial Hospital ( Site 0092), Heifei, Anhui, China|Beijing Cancer Hospital ( Site 0099), Beijing, Beijing, China|Beijing Cancer Hospital ( Site 0105), Beijing, Beijing, China|Peking Union Medical College Hospital ( Site 0087), Beijing, Beijing, China|Chinese People s Liberation Army Army Characteristic Medical Center ( Site 0117), Chongqing, Chongqing, China|Mengchao Hepatobiliary Hospital of Fujian Medical University ( Site 0121), Fuzhou, Fujian, China|Fujian Provincial Cancer Hospital ( Site 0085), Fuzhou, Fujian, China|The First Affiliated Hospital of Fujian Medical University ( Site 0089), Fuzhou, Fujian, China|Zhongshan Hospital Fudan University (Xiamen Branch) ( Site 0133), Xiamen, Fujian, China|Zhujiang Hospital of Southern Medical University ( Site 0115), Guangzhou, Guangdong, China|Guangdong Provincial People s Hospital ( Site 0100), Guangzhou, Guangdong, China|Nanfang Hospital of Southern Medical University ( Site 0088), Guangzhou, Guangdong, China|SUN YAT-SEN UNIVERSITY CANCER CENTRE-Department of Medical Imaging and Interventional Radiology ( Si, Guangzhou, Guangdong, China|Hainan General Hospital ( Site 0112), Haikou, Hainan, China|Harbin Medical University Cancer Hospital ( Site 0090), Harbin, Heilongjiang, China|Henan Cancer Hospital ( Site 0114), Zhengzhou, Henan, China|Tongji Hospital Tongji Medical,Science & Technology ( Site 0126), Wuhan, Hubei, China|Hubei Cancer Hospital ( Site 0101), Wuhan, Hubei, China|Hunan Provincial People's Hospital ( Site 0113), Changsha, Hunan, China|Hunan Cancer Hospital ( Site 0096), Changsha, Hunan, China|The First Affiliated Hospital of Soochow University ( Site 0120), Suzhou, Jiangsu, China|Jiangxi Provincial Cancer Hospital-Cancer Hospital ( Site 0134), Nanchang, Jiangxi, China|Xi'an International Medical Center Hospital ( Site 0860), Xi'an, Shaanxi, China|The Third Affiliated Hospital of Naval Medical University ( Site 0123), Shanghai, Shanghai, China|Fudan University Shanghai Cancer Center ( Site 0106), Shanghai, Shanghai, China|Zhongshan Hospital Fudan University ( Site 0084), Shanghai, Shanghai, China|The First Affiliated Hospital of Xi an Jiaotong University ( Site 0108), XI An, Shanxi, China|West China Hospital of Sichuan University ( Site 0119), Chengdu, Sichuan, China|Suining Central Hospital ( Site 0857), Suining, Sichuan, China|Tianjin Medical University Cancer Institute & Hospital ( Site 0098), Tianjin, Tianjin, China|The First Hospital of Kunming ( Site 0124), Kunming, Yunnan, China|2nd Affil Hosp of Zhejiang University College of Medicine ( Site 0110), Hangzhou, Zhejiang, China|Sir Run Run Shaw Hospital ( Site 0094), Hangzhou, Zhejiang, China|Zhejiang Cancer Hospital ( Site 0103), Hangzhou, Zhejiang, China|Ningbo Medical Center ( Site 0132), Ningbo, Zhejiang, China|Hospital Pablo Tobon Uribe ( Site 0145), Medellin, Antioquia, Colombia|Administradora Country S.A. ( Site 0137), Bogota, Distrito Capital De Bogota, Colombia|Fundacion Cardiovascular de Colombia ( Site 0136), Bucaramanca, Santander, Colombia|Fundacion Valle del Lili ( Site 0140), Cali, Valle Del Cauca, Colombia|Herlev Hospital ( Site 0170), Herlev, Hovedstaden, Denmark|Aarhus Universitets hospital ( Site 0175), Aarhus N, Midtjylland, Denmark|Odense Universitetshospital ( Site 0160), Odense, Syddanmark, Denmark|Hopital de la Croix-Rousse ( Site 0193), Lyon, Auvergne, France|Hopital de la Timone ( Site 0188), Marseille, Bouches-du-Rhone, France|CHU Bordeaux Haut-Leveque ( Site 0185), Pessac Cedex, Gironde, France|C.H.U. de Nancy. Hopital de Brabois Adultes ( Site 0180), Vandoeuvre les Nancy, Meurthe-et-Moselle, France|A.P.H. Paris, Hopital Henri Mondor ( Site 0179), Creteil, Val-de-Marne, France|Hopital Paul Brousse ( Site 0182), Villejuif, Val-de-Marne, France|Universitaetsklinikum Freiburg ( Site 0199), Freiburg, Baden-Wurttemberg, Germany|Krankenhaus Nord-West GmbH ( Site 0208), Frankfurt am Main, Hessen, Germany|Medizinische Hochschule Hannover ( Site 0200), Hannover, Niedersachsen, Germany|Universitaetsklinikum Bonn ( Site 0203), Bonn, Nordrhein-Westfalen, Germany|Universitaetsklinikum Halle ( Site 0213), Halle (Saale), Sachsen-Anhalt, Germany|Universitaetsklinikum Leipzig ( Site 0202), Leipzig, Sachsen, Germany|Universitaetsklinikum Schleswig-Holstein-Campus Lubeck ( Site 0215), Luebeck, Schleswig-Holstein, Germany|Charite - Universitaetsmedizin ( Site 0204), Berlin, Germany|Universitaetsklinikum Hamburg-Eppendorf ( Site 0207), Hamburg, Germany|Somogy Megyei Kaposi Mór Oktató Kórház-Oncology center ( Site 0267), Kaposvár, Somogy, Hungary|Zala Megyei Szent Rafael Korhaz ( Site 0265), Zalaegerszeg, Zala, Hungary|Semmelweis University ( Site 0264), Budapest, Hungary|St Vincents University Hospital ( Site 0690), Dublin, Ireland|Rambam Health Care Campus-Oncology Division ( Site 0305), Haifa, Israel|Hadassah Ein Karem Jerusalem ( Site 0303), Jerusaelm, Israel|Rabin Medical Center ( Site 0304), Petah Tikva, Israel|Sourasky Medical Center ( Site 0306), Tel Aviv, Israel|Ospedale del Mare ( Site 0327), Napoli, Campania, Italy|ASST Grande Ospedale Metropolitano Niguarda-Oncologia Falck ( Site 0331), Milan, Milano, Italy|AOU Policlinico G. Martino ( Site 0324), Messina, Sicilia, Italy|Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico ( Site 0325), Milano, Italy|Az Osp di Rilievo Nazionale A. Cardarelli ( Site 0329), Napoli, Italy|Azienda USL della Romagna-Dipartimento di Oncologia ed Ematologia ( Site 0332), Ravenna, Italy|Policlinico Universitario -Agostino Gemelli ( Site 0328), Roma, Italy|National Cancer Center Hospital East ( Site 0347), Kashiwa, Chiba, Japan|Ehime University Hospital ( Site 0368), Toon, Ehime, Japan|Kurume University Hospital ( Site 0362), Kurume, Fukuoka, Japan|Hokkaido P.W.F.A.C Sapporo-Kosei General Hospital ( Site 0345), Sapporo, Hokkaido, Japan|Kanazawa University Hospital ( Site 0354), Kanazawa, Ishikawa, Japan|Kagawa Prefectural Central Hospital ( Site 0364), Takamatsu, Kagawa, Japan|Toranomon Hospital Kajigaya ( Site 0369), Kawasaki, Kanagawa, Japan|Yokohama City University Medical Center ( Site 0351), Yokohama, Kanagawa, Japan|Kanagawa Cancer Center ( Site 0352), Yokohama, Kanagawa, Japan|Nara Medical University Hospital ( Site 0359), Kashihara, Nara, Japan|Kindai University Hospital ( Site 0358), Osakasayama, Osaka, Japan|Saitama Medical University Hospital ( Site 0370), Iruma-gun, Saitama, Japan|Shizuoka Cancer Center Hospital and Research Institute ( Site 0365), Sunto-gun, Shizuoka, Japan|Jichi Medical University Hospital ( Site 0353), Shimotsuke, Tochigi, Japan|Chiba University Hospital ( Site 0346), Chiba, Japan|National Hospital Organization Kyushu Medical Center ( Site 0361), Fukuoka, Japan|Hiroshima University Hospital ( Site 0360), Hiroshima, Japan|Kumamoto University ( Site 0372), Kumamoto, Japan|University Hospital, Kyoto Prefectural University of Medicine ( Site 0367), Kyoto, Japan|Osaka International Cancer Institute ( Site 0357), Osaka, Japan|Japanese Red Cross Osaka Hospital ( Site 0356), Osaka, Japan|Saga-Ken Medical Centre Koseikan ( Site 0363), Saga, Japan|Toranomon Hospital ( Site 0349), Tokyo, Japan|Juntendo University Hospital ( Site 0371), Tokyo, Japan|The University of Tokyo Hospital ( Site 0348), Tokyo, Japan|Chonnam National University Hwasun Hospital ( Site 0572), Hwasun, Jeonranamdo, Korea, Republic of|Seoul National University Bundang Hospital ( Site 0570), Seongnam-si, Kyonggi-do, Korea, Republic of|Pusan National University Hospital ( Site 0568), Busan, Pusan-Kwangyokshi, Korea, Republic of|Kyungpook National University Hospital ( Site 0569), Daegu, Taegu-Kwangyokshi, Korea, Republic of|Seoul National University Hospital ( Site 0567), Seoul, Korea, Republic of|Severance Hospital Yonsei University Health System ( Site 0564), Seoul, Korea, Republic of|Asan Medical Center ( Site 0565), Seoul, Korea, Republic of|Samsung Medical Center ( Site 0566), Seoul, Korea, Republic of|The Catholic University of Korea St. Mary s Hospital ( Site 0571), Seoul, Korea, Republic of|Korea University Guro Hospital ( Site 0573), Seoul, Korea, Republic of|Maastricht University Medical Centre ( Site 0440), Maastricht, Limburg, Netherlands|AMC ( Site 0438), Amsterdam, Noord-Holland, Netherlands|Leids Universitair Medisch Centrum-Medical Oncology ( Site 0442), Leiden, Zuid-Holland, Netherlands|Erasmus University Medical Center ( Site 0439), Rotterdam, Zuid-Holland, Netherlands|Universitair Medisch Centrum Utrecht-Medical Oncology ( Site 0441), Utrecht, Netherlands|Auckland City Hospital ( Site 0459), Auckland, New Zealand|Centro Hospitalar e Universitario de Coimbra ( Site 0502), Coimbra, Portugal|Centro Hospitalar de Lisboa Central, EPE - Hosp St. Ant dos Capuchos ( Site 0505), Lisboa, Portugal|Centro Hospitalar do Porto, E.P.E. - Hospital Geral de Sto. Antonio ( Site 0504), Porto, Portugal|Inst. Portugues de Oncologia de Porto Francisco Gentil EPE ( Site 0503), Porto, Portugal|Centro Hospitalar de Sao Joao. EPE - Hospital de Sao Joao ( Site 0501), Porto, Portugal|Ad-Vance Medical Research LLC ( Site 0527), Ponce, Puerto Rico|Puerto Rico Medical Research Center LLC ( Site 0523), San Juan, Puerto Rico|VA Caribbean Healthcare System ( Site 0524), San Juan, Puerto Rico|Fundacion de Investigacion de Diego ( Site 0522), San Juan, Puerto Rico|Hospital Universitario Puerta de Hierro ( Site 0596), Majadahonda, Madrid, Spain|Hospital General Universitario de Valencia ( Site 0595), Valencia, Valenciana, Comunitat, Spain|Hospital General Universitario Gregorio Maranon ( Site 0598), Madrid, Spain|Hospital Ramon y Cajal ( Site 0593), Madrid, Spain|Hospital Clinico San Carlos ( Site 0597), Madrid, Spain|Hospital Virgen del Rocio ( Site 0591), Sevilla, Spain|Chang Gung Medical Foundation. Kaohsiung Branch ( Site 0609), Kaohsiung City, Kaohsiung, Taiwan|Kaohsiung Medical University Hospital ( Site 0611), Kaohsiung, Taiwan|China Medical University Hospital-Surgical Department ( Site 0610), Taichung, Taiwan|National Cheng Kung University Hospital ( Site 0608), Tainan, Taiwan|National Taiwan University Hospital ( Site 0606), Taipei, Taiwan|Chang Gung Medical Foundation. Linkou ( Site 0607), Taoyuan, Taiwan|Chulalongkorn University ( Site 0627), Bangkok, Krung Thep Maha Nakhon, Thailand|Ramathibodi Hospital, Mahidol University ( Site 0628), Bangkok, Krung Thep Maha Nakhon, Thailand|Faculty of Medicine Siriraj Hospital ( Site 0629), Bangkok, Krung Thep Maha Nakhon, Thailand|Hacettepe University Medical Faculty ( Site 0653), Ankara, Turkey|Trakya University Medical Faculty Balkan Oncology Hospital ( Site 0648), Edirne, Turkey|Ege University Medical Faculty Tulay Aktas Oncology Hospital ( Site 0654), Izmir, Turkey|Izmir Medical Park Hospital Department of Medical Oncology ( Site 0649), Izmir, Turkey|Konya Necmettin Erbakan University Medical Faculty ( Site 0652), Konya, Turkey|Inonu Universitesi Medical Fakultesi ( Site 0650), Malatya, Turkey|Grigoriev Institute for medical Radiology NAMS of Ukraine ( Site 0673), Kharkiv, Kharkivska Oblast, Ukraine|Communal non profit enterprise Regional Clinical Oncology Center ( Site 0669), Kharkiv, Kharkivska Oblast, Ukraine|Shalimov s NI of Surgery and Transplantation ( Site 0671), Kyiv, Kyivska Oblast, Ukraine|Barts Health NHS Trust ( Site 0692), London, London, City Of, United Kingdom|Royal Marsden NHS Foundation Trust ( Site 0694), London, London, City Of, United Kingdom|Royal Marsden NHS Trust ( Site 0693), Sutton, Surrey, United Kingdom	https://ClinicalTrials.gov/show/NCT04246177
2034	A Randomized, Double-Blinded, Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma	Completed	Has Results	Carcinoma, Hepatocellular	Drug: Sorafenib (Nexavar, BAY43-9006)|Drug: Placebo	Hefei, Anhui, China|Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Wuhan, Hubei, China|Nanjing, Jiangsu, China|Nanjing, Jiangsu, China|Dalian, Liaoning, China|Dalian, Liaoning, China|Hangzhou, Zhejiang, China|Beijing, China|Beijing, China|Chongqing, China|Shanghai, China|Shanghai, China|Tianjin, China|Seoul, Seoul Teugbyeolsi, Korea, Republic of|Daegu, Korea, Republic of|Seoul, Korea, Republic of|Changhua, Taiwan|Tainan, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan	https://ClinicalTrials.gov/show/NCT00492752
2035	Multimetabolic 18F-Fluorodeoxyglucose (FDG) and 18F-Fluorocholine (FCH) Positron Emission Tomography (PET) as an Early Predictive Factor of Overall Survival in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib	Unknown status	No Results Available	Carcinoma, Hepatocellular	Other: FDG Positron Emission Tomography|Other: FCH Positron Emission Tomography	Emilie REDERSTORFF, Dijon, France	https://ClinicalTrials.gov/show/NCT02847468
2036	A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation	Active, not recruiting	No Results Available	Carcinoma, Hepatocellular	Drug: Atezolizumab|Drug: Bevacizumab	Kaiser Permanente Los Angeles, Los Angeles, California, United States|Mercy Medical Center, Baltimore, Maryland, United States|Henry Ford Health System, Detroit, Michigan, United States|Columbia University Medical Center, New York, New York, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Tennessee Oncology; Sarah Cannon Research Institute, Nashville, Tennessee, United States|The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Swedish Cancer Institute - Edmonds Campus, Edmonds, Washington, United States|Swedish Cancer Institute - Issaquah, Issaquah, Washington, United States|Swedish Cancer Inst., Seattle, Washington, United States|St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|Riverina Cancer Care Centre, Wagga Wagga, New South Wales, Australia|Lkh-Univ. Klinikum Graz, Graz, Austria|Klinikum Klagenfurt am Wörtersee; Abt.Gastroenterologie&Hepatologie,Endokrinologie, Klagenfurt, Austria|Medizinische Universität Wien; Univ.Klinik für Innere Medizin III - Gastroenterologie & Hepatologie, Wien, Austria|Imeldaziekenhuis, Bonheiden, Belgium|AZ Delta (Campus Rumbeke), Roeselare, Belgium|Hospital Sao Rafael - HSR, Salvador, BA, Brazil|Sociedade beneficente de senhoras Hospital Sirio Libanes, Brasilia, DF, Brazil|Hospital do Cancer UOPECCAN; Pesquisa Clínica, Cascavel, PR, Brazil|Hospital das Clinicas - UFRGS, Porto Alegre, RS, Brazil|Faculdade de Medicina de Ribeirão Preto - Universidade de Sao Paulo, Ribeirao Preto, SP, Brazil|Hospital Alemao Oswaldo Cruz; Oncologia, Sao Paulo, SP, Brazil|Gordon & Leslie Diamond Health Care Centre, Vancouver, British Columbia, Canada|McGill University Health Centre - Glen Site, Montreal, Quebec, Canada|Peking Union Medical College Hospital, Beijing City, China|Cancer Hospital Chinese Academy of Medical Sciences., Beijing, China|Beijing Cancer Hospital, Beijing, China|Affiliated Hospital of Bengbu Medical College, Bengbu, China|The First Hospital of Jilin University, Changchun City, China|West China Hospital, Sichuan University, Chengdu, China|Daping Hospital of Third Military Medical University, Chongqing, China|The Second Affiliated Hospital of Dalian Medical University, Dalian, China|Mengchao Hepatobiliary Hospital Of Fujian Medical University, Fuzhou City, China|Fujian Cancer Hospital, Fuzhou, China|Cancer Center of Guangzhou Medical University, Guangzhou, China|Sun Yet-sen University Cancer Center, Guangzhou, China|Zhujiang Hospital, Southern Medical University, Guangzhou, China|Nanfang Hospital, Southern Medical University, Guangzhou, China|Zhejiang Cancer Hospital; Zhejiang Cancer Hospital cancer department, Hangzhou City, China|Harbin Medical University Cancer Hospital, Harbin, China|Anhui Province Cancer Hospital, Hefei, China|Anhui Provincial Hospital, Hefei, China|The Second Affiliated Hospital of Anhui Medical University, Hefei, China|Shandong Cancer Hospital, Jinan, China|The 81st Hospital of P.L.A., Nanjing City, China|Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing City, China|Zhongda Hospital Affiliated to Southeast University, Nanjing, China|Guangxi Cancer Hospital of Guangxi Medical University, Nanning, China|The First Affiliate Hospital of Guangxi Medical University, Nanning, China|Zhongshan Hospital Fudan Unvierstiy, Shanghai City, China|Huashan Hospital Affiliated to Fudan University, Shanghai City, China|Fudan University Shanghai Cancer Center, Shanghai City, China|Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China|The First Affiliated Hospital of China Medical University, Shenyang City, China|Shengjing Hospital of China Medical University, ShenYang, China|Tianjin Cancer Hospital, Tianjin, China|The Tumor Hospital of Xinjiang Medical University, Urumqi, China|Wuhan Union Hospital Tongji Medical College, Huazhong University of Science and Technology, Wuhan City, China|Renmin Hospital of Wuhan University, Wuhan, China|Zhongnan Hospital of Wuhan University, Wuhan, China|Hubei Cancer Hospital, Wuhan, China|Northern Jangsu People's Hospital, Yangzhou City, China|Clinica CIMCA, San José, Costa Rica|Fakultni nemocnice Brno; Interni hematologicka a onkologicka klinika, Brno, Czechia|Fakultni Thomayerova Nemocnice; Onkologicke Oddeleni, Praha, Czechia|Hopital Jean Minoz; Oncologie, Besancon, France|Hôpital Avicenne - Groupement Hospitalier Universitaire Paris Seine St Denis; Service d'Hépatologie, Bobigny Cedex, France|Hôpital Albert Michallon, La Tronche, France|Fondation Hopital Saint Joseph; Gastro-Enterologie, Marseille, France|CHU Bordeaux - Hôpital Haut-Lévêque; Service d'Hépato-Gastroentérologie et d Oncologie digestive, Pessac, France|Hopital Robert Debre; Gastro Enterologie, Reims, France|Hopital de Pontchaillou; Service Hepato Gastro Enterologie, Rennes, France|CHU de Toulouse - Hôpital Rangueil, Toulouse Cedex 09, France|Hopitaux de Brabois - Gastro-Entereologie, Vandoeuvre-les-nancy, France|Universitätsklinikum Bonn, Medizinische Klinik und Poliklinik I.; Onkologische Gastroenterologie, Bonn, Germany|Klinik Johann Wolfgang von Goethe Uni; Zentrum der Inneren Medizin; Medizinische Klinik I, Frankfurt, Germany|Klinikum der Uni Regensburg; Klinik f.Innere Medizin I Abt. Hämatologie und Internistische Onkologie, Regensburg, Germany|Universitätsklinikum Ulm; Zentrum für Innere Medizin Klinik für Innere Medizin I, Ulm, Germany|Queen Mary Hospital; Dept. Of Haematology & Oncology, Hong Kong, Hong Kong|Prince of Wales Hospital; Department of Clinical Onocology, Shatin, Hong Kong|Ospedale Regionale Di Parma; Divisione Di Oncologia Medica, Parma, Emilia-Romagna, Italy|Ospedale Maggiore Policlinico; U.O.C. di Oncologia Medica, Milano, Lombardia, Italy|Asst Santi Paolo E Carlo, Milano, Lombardia, Italy|Azlenda Ospendaliero-Universitaria Pisana; C.O. Oncologia 2, Pisa, Toscana, Italy|Chiba University Hospital, Chiba, Japan|Ehime Prefectural Central Hospital, Ehime, Japan|Hiroshima University Hospital, Hiroshima, Japan|Sapporo Kosei General Hosopital, Hokkaido, Japan|Hyogo College of Medicine Hospital, Hyogo, Japan|Japanese Red Cross Society Himeji Hospital, Hyogo, Japan|Kanazawa University Hospital, Ishikawa, Japan|Yokohama City University Medical Center, Kanagawa, Japan|Kanagawa Cancer Center, Kanagawa, Japan|Kitasato University Hospital, Kanagawa, Japan|Kumamoto University Hospital, Kumamoto, Japan|Osaka Red Cross Hospital, Osaka, Japan|Kindai University Hospital, Osaka, Japan|Tokushima University Hospital, Tokushima, Japan|Toranomon Hospital, Tokyo, Japan|The University of Tokyo Hospital, Tokyo, Japan|Japanese Red Cross Musashino Hospital, Tokyo, Japan|Pusan National University Hospital, Busan, Korea, Republic of|Kyungpook National University Hospital, Daegu, Korea, Republic of|CHA Bundang Medical Center, Gyeonggi-do, Korea, Republic of|Ajou University Medical Center, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul St Mary's Hospital, Seoul, Korea, Republic of|Borame Medical Center, Seoul, Korea, Republic of|Ulsan University Hosiptal, Ulsan, Korea, Republic of|Centro Medico Dalinde, Cdmx, Mexico CITY (federal District), Mexico|Christus Muguerza Clinica Vidriera, Monterrey, Nuevo LEON, Mexico|Oaxaca Site Management Organization, Oaxaca, Mexico|Maastricht University Medical Center, Maastricht, Netherlands|Auckland City Hospital, Auckland, New Zealand|Clínica San Gabriel; Unidad de Investigación Oncológica de la Clínica San Gabriel, Lima, Peru|Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru|Narodowy Instytut Onkologii im. M. Sklodowskiej-Curie; Klinika Gastroenterologii Onkologicznej, Warszawa, Poland|Group of companies "Medci", Moskva, Moskovskaja Oblast, Russian Federation|Clinical hospital #1, FBHI Volga district medical center, Federal Medical and Biological Agency, Nizhny Novgorod, Niznij Novgorod, Russian Federation|First Moscow State Medical University n.a. I.M. Sechenov, Moscow, Russian Federation|Russian Scientific Center of Radiology and Surgical Technologies; Dept of Radiology, St.Petersburg, Pesochny, Russian Federation|National Cancer Centre, Singapore, Singapore|Tan Tock Seng Hospital; Oncology, Singapore, Singapore|Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain|Hospital Universitario Infanta Cristina; Servicio de Oncologia, Badajoz, Spain|Hospital General Universitario Gregorio Marañon; Servicio de Oncologia, Madrid, Spain|Changhua Christian Hospital, Chang Hua, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, Taiwan|National Taiwan Uni Hospital; Dept of Oncology, Taipei, Taiwan|Taipei Veterans General Hospital; Gastroenterology Division, Taipei, Taiwan|Chang Gung Medical Foundation - Linkou; Dept. of Hepato-Gastroenterology, Taoyuan, Taiwan|Rajavithi Hospital; Division of Medical Oncology, Bangkok, Thailand|Siriraj Hospital; Medical Oncology Unit, Bangkok, Thailand|Chiang Rai Prachanukroh Hospital; Department Of Medicine, Chiang Rai, Thailand|Chulabhorn Hospital; Medical Oncology, Lak Si, Thailand|Adana Baskent University Hospital; Medical Oncology, Adana, Turkey	https://ClinicalTrials.gov/show/NCT04102098
2037	A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Sorafenib in Participants With Advanced Hepatocellular Carcinoma	Completed	No Results Available	Carcinoma, Hepatocellular	Drug: Onartuzumab|Drug: Sorafenib	Sarasota, Florida, United States|Baltimore, Maryland, United States|New York, New York, United States|Nashville, Tennessee, United States|Houston, Texas, United States|Pokfulam, Hong Kong|Singapore, Singapore|Singapore, Singapore|Tainan, Taiwan|Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT01897038
2038	Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma	Completed	Has Results	Carcinoma, Hepatocellular	Drug: Sorafenib (Nexavar, BAY43-9006)|Drug: Erlotinib (Tarceva)|Drug: Placebo	San Francisco, California, United States|Washington, District of Columbia, United States|Gainesville, Florida, United States|Miami, Florida, United States|Atlanta, Georgia, United States|Honolulu, Hawaii, United States|Maywood, Illinois, United States|Westwood, Kansas, United States|Louisville, Kentucky, United States|New Orleans, Louisiana, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Worcester, Massachusetts, United States|Detroit, Michigan, United States|Minneapolis, Minnesota, United States|New York, New York, United States|Rochester, New York, United States|Valhalla, New York, United States|Charlotte, North Carolina, United States|Philadelphia, Pennsylvania, United States|Houston, Texas, United States|Seattle, Washington, United States|Randwick, New South Wales, Australia|Brisbane, Queensland, Australia|Herston, Queensland, Australia|Clayton, Victoria, Australia|Melbourne, Victoria, Australia|Nedlands, Western Australia, Australia|Wien, Austria|Bruxelles - Brussel, Belgium|Edegem, Belgium|Gent, Belgium|Kortrijk, Belgium|La Louviere, Belgium|Leuven, Belgium|Liege, Belgium|Belo Horizonte, Minas Gerais, Brazil|Porto Alegre, Rio Grande Do Sul, Brazil|São Paulo, Sao Paulo, Brazil|Rio de Janeiro, Brazil|Sao Paulo, Brazil|Sao Paulo, Brazil|Plovdiv, Bulgaria|Sofia, Bulgaria|Varna, Bulgaria|Varna, Bulgaria|Edmonton, Alberta, Canada|Montreal, Quebec, Canada|Santiago, Chile|Santiago, Chile|Guangzhou, Guangdong, China|Nanjing, Jiangsu, China|Hangzhou, Zhejiang, China|Beijing, China|Beijing, China|Floridablanca, Colombia|Medellín, Colombia|Bordeaux, France|Clichy, France|Creteil, France|La Roche Sur Yon, France|Lille, France|Lyon, France|Marseille, France|Paris, France|Pessac, France|Vandoeuvre-les-nancy, France|Villejuif, France|Freiburg, Baden-Württemberg, Germany|Tübingen, Baden-Württemberg, Germany|München, Bayern, Germany|Regensburg, Bayern, Germany|Frankfurt, Hessen, Germany|Hannover, Niedersachsen, Germany|Essen, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Mainz, Rheinland-Pfalz, Germany|Homburg, Saarland, Germany|Berlin, Germany|Athens, Greece|Larissa, Greece|Thessaloniki, Greece|Thessaloniki, Greece|Hong Kong, Hong Kong|Shatin, Hong Kong|Beer Sheva, Israel|Haifa, Israel|Petah Tikva, Israel|Rehovot, Israel|Zrifin, Israel|Milano, Lombardia, Italy|Goyang-si, Gyeonggido, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Auckland, New Zealand|Christchurch, New Zealand|Wellington South, New Zealand|Lima, Peru|Lima, Peru|Bydgoszcz, Poland|Gdansk, Poland|Gliwice, Poland|Warszawa, Poland|Barnaul, Russian Federation|Moscow, Russian Federation|Nizhny Novgorod, Russian Federation|Singapore, Singapore|Singapore, Singapore|Johannesburg, Gauteng, South Africa|Cape Town, Western Cape, South Africa|Hospitalet de Llobregat, Barcelona, Spain|Barcelona, Spain|Lugo, Spain|Madrid, Spain|Santander, Spain|Valencia, Spain|Valencia, Spain|Tainan, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan|Sheffield, South Yorkshire, United Kingdom|Glasgow, United Kingdom|London, United Kingdom|Newcastle Upon Tyne, United Kingdom	https://ClinicalTrials.gov/show/NCT00901901
2039	Study of SECOX Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (HCC)	Completed	No Results Available	Carcinoma, Hepatocellular|Secondary	Drug: Sorafenib|Drug: Capecitabine|Drug: Oxaliplatin	Queen Mary Hospital, Hong Kong, Hong Kong	https://ClinicalTrials.gov/show/NCT02716766
2040	Combination of Transcatheter Arterial Chemoembolization (TACE) and Sorafenib for Patients With Unresectable Hepatocellular Carcinoma (HCC)	Completed	No Results Available	Carcinoma, Hepatocellular	Procedure: TACE (Transcatheter Arterial Chemoembolization )	National Cancer Center, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT00919009
2041	A Trial of Thymalfasin in Adult Patients With Hepatocellular Carcinoma	Completed	No Results Available	Carcinoma, Hepatocellular	Drug: Thymalfasin (thymosin alpha-1)|Procedure: Trans arterial chemoembolization (TACE)	California Pacific Medical Center, San Francisco, California, United States|University of Florida, Gainesville, Florida, United States|William Beaumont Hospital, Royal Oak, Michigan, United States|Columbia University, New York, New York, United States|Metropolitan Research, Fairfax, Virginia, United States	https://ClinicalTrials.gov/show/NCT00082082
2042	Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma	Completed	Has Results	Carcinoma, Hepatocellular	Drug: Sorafenib|Drug: BIBF 1120	1199.37.43001 Boehringer Ingelheim Investigational Site, Wien, Austria|1199.37.43002 Boehringer Ingelheim Investigational Site, Wien, Austria|1199.37.33001 Boehringer Ingelheim Investigational Site, Paris, France|1199.37.33002 Boehringer Ingelheim Investigational Site, Paris, France|1199.37.49008 Boehringer Ingelheim Investigational Site, Berlin, Germany|1199.37.49009 Boehringer Ingelheim Investigational Site, Erlangen, Germany|1199.37.49002 Boehringer Ingelheim Investigational Site, Freiburg, Germany|1199.37.49001 Boehringer Ingelheim Investigational Site, Hannover, Germany|1199.37.49010 Boehringer Ingelheim Investigational Site, Heidelberg, Germany|1199.37.49005 Boehringer Ingelheim Investigational Site, Jena, Germany|1199.37.49004 Boehringer Ingelheim Investigational Site, Magdeburg, Germany|1199.37.49003 Boehringer Ingelheim Investigational Site, München, Germany|1199.37.49006 Boehringer Ingelheim Investigational Site, Tübingen, Germany|1199.37.36001 Boehringer Ingelheim Investigational Site, Debrecen, Hungary|1199.37.31002 Boehringer Ingelheim Investigational Site, Leiden, Netherlands|1199.37.31001 Boehringer Ingelheim Investigational Site, Utrecht, Netherlands|1199.37.48002 Boehringer Ingelheim Investigational Site, Olsztyn, Poland|1199.37.48003 Boehringer Ingelheim Investigational Site, Warsaw, Poland|1199.37.48001 Boehringer Ingelheim Investigational Site, Warszawa, Poland|1199.37.40002 Boehringer Ingelheim Investigational Site, Bucharest, Romania|1199.37.40003 Boehringer Ingelheim Investigational Site, Cluj-Napoca, Romania|1199.37.44001 Boehringer Ingelheim Investigational Site, Edgbaston, Birmingham, United Kingdom|1199.37.44005 Boehringer Ingelheim Investigational Site, Glasgow, United Kingdom|1199.37.44008 Boehringer Ingelheim Investigational Site, Liverpool, United Kingdom|1199.37.44002 Boehringer Ingelheim Investigational Site, London, United Kingdom|1199.37.44003 Boehringer Ingelheim Investigational Site, London, United Kingdom|1199.37.44006 Boehringer Ingelheim Investigational Site, Manchester, United Kingdom|1199.37.44004 Boehringer Ingelheim Investigational Site, Nottingham, United Kingdom	https://ClinicalTrials.gov/show/NCT01004003
2043	A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC)	Completed	No Results Available	Carcinoma, Hepatocellular	Drug: RO7070179	Indiana University, Indianapolis, Indiana, United States|Laura and ISAAC Perlmutter Cancer Center at NYU Langone., New York, New York, United States|NYU Langone Medical Center; Bellevue Hospital, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Gabrail Cancer Center, Canton, Ohio, United States|Ohio State University, Columbus, Ohio, United States	https://ClinicalTrials.gov/show/NCT02564614
2044	Durvalumab (MEDI4736) and Tremelimumab in Combination With Either Y-90 SIRT or TACE for Intermediate Stage HCC With Pick-the-winner Design	Recruiting	No Results Available	Hepatocellular Carcinoma Non-resectable	Drug: Tremelimumab|Drug: Durvalumab|Procedure: Y-90 SIRT|Procedure: TACE	Hannover Medical School, Hanover, Germany|Universtitätsklinikum Schleswig-Holstein Campus Lübeck, Lübeck, Germany	https://ClinicalTrials.gov/show/NCT04522544
2045	A Dose-Finding and Exploratory Study of RO5323441 in Combination With Sorafenib in Patients With Hepatocellular Carcinoma	Completed	No Results Available	Carcinoma, Hepatocellular	Drug: RO5323441|Drug: sorafenib	Singapore, Singapore|Singapore, Singapore	https://ClinicalTrials.gov/show/NCT01308723
2046	Oral Vitamin D Treatment for the Prevention of Hepatocellular Carcinoma	Not yet recruiting	No Results Available	Hepatitis B|Carcinoma, Hepatocellular	Drug: Vitamin D3		https://ClinicalTrials.gov/show/NCT02779465
2047	Safety And Efficacy Of Irinotecan Plus Capecitabine As First-Line Treatment In Asian Subjects With Hepatocellular Carcinoma	Completed	No Results Available	Carcinoma, Hepatocellular	Drug: Irinotecan plus capecitabine	Pfizer Investigational Site, Shanghai, China|Pfizer Investigational Site, Hong Kong SAR, Hong Kong|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Keelung, Taiwan|Pfizer Investigational Site, Taipei, Taiwan|Pfizer Investigational Site, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT00635323
2048	Efficacy Study of TACE to Treat Hepatocellular Carcinoma After Operation	Unknown status	No Results Available	Carcinoma, Hepatocellular|Neoplastic Cells, Circulating	Procedure: TACE|Drug: Epirubicin|Drug: lipiodol	Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China|Nantong Tumor Hospital, Nantong, Jiangsu, China|The First Affiliated Hospital of Soochow University, Soochow, Jiangsu, China|Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, Shanghai, China|Xinhua Hospital, Affliated with Shanghai Jiao Tong University, School of Medicine, Shanghai, Shanghai, China|Zhongshan hospital, Fudan University, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT02631499
2049	Cabozantinib in Hepatocellular Carcinoma	Recruiting	No Results Available	HCC	Drug: Cabozantinib	Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong, Hong Kong|ASAN Medical Center, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT04588051
2050	Safety and Efficacy of Arsenic Trioxide Contained in TACE in the Treatment of HCC	Unknown status	No Results Available	Carcinoma, Hepatocellular	Drug: TACE containing As2O3|Drug: TACE containing placebo	Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China|Zhongda Hospital Southeast University, Nanjing, Jiangsu, China|The First Hospital of China Medical University, Shenyang, Liaoning, China|Xijing Hospital，Fourth Military Medical University, Xi'an, Shaanxi, China|Zhongshan Hospital Fudan University, Shanghai, China	https://ClinicalTrials.gov/show/NCT02018757
2051	Sorafenib Plus Tegafur-uracil (UFT) Versus Sorafenib as First Line Systemic Treatment for Patients With Advanced Stage HCC, Unresectable & Not Eligible for Local Ablation and/or TACE	Terminated	No Results Available	Advanced Hepatocellular Carcinoma	Drug: Sorafenib|Drug: sorafenib plus tegafur-uracil	Ain shams university, Cairo, Egypt|Cairo University Hospitals, Cairo, Egypt|National cancer institute, Cairo, Egypt|NHTMRI, Cairo, Egypt|National Liver Institute, Monofeiya, Egypt	https://ClinicalTrials.gov/show/NCT01539018
2052	Stereotactic Body Radiotherapy for Hepatocellular Carcinoma, and Intrahepatic Cholangiocarcinoma	Completed	No Results Available	Carcinoma, Hepatocellular|Intrahepatic Cholangiocarcinoma	Radiation: Stereotactic radiation	Washington University School of Medicine, St. Louis, Missouri, United States	https://ClinicalTrials.gov/show/NCT01668134
2053	Can Quantitative MRI After cTACE Help Predict Survival ?	Completed	No Results Available	Hepatocellular Carcinoma (HCC)	Other: MRI post-TACE	Medical College of Wisconsin/Froedtert Memorial Lutheran Hospital, Milwaukee, Wisconsin, United States	https://ClinicalTrials.gov/show/NCT02173119
2054	Diagnostic Significance of Single Center, Open and Prospective Evaluation of <Sup>18<Sup>F-FDG PET/CT Dynamic Imaging and Genomic Sequencing in Detecting Metastatic Lesions of Primary Hepatocellular Carcinoma	Recruiting	No Results Available	Positron-Emission Tomography|Carcinoma, Hepatocellular	Diagnostic Test: PET/CT dynamic scan	Hongjun Jin, Zhuhai, Guangzhou, China	https://ClinicalTrials.gov/show/NCT03636607
2055	Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers	Terminated	Has Results	Hepatocellular Carcinoma|Cholangiocellular Carcinoma|Cholangiocarcinoma of the Extrahepatic Bile Duct|Bile Duct Cancer|Periampullary Adenocarcinoma|Gallbladder Cancer|Extrahepatic Bile Duct Cancer	Drug: Cisplatin|Drug: Erlotinib|Drug: Gemcitabine	California Pacific Medical Center, San Francisco, California, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States	https://ClinicalTrials.gov/show/NCT00832637
2056	Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) Versus Doxorubicin as Palliative Chemotherapy in Advanced Hepatocellular Carcinoma Patients	Completed	No Results Available	Carcinoma, Hepatocellular	Drug: Oxaliplatin + 5-Fluorouracil/Leucovorin|Drug: Doxorubicin	Sanofi-Aventis Administrative Office, Shanghai, China|Sanofi-Aventis Administrative Office, Seoul, Korea, Republic of|Sanofi-Aventis Administrative Office, Taipei, Taiwan|Sanofi-Aventis Administrative Office, Bangkok, Thailand	https://ClinicalTrials.gov/show/NCT00471965
2057	Chronic Hepatitis B Virus Infection in Zambia	Recruiting	No Results Available	HBV|Fibrosis, Liver|Cirrhosis, Liver|Alcoholic Hepatitis|Hepatocellular Carcinoma|Hepatitis, Delta	Other: Standard of care	Tropical Gastroenterology and Nutrition Group, Lusaka, Zambia	https://ClinicalTrials.gov/show/NCT03158818
2058	TACE for HCC by TANDEM and Idarubicin	Completed	No Results Available	Hepatocellular Carcinoma (HCC)	Drug: Transarterial chemoembolization using TANDEM and idarubicin	Uhmontpellier, Montpellier, France	https://ClinicalTrials.gov/show/NCT03349957
2059	Pembrolizumab in Hepatocellular Carcinoma	Recruiting	No Results Available	HCC	Drug: pembrolizumab	Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong, Hong Kong	https://ClinicalTrials.gov/show/NCT03419481
2060	Netrin-1 & Hepatocellular Carcinoma HCC	Recruiting	No Results Available	HCC	Procedure: Quantification of netrin-1 signals by antibody-based approaches	Hepatogastroenterology service of the Croix-Rousse Hospital, Lyon, France	https://ClinicalTrials.gov/show/NCT04766736
2061	A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC).	Completed	Has Results	Carcinoma, Hepatocellular	Drug: Sorafenib (Nexavar, BAY43-9006)|Drug: Placebo	La Jolla, California, United States|Los Angeles, California, United States|San Francisco, California, United States|Gainesville, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|Atlanta, Georgia, United States|Ann Arbor, Michigan, United States|Detroit, Michigan, United States|Abbott Northwestern Hospital, Minneapolis, Minnesota, United States|Saint Louis, Missouri, United States|New York, New York, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Portland, Oregon, United States|Richmond, Virginia, United States|Seattle, Washington, United States|Seattle, Washington, United States|Camperdown, New South Wales, Australia|St Leonards, New South Wales, Australia|Greenslopes, Queensland, Australia|Clayton, Victoria, Australia|Heidelberg, Victoria, Australia|Melbourne, Victoria, Australia|Nedlands, Western Australia, Australia|Innsbruck, Austria|Wien, Austria|Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Leuven, Belgium|Liege, Belgium|Calgary, Alberta, Canada|Halifax, Nova Scotia, Canada|Toronto, Ontario, Canada|Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Xi'an, Shannxi, China|Beijing, China|Beijing, China|Shanghai, China|Shanghai, China|Creteil, France|Lille, France|Lyon Cedex, France|Lyon, France|Marseille, France|Paris, France|Paris, France|Vandoeuvre-les-nancy, France|Villejuif, France|Villejuif, France|Freiburg, Baden-Württemberg, Germany|Heidelberg, Baden-Württemberg, Germany|Tübingen, Baden-Württemberg, Germany|Erlangen, Bayern, Germany|München, Bayern, Germany|Regensburg, Bayern, Germany|Frankfurt, Hessen, Germany|Hannover, Niedersachsen, Germany|Essen, Nordrhein-Westfalen, Germany|Essen, Nordrhein-Westfalen, Germany|Münster, Nordrhein-Westfalen, Germany|Mainz, Rheinland-Pfalz, Germany|Homburg, Saarland, Germany|Jena, Thüringen, Germany|Berlin, Germany|Hamburg, Germany|Napoli, Campania, Italy|Bologna, Emilia-Romagna, Italy|Roma, Lazio, Italy|Roma, Lazio, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Torino, Piemonte, Italy|Bari, Puglia, Italy|Palermo, Sicilia, Italy|Pisa, Toscana, Italy|Padova, Veneto, Italy|Verona, Veneto, Italy|Daegu, Korea, Republic of|Gyeonggi-do, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Gangnam Severance Hospital, Yonsei University, Seoul, Korea, Republic of|Singapore, Singapore|Singapore, Singapore|Santiago de Compostela, A Coruña, Spain|Hospital Central de Asturias, Oviedo, Asturias, Spain|Badalona, Barcelona, Spain|Sabadell, Barcelona, Spain|Cruces/Barakaldo, Bilbao, Spain|Barcelona, Catalunya, Spain|Fundación Hospital Alcorcón, Alcorcón, Madrid, Spain|La Laguna, Santa Cruz de Tenerife, Spain|A Coruña, Spain|Alicante, Spain|Barcelona, Spain|Córdoba, Spain|Madrid, Spain|Madrid, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Valencia, Spain|Changhua Christian Hospital, Changhua, Taiwan|Taipei, Taiwan|Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT00855218
2062	Small and Steatotic Hepatocellular Carcinoma	Completed	No Results Available	HCC		Uhmontpellier, Montpellier, France	https://ClinicalTrials.gov/show/NCT03428321
2063	Effectiveness and Safety of the Simultaneous Radiotherapy and Hyperthermia After Transarterial Chemoembolization in Hepatocellular Carcinoma Patients Combined With Portal Vein Tumor Thrombosis	Completed	No Results Available	Carcinoma. Hepatocellular	Radiation: RT and hyperthermia after TACE	Samsung Medical Center, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT01911000
2064	Follow-up Strategy of Chronic Hepatitis B for Early Detection and Diagnosis of Hepatocellular Carcinoma: A Randomized Control Trial	Unknown status	No Results Available	Chronic Hepatitis B	Other: 3 months|Other: 6 months|Other: 3 month ultrasound(US)+3 month CT/MRI+3 month US+3 month CT/MRI	The department of Ultrasound, the third affiliated hospital of Sun Yat-sen University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT02817685
2065	Role of LncRNA H19 in The Regulation of IGF-1R Expression	Completed	No Results Available	Hepatocellular Carcinoma|Type 2 Diabetes|Cancer	Other: Blood sample collection	Gastroenterology Center, Mansoura University, Mansoura, Dakahliya, Egypt|Specialized Medical Hospital, Mansoura University, Mansoura, Dakahliya, Egypt	https://ClinicalTrials.gov/show/NCT04767750
2066	Golgi Protein for HCC Diagnosis	Completed	No Results Available	Screening for Hepatocellular Carcinoma	Diagnostic Test: Serum Golgi Protein 73		https://ClinicalTrials.gov/show/NCT03039322
2067	TILA-TACE in Treatment of Hepatocellular Carcinoma	Recruiting	No Results Available	Tumor Response Rate|Overall Survival	Procedure: TILA-TACE treatment	The Second affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China	https://ClinicalTrials.gov/show/NCT03910140
2068	Effectiveness of Drug Eluting TACE in Primary HCC	Unknown status	No Results Available	Hepatic Cell Carcinoma	Drug: HepaSphere Microspheres/Doxorubicin Hydrochloride|Drug: Lipiodol		https://ClinicalTrials.gov/show/NCT04048317
2069	Novel GPC3 CAR-T Cell Therapy for Hepatocellular Carcinoma	Not yet recruiting	No Results Available		Biological: GPC3-CAR-T cells		https://ClinicalTrials.gov/show/NCT05344664
2070	Comparison of Efficacy in SBRT of HCC ≤5 cm With or Without TACE	Recruiting	No Results Available	Small Hepatocellular Carcinoma|Stereotactic Body Radiation Therapy|Transcatheter Arterial Chemoembolization	Procedure: transcatheter arterial chemoembolization	The Fifth Medical Center of PLA General Hospital (Beijing 302 hospital), Beijing, China	https://ClinicalTrials.gov/show/NCT04161287
2071	Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases	Completed	No Results Available	Colorectal Cancer|Islet Cell Tumor|Liver Cancer|Metastatic Cancer|Neuroendocrine Carcinoma	Drug: isolated perfusion|Drug: melphalan|Procedure: conventional surgery	Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States	https://ClinicalTrials.gov/show/NCT00019786
2072	Selection Criteria for Safe Hepatectomy for Hepatocellular Carcinoma	Completed	No Results Available	Hepatectomy|Hepatecellular Carcinoma|Cirrhosis	Procedure: Hepatectomy	Humanitas Research Hospital, Rozzano, Milan, Italy	https://ClinicalTrials.gov/show/NCT02056041
2073	Combination of PD-1 and VEGFR-2 Blockade for Advanced Hepatocellular Carcinoma	Completed	No Results Available	Progress Free Survival (PFS) and Overall Survival (OS)	Drug: Bevacizumab Injection|Drug: Nivolumab	Fuda Cnacer Hospital, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT04393220
2074	Role of Serum Regucalcin in Diagnosis of Hepatocellular Carcinoma	Unknown status	No Results Available	Role of Serum Regucalcin in Diagnosis of HCC	Diagnostic Test: serum regucalcin antibody	Oncology Center Mansoura University, Mansoura, Dakahlia, Egypt	https://ClinicalTrials.gov/show/NCT03206866
2075	Circulating Tumor Cell Detection in Hepatocellular Carcinoma	Completed	No Results Available	Circulating Tumor Cell		Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China	https://ClinicalTrials.gov/show/NCT05297955
2076	Phase III Study of Toripalimab（JS001） Combined With Lenvatinib for Advanced HCC	Recruiting	No Results Available	Advanced Hepatocellular Carcinoma (HCC)	Combination Product: Toripalimab combined with Lenvatinib|Combination Product: Placebo combined with Lanvatinib	Alliance for Multispecialty Research, LLC, Kansas City, Missouri, United States|Qinhuai Medical Area, General Hospital of PLA Eastern Theater Command, Nanjing, China|Azienda Ospedaliera Universitaria Careggi, Firenze, Italy|Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico,Oncologia Medica, Milan, Italy|IRCCS Fondazione Giovanni Pascale, Istituto Nazionale Dei Tumori, Napoli, Italy|Azienda Ospedaliero Universitaria Pisana, Pisa, Italy|A.O.U. Citta della Salute e della Scienza di Torino, Tortona, Italy|AOUI Verona - Policlinico "G.B. Rossi" di Borgo Roma, Verona, Italy|Copernicus Podmiot Leczniczy sp. z o.o., Wojewodzkie Centrum Onkologii, Oddzial Onkologii Klinicznej/Chemioterapii, Gdansk, Poland|Szpital Wojewódzki im. Mikołaja Kopernika w Koszalinie, Oddzial Dzienny Chemioterapii, Koszalin, Poland|PRATIA MCM Kraków, Krakow, Poland|ID Clinic, Mysłowice, Poland|Wielkopolskie Centrum Onkologii, Oddział Onkologii Klinicznej i Immunoonkologii z Pododdziałem Dziennym i Izbą Przyjęć, Poznan, Poland|Centrum Medyczne Pratia Poznań, Skórzewo, Poland|Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy, Klinika Onkologii i Radioterapii, Warszawa, Poland|National Cancer Centre Singapore, Singapore, Singapore|Communal Non-commercial Enterprise City Clinical Hospital #4 of Dnipro City Council, Department of Chemotherapy, Dnipro, Ukraine|Communal Non-profit Enterprise "Regional Center of Oncology", Department of Liver and Pancreas Gland Oncosurgery, Kharkiv, Ukraine|Communal Non-Profit Institution of Kharkiv Regional Council Regional Clinical Specialized Dispensary of Radiation Protection of Population, Kharkiv, Ukraine|State Inst.O.O.Shalimov Nat.Institute of Surgery and Transplantology of Nat.Academy of Med.Sciences of Ukraine, Dep.of Oncology, Kyiv, Ukraine|The Municipal Enterprise Volyn Regional Medical Oncology Center of the Volyn Regional Council, Oncology Chemotherapy Department, Luts'k, Ukraine|Communal Non-commercial Enterprise Odesa Regional Clinical Hospital of Odesa Regional Council, Department of General Surgery, Odesa, Ukraine|Communal Non-commercial Enterprise of Sumy Regional Council, Sumy Regional Clinical Oncological Dispensar, Sumy, Ukraine|Communal Non-commercial Enterprise Zaporizhzhia Regional Antitumor Center of Zaporizhzhia Regional Council, Zaporizhzhia, Ukraine	https://ClinicalTrials.gov/show/NCT04523493
2077	Hepatocellular Carcinoma (HCC)_Torisel_	Completed	No Results Available	Inoperable HCC	Drug: Torisel	Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong, Hong Kong	https://ClinicalTrials.gov/show/NCT01251458
2078	Effect of Polymorphisms in the IL-1 Gene Complex on the Development of Chronic Hepatitis and Hepatocellular Carcinoma	Unknown status	No Results Available	Hepatitis B|Carcinoma, Hepatocellular|Polymorphism, Genetic		Department of Medical Genetics; National Taiwan University Hospital, Taipei, Taiwan	https://ClinicalTrials.gov/show/NCT00155103
2079	Hepatitis B and Hepatitis C as Risk Factors for Hepatocellular Carcinoma in African and Asian Immigrants	Active, not recruiting	No Results Available	Hepatitis B|Hepatitis C|Carcinoma, Hepatocellular		Mayo Clinic, Rochester, Minnesota, United States	https://ClinicalTrials.gov/show/NCT02366286
2080	Study of microRNAs as a Diagnostic Tool for HCV-related Hepatocellular Carcinoma	Unknown status	No Results Available	miRna in HCC			https://ClinicalTrials.gov/show/NCT03429530
2081	KN046 Combined With Ningatinib in the Treatment of Advanced Hepatocellular Carcinoma	Active, not recruiting	No Results Available	Advanced HCC	Drug: KN046 （PD-L1/CTLA4 BsAb）|Drug: Ningetinib Tosylate（multi-target TKI）	Chinese Pla General Hospital Chinese Pla Medical School, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT04601610
2082	The Study of KN046 in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma	Recruiting	No Results Available	HCC	Biological: KN046|Drug: Lenvatinib	Beijing Cancer Hospital, Beijing, Beijing, China	https://ClinicalTrials.gov/show/NCT04542837
2083	Treatment of Advanced Hepatocellular Carcinoma	Unknown status	No Results Available	HCC	Other: Basic drugs therapy of HCC|Drug: Arginine hydrochloride|Drug: Trimetazidine hydrochloride	The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China	https://ClinicalTrials.gov/show/NCT03278444
2084	Radomised Phase II Study of MTL-CEBPA Plus Sorafenib or Sorafenib Alone	Recruiting	No Results Available	Hepatocellular Carcinoma|Hepatitis B|Hepatitis C	Drug: MTL-CEBPA|Drug: Sorafenib	City of Hope, Duarte, California, United States|National University Hospital Singapore, Singapore, Singapore	https://ClinicalTrials.gov/show/NCT04710641
2085	Electronic Monitoring Device of Patient-Reported Outcomes and Function in Improving Patient-Centered Care in Patients With Gastrointestinal Cancer Undergoing Surgery	Completed	No Results Available	Stage I Adult Liver Cancer|Stage I Colorectal Cancer|Stage IA Gastric Cancer|Stage IA Pancreatic Cancer|Stage IB Gastric Cancer|Stage IB Pancreatic Cancer|Stage II Adult Liver Cancer|Stage IIA Colorectal Cancer|Stage IIA Gastric Cancer|Stage IIA Pancreatic Cancer|Stage IIB Colorectal Cancer|Stage IIB Gastric Cancer|Stage IIB Pancreatic Cancer|Stage IIC Colorectal Cancer|Stage III Pancreatic Cancer|Stage IIIA Adult Liver Cancer|Stage IIIA Colorectal Cancer|Stage IIIA Gastric Cancer|Stage IIIB Adult Liver Cancer|Stage IIIB Colorectal Cancer|Stage IIIB Gastric Cancer|Stage IIIC Adult Liver Cancer|Stage IIIC Colorectal Cancer|Stage IIIC Gastric Cancer|Stage IV Gastric Cancer|Stage IVA Colorectal Cancer|Stage IVA Liver Cancer|Stage IVA Pancreatic Cancer|Stage IVB Colorectal Cancer|Stage IVB Liver Cancer|Stage IVB Pancreatic Cancer	Other: Computer-Assisted Intervention|Device: Vivofit watch|Other: Quality-of-Life Assessment|Other: Questionnaire Administration	City of Hope Medical Center, Duarte, California, United States	https://ClinicalTrials.gov/show/NCT02511821
2086	Clinical Application of 68Ga-PSMA PET/MR for Diagnosis and Staging in Hepatocellular Carcinoma	Recruiting	No Results Available	Malignant Neoplasm	Drug: 68Ga-PSMA|Device: PET/MR|Device: PET/CT	China, Hubei Province, Wuhan, Hubei, China	https://ClinicalTrials.gov/show/NCT05006326
2087	Safety and Efficacy of Donafenib in Patients With Advanced Hepatocellular Carcinoma	Completed	No Results Available	HCC	Drug: Donafenib(200mg)|Drug: Donafenib(300mg)	West China Hospital,SCU, Chengdu, Sichuan, China	https://ClinicalTrials.gov/show/NCT02229071
2088	Statin Combination Therapy in Patients Receiving Sorafenib for Advanced Hepatocellular Carcinoma	Terminated	No Results Available	Overall Survival|Tumor Responses	Drug: Atorvastatin 10mg|Drug: Placebo Oral Tablet	Taichung Veterans General Hospital, Taichung, Taiwan	https://ClinicalTrials.gov/show/NCT03275376
2089	"No-Touch" Radiofrequency Ablation for Small Hepatocellular Carcinoma (≤ 3cm): A Prospective Multicenter Study	Terminated	No Results Available	Radiofrequency Ablation|Microwave Ablation	Procedure: "No-Touch" Radiofrequency Ablation	Seoul National University Hospital, Seoul, Korea, Republic of	https://ClinicalTrials.gov/show/NCT04803890
2090	Clinical Intervention Strategy for High-risk Group of Hepatitis B Related Hepatocellular Carcinoma	Not yet recruiting	No Results Available	Time	Other: Long term follow-up		https://ClinicalTrials.gov/show/NCT05256459
2091	Role of (LMWH) in Prevention of Thromboembolic Complication After (TACE) in Hepatocellular Carcinoma.	Not yet recruiting	No Results Available	HCC	Drug: LMWH|Procedure: TACE	Tanta university - faculty of medicine, Tanta, Egypt	https://ClinicalTrials.gov/show/NCT02715492
2092	Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma	Completed	No Results Available	HCC	Drug: Donafenib|Drug: Sorafenib	The PLA 81 Hospital, Nanjing, Jiangsu, China|West China Hospital Sichuan University, Chengdu, Sichuan, China	https://ClinicalTrials.gov/show/NCT02645981
2093	Treatment of Intermediate-stage Hepatocellular Carcinoma	Unknown status	No Results Available	HCC	Device: Basic drugs therapy of HCC by TACE|Drug: Arginine hydrochloride|Drug: Trimetazidine hydrochloride	The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China	https://ClinicalTrials.gov/show/NCT03274427
2094	Neutrophil Extracellular Traps as a Biomarker to Predict Portal Vein Tumor Thrombosis in Patients With Hepatocellular Carcinoma	Completed	No Results Available	Neutrophil Extracellular Trap Formation|Portal Vein Tumor Thrombosis	Other: test NETs markers	the Affiliated Hospital of Qingdao University, Qingdao, Shandong, China	https://ClinicalTrials.gov/show/NCT05040347
2095	An Open-label Phase I/II Clinical Trial of PT-112 Injection for Advanced Solid Tumors and Advanced Hepatocellular Carcinoma	Unknown status	No Results Available	Advanced Solid Tumors	Drug: PT-112 Injection	Shanghai East Hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT03439761
2096	Role of EUS Guided FNA of Portal Vein Thrombus in the Diagnosis and Staging of Hepatocellular Carcinoma	Unknown status	No Results Available	Portal Vein Thrombosis	Procedure: EUS guided fine needle aspiration of portal vein thrombus	specialized medical hospital, Mansourah University, Mansourah, Dakahlia, Egypt	https://ClinicalTrials.gov/show/NCT03902678
2097	EUS Guided Cyanoacrylate Injection vs Endoscopic Variceal Band Ligation for Prevention of Rebleeding in Patients With Hepatocellular Carcinoma and Esophageal Variceal Bleeding	Recruiting	No Results Available	EUS Guided Cyanoacrylate Injection|Endoscopic Variceal Band Ligation|Hepatocelular Carcinoma|Esophageal Variceal Bleeding		Prince of Wales Hospital, The Chinese University of Hong Kong, Sha Tin, New Territories, Hong Kong	https://ClinicalTrials.gov/show/NCT04918459
2098	Efficacy and Safety of Sorafenib as Adjuvant and Latter Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma	Unknown status	No Results Available	HCC	Procedure: RFA|Drug: Sorafenib	Southwest Hospital, Chongqing, Chongqing, China	https://ClinicalTrials.gov/show/NCT03097848
2099	Sorafenib Versus Best Supportive Care in Egyptian Hepatocellular Carcinoma Patients.	Completed	No Results Available	HCC	Drug: Sorafenib|Drug: Best Supportive care	El Kahraba Hosital, Cairo, N/A = Not Applicable, Egypt|Ain Shams University Hospital, Cairo, Egypt|Nasser Institute, Cairo, Egypt	https://ClinicalTrials.gov/show/NCT02971696
2100	A Clinical Trail of Iodine[131I] Metuximab Injection With CIK Cells for Preventing Hepatocellular Carcinoma	Unknown status	No Results Available	Multiple Drug Use	Biological: Licartin and CIK	Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China	https://ClinicalTrials.gov/show/NCT01758679
2101	p53 Gene Therapy in Treatment of Diabetes Concurrent With Hepatocellular Carcinoma	Unknown status	No Results Available	HCC|Diabetes	Drug: p53 gene therapy|Drug: Trans-catheter embolization	first affiliated hospital in Dalian University, Dalian, Liaoning, China	https://ClinicalTrials.gov/show/NCT02561546
2102	Evaluation the Possible Influence of Transcatheter Arterial Chemoembolization on Hepatitis B Viral Replication	Completed	No Results Available	Hepatocellular Carcinoma|Hepatitis B Virus		Kaohsiung Medical University Hospital, Kaohsiung, Taiwan	https://ClinicalTrials.gov/show/NCT00769730
2103	The Investigation of Peginterferon Alfa-2a on the RFS of the Subjects With HCC Who Have Been Treated by Resection	Unknown status	No Results Available	Chronic Hepatitis b|Hepatic Carcinoma	Drug: ETV；TDF；ADV|Drug: Peginterferon Alfa-2a	Huashan Hospital, Shanghai, China	https://ClinicalTrials.gov/show/NCT03253250
2104	Study of the Early Occurrence of Hepatocellular Carcinoma (HCC) in Egyptian HCV Infected Patients Receiving Sofosbuvir and Daclatasvir	Unknown status	No Results Available	Hepatitis C	Drug: Sofosbuvir 400 mg, Daclatasvir, Ribavirin	National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt	https://ClinicalTrials.gov/show/NCT03247296
2105	Validity and Cost-Effectiveness of a New Screening Test for Hepatocellular Carcinoma	Completed	No Results Available	Hepatitis B Virus			https://ClinicalTrials.gov/show/NCT00912847
2106	Combined Fluorocholine Positron Emission Tomography and Magnetic Resonance Imaging (FCH-PET/MRI) in Curative Treatment of a Hepatocellular Carcinoma	Recruiting	No Results Available	Patients Eligible to a Curative Treatment for Primary HCC	Device: PET/MRI system (SIEMENS AG, Munich, Germany; distributed in France by SIEMENS S.A.S, Saint-Denis, France)	CHU de Grenoble, Servide d'Hépato-gastro-entérologie, La Tronche, France|HCL, Hôpital Edouard Herriot, service d'hépato-gastro-entérologie, Lyon, France|HCL, Hôpital de la Croix-Rousse, service d'Hépato-gastro-entérologie, Lyon, France|Hospices Civils de Lyon, Groupement Hospitalier Lyon Sud, Service de radiologie digestive, Pierre-Bénite, France	https://ClinicalTrials.gov/show/NCT02824185
2107	Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors	Recruiting	No Results Available	Solid Tumor, Adult|Hepatocellular Carcinoma	Drug: Combination of three inhibitors Trametinib, Everolimus and Lenvatinib	The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China	https://ClinicalTrials.gov/show/NCT04803318
2108	Associating Liver Partition With Portal Vein Ligation For Staged Hepatectomy (ALPPS) or Portal Vein Occlusion in Treating Patients With Liver Cancer	Withdrawn	No Results Available	Carcinoma, Hepatocellular	Procedure: ALPPS surgery|Procedure: PVO surgery		https://ClinicalTrials.gov/show/NCT01722175
2109	Rg3 in Combination With TACE in Hepatocellular Carcinoma Patients With High Expression of Notch1	Completed	No Results Available	Hepatocellular Carcinoma|TACE|Notch1|Rg3	Procedure: TACE|Drug: Rg3|Other: TACE + Rg3|Procedure: protective therapy	Eastern hepatobilliary surgery hospital, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT02724358
2110	Impact of IL-28B rs12979860 and rs4803217 Gene Polymorphisms Associated With miRNAs Deregulation on HCV-related Hepatocellular Carcinoma	Unknown status	No Results Available	HCV Infection ( Genotype 4)	Biological: IL28B Polymorphism|Biological: miRNA quantification	Egyptian Liver Hospital, Sherbein, Dakhlya, Egypt	https://ClinicalTrials.gov/show/NCT02507882
2111	Impact of C-arm CT in Decreased Renal Function Undergoing TACE for Tx of Hepato-Cellular Carcinoma	Terminated	No Results Available	Kidney (Renal Cell) Cancer	Device: dTA/dBA C-arm fluoroscopy system with Dyna CT|Procedure: DSA arteriogram- hepatic arteries|Procedure: CO2 aortogram	Stanford University School of Medicine, Stanford, California, United States	https://ClinicalTrials.gov/show/NCT01326390
2112	Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)	Unknown status	No Results Available	HCC	Drug: Sorafenib|Drug: VT-122 (propranolol plus etodolac)|Drug: Placebo	Vicus Clinical Site, Berkeley, California, United States|Vicus Clinical Site, Atlanta, Georgia, United States|Vicus Clinical Site, New Brunswick, New Jersey, United States|Vicus Clinical Site, Newark, New Jersey, United States|Vicus Clinical Site, Paterson, New Jersey, United States|Vicus Clinical Site, Buffalo, New York, United States|Vicus Clinical Site, New York, New York, United States|Vicus Clinical Site, Philadelphia, Pennsylvania, United States|Vicus Clinical Site, Houston, Texas, United States|Vicus Clinical Site, Houston, Texas, United States	https://ClinicalTrials.gov/show/NCT01265576
2113	Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma	Not yet recruiting	No Results Available	BCLC Stage B Hepatocellular Carcinoma|BCLC Stage C Hepatocellular Carcinoma|Locally Advanced Hepatocellular Carcinoma|Recurrent Hepatocellular Carcinoma|Unresectable Hepatocellular Carcinoma	Biological: Atezolizumab|Procedure: Biopsy|Drug: Cabozantinib S-malate|Radiation: Yttrium Y 90 Glass Microspheres	OHSU Knight Cancer Institute, Portland, Oregon, United States	https://ClinicalTrials.gov/show/NCT05327738
2114	Study of Entecavir for Reducing the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients	Recruiting	No Results Available	Chronic Hepatitis B		Soon Chun Hyang University Hospital Bucheon, Bucheon, Korea, Republic of|Soon Chun Hyang University Hospital Cheonan, Cheonan, Korea, Republic of|Bundang Jesaeng Hospital, Gyeonggi-do, Korea, Republic of|Catholic University of Korea, Uijeongbu ST. Mary's Hospital, Gyeonggi-do, Korea, Republic of|CHA Bundang Medical Center, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Ajou University Hospital, Suwon, Korea, Republic of|The Catholic University of Korea, St. Vincent's Hospital, Suwon, Korea, Republic of|Gachon University, Donginchoen Gil Hospital, Sŏngnam, Korea, Republic of	https://ClinicalTrials.gov/show/NCT04646928
2115	Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With SBRT for HCC Patients With Portal Vein Thrombosis.	Not yet recruiting	No Results Available	Unresectable Hepatocellular Carcinoma|Pembrolizumab|Lenvatinib|Stereotactic Body Radiotherapy	Drug: Lenvatinib/Pembrolizumab plus SBRT combinations	National Taiwan University Hospital, Taipei City, Taiawn, Taiwan	https://ClinicalTrials.gov/show/NCT05286320
2116	A Study of Vismodegib in Patients With Advanced Solid Malignancies Including Hepatocellular Carcinoma With Varying Degrees of Renal or Hepatic Function	Completed	Has Results	Cancer	Drug: Vismodegib	Chicago, Illinois, United States|Baltimore, Maryland, United States|Detroit, Michigan, United States|Lebanon, New Hampshire, United States|New York, New York, United States	https://ClinicalTrials.gov/show/NCT01546519
2117	Remote Ischemic Conditioning (RIC) in Recipients of Brain Death Donor Livers - A Feasibility and Safety Study	Completed	Has Results	Liver Failure|Carcinoma, Hepatocellular	Procedure: Remote Ischemic Conditioning (RIC)|Device: Pneumatic tourniquet	Rutgers University - University Hospital, Newark, New Jersey, United States	https://ClinicalTrials.gov/show/NCT02635347
2118	Study of TACE Combined With Lenvatinib to Prevent Postoperative Recurrence in Patients With MVI Positive HCC	Not yet recruiting	No Results Available	Hepatocellular Carcinoma|Lenvatinib	Drug: Lenvatinib|Procedure: TACE		https://ClinicalTrials.gov/show/NCT04911959
2119	Clinical Study of Effectiveness of Radiotherapy Before Surgery in High-risk Relapse Hepatocellular Cancer Patients	Unknown status	No Results Available	Carcinoma, Hepatocellular	Radiation: radiotherapy	WU FAN, Beijing, China	https://ClinicalTrials.gov/show/NCT02580929
2120	Impact of Sarcopenia on Postoperative Outcomes of Patients Undergoing Liver Resection	Completed	No Results Available	Liver Neoplasms|Sarcopenia|Postoperative Complications	Procedure: Liver resection	San Camillo Hospital, Rome, Italy	https://ClinicalTrials.gov/show/NCT03630978
2121	Endovascular Brachytherapy Combined With Stent Placement and TACE for HCC With Main Portal Vein Tumor Thrombus	Recruiting	No Results Available	Hepatocellular Carcinoma|Portal Vein Tumor Thrombus	Procedure: Stent and Iodine-125 seed strand implantation|Device: Stent|Device: Iodine-125 seed|Drug: Epirubicin|Drug: Ultra-fluid lipiodol|Other: Gelatin sponge articles	Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China	https://ClinicalTrials.gov/show/NCT02971345
2122	HCC Surveillance: Comparison of Abbreviated Non-contrast MRI and Ultrasound Surveillance in Cirrhotic Patients With Suboptimal Ultrasound Visualisation	Recruiting	No Results Available	Hepatocellular Carcinoma|HCC	Diagnostic Test: Abbreviated non-contrast MRI of the liver|Diagnostic Test: Ultrasound surveillance|Diagnostic Test: Multiphase contrast-enhanced liver MRI	Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|Concord Repatriation General Hospital, Concord, New South Wales, Australia|Gosford Hospital, Gosford, New South Wales, Australia|Prince of Wales Hospital, Randwick, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia|Austin Hospital, Heidelberg, Victoria, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|North Shore Hospital, Takapuna, Auckland, New Zealand	https://ClinicalTrials.gov/show/NCT04455932
2123	Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Malignancy Other Than Hepatocellular Carcinoma	Completed	No Results Available	Chronic Hepatitis C|Neoplasms	Drug: pegylated interferon alpha 2a and plus ribavirin	Kaohsiung Medical University Hospital, Kaohsiung, Taiwan	https://ClinicalTrials.gov/show/NCT00630084
2124	Study to Evaluate VORTX Rx (Theresa)	Completed	Has Results	Carcinoma, Hepatocellular|Liver Metastases	Device: VORTX Rx treatment	Clinica Diagonal, Esplugues De Llobregat, Barcelona, Spain|Hospital universitario Mutua Terrassa, Terrassa, Barcelona, Spain|Hospital Universitario Vall d´Hebrón, Barcelona, Spain	https://ClinicalTrials.gov/show/NCT03741088
2125	RCT of Screening Strategies Among Patients at High Risk for Developing HCC in a Safety-net Health System	Completed	No Results Available	Carcinoma, Hepatocellular|Liver Neoplasms	Other: Mailed Outreach Invitation|Other: Mailed Outreach Invitation and Patient Navigation	Parkland Health & Hospital System, Dallas, Texas, United States	https://ClinicalTrials.gov/show/NCT02312817
2126	Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant	Completed	Has Results	Hepatitis C|Hepatocellular Carcinoma	Drug: Sofosbuvir|Drug: Ribavirin	UCLA Medical Center-The Pfleger Liver Institute, Los Angeles, California, United States|UC San Diego, San Diego, California, United States|University of California, San Francisco, San Francisco, California, United States|University of Colorado, Aurora, Colorado, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|University of Miami, Miami, Florida, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Lahey Clinic Medical Center, Burlington, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|St. Louis University Hospital, St. Louis, Missouri, United States|Columbia University, New York, New York, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Baylor Health Care System, Dallas, Texas, United States|Auckland Clinical Studies, Auckland, New Zealand|Liver Unit Clinica University de Navara, Pamplona, Spain	https://ClinicalTrials.gov/show/NCT01559844
